assays_assay_id,assays_assay_subcellular_fraction,assays_assay_test_type,assays_assay_tissue,assays_assay_type,assays_assay_cell_type,assays_cell_id,assays_assay_category,assays_description,assays_relationship_type,assays_assay_strain,assays_src_id,assays_src_assay_id,assays_chembl_id,assays_bao_format,assays_tissue_id,assays_variant_id
1,,,,B,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,H,,1,,CHEMBL615117,BAO_0000019,,
2,,,,F,,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,U,,1,,CHEMBL615118,BAO_0000219,,
3,,,,B,,,,,U,,1,,CHEMBL615119,BAO_0000019,,
4,,,,B,,,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,H,,1,,CHEMBL615120,BAO_0000249,,
5,,,,F,143B,163.0,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),N,,1,,CHEMBL615121,BAO_0000219,,
6,,,,F,143B,163.0,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),N,,1,,CHEMBL615122,BAO_0000219,,
7,,,,F,143B,163.0,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,N,,1,,CHEMBL615123,BAO_0000219,,
8,,,,F,143B,163.0,,In vitro cell cytotoxicity was determined against 143B cell line,N,,1,,CHEMBL615124,BAO_0000219,,
9,,,,F,143B,163.0,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,N,,1,,CHEMBL615125,BAO_0000219,,
10,,,,F,143B,163.0,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,N,,1,,CHEMBL615126,BAO_0000219,,
11,,,,F,143B,163.0,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,N,,1,,CHEMBL615127,BAO_0000219,,
12,,,,F,143B,163.0,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,N,,1,,CHEMBL615128,BAO_0000219,,
13,,,,F,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,,1,,CHEMBL857900,BAO_0000218,,
14,,,,F,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,,1,,CHEMBL615129,BAO_0000218,,
15,,,,F,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,,1,,CHEMBL615130,BAO_0000218,,
16,,,,F,,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,,1,,CHEMBL615131,BAO_0000218,,
17,,,,A,,,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,D,,1,,CHEMBL884521,BAO_0000357,,
18,,,,B,,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),H,,1,,CHEMBL615132,BAO_0000357,,
19,,,,B,,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,H,,1,,CHEMBL615133,BAO_0000019,,
20,,,,B,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),H,,1,,CHEMBL615134,BAO_0000357,,
21,,,,B,,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),H,,1,,CHEMBL615135,BAO_0000357,,
22,,,,B,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),H,,1,,CHEMBL615136,BAO_0000357,,
23,,,,B,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,H,,1,,CHEMBL615137,BAO_0000357,,
24,,,,B,,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,H,,1,,CHEMBL615138,BAO_0000357,,
25,,,,B,,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",U,,1,,CHEMBL836324,BAO_0000219,,
26,,,,B,,,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,H,,1,,CHEMBL615139,BAO_0000357,,
27,,,,B,,,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),H,,1,,CHEMBL615140,BAO_0000357,,
28,,,,B,,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,H,,1,,CHEMBL615141,BAO_0000219,,
29,,,,B,,,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,H,,1,,CHEMBL615142,BAO_0000357,,
30,,,,B,,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,H,,1,,CHEMBL615143,BAO_0000357,,
31,,,,B,,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,H,,1,,CHEMBL615144,BAO_0000357,,
32,,,,B,,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,H,,1,,CHEMBL872867,BAO_0000357,,
33,,,,B,,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,H,,1,,CHEMBL615145,BAO_0000357,,
34,,,,B,,,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,H,,1,,CHEMBL615146,BAO_0000357,,
35,,,,B,,,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,H,,1,,CHEMBL615147,BAO_0000357,,
36,,,,A,,,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,U,,1,,CHEMBL615148,BAO_0000019,,
37,,,,B,,,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,U,,1,,CHEMBL615149,BAO_0000019,,
38,,,,B,,,,Dissociation constant with dimeric 16S rRNA RNA construct B,U,,1,,CHEMBL615150,BAO_0000019,,
39,,,,B,,,,Dissociation constant towards 16S rRNA construct A,M,,1,,CHEMBL615151,BAO_0000225,,
40,,,,B,,,,Dissociation constant towards 16S rRNA construct B,M,,1,,CHEMBL615152,BAO_0000225,,
41,,,,B,,,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,M,,1,,CHEMBL615153,BAO_0000225,,
42,,,,B,,,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,M,,1,,CHEMBL615154,BAO_0000225,,
43,,,,B,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),H,,1,,CHEMBL615155,BAO_0000019,,
44,,,,B,,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),H,,1,,CHEMBL615156,BAO_0000019,,
45,,,,B,,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,H,,1,,CHEMBL615157,BAO_0000019,,
46,,,,B,,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,H,,1,,CHEMBL615158,BAO_0000019,,
47,,,,B,,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",D,,1,,CHEMBL615159,BAO_0000019,,
48,,,,B,,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",D,,1,,CHEMBL615172,BAO_0000019,,
49,,,,B,,,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",D,,1,,CHEMBL615173,BAO_0000019,,
50,,,,B,,,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",D,,1,,CHEMBL615174,BAO_0000019,,
51,,,,B,,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),H,,1,,CHEMBL884518,BAO_0000019,,
52,,,,B,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),H,,1,,CHEMBL615175,BAO_0000357,,
53,,,,B,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,H,,1,,CHEMBL615176,BAO_0000357,,
54,,,,B,,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,H,,1,,CHEMBL615177,BAO_0000357,,
55,Membranes,,,B,,,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,D,,1,,CHEMBL615178,BAO_0000249,,
56,,,,F,1A9,506.0,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,N,,1,,CHEMBL615179,BAO_0000219,,
57,,,,F,Oocytes,,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,D,,1,,CHEMBL615180,BAO_0000219,,
58,,,,F,Oocytes,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,D,,1,,CHEMBL615181,BAO_0000219,,
59,,,,F,Oocytes,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,D,,1,,CHEMBL615182,BAO_0000219,,
60,,,,F,1A9,506.0,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,N,,1,,CHEMBL615183,BAO_0000219,,
61,,,,F,1A9,506.0,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,N,,1,,CHEMBL615184,BAO_0000219,,
62,,,,F,1A9,506.0,,Cytotoxic activity against human ovarian cancer (1A9) cell line,N,,1,,CHEMBL615185,BAO_0000219,,
63,,,,F,1A9,506.0,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,N,,1,,CHEMBL615186,BAO_0000219,,
64,,,,F,1A9,506.0,,Effective dose of compound against replication of 1A9 cell line was evaluated,N,,1,,CHEMBL615187,BAO_0000219,,
65,,,,F,1A9,506.0,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,N,,1,,CHEMBL885343,BAO_0000219,,
66,,,,F,1A9,506.0,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),N,,1,,CHEMBL615188,BAO_0000219,,
67,,,,F,1A9,506.0,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,N,,1,,CHEMBL615189,BAO_0000219,,
68,,,,F,1A9,506.0,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,N,,1,,CHEMBL615190,BAO_0000219,,
69,,,,F,1A9,506.0,,Inhibitory activity against Taxol resistant 1A9 cell lines,N,,1,,CHEMBL615191,BAO_0000219,,
70,,,,F,1A9,506.0,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,N,,1,,CHEMBL615192,BAO_0000219,,
71,,,,F,1A9,506.0,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,N,,1,,CHEMBL827083,BAO_0000219,,
72,,,,F,1A9,506.0,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,N,,1,,CHEMBL615193,BAO_0000219,,
73,,,,F,1A9,506.0,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,N,,1,,CHEMBL615194,BAO_0000219,,
74,,,,F,1A9,506.0,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,N,,1,,CHEMBL615195,BAO_0000219,,
75,,,,F,1A9,506.0,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,N,,1,,CHEMBL615196,BAO_0000219,,
76,,,,F,Jurkat,503.0,,Inhibitory concentration against Jurkat cells,N,,1,,CHEMBL615197,BAO_0000219,,
77,,,,F,,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,U,,1,,CHEMBL615198,BAO_0000019,,
78,,,,A,,,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,D,,1,,CHEMBL615199,BAO_0000357,,
79,,,,B,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",H,,1,,CHEMBL615200,BAO_0000357,,
80,,,,B,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",H,,1,,CHEMBL615201,BAO_0000357,,
81,,,,B,,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",H,,1,,CHEMBL615202,BAO_0000357,,
82,Microsomes,,,B,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",H,,1,,CHEMBL615203,BAO_0000251,,
83,Microsomes,,,B,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",H,,1,,CHEMBL615204,BAO_0000251,,
84,Microsomes,,,B,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",H,,1,,CHEMBL615205,BAO_0000251,,
85,Microsomes,,,B,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",H,,1,,CHEMBL615206,BAO_0000251,,
86,Microsomes,,Liver,B,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",H,,1,,CHEMBL615207,BAO_0000251,2107.0,
87,,,,B,,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",H,,1,,CHEMBL827084,BAO_0000019,,
88,,,,B,,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",H,,1,,CHEMBL615208,BAO_0000019,,
89,,,,B,,,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",H,,1,,CHEMBL615209,BAO_0000019,,
90,Microsomes,,Liver,B,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",D,,1,,CHEMBL615210,BAO_0000251,2107.0,
91,Microsomes,,Liver,B,,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",D,,1,,CHEMBL615211,BAO_0000251,2107.0,
92,Microsomes,,Liver,B,,,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",D,,1,,CHEMBL615212,BAO_0000251,2107.0,
93,,,,B,,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),H,,1,,CHEMBL615213,BAO_0000357,,
94,,,,B,,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,H,,1,,CHEMBL615273,BAO_0000357,,
95,,,,F,HepG2,726.0,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,N,,1,,CHEMBL615274,BAO_0000219,,
96,,,,F,HepG2,726.0,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,N,,1,,CHEMBL615275,BAO_0000219,,
97,,,,F,HepG2,726.0,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,N,,1,,CHEMBL615276,BAO_0000219,,
98,,,,F,HepG2,726.0,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,N,,1,,CHEMBL615277,BAO_0000219,,
99,,,,F,HepG2,726.0,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,N,,1,,CHEMBL615326,BAO_0000219,,
100,,,,F,,,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,N,,1,,CHEMBL883130,BAO_0000218,,
101,,,,F,HepG2,726.0,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,N,,1,,CHEMBL884519,BAO_0000219,,
102,,,,F,HepG2,726.0,,Concentration required to inhibit 50% of 2.2.15 cell line,N,,1,,CHEMBL615327,BAO_0000219,,
103,,,,A,HepG2,726.0,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,N,,1,,CHEMBL615328,BAO_0000219,,
104,,,,F,2.2.15,,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,N,,1,,CHEMBL615329,BAO_0000218,,
105,,,,F,2.2.15,,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,N,,1,,CHEMBL615330,BAO_0000218,,
106,,,,F,2.2.15,,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",N,,1,,CHEMBL615331,BAO_0000218,,
107,,,,F,2.2.15,,,In vitro anti-HBV activity in 2.2.15 cells,N,,1,,CHEMBL615332,BAO_0000218,,
108,,,,F,2.2.15,,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,N,,1,,CHEMBL615333,BAO_0000218,,
109,,,,F,2.2.15,,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,N,,1,,CHEMBL615334,BAO_0000218,,
110,,,,F,2.2.15,,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,N,,1,,CHEMBL615335,BAO_0000218,,
111,,,,F,2.2.15,,,Cytotoxicity in 2.2.15 cells,N,,1,,CHEMBL615336,BAO_0000218,,
112,,,,F,2.2.15,,,Cytotoxicity in 2.2.15 cells; Not determined,N,,1,,CHEMBL615337,BAO_0000218,,
113,,,,F,2.2.15,,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,N,,1,,CHEMBL615338,BAO_0000218,,
114,,,,F,2.2.15,,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,N,,1,,CHEMBL615339,BAO_0000218,,
115,,,,F,2.2.15,,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,N,,1,,CHEMBL615340,BAO_0000218,,
116,,,,F,HepG2,726.0,,Antiviral activity against HBV was determined in 2.215 cell line,N,,1,,CHEMBL615341,BAO_0000219,,
117,Microsomes,,,B,,,,Inhibition of 20-HETE synthesis in human renal microsomes,U,,1,,CHEMBL615342,BAO_0000251,,
118,,,,B,,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,U,,1,,CHEMBL615343,BAO_0000019,,
119,,,,F,2008,388.0,,Inhibitory concentration against 2008 (ovarian) cells,N,,1,,CHEMBL615344,BAO_0000219,,
120,,,,F,2008,388.0,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,N,,1,,CHEMBL615345,BAO_0000219,,
121,,,,F,2008,388.0,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),N,,1,,CHEMBL615346,BAO_0000219,,
122,,,,F,2008,388.0,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,N,,1,,CHEMBL615347,BAO_0000219,,
123,,,,F,2008,388.0,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,N,,1,,CHEMBL615348,BAO_0000219,,
124,,,,F,2008/R,561.0,,In vitro inhibition of 2008/R ovarian cancer cell line,N,,1,,CHEMBL827085,BAO_0000219,,
125,,,,F,2008/R,561.0,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,N,,1,,CHEMBL615349,BAO_0000219,,
126,,,,F,2008/S,389.0,,In vitro inhibition of 2008/S ovarian cancer cell line,N,,1,,CHEMBL615350,BAO_0000219,,
127,,,,F,2008/S,389.0,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,N,,1,,CHEMBL615351,BAO_0000219,,
128,,,,B,,,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,S,,1,,CHEMBL615352,BAO_0000220,,
129,,,,B,,,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,S,,1,,CHEMBL615353,BAO_0000220,,
130,,,,B,,,,Inhibition of chymotrypsin-like activity of 20S proteasome,S,,1,,CHEMBL615354,BAO_0000220,,
131,,,,B,,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,S,,1,,CHEMBL615355,BAO_0000220,,
132,,,,B,,,,Inhibitory activity against 20S proteosome,S,,1,,CHEMBL615356,BAO_0000220,,
133,,,,B,,,,Compound was tested for inhibitory activity against tryptase,U,,1,,CHEMBL615357,BAO_0000019,,
134,,,,F,HepG2,726.0,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,N,,1,,CHEMBL615358,BAO_0000219,,
135,,,,F,HepG2,726.0,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,N,,1,,CHEMBL827086,BAO_0000219,,
136,,,,B,,,,Compound was tested for the inhibition of Alpha-glucosidase,U,,1,,CHEMBL615359,BAO_0000019,,
137,,,,B,,,,Inhibitory concentration against human neutrophil elastase (HNE),H,,1,,CHEMBL615360,BAO_0000357,,
138,,,Heart,F,,,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,U,,1,,CHEMBL615361,BAO_0000218,948.0,
139,,,,F,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,H,,1,,CHEMBL615362,BAO_0000019,,
140,,,,F,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,H,,1,,CHEMBL615363,BAO_0000019,,
141,,,,B,,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,H,,1,,CHEMBL615364,BAO_0000357,,
142,,,,F,,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,H,,1,,CHEMBL615365,BAO_0000019,,
143,,,,F,P338,524.0,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,N,,1,,CHEMBL615366,BAO_0000219,,
144,,,,F,P338,524.0,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,N,,1,,CHEMBL615367,BAO_0000219,,
145,,,,F,PBL,554.0,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,N,,1,,CHEMBL615368,BAO_0000219,,
146,,,,F,,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,U,,1,,CHEMBL615369,BAO_0000019,,
147,,,,F,,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,U,,1,,CHEMBL615370,BAO_0000019,,
148,,,,B,,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),H,,1,,CHEMBL615673,BAO_0000357,,
149,,,,F,,,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,U,,1,,CHEMBL615674,BAO_0000019,,
150,,,,F,,,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,U,,1,,CHEMBL615675,BAO_0000019,,
151,,,,F,CCRF-CEM,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,U,,1,,CHEMBL615676,BAO_0000219,,
152,,,,F,CCRF-CEM,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,U,,1,,CHEMBL615677,BAO_0000219,,
153,,,,F,CCRF-CEM,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,U,,1,,CHEMBL615678,BAO_0000219,,
154,,,,F,CCRF-CEM,635.0,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,U,,1,,CHEMBL615679,BAO_0000219,,
155,,,,F,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,U,,1,,CHEMBL615680,BAO_0000019,,
156,,,,F,,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,U,,1,,CHEMBL615681,BAO_0000019,,
157,,,,B,,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,H,,1,,CHEMBL857972,BAO_0000249,,
158,,,,F,,,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,N,,1,,CHEMBL857899,BAO_0000218,,
159,,,,F,,,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),N,,1,,CHEMBL615371,BAO_0000218,,
160,,,,F,HEL,468.0,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,N,,1,,CHEMBL615372,BAO_0000218,,
161,,,,F,,,,Antiviral activity against 07/1 strain of VZV; ND: No data,N,,1,,CHEMBL615373,BAO_0000218,,
162,,,,F,,,,Antiviral activity against 07/1 strain of VZV; ND=No data,N,,1,,CHEMBL615374,BAO_0000218,,
163,,,,F,,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",N,,1,,CHEMBL615375,BAO_0000218,,
164,,,,B,,,,Ratio of Ki at A2 to Ki at A1 receptors,U,,1,,CHEMBL615376,BAO_0000019,,
165,,,,B,,,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",H,,1,,CHEMBL615377,BAO_0000249,,
166,,,,B,,,,"Inhibition of 1,3-beta-glucan synthase",H,,1,,CHEMBL615378,BAO_0000357,,
167,,,,F,1-87 tumor cell line,832.0,,Inhibition of growth of 1-87 human tumor cell line,N,,1,,CHEMBL615379,BAO_0000219,,
168,,,,B,,,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,D,,1,,CHEMBL615380,BAO_0000219,,
169,,,,B,,,,Inhibitory activity against soybean 1-lipoxygenase (SLO),D,,1,,CHEMBL615381,BAO_0000357,,
170,,,,B,,,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,D,,1,,CHEMBL615382,BAO_0000357,,
171,,,,B,,,,% inhibition against soybean 1-lipoxygenase (SLO),D,,1,,CHEMBL615383,BAO_0000357,,
172,,,,B,,,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,D,,1,,CHEMBL615384,BAO_0000357,,
173,,,,B,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,D,,1,,CHEMBL615385,BAO_0000357,,
174,,,,B,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,D,,1,,CHEMBL615386,BAO_0000357,,
175,,,,B,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,D,,1,,CHEMBL615387,BAO_0000357,,
176,,,,B,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,D,,1,,CHEMBL615388,BAO_0000357,,
177,,,,B,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,D,,1,,CHEMBL615214,BAO_0000357,,
178,,,,B,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,D,,1,,CHEMBL827087,BAO_0000357,,
179,,,,B,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,D,,1,,CHEMBL615215,BAO_0000357,,
180,,,,B,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,D,,1,,CHEMBL615216,BAO_0000357,,
181,,,,B,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,D,,1,,CHEMBL615217,BAO_0000357,,
182,,,,B,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,D,,1,,CHEMBL615218,BAO_0000357,,
183,,,,B,,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,D,,1,,CHEMBL615219,BAO_0000357,,
184,,,,B,,,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,U,,1,,CHEMBL615220,BAO_0000019,,
185,,,,F,C3H 10T1/2,294.0,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),N,,1,,CHEMBL615221,BAO_0000219,,
186,,,,F,,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,U,,1,,CHEMBL615222,BAO_0000019,,
187,,,,B,,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),H,,1,,CHEMBL615223,BAO_0000357,,
188,,,,B,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),H,,1,,CHEMBL615224,BAO_0000357,,
189,,,,B,,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,H,,1,,CHEMBL615225,BAO_0000357,,
190,,,,B,,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,H,,1,,CHEMBL615226,BAO_0000357,,
191,,,,B,,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,H,,1,,CHEMBL615227,BAO_0000357,,
192,,,,F,,,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,D,,1,,CHEMBL615228,BAO_0000019,,
193,,,,B,,,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,D,,1,,CHEMBL615229,BAO_0000357,,
194,,,Adrenal gland,B,,,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,D,,1,,CHEMBL615230,BAO_0000357,2369.0,
195,,,,B,,,,Inhibition of rat adrenal 11-beta-hydroxylase,D,,1,,CHEMBL615231,BAO_0000357,,
196,,,,B,,,,Inhibition of rat adrenal 11-beta-hydroxylase,D,,1,,CHEMBL884520,BAO_0000357,,
197,,,,B,,,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,D,,1,,CHEMBL615232,BAO_0000357,,
198,,,,B,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,H,,1,,CHEMBL615233,BAO_0000019,,
199,,,,B,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,H,,1,,CHEMBL827088,BAO_0000357,,
200,,,,B,,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,H,,1,,CHEMBL615234,BAO_0000357,,
201,,,,F,,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,H,,1,,CHEMBL615235,BAO_0000019,,
202,,,,B,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,H,,1,,CHEMBL615236,BAO_0000019,,
203,,,,B,,,,Compound was tested in vitro for inhibition of 12-LO human platelet,H,,1,,CHEMBL615237,BAO_0000019,,
204,,,,F,,,,Inhibitory concentration against human platelet 12-lipoxygenase,H,,1,,CHEMBL615238,BAO_0000019,,
205,,,,B,,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,H,,1,,CHEMBL615239,BAO_0000019,,
206,,,,F,,,,Inhibitory concentration against human platelet 12-lipoxygenase,D,,1,,CHEMBL615240,BAO_0000019,,
207,,,,B,,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,H,,1,,CHEMBL615241,BAO_0000019,,
208,,,,B,,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,H,,1,,CHEMBL615242,BAO_0000357,,
209,,,,B,,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),H,,1,,CHEMBL615243,BAO_0000019,,
210,,,,B,,,,Inhibitory activity against human platelet 12-lipoxygenase,H,,1,,CHEMBL615244,BAO_0000019,,
211,,,,B,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,H,,1,,CHEMBL615245,BAO_0000019,,
212,,,,B,,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),H,,1,,CHEMBL615246,BAO_0000019,,
213,,,,B,,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,H,,1,,CHEMBL615247,BAO_0000019,,
214,,,,B,,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,H,,1,,CHEMBL615248,BAO_0000019,,
215,,,,B,,,,Inhibitory activity towards porcine 12-lipoxygenase,H,,1,,CHEMBL615249,BAO_0000357,,
216,,,,B,,,,Tested for inhibition against porcine 12-LO,H,,1,,CHEMBL615250,BAO_0000357,,
217,,,,B,,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,H,,1,,CHEMBL615251,BAO_0000019,,
218,,,,B,,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,H,,1,,CHEMBL615252,BAO_0000019,,
219,,,,B,,,,In vitro inhibition of rat platelet 12-lipoxygenase,H,,1,,CHEMBL828340,BAO_0000019,,
220,,,,B,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,H,,1,,CHEMBL615253,BAO_0000019,,
221,,,,B,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,H,,1,,CHEMBL615254,BAO_0000019,,
222,,,,B,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,H,,1,,CHEMBL615255,BAO_0000019,,
223,,,,B,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,H,,1,,CHEMBL615256,BAO_0000019,,
224,,,,B,,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,H,,1,,CHEMBL615257,BAO_0000019,,
225,,,,B,,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,H,,1,,CHEMBL615258,BAO_0000019,,
226,,,,F,41M,621.0,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,N,,1,,CHEMBL615259,BAO_0000219,,
227,,,,F,41M,621.0,,In vitro antitumor activity against 41M cell line.,N,,1,,CHEMBL615260,BAO_0000219,,
228,,,,F,41M,621.0,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,N,,1,,CHEMBL615261,BAO_0000219,,
229,,,,F,41M,621.0,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,N,,1,,CHEMBL615262,BAO_0000219,,
230,,,,F,41M,621.0,,In vitro antitumor activity against 41McisR cell line.,N,,1,,CHEMBL615263,BAO_0000219,,
231,,,,F,41M,621.0,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,N,,1,,CHEMBL838393,BAO_0000219,,
232,,,,F,41M,621.0,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,N,,1,,CHEMBL615264,BAO_0000219,,
233,,,,B,,,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),D,,1,,CHEMBL615265,BAO_0000357,,
234,,,,B,,,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),D,,1,,CHEMBL615266,BAO_0000357,,
235,,,,B,,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),H,,1,,CHEMBL615267,BAO_0000357,,
236,,,,B,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,H,,1,,CHEMBL615268,BAO_0000357,,
237,,,,B,,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,H,,1,,CHEMBL615269,BAO_0000357,,
238,,,,B,,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,H,,1,,CHEMBL615270,BAO_0000357,,
239,,,,B,,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",H,,1,,CHEMBL615271,BAO_0000357,,
240,,,,B,,,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",H,,1,,CHEMBL615272,BAO_0000357,,
241,,,,B,,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",H,,1,,CHEMBL615103,BAO_0000357,,
242,,,,B,,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",H,,1,,CHEMBL615104,BAO_0000357,,
243,,,,B,,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",H,,1,,CHEMBL615105,BAO_0000357,,
244,,,,B,,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",H,,1,,CHEMBL872866,BAO_0000357,,
245,,,,B,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",H,,1,,CHEMBL615106,BAO_0000357,,
246,,,,B,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",H,,1,,CHEMBL615107,BAO_0000019,,
247,,,,B,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",H,,1,,CHEMBL615108,BAO_0000357,,
248,,,,B,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",H,,1,,CHEMBL615109,BAO_0000357,,
249,,,,B,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",H,,1,,CHEMBL615110,BAO_0000357,,
250,,,,B,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",H,,1,,CHEMBL840105,BAO_0000019,,
251,,,,B,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",H,,1,,CHEMBL615111,BAO_0000019,,
252,,,,B,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",H,,1,,CHEMBL615112,BAO_0000019,,
253,,,,B,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",H,,1,,CHEMBL615113,BAO_0000019,,
254,,,,B,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",H,,1,,CHEMBL615114,BAO_0000019,,
255,,,,B,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",H,,1,,CHEMBL615115,BAO_0000357,,
256,,,,B,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",H,,1,,CHEMBL615116,BAO_0000019,,
257,,,,B,,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",H,,1,,CHEMBL615698,BAO_0000357,,
258,,,,B,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",U,,1,,CHEMBL615699,BAO_0000019,,
259,,,,B,,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",U,,1,,CHEMBL615700,BAO_0000019,,
260,,,,B,,,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,H,,1,,CHEMBL615701,BAO_0000357,,
261,,,,B,,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,U,,1,,CHEMBL615702,BAO_0000019,,
262,,,,B,,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,U,,1,,CHEMBL615703,BAO_0000019,,
263,,,,B,,,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",U,,1,,CHEMBL615704,BAO_0000019,,
264,,,,F,,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",H,,1,,CHEMBL615705,BAO_0000019,,
265,,,,F,,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",H,,1,,CHEMBL615706,BAO_0000019,,
266,,,Ileum,F,,,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,D,,1,,CHEMBL615707,BAO_0000221,2116.0,
267,,,,F,,,,Stimulatory activity of intragastric pressure was tested in the rat,H,,1,,CHEMBL615708,BAO_0000019,,
268,,,,B,,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,H,,1,,CHEMBL615709,BAO_0000357,,
269,,,,F,,,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),U,,1,,CHEMBL615710,BAO_0000218,,
270,,,,F,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,H,,1,,CHEMBL615711,BAO_0000019,,
271,,,,B,,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,D,,1,,CHEMBL615712,BAO_0000357,,
272,,,,B,,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,D,,1,,CHEMBL836325,BAO_0000357,,
273,,,,F,,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,H,,1,,CHEMBL615713,BAO_0000019,,
274,,,,B,,,,Inhibition constant of high-affinity 5-HT uptake,H,,1,,CHEMBL615714,BAO_0000357,,
275,,,,F,,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,H,,1,,CHEMBL615715,BAO_0000019,,
276,,,,F,,,,Maximum rate was determined for high affinity transport of 5-HT,H,,1,,CHEMBL615716,BAO_0000019,,
277,,,,F,,,,Compound was tested for agonistic activity against 5-HT uptake,H,,1,,CHEMBL615717,BAO_0000019,,
278,,,,B,,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,H,,1,,CHEMBL881818,BAO_0000019,,
279,,,,B,,,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,H,,1,,CHEMBL884540,BAO_0000357,,
280,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,D,,1,,CHEMBL615718,BAO_0000224,,
281,,,,B,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,H,,1,,CHEMBL615719,BAO_0000224,,
282,Membranes,,,B,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,H,,1,,CHEMBL615720,BAO_0000249,,
283,Membranes,,,B,,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,H,,1,,CHEMBL615721,BAO_0000249,,
284,,,,B,,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,,1,,CHEMBL615722,BAO_0000019,,
285,,,,F,,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,H,,1,,CHEMBL615723,BAO_0000019,,
286,,,Hippocampus,B,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,1,,CHEMBL615724,BAO_0000221,10000000.0,
287,,,Hippocampus,B,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,H,,1,,CHEMBL615725,BAO_0000221,10000000.0,
288,,,Hippocampus,B,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,1,,CHEMBL615726,BAO_0000221,10000000.0,
289,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),H,,1,,CHEMBL615727,BAO_0000218,,
290,,,,F,,,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,D,,1,,CHEMBL615728,BAO_0000019,,
291,,,,B,CHO,449.0,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,,1,,CHEMBL857971,BAO_0000219,,
292,,,,B,,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL615729,BAO_0000357,,
293,,,,F,,,,Efficacy against 5-hydroxytryptamine 2A receptor,D,,1,,CHEMBL615730,BAO_0000019,,
294,,,,F,,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,H,,1,,CHEMBL615731,BAO_0000019,,
295,,,,F,,,,Relative potency towards 5-HT2A receptor of rat tail artery,H,,1,,CHEMBL615732,BAO_0000019,,
296,,,,F,,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,H,,1,,CHEMBL615733,BAO_0000019,,
297,,,,F,,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,H,,1,,CHEMBL615734,BAO_0000019,,
298,,,,F,,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,H,,1,,CHEMBL615735,BAO_0000019,,
299,,,,F,,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,H,,1,,CHEMBL615736,BAO_0000019,,
300,,,Ileum,F,,,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,D,,1,,CHEMBL615737,BAO_0000221,2116.0,
301,,,Ileum,F,,,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),D,,1,,CHEMBL615738,BAO_0000221,2116.0,
302,,,Ileum,F,,,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,D,,1,,CHEMBL615739,BAO_0000221,2116.0,
303,,,,B,,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,H,,1,,CHEMBL615278,BAO_0000357,,
304,,,,F,,,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,D,,1,,CHEMBL615279,BAO_0000019,,
305,,,,B,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,H,,1,,CHEMBL615280,BAO_0000357,,
306,,,,B,,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,U,,1,,CHEMBL615281,BAO_0000019,,
307,,,,F,,,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,U,,1,,CHEMBL615282,BAO_0000019,,
308,,,,F,,,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,U,,1,,CHEMBL615283,BAO_0000019,,
309,,,,B,HL-60,649.0,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,N,,1,,CHEMBL615284,BAO_0000219,,
310,,,,B,,,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,U,,1,,CHEMBL615285,BAO_0000019,,
311,,,,B,,,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,U,,1,,CHEMBL615286,BAO_0000019,,
312,,,,B,Oocytes,,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,D,,1,,CHEMBL615287,BAO_0000219,,
313,,,,F,,,,Chymotryptic inhibitory activity against 26S proteasome,S,,1,,CHEMBL615288,BAO_0000220,,
314,,,,B,,,,Inhibitory activity against 26S proteasome degradation of IkB,S,,1,,CHEMBL615289,BAO_0000220,,
315,,,,F,A2780,478.0,,In vitro inhibition of 2780/DOX ovarian cancer cell line,N,,1,,CHEMBL615290,BAO_0000219,,
316,,,,F,A2780,478.0,,In vitro inhibition of 2780/S ovarian cancer cell line,N,,1,,CHEMBL884522,BAO_0000219,,
317,,,,F,,,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,U,,1,,CHEMBL615291,BAO_0000019,,
318,,,,B,,,,Association constant for binding to AATT 28-mer AATT hairpin,M,,1,,CHEMBL615292,BAO_0000225,,
319,,,,B,,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,M,,1,,CHEMBL615293,BAO_0000225,,
320,,,,B,,,,Reaction Rate Parameter for 28-mer AATT hairpin,M,,1,,CHEMBL615294,BAO_0000225,,
321,,,,B,,,,Reaction Rate Parameter for 28-mer AATT hairpin,M,,1,,CHEMBL615295,BAO_0000225,,
322,,,,F,,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),U,,1,,CHEMBL825021,BAO_0000019,,
323,,,,F,,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),U,,1,,CHEMBL615296,BAO_0000019,,
324,,,,F,,,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,U,,1,,CHEMBL615297,BAO_0000019,,
325,,,,F,,,,Cytotoxicity against cell line 2SC/20 determined by MTT test,U,,1,,CHEMBL615298,BAO_0000019,,
326,,,,F,,,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,U,,1,,CHEMBL615299,BAO_0000019,,
327,,,,F,,,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,U,,1,,CHEMBL615300,BAO_0000019,,
328,,,,B,,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,H,,1,,CHEMBL615301,BAO_0000357,,
329,,,,B,,,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,D,,1,,CHEMBL615302,BAO_0000357,,
330,,,,B,,,,Selectivity ratio of ID50 in liver and heart,U,,1,,CHEMBL615303,BAO_0000019,,
331,,,,B,,,,"Selectivity, ratio of relative ID50 in liver and heart",H,,1,,CHEMBL615304,BAO_0000019,,
332,,,,B,,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,H,,1,,CHEMBL615305,BAO_0000019,,
333,,,,B,,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,,1,,CHEMBL615306,BAO_0000218,,
334,,,,B,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,,1,,CHEMBL615307,BAO_0000218,,
335,,In vivo,,B,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,,1,,CHEMBL615308,BAO_0000218,,
336,,In vivo,,F,,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,,1,,CHEMBL615309,BAO_0000218,,
337,,,,B,,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",U,,1,,CHEMBL615310,BAO_0000019,,
338,,,,B,,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,H,,1,,CHEMBL615311,BAO_0000019,,
339,,,,B,,,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",U,,1,,CHEMBL615312,BAO_0000019,,
340,,,,B,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,H,,1,,CHEMBL615313,BAO_0000019,,
341,,,,F,,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,H,,1,,CHEMBL615314,BAO_0000019,,
342,,,,B,,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",H,,1,,CHEMBL615315,BAO_0000019,,
343,,,,B,,,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",U,,1,,CHEMBL615316,BAO_0000218,,
344,,In vivo,,B,,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,H,,1,,CHEMBL615317,BAO_0000218,,
345,,,,B,,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,,1,,CHEMBL615318,BAO_0000218,,
346,,,,B,,,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",U,,1,,CHEMBL615319,BAO_0000218,,
347,,,,B,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",H,,1,,CHEMBL615320,BAO_0000019,,
348,,,,F,,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",H,,1,,CHEMBL615321,BAO_0000019,,
349,,,,B,,,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",U,,1,,CHEMBL615322,BAO_0000019,,
350,,,,B,,,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,H,,1,,CHEMBL615323,BAO_0000357,,
351,,,,B,,,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,H,,1,,CHEMBL615407,BAO_0000357,,
352,,,,B,,,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,H,,1,,CHEMBL857267,BAO_0000357,,
353,,,,B,,,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,H,,1,,CHEMBL615408,BAO_0000357,,
354,,,,B,,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,H,,1,,CHEMBL615409,BAO_0000357,,
355,,,,B,,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,H,,1,,CHEMBL615410,BAO_0000357,,
356,,,,B,,,,Inhibition constant against 3-dehydroquinate synthase,H,,1,,CHEMBL615411,BAO_0000357,,
357,,,,B,,,,Association rate constant against 3-dehydroquinate synthase,H,,1,,CHEMBL615412,BAO_0000357,,
358,,,,B,,,,Rate constant against 3-dehydroquinate synthase,H,,1,,CHEMBL615413,BAO_0000357,,
359,,,,B,,,,Inhibitory activity against fuc-TVII,U,,1,,CHEMBL615414,BAO_0000019,,
360,Microsomes,,Liver,B,,,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,,1,,CHEMBL615415,BAO_0000251,2107.0,
361,Microsomes,,Liver,B,,,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,,1,,CHEMBL615416,BAO_0000251,2107.0,
362,Microsomes,,Liver,B,,,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,,1,,CHEMBL615417,BAO_0000251,2107.0,
363,Microsomes,,Liver,B,,,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,,1,,CHEMBL615418,BAO_0000251,2107.0,
364,Microsomes,,Liver,B,,,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,,1,,CHEMBL615419,BAO_0000251,2107.0,
365,Microsomes,,Liver,B,,,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,D,,1,,CHEMBL615420,BAO_0000251,2107.0,
366,Microsomes,,Liver,B,,,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,D,,1,,CHEMBL615421,BAO_0000251,2107.0,
367,Microsomes,,Liver,B,,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,D,,1,,CHEMBL615422,BAO_0000251,2107.0,
368,Microsomes,,Liver,B,,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,D,,1,,CHEMBL615423,BAO_0000251,2107.0,
369,Microsomes,,Liver,B,,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,D,,1,,CHEMBL872868,BAO_0000251,2107.0,
370,Microsomes,,Liver,B,,,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,D,,1,,CHEMBL615424,BAO_0000251,2107.0,
371,,,,B,,,,Inhibitory activity against 3-phosphoglycerate kinase.,H,,1,,CHEMBL825022,BAO_0000224,,
372,,,,B,,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,H,,1,,CHEMBL615425,BAO_0000224,,
373,,,,B,,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",H,,1,,CHEMBL615426,BAO_0000224,,
374,,,,B,,,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,D,,1,,CHEMBL615427,BAO_0000357,,
375,,,,F,3677 melanoma cell line,844.0,,Cytotoxicity on 3677 melanoma cells,N,,1,,CHEMBL615428,BAO_0000219,,
376,,,,F,3677 melanoma cell line,844.0,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,N,,1,,CHEMBL615429,BAO_0000219,,
377,,,,F,MC-38,700.0,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,N,,1,,CHEMBL615430,BAO_0000219,,
378,,,,F,,,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,U,,1,,CHEMBL615431,BAO_0000019,,
379,,,,F,B16,798.0,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,U,,1,,CHEMBL615432,BAO_0000218,,
380,,,,F,B16,798.0,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,U,,1,,CHEMBL615433,BAO_0000218,,
381,,,,F,,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,D,,1,,CHEMBL615434,BAO_0000019,,
382,,,,F,,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,N,,1,,CHEMBL615435,BAO_0000218,,
383,,,,F,,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,N,,1,,CHEMBL615436,BAO_0000218,,
384,,,,F,,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,N,,1,,CHEMBL615437,BAO_0000218,,
385,,,,F,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,D,,1,,CHEMBL615438,BAO_0000019,,
386,,,,F,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,D,,1,,CHEMBL615439,BAO_0000019,,
387,,,,F,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,D,,1,,CHEMBL615440,BAO_0000019,,
388,,,,F,,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,D,,1,,CHEMBL615441,BAO_0000019,,
389,,,,F,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,N,,1,,CHEMBL615641,BAO_0000218,,
390,,,,F,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,N,,1,,CHEMBL872065,BAO_0000218,,
391,,,,F,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,N,,1,,CHEMBL825023,BAO_0000218,,
392,,,,F,,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,N,,1,,CHEMBL615642,BAO_0000218,,
393,,,,B,,,,Inhibition of human rhinovirus 3C protease,H,,1,,CHEMBL615643,BAO_0000357,,
394,,,,B,,,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,U,,1,,CHEMBL615644,BAO_0000019,,
395,,,,F,3EM 37,833.0,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),N,,1,,CHEMBL615645,BAO_0000218,,
396,,,,F,3EM 37,833.0,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),N,,1,,CHEMBL615646,BAO_0000218,,
397,,,,F,3EM 37,833.0,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),N,,1,,CHEMBL615647,BAO_0000218,,
398,,,,F,3EM 37,833.0,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),N,,1,,CHEMBL615648,BAO_0000218,,
399,,,,F,3EM 37,833.0,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,N,,1,,CHEMBL615649,BAO_0000218,,
400,,,,F,3EM 37,833.0,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,N,,1,,CHEMBL615650,BAO_0000218,,
401,,,,F,3LL cell line,847.0,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,N,,1,,CHEMBL615651,BAO_0000218,,
402,,,,F,3LL cell line,847.0,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,N,,1,,CHEMBL615652,BAO_0000218,,
403,,,,F,3LL cell line,847.0,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,N,,1,,CHEMBL615653,BAO_0000218,,
404,,,,F,3LL cell line,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,N,,1,,CHEMBL615654,BAO_0000219,,
405,,,,F,3LL cell line,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,N,,1,,CHEMBL615655,BAO_0000219,,
406,,,,F,3LL cell line,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,N,,1,,CHEMBL825024,BAO_0000219,,
407,,,,F,3LL cell line,847.0,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,N,,1,,CHEMBL615656,BAO_0000219,,
408,,,,F,3LL cell line,847.0,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,N,,1,,CHEMBL615657,BAO_0000219,,
409,,,,F,3LL cell line,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,N,,1,,CHEMBL615658,BAO_0000219,,
410,,,,F,3LL cell line,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,N,,1,,CHEMBL615659,BAO_0000219,,
411,,,,F,3LL cell line,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,N,,1,,CHEMBL615660,BAO_0000219,,
412,,,,F,3LL cell line,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,N,,1,,CHEMBL615661,BAO_0000219,,
413,,,,F,3LL cell line,847.0,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,N,,1,,CHEMBL615662,BAO_0000219,,
414,,,,F,3LL cell line,847.0,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,N,,1,,CHEMBL615663,BAO_0000219,,
415,,,,F,3LL cell line,847.0,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,N,,1,,CHEMBL615664,BAO_0000219,,
416,,,,F,3LL cell line,847.0,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,N,,1,,CHEMBL615665,BAO_0000219,,
417,,,,F,3LL cell line,847.0,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,N,,1,,CHEMBL615666,BAO_0000219,,
418,,,,F,3LL cell line,847.0,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,N,,1,,CHEMBL615667,BAO_0000219,,
419,,,,F,3LL cell line,847.0,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,N,,1,,CHEMBL615668,BAO_0000219,,
420,,,,F,3LL cell line,847.0,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,N,,1,,CHEMBL615669,BAO_0000219,,
421,,,,F,3LL cell line,847.0,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,N,,1,,CHEMBL615670,BAO_0000219,,
422,,,,F,3LL cell line,847.0,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,N,,1,,CHEMBL836739,BAO_0000219,,
423,,,,F,3LL cell line,847.0,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,N,,1,,CHEMBL615671,BAO_0000219,,
424,,,,F,3LL cell line,847.0,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,N,,1,,CHEMBL615672,BAO_0000219,,
425,,,,F,3LL cell line,847.0,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,N,,1,,CHEMBL615791,BAO_0000219,,
426,,,,F,3LL cell line,847.0,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,N,,1,,CHEMBL615792,BAO_0000219,,
427,,,,F,3LL cell line,847.0,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,N,,1,,CHEMBL615793,BAO_0000219,,
428,,,,F,3LL cell line,847.0,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,N,,1,,CHEMBL615794,BAO_0000219,,
429,,,,F,3LL cell line,847.0,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,N,,1,,CHEMBL615795,BAO_0000219,,
430,,,,F,3LLD122,971.0,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,N,,1,,CHEMBL615590,BAO_0000219,,
431,,,,F,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,U,,1,,CHEMBL615591,BAO_0000218,,
432,,,,F,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,U,,1,,CHEMBL615592,BAO_0000218,,
433,,,,F,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,U,,1,,CHEMBL615593,BAO_0000218,,
434,,,,F,,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,U,,1,,CHEMBL615594,BAO_0000218,,
435,,,,F,NIH3T3,723.0,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,N,,1,,CHEMBL615595,BAO_0000219,,
436,,,,F,NIH3T3,723.0,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,N,,1,,CHEMBL615596,BAO_0000219,,
437,,,,F,NIH3T3,723.0,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,H,,1,,CHEMBL615597,BAO_0000219,,
438,,,,F,NIH3T3,723.0,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,N,,1,,CHEMBL615598,BAO_0000219,,
439,,,,F,NIH3T3,723.0,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,N,,1,,CHEMBL615599,BAO_0000219,,
440,,,,F,NIH3T3,723.0,,Effective dose against murine 3T3 fibroblasts cells,N,,1,,CHEMBL615600,BAO_0000219,,
441,,,,F,NIH3T3,723.0,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,N,,1,,CHEMBL615601,BAO_0000219,,
442,,,,F,NIH3T3,723.0,,Cytotoxic effect on 3T3 cells,N,,1,,CHEMBL615602,BAO_0000219,,
443,,,,F,NIH3T3,723.0,,Cytotoxic effect on 3T3 cells,N,,1,,CHEMBL615603,BAO_0000219,,
444,,,,F,NIH3T3,723.0,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,N,,1,,CHEMBL615604,BAO_0000219,,
445,,,,F,NIH3T3,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,N,,1,,CHEMBL615605,BAO_0000219,,
446,,,,F,NIH3T3,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,N,,1,,CHEMBL615606,BAO_0000219,,
447,,,,F,NIH3T3,723.0,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,N,,1,,CHEMBL884526,BAO_0000219,,
448,,,,F,NIH3T3,723.0,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,N,,1,,CHEMBL615607,BAO_0000219,,
449,,,,F,NIH3T3,723.0,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,N,,1,,CHEMBL615608,BAO_0000219,,
450,,,,F,NIH3T3,723.0,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,N,,1,,CHEMBL615609,BAO_0000219,,
451,,,,F,NIH3T3,723.0,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,N,,1,,CHEMBL615682,BAO_0000219,,
452,,,,F,NIH3T3,723.0,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,N,,1,,CHEMBL615683,BAO_0000219,,
453,,,,F,NIH3T3,723.0,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,N,,1,,CHEMBL615684,BAO_0000218,,
454,,,,F,,,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,D,,1,,CHEMBL615685,BAO_0000219,,
455,,,,F,NIH3T3,723.0,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,N,,1,,CHEMBL615686,BAO_0000219,,
456,,,,F,NIH3T3,723.0,,Inhibitory activity against 3T3 cell line,N,,1,,CHEMBL615687,BAO_0000219,,
457,,,,F,NIH3T3,723.0,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,N,,1,,CHEMBL884523,BAO_0000219,,
458,,,,F,,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,H,,1,,CHEMBL615688,BAO_0000019,,
459,,,,F,NIH3T3,723.0,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,N,,1,,CHEMBL615689,BAO_0000219,,
460,,,,F,NIH3T3,723.0,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,N,,1,,CHEMBL615690,BAO_0000219,,
461,,,,F,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,H,,1,,CHEMBL615691,BAO_0000019,,
462,,,,F,,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,H,,1,,CHEMBL615692,BAO_0000019,,
463,,,,F,NIH3T3,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,N,,1,,CHEMBL615693,BAO_0000219,,
464,,,,F,NIH3T3,723.0,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,N,,1,,CHEMBL615324,BAO_0000219,,
465,,,,F,NIH3T3,723.0,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,D,,1,,CHEMBL615325,BAO_0000219,,
466,,,,F,NIH3T3,723.0,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),D,,1,,CHEMBL615490,BAO_0000219,,
467,,,,F,NIH3T3,723.0,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,D,,1,,CHEMBL615491,BAO_0000219,,
468,,,,F,NIH3T3,723.0,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),D,,1,,CHEMBL615492,BAO_0000219,,
469,,,,F,NIH3T3,723.0,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,N,,1,,CHEMBL615493,BAO_0000219,,
470,,,,F,NIH3T3,723.0,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,N,,1,,CHEMBL615494,BAO_0000219,,
471,,,,F,NIH3T3,723.0,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,N,,1,,CHEMBL615495,BAO_0000219,,
472,,,,F,NIH3T3,723.0,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,N,,1,,CHEMBL615496,BAO_0000219,,
473,,,,F,NIH3T3,723.0,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,N,,1,,CHEMBL615497,BAO_0000219,,
474,,,,F,NIH3T3,723.0,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,N,,1,,CHEMBL615498,BAO_0000219,,
475,,,,A,NIH3T3,723.0,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,N,,1,,CHEMBL615499,BAO_0000219,,
476,,,,F,NIH3T3,723.0,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,N,,1,,CHEMBL835522,BAO_0000219,,
477,,,,F,NIH3T3,723.0,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,N,,1,,CHEMBL615500,BAO_0000219,,
478,,,,F,NIH3T3,723.0,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,,1,,CHEMBL615501,BAO_0000219,,
479,,,,F,NIH3T3,723.0,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,,1,,CHEMBL615502,BAO_0000219,,
480,,,,F,NIH3T3,723.0,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,,1,,CHEMBL615503,BAO_0000219,,
481,,,,F,NIH3T3,723.0,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,,1,,CHEMBL615504,BAO_0000219,,
482,,,,F,NIH3T3,723.0,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,,1,,CHEMBL615505,BAO_0000219,,
483,,,,F,NIH3T3,723.0,,Inhibition of swiss 3T3 mouse fibroblast proliferation,N,,1,,CHEMBL615506,BAO_0000219,,
484,,,,F,NIH3T3,723.0,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,N,,1,,CHEMBL615507,BAO_0000219,,
485,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,N,,1,,CHEMBL615508,BAO_0000218,,
486,,,,F,3T3-L1,620.0,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,N,,1,,CHEMBL615509,BAO_0000219,,
487,,,,F,3T3-L1,620.0,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,N,,1,,CHEMBL615510,BAO_0000219,,
488,,,,F,3T3-L1,620.0,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,N,,1,,CHEMBL615511,BAO_0000219,,
489,,,,F,3T3-L1,620.0,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,N,,1,,CHEMBL615512,BAO_0000219,,
490,,,,F,3T3-L1,620.0,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",N,,1,,CHEMBL615513,BAO_0000218,,
491,,,,F,3T3-L1,620.0,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",N,,1,,CHEMBL615514,BAO_0000218,,
492,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,N,,1,,CHEMBL615515,BAO_0000219,,
493,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,N,,1,,CHEMBL615516,BAO_0000219,,
494,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,N,,1,,CHEMBL615517,BAO_0000219,,
495,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,N,,1,,CHEMBL615518,BAO_0000219,,
496,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,N,,1,,CHEMBL615519,BAO_0000219,,
497,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,N,,1,,CHEMBL615520,BAO_0000218,,
498,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,N,,1,,CHEMBL615521,BAO_0000218,,
499,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,N,,1,,CHEMBL615522,BAO_0000218,,
500,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,N,,1,,CHEMBL615523,BAO_0000218,,
501,,,,F,3T3-L1,620.0,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,N,,1,,CHEMBL615524,BAO_0000218,,
502,,,,F,3T3-L1,620.0,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,N,,1,,CHEMBL615525,BAO_0000218,,
503,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,N,,1,,CHEMBL615526,BAO_0000218,,
504,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,N,,1,,CHEMBL615527,BAO_0000218,,
505,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,N,,1,,CHEMBL615528,BAO_0000218,,
506,,,,F,3T3-L1,620.0,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,N,,1,,CHEMBL615529,BAO_0000218,,
507,,,,F,3T3-L1,620.0,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,N,,1,,CHEMBL615530,BAO_0000218,,
508,,,,F,3T3-L1,620.0,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,N,,1,,CHEMBL615531,BAO_0000218,,
509,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,N,,1,,CHEMBL615532,BAO_0000219,,
510,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,N,,1,,CHEMBL615533,BAO_0000219,,
511,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,N,,1,,CHEMBL615534,BAO_0000219,,
512,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,N,,1,,CHEMBL615535,BAO_0000218,,
513,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,N,,1,,CHEMBL615536,BAO_0000218,,
514,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,N,,1,,CHEMBL615537,BAO_0000218,,
515,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,N,,1,,CHEMBL615538,BAO_0000218,,
516,,,,F,3T3-L1,620.0,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,N,,1,,CHEMBL836166,BAO_0000218,,
517,,,,F,3T3-L1,620.0,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,H,,1,,CHEMBL615539,BAO_0000219,,
518,,,,F,3T3-L1,620.0,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,N,,1,,CHEMBL615540,BAO_0000219,,
519,,,,F,3T3-L1,620.0,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,H,,1,,CHEMBL615541,BAO_0000219,,
520,,,,F,3T3-L1,620.0,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,N,,1,,CHEMBL615542,BAO_0000219,,
521,,,,F,3T3-L1,620.0,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,N,,1,,CHEMBL615543,BAO_0000219,,
522,,,,F,3T3-L1,620.0,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,N,,1,,CHEMBL615544,BAO_0000219,,
523,,,,F,3T3-L1,620.0,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,N,,1,,CHEMBL615545,BAO_0000219,,
524,,,,F,3T3-L1,620.0,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,N,,1,,CHEMBL615546,BAO_0000219,,
525,,,,F,3T3-L1,620.0,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,N,,1,,CHEMBL615547,BAO_0000219,,
526,,,,F,3T3-L1,620.0,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,N,,1,,CHEMBL615548,BAO_0000219,,
527,,,,F,3T3-L1,620.0,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,N,,1,,CHEMBL615549,BAO_0000219,,
528,,,,F,3T3-L1,620.0,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,N,,1,,CHEMBL615550,BAO_0000219,,
529,,,,F,3Y1 cell line,1118.0,,Inhibitory activity against rat fibroblast (3Y1) cell line,N,,1,,CHEMBL615551,BAO_0000219,,
530,,,,F,3Y1 cell line,1118.0,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,N,,1,,CHEMBL615552,BAO_0000219,,
531,,,,F,3Y1 cell line,1118.0,,Cytotoxicity in 3Y1 cells.,N,,1,,CHEMBL615553,BAO_0000219,,
532,,,,F,3Y1 cell line,1118.0,,Cytostatic effect in 3Y1 cells.,N,,1,,CHEMBL615554,BAO_0000219,,
533,,,,F,3Y1 cell line,1118.0,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",N,,1,,CHEMBL615555,BAO_0000219,,
534,,,,F,3Y1 cell line,1118.0,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,N,,1,,CHEMBL615556,BAO_0000219,,
535,,,,B,,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,U,,1,,CHEMBL615557,BAO_0000019,,
536,,,,B,,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,U,,1,,CHEMBL615558,BAO_0000019,,
537,,,,B,,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,U,,1,,CHEMBL872066,BAO_0000019,,
538,,,,B,,,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,D,,1,,CHEMBL615559,BAO_0000019,,
539,,,,B,,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,H,,1,,CHEMBL615560,BAO_0000019,,
540,,,,B,,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,H,,1,,CHEMBL615561,BAO_0000019,,
541,,,,B,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,H,,1,,CHEMBL857062,BAO_0000019,,
542,,,,B,,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),H,,1,,CHEMBL615562,BAO_0000019,,
543,,,,B,,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,H,,1,,CHEMBL615563,BAO_0000019,,
544,,,,B,,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),H,,1,,CHEMBL615564,BAO_0000357,,
545,,,,B,,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,H,,1,,CHEMBL615565,BAO_0000019,,
546,,,,B,,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,H,,1,,CHEMBL615566,BAO_0000019,,
547,,,,B,,,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,D,,1,,CHEMBL615567,BAO_0000019,,
548,,,,B,,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,H,,1,,CHEMBL615568,BAO_0000019,,
549,,,,B,,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),H,,1,,CHEMBL615569,BAO_0000357,,
550,,,,B,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,H,,1,,CHEMBL615570,BAO_0000019,,
551,,,,B,,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),H,,1,,CHEMBL615571,BAO_0000019,,
552,,,,B,,,,Binding affinity against melatonin (MT1) receptor (pC1),H,,1,,CHEMBL615572,BAO_0000224,,
553,,,,B,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,U,,1,,CHEMBL615573,BAO_0000019,,
554,,,,B,,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,U,,1,,CHEMBL615574,BAO_0000019,,
555,,,,B,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,U,,1,,CHEMBL615575,BAO_0000019,,
556,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,H,,1,,CHEMBL615576,BAO_0000357,,
557,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,H,,1,,CHEMBL615577,BAO_0000357,,
558,,,Hippocampus,B,,,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,H,,1,,CHEMBL615578,BAO_0000221,10000000.0,
559,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615579,BAO_0000357,,
560,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615580,BAO_0000357,,
561,,,,B,,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,H,,1,,CHEMBL615581,BAO_0000019,,
562,,,Hippocampus,B,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,,1,,CHEMBL615582,BAO_0000221,10000000.0,
563,,,Hippocampus,B,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,,1,,CHEMBL615583,BAO_0000221,10000000.0,
564,,,Hippocampus,B,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,H,,1,,CHEMBL615584,BAO_0000221,10000000.0,
565,,,Hippocampus,B,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,1,,CHEMBL833691,BAO_0000221,10000000.0,
566,,,Hippocampus,B,,,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,H,,1,,CHEMBL615585,BAO_0000221,10000000.0,
567,,,Hippocampus,B,,,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,H,,1,,CHEMBL615586,BAO_0000221,10000000.0,
568,,,Hippocampus,B,,,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,1,,CHEMBL884524,BAO_0000221,10000000.0,
569,,,Hippocampus,B,,,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,,1,,CHEMBL615587,BAO_0000221,10000000.0,
570,,,Hippocampus,B,,,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",H,,1,,CHEMBL615588,BAO_0000221,10000000.0,
571,Membranes,,,B,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,D,,1,,CHEMBL615589,BAO_0000249,,
572,,,Hippocampus,B,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,H,,1,,CHEMBL615442,BAO_0000221,10000000.0,
573,,,Hippocampus,B,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,H,,1,,CHEMBL615443,BAO_0000221,10000000.0,
574,,,Hippocampus,B,,,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,H,,1,,CHEMBL615444,BAO_0000221,10000000.0,
575,,,Hippocampus,B,,,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,H,,1,,CHEMBL615445,BAO_0000221,10000000.0,
576,,,Hippocampus,B,,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,H,,1,,CHEMBL615446,BAO_0000221,10000000.0,
577,,,,B,CHO,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,H,,1,,CHEMBL615447,BAO_0000219,,
578,,,Hippocampus,B,,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,,1,,CHEMBL615448,BAO_0000221,10000000.0,
579,,,Hippocampus,B,,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,,1,,CHEMBL615449,BAO_0000221,10000000.0,
580,,,,B,CHO,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,,1,,CHEMBL615450,BAO_0000219,,
581,,,Hippocampus,B,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",H,,1,,CHEMBL615451,BAO_0000221,10000000.0,
582,,,,B,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,H,,1,,CHEMBL615452,BAO_0000357,,
583,,,Hippocampus,B,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,H,,1,,CHEMBL615453,BAO_0000221,10000000.0,
584,,,Hippocampus,B,,,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,1,,CHEMBL615454,BAO_0000221,10000000.0,
585,,,Hippocampus,B,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,H,,1,,CHEMBL615455,BAO_0000221,10000000.0,
586,,,Hippocampus,B,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,1,,CHEMBL615456,BAO_0000221,10000000.0,
587,,,Hippocampus,B,,,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,H,,1,,CHEMBL615457,BAO_0000221,10000000.0,
588,,,Hippocampus,B,,,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,H,,1,,CHEMBL615458,BAO_0000218,10000000.0,
589,,,Hippocampus,B,,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,1,,CHEMBL615459,BAO_0000221,10000000.0,
590,,,,B,CHO,449.0,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",D,,1,,CHEMBL615460,BAO_0000219,,
591,,,,F,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,H,,1,,CHEMBL615461,BAO_0000019,,
592,,,,F,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,H,,1,,CHEMBL615462,BAO_0000019,,
593,,,Hippocampus,F,,,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,H,,1,,CHEMBL615463,BAO_0000221,10000000.0,
594,,,Ileum,B,,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,H,,1,,CHEMBL615464,BAO_0000221,2116.0,
595,,,Ileum,B,,,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,H,,1,,CHEMBL615465,BAO_0000221,2116.0,
596,,,Ileum,B,,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,H,,1,,CHEMBL615466,BAO_0000221,2116.0,
597,,,Ileum,B,,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,H,,1,,CHEMBL615467,BAO_0000221,2116.0,
598,,,Ileum,B,,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,H,,1,,CHEMBL615468,BAO_0000221,2116.0,
599,,,Ileum,B,,,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,H,,1,,CHEMBL615469,BAO_0000221,2116.0,
600,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615470,BAO_0000357,,
601,,,,B,,,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615471,BAO_0000357,,
602,,,,B,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615472,BAO_0000357,,
603,,,Hippocampus,B,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,H,,1,,CHEMBL883242,BAO_0000221,10000000.0,
604,,,Hippocampus,F,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,H,,1,,CHEMBL615473,BAO_0000221,10000000.0,
605,,,,B,CHO,449.0,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),H,,1,,CHEMBL615474,BAO_0000218,,
606,,,,B,,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615475,BAO_0000357,,
607,,,,F,HeLa,308.0,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,H,,1,,CHEMBL615476,BAO_0000219,,
608,,,,F,HeLa,308.0,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,H,,1,,CHEMBL615477,BAO_0000219,,
609,,,,F,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615478,BAO_0000019,,
610,,,,F,CHO,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615160,BAO_0000219,,
611,,,,F,CHO,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615161,BAO_0000219,,
612,,,,F,CHO,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,H,,1,,CHEMBL615162,BAO_0000219,,
613,,,,F,CHO,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,H,,1,,CHEMBL615163,BAO_0000219,,
614,,,,B,CHO,449.0,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,,1,,CHEMBL615164,BAO_0000219,,
615,,,,B,CHO,449.0,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,,1,,CHEMBL615165,BAO_0000219,,
616,,,,B,CHO,449.0,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,H,,1,,CHEMBL615166,BAO_0000219,,
617,,,,F,,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,H,,1,,CHEMBL615167,BAO_0000219,,
618,,,,B,HeLa,308.0,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,D,,1,,CHEMBL615168,BAO_0000219,,
619,,,,B,HeLa,308.0,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,D,,1,,CHEMBL615169,BAO_0000219,,
620,,,,B,CHO,449.0,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL615170,BAO_0000219,,
621,,,,B,CHO,449.0,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,D,,1,,CHEMBL615171,BAO_0000219,,
622,,,,F,,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615694,BAO_0000019,,
623,,,,F,,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615695,BAO_0000019,,
624,,,,F,,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",H,,1,,CHEMBL615696,BAO_0000019,,
625,,,,F,CHO,449.0,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,H,,1,,CHEMBL615697,BAO_0000219,,
626,,,,F,CHO,449.0,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),D,,1,,CHEMBL859410,BAO_0000219,,
627,,,,F,CHO,449.0,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),H,,1,,CHEMBL615841,BAO_0000219,,
628,,,,F,CHO,449.0,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),D,,1,,CHEMBL615842,BAO_0000219,,
629,,,,F,CHO,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,H,,1,,CHEMBL835003,BAO_0000219,,
630,,,,F,CHO,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),H,,1,,CHEMBL615843,BAO_0000219,,
631,,,,F,CHO,449.0,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),D,,1,,CHEMBL615979,BAO_0000219,,
632,,,,F,CHO,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),H,,1,,CHEMBL615980,BAO_0000219,,
633,,,,F,CHO,449.0,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),D,,1,,CHEMBL615981,BAO_0000219,,
634,,,,F,,,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,D,,1,,CHEMBL615982,BAO_0000019,,
635,,,,F,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",D,,1,,CHEMBL615983,BAO_0000019,,
636,,,,F,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",D,,1,,CHEMBL615984,BAO_0000019,,
637,,,,F,,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",D,,1,,CHEMBL615985,BAO_0000019,,
638,,,,F,CHO,449.0,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,H,,1,,CHEMBL615986,BAO_0000219,,
639,,,,F,CHO,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,H,,1,,CHEMBL615987,BAO_0000219,,
640,,,,F,CHO,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,H,,1,,CHEMBL615988,BAO_0000219,,
641,,,,F,CHO,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,H,,1,,CHEMBL615989,BAO_0000219,,
642,,,,F,CHO,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,H,,1,,CHEMBL615990,BAO_0000219,,
643,,,,F,CHO,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,H,,1,,CHEMBL615991,BAO_0000219,,
644,,,,F,CHO,449.0,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,H,,1,,CHEMBL615992,BAO_0000219,,
645,,,,F,CHO,449.0,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,H,,1,,CHEMBL615993,BAO_0000219,,
646,,,,F,CHO,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,H,,1,,CHEMBL615994,BAO_0000219,,
647,,,,F,CHO,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,H,,1,,CHEMBL615995,BAO_0000219,,
648,,,,F,CHO,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,H,,1,,CHEMBL615996,BAO_0000219,,
649,,,,F,CHO,449.0,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,H,,1,,CHEMBL615997,BAO_0000219,,
650,,,,F,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,,1,,CHEMBL615998,BAO_0000019,,
651,,,,F,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,,1,,CHEMBL615999,BAO_0000019,,
652,,,,F,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,H,,1,,CHEMBL616000,BAO_0000019,,
653,,,,F,HEK293,722.0,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,,1,,CHEMBL616001,BAO_0000219,,
654,,,,F,,,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",D,,1,,CHEMBL616002,BAO_0000019,,
655,,,,F,,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",H,,1,,CHEMBL616003,BAO_0000019,,
656,,,,F,,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616004,BAO_0000019,,
657,,,,F,,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,D,,1,,CHEMBL616005,BAO_0000019,,
658,,,,F,,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",H,,1,,CHEMBL616006,BAO_0000019,,
659,,,,F,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",H,,1,,CHEMBL616007,BAO_0000019,,
660,,,,F,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",H,,1,,CHEMBL616008,BAO_0000019,,
661,,,,F,,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",H,,1,,CHEMBL616009,BAO_0000019,,
662,,,,F,,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",H,,1,,CHEMBL616010,BAO_0000019,,
663,,,,F,,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",D,,1,,CHEMBL616011,BAO_0000019,,
664,,,,F,,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",D,,1,,CHEMBL615740,BAO_0000019,,
665,,,,F,,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",H,,1,,CHEMBL615741,BAO_0000019,,
666,,,,F,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",H,,1,,CHEMBL615742,BAO_0000019,,
667,,,,F,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",H,,1,,CHEMBL615743,BAO_0000019,,
668,,,,F,CHO,449.0,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,H,,1,,CHEMBL615744,BAO_0000219,,
669,,,,F,CHO,449.0,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,H,,1,,CHEMBL615745,BAO_0000219,,
670,,,,B,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,H,,1,,CHEMBL615746,BAO_0000357,,
671,,,,B,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,H,,1,,CHEMBL615747,BAO_0000357,,
672,,,,F,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,,1,,CHEMBL615748,BAO_0000019,,
673,,,,F,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",H,,1,,CHEMBL615749,BAO_0000019,,
674,,,,F,,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,H,,1,,CHEMBL615750,BAO_0000019,,
675,,,,F,,,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616259,BAO_0000019,,
676,,,,F,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,,1,,CHEMBL616260,BAO_0000019,,
677,,,,F,,,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,D,,1,,CHEMBL616261,BAO_0000019,,
678,,,,F,,,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",D,,1,,CHEMBL616262,BAO_0000019,,
679,,,,F,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",D,,1,,CHEMBL616263,BAO_0000019,,
680,,,,F,,,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,D,,1,,CHEMBL616264,BAO_0000019,,
681,,,,F,,,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,D,,1,,CHEMBL616265,BAO_0000019,,
682,,,,F,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",D,,1,,CHEMBL616266,BAO_0000019,,
683,,,,F,,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",D,,1,,CHEMBL616267,BAO_0000019,,
684,,,,F,,,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,D,,1,,CHEMBL616268,BAO_0000019,,
685,,,,B,,,,Inhibition of human 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616269,BAO_0000357,,
686,,,,B,CHO,449.0,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,,1,,CHEMBL884528,BAO_0000219,,
687,,,,B,HEK293,722.0,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,D,,1,,CHEMBL616270,BAO_0000219,,
688,,,,B,CHO,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,H,,1,,CHEMBL616271,BAO_0000219,,
689,,,,F,CHO,449.0,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616272,BAO_0000219,,
690,,,,B,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,H,,1,,CHEMBL616273,BAO_0000357,,
691,,,,B,,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616274,BAO_0000357,,
692,,,,B,CHO,449.0,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,H,,1,,CHEMBL616275,BAO_0000219,,
693,,,,B,CHO,449.0,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,,1,,CHEMBL616276,BAO_0000219,,
694,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,U,,1,,CHEMBL616277,BAO_0000218,,
695,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,U,,1,,CHEMBL616278,BAO_0000218,,
696,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,U,,1,,CHEMBL616279,BAO_0000218,,
697,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,U,,1,,CHEMBL616280,BAO_0000218,,
698,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,U,,1,,CHEMBL616281,BAO_0000218,,
699,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,U,,1,,CHEMBL616282,BAO_0000218,,
700,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,U,,1,,CHEMBL616283,BAO_0000218,,
701,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,U,,1,,CHEMBL616284,BAO_0000218,,
702,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,U,,1,,CHEMBL616285,BAO_0000218,,
703,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,U,,1,,CHEMBL616286,BAO_0000218,,
704,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,U,,1,,CHEMBL616287,BAO_0000218,,
705,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,U,,1,,CHEMBL616288,BAO_0000218,,
706,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,U,,1,,CHEMBL616289,BAO_0000218,,
707,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,U,,1,,CHEMBL615610,BAO_0000218,,
708,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,U,,1,,CHEMBL615611,BAO_0000218,,
709,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,U,,1,,CHEMBL615612,BAO_0000218,,
710,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,U,,1,,CHEMBL615613,BAO_0000218,,
711,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,U,,1,,CHEMBL615614,BAO_0000218,,
712,,In vivo,,F,,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,U,,1,,CHEMBL615615,BAO_0000218,,
713,,,,B,,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,H,,1,,CHEMBL615616,BAO_0000019,,
714,,,Hypothalamus,B,,,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,H,,1,,CHEMBL615617,BAO_0000249,1898.0,
715,,,,B,,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,H,,1,,CHEMBL615618,BAO_0000019,,
716,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,H,,1,,CHEMBL615619,BAO_0000019,,
717,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,H,,1,,CHEMBL615620,BAO_0000019,,
718,,,,B,,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",H,,1,,CHEMBL615621,BAO_0000357,,
719,,,,B,,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",H,,1,,CHEMBL615622,BAO_0000357,,
720,,,,F,,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),H,,1,,CHEMBL615623,BAO_0000019,,
721,,,,F,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,H,,1,,CHEMBL615624,BAO_0000019,,
722,,,,F,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,H,,1,,CHEMBL615625,BAO_0000019,,
723,,,,F,,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,H,,1,,CHEMBL767045,BAO_0000019,,
724,,,,F,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,H,,1,,CHEMBL615626,BAO_0000019,,
725,,,,F,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,H,,1,,CHEMBL615627,BAO_0000019,,
726,,,,B,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,H,,1,,CHEMBL615628,BAO_0000019,,
727,,,,B,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,H,,1,,CHEMBL615629,BAO_0000357,,
728,,,,B,,,,Inhibitory concentration against 5-lipoxygenase from human whole blood,D,,1,,CHEMBL615630,BAO_0000357,,
729,,,,B,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],H,,1,,CHEMBL615631,BAO_0000219,,
730,,,,F,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,H,,1,,CHEMBL615632,BAO_0000218,,
731,,,,B,,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,H,,1,,CHEMBL615633,BAO_0000357,,
732,,,,F,,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,H,,1,,CHEMBL615634,BAO_0000218,,
733,,,,B,,,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,H,,1,,CHEMBL615635,BAO_0000019,,
734,,,,B,,,,In vitro inhibition of rat 5-Lipoxygenase,H,,1,,CHEMBL615636,BAO_0000357,,
735,,,,B,,,,Inhibitory activity against 5-Lipoxygenase,D,,1,,CHEMBL615637,BAO_0000357,,
736,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,H,,1,,CHEMBL615638,BAO_0000219,,
737,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),H,,1,,CHEMBL615639,BAO_0000219,,
738,,,,B,RBL-1,702.0,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,H,,1,,CHEMBL615640,BAO_0000219,,
739,,,,B,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,H,,1,,CHEMBL615796,BAO_0000019,,
740,,,,B,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],H,,1,,CHEMBL615845,BAO_0000219,,
741,,,,B,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,H,,1,,CHEMBL615846,BAO_0000357,,
742,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,H,,1,,CHEMBL615847,BAO_0000219,,
743,,,,B,,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,H,,1,,CHEMBL615848,BAO_0000357,,
744,,,,B,,,,Ratio of IC50 against 5-LO and COX,U,,1,,CHEMBL615849,BAO_0000019,,
745,,,,B,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,H,,1,,CHEMBL615850,BAO_0000357,,
746,,,,B,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,H,,1,,CHEMBL615851,BAO_0000357,,
747,,,,B,,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,H,,1,,CHEMBL615852,BAO_0000219,,
748,,,,F,,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,H,,1,,CHEMBL615853,BAO_0000019,,
749,,,Prostate gland,B,,,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,H,,1,,CHEMBL884527,BAO_0000357,2367.0,
750,,,,B,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,U,,1,,CHEMBL872871,BAO_0000019,,
751,,,,B,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,U,,1,,CHEMBL615854,BAO_0000019,,
752,,,,B,,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,U,,1,,CHEMBL767046,BAO_0000019,,
753,,,,B,,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,H,,1,,CHEMBL615855,BAO_0000357,,
754,,,,F,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,D,,1,,CHEMBL615856,BAO_0000019,,
755,,,,F,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),D,,1,,CHEMBL615857,BAO_0000019,,
756,,,,F,,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),D,,1,,CHEMBL615858,BAO_0000019,,
757,,,Hippocampus,B,,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,H,,1,,CHEMBL615859,BAO_0000221,10000000.0,
758,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,H,,1,,CHEMBL615860,BAO_0000357,,
759,,,,B,,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,U,,1,,CHEMBL615861,BAO_0000019,,
760,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,U,,1,,CHEMBL615862,BAO_0000019,,
761,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,U,,1,,CHEMBL615863,BAO_0000019,,
762,,,,B,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,U,,1,,CHEMBL615864,BAO_0000019,,
763,,,Hippocampus,B,,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,H,,1,,CHEMBL615865,BAO_0000221,10000000.0,
764,,,Hippocampus,B,,,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,H,,1,,CHEMBL615866,BAO_0000221,10000000.0,
765,,,Hippocampus,B,,,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,H,,1,,CHEMBL615867,BAO_0000221,10000000.0,
766,Membranes,,,B,,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,H,,1,,CHEMBL615868,BAO_0000249,,
767,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,D,,1,,CHEMBL615869,BAO_0000249,,
768,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,D,,1,,CHEMBL615870,BAO_0000019,,
769,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,D,,1,,CHEMBL615871,BAO_0000019,,
770,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,H,,1,,CHEMBL615872,BAO_0000224,,
771,,,Hippocampus,B,,,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,H,,1,,CHEMBL833492,BAO_0000221,10000000.0,
772,,,Hippocampus,B,,,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,H,,1,,CHEMBL615873,BAO_0000221,10000000.0,
773,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,H,,1,,CHEMBL615479,BAO_0000224,,
774,,,,B,,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,H,,1,,CHEMBL615480,BAO_0000019,,
775,,,,B,,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,D,,1,,CHEMBL615481,BAO_0000249,,
776,,,,B,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,,1,,CHEMBL872869,BAO_0000019,,
777,,,,B,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,,1,,CHEMBL615482,BAO_0000019,,
778,,,Brain,B,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,H,,1,,CHEMBL615483,BAO_0000221,955.0,
779,,,Brain,B,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,H,,1,,CHEMBL615484,BAO_0000221,955.0,
780,,,,B,,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,H,,1,,CHEMBL615485,BAO_0000019,,
781,,,,B,,,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,D,,1,,CHEMBL615486,BAO_0000224,,
782,,,,B,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,H,,1,,CHEMBL615487,BAO_0000224,,
783,,,,B,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,H,,1,,CHEMBL615488,BAO_0000224,,
784,,,,B,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,H,,1,,CHEMBL615489,BAO_0000224,,
785,,,,B,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,H,,1,,CHEMBL615389,BAO_0000224,,
786,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,H,,1,,CHEMBL615390,BAO_0000019,,
787,,,,B,,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,H,,1,,CHEMBL615391,BAO_0000019,,
788,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,H,,1,,CHEMBL615392,BAO_0000224,,
789,,,,B,,,,Affinity for 5-hydroxytryptamine 1 receptor,U,,1,,CHEMBL615393,BAO_0000019,,
790,,,Brain,B,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,H,,1,,CHEMBL615394,BAO_0000221,955.0,
791,,,Brain,B,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,H,,1,,CHEMBL615395,BAO_0000221,955.0,
792,,,,B,,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,H,,1,,CHEMBL615396,BAO_0000224,,
793,,,Brain,B,,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,H,,1,,CHEMBL615397,BAO_0000221,955.0,
794,,,,B,,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,,1,,CHEMBL615398,BAO_0000019,,
795,,,,B,,,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,U,,1,,CHEMBL615399,BAO_0000019,,
796,,,,B,,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,H,,1,,CHEMBL615400,BAO_0000019,,
797,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,D,,1,,CHEMBL615401,BAO_0000019,,
798,,,,B,,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,U,,1,,CHEMBL615402,BAO_0000019,,
799,,,,B,,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,H,,1,,CHEMBL615403,BAO_0000019,,
800,,,Brain,B,,,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,H,,1,,CHEMBL615404,BAO_0000221,955.0,
801,,,,B,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,H,,1,,CHEMBL615781,BAO_0000019,,
802,,,Brain,B,,,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,H,,1,,CHEMBL615782,BAO_0000220,955.0,
803,,,Brain,B,,,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,H,,1,,CHEMBL615783,BAO_0000221,955.0,
804,,,,B,,,,Compound was tested for binding affinity against 5-HT1 receptor,U,,1,,CHEMBL873481,BAO_0000019,,
805,,,,B,,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,U,,1,,CHEMBL615784,BAO_0000019,,
806,,,,B,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,H,,1,,CHEMBL615785,BAO_0000357,,
807,,,,F,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",H,,1,,CHEMBL615786,BAO_0000249,,
808,,In vivo,,F,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,H,,1,,CHEMBL615787,BAO_0000218,,
809,,In vivo,,F,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,H,,1,,CHEMBL615788,BAO_0000218,,
810,,,,F,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL767044,BAO_0000019,,
811,,In vivo,,F,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,H,,1,,CHEMBL615789,BAO_0000218,,
812,,In vivo,,F,,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,H,,1,,CHEMBL615790,BAO_0000218,,
813,,,,F,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,H,,1,,CHEMBL615813,BAO_0000019,,
814,,,,F,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,H,,1,,CHEMBL615814,BAO_0000219,,
815,,,,F,,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,H,,1,,CHEMBL615815,BAO_0000219,,
816,,,,F,,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,H,,1,,CHEMBL615816,BAO_0000219,,
817,,,,B,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,H,,1,,CHEMBL615817,BAO_0000249,,
818,,,Hippocampus,B,,,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,H,,1,,CHEMBL615818,BAO_0000221,10000000.0,
819,,,Hippocampus,B,,,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,H,,1,,CHEMBL615819,BAO_0000221,10000000.0,
820,Membranes,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,H,,1,,CHEMBL615820,BAO_0000249,,
821,,,Hippocampus,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,D,,1,,CHEMBL615821,BAO_0000221,10000000.0,
822,,,Hippocampus,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,D,,1,,CHEMBL615822,BAO_0000221,10000000.0,
823,,,Hippocampus,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615823,BAO_0000221,10000000.0,
824,,,Hippocampus,B,,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,D,,1,,CHEMBL615824,BAO_0000221,10000000.0,
825,,,Hippocampus,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,D,,1,,CHEMBL615825,BAO_0000221,10000000.0,
826,,,,B,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615826,BAO_0000357,,
827,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615827,BAO_0000249,,
828,,,Hippocampus,B,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615828,BAO_0000249,10000000.0,
829,,,Hippocampus,B,,,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,1,,CHEMBL615829,BAO_0000221,10000000.0,
830,,,Hippocampus,B,,,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615830,BAO_0000221,10000000.0,
831,,,Hippocampus,B,,,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,H,,1,,CHEMBL615831,BAO_0000221,10000000.0,
832,,,,B,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615832,BAO_0000357,,
833,,,,B,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,H,,1,,CHEMBL615833,BAO_0000019,,
834,,,Hippocampus,B,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,H,,1,,CHEMBL615834,BAO_0000221,10000000.0,
835,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,H,,1,,CHEMBL615835,BAO_0000249,,
836,,,Hippocampus,B,,,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,H,,1,,CHEMBL615836,BAO_0000249,10000000.0,
837,,,,B,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,D,,1,,CHEMBL615837,BAO_0000019,,
838,,,,B,,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,D,,1,,CHEMBL615838,BAO_0000019,,
839,,,,B,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",H,,1,,CHEMBL615839,BAO_0000249,,
840,,,,B,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,H,,1,,CHEMBL884525,BAO_0000019,,
841,,,,B,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,H,,1,,CHEMBL615840,BAO_0000249,,
842,,,Hippocampus,B,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,1,,CHEMBL615405,BAO_0000221,10000000.0,
843,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,H,,1,,CHEMBL615406,BAO_0000019,,
844,,,Hippocampus,B,,,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,H,,1,,CHEMBL615900,BAO_0000221,10000000.0,
845,,,Hippocampus,B,,,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,H,,1,,CHEMBL615901,BAO_0000221,10000000.0,
846,,,,B,,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,H,,1,,CHEMBL615902,BAO_0000357,,
847,,,Hippocampus,B,,,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,H,,1,,CHEMBL615903,BAO_0000221,10000000.0,
848,,,,B,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,H,,1,,CHEMBL615904,BAO_0000357,,
849,,,,B,,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,H,,1,,CHEMBL615905,BAO_0000357,,
850,,,,B,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,H,,1,,CHEMBL615906,BAO_0000019,,
851,,,,F,,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,H,,1,,CHEMBL615907,BAO_0000019,,
852,,,,B,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,H,,1,,CHEMBL615908,BAO_0000019,,
853,,,Hippocampus,B,,,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,H,,1,,CHEMBL615909,BAO_0000221,10000000.0,
854,,,,B,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",H,,1,,CHEMBL615910,BAO_0000019,,
855,,,,B,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",H,,1,,CHEMBL615911,BAO_0000019,,
856,,,,B,,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",H,,1,,CHEMBL615912,BAO_0000019,,
857,,,,B,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615913,BAO_0000019,,
858,,,,B,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,H,,1,,CHEMBL615914,BAO_0000357,,
859,,,Hippocampus,B,,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,H,,1,,CHEMBL615915,BAO_0000221,10000000.0,
860,,,,B,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,H,,1,,CHEMBL615916,BAO_0000357,,
861,,,,B,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,H,,1,,CHEMBL615917,BAO_0000357,,
862,,,,B,,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615918,BAO_0000357,,
863,,,Hippocampus,B,,,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,H,,1,,CHEMBL615919,BAO_0000249,10000000.0,
864,,,Hippocampus,B,,,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,D,,1,,CHEMBL615920,BAO_0000221,10000000.0,
865,,,,B,,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615921,BAO_0000357,,
866,,,,B,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),H,,1,,CHEMBL615922,BAO_0000357,,
867,,,,F,,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",D,,1,,CHEMBL881290,BAO_0000249,,
868,,,Hippocampus,B,,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",H,,1,,CHEMBL615923,BAO_0000221,10000000.0,
869,,,Hippocampus,F,,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,1,,CHEMBL615924,BAO_0000221,10000000.0,
870,,,Hippocampus,F,,,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,1,,CHEMBL615925,BAO_0000221,10000000.0,
871,,,,B,,,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL615926,BAO_0000357,,
872,,,,B,,,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL615927,BAO_0000019,,
873,,,Hippocampus,B,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,,1,,CHEMBL615928,BAO_0000221,10000000.0,
874,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,D,,1,,CHEMBL615929,BAO_0000357,,
875,,,Hippocampus,B,,,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,H,,1,,CHEMBL615930,BAO_0000221,10000000.0,
876,,,,B,CHO,449.0,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,,1,,CHEMBL615931,BAO_0000219,,
877,,,,F,CHO,449.0,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615932,BAO_0000219,,
878,,,,F,CHO,449.0,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615933,BAO_0000219,,
879,,,,B,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615934,BAO_0000357,,
880,,,,B,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,H,,1,,CHEMBL615935,BAO_0000357,,
881,,,,F,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,,1,,CHEMBL615936,BAO_0000019,,
882,,,,B,CHO,449.0,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,H,,1,,CHEMBL615937,BAO_0000219,,
883,,,,B,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615938,BAO_0000357,,
884,,,,B,,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),H,,1,,CHEMBL615797,BAO_0000357,,
885,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615798,BAO_0000357,,
886,,,,B,,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,H,,1,,CHEMBL872870,BAO_0000357,,
887,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,H,,1,,CHEMBL615799,BAO_0000357,,
888,,,,B,,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615800,BAO_0000357,,
889,,,,F,HEK293,722.0,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,,1,,CHEMBL615801,BAO_0000219,,
890,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,H,,1,,CHEMBL615802,BAO_0000019,,
891,,,,B,,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,H,,1,,CHEMBL615803,BAO_0000357,,
892,,,,F,,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",H,,1,,CHEMBL835002,BAO_0000019,,
893,,,,F,,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",H,,1,,CHEMBL615804,BAO_0000019,,
894,,,,B,HeLa,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615805,BAO_0000219,,
895,,,,B,CHO,449.0,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615806,BAO_0000219,,
896,,,,B,,,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,D,,1,,CHEMBL615807,BAO_0000357,,
897,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,H,,1,,CHEMBL615808,BAO_0000357,,
898,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL615809,BAO_0000357,,
899,,,,B,HeLa,308.0,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,H,,1,,CHEMBL615810,BAO_0000219,,
900,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615811,BAO_0000357,,
901,,,,B,CHO,449.0,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,H,,1,,CHEMBL615812,BAO_0000219,,
902,,,,B,CHO,449.0,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,,1,,CHEMBL615751,BAO_0000219,,
903,,,,B,,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615752,BAO_0000357,,
904,,,,B,CHO,449.0,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,H,,1,,CHEMBL615753,BAO_0000219,,
905,,,,B,CHO,449.0,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,H,,1,,CHEMBL615754,BAO_0000219,,
906,,,,B,,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615755,BAO_0000357,,
907,,,,B,CHO,449.0,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,D,,1,,CHEMBL615756,BAO_0000219,,
908,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615757,BAO_0000019,,
909,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,H,,1,,CHEMBL615758,BAO_0000357,,
910,,,,B,,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,H,,1,,CHEMBL615759,BAO_0000357,,
911,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615760,BAO_0000357,,
912,,,,B,HeLa,308.0,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,H,,1,,CHEMBL615761,BAO_0000219,,
913,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,H,,1,,CHEMBL872104,BAO_0000357,,
914,,,,B,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615762,BAO_0000357,,
915,,,,B,,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615763,BAO_0000357,,
916,,,,B,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,H,,1,,CHEMBL615764,BAO_0000357,,
917,,,,B,Cell line,1167.0,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),H,,1,,CHEMBL615765,BAO_0000219,,
918,,,,B,,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),H,,1,,CHEMBL615766,BAO_0000019,,
919,,,,B,,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615767,BAO_0000357,,
920,,,,B,,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615768,BAO_0000357,,
921,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615769,BAO_0000357,,
922,,,,B,,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,H,,1,,CHEMBL615770,BAO_0000357,,
923,,,,B,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615771,BAO_0000357,,
924,,,,B,,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,H,,1,,CHEMBL615772,BAO_0000357,,
925,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615773,BAO_0000357,,
926,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615774,BAO_0000357,,
927,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615775,BAO_0000357,,
928,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,H,,1,,CHEMBL615776,BAO_0000357,,
929,,,,B,,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615777,BAO_0000357,,
930,,,,B,,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,H,,1,,CHEMBL615778,BAO_0000219,,
931,,,,B,,,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,D,,1,,CHEMBL615779,BAO_0000357,,
932,,,,B,,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,H,,1,,CHEMBL615780,BAO_0000357,,
933,,,,B,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616298,BAO_0000357,,
934,,,,B,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616299,BAO_0000357,,
935,,,,B,CHO-K1,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,H,,1,,CHEMBL616300,BAO_0000219,,
936,,,,F,CHO-K1,485.0,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,H,,1,,CHEMBL616301,BAO_0000219,,
937,,,,B,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616302,BAO_0000019,,
938,,,,B,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),H,,1,,CHEMBL616117,BAO_0000019,,
939,,,,B,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),H,,1,,CHEMBL616118,BAO_0000019,,
940,,,,B,,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,H,,1,,CHEMBL616119,BAO_0000019,,
941,,,,B,HeLa,308.0,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,D,,1,,CHEMBL616120,BAO_0000219,,
942,,,,B,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616121,BAO_0000357,,
943,,,,B,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,H,,1,,CHEMBL616122,BAO_0000357,,
944,,,,B,,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616123,BAO_0000357,,
945,,,,B,,,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616124,BAO_0000357,,
946,,,,B,,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,H,,1,,CHEMBL616125,BAO_0000357,,
947,,,,B,,,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,H,,1,,CHEMBL616126,BAO_0000357,,
948,,,,B,CHO,449.0,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616127,BAO_0000219,,
949,,,,B,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616128,BAO_0000019,,
950,,,,B,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,H,,1,,CHEMBL616129,BAO_0000357,,
951,,,,B,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616130,BAO_0000357,,
952,,,,B,,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,H,,1,,CHEMBL616131,BAO_0000357,,
953,,,,B,HeLa,308.0,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,H,,1,,CHEMBL616132,BAO_0000219,,
954,,,,B,HeLa,308.0,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,D,,1,,CHEMBL616133,BAO_0000219,,
955,,,,B,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616134,BAO_0000357,,
956,,,,B,,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,H,,1,,CHEMBL616135,BAO_0000357,,
957,,,,B,,,,Affinity for 5-hydroxytryptamine 1A receptor subtype,D,,1,,CHEMBL616136,BAO_0000357,,
958,,,,B,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,H,,1,,CHEMBL616137,BAO_0000019,,
959,,,,B,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,H,,1,,CHEMBL872105,BAO_0000019,,
960,,,,B,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,H,,1,,CHEMBL616138,BAO_0000357,,
961,,,,B,,,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616139,BAO_0000357,,
962,,,,F,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",H,,1,,CHEMBL616140,BAO_0000019,,
963,,,,B,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,H,,1,,CHEMBL616141,BAO_0000019,,
964,,,,B,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616142,BAO_0000357,,
965,,,,B,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,H,,1,,CHEMBL616143,BAO_0000357,,
966,,,,B,HeLa,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,H,,1,,CHEMBL616144,BAO_0000219,,
967,,,,B,HeLa,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,H,,1,,CHEMBL616145,BAO_0000219,,
968,,,,B,HeLa,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,H,,1,,CHEMBL616012,BAO_0000219,,
969,,,,B,HeLa,308.0,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,H,,1,,CHEMBL616013,BAO_0000219,,
970,,,,F,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",H,,1,,CHEMBL616014,BAO_0000019,,
971,,,,F,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",H,,1,,CHEMBL616015,BAO_0000019,,
972,,,,F,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",H,,1,,CHEMBL616016,BAO_0000019,,
973,,In vivo,,F,,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,H,,1,,CHEMBL616017,BAO_0000218,,
974,,,,B,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,H,,1,,CHEMBL616018,BAO_0000019,,
975,,,,F,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,H,,1,,CHEMBL616019,BAO_0000019,,
976,,,,F,,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,H,,1,,CHEMBL616020,BAO_0000019,,
977,,,,B,,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL858018,BAO_0000357,,
978,,,,F,HEK293,722.0,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,,1,,CHEMBL616021,BAO_0000219,,
979,,,,F,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",H,,1,,CHEMBL616022,BAO_0000019,,
980,,,,F,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",H,,1,,CHEMBL616023,BAO_0000019,,
981,,,,F,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",H,,1,,CHEMBL616024,BAO_0000019,,
982,,,,F,,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",H,,1,,CHEMBL616025,BAO_0000019,,
983,,,,F,CHO,449.0,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,H,,1,,CHEMBL616026,BAO_0000219,,
984,,,,F,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",H,,1,,CHEMBL616027,BAO_0000019,,
985,,,,F,,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",D,,1,,CHEMBL616028,BAO_0000019,,
986,,,,F,,,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,D,,1,,CHEMBL616029,BAO_0000019,,
987,,,,B,CHO,449.0,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,H,,1,,CHEMBL616030,BAO_0000219,,
988,,,,B,,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,H,,1,,CHEMBL616031,BAO_0000019,,
989,,,,F,,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,D,,1,,CHEMBL616032,BAO_0000019,,
990,,,,F,,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,D,,1,,CHEMBL616033,BAO_0000019,,
991,,,,F,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,,1,,CHEMBL616034,BAO_0000019,,
992,,,,F,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,,1,,CHEMBL616035,BAO_0000019,,
993,,,,F,,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616036,BAO_0000019,,
994,,,,F,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,,1,,CHEMBL616037,BAO_0000019,,
995,,,,F,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,,1,,CHEMBL616038,BAO_0000019,,
996,,,,F,,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,,1,,CHEMBL616039,BAO_0000019,,
997,,,,F,,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616040,BAO_0000019,,
998,,,,F,HeLa,308.0,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,D,,1,,CHEMBL616041,BAO_0000219,,
999,,,,F,HeLa,308.0,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,D,,1,,CHEMBL616042,BAO_0000219,,
1000,,,,F,HeLa,308.0,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,D,,1,,CHEMBL616043,BAO_0000219,,
1001,,,,F,,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",H,,1,,CHEMBL616044,BAO_0000019,,
1002,,,,F,,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",H,,1,,CHEMBL616045,BAO_0000019,,
1003,,,,F,HEK293,722.0,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,,1,,CHEMBL616046,BAO_0000219,,
1004,,,,F,CHO,449.0,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),H,,1,,CHEMBL616047,BAO_0000219,,
1005,,,,F,CHO,449.0,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,H,,1,,CHEMBL616048,BAO_0000219,,
1006,,,,F,CHO,449.0,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),D,,1,,CHEMBL616049,BAO_0000219,,
1007,,,,F,CHO,449.0,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),H,,1,,CHEMBL616050,BAO_0000219,,
1008,,,,F,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,H,,1,,CHEMBL616051,BAO_0000219,,
1009,,,,F,,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,H,,1,,CHEMBL616212,BAO_0000219,,
1010,,,,F,,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",H,,1,,CHEMBL616213,BAO_0000019,,
1011,,In vitro,,B,,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,H,,1,,CHEMBL616214,BAO_0000219,,
1012,,In vitro,,B,,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,H,,1,,CHEMBL616215,BAO_0000219,,
1013,,,,B,,,,Binding activity radioligand.,H,,1,,CHEMBL616216,BAO_0000357,,
1014,,,,B,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,,1,,CHEMBL616217,BAO_0000019,,
1015,,,,B,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616218,BAO_0000357,,
1016,,,,B,,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616219,BAO_0000357,,
1017,,,,B,,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616220,BAO_0000357,,
1018,,,,B,,,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL833493,BAO_0000357,,
1019,,,,B,,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616221,BAO_0000357,,
1020,,,,B,CHO,449.0,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,D,,1,,CHEMBL616222,BAO_0000219,,
1021,,,,F,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616223,BAO_0000019,,
1022,,,,F,,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,H,,1,,CHEMBL616224,BAO_0000019,,
1023,,,,B,,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,H,,1,,CHEMBL616225,BAO_0000019,,
1024,,,,B,HEK293,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,D,,1,,CHEMBL616226,BAO_0000219,,
1025,,,,B,HEK293,722.0,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,H,,1,,CHEMBL616227,BAO_0000219,,
1026,,,,B,HEK293,722.0,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616228,BAO_0000219,,
1027,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,H,,1,,CHEMBL616229,BAO_0000219,,
1028,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,H,,1,,CHEMBL616230,BAO_0000219,,
1029,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,H,,1,,CHEMBL616231,BAO_0000219,,
1030,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616232,BAO_0000357,,
1031,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,H,,1,,CHEMBL616233,BAO_0000219,,
1032,,,,B,HEK293,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,H,,1,,CHEMBL857973,BAO_0000219,,
1033,,,,B,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,H,,1,,CHEMBL616234,BAO_0000219,,
1034,,,,B,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616235,BAO_0000357,,
1035,,,,B,HeLa,308.0,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,H,,1,,CHEMBL616236,BAO_0000219,,
1036,,,,B,,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,H,,1,,CHEMBL616237,BAO_0000019,,
1037,,,,B,HEK293,722.0,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,H,,1,,CHEMBL616238,BAO_0000219,,
1038,,,,B,HEK293,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,H,,1,,CHEMBL616239,BAO_0000219,,
1039,,,,B,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,H,,1,,CHEMBL616240,BAO_0000219,,
1040,,,,B,HeLa,308.0,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,D,,1,,CHEMBL616241,BAO_0000219,,
1041,,,,B,HEK293,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,H,,1,,CHEMBL616242,BAO_0000219,,
1042,,,,B,HEK293,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",H,,1,,CHEMBL616243,BAO_0000219,,
1043,,,,B,,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616244,BAO_0000357,,
1044,,,,B,,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616245,BAO_0000357,,
1045,,,,B,,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,H,,1,,CHEMBL616246,BAO_0000357,,
1046,,,,B,,,,Binding affinity against 5-HT1D receptor,H,,1,,CHEMBL616247,BAO_0000357,,
1047,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616248,BAO_0000357,,
1048,,,,B,,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,H,,1,,CHEMBL616249,BAO_0000357,,
1049,,,,B,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,H,,1,,CHEMBL616250,BAO_0000357,,
1050,,,,B,,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616251,BAO_0000357,,
1051,,In vivo,,F,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,H,,1,,CHEMBL616252,BAO_0000218,,
1052,,In vivo,,F,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,H,,1,,CHEMBL616253,BAO_0000218,,
1053,,In vivo,,F,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,H,,1,,CHEMBL616254,BAO_0000218,,
1054,,,,F,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,D,,1,,CHEMBL616255,BAO_0000218,,
1055,,,,F,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,D,,1,,CHEMBL832872,BAO_0000218,,
1056,,,,F,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,D,,1,,CHEMBL616256,BAO_0000218,,
1057,,,,F,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,D,,1,,CHEMBL616257,BAO_0000218,,
1058,,,,F,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,D,,1,,CHEMBL616258,BAO_0000218,,
1059,,,,F,,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,D,,1,,CHEMBL616384,BAO_0000218,,
1060,,,Hippocampus,B,,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,H,,1,,CHEMBL616385,BAO_0000221,10000000.0,
1061,,,,B,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,H,,1,,CHEMBL616386,BAO_0000357,,
1062,,,Hippocampus,B,,,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,D,,1,,CHEMBL616387,BAO_0000221,10000000.0,
1063,,,Hippocampus,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,H,,1,,CHEMBL616388,BAO_0000221,10000000.0,
1064,,,Hippocampus,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,D,,1,,CHEMBL616389,BAO_0000221,10000000.0,
1065,,,Hippocampus,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,H,,1,,CHEMBL616390,BAO_0000221,10000000.0,
1066,,,,B,,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,H,,1,,CHEMBL616391,BAO_0000357,,
1067,,,Hippocampus,B,,,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,D,,1,,CHEMBL616392,BAO_0000221,10000000.0,
1068,,,,B,,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616393,BAO_0000357,,
1069,,,,B,,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,H,,1,,CHEMBL616394,BAO_0000357,,
1070,,,,B,,,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,H,,1,,CHEMBL616395,BAO_0000019,,
1071,,,,B,,,,Compound was evaluated for the binding affinity at 5- HT1A receptor,H,,1,,CHEMBL616396,BAO_0000357,,
1072,,,,B,,,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,H,,1,,CHEMBL872907,BAO_0000019,,
1073,,,,B,,,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,H,,1,,CHEMBL616397,BAO_0000019,,
1074,,,,B,,,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,H,,1,,CHEMBL616398,BAO_0000019,,
1075,,,,B,,,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616399,BAO_0000357,,
1076,,,,B,,,,Binding activity radioligand.,H,,1,,CHEMBL857065,BAO_0000357,,
1077,,,,B,,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,H,,1,,CHEMBL616400,BAO_0000019,,
1078,,,,B,,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,H,,1,,CHEMBL616401,BAO_0000019,,
1079,,,,B,,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,H,,1,,CHEMBL616402,BAO_0000019,,
1080,,,,B,,,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616403,BAO_0000019,,
1081,,,Hippocampus,B,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,H,,1,,CHEMBL616404,BAO_0000221,10000000.0,
1082,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,H,,1,,CHEMBL616405,BAO_0000249,,
1083,,,,B,,,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,H,,1,,CHEMBL616406,BAO_0000019,,
1084,,,,F,,,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,H,,1,,CHEMBL616407,BAO_0000019,,
1085,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,H,,1,,CHEMBL616408,BAO_0000019,,
1086,,,,B,,,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,D,,1,,CHEMBL616409,BAO_0000249,,
1087,,,Hippocampus,B,,,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",D,,1,,CHEMBL616410,BAO_0000221,10000000.0,
1088,,,,B,,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,H,,1,,CHEMBL616411,BAO_0000357,,
1089,Membranes,,,F,,,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",D,,1,,CHEMBL616412,BAO_0000249,,
1090,Membranes,,Hippocampus,F,,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",D,,1,,CHEMBL616413,BAO_0000249,10000000.0,
1091,,,Hippocampus,B,,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,,1,,CHEMBL616414,BAO_0000221,10000000.0,
1092,,,Hippocampus,B,,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,D,,1,,CHEMBL616415,BAO_0000221,10000000.0,
1093,,,,B,,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,H,,1,,CHEMBL616416,BAO_0000019,,
1094,,,,B,,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,H,,1,,CHEMBL616417,BAO_0000357,,
1095,,,,B,,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,H,,1,,CHEMBL616418,BAO_0000357,,
1096,,In vitro,,B,,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,H,,1,,CHEMBL616419,BAO_0000219,,
1097,,,,B,,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,H,,1,,CHEMBL616420,BAO_0000357,,
1098,Membranes,,,B,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,H,,1,,CHEMBL616421,BAO_0000249,,
1099,Membranes,,,B,,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,H,,1,,CHEMBL616422,BAO_0000249,,
1100,Membranes,,,B,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,H,,1,,CHEMBL616423,BAO_0000249,,
1101,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,D,,1,,CHEMBL616424,BAO_0000357,,
1102,,,,B,,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616425,BAO_0000357,,
1103,,,,B,,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,H,,1,,CHEMBL616426,BAO_0000357,,
1104,,,Hippocampus,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,H,,1,,CHEMBL616427,BAO_0000221,10000000.0,
1105,,,Hippocampus,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,H,,1,,CHEMBL616428,BAO_0000221,10000000.0,
1106,,,Hippocampus,B,,,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,1,,CHEMBL616290,BAO_0000221,10000000.0,
1107,,,,B,,,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616052,BAO_0000357,,
1108,,,,B,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616053,BAO_0000357,,
1109,,,,B,,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616054,BAO_0000249,,
1110,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616055,BAO_0000357,,
1111,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,H,,1,,CHEMBL616056,BAO_0000357,,
1112,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,H,,1,,CHEMBL616057,BAO_0000019,,
1113,,,Brain,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,D,,1,,CHEMBL616058,BAO_0000221,955.0,
1114,,,Brain,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,H,,1,,CHEMBL616059,BAO_0000221,955.0,
1115,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616060,BAO_0000249,,
1116,,,Hippocampus,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,D,,1,,CHEMBL616061,BAO_0000221,10000000.0,
1117,,,Hippocampus,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,H,,1,,CHEMBL616062,BAO_0000221,10000000.0,
1118,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616063,BAO_0000249,,
1119,,,Striatum,B,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",H,,1,,CHEMBL616064,BAO_0000249,2435.0,
1120,Membranes,,,B,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,D,,1,,CHEMBL616065,BAO_0000249,,
1121,Membranes,,,B,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,D,,1,,CHEMBL616066,BAO_0000249,,
1122,,,Hippocampus,B,,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616067,BAO_0000221,10000000.0,
1123,,,Hippocampus,B,,,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,H,,1,,CHEMBL616068,BAO_0000221,10000000.0,
1124,,,Hippocampus,B,,,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616069,BAO_0000221,10000000.0,
1125,,,,B,,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,H,,1,,CHEMBL616070,BAO_0000249,,
1126,,,Hippocampus,B,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616071,BAO_0000221,10000000.0,
1127,,,Hippocampus,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,H,,1,,CHEMBL616072,BAO_0000221,10000000.0,
1128,,,Hippocampus,B,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,H,,1,,CHEMBL616073,BAO_0000221,10000000.0,
1129,,,Hippocampus,B,,,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,H,,1,,CHEMBL616074,BAO_0000221,10000000.0,
1130,,,,B,,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,H,,1,,CHEMBL616075,BAO_0000019,,
1131,,,,B,,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616076,BAO_0000357,,
1132,,,,B,,,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,D,,1,,CHEMBL616077,BAO_0000019,,
1133,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,D,,1,,CHEMBL616078,BAO_0000019,,
1134,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,D,,1,,CHEMBL616079,BAO_0000019,,
1135,,,,B,CHO-K1,485.0,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,D,,1,,CHEMBL616080,BAO_0000219,,
1136,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616081,BAO_0000357,,
1137,,,Hippocampus,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,D,,1,,CHEMBL616082,BAO_0000221,10000000.0,
1138,,,Hippocampus,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,H,,1,,CHEMBL616083,BAO_0000221,10000000.0,
1139,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,H,,1,,CHEMBL616084,BAO_0000019,,
1140,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,H,,1,,CHEMBL616085,BAO_0000019,,
1141,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,H,,1,,CHEMBL616086,BAO_0000019,,
1142,,,Hippocampus,B,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",H,,1,,CHEMBL616087,BAO_0000221,10000000.0,
1143,,,,B,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,H,,1,,CHEMBL616088,BAO_0000357,,
1144,,,,B,,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,H,,1,,CHEMBL616089,BAO_0000019,,
1145,,,,B,,,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,D,,1,,CHEMBL616090,BAO_0000357,,
1146,,,,B,,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,H,,1,,CHEMBL616091,BAO_0000357,,
1147,Membranes,,Striatum,B,,,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",H,,1,,CHEMBL616092,BAO_0000249,2435.0,
1148,,,,B,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),H,,1,,CHEMBL616093,BAO_0000357,,
1149,,In vivo,,B,,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),H,,1,,CHEMBL616094,BAO_0000218,,
1150,,,Brain,B,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,H,,1,,CHEMBL616095,BAO_0000221,955.0,
1151,,,,B,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616096,BAO_0000357,,
1152,,,,B,,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,H,,1,,CHEMBL616097,BAO_0000249,,
1153,Membranes,,,B,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,D,,1,,CHEMBL616098,BAO_0000249,,
1154,,,Hippocampus,B,,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616099,BAO_0000221,10000000.0,
1155,,,Hippocampus,B,,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616100,BAO_0000221,10000000.0,
1156,,,,B,,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616101,BAO_0000357,,
1157,,,,B,,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,H,,1,,CHEMBL616102,BAO_0000249,,
1158,,,,B,,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616103,BAO_0000357,,
1159,,,,B,,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,H,,1,,CHEMBL616104,BAO_0000019,,
1160,,,,B,,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",H,,1,,CHEMBL616105,BAO_0000019,,
1161,,,,B,,,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616106,BAO_0000019,,
1162,,,,B,,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,H,,1,,CHEMBL616107,BAO_0000019,,
1163,,,,B,,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,H,,1,,CHEMBL616108,BAO_0000357,,
1164,,,Hippocampus,B,,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,H,,1,,CHEMBL616109,BAO_0000221,10000000.0,
1165,,,,B,,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,H,,1,,CHEMBL616110,BAO_0000357,,
1166,,,,B,CHO,449.0,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,H,,1,,CHEMBL616111,BAO_0000219,,
1167,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,H,,1,,CHEMBL616112,BAO_0000019,,
1168,,,Hippocampus,B,,,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,H,,1,,CHEMBL616113,BAO_0000221,10000000.0,
1169,,,,B,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616114,BAO_0000019,,
1170,,,,B,,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616115,BAO_0000019,,
1171,,,,B,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616116,BAO_0000357,,
1172,,,Brain,B,,,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615844,BAO_0000221,955.0,
1173,,,Hippocampus,B,,,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL615939,BAO_0000221,10000000.0,
1174,,,,B,,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,H,,1,,CHEMBL615940,BAO_0000019,,
1175,,,Hippocampus,B,,,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,H,,1,,CHEMBL615941,BAO_0000221,10000000.0,
1176,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,H,,1,,CHEMBL615942,BAO_0000221,10000000.0,
1177,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,H,,1,,CHEMBL615943,BAO_0000221,10000000.0,
1178,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,H,,1,,CHEMBL615944,BAO_0000221,10000000.0,
1179,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,H,,1,,CHEMBL615945,BAO_0000221,10000000.0,
1180,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,H,,1,,CHEMBL615946,BAO_0000221,10000000.0,
1181,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,H,,1,,CHEMBL615947,BAO_0000221,10000000.0,
1182,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,H,,1,,CHEMBL615948,BAO_0000221,10000000.0,
1183,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,H,,1,,CHEMBL615949,BAO_0000221,10000000.0,
1184,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,H,,1,,CHEMBL615950,BAO_0000221,10000000.0,
1185,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,H,,1,,CHEMBL615951,BAO_0000221,10000000.0,
1186,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,H,,1,,CHEMBL615952,BAO_0000221,10000000.0,
1187,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,H,,1,,CHEMBL615953,BAO_0000221,10000000.0,
1188,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,H,,1,,CHEMBL615954,BAO_0000221,10000000.0,
1189,,,Hippocampus,B,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,D,,1,,CHEMBL615955,BAO_0000221,10000000.0,
1190,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,H,,1,,CHEMBL615956,BAO_0000221,10000000.0,
1191,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,H,,1,,CHEMBL615957,BAO_0000221,10000000.0,
1192,,,,B,,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,H,,1,,CHEMBL615958,BAO_0000019,,
1193,,,,B,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,H,,1,,CHEMBL615959,BAO_0000019,,
1194,,,,B,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),H,,1,,CHEMBL615960,BAO_0000019,,
1195,,,,B,,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),H,,1,,CHEMBL615961,BAO_0000019,,
1196,,,Brain,B,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,H,,1,,CHEMBL615962,BAO_0000221,955.0,
1197,,,,B,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,H,,1,,CHEMBL615963,BAO_0000019,,
1198,,,,B,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,H,,1,,CHEMBL615964,BAO_0000019,,
1199,,,,B,,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,H,,1,,CHEMBL615965,BAO_0000019,,
1200,,,,B,CHO,449.0,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,H,,1,,CHEMBL615966,BAO_0000219,,
1201,,,,B,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,H,,1,,CHEMBL615967,BAO_0000249,,
1202,,,,B,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,H,,1,,CHEMBL615968,BAO_0000019,,
1203,,,,B,CHO,449.0,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),H,,1,,CHEMBL615969,BAO_0000218,,
1204,,,,B,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),H,,1,,CHEMBL615970,BAO_0000218,,
1205,,,,B,,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,D,,1,,CHEMBL615971,BAO_0000357,,
1206,Membranes,,,B,,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,H,,1,,CHEMBL615972,BAO_0000249,,
1207,,,,B,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,H,,1,,CHEMBL615973,BAO_0000249,,
1208,,,,B,,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,H,,1,,CHEMBL615974,BAO_0000249,,
1209,,,,B,CHO,449.0,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,D,,1,,CHEMBL615975,BAO_0000219,,
1210,,,,B,,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,H,,1,,CHEMBL615976,BAO_0000249,,
1211,,,Hippocampus,B,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,D,,1,,CHEMBL872106,BAO_0000221,10000000.0,
1212,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL615977,BAO_0000357,,
1213,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,H,,1,,CHEMBL615978,BAO_0000357,,
1214,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,H,,1,,CHEMBL616166,BAO_0000357,,
1215,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,H,,1,,CHEMBL616167,BAO_0000357,,
1216,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,H,,1,,CHEMBL616168,BAO_0000357,,
1217,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,H,,1,,CHEMBL616169,BAO_0000357,,
1218,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,H,,1,,CHEMBL616170,BAO_0000357,,
1219,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,H,,1,,CHEMBL616171,BAO_0000357,,
1220,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,H,,1,,CHEMBL616172,BAO_0000357,,
1221,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,H,,1,,CHEMBL616173,BAO_0000357,,
1222,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,H,,1,,CHEMBL616174,BAO_0000357,,
1223,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,H,,1,,CHEMBL616175,BAO_0000357,,
1224,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,H,,1,,CHEMBL616176,BAO_0000357,,
1225,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,H,,1,,CHEMBL616177,BAO_0000357,,
1226,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,H,,1,,CHEMBL616178,BAO_0000357,,
1227,,,,B,,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,H,,1,,CHEMBL616179,BAO_0000019,,
1228,,,,B,,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616180,BAO_0000357,,
1229,,,,B,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,H,,1,,CHEMBL616181,BAO_0000357,,
1230,,,,B,,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,H,,1,,CHEMBL616182,BAO_0000019,,
1231,,,Hippocampus,B,,,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616183,BAO_0000221,10000000.0,
1232,,,,B,,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,H,,1,,CHEMBL615874,BAO_0000019,,
1233,,,,B,CHO-K1,485.0,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,D,,1,,CHEMBL615875,BAO_0000219,,
1234,,,,B,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,H,,1,,CHEMBL615876,BAO_0000019,,
1235,,,,B,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,H,,1,,CHEMBL615877,BAO_0000019,,
1236,,,,B,,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),H,,1,,CHEMBL615878,BAO_0000357,,
1237,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,H,,1,,CHEMBL615879,BAO_0000357,,
1238,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,H,,1,,CHEMBL615880,BAO_0000357,,
1239,,,,B,,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",H,,1,,CHEMBL615881,BAO_0000019,,
1240,,,,B,,,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",D,,1,,CHEMBL615882,BAO_0000019,,
1241,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,H,,1,,CHEMBL615883,BAO_0000218,,
1242,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),H,,1,,CHEMBL615884,BAO_0000218,,
1243,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),H,,1,,CHEMBL615885,BAO_0000218,,
1244,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),H,,1,,CHEMBL615886,BAO_0000218,,
1245,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),H,,1,,CHEMBL615887,BAO_0000218,,
1246,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),H,,1,,CHEMBL615888,BAO_0000218,,
1247,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),H,,1,,CHEMBL615889,BAO_0000218,,
1248,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),H,,1,,CHEMBL615890,BAO_0000218,,
1249,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),H,,1,,CHEMBL615891,BAO_0000218,,
1250,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),H,,1,,CHEMBL615892,BAO_0000218,,
1251,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),H,,1,,CHEMBL615893,BAO_0000218,,
1252,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),H,,1,,CHEMBL615894,BAO_0000218,,
1253,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),H,,1,,CHEMBL615895,BAO_0000218,,
1254,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),H,,1,,CHEMBL615896,BAO_0000218,,
1255,,In vivo,,F,,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,H,,1,,CHEMBL615897,BAO_0000218,,
1256,Membranes,,,F,,,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",D,,1,,CHEMBL615898,BAO_0000249,,
1257,,,,B,,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,H,,1,,CHEMBL615899,BAO_0000019,,
1258,,,,B,,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,H,,1,,CHEMBL616291,BAO_0000019,,
1259,,,,B,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,H,,1,,CHEMBL616292,BAO_0000357,,
1260,,,,F,,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",H,,1,,CHEMBL616293,BAO_0000249,,
1261,,,Hippocampus,B,,,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,1,,CHEMBL616294,BAO_0000221,10000000.0,
1262,,,Hippocampus,B,,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,H,,1,,CHEMBL616295,BAO_0000249,10000000.0,
1263,,,Brain,B,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,H,,1,,CHEMBL616296,BAO_0000221,955.0,
1264,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,H,,1,,CHEMBL616297,BAO_0000019,,
1265,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,H,,1,,CHEMBL616605,BAO_0000019,,
1266,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,H,,1,,CHEMBL616606,BAO_0000019,,
1267,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,H,,1,,CHEMBL616607,BAO_0000019,,
1268,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,H,,1,,CHEMBL616608,BAO_0000019,,
1269,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,H,,1,,CHEMBL616609,BAO_0000019,,
1270,,,,F,,,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,D,,1,,CHEMBL616610,BAO_0000019,,
1271,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,H,,1,,CHEMBL616611,BAO_0000019,,
1272,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,H,,1,,CHEMBL616612,BAO_0000019,,
1273,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,H,,1,,CHEMBL616613,BAO_0000019,,
1274,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,H,,1,,CHEMBL616614,BAO_0000019,,
1275,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,H,,1,,CHEMBL616615,BAO_0000019,,
1276,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,H,,1,,CHEMBL616616,BAO_0000019,,
1277,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,H,,1,,CHEMBL616617,BAO_0000019,,
1278,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,H,,1,,CHEMBL616618,BAO_0000019,,
1279,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,H,,1,,CHEMBL616619,BAO_0000019,,
1280,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,H,,1,,CHEMBL616620,BAO_0000019,,
1281,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,H,,1,,CHEMBL616621,BAO_0000019,,
1282,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,H,,1,,CHEMBL616622,BAO_0000019,,
1283,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,H,,1,,CHEMBL616146,BAO_0000019,,
1284,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,H,,1,,CHEMBL832873,BAO_0000019,,
1285,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,H,,1,,CHEMBL616147,BAO_0000019,,
1286,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,H,,1,,CHEMBL872872,BAO_0000019,,
1287,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,H,,1,,CHEMBL616148,BAO_0000019,,
1288,,,Hippocampus,B,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,H,,1,,CHEMBL616149,BAO_0000221,10000000.0,
1289,,,Hippocampus,B,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,H,,1,,CHEMBL616150,BAO_0000221,10000000.0,
1290,Membranes,,,B,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,D,,1,,CHEMBL616151,BAO_0000249,,
1291,,,Hippocampus,B,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,H,,1,,CHEMBL872873,BAO_0000221,10000000.0,
1292,,,Hippocampus,B,,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,H,,1,,CHEMBL616670,BAO_0000221,10000000.0,
1293,,,Hippocampus,B,,,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,H,,1,,CHEMBL616671,BAO_0000221,10000000.0,
1294,,,,F,,,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",D,,1,,CHEMBL884861,BAO_0000249,,
1295,,,,B,,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,H,,1,,CHEMBL616672,BAO_0000357,,
1296,,,,B,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,H,,1,,CHEMBL616673,BAO_0000019,,
1297,,,,F,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,H,,1,,CHEMBL616674,BAO_0000019,,
1298,,,,B,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,H,,1,,CHEMBL616675,BAO_0000357,,
1299,,,Hippocampus,B,,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,H,,1,,CHEMBL616676,BAO_0000221,10000000.0,
1300,,,Hippocampus,B,,,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,,1,,CHEMBL616677,BAO_0000221,10000000.0,
1301,,,Hippocampus,B,,,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,,1,,CHEMBL616678,BAO_0000221,10000000.0,
1302,,,,B,,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616679,BAO_0000357,,
1303,,,Hippocampus,B,,,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,H,,1,,CHEMBL616680,BAO_0000221,10000000.0,
1304,,,Hippocampus,B,,,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,1,,CHEMBL616681,BAO_0000221,10000000.0,
1305,,,Hippocampus,B,,,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,1,,CHEMBL616682,BAO_0000221,10000000.0,
1306,,,Hippocampus,B,,,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616683,BAO_0000221,10000000.0,
1307,,,Hippocampus,B,,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616684,BAO_0000221,10000000.0,
1308,,,Hippocampus,B,,,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,H,,1,,CHEMBL616685,BAO_0000221,10000000.0,
1309,,,Brain,B,,,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,H,,1,,CHEMBL616686,BAO_0000221,955.0,
1310,,,,B,,,,Affinity for 5-hydroxytryptamine 1A receptor site,H,,1,,CHEMBL616687,BAO_0000357,,
1311,,,,B,,,,Affinity for 5-hydroxytryptamine 1A receptor site,H,,1,,CHEMBL616688,BAO_0000357,,
1312,,,Hippocampus,B,,,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,H,,1,,CHEMBL616689,BAO_0000221,10000000.0,
1313,,,,B,,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,H,,1,,CHEMBL616690,BAO_0000357,,
1314,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,H,,1,,CHEMBL616691,BAO_0000357,,
1315,,,Hippocampus,B,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,D,,1,,CHEMBL616692,BAO_0000221,10000000.0,
1316,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,H,,1,,CHEMBL616693,BAO_0000249,,
1317,,,,B,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",D,,1,,CHEMBL616694,BAO_0000019,,
1318,,,Hippocampus,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,H,,1,,CHEMBL616695,BAO_0000221,10000000.0,
1319,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,H,,1,,CHEMBL616696,BAO_0000357,,
1320,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,H,,1,,CHEMBL616697,BAO_0000357,,
1321,,,,B,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616698,BAO_0000357,,
1322,,,,B,,,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616949,BAO_0000019,,
1323,,,Hippocampus,B,,,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,H,,1,,CHEMBL616950,BAO_0000221,10000000.0,
1324,,,,B,,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,H,,1,,CHEMBL832875,BAO_0000357,,
1325,,,Brain,B,,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,H,,1,,CHEMBL616951,BAO_0000221,955.0,
1326,,,Brain,B,,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,H,,1,,CHEMBL616952,BAO_0000221,955.0,
1327,,,,B,,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,H,,1,,CHEMBL616953,BAO_0000357,,
1328,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,H,,1,,CHEMBL616954,BAO_0000357,,
1329,,,,B,,,,GTPgammaS radioligand binding assay,H,,1,,CHEMBL616955,BAO_0000357,,
1330,,,,B,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,H,,1,,CHEMBL616956,BAO_0000357,,
1331,,,,F,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,H,,1,,CHEMBL616957,BAO_0000019,,
1332,,,,F,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,H,,1,,CHEMBL616958,BAO_0000019,,
1333,,,,B,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616959,BAO_0000357,,
1334,,,,B,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,H,,1,,CHEMBL616960,BAO_0000357,,
1335,,,,F,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,H,,1,,CHEMBL616961,BAO_0000019,,
1336,,,,B,HeLa,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616962,BAO_0000219,,
1337,,,,B,HeLa,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,H,,1,,CHEMBL616963,BAO_0000219,,
1338,,,,B,,,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,D,,1,,CHEMBL616524,BAO_0000357,,
1339,,,,B,CHO,449.0,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,H,,1,,CHEMBL616525,BAO_0000219,,
1340,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,H,,1,,CHEMBL872908,BAO_0000019,,
1341,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,H,,1,,CHEMBL616526,BAO_0000019,,
1342,,,,B,,,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,D,,1,,CHEMBL616527,BAO_0000357,,
1343,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,H,,1,,CHEMBL616528,BAO_0000219,,
1344,,,,B,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,H,,1,,CHEMBL616529,BAO_0000357,,
1345,,,,B,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,H,,1,,CHEMBL616530,BAO_0000357,,
1346,,,,B,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616531,BAO_0000357,,
1347,,,,B,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616532,BAO_0000357,,
1348,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616533,BAO_0000357,,
1349,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616534,BAO_0000357,,
1350,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,H,,1,,CHEMBL616535,BAO_0000357,,
1351,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,H,,1,,CHEMBL616536,BAO_0000357,,
1352,,,,B,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616537,BAO_0000357,,
1353,,,,F,CHO-K1,485.0,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,H,,1,,CHEMBL616538,BAO_0000219,,
1354,,,,F,,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616539,BAO_0000019,,
1355,,,,B,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616540,BAO_0000019,,
1356,,,,B,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,H,,1,,CHEMBL616429,BAO_0000357,,
1357,,,,B,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616430,BAO_0000357,,
1358,,,,B,,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,D,,1,,CHEMBL616431,BAO_0000219,,
1359,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,D,,1,,CHEMBL616432,BAO_0000357,,
1360,,,,B,,,,Affinity for 5-hydroxytryptamine 1B receptor subtype,D,,1,,CHEMBL616433,BAO_0000357,,
1361,,,,B,,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,D,,1,,CHEMBL616434,BAO_0000357,,
1362,,,,B,CHO,449.0,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,H,,1,,CHEMBL616435,BAO_0000219,,
1363,,,,B,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,H,,1,,CHEMBL616436,BAO_0000019,,
1364,,,,B,HeLa,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,H,,1,,CHEMBL616437,BAO_0000219,,
1365,,,,B,HeLa,308.0,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,H,,1,,CHEMBL616438,BAO_0000219,,
1366,,,,B,HeLa,308.0,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,H,,1,,CHEMBL616439,BAO_0000219,,
1367,,,,B,,,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,D,,1,,CHEMBL616440,BAO_0000357,,
1368,,,,B,CHO-K1,485.0,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,H,,1,,CHEMBL616441,BAO_0000219,,
1369,,,,B,,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,H,,1,,CHEMBL616442,BAO_0000357,,
1370,,,,B,,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616443,BAO_0000357,,
1371,,,,B,CHO-K1,485.0,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616444,BAO_0000219,,
1372,,,,B,,,,Binding activity against human 5-hydroxytryptamine 1B receptor,D,,1,,CHEMBL616445,BAO_0000357,,
1373,,,,B,,,,Binding activity against human 5-hydroxytryptamine 1B receptor,D,,1,,CHEMBL616446,BAO_0000357,,
1374,,,,B,CHO,449.0,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,D,,1,,CHEMBL616447,BAO_0000219,,
1375,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,H,,1,,CHEMBL616448,BAO_0000357,,
1376,,,,B,CHO,449.0,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,H,,1,,CHEMBL616449,BAO_0000219,,
1377,,,,B,CHO,449.0,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,H,,1,,CHEMBL616450,BAO_0000219,,
1378,,,,B,CHO,449.0,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,H,,1,,CHEMBL857974,BAO_0000219,,
1379,,,,B,CHO,449.0,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,H,,1,,CHEMBL616451,BAO_0000219,,
1380,,,,B,CHO,449.0,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,H,,1,,CHEMBL616452,BAO_0000219,,
1381,,,,B,CHO,449.0,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,H,,1,,CHEMBL616453,BAO_0000219,,
1382,,,,B,CHO,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,H,,1,,CHEMBL616454,BAO_0000219,,
1383,,,,B,,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,D,,1,,CHEMBL616455,BAO_0000357,,
1384,,,,B,CHO,449.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,H,,1,,CHEMBL616456,BAO_0000219,,
1385,,,,B,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,H,,1,,CHEMBL616457,BAO_0000357,,
1386,,,,B,CHO,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,H,,1,,CHEMBL616458,BAO_0000219,,
1387,,,,B,CHO,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",H,,1,,CHEMBL616459,BAO_0000219,,
1388,,,,F,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,H,,1,,CHEMBL616460,BAO_0000019,,
1389,,,,F,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,H,,1,,CHEMBL616461,BAO_0000019,,
1390,,,,F,CHO,449.0,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",H,,1,,CHEMBL616462,BAO_0000219,,
1391,,,,F,CHO,449.0,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",H,,1,,CHEMBL616463,BAO_0000219,,
1392,,,,F,,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",H,,1,,CHEMBL616464,BAO_0000019,,
1393,,,,B,CHO,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,H,,1,,CHEMBL616465,BAO_0000219,,
1394,,,,B,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL832874,BAO_0000357,,
1395,,,,F,,,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,H,,1,,CHEMBL616184,BAO_0000019,,
1396,,,,B,,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,H,,1,,CHEMBL616185,BAO_0000019,,
1397,,,,B,,,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",H,,1,,CHEMBL616186,BAO_0000019,,
1398,,,,B,,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,H,,1,,CHEMBL616187,BAO_0000019,,
1399,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,H,,1,,CHEMBL616188,BAO_0000357,,
1400,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1B receptor,D,,1,,CHEMBL873475,BAO_0000357,,
1401,,,Striatum,B,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,D,,1,,CHEMBL616189,BAO_0000019,2435.0,
1402,,,,B,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,H,,1,,CHEMBL616190,BAO_0000357,,
1403,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,H,,1,,CHEMBL616191,BAO_0000357,,
1404,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,H,,1,,CHEMBL616192,BAO_0000357,,
1405,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,H,,1,,CHEMBL616193,BAO_0000357,,
1406,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,H,,1,,CHEMBL616194,BAO_0000357,,
1407,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,H,,1,,CHEMBL616195,BAO_0000357,,
1408,,,,B,,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,H,,1,,CHEMBL616196,BAO_0000357,,
1409,,,Hippocampus,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,H,,1,,CHEMBL616197,BAO_0000249,10000000.0,
1410,,,,B,,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616198,BAO_0000019,,
1411,,,Hippocampus,B,,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,H,,1,,CHEMBL616199,BAO_0000221,10000000.0,
1412,,,Hippocampus,B,,,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,H,,1,,CHEMBL616200,BAO_0000221,10000000.0,
1413,,,Hippocampus,B,,,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616201,BAO_0000221,10000000.0,
1414,,,Hippocampus,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,H,,1,,CHEMBL616202,BAO_0000221,10000000.0,
1415,,,Hippocampus,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,H,,1,,CHEMBL616203,BAO_0000221,10000000.0,
1416,,,Hippocampus,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,H,,1,,CHEMBL616204,BAO_0000221,10000000.0,
1417,,,Hippocampus,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,H,,1,,CHEMBL616205,BAO_0000221,10000000.0,
1418,,,Hippocampus,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,H,,1,,CHEMBL616206,BAO_0000221,10000000.0,
1419,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,H,,1,,CHEMBL616207,BAO_0000249,,
1420,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,H,,1,,CHEMBL616208,BAO_0000249,,
1421,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,H,,1,,CHEMBL616209,BAO_0000249,,
1422,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,H,,1,,CHEMBL616210,BAO_0000357,,
1423,,,Hippocampus,B,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,H,,1,,CHEMBL616211,BAO_0000221,10000000.0,
1424,,,Hippocampus,B,,,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,H,,1,,CHEMBL616504,BAO_0000221,10000000.0,
1425,,,Hippocampus,B,,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616505,BAO_0000221,10000000.0,
1426,,,,F,,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616506,BAO_0000019,,
1427,,,Hippocampus,B,,,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,,1,,CHEMBL872107,BAO_0000221,10000000.0,
1428,,,Hippocampus,B,,,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,D,,1,,CHEMBL616507,BAO_0000221,10000000.0,
1429,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,H,,1,,CHEMBL616303,BAO_0000249,,
1430,,,Hippocampus,B,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,H,,1,,CHEMBL616304,BAO_0000221,10000000.0,
1431,,,Hippocampus,B,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,H,,1,,CHEMBL616305,BAO_0000221,10000000.0,
1432,,,Hippocampus,F,,,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616306,BAO_0000221,10000000.0,
1433,,,,B,,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616307,BAO_0000357,,
1434,,,Hippocampus,B,,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,D,,1,,CHEMBL881829,BAO_0000221,10000000.0,
1435,,,,B,,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,H,,1,,CHEMBL616308,BAO_0000357,,
1436,,,,B,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,H,,1,,CHEMBL616309,BAO_0000019,,
1437,,,,B,,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,H,,1,,CHEMBL616310,BAO_0000019,,
1438,,,,B,CHO,449.0,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,H,,1,,CHEMBL616311,BAO_0000219,,
1439,,,,B,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616312,BAO_0000357,,
1440,,,,B,,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,H,,1,,CHEMBL616313,BAO_0000357,,
1441,,,Hippocampus,B,,,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616314,BAO_0000221,10000000.0,
1442,,,Hippocampus,B,,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,1,,CHEMBL616315,BAO_0000221,10000000.0,
1443,,,Hippocampus,B,,,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,H,,1,,CHEMBL616567,BAO_0000221,10000000.0,
1444,,,Hippocampus,B,,,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,H,,1,,CHEMBL616568,BAO_0000221,10000000.0,
1445,,,,B,,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,H,,1,,CHEMBL616569,BAO_0000019,,
1446,,,,B,,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,H,,1,,CHEMBL616570,BAO_0000357,,
1447,,,,B,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,H,,1,,CHEMBL616571,BAO_0000357,,
1448,,,Hippocampus,B,,,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,H,,1,,CHEMBL616572,BAO_0000221,10000000.0,
1449,,,,B,,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,H,,1,,CHEMBL616573,BAO_0000249,,
1450,,,,B,,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,D,,1,,CHEMBL616574,BAO_0000357,,
1451,,,Hippocampus,B,,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,H,,1,,CHEMBL616575,BAO_0000221,10000000.0,
1452,,,Hippocampus,B,,,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,H,,1,,CHEMBL872108,BAO_0000221,10000000.0,
1453,,,,B,,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,H,,1,,CHEMBL616576,BAO_0000357,,
1454,,,,B,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,H,,1,,CHEMBL616577,BAO_0000249,,
1455,,,,B,,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,H,,1,,CHEMBL616578,BAO_0000249,,
1456,,,,B,,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,H,,1,,CHEMBL616579,BAO_0000357,,
1457,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,D,,1,,CHEMBL616580,BAO_0000019,,
1458,,,,B,,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,H,,1,,CHEMBL616581,BAO_0000019,,
1459,,,Hippocampus,B,,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,1,,CHEMBL616582,BAO_0000221,10000000.0,
1460,,,Hippocampus,B,,,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,1,,CHEMBL616583,BAO_0000221,10000000.0,
1461,,,Hippocampus,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,D,,1,,CHEMBL616584,BAO_0000221,10000000.0,
1462,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616585,BAO_0000357,,
1463,,,Hippocampus,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,D,,1,,CHEMBL616586,BAO_0000221,10000000.0,
1464,,,Hippocampus,B,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,H,,1,,CHEMBL616587,BAO_0000221,10000000.0,
1465,,,Hippocampus,B,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,H,,1,,CHEMBL616588,BAO_0000221,10000000.0,
1466,,,Hippocampus,B,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,H,,1,,CHEMBL616589,BAO_0000221,10000000.0,
1467,,,Hippocampus,B,,,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616590,BAO_0000221,10000000.0,
1468,,,,B,CHO,449.0,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",H,,1,,CHEMBL616591,BAO_0000219,,
1469,,,,B,,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616592,BAO_0000357,,
1470,,,,B,,,,The inhibition activity of 5-HT1A at 1 uM,H,,1,,CHEMBL616593,BAO_0000357,,
1471,,,,B,CHO-K1,485.0,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",H,,1,,CHEMBL616594,BAO_0000219,,
1472,,,,B,,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,H,,1,,CHEMBL616595,BAO_0000249,,
1473,,,,B,,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,H,,1,,CHEMBL616596,BAO_0000357,,
1474,,,Hippocampus,B,,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,H,,1,,CHEMBL616597,BAO_0000221,10000000.0,
1475,,,Hippocampus,B,,,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,H,,1,,CHEMBL616598,BAO_0000221,10000000.0,
1476,Membranes,,,F,,,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,D,,1,,CHEMBL616599,BAO_0000249,,
1477,Membranes,,Hippocampus,F,,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",D,,1,,CHEMBL616600,BAO_0000249,10000000.0,
1478,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,H,,1,,CHEMBL616601,BAO_0000019,,
1479,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,H,,1,,CHEMBL616602,BAO_0000019,,
1480,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,H,,1,,CHEMBL616603,BAO_0000019,,
1481,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,H,,1,,CHEMBL616604,BAO_0000019,,
1482,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,H,,1,,CHEMBL616316,BAO_0000249,,
1483,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,H,,1,,CHEMBL616317,BAO_0000249,,
1484,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,D,,1,,CHEMBL616318,BAO_0000019,,
1485,,,Hippocampus,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,H,,1,,CHEMBL616319,BAO_0000221,10000000.0,
1486,,,Hippocampus,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,H,,1,,CHEMBL616320,BAO_0000221,10000000.0,
1487,,,Hippocampus,B,,,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,D,,1,,CHEMBL616321,BAO_0000221,10000000.0,
1488,,,,F,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,H,,1,,CHEMBL616322,BAO_0000019,,
1489,,,,F,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,H,,1,,CHEMBL616323,BAO_0000019,,
1490,,,,B,,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,H,,1,,CHEMBL616324,BAO_0000357,,
1491,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,H,,1,,CHEMBL616325,BAO_0000221,10000000.0,
1492,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,H,,1,,CHEMBL616326,BAO_0000221,10000000.0,
1493,,,Hippocampus,B,,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,H,,1,,CHEMBL616327,BAO_0000221,10000000.0,
1494,,,,B,,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616328,BAO_0000357,,
1495,,,,B,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),H,,1,,CHEMBL858110,BAO_0000249,,
1496,,,,F,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),H,,1,,CHEMBL616329,BAO_0000249,,
1497,,,,B,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),H,,1,,CHEMBL616330,BAO_0000249,,
1498,,,,F,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),H,,1,,CHEMBL616331,BAO_0000249,,
1499,,,,F,,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,H,,1,,CHEMBL616332,BAO_0000249,,
1500,,,Brain,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,,1,,CHEMBL857063,BAO_0000249,955.0,
1501,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,H,,1,,CHEMBL616333,BAO_0000019,,
1502,,,,F,,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,H,,1,,CHEMBL616334,BAO_0000019,,
1503,,,Hippocampus,B,,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,H,,1,,CHEMBL616335,BAO_0000221,10000000.0,
1504,,,,B,,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,H,,1,,CHEMBL616336,BAO_0000019,,
1505,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,H,,1,,CHEMBL616337,BAO_0000249,,
1506,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,H,,1,,CHEMBL616338,BAO_0000019,,
1507,,,Hippocampus,B,,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,H,,1,,CHEMBL616339,BAO_0000221,10000000.0,
1508,,,Hippocampus,B,,,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,H,,1,,CHEMBL616340,BAO_0000221,10000000.0,
1509,,,,B,,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,H,,1,,CHEMBL616341,BAO_0000357,,
1510,,,,B,,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616342,BAO_0000357,,
1511,,,,B,,,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,D,,1,,CHEMBL616343,BAO_0000019,,
1512,,,,B,,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,H,,1,,CHEMBL616344,BAO_0000019,,
1513,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,H,,1,,CHEMBL616345,BAO_0000357,,
1514,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,H,,1,,CHEMBL616346,BAO_0000019,,
1515,,,Hippocampus,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,H,,1,,CHEMBL616347,BAO_0000221,10000000.0,
1516,,,,B,,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,H,,1,,CHEMBL616348,BAO_0000019,,
1517,,,,B,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616349,BAO_0000357,,
1518,Membranes,,,B,,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,D,,1,,CHEMBL616152,BAO_0000249,,
1519,,,,B,,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,H,,1,,CHEMBL616153,BAO_0000249,,
1520,,,,B,,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",H,,1,,CHEMBL616154,BAO_0000019,,
1521,,,,B,,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,H,,1,,CHEMBL616155,BAO_0000019,,
1522,,,Hippocampus,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,D,,1,,CHEMBL616156,BAO_0000221,10000000.0,
1523,,,Hippocampus,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,D,,1,,CHEMBL616157,BAO_0000221,10000000.0,
1524,,,Hippocampus,B,,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,H,,1,,CHEMBL616158,BAO_0000221,10000000.0,
1525,,,,B,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,H,,1,,CHEMBL616159,BAO_0000357,,
1526,,,,B,,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,H,,1,,CHEMBL616160,BAO_0000357,,
1527,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,H,,1,,CHEMBL616161,BAO_0000019,,
1528,,,,F,,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,H,,1,,CHEMBL616162,BAO_0000019,,
1529,,,,B,,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,D,,1,,CHEMBL616163,BAO_0000357,,
1530,Membranes,,,B,,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,H,,1,,CHEMBL616164,BAO_0000249,,
1531,,,Brain,B,,,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,H,,1,,CHEMBL616165,BAO_0000221,955.0,
1532,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,H,,1,,CHEMBL616355,BAO_0000019,,
1533,,,,F,,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,H,,1,,CHEMBL616356,BAO_0000019,,
1534,,,Brain,B,,,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,H,,1,,CHEMBL616357,BAO_0000221,955.0,
1535,,,,B,,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",H,,1,,CHEMBL616358,BAO_0000019,,
1536,,,,B,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616359,BAO_0000357,,
1537,,,,B,,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,H,,1,,CHEMBL616360,BAO_0000357,,
1538,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616361,BAO_0000357,,
1539,,,,B,,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616362,BAO_0000357,,
1540,Brain membranes,,,B,,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,H,,1,,CHEMBL616363,BAO_0000249,,
1541,,,,B,,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,H,,1,,CHEMBL616364,BAO_0000357,,
1542,,,,B,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616365,BAO_0000357,,
1543,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616366,BAO_0000357,,
1544,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL872906,BAO_0000357,,
1545,,,,B,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,H,,1,,CHEMBL616367,BAO_0000357,,
1546,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616368,BAO_0000357,,
1547,,,,B,,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,H,,1,,CHEMBL616369,BAO_0000357,,
1548,,,,B,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,D,,1,,CHEMBL616370,BAO_0000357,,
1549,,,,B,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,D,,1,,CHEMBL616371,BAO_0000357,,
1550,,,,B,CHO,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,,1,,CHEMBL616372,BAO_0000219,,
1551,,,,B,,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,H,,1,,CHEMBL616373,BAO_0000219,,
1552,,In vivo,,B,,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616374,BAO_0000218,,
1553,,,Hippocampus,B,,,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,1,,CHEMBL616375,BAO_0000221,10000000.0,
1554,,,,B,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,H,,1,,CHEMBL616376,BAO_0000357,,
1555,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,H,,1,,CHEMBL857064,BAO_0000357,,
1556,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,H,,1,,CHEMBL616377,BAO_0000357,,
1557,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,H,,1,,CHEMBL616378,BAO_0000357,,
1558,,,,B,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616379,BAO_0000357,,
1559,,,,B,,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616380,BAO_0000357,,
1560,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,H,,1,,CHEMBL616381,BAO_0000357,,
1561,,,,B,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616382,BAO_0000357,,
1562,,,,B,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,H,,1,,CHEMBL616383,BAO_0000357,,
1563,,,,B,CHO,449.0,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,D,,1,,CHEMBL616350,BAO_0000219,,
1564,,,,B,,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616351,BAO_0000357,,
1565,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,H,,1,,CHEMBL616352,BAO_0000357,,
1566,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616353,BAO_0000357,,
1567,,,,B,,,,Binding affinity against serotonergic 5-HT1a receptor,H,,1,,CHEMBL616354,BAO_0000357,,
1568,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616508,BAO_0000357,,
1569,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616559,BAO_0000357,,
1570,,,,B,,,,Binding affinity at 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616560,BAO_0000357,,
1571,,,,B,,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",H,,1,,CHEMBL616561,BAO_0000357,,
1572,,,,B,CHO,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,,1,,CHEMBL616562,BAO_0000219,,
1573,,,,B,CHO,449.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,,1,,CHEMBL616563,BAO_0000219,,
1574,,,,B,,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616564,BAO_0000357,,
1575,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,H,,1,,CHEMBL616565,BAO_0000357,,
1576,,,,B,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616566,BAO_0000218,,
1577,,,,B,,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,H,,1,,CHEMBL616989,BAO_0000357,,
1578,,,,B,,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL857975,BAO_0000357,,
1579,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,D,,1,,CHEMBL616990,BAO_0000357,,
1580,,,,B,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,H,,1,,CHEMBL616991,BAO_0000357,,
1581,,,,B,,,,Tested against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616992,BAO_0000357,,
1582,,,,B,,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL616993,BAO_0000357,,
1583,,,,B,,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,H,,1,,CHEMBL616994,BAO_0000019,,
1584,,,,B,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,H,,1,,CHEMBL616995,BAO_0000019,,
1585,,,,B,HEK293,722.0,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,D,,1,,CHEMBL616996,BAO_0000219,,
1586,,In vivo,,F,,,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,H,,1,,CHEMBL616997,BAO_0000218,,
1587,,In vivo,,F,,,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,H,,1,,CHEMBL616998,BAO_0000218,,
1588,,,,F,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,H,,1,,CHEMBL616999,BAO_0000019,,
1589,,,,F,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,H,,1,,CHEMBL617000,BAO_0000019,,
1590,,,,F,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,H,,1,,CHEMBL617001,BAO_0000019,,
1591,,,,F,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,H,,1,,CHEMBL858111,BAO_0000019,,
1592,,,,F,,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,H,,1,,CHEMBL617002,BAO_0000019,,
1593,,,,F,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),H,,1,,CHEMBL617003,BAO_0000019,,
1594,,,,F,,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),H,,1,,CHEMBL617004,BAO_0000019,,
1595,,,,F,,,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,D,,1,,CHEMBL617005,BAO_0000019,,
1596,,,,F,CHO-K1,485.0,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,D,,1,,CHEMBL616623,BAO_0000219,,
1597,,,,F,CHO,449.0,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,H,,1,,CHEMBL616624,BAO_0000219,,
1598,,,,B,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL883243,BAO_0000357,,
1599,,,,F,,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,H,,1,,CHEMBL616625,BAO_0000019,,
1600,,,,F,CHO,449.0,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",H,,1,,CHEMBL616626,BAO_0000219,,
1601,,,,F,CHO,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,H,,1,,CHEMBL616627,BAO_0000219,,
1602,,,,F,CHO,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,H,,1,,CHEMBL616628,BAO_0000219,,
1603,,,,F,CHO,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,H,,1,,CHEMBL616629,BAO_0000219,,
1604,,,,F,CHO,449.0,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,H,,1,,CHEMBL616630,BAO_0000219,,
1605,,,,F,,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",H,,1,,CHEMBL616631,BAO_0000019,,
1606,,,,F,,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",H,,1,,CHEMBL616632,BAO_0000019,,
1607,,,,B,,,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,D,,1,,CHEMBL616633,BAO_0000357,,
1608,,,,B,CHO,449.0,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,H,,1,,CHEMBL616634,BAO_0000219,,
1609,,,,B,,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,H,,1,,CHEMBL616635,BAO_0000357,,
1610,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1B receptor,D,,1,,CHEMBL885358,BAO_0000357,,
1611,,,,B,CHO,449.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,D,,1,,CHEMBL616636,BAO_0000219,,
1612,,,,B,CHO,449.0,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,H,,1,,CHEMBL616637,BAO_0000219,,
1613,,,,B,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616638,BAO_0000357,,
1614,,,,B,CHO,449.0,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,H,,1,,CHEMBL616639,BAO_0000219,,
1615,,,,B,CHO,449.0,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,H,,1,,CHEMBL616640,BAO_0000219,,
1616,,,,B,CHO,449.0,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,H,,1,,CHEMBL616641,BAO_0000219,,
1617,,,,B,CHO,449.0,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,H,,1,,CHEMBL616642,BAO_0000219,,
1618,,,,B,CHO,449.0,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,H,,1,,CHEMBL616643,BAO_0000219,,
1619,,,,B,,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),H,,1,,CHEMBL616644,BAO_0000357,,
1620,,,,B,,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,H,,1,,CHEMBL616645,BAO_0000357,,
1621,,,,F,,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),H,,1,,CHEMBL616646,BAO_0000019,,
1622,,,,F,,,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),H,,1,,CHEMBL616647,BAO_0000019,,
1623,,,,B,,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),H,,1,,CHEMBL616509,BAO_0000357,,
1624,,,,B,,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),H,,1,,CHEMBL616510,BAO_0000357,,
1625,,,,B,,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616511,BAO_0000357,,
1626,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,H,,1,,CHEMBL616512,BAO_0000357,,
1627,,,,B,,,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,H,,1,,CHEMBL616513,BAO_0000357,,
1628,,,Striatum,B,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,H,,1,,CHEMBL616514,BAO_0000019,2435.0,
1629,,,,B,,,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,H,,1,,CHEMBL616515,BAO_0000357,,
1630,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,H,,1,,CHEMBL616516,BAO_0000019,,
1631,,,,B,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,H,,1,,CHEMBL616517,BAO_0000357,,
1632,,,,B,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,H,,1,,CHEMBL616518,BAO_0000357,,
1633,,,,B,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,H,,1,,CHEMBL616519,BAO_0000357,,
1634,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,H,,1,,CHEMBL616520,BAO_0000357,,
1635,,,,B,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,H,,1,,CHEMBL616521,BAO_0000357,,
1636,,,,B,,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,H,,1,,CHEMBL616522,BAO_0000357,,
1637,,,,B,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,H,,1,,CHEMBL884531,BAO_0000357,,
1638,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,H,,1,,CHEMBL616523,BAO_0000357,,
1639,,,Striatum,B,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,H,,1,,CHEMBL616731,BAO_0000019,2435.0,
1640,,,,B,,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,H,,1,,CHEMBL616732,BAO_0000019,,
1641,,,,B,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,H,,1,,CHEMBL616733,BAO_0000357,,
1642,,,,B,,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,H,,1,,CHEMBL616734,BAO_0000357,,
1643,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,H,,1,,CHEMBL616735,BAO_0000249,,
1644,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,H,,1,,CHEMBL616736,BAO_0000249,,
1645,,,,F,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,,1,,CHEMBL616737,BAO_0000019,,
1646,,,,B,,,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,H,,1,,CHEMBL616738,BAO_0000019,,
1647,,,,F,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,,1,,CHEMBL616739,BAO_0000019,,
1648,,,,F,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,,1,,CHEMBL616740,BAO_0000019,,
1649,,,,F,,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,,1,,CHEMBL616741,BAO_0000019,,
1650,,,,B,HEK293,722.0,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,H,,1,,CHEMBL616742,BAO_0000219,,
1651,,,,B,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,D,,1,,CHEMBL616743,BAO_0000019,,
1652,,,,B,,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,D,,1,,CHEMBL616744,BAO_0000019,,
1653,,,,F,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,D,,1,,CHEMBL616745,BAO_0000019,,
1654,,,,F,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,,1,,CHEMBL616746,BAO_0000019,,
1655,,,,F,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,D,,1,,CHEMBL616747,BAO_0000019,,
1656,,,,F,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,D,,1,,CHEMBL616748,BAO_0000019,,
1657,,,,F,,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,D,,1,,CHEMBL616648,BAO_0000019,,
1658,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,D,,1,,CHEMBL616649,BAO_0000357,,
1659,,,,B,,,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,D,,1,,CHEMBL616650,BAO_0000357,,
1660,,,,F,,,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,,1,,CHEMBL616651,BAO_0000218,,
1661,,,,F,,,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,,1,,CHEMBL616652,BAO_0000218,,
1662,,,,F,,,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,,1,,CHEMBL616653,BAO_0000218,,
1663,,,,F,,,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,D,,1,,CHEMBL616654,BAO_0000218,,
1664,,,,B,,,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,D,,1,,CHEMBL616655,BAO_0000019,,
1665,,,,B,,,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,D,,1,,CHEMBL616656,BAO_0000357,,
1666,,,,B,,,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,H,,1,,CHEMBL616657,BAO_0000019,,
1667,,,Striatum,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,D,,1,,CHEMBL616658,BAO_0000357,2435.0,
1668,,,,B,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,D,,1,,CHEMBL616659,BAO_0000357,,
1669,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616660,BAO_0000357,,
1670,,,,B,,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,H,,1,,CHEMBL616661,BAO_0000357,,
1671,,,,F,,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616662,BAO_0000019,,
1672,,,,F,,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616663,BAO_0000019,,
1673,,,,F,,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616664,BAO_0000019,,
1674,,,,F,CHO,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",D,,1,,CHEMBL881820,BAO_0000219,,
1675,,,,F,CHO,449.0,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",H,,1,,CHEMBL616665,BAO_0000219,,
1676,,,,B,CHO,449.0,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616666,BAO_0000219,,
1677,,,,B,CHO,449.0,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616667,BAO_0000219,,
1678,,,,F,CHO,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",H,,1,,CHEMBL616668,BAO_0000219,,
1679,,,,F,CHO,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",D,,1,,CHEMBL616669,BAO_0000219,,
1680,,,,F,CHO,449.0,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",H,,1,,CHEMBL617040,BAO_0000219,,
1681,,,,F,CHO,449.0,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",H,,1,,CHEMBL617041,BAO_0000219,,
1682,,,,F,CHO,449.0,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",H,,1,,CHEMBL617042,BAO_0000219,,
1683,,,,F,CHO,449.0,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",H,,1,,CHEMBL617043,BAO_0000219,,
1684,,,,F,,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL617044,BAO_0000019,,
1685,,,,F,CHO,449.0,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL617045,BAO_0000219,,
1686,,,,F,CHO,449.0,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",D,,1,,CHEMBL617046,BAO_0000219,,
1687,,,,F,CHO,449.0,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",D,,1,,CHEMBL617047,BAO_0000219,,
1688,,,,F,,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",H,,1,,CHEMBL617048,BAO_0000019,,
1689,,,,F,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",H,,1,,CHEMBL616897,BAO_0000019,,
1690,,,,F,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",D,,1,,CHEMBL616898,BAO_0000019,,
1691,,,,F,CHO,449.0,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,D,,1,,CHEMBL858201,BAO_0000219,,
1692,,,,F,,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616899,BAO_0000019,,
1693,,In vitro,,B,,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),H,,1,,CHEMBL616900,BAO_0000219,,
1694,,,,B,CHO,449.0,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,H,,1,,CHEMBL616901,BAO_0000219,,
1695,,,,B,,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,H,,1,,CHEMBL616902,BAO_0000357,,
1696,,,,B,CHO,449.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,D,,1,,CHEMBL616903,BAO_0000219,,
1697,,,,B,CHO,449.0,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,H,,1,,CHEMBL616904,BAO_0000219,,
1698,,,,B,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616905,BAO_0000357,,
1699,,,,B,CHO,449.0,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,H,,1,,CHEMBL616906,BAO_0000219,,
1700,,,,B,CHO,449.0,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,H,,1,,CHEMBL616907,BAO_0000219,,
1701,,,,B,CHO,449.0,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,H,,1,,CHEMBL616908,BAO_0000219,,
1702,,,,B,CHO,449.0,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,D,,1,,CHEMBL616909,BAO_0000219,,
1703,,,,B,CHO,449.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,D,,1,,CHEMBL616910,BAO_0000219,,
1704,,,,B,CHO,449.0,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,H,,1,,CHEMBL616911,BAO_0000219,,
1705,,,,B,CHO,449.0,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,H,,1,,CHEMBL616912,BAO_0000219,,
1706,,,,B,,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),H,,1,,CHEMBL616913,BAO_0000357,,
1707,,,,B,CHO,449.0,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,D,,1,,CHEMBL616914,BAO_0000219,,
1708,,,,B,CHO,449.0,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,H,,1,,CHEMBL616915,BAO_0000219,,
1709,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,H,,1,,CHEMBL616916,BAO_0000019,,
1710,,,,B,,,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,D,,1,,CHEMBL616917,BAO_0000357,,
1711,,,,B,,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",H,,1,,CHEMBL616918,BAO_0000357,,
1712,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,H,,1,,CHEMBL616919,BAO_0000219,,
1713,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,H,,1,,CHEMBL616920,BAO_0000357,,
1714,,,,B,,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,H,,1,,CHEMBL872914,BAO_0000357,,
1715,,,,B,,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,H,,1,,CHEMBL616921,BAO_0000357,,
1716,,,,B,,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616922,BAO_0000357,,
1717,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616923,BAO_0000357,,
1718,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616924,BAO_0000357,,
1719,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,H,,1,,CHEMBL875909,BAO_0000357,,
1720,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,H,,1,,CHEMBL616925,BAO_0000357,,
1721,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,H,,1,,CHEMBL616926,BAO_0000357,,
1722,,,,B,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616927,BAO_0000357,,
1723,,,,F,CHO-K1,485.0,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,H,,1,,CHEMBL616928,BAO_0000219,,
1724,,In vitro,,B,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),D,,1,,CHEMBL616929,BAO_0000219,,
1725,,,,B,,,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,D,,1,,CHEMBL616930,BAO_0000357,,
1726,,,,B,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616931,BAO_0000019,,
1727,,,,B,,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,H,,1,,CHEMBL616932,BAO_0000357,,
1728,,,,B,,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616933,BAO_0000357,,
1729,,,,B,,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,D,,1,,CHEMBL616934,BAO_0000219,,
1730,,,,B,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,D,,1,,CHEMBL616935,BAO_0000357,,
1731,,,,B,,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,H,,1,,CHEMBL616936,BAO_0000357,,
1732,,,,B,,,,Affinity for 5-hydroxytryptamine 1D receptor subtype,D,,1,,CHEMBL616937,BAO_0000357,,
1733,,,,B,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,D,,1,,CHEMBL616938,BAO_0000357,,
1734,,,,B,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616939,BAO_0000019,,
1735,,,,B,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,H,,1,,CHEMBL616940,BAO_0000019,,
1736,,,,B,,,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,D,,1,,CHEMBL616941,BAO_0000357,,
1737,,,,B,CHO-K1,485.0,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,H,,1,,CHEMBL616942,BAO_0000219,,
1738,,,,B,CHO-K1,485.0,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,H,,1,,CHEMBL616943,BAO_0000219,,
1739,,,,B,CHO,449.0,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,H,,1,,CHEMBL616944,BAO_0000219,,
1740,,,,F,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",H,,1,,CHEMBL616945,BAO_0000019,,
1741,,,,B,,,,Binding activity radioligand.,H,,1,,CHEMBL616946,BAO_0000357,,
1742,,,,B,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,,1,,CHEMBL616947,BAO_0000019,,
1743,,,,B,CHO-K1,485.0,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616948,BAO_0000219,,
1744,,,,B,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616851,BAO_0000357,,
1745,,,,B,,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616852,BAO_0000357,,
1746,,,,B,,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616853,BAO_0000357,,
1747,,,,B,,,,Binding activity against human 5-hydroxytryptamine 1D receptor,D,,1,,CHEMBL616854,BAO_0000357,,
1748,,,,B,CHO,449.0,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,D,,1,,CHEMBL616855,BAO_0000219,,
1749,,,,B,CHO,449.0,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,H,,1,,CHEMBL616856,BAO_0000219,,
1750,,,,B,CHO,449.0,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,,1,,CHEMBL616857,BAO_0000219,,
1751,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616858,BAO_0000357,,
1752,,,,B,CHO,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,H,,1,,CHEMBL616859,BAO_0000219,,
1753,,,,B,CHO,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,H,,1,,CHEMBL616860,BAO_0000219,,
1754,,,,B,HEK293,722.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,H,,1,,CHEMBL616861,BAO_0000219,,
1755,,,,B,HEK293,722.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,H,,1,,CHEMBL616541,BAO_0000219,,
1756,,,,B,HEK293,722.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,H,,1,,CHEMBL616542,BAO_0000219,,
1757,,,,B,CHO,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,H,,1,,CHEMBL616543,BAO_0000219,,
1758,,,,B,,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,D,,1,,CHEMBL616544,BAO_0000357,,
1759,,,,B,CHO,449.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,H,,1,,CHEMBL616545,BAO_0000219,,
1760,,,,B,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,H,,1,,CHEMBL616546,BAO_0000357,,
1761,,,,B,CHO,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,H,,1,,CHEMBL616547,BAO_0000219,,
1762,,,,B,CHO,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",H,,1,,CHEMBL616548,BAO_0000219,,
1763,,,,F,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,H,,1,,CHEMBL616549,BAO_0000019,,
1764,,,,F,,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,H,,1,,CHEMBL616550,BAO_0000019,,
1765,,,,B,,,,Binding affinity against 5-HT2C receptor,H,,1,,CHEMBL857066,BAO_0000357,,
1766,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616551,BAO_0000357,,
1767,,,,B,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,H,,1,,CHEMBL616552,BAO_0000357,,
1768,,,,F,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,H,,1,,CHEMBL832876,BAO_0000019,,
1769,,,,B,,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",H,,1,,CHEMBL616553,BAO_0000019,,
1770,,,,B,,,,Binding affinity towards 5-HT1B was determined,H,,1,,CHEMBL616554,BAO_0000357,,
1771,,,,B,,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,H,,1,,CHEMBL616555,BAO_0000019,,
1772,,,,B,,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",H,,1,,CHEMBL616556,BAO_0000019,,
1773,,,,B,,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",H,,1,,CHEMBL616557,BAO_0000019,,
1774,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,H,,1,,CHEMBL616558,BAO_0000019,,
1775,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,D,,1,,CHEMBL616749,BAO_0000019,,
1776,,,,B,,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,H,,1,,CHEMBL616750,BAO_0000357,,
1777,,,,B,,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",H,,1,,CHEMBL616751,BAO_0000357,,
1778,,,,B,,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,H,,1,,CHEMBL616752,BAO_0000249,,
1779,,,Striatum,B,,,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,H,,1,,CHEMBL616753,BAO_0000019,2435.0,
1780,,,,B,,,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,D,,1,,CHEMBL616754,BAO_0000357,,
1781,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,H,,1,,CHEMBL616755,BAO_0000019,,
1782,,,Striatum,B,,,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,H,,1,,CHEMBL616756,BAO_0000019,2435.0,
1783,,,Striatum,B,,,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,H,,1,,CHEMBL616757,BAO_0000019,2435.0,
1784,,,Striatum,B,,,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,H,,1,,CHEMBL616758,BAO_0000357,2435.0,
1785,,,,B,,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,H,,1,,CHEMBL616759,BAO_0000249,,
1786,,,,B,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,H,,1,,CHEMBL616760,BAO_0000357,,
1787,,,Striatum,B,,,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,H,,1,,CHEMBL616761,BAO_0000019,2435.0,
1788,,,Striatum,B,,,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,H,,1,,CHEMBL616762,BAO_0000019,2435.0,
1789,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,H,,1,,CHEMBL616763,BAO_0000019,,
1790,,,,B,,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,H,,1,,CHEMBL872909,BAO_0000357,,
1791,,,,B,,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616764,BAO_0000357,,
1792,,,,B,,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,D,,1,,CHEMBL616765,BAO_0000357,,
1793,,,Striatum,B,,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,H,,1,,CHEMBL616766,BAO_0000357,2435.0,
1794,,,Striatum,B,,,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,H,,1,,CHEMBL616767,BAO_0000357,2435.0,
1795,,,,B,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616768,BAO_0000357,,
1796,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,H,,1,,CHEMBL616769,BAO_0000357,,
1797,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,H,,1,,CHEMBL616770,BAO_0000019,,
1798,,,,B,,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,H,,1,,CHEMBL616771,BAO_0000019,,
1799,,,Striatum,B,,,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,H,,1,,CHEMBL616772,BAO_0000019,2435.0,
1800,,,,B,,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,H,,1,,CHEMBL616773,BAO_0000019,,
1801,,,,B,,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,H,,1,,CHEMBL616774,BAO_0000019,,
1802,,,,B,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616775,BAO_0000357,,
1803,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,H,,1,,CHEMBL616776,BAO_0000249,,
1804,,,,B,,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,H,,1,,CHEMBL616777,BAO_0000357,,
1805,,,,B,,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,H,,1,,CHEMBL616778,BAO_0000357,,
1806,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,D,,1,,CHEMBL616779,BAO_0000249,,
1807,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,D,,1,,CHEMBL616780,BAO_0000357,,
1808,,,,B,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,H,,1,,CHEMBL616781,BAO_0000019,,
1809,,,,B,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,H,,1,,CHEMBL616782,BAO_0000357,,
1810,,,,B,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,H,,1,,CHEMBL616783,BAO_0000357,,
1811,,,Striatum,B,,,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,H,,1,,CHEMBL616784,BAO_0000019,2435.0,
1812,,,,B,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,H,,1,,CHEMBL616785,BAO_0000357,,
1813,,,Brain,B,,,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,,1,,CHEMBL857067,BAO_0000249,955.0,
1814,,,,B,,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,H,,1,,CHEMBL616786,BAO_0000019,,
1815,,,Brain,B,,,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,,1,,CHEMBL616787,BAO_0000249,955.0,
1816,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,H,,1,,CHEMBL616788,BAO_0000357,,
1817,,,,B,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616789,BAO_0000357,,
1818,,,,B,,,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,D,,1,,CHEMBL616790,BAO_0000019,,
1819,,,,B,,,,Binding affinity at 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616791,BAO_0000357,,
1820,,,,B,,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,H,,1,,CHEMBL616792,BAO_0000019,,
1821,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,D,,1,,CHEMBL616793,BAO_0000249,,
1822,,,,B,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,H,,1,,CHEMBL616794,BAO_0000357,,
1823,,,,B,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,H,,1,,CHEMBL616795,BAO_0000357,,
1824,,,,B,,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,H,,1,,CHEMBL616796,BAO_0000019,,
1825,,,,B,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616797,BAO_0000357,,
1826,Brain membranes,,,B,,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,H,,1,,CHEMBL616798,BAO_0000249,,
1827,,,,B,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,H,,1,,CHEMBL616799,BAO_0000357,,
1828,,,,B,,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,H,,1,,CHEMBL616800,BAO_0000357,,
1829,,,,B,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616801,BAO_0000357,,
1830,,,,B,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,H,,1,,CHEMBL616802,BAO_0000357,,
1831,,,,B,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,H,,1,,CHEMBL616803,BAO_0000357,,
1832,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,H,,1,,CHEMBL857068,BAO_0000357,,
1833,,,,B,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,H,,1,,CHEMBL616804,BAO_0000357,,
1834,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,H,,1,,CHEMBL616805,BAO_0000357,,
1835,,,,B,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616806,BAO_0000357,,
1836,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1B receptor,H,,1,,CHEMBL616807,BAO_0000357,,
1837,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,H,,1,,CHEMBL616808,BAO_0000357,,
1838,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,H,,1,,CHEMBL616809,BAO_0000357,,
1839,,,,B,,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,H,,1,,CHEMBL616810,BAO_0000357,,
1840,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,H,,1,,CHEMBL616811,BAO_0000224,,
1841,,,,B,,,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,H,,1,,CHEMBL616812,BAO_0000357,,
1842,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,H,,1,,CHEMBL616813,BAO_0000357,,
1843,,,,B,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,H,,1,,CHEMBL616814,BAO_0000357,,
1844,,,,B,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,H,,1,,CHEMBL616815,BAO_0000357,,
1845,,,,B,,,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,H,,1,,CHEMBL616816,BAO_0000357,,
1846,,,,B,,,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,H,,1,,CHEMBL616817,BAO_0000357,,
1847,,,,B,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,H,,1,,CHEMBL616818,BAO_0000357,,
1848,,,,B,,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,H,,1,,CHEMBL616819,BAO_0000357,,
1849,,,,B,,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,H,,1,,CHEMBL616820,BAO_0000357,,
1850,,,,B,,,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,H,,1,,CHEMBL616821,BAO_0000019,,
1851,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,H,,1,,CHEMBL616822,BAO_0000357,,
1852,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,H,,1,,CHEMBL616823,BAO_0000019,,
1853,,,,B,,,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,D,,1,,CHEMBL616824,BAO_0000357,,
1854,,,,B,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,D,,1,,CHEMBL616825,BAO_0000357,,
1855,,,,B,,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,D,,1,,CHEMBL616826,BAO_0000357,,
1856,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,D,,1,,CHEMBL616827,BAO_0000019,,
1857,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,D,,1,,CHEMBL616828,BAO_0000357,,
1858,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,D,,1,,CHEMBL616829,BAO_0000357,,
1859,,,,B,,,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,D,,1,,CHEMBL616830,BAO_0000019,,
1860,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,D,,1,,CHEMBL616831,BAO_0000357,,
1861,,,,B,,,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,,1,,CHEMBL616832,BAO_0000019,,
1862,,,,B,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,,1,,CHEMBL616833,BAO_0000019,,
1863,,,,B,,,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,,1,,CHEMBL616834,BAO_0000019,,
1864,,,,B,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,,1,,CHEMBL829595,BAO_0000019,,
1865,,,,B,,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,D,,1,,CHEMBL616835,BAO_0000357,,
1866,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,D,,1,,CHEMBL872910,BAO_0000249,,
1867,,,,B,,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,H,,1,,CHEMBL616836,BAO_0000357,,
1868,,,,B,,,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,D,,1,,CHEMBL616837,BAO_0000357,,
1869,,,,B,,,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,D,,1,,CHEMBL616466,BAO_0000019,,
1870,,,,B,HEK293,722.0,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,D,,1,,CHEMBL616467,BAO_0000219,,
1871,,,,B,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,H,,1,,CHEMBL616468,BAO_0000357,,
1872,,,,B,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,H,,1,,CHEMBL616469,BAO_0000357,,
1873,,,,B,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,H,,1,,CHEMBL616470,BAO_0000357,,
1874,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,H,,1,,CHEMBL616471,BAO_0000357,,
1875,,,,B,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,H,,1,,CHEMBL616472,BAO_0000357,,
1876,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1C receptor,H,,1,,CHEMBL616473,BAO_0000357,,
1877,,,,B,,,,Binding affinity against serotonergic 5-HT1c receptor,H,,1,,CHEMBL616474,BAO_0000357,,
1878,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,H,,1,,CHEMBL616475,BAO_0000357,,
1879,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,H,,1,,CHEMBL616476,BAO_0000357,,
1880,,,,B,,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),H,,1,,CHEMBL616477,BAO_0000019,,
1881,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,H,,1,,CHEMBL616478,BAO_0000224,,
1882,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,H,,1,,CHEMBL616479,BAO_0000224,,
1883,,,,B,,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,H,,1,,CHEMBL616480,BAO_0000019,,
1884,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,D,,1,,CHEMBL616481,BAO_0000019,,
1885,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,D,,1,,CHEMBL616482,BAO_0000249,,
1886,,,Brain,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,D,,1,,CHEMBL884713,BAO_0000221,955.0,
1887,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,H,,1,,CHEMBL616483,BAO_0000224,,
1888,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,H,,1,,CHEMBL616484,BAO_0000224,,
1889,,,,B,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,H,,1,,CHEMBL616485,BAO_0000019,,
1890,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,H,,1,,CHEMBL616486,BAO_0000224,,
1891,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,H,,1,,CHEMBL616487,BAO_0000224,,
1892,,,,B,,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,H,,1,,CHEMBL616488,BAO_0000224,,
1893,,,,B,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,,1,,CHEMBL616489,BAO_0000019,,
1894,,,,B,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,,1,,CHEMBL616490,BAO_0000019,,
1895,,,,B,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,H,,1,,CHEMBL616491,BAO_0000019,,
1896,,,,B,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,H,,1,,CHEMBL616492,BAO_0000019,,
1897,,,,B,,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,,1,,CHEMBL616493,BAO_0000019,,
1898,,,,B,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,H,,1,,CHEMBL616494,BAO_0000019,,
1899,,,,B,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,H,,1,,CHEMBL616495,BAO_0000019,,
1900,,,,B,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,H,,1,,CHEMBL616496,BAO_0000019,,
1901,,,,B,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,,1,,CHEMBL616497,BAO_0000019,,
1902,,,,B,,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,,1,,CHEMBL616498,BAO_0000019,,
1903,,,,B,,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,H,,1,,CHEMBL616499,BAO_0000019,,
1904,,,,B,,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,H,,1,,CHEMBL616500,BAO_0000019,,
1905,,,Brain,B,,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,D,,1,,CHEMBL616501,BAO_0000221,955.0,
1906,,,Brain,B,,,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,H,,1,,CHEMBL616502,BAO_0000221,955.0,
1907,Membranes,,,B,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,H,,1,,CHEMBL884529,BAO_0000249,,
1908,Membranes,,,B,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,H,,1,,CHEMBL616503,BAO_0000249,,
1909,,,,B,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL616964,BAO_0000224,,
1910,Membranes,,,B,,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,H,,1,,CHEMBL616965,BAO_0000249,,
1911,,,,B,,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,H,,1,,CHEMBL616966,BAO_0000224,,
1912,,,,B,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,H,,1,,CHEMBL616967,BAO_0000224,,
1913,,,,B,,,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,D,,1,,CHEMBL616968,BAO_0000224,,
1914,,,,B,,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,H,,1,,CHEMBL616969,BAO_0000224,,
1915,,,,B,,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,H,,1,,CHEMBL884530,BAO_0000019,,
1916,,,,B,,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL616970,BAO_0000224,,
1917,,,,B,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,H,,1,,CHEMBL616971,BAO_0000224,,
1918,,,,B,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",H,,1,,CHEMBL616972,BAO_0000224,,
1919,,,,B,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,H,,1,,CHEMBL616973,BAO_0000224,,
1920,,,,B,,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,H,,1,,CHEMBL616974,BAO_0000224,,
1921,,,,B,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,H,,1,,CHEMBL616975,BAO_0000019,,
1922,,,,B,,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,H,,1,,CHEMBL616976,BAO_0000019,,
1923,,,,B,,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,H,,1,,CHEMBL616977,BAO_0000224,,
1924,,,,B,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,H,,1,,CHEMBL616978,BAO_0000224,,
1925,,,,B,,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,H,,1,,CHEMBL616979,BAO_0000224,,
1926,,,,B,,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL616980,BAO_0000224,,
1927,Membranes,,,B,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,H,,1,,CHEMBL616981,BAO_0000249,,
1928,Membranes,,,B,,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,H,,1,,CHEMBL616982,BAO_0000249,,
1929,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,H,,1,,CHEMBL616983,BAO_0000224,,
1930,,,,B,,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,H,,1,,CHEMBL616984,BAO_0000019,,
1931,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,D,,1,,CHEMBL616985,BAO_0000224,,
1932,,,,B,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,H,,1,,CHEMBL616986,BAO_0000224,,
1933,,,,B,,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,H,,1,,CHEMBL616987,BAO_0000224,,
1934,,,,B,,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,H,,1,,CHEMBL616988,BAO_0000019,,
1935,,,,B,,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,H,,1,,CHEMBL617243,BAO_0000019,,
1936,,,,B,,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,H,,1,,CHEMBL617244,BAO_0000019,,
1937,,,,B,CHO-K1,485.0,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,D,,1,,CHEMBL617245,BAO_0000219,,
1938,Membranes,,,B,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,H,,1,,CHEMBL617246,BAO_0000249,,
1939,,,,B,,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),H,,1,,CHEMBL617546,BAO_0000224,,
1940,Brain membranes,,,B,,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),H,,1,,CHEMBL617547,BAO_0000249,,
1941,,In vitro,,B,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,H,,1,,CHEMBL617548,BAO_0000219,,
1942,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617549,BAO_0000224,,
1943,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,H,,1,,CHEMBL617550,BAO_0000224,,
1944,,,,B,,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,H,,1,,CHEMBL617551,BAO_0000224,,
1945,Membranes,,,B,,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,H,,1,,CHEMBL617552,BAO_0000249,,
1946,Membranes,,,B,,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,H,,1,,CHEMBL617553,BAO_0000249,,
1947,,,Thoracic aorta,F,,,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,H,,1,,CHEMBL617554,BAO_0000019,1515.0,
1948,,,,B,,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617555,BAO_0000019,,
1949,,,,B,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,H,,1,,CHEMBL617556,BAO_0000224,,
1950,,,,B,,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,H,,1,,CHEMBL617557,BAO_0000357,,
1951,,,,B,,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,H,,1,,CHEMBL617558,BAO_0000357,,
1952,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,H,,1,,CHEMBL617559,BAO_0000357,,
1953,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1D receptor,D,,1,,CHEMBL617560,BAO_0000357,,
1954,,,,B,,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,H,,1,,CHEMBL617561,BAO_0000249,,
1955,,,,B,,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,H,,1,,CHEMBL617562,BAO_0000249,,
1956,,,Striatum,B,,,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,H,,1,,CHEMBL617563,BAO_0000357,2435.0,
1957,,,,F,,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL617564,BAO_0000019,,
1958,,,,B,,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,H,,1,,CHEMBL617565,BAO_0000019,,
1959,,,,B,,,,Binding activity radioligand.,H,,1,,CHEMBL856076,BAO_0000357,,
1960,,,,B,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,H,,1,,CHEMBL617566,BAO_0000019,,
1961,,,,B,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,,1,,CHEMBL875911,BAO_0000019,,
1962,,,,B,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,H,,1,,CHEMBL617567,BAO_0000019,,
1963,,,,B,,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,H,,1,,CHEMBL617568,BAO_0000249,,
1964,,,,B,,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,H,,1,,CHEMBL617569,BAO_0000019,,
1965,,,,B,,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,H,,1,,CHEMBL617570,BAO_0000249,,
1966,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,H,,1,,CHEMBL617571,BAO_0000357,,
1967,,,,B,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,H,,1,,CHEMBL617572,BAO_0000357,,
1968,,,,B,,,,The compound was tested for intrinsic activity against 5-HT1D receptor,H,,1,,CHEMBL617573,BAO_0000357,,
1969,,,,B,,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,H,,1,,CHEMBL617574,BAO_0000019,,
1970,,,,B,,,,The compound was tested for binding affinity against 5-HT1D receptor,H,,1,,CHEMBL617575,BAO_0000357,,
1971,,,,B,,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,H,,1,,CHEMBL617576,BAO_0000357,,
1972,,,,F,,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,H,,1,,CHEMBL617577,BAO_0000019,,
1973,,,,F,,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL617578,BAO_0000019,,
1974,,,,B,,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL617579,BAO_0000357,,
1975,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,H,,1,,CHEMBL617580,BAO_0000019,,
1976,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,H,,1,,CHEMBL617581,BAO_0000249,,
1977,,,,B,,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,H,,1,,CHEMBL617582,BAO_0000357,,
1978,,,,B,,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,H,,1,,CHEMBL617583,BAO_0000019,,
1979,,,,B,,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,H,,1,,CHEMBL617584,BAO_0000357,,
1980,,,,B,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL617585,BAO_0000357,,
1981,,,,B,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,H,,1,,CHEMBL875912,BAO_0000357,,
1982,,,,B,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL617586,BAO_0000357,,
1983,,,,B,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,H,,1,,CHEMBL617587,BAO_0000357,,
1984,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,H,,1,,CHEMBL617588,BAO_0000357,,
1985,,,,B,,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL857980,BAO_0000357,,
1986,,,,B,,,,Tested against 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL617589,BAO_0000357,,
1987,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,H,,1,,CHEMBL617590,BAO_0000357,,
1988,,,,B,HEK293,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,H,,1,,CHEMBL617591,BAO_0000219,,
1989,,,,B,,,,Binding affinity against 5-Hydroxytryptamine 1D receptor,D,,1,,CHEMBL617592,BAO_0000357,,
1990,,,,B,,,,,H,,1,,CHEMBL617593,BAO_0000357,,
1991,,,,B,CHO-K1,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,H,,1,,CHEMBL617594,BAO_0000219,,
1992,,,,B,CHO-K1,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,H,,1,,CHEMBL617595,BAO_0000219,,
1993,,,,B,HEK293,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,H,,1,,CHEMBL617596,BAO_0000219,,
1994,,,,B,HEK293,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,H,,1,,CHEMBL617597,BAO_0000219,,
1995,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,H,,1,,CHEMBL617598,BAO_0000019,,
1996,,,,B,,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,H,,1,,CHEMBL872916,BAO_0000357,,
1997,,,,B,,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,H,,1,,CHEMBL617599,BAO_0000357,,
1998,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,H,,1,,CHEMBL617091,BAO_0000357,,
1999,,,,B,CHO-K1,485.0,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",H,,1,,CHEMBL617092,BAO_0000219,,
2000,,,,B,CHO-K1,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,H,,1,,CHEMBL617093,BAO_0000219,,
2001,,,,F,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,H,,1,,CHEMBL617094,BAO_0000019,,
2002,,,,F,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,H,,1,,CHEMBL617095,BAO_0000019,,
2003,,,,F,,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,H,,1,,CHEMBL617096,BAO_0000019,,
2004,,,,F,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,H,,1,,CHEMBL617097,BAO_0000019,,
2005,,,,F,,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,H,,1,,CHEMBL617098,BAO_0000019,,
2006,,,,B,,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,H,,1,,CHEMBL617301,BAO_0000357,,
2007,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,H,,1,,CHEMBL617302,BAO_0000357,,
2008,,,,B,,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,H,,1,,CHEMBL617303,BAO_0000357,,
2009,,,,B,,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,H,,1,,CHEMBL617304,BAO_0000357,,
2010,,,,B,CHO,449.0,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",H,,1,,CHEMBL617305,BAO_0000219,,
2011,,,,B,,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,D,,1,,CHEMBL617306,BAO_0000219,,
2012,,,,B,,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,H,,1,,CHEMBL617307,BAO_0000357,,
2013,,,,B,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,H,,1,,CHEMBL617308,BAO_0000019,,
2014,,,,B,,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,H,,1,,CHEMBL617309,BAO_0000357,,
2015,,,,B,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,H,,1,,CHEMBL617310,BAO_0000357,,
2016,,,,B,,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,H,,1,,CHEMBL617311,BAO_0000357,,
2017,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL617312,BAO_0000357,,
2018,,,,B,,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,H,,1,,CHEMBL617313,BAO_0000357,,
2019,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,H,,1,,CHEMBL617314,BAO_0000357,,
2020,,,,F,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,H,,1,,CHEMBL617315,BAO_0000019,,
2021,,,,B,HEK293,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,H,,1,,CHEMBL617316,BAO_0000219,,
2022,,,,B,HEK293,722.0,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,H,,1,,CHEMBL617317,BAO_0000219,,
2023,,,,B,CHO,449.0,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",H,,1,,CHEMBL617318,BAO_0000219,,
2024,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,H,,1,,CHEMBL617319,BAO_0000019,,
2025,,,,B,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,D,,1,,CHEMBL617320,BAO_0000357,,
2026,,,,B,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,D,,1,,CHEMBL617321,BAO_0000357,,
2027,,,,B,,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,D,,1,,CHEMBL617322,BAO_0000357,,
2028,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616862,BAO_0000357,,
2029,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL616863,BAO_0000357,,
2030,,,,B,CHO,449.0,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,H,,1,,CHEMBL616864,BAO_0000219,,
2031,,,,B,CHO-K1,485.0,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,H,,1,,CHEMBL616865,BAO_0000219,,
2032,,,,B,CHO-K1,485.0,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,H,,1,,CHEMBL616866,BAO_0000219,,
2033,,,,F,,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,H,,1,,CHEMBL616867,BAO_0000019,,
2034,,,,B,CHO-K1,485.0,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",H,,1,,CHEMBL616868,BAO_0000219,,
2035,,,,B,,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,H,,1,,CHEMBL616869,BAO_0000357,,
2036,,,,B,CHO,449.0,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",H,,1,,CHEMBL616870,BAO_0000219,,
2037,,,,F,CHO-K1,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,H,,1,,CHEMBL616871,BAO_0000219,,
2038,,,,F,CHO-K1,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,H,,1,,CHEMBL616872,BAO_0000219,,
2039,,,,F,CHO-K1,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,H,,1,,CHEMBL616873,BAO_0000219,,
2040,,,,F,CHO-K1,485.0,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,H,,1,,CHEMBL616838,BAO_0000219,,
2041,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,H,,1,,CHEMBL616839,BAO_0000357,,
2042,,,,B,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,H,,1,,CHEMBL616840,BAO_0000019,,
2043,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,H,,1,,CHEMBL616841,BAO_0000357,,
2044,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,H,,1,,CHEMBL616842,BAO_0000357,,
2045,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,H,,1,,CHEMBL857976,BAO_0000357,,
2046,,,,B,CHO,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,H,,1,,CHEMBL616843,BAO_0000219,,
2047,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,D,,1,,CHEMBL616844,BAO_0000357,,
2048,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,H,,1,,CHEMBL616845,BAO_0000357,,
2049,,,,B,,,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,D,,1,,CHEMBL616846,BAO_0000357,,
2050,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,H,,1,,CHEMBL616847,BAO_0000357,,
2051,,,,B,,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,H,,1,,CHEMBL616848,BAO_0000019,,
2052,,,,B,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,H,,1,,CHEMBL616849,BAO_0000357,,
2053,,,,B,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,H,,1,,CHEMBL872911,BAO_0000357,,
2054,,,,B,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,H,,1,,CHEMBL616850,BAO_0000019,,
2055,,,,B,CHO,449.0,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,D,,1,,CHEMBL616699,BAO_0000219,,
2056,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,H,,1,,CHEMBL616700,BAO_0000357,,
2057,,,,B,CHO,449.0,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,,1,,CHEMBL616701,BAO_0000219,,
2058,,,,B,CHO,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,H,,1,,CHEMBL616702,BAO_0000219,,
2059,,,,B,CHO,449.0,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,H,,1,,CHEMBL616703,BAO_0000219,,
2060,,,,B,,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,H,,1,,CHEMBL616704,BAO_0000357,,
2061,,,,B,CHO,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,H,,1,,CHEMBL616705,BAO_0000219,,
2062,,,,B,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,H,,1,,CHEMBL616706,BAO_0000357,,
2063,,,,B,CHO,449.0,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,H,,1,,CHEMBL616707,BAO_0000219,,
2064,,,,B,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,H,,1,,CHEMBL616708,BAO_0000357,,
2065,,,,B,,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,H,,1,,CHEMBL616709,BAO_0000357,,
2066,,,,B,CHO,449.0,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,H,,1,,CHEMBL616710,BAO_0000219,,
2067,,,,B,CHO,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,H,,1,,CHEMBL616711,BAO_0000219,,
2068,,,,B,CHO,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",H,,1,,CHEMBL616712,BAO_0000219,,
2069,,,,B,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,H,,1,,CHEMBL616713,BAO_0000357,,
2070,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,H,,1,,CHEMBL616714,BAO_0000357,,
2071,,,,B,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,H,,1,,CHEMBL616715,BAO_0000357,,
2072,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,H,,1,,CHEMBL616716,BAO_0000357,,
2073,,,,F,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",H,,1,,CHEMBL616717,BAO_0000019,,
2074,,,,F,,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",H,,1,,CHEMBL616718,BAO_0000019,,
2075,,,,F,,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,H,,1,,CHEMBL875905,BAO_0000019,,
2076,,,,F,,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,H,,1,,CHEMBL616719,BAO_0000019,,
2077,,,,F,,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",H,,1,,CHEMBL616720,BAO_0000019,,
2078,,,,B,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,H,,1,,CHEMBL616721,BAO_0000357,,
2079,,,,B,CHO,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,H,,1,,CHEMBL616722,BAO_0000219,,
2080,,,,B,,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),H,,1,,CHEMBL616723,BAO_0000357,,
2081,,,,B,CHO,449.0,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,H,,1,,CHEMBL616724,BAO_0000219,,
2082,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,H,,1,,CHEMBL616725,BAO_0000357,,
2083,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,H,,1,,CHEMBL616726,BAO_0000357,,
2084,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,H,,1,,CHEMBL616727,BAO_0000357,,
2085,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,H,,1,,CHEMBL616728,BAO_0000357,,
2086,,,,B,,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,H,,1,,CHEMBL616729,BAO_0000357,,
2087,,,,B,,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,H,,1,,CHEMBL616730,BAO_0000019,,
2088,,,,B,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,H,,1,,CHEMBL617125,BAO_0000357,,
2089,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,H,,1,,CHEMBL857977,BAO_0000357,,
2090,,,,B,CHO,449.0,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,,1,,CHEMBL617126,BAO_0000219,,
2091,,,,B,CHO,449.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,H,,1,,CHEMBL617127,BAO_0000219,,
2092,,,,B,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,H,,1,,CHEMBL617128,BAO_0000357,,
2093,,,,B,CHO,449.0,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,H,,1,,CHEMBL617129,BAO_0000219,,
2094,,,,B,,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,H,,1,,CHEMBL617130,BAO_0000357,,
2095,,,,B,CHO,449.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,H,,1,,CHEMBL617131,BAO_0000219,,
2096,,,,B,CHO,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",H,,1,,CHEMBL617132,BAO_0000219,,
2097,,,,B,CHO,449.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",H,,1,,CHEMBL617133,BAO_0000219,,
2098,,,,B,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,H,,1,,CHEMBL617134,BAO_0000357,,
2099,,,,B,,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,H,,1,,CHEMBL617135,BAO_0000357,,
2100,,,,B,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,H,,1,,CHEMBL617136,BAO_0000357,,
2101,,,,B,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",H,,1,,CHEMBL617137,BAO_0000019,,
2102,,,,B,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",H,,1,,CHEMBL617138,BAO_0000019,,
2103,,,,B,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",H,,1,,CHEMBL617139,BAO_0000019,,
2104,,,,B,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617140,BAO_0000019,,
2105,,In vivo,,F,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",H,,1,,CHEMBL617141,BAO_0000218,,
2106,,,,F,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,,1,,CHEMBL858112,BAO_0000019,,
2107,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,H,,1,,CHEMBL617142,BAO_0000019,,
2108,,,,B,,,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",U,,1,,CHEMBL617143,BAO_0000019,,
2109,,,,B,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,U,,1,,CHEMBL617144,BAO_0000019,,
2110,,,,B,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,U,,1,,CHEMBL617145,BAO_0000019,,
2111,,,,B,,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,U,,1,,CHEMBL617146,BAO_0000019,,
2112,,,,B,,,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,H,,1,,CHEMBL617147,BAO_0000019,,
2113,,,,B,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,H,,1,,CHEMBL617148,BAO_0000019,,
2114,,,,B,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,H,,1,,CHEMBL617149,BAO_0000019,,
2115,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,H,,1,,CHEMBL617150,BAO_0000224,,
2116,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,H,,1,,CHEMBL617151,BAO_0000224,,
2117,,,,B,,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617201,BAO_0000224,,
2118,,,,B,,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,H,,1,,CHEMBL617202,BAO_0000357,,
2119,,In vivo,,B,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,H,,1,,CHEMBL617203,BAO_0000218,,
2120,,,,B,,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,H,,1,,CHEMBL617204,BAO_0000019,,
2121,,,,B,,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,H,,1,,CHEMBL617205,BAO_0000224,,
2122,,,,B,,,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,D,,1,,CHEMBL617206,BAO_0000019,,
2123,,In vivo,,B,,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,H,,1,,CHEMBL617207,BAO_0000218,,
2124,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,D,,1,,CHEMBL617208,BAO_0000019,,
2125,,,,B,,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617209,BAO_0000224,,
2126,,,,B,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,H,,1,,CHEMBL617210,BAO_0000224,,
2127,,,,B,,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,H,,1,,CHEMBL617211,BAO_0000224,,
2128,,,,B,,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,D,,1,,CHEMBL617212,BAO_0000019,,
2129,,,,B,,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,H,,1,,CHEMBL617213,BAO_0000224,,
2130,,,,B,,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,H,,1,,CHEMBL617214,BAO_0000224,,
2131,,,,B,,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,U,,1,,CHEMBL617215,BAO_0000221,,
2132,,,,B,,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,U,,1,,CHEMBL617216,BAO_0000221,,
2133,,,,B,,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617217,BAO_0000357,,
2134,,,,B,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617218,BAO_0000019,,
2135,,,,B,,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL872913,BAO_0000019,,
2136,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,H,,1,,CHEMBL617219,BAO_0000019,,
2137,,,,B,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL873482,BAO_0000224,,
2138,,,,B,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,D,,1,,CHEMBL617220,BAO_0000019,,
2139,,,,B,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,H,,1,,CHEMBL617221,BAO_0000019,,
2140,,,,B,,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,H,,1,,CHEMBL617222,BAO_0000019,,
2141,,,,F,,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,H,,1,,CHEMBL875906,BAO_0000019,,
2142,,,,B,,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,H,,1,,CHEMBL617223,BAO_0000019,,
2143,,,,B,,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617224,BAO_0000224,,
2144,,,,B,,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,D,,1,,CHEMBL617225,BAO_0000224,,
2145,,,,B,,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,H,,1,,CHEMBL617226,BAO_0000224,,
2146,,,,B,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,H,,1,,CHEMBL617227,BAO_0000224,,
2147,,,,B,,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,H,,1,,CHEMBL617228,BAO_0000224,,
2148,,,,B,,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,H,,1,,CHEMBL617229,BAO_0000224,,
2149,,,,B,,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,H,,1,,CHEMBL617230,BAO_0000224,,
2150,,,,B,,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",H,,1,,CHEMBL617231,BAO_0000224,,
2151,,,,B,,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,H,,1,,CHEMBL617232,BAO_0000224,,
2152,,,,B,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617233,BAO_0000224,,
2153,,,,B,,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,H,,1,,CHEMBL617234,BAO_0000224,,
2154,,,,F,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,H,,1,,CHEMBL617235,BAO_0000019,,
2155,,,,F,,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,H,,1,,CHEMBL617236,BAO_0000019,,
2156,,,Hippocampus,B,,,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,H,,1,,CHEMBL617237,BAO_0000221,10000000.0,
2157,,,Hippocampus,B,,,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,H,,1,,CHEMBL617238,BAO_0000221,10000000.0,
2158,,,Brain,B,,,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,D,,1,,CHEMBL617239,BAO_0000221,955.0,
2159,,,,B,,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,H,,1,,CHEMBL617240,BAO_0000019,,
2160,Membranes,,,B,,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,H,,1,,CHEMBL617241,BAO_0000249,,
2161,Membranes,,,B,,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,H,,1,,CHEMBL875907,BAO_0000249,,
2162,,,,B,,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,H,,1,,CHEMBL617242,BAO_0000019,,
2163,,,,F,,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,H,,1,,CHEMBL617152,BAO_0000019,,
2164,,,Brain,B,,,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,D,,1,,CHEMBL617153,BAO_0000221,955.0,
2165,Membranes,,,B,,,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,D,,1,,CHEMBL617154,BAO_0000249,,
2166,,,Brain,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,H,,1,,CHEMBL617155,BAO_0000221,955.0,
2167,,,,F,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,H,,1,,CHEMBL617156,BAO_0000019,,
2168,,,,F,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,H,,1,,CHEMBL617157,BAO_0000019,,
2169,,,,F,,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,,1,,CHEMBL617158,BAO_0000019,,
2170,,,,F,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,H,,1,,CHEMBL617159,BAO_0000019,,
2171,,,,F,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,H,,1,,CHEMBL617160,BAO_0000019,,
2172,,,,F,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,,1,,CHEMBL858113,BAO_0000019,,
2173,,,Brain,B,,,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,H,,1,,CHEMBL617247,BAO_0000220,955.0,
2174,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,H,,1,,CHEMBL617248,BAO_0000019,,
2175,,,Brain,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,,1,,CHEMBL617249,BAO_0000249,955.0,
2176,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,H,,1,,CHEMBL617250,BAO_0000019,,
2177,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,H,,1,,CHEMBL617251,BAO_0000019,,
2178,,,,B,,,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,D,,1,,CHEMBL617252,BAO_0000019,,
2179,,,,B,,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,H,,1,,CHEMBL617006,BAO_0000019,,
2180,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,H,,1,,CHEMBL617007,BAO_0000019,,
2181,,,,F,,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",H,,1,,CHEMBL617008,BAO_0000019,,
2182,,,,B,,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,H,,1,,CHEMBL617009,BAO_0000019,,
2183,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,D,,1,,CHEMBL617010,BAO_0000224,,
2184,,,,B,,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,D,,1,,CHEMBL857978,BAO_0000019,,
2185,,,,B,,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,D,,1,,CHEMBL617011,BAO_0000019,,
2186,,,,B,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,D,,1,,CHEMBL617012,BAO_0000019,,
2187,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,H,,1,,CHEMBL617013,BAO_0000224,,
2188,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,H,,1,,CHEMBL617014,BAO_0000249,,
2189,,,,B,,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617015,BAO_0000019,,
2190,,,,B,,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,H,,1,,CHEMBL617016,BAO_0000019,,
2191,,,,B,,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,H,,1,,CHEMBL617017,BAO_0000224,,
2192,,,Brain,B,,,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,H,,1,,CHEMBL617018,BAO_0000221,955.0,
2193,,,,F,,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,H,,1,,CHEMBL617019,BAO_0000019,,
2194,,,,B,,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,H,,1,,CHEMBL617020,BAO_0000019,,
2195,,,,B,,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,H,,1,,CHEMBL617021,BAO_0000019,,
2196,,,,B,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,H,,1,,CHEMBL617022,BAO_0000019,,
2197,,,,B,,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,H,,1,,CHEMBL617023,BAO_0000019,,
2198,,,,B,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,H,,1,,CHEMBL617024,BAO_0000019,,
2199,,,,B,,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,H,,1,,CHEMBL617025,BAO_0000019,,
2200,,,,B,,,,Hill coefficient of compound was determined,H,,1,,CHEMBL617026,BAO_0000224,,
2201,,,,B,,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,U,,1,,CHEMBL617027,BAO_0000019,,
2202,,,,B,,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,D,,1,,CHEMBL617028,BAO_0000019,,
2203,,,,B,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,H,,1,,CHEMBL617029,BAO_0000019,,
2204,,,,B,,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,H,,1,,CHEMBL875908,BAO_0000019,,
2205,,,,B,,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),H,,1,,CHEMBL617030,BAO_0000357,,
2206,,,,B,,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),H,,1,,CHEMBL617031,BAO_0000019,,
2207,,,,B,,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,H,,1,,CHEMBL617032,BAO_0000019,,
2208,,,,B,,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,D,,1,,CHEMBL617033,BAO_0000224,,
2209,,,,B,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",H,,1,,CHEMBL617034,BAO_0000224,,
2210,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,H,,1,,CHEMBL617035,BAO_0000224,,
2211,,,,B,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",H,,1,,CHEMBL617036,BAO_0000019,,
2212,,,,B,,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617037,BAO_0000224,,
2213,,,,B,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,U,,1,,CHEMBL617038,BAO_0000219,,
2214,,,,B,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",H,,1,,CHEMBL617039,BAO_0000219,,
2215,,,,B,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617161,BAO_0000224,,
2216,,,,B,,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617162,BAO_0000224,,
2217,,,,B,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617163,BAO_0000224,,
2218,,,,B,,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617164,BAO_0000224,,
2219,Brain membranes,,,B,,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,H,,1,,CHEMBL617165,BAO_0000249,,
2220,,,,B,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,H,,1,,CHEMBL617166,BAO_0000224,,
2221,,,,B,,,,Binding affinity towards 5-HT2 receptor,H,,1,,CHEMBL617167,BAO_0000224,,
2222,,,,B,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL872912,BAO_0000224,,
2223,,,,B,,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,H,,1,,CHEMBL617168,BAO_0000224,,
2224,,,,B,,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,H,,1,,CHEMBL617169,BAO_0000224,,
2225,,,,B,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617170,BAO_0000224,,
2226,,,,B,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,H,,1,,CHEMBL617171,BAO_0000224,,
2227,,,,B,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,H,,1,,CHEMBL617172,BAO_0000224,,
2228,,,,B,,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617173,BAO_0000224,,
2229,,,,B,,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,U,,1,,CHEMBL617174,BAO_0000019,,
2230,,,,B,,,,5-hydroxytryptamine 2 receptor binding affinity,H,,1,,CHEMBL617175,BAO_0000224,,
2231,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,H,,1,,CHEMBL617176,BAO_0000357,,
2232,,,,B,,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,H,,1,,CHEMBL617177,BAO_0000357,,
2233,,,,B,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,H,,1,,CHEMBL617178,BAO_0000224,,
2234,,,,B,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,H,,1,,CHEMBL617179,BAO_0000224,,
2235,,,,B,,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,H,,1,,CHEMBL617180,BAO_0000224,,
2236,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,H,,1,,CHEMBL617181,BAO_0000357,,
2237,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617182,BAO_0000357,,
2238,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617183,BAO_0000357,,
2239,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,H,,1,,CHEMBL617184,BAO_0000357,,
2240,,,,B,,,,Binding affinity against serotonergic 5-HT2 receptor,H,,1,,CHEMBL617185,BAO_0000357,,
2241,,,,B,,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,H,,1,,CHEMBL617186,BAO_0000357,,
2242,,,,B,,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,H,,1,,CHEMBL617187,BAO_0000357,,
2243,,,,B,,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617188,BAO_0000357,,
2244,,,,B,,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617189,BAO_0000218,,
2245,,,,B,,,,Inhibitory activity against cloned human 5-HT2 receptor,D,,1,,CHEMBL617190,BAO_0000224,,
2246,,,,B,CHO,449.0,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",D,,1,,CHEMBL617191,BAO_0000219,,
2247,,,,B,CHO,449.0,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",D,,1,,CHEMBL617192,BAO_0000219,,
2248,,,,B,CHO,449.0,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",D,,1,,CHEMBL617193,BAO_0000219,,
2249,,,,B,CHO,449.0,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",D,,1,,CHEMBL617194,BAO_0000219,,
2250,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617195,BAO_0000224,,
2251,,,,B,,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,H,,1,,CHEMBL881830,BAO_0000224,,
2252,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617196,BAO_0000357,,
2253,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,H,,1,,CHEMBL617197,BAO_0000224,,
2254,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,H,,1,,CHEMBL617198,BAO_0000357,,
2255,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL873476,BAO_0000357,,
2256,,,,B,,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,H,,1,,CHEMBL617199,BAO_0000019,,
2257,,,,B,,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617200,BAO_0000357,,
2258,,,,B,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,,1,,CHEMBL617484,BAO_0000357,,
2259,,,,B,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,,1,,CHEMBL617485,BAO_0000357,,
2260,,,,B,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,,1,,CHEMBL617486,BAO_0000357,,
2261,,,,B,,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,H,,1,,CHEMBL858022,BAO_0000357,,
2262,,,,B,CHO,449.0,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,H,,1,,CHEMBL617049,BAO_0000219,,
2263,,,,F,CHO,449.0,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,D,,1,,CHEMBL617050,BAO_0000219,,
2264,,,,F,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,H,,1,,CHEMBL617051,BAO_0000219,,
2265,,,,F,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,H,,1,,CHEMBL617052,BAO_0000219,,
2266,,,,F,,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,H,,1,,CHEMBL617053,BAO_0000219,,
2267,,,,B,CHO,449.0,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",H,,1,,CHEMBL617054,BAO_0000219,,
2268,,,,B,CHO,449.0,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",H,,1,,CHEMBL617055,BAO_0000219,,
2269,,,,B,,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,H,,1,,CHEMBL882924,BAO_0000357,,
2270,,,,B,,,,Inhibition of human 5-hydroxytryptamine 2A receptor,D,,1,,CHEMBL617056,BAO_0000357,,
2271,,,,B,CHO,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,,1,,CHEMBL617057,BAO_0000219,,
2272,,,,B,,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,H,,1,,CHEMBL617058,BAO_0000219,,
2273,,,,B,,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),H,,1,,CHEMBL617059,BAO_0000357,,
2274,,,,B,CHO,449.0,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,H,,1,,CHEMBL617060,BAO_0000219,,
2275,,,,B,CHO,449.0,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,H,,1,,CHEMBL617061,BAO_0000219,,
2276,,,,B,L929,307.0,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,H,,1,,CHEMBL617062,BAO_0000219,,
2277,,,,B,CHO,449.0,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,,1,,CHEMBL617063,BAO_0000219,,
2278,,,,F,,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,H,,1,,CHEMBL617064,BAO_0000019,,
2279,,,,F,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,,1,,CHEMBL617065,BAO_0000019,,
2280,,,,B,CHO,449.0,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,H,,1,,CHEMBL617066,BAO_0000219,,
2281,,,,B,CHO,449.0,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,H,,1,,CHEMBL617067,BAO_0000219,,
2282,,,,F,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,H,,1,,CHEMBL617068,BAO_0000019,,
2283,,,,F,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,H,,1,,CHEMBL617069,BAO_0000019,,
2284,,,,F,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,,1,,CHEMBL617070,BAO_0000019,,
2285,,,,B,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,H,,1,,CHEMBL617071,BAO_0000357,,
2286,,,,B,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,,1,,CHEMBL872915,BAO_0000357,,
2287,,,,B,,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,H,,1,,CHEMBL617072,BAO_0000357,,
2288,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,H,,1,,CHEMBL617073,BAO_0000357,,
2289,,,,B,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,H,,1,,CHEMBL617074,BAO_0000357,,
2290,,,,B,CHO,449.0,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,,1,,CHEMBL617075,BAO_0000219,,
2291,,,,B,,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617076,BAO_0000357,,
2292,,,,B,,,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,D,,1,,CHEMBL617077,BAO_0000019,,
2293,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,H,,1,,CHEMBL617078,BAO_0000357,,
2294,,,,B,,,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,D,,1,,CHEMBL617079,BAO_0000357,,
2295,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,H,,1,,CHEMBL617080,BAO_0000357,,
2296,,,,B,CHO,449.0,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,H,,1,,CHEMBL617081,BAO_0000219,,
2297,,,,B,,,,Binding affinity towards human 5-HT2A receptor in BEK cells,H,,1,,CHEMBL617082,BAO_0000219,,
2298,,,,B,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617083,BAO_0000357,,
2299,,,,B,,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,H,,1,,CHEMBL617084,BAO_0000357,,
2300,,,,B,,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,D,,1,,CHEMBL617085,BAO_0000357,,
2301,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,,1,,CHEMBL617086,BAO_0000357,,
2302,,,,B,,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,H,,1,,CHEMBL617087,BAO_0000219,,
2303,,,,B,,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617088,BAO_0000357,,
2304,,,,B,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617089,BAO_0000357,,
2305,,,,B,,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",H,,1,,CHEMBL617090,BAO_0000019,,
2306,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,H,,1,,CHEMBL617513,BAO_0000357,,
2307,,,,B,HEK293,722.0,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,H,,1,,CHEMBL617514,BAO_0000219,,
2308,,,,B,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617515,BAO_0000019,,
2309,,,,B,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,,1,,CHEMBL617516,BAO_0000357,,
2310,,,,B,,,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,D,,1,,CHEMBL617517,BAO_0000357,,
2311,,,,B,CHO,449.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,D,,1,,CHEMBL617518,BAO_0000219,,
2312,,,,B,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617519,BAO_0000357,,
2313,,,,B,,,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,D,,1,,CHEMBL617520,BAO_0000357,,
2314,,,,B,,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,H,,1,,CHEMBL617521,BAO_0000357,,
2315,,,,B,,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,D,,1,,CHEMBL617522,BAO_0000357,,
2316,,,,B,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,H,,1,,CHEMBL617523,BAO_0000357,,
2317,,,,B,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,,1,,CHEMBL617524,BAO_0000357,,
2318,,,,B,,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,H,,1,,CHEMBL617525,BAO_0000019,,
2319,,,,B,,,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,D,,1,,CHEMBL617526,BAO_0000019,,
2320,,,,B,,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,H,,1,,CHEMBL617527,BAO_0000224,,
2321,,,,B,,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,H,,1,,CHEMBL617528,BAO_0000019,,
2322,,,,B,,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,H,,1,,CHEMBL617529,BAO_0000019,,
2323,,,,B,,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,H,,1,,CHEMBL617530,BAO_0000224,,
2324,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,H,,1,,CHEMBL617531,BAO_0000019,,
2325,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,H,,1,,CHEMBL617532,BAO_0000019,,
2326,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,H,,1,,CHEMBL617533,BAO_0000019,,
2327,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,H,,1,,CHEMBL617534,BAO_0000019,,
2328,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,H,,1,,CHEMBL617535,BAO_0000224,,
2329,,,,B,,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,H,,1,,CHEMBL617536,BAO_0000224,,
2330,,,,B,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617537,BAO_0000224,,
2331,,,,B,,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617538,BAO_0000224,,
2332,,In vitro,,B,,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,H,,1,,CHEMBL617539,BAO_0000219,,
2333,,,,B,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,D,,1,,CHEMBL617540,BAO_0000224,,
2334,,,,B,,,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,D,,1,,CHEMBL617541,BAO_0000224,,
2335,,,,B,,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617542,BAO_0000224,,
2336,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,H,,1,,CHEMBL617543,BAO_0000224,,
2337,,,,B,CHO-K1,485.0,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,D,,1,,CHEMBL617544,BAO_0000219,,
2338,,,,B,CHO-K1,485.0,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,D,,1,,CHEMBL617545,BAO_0000219,,
2339,,,,B,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,D,,1,,CHEMBL617413,BAO_0000019,,
2340,,,,B,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,H,,1,,CHEMBL617414,BAO_0000019,,
2341,,,,B,,,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,D,,1,,CHEMBL617415,BAO_0000019,,
2342,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617416,BAO_0000224,,
2343,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,H,,1,,CHEMBL617417,BAO_0000224,,
2344,,,,B,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",H,,1,,CHEMBL617418,BAO_0000019,,
2345,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,H,,1,,CHEMBL617419,BAO_0000019,,
2346,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,H,,1,,CHEMBL617420,BAO_0000224,,
2347,,,,B,,,,Affinity for 5-hydroxytryptamine 2 receptor,D,,1,,CHEMBL617421,BAO_0000224,,
2348,,,,B,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,H,,1,,CHEMBL617422,BAO_0000224,,
2349,,,,B,,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,H,,1,,CHEMBL617423,BAO_0000019,,
2350,,,,B,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,H,,1,,CHEMBL617424,BAO_0000019,,
2351,,,,B,,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,H,,1,,CHEMBL617425,BAO_0000019,,
2352,,,,B,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),H,,1,,CHEMBL617426,BAO_0000224,,
2353,,In vivo,,B,,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),H,,1,,CHEMBL617427,BAO_0000218,,
2354,,,Brain,B,,,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,H,,1,,CHEMBL617428,BAO_0000221,955.0,
2355,,,,B,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,H,,1,,CHEMBL617429,BAO_0000224,,
2356,,,,B,,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,H,,1,,CHEMBL617430,BAO_0000019,,
2357,,,,B,,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,H,,1,,CHEMBL617431,BAO_0000019,,
2358,,,Frontal cortex,B,,,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,H,,1,,CHEMBL617432,BAO_0000019,1870.0,
2359,,,,B,,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617433,BAO_0000224,,
2360,,,,B,,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617434,BAO_0000224,,
2361,,,,B,,,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,D,,1,,CHEMBL617435,BAO_0000224,,
2362,,,,B,,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,H,,1,,CHEMBL617436,BAO_0000019,,
2363,,,Striatum,B,,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,D,,1,,CHEMBL617437,BAO_0000019,2435.0,
2364,,,,B,,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",H,,1,,CHEMBL617438,BAO_0000019,,
2365,,,,B,,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",H,,1,,CHEMBL617439,BAO_0000019,,
2366,,,,B,,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617440,BAO_0000224,,
2367,,,,B,,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617441,BAO_0000224,,
2368,,,,B,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,D,,1,,CHEMBL872918,BAO_0000019,,
2369,,,,B,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,D,,1,,CHEMBL617442,BAO_0000019,,
2370,,,,B,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,H,,1,,CHEMBL617443,BAO_0000019,,
2371,,,,B,,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,H,,1,,CHEMBL617444,BAO_0000019,,
2372,,,,B,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,H,,1,,CHEMBL617445,BAO_0000019,,
2373,,,,B,,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,H,,1,,CHEMBL617446,BAO_0000019,,
2374,,,,B,,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,H,,1,,CHEMBL617447,BAO_0000249,,
2375,,,,B,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,H,,1,,CHEMBL617448,BAO_0000019,,
2376,,,,B,,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,H,,1,,CHEMBL617449,BAO_0000019,,
2377,,,,B,,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,H,,1,,CHEMBL617450,BAO_0000019,,
2378,,,,B,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,H,,1,,CHEMBL617451,BAO_0000019,,
2379,,,,B,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,H,,1,,CHEMBL617452,BAO_0000019,,
2380,,,,B,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,H,,1,,CHEMBL617453,BAO_0000019,,
2381,,,,B,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,H,,1,,CHEMBL617660,BAO_0000019,,
2382,,,,B,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,H,,1,,CHEMBL617661,BAO_0000019,,
2383,,,,B,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,H,,1,,CHEMBL617662,BAO_0000019,,
2384,,,,B,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,H,,1,,CHEMBL872919,BAO_0000019,,
2385,,,,B,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,H,,1,,CHEMBL617663,BAO_0000019,,
2386,,,,B,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,H,,1,,CHEMBL617664,BAO_0000019,,
2387,,,,B,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,H,,1,,CHEMBL617665,BAO_0000019,,
2388,,,,B,,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,H,,1,,CHEMBL617666,BAO_0000019,,
2389,,,,B,,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,H,,1,,CHEMBL617667,BAO_0000019,,
2390,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,H,,1,,CHEMBL617668,BAO_0000249,,
2391,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,H,,1,,CHEMBL617669,BAO_0000249,,
2392,,,,B,,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617670,BAO_0000224,,
2393,,,,B,,,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,D,,1,,CHEMBL617671,BAO_0000224,,
2394,,,,B,,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617672,BAO_0000224,,
2395,,,,B,,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,H,,1,,CHEMBL617673,BAO_0000019,,
2396,,,,B,,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,H,,1,,CHEMBL617674,BAO_0000224,,
2397,,,,B,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,H,,1,,CHEMBL617675,BAO_0000019,,
2398,,,,B,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,H,,1,,CHEMBL617676,BAO_0000019,,
2399,,,,B,,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,H,,1,,CHEMBL617677,BAO_0000019,,
2400,,,,B,,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,D,,1,,CHEMBL617678,BAO_0000019,,
2401,,,,B,,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,H,,1,,CHEMBL617679,BAO_0000224,,
2402,,,,B,,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,H,,1,,CHEMBL617680,BAO_0000224,,
2403,,,,B,,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,H,,1,,CHEMBL617681,BAO_0000019,,
2404,,,Brain,B,,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,H,,1,,CHEMBL617682,BAO_0000221,955.0,
2405,,,,B,,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,H,,1,,CHEMBL617683,BAO_0000224,,
2406,,,,B,,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,H,,1,,CHEMBL617684,BAO_0000224,,
2407,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,D,,1,,CHEMBL617685,BAO_0000224,,
2408,,,,B,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,H,,1,,CHEMBL617686,BAO_0000019,,
2409,,,,B,,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,H,,1,,CHEMBL617687,BAO_0000224,,
2410,,,,B,,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,H,,1,,CHEMBL617688,BAO_0000224,,
2411,,,,F,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,,1,,CHEMBL617689,BAO_0000019,,
2412,,,,F,,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,,1,,CHEMBL617690,BAO_0000019,,
2413,,In vivo,,F,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",H,,1,,CHEMBL617691,BAO_0000218,,
2414,,In vivo,,F,,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",H,,1,,CHEMBL617692,BAO_0000218,,
2415,,In vivo,,F,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",H,,1,,CHEMBL617693,BAO_0000218,,
2416,,In vivo,,F,,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",H,,1,,CHEMBL617694,BAO_0000218,,
2417,,,Brain,B,,,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,H,,1,,CHEMBL857985,BAO_0000221,955.0,
2418,,,,B,,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,D,,1,,CHEMBL617695,BAO_0000019,,
2419,,,,B,,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,H,,1,,CHEMBL617696,BAO_0000019,,
2420,,,,B,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,H,,1,,CHEMBL617697,BAO_0000357,,
2421,,,,B,,,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,D,,1,,CHEMBL617257,BAO_0000019,,
2422,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,D,,1,,CHEMBL617258,BAO_0000357,,
2423,,,,B,,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,H,,1,,CHEMBL617259,BAO_0000019,,
2424,,,,B,,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,H,,1,,CHEMBL617260,BAO_0000357,,
2425,,,,B,,,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,D,,1,,CHEMBL617261,BAO_0000357,,
2426,,,,B,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,H,,1,,CHEMBL617262,BAO_0000019,,
2427,,,,B,,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,H,,1,,CHEMBL617263,BAO_0000019,,
2428,,,,B,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,H,,1,,CHEMBL617264,BAO_0000019,,
2429,,,,B,,,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,D,,1,,CHEMBL617265,BAO_0000019,,
2430,Membranes,,,B,,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617266,BAO_0000249,,
2431,,,,B,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,H,,1,,CHEMBL617267,BAO_0000019,,
2432,,,,B,,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,H,,1,,CHEMBL617268,BAO_0000019,,
2433,,,,B,CHO,449.0,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,H,,1,,CHEMBL617269,BAO_0000219,,
2434,,,,B,,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,H,,1,,CHEMBL617323,BAO_0000357,,
2435,,,,B,,,,Serotonergic activity of the compound.,H,,1,,CHEMBL617324,BAO_0000357,,
2436,,,,B,,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,H,,1,,CHEMBL617325,BAO_0000249,,
2437,,,,B,,,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,D,,1,,CHEMBL617326,BAO_0000019,,
2438,,,,B,,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,H,,1,,CHEMBL617327,BAO_0000249,,
2439,,,,F,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,,1,,CHEMBL617328,BAO_0000019,,
2440,,,,F,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,,1,,CHEMBL617329,BAO_0000019,,
2441,,,,F,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,,1,,CHEMBL617330,BAO_0000019,,
2442,,,,B,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,,1,,CHEMBL617331,BAO_0000357,,
2443,,,,B,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,H,,1,,CHEMBL617332,BAO_0000357,,
2444,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617333,BAO_0000357,,
2445,,,,B,,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,H,,1,,CHEMBL617334,BAO_0000357,,
2446,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,H,,1,,CHEMBL617335,BAO_0000357,,
2447,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,H,,1,,CHEMBL617336,BAO_0000357,,
2448,,,,B,,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,H,,1,,CHEMBL617337,BAO_0000357,,
2449,,,,B,,,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,D,,1,,CHEMBL617338,BAO_0000357,,
2450,,,,B,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617339,BAO_0000357,,
2451,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617340,BAO_0000357,,
2452,,,,B,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,H,,1,,CHEMBL617341,BAO_0000357,,
2453,,,,B,,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617342,BAO_0000357,,
2454,,,,B,,,,Affinity for 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617343,BAO_0000357,,
2455,,,,B,NIH3T3,723.0,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,H,,1,,CHEMBL617344,BAO_0000219,,
2456,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,H,,1,,CHEMBL617345,BAO_0000357,,
2457,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,H,,1,,CHEMBL617346,BAO_0000357,,
2458,,,,B,,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617347,BAO_0000357,,
2459,,,,B,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,H,,1,,CHEMBL617348,BAO_0000357,,
2460,,,,B,,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,H,,1,,CHEMBL617349,BAO_0000357,,
2461,,,,F,,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617350,BAO_0000019,,
2462,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,H,,1,,CHEMBL872339,BAO_0000357,,
2463,,,,B,,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,H,,1,,CHEMBL617351,BAO_0000357,,
2464,,,,B,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617352,BAO_0000357,,
2465,,,,B,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617353,BAO_0000357,,
2466,,,,B,,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617354,BAO_0000357,,
2467,,,,B,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617355,BAO_0000357,,
2468,,,,B,CHO,449.0,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,H,,1,,CHEMBL617356,BAO_0000219,,
2469,,,,B,,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617357,BAO_0000357,,
2470,,,,B,,,,Binding affinity at 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617358,BAO_0000357,,
2471,,,,B,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617359,BAO_0000357,,
2472,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,H,,1,,CHEMBL617360,BAO_0000357,,
2473,,,,B,,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,H,,1,,CHEMBL875913,BAO_0000357,,
2474,,,,B,,,,Affinity against 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617361,BAO_0000357,,
2475,,,,B,,,,Binding affinity against 5-Hydroxytryptamine 2A receptor,D,,1,,CHEMBL617362,BAO_0000357,,
2476,,,,B,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,H,,1,,CHEMBL617363,BAO_0000357,,
2477,,,,B,,,,Tested against 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617364,BAO_0000357,,
2478,,,,B,,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,H,,1,,CHEMBL617365,BAO_0000224,,
2479,,,,B,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,H,,1,,CHEMBL617366,BAO_0000224,,
2480,,,,B,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,H,,1,,CHEMBL617367,BAO_0000224,,
2481,,,,B,,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,H,,1,,CHEMBL617368,BAO_0000224,,
2482,,,,B,,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),H,,1,,CHEMBL617369,BAO_0000357,,
2483,,,,B,HEK293,722.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,D,,1,,CHEMBL617370,BAO_0000219,,
2484,,,,F,CHO,449.0,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,D,,1,,CHEMBL617371,BAO_0000219,,
2485,,,,B,,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),H,,1,,CHEMBL617372,BAO_0000357,,
2486,,,,B,,,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,D,,1,,CHEMBL617373,BAO_0000357,,
2487,,,,F,,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,H,,1,,CHEMBL617374,BAO_0000019,,
2488,,,,F,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,H,,1,,CHEMBL617375,BAO_0000019,,
2489,,,,F,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,H,,1,,CHEMBL617376,BAO_0000019,,
2490,,,,F,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,H,,1,,CHEMBL617377,BAO_0000019,,
2491,,,,F,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,H,,1,,CHEMBL617378,BAO_0000019,,
2492,,,,F,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,H,,1,,CHEMBL617379,BAO_0000019,,
2493,,,,B,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,H,,1,,CHEMBL617380,BAO_0000357,,
2494,,,,B,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,H,,1,,CHEMBL617381,BAO_0000357,,
2495,,,,B,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,H,,1,,CHEMBL617382,BAO_0000357,,
2496,,,,B,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617383,BAO_0000357,,
2497,,,,B,,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,H,,1,,CHEMBL617384,BAO_0000357,,
2498,,,,B,,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,H,,1,,CHEMBL617385,BAO_0000357,,
2499,,,,B,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,H,,1,,CHEMBL617386,BAO_0000019,,
2500,,,,B,,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,H,,1,,CHEMBL617387,BAO_0000019,,
2501,,,,B,NIH3T3,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,,1,,CHEMBL617388,BAO_0000219,,
2502,,,,F,CHO,449.0,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,H,,1,,CHEMBL617389,BAO_0000219,,
2503,,,,F,CHO,449.0,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,,1,,CHEMBL617390,BAO_0000219,,
2504,,,,B,,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,H,,1,,CHEMBL617391,BAO_0000224,,
2505,,,,B,,,,Binding activity radioligand.,H,,1,,CHEMBL617392,BAO_0000357,,
2506,,,,B,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,H,,1,,CHEMBL617393,BAO_0000019,,
2507,,,,B,L929,307.0,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,H,,1,,CHEMBL617394,BAO_0000219,,
2508,,,,B,L929,307.0,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,H,,1,,CHEMBL617395,BAO_0000219,,
2509,,,,B,L929,307.0,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,H,,1,,CHEMBL617396,BAO_0000219,,
2510,,,,B,L929,307.0,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,H,,1,,CHEMBL617397,BAO_0000219,,
2511,,,,B,,,,Binding affinity against 5-HT2A receptor,H,,1,,CHEMBL617398,BAO_0000357,,
2512,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617399,BAO_0000357,,
2513,,,,B,HEK293,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,H,,1,,CHEMBL617400,BAO_0000219,,
2514,,,,B,HEK293,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,H,,1,,CHEMBL617401,BAO_0000219,,
2515,,,,B,HEK293,722.0,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,D,,1,,CHEMBL617402,BAO_0000219,,
2516,,,,B,HEK293,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,,1,,CHEMBL617403,BAO_0000219,,
2517,,,,B,,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,H,,1,,CHEMBL617404,BAO_0000357,,
2518,,,,B,HEK293,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,,1,,CHEMBL857981,BAO_0000219,,
2519,,,,B,HEK293,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,,1,,CHEMBL617405,BAO_0000219,,
2520,,,,B,HEK293,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,D,,1,,CHEMBL617253,BAO_0000219,,
2521,,,,B,,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,H,,1,,CHEMBL617254,BAO_0000357,,
2522,,,,B,HEK293,722.0,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,H,,1,,CHEMBL617255,BAO_0000219,,
2523,,,,B,HEK293,722.0,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,H,,1,,CHEMBL617256,BAO_0000219,,
2524,,,,B,HEK293,722.0,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,H,,1,,CHEMBL616874,BAO_0000219,,
2525,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,D,,1,,CHEMBL616875,BAO_0000219,,
2526,,,,B,HEK293,722.0,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,H,,1,,CHEMBL616876,BAO_0000219,,
2527,,,,B,HEK293,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",H,,1,,CHEMBL616877,BAO_0000219,,
2528,,,,B,HEK293,722.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,D,,1,,CHEMBL616878,BAO_0000219,,
2529,,,,B,HEK293,722.0,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,H,,1,,CHEMBL616879,BAO_0000219,,
2530,,,,B,HEK293,722.0,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,H,,1,,CHEMBL616880,BAO_0000219,,
2531,,,,B,HEK293,722.0,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,,1,,CHEMBL616881,BAO_0000219,,
2532,,,,B,NIH3T3,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,H,,1,,CHEMBL616882,BAO_0000219,,
2533,,,,B,NIH3T3,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,,1,,CHEMBL616883,BAO_0000219,,
2534,,,,B,NIH3T3,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,,1,,CHEMBL616884,BAO_0000219,,
2535,,,,B,HEK293,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,H,,1,,CHEMBL616885,BAO_0000219,,
2536,,,,B,CHO-K1,485.0,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,H,,1,,CHEMBL616886,BAO_0000219,,
2537,,,,B,CHO-K1,485.0,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,H,,1,,CHEMBL616887,BAO_0000219,,
2538,,,,B,,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,D,,1,,CHEMBL616888,BAO_0000357,,
2539,,,,B,HEK293,722.0,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,H,,1,,CHEMBL616889,BAO_0000219,,
2540,,,,B,HEK293,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,H,,1,,CHEMBL616890,BAO_0000219,,
2541,,,,B,CHO,449.0,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,D,,1,,CHEMBL616891,BAO_0000219,,
2542,,,,B,HEK293,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,H,,1,,CHEMBL616892,BAO_0000219,,
2543,,,,B,HEK293,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",H,,1,,CHEMBL616893,BAO_0000219,,
2544,,,,F,NIH3T3,723.0,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,H,,1,,CHEMBL616894,BAO_0000219,,
2545,,,,B,NIH3T3,723.0,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,H,,1,,CHEMBL616895,BAO_0000219,,
2546,,,,F,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL616896,BAO_0000019,,
2547,,,,B,,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617099,BAO_0000357,,
2548,,,,B,,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,H,,1,,CHEMBL617100,BAO_0000357,,
2549,,,,B,,,,Binding affinity against rabbit aorta 5-HT2A receptor,H,,1,,CHEMBL884532,BAO_0000357,,
2550,,,,B,,,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,H,,1,,CHEMBL617101,BAO_0000357,,
2551,,,,B,,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,H,,1,,CHEMBL617102,BAO_0000357,,
2552,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,H,,1,,CHEMBL617103,BAO_0000019,,
2553,,,,B,,,,The compound was tested for binding affinity against 5-HT2A receptor,H,,1,,CHEMBL617104,BAO_0000357,,
2554,,,,B,CHO-K1,485.0,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,H,,1,,CHEMBL857979,BAO_0000219,,
2555,,,,B,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,H,,1,,CHEMBL857502,BAO_0000019,,
2556,,,,B,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,H,,1,,CHEMBL617105,BAO_0000019,,
2557,,,Stomach,B,,,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,H,,1,,CHEMBL858021,BAO_0000019,945.0,
2558,,,Stomach,B,,,,Binding affinity for 5-HT 2A in rat stomach fundus,D,,1,,CHEMBL875910,BAO_0000019,945.0,
2559,,,,B,,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,H,,1,,CHEMBL617106,BAO_0000019,,
2560,,,,B,NIH3T3,723.0,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617107,BAO_0000219,,
2561,,,,F,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617108,BAO_0000019,,
2562,,,,F,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617109,BAO_0000019,,
2563,,,,B,,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617110,BAO_0000357,,
2564,,,,B,,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,H,,1,,CHEMBL617111,BAO_0000357,,
2565,,,,F,,,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,D,,1,,CHEMBL617112,BAO_0000019,,
2566,,,,B,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617113,BAO_0000357,,
2567,,,,B,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617114,BAO_0000357,,
2568,,,,B,,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617115,BAO_0000357,,
2569,,,,F,,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,H,,1,,CHEMBL617116,BAO_0000219,,
2570,,,,F,,,,Efficacy at 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617117,BAO_0000019,,
2571,,,,B,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),H,,1,,CHEMBL617118,BAO_0000357,,
2572,,,,B,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),D,,1,,CHEMBL617119,BAO_0000357,,
2573,,,,B,,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),D,,1,,CHEMBL617120,BAO_0000357,,
2574,,,,F,,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,D,,1,,CHEMBL617121,BAO_0000219,,
2575,,,,F,,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,H,,1,,CHEMBL617122,BAO_0000219,,
2576,,,,B,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617123,BAO_0000019,,
2577,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,H,,1,,CHEMBL617124,BAO_0000019,,
2578,,,,B,,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,H,,1,,CHEMBL617600,BAO_0000249,,
2579,,,,B,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,H,,1,,CHEMBL617601,BAO_0000357,,
2580,,,,B,,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,H,,1,,CHEMBL882923,BAO_0000019,,
2581,,,,B,,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617602,BAO_0000357,,
2582,,,,B,,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,H,,1,,CHEMBL617603,BAO_0000019,,
2583,,,,B,,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617604,BAO_0000357,,
2584,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,H,,1,,CHEMBL617605,BAO_0000019,,
2585,,,,B,,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,H,,1,,CHEMBL617606,BAO_0000019,,
2586,,,,B,,,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,D,,1,,CHEMBL617607,BAO_0000019,,
2587,,,,B,,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,,1,,CHEMBL617455,BAO_0000249,,
2588,,,,B,,,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,D,,1,,CHEMBL617456,BAO_0000019,,
2589,,,,B,,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),H,,1,,CHEMBL617457,BAO_0000357,,
2590,,,,B,,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,D,,1,,CHEMBL617458,BAO_0000357,,
2591,,,,B,,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,D,,1,,CHEMBL617459,BAO_0000019,,
2592,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,H,,1,,CHEMBL617460,BAO_0000357,,
2593,,,,B,,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",H,,1,,CHEMBL617461,BAO_0000357,,
2594,,,,B,,,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,D,,1,,CHEMBL617462,BAO_0000019,,
2595,,,,B,,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,H,,1,,CHEMBL617463,BAO_0000357,,
2596,,,,B,,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",H,,1,,CHEMBL617464,BAO_0000019,,
2597,,,,B,,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",H,,1,,CHEMBL617465,BAO_0000019,,
2598,,,,B,,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,H,,1,,CHEMBL617466,BAO_0000019,,
2599,,,,B,,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,H,,1,,CHEMBL617467,BAO_0000019,,
2600,,,,B,,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,H,,1,,CHEMBL617468,BAO_0000019,,
2601,,,,B,,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,H,,1,,CHEMBL617469,BAO_0000019,,
2602,,,,B,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617470,BAO_0000019,,
2603,,,,B,,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,H,,1,,CHEMBL617471,BAO_0000019,,
2604,,,,B,NIH3T3,723.0,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,H,,1,,CHEMBL617472,BAO_0000219,,
2605,,,,B,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,H,,1,,CHEMBL617473,BAO_0000357,,
2606,,,,B,,,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,D,,1,,CHEMBL617474,BAO_0000019,,
2607,,,,B,,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,D,,1,,CHEMBL617475,BAO_0000019,,
2608,,,Brain,B,,,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,H,,1,,CHEMBL617476,BAO_0000221,955.0,
2609,,,,B,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617477,BAO_0000357,,
2610,,,,B,NIH3T3,723.0,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617478,BAO_0000219,,
2611,,,,F,,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",H,,1,,CHEMBL617479,BAO_0000221,,
2612,,,,B,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,H,,1,,CHEMBL617480,BAO_0000357,,
2613,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617481,BAO_0000357,,
2614,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,H,,1,,CHEMBL617482,BAO_0000019,,
2615,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,H,,1,,CHEMBL617483,BAO_0000019,,
2616,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,,1,,CHEMBL621528,BAO_0000357,,
2617,,,,B,NIH3T3,723.0,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,D,,1,,CHEMBL621529,BAO_0000219,,
2618,,,,B,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,,1,,CHEMBL621530,BAO_0000357,,
2619,,,,B,,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,,1,,CHEMBL621531,BAO_0000357,,
2620,,,,B,,,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,D,,1,,CHEMBL621532,BAO_0000019,,
2621,,,,B,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,,1,,CHEMBL621533,BAO_0000357,,
2622,,,,B,CHO,449.0,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,,1,,CHEMBL621534,BAO_0000219,,
2623,,,,B,,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,H,,1,,CHEMBL621535,BAO_0000019,,
2624,,,,B,,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,H,,1,,CHEMBL621536,BAO_0000357,,
2625,,,,B,,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL621537,BAO_0000357,,
2626,,,,B,,,,Binding affinity for 5-hydroxytryptamine 2A receptor,D,,1,,CHEMBL621538,BAO_0000357,,
2627,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,H,,1,,CHEMBL621539,BAO_0000019,,
2628,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,H,,1,,CHEMBL621540,BAO_0000019,,
2629,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,H,,1,,CHEMBL621541,BAO_0000019,,
2630,,,,B,,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,H,,1,,CHEMBL621542,BAO_0000019,,
2631,,,,B,,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,H,,1,,CHEMBL621543,BAO_0000357,,
2632,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,H,,1,,CHEMBL621544,BAO_0000357,,
2633,,,,B,,,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,D,,1,,CHEMBL621545,BAO_0000357,,
2634,,,,B,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,,1,,CHEMBL621546,BAO_0000357,,
2635,,,,B,,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,H,,1,,CHEMBL621547,BAO_0000357,,
2636,,,,B,NIH3T3,723.0,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL618692,BAO_0000219,,
2637,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL618693,BAO_0000357,,
2638,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,,1,,CHEMBL872922,BAO_0000357,,
2639,,,,B,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,H,,1,,CHEMBL618694,BAO_0000357,,
2640,,,,B,,,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,D,,1,,CHEMBL618695,BAO_0000357,,
2641,,,,B,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,H,,1,,CHEMBL618696,BAO_0000357,,
2642,,,,B,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,H,,1,,CHEMBL618697,BAO_0000357,,
2643,,,,B,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,H,,1,,CHEMBL618892,BAO_0000357,,
2644,,,,B,,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,H,,1,,CHEMBL618893,BAO_0000357,,
2645,,,,B,,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL618894,BAO_0000357,,
2646,,,,B,NIH3T3,723.0,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,H,,1,,CHEMBL618895,BAO_0000219,,
2647,,,,B,,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,D,,1,,CHEMBL618896,BAO_0000357,,
2648,,,Caudate-putamen,B,,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,H,,1,,CHEMBL618897,BAO_0000019,5383.0,
2649,,,,B,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,H,,1,,CHEMBL618898,BAO_0000357,,
2650,,,,B,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,H,,1,,CHEMBL618899,BAO_0000357,,
2651,,,,B,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,H,,1,,CHEMBL618900,BAO_0000357,,
2652,,,,B,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,H,,1,,CHEMBL618901,BAO_0000019,,
2653,,,,B,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL618902,BAO_0000357,,
2654,,,Hippocampus,B,,,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,D,,1,,CHEMBL618903,BAO_0000221,10000000.0,
2655,,,,B,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL618904,BAO_0000357,,
2656,,,,B,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,H,,1,,CHEMBL618905,BAO_0000357,,
2657,,,,B,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,H,,1,,CHEMBL618906,BAO_0000357,,
2658,,,,B,NIH3T3,723.0,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,H,,1,,CHEMBL618907,BAO_0000219,,
2659,,,,B,,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,H,,1,,CHEMBL618908,BAO_0000019,,
2660,,,,B,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617909,BAO_0000357,,
2661,,,,B,,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,H,,1,,CHEMBL617910,BAO_0000019,,
2662,,,Brain,B,,,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,H,,1,,CHEMBL617911,BAO_0000221,955.0,
2663,,,,B,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,,1,,CHEMBL872923,BAO_0000249,,
2664,,,,B,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,,1,,CHEMBL617912,BAO_0000249,,
2665,,,,B,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,D,,1,,CHEMBL617913,BAO_0000019,,
2666,,,,B,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,,1,,CHEMBL617914,BAO_0000249,,
2667,,,,B,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,,1,,CHEMBL617915,BAO_0000249,,
2668,,,,B,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,,1,,CHEMBL617916,BAO_0000249,,
2669,,,,B,,,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,D,,1,,CHEMBL617917,BAO_0000019,,
2670,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,H,,1,,CHEMBL617918,BAO_0000019,,
2671,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,H,,1,,CHEMBL617919,BAO_0000019,,
2672,,,,B,,,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,D,,1,,CHEMBL617920,BAO_0000019,,
2673,,,,B,,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,D,,1,,CHEMBL617921,BAO_0000019,,
2674,,,,B,,,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",D,,1,,CHEMBL617922,BAO_0000224,,
2675,,,,B,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,,1,,CHEMBL617923,BAO_0000357,,
2676,,,,B,,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,,1,,CHEMBL617924,BAO_0000357,,
2677,,,,B,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,H,,1,,CHEMBL617925,BAO_0000357,,
2678,,,,B,,,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,D,,1,,CHEMBL617926,BAO_0000357,,
2679,,,,B,,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,H,,1,,CHEMBL617927,BAO_0000357,,
2680,,,,B,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,H,,1,,CHEMBL617928,BAO_0000357,,
2681,,,,B,,,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,,1,,CHEMBL617929,BAO_0000019,,
2682,,,,B,,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,H,,1,,CHEMBL617930,BAO_0000019,,
2683,,,,B,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,H,,1,,CHEMBL617931,BAO_0000019,,
2684,,,,B,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,H,,1,,CHEMBL617932,BAO_0000019,,
2685,,,,B,CHO,449.0,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,H,,1,,CHEMBL617933,BAO_0000219,,
2686,,,,B,,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,H,,1,,CHEMBL617934,BAO_0000019,,
2687,,,,B,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,H,,1,,CHEMBL617935,BAO_0000019,,
2688,,,,B,,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,H,,1,,CHEMBL617936,BAO_0000357,,
2689,,,,B,,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,H,,1,,CHEMBL617937,BAO_0000019,,
2690,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,H,,1,,CHEMBL617938,BAO_0000019,,
2691,,,,B,,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,H,,1,,CHEMBL617939,BAO_0000218,,
2692,,,,B,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,H,,1,,CHEMBL617940,BAO_0000218,,
2693,,,,B,,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,H,,1,,CHEMBL617941,BAO_0000218,,
2694,,,,B,,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,H,,1,,CHEMBL617942,BAO_0000357,,
2695,,,,B,,,,Ratio of pKi of 5-HT2A to that of D2 receptor,H,,1,,CHEMBL617943,BAO_0000357,,
2696,,,,B,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,H,,1,,CHEMBL617944,BAO_0000224,,
2697,,,,B,,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,H,,1,,CHEMBL617945,BAO_0000224,,
2698,,,,B,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617946,BAO_0000224,,
2699,,,,B,,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,H,,1,,CHEMBL617947,BAO_0000357,,
2700,,,,B,,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,H,,1,,CHEMBL617948,BAO_0000357,,
2701,,,,F,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,H,,1,,CHEMBL858116,BAO_0000019,,
2702,,,,F,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,H,,1,,CHEMBL617949,BAO_0000019,,
2703,,,,F,,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,H,,1,,CHEMBL617950,BAO_0000019,,
2704,,,Thoracic aorta,F,,,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,H,,1,,CHEMBL617951,BAO_0000019,1515.0,
2705,,,Thoracic aorta,F,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,H,,1,,CHEMBL617952,BAO_0000019,1515.0,
2706,,,Thoracic aorta,F,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,H,,1,,CHEMBL617953,BAO_0000019,1515.0,
2707,,,,B,,,,Binding activity radioligand.,H,,1,,CHEMBL617954,BAO_0000357,,
2708,,,,B,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,H,,1,,CHEMBL617955,BAO_0000019,,
2709,,,,B,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,H,,1,,CHEMBL857071,BAO_0000019,,
2710,,,,B,,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,H,,1,,CHEMBL617270,BAO_0000019,,
2711,,,,B,N1E-115,339.0,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,H,,1,,CHEMBL617271,BAO_0000219,,
2712,,,,B,N1E-115,339.0,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,H,,1,,CHEMBL617272,BAO_0000219,,
2713,,,,B,,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,H,,1,,CHEMBL617273,BAO_0000019,,
2714,,,,F,,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,D,,1,,CHEMBL617274,BAO_0000019,,
2715,,,,B,,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617275,BAO_0000357,,
2716,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617276,BAO_0000357,,
2717,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617277,BAO_0000357,,
2718,,,,B,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617278,BAO_0000019,,
2719,,,,B,,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,H,,1,,CHEMBL617279,BAO_0000019,,
2720,,,,B,,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617280,BAO_0000019,,
2721,,,,B,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617281,BAO_0000357,,
2722,,,,B,,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617282,BAO_0000357,,
2723,,,,B,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,H,,1,,CHEMBL617283,BAO_0000019,,
2724,,,,B,,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,H,,1,,CHEMBL617284,BAO_0000019,,
2725,,,,B,HEK293,722.0,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,H,,1,,CHEMBL617285,BAO_0000219,,
2726,,,,B,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617286,BAO_0000019,,
2727,,,,B,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,D,,1,,CHEMBL617287,BAO_0000357,,
2728,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,H,,1,,CHEMBL617288,BAO_0000357,,
2729,,,,B,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,H,,1,,CHEMBL617289,BAO_0000357,,
2730,,,,B,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,,1,,CHEMBL872917,BAO_0000357,,
2731,,,,B,,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,H,,1,,CHEMBL617290,BAO_0000357,,
2732,,,,B,CHO,449.0,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,H,,1,,CHEMBL617291,BAO_0000219,,
2733,,,,B,CHO,449.0,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,H,,1,,CHEMBL617292,BAO_0000219,,
2734,,,,B,NIH3T3,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,,1,,CHEMBL617293,BAO_0000219,,
2735,,,,F,CHO,449.0,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,,1,,CHEMBL617294,BAO_0000219,,
2736,,,,B,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,H,,1,,CHEMBL617295,BAO_0000019,,
2737,,,,B,,,,Binding activity radioligand.,H,,1,,CHEMBL617296,BAO_0000357,,
2738,,,,B,,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,H,,1,,CHEMBL617297,BAO_0000019,,
2739,,,,B,CHO,449.0,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,H,,1,,CHEMBL617298,BAO_0000219,,
2740,,,,B,CHO,449.0,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,H,,1,,CHEMBL617299,BAO_0000219,,
2741,,,,B,CHO,449.0,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,H,,1,,CHEMBL617300,BAO_0000219,,
2742,,,,B,,,,Binding affinity against 5-HT2C receptor,H,,1,,CHEMBL617454,BAO_0000357,,
2743,,,,B,HEK293,722.0,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,H,,1,,CHEMBL617505,BAO_0000219,,
2744,,,,B,HEK293,722.0,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,D,,1,,CHEMBL617506,BAO_0000219,,
2745,,,,B,HEK293,722.0,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,D,,1,,CHEMBL617507,BAO_0000219,,
2746,,,,B,,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,H,,1,,CHEMBL617508,BAO_0000357,,
2747,,,,B,HEK293,722.0,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,D,,1,,CHEMBL857982,BAO_0000219,,
2748,,,,B,HEK293,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,D,,1,,CHEMBL617509,BAO_0000219,,
2749,,,,B,HEK293,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,D,,1,,CHEMBL617510,BAO_0000219,,
2750,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,H,,1,,CHEMBL617511,BAO_0000357,,
2751,,,,B,HEK293,722.0,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,H,,1,,CHEMBL617512,BAO_0000219,,
2752,,,,B,HEK293,722.0,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,H,,1,,CHEMBL617749,BAO_0000219,,
2753,,,,B,HEK293,722.0,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,,1,,CHEMBL617750,BAO_0000219,,
2754,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,,1,,CHEMBL617751,BAO_0000219,,
2755,,,,B,HEK293,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,H,,1,,CHEMBL617752,BAO_0000219,,
2756,,,,B,HEK293,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",H,,1,,CHEMBL617753,BAO_0000219,,
2757,,,,B,HEK293,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",H,,1,,CHEMBL617754,BAO_0000219,,
2758,,,,B,HEK293,722.0,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,D,,1,,CHEMBL617755,BAO_0000219,,
2759,,,,B,HEK293,722.0,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",H,,1,,CHEMBL617756,BAO_0000219,,
2760,,,,B,HEK293,722.0,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,H,,1,,CHEMBL617757,BAO_0000219,,
2761,,,,B,HEK293,722.0,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,H,,1,,CHEMBL617758,BAO_0000219,,
2762,,,,B,NIH3T3,723.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,H,,1,,CHEMBL617759,BAO_0000219,,
2763,,,,B,HEK293,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,H,,1,,CHEMBL617760,BAO_0000219,,
2764,,,,B,CHO-K1,485.0,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,H,,1,,CHEMBL617761,BAO_0000219,,
2765,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,D,,1,,CHEMBL617762,BAO_0000357,,
2766,,,,B,,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617763,BAO_0000357,,
2767,,,,B,HEK293,722.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,H,,1,,CHEMBL857983,BAO_0000219,,
2768,,,,B,HEK293,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,H,,1,,CHEMBL617764,BAO_0000219,,
2769,,,,B,HeLa,308.0,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,H,,1,,CHEMBL617765,BAO_0000219,,
2770,,,,F,,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,H,,1,,CHEMBL617766,BAO_0000019,,
2771,,,Hippocampus,F,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,H,,1,,CHEMBL617767,BAO_0000221,10000000.0,
2772,,,,B,HEK293,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,H,,1,,CHEMBL617768,BAO_0000219,,
2773,,,,B,HEK293,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",H,,1,,CHEMBL617769,BAO_0000219,,
2774,,,,B,,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,H,,1,,CHEMBL858023,BAO_0000357,,
2775,,,Stomach,B,,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,H,,1,,CHEMBL617770,BAO_0000019,945.0,
2776,,,Stomach,B,,,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,H,,1,,CHEMBL617771,BAO_0000019,945.0,
2777,,,,F,A9,625.0,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,H,,1,,CHEMBL617772,BAO_0000219,,
2778,,,,B,NIH3T3,723.0,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,H,,1,,CHEMBL617773,BAO_0000219,,
2779,,,,B,NIH3T3,723.0,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,H,,1,,CHEMBL617850,BAO_0000219,,
2780,,,,B,NIH3T3,723.0,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,H,,1,,CHEMBL617851,BAO_0000219,,
2781,,,,F,,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617852,BAO_0000019,,
2782,,,Stomach,B,,,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,H,,1,,CHEMBL858024,BAO_0000019,945.0,
2783,,,Stomach,B,,,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,D,,1,,CHEMBL617853,BAO_0000019,945.0,
2784,,,,B,,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,H,,1,,CHEMBL617854,BAO_0000357,,
2785,,,,B,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL873477,BAO_0000357,,
2786,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617855,BAO_0000357,,
2787,,,,B,,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,H,,1,,CHEMBL617856,BAO_0000019,,
2788,,,,B,,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,H,,1,,CHEMBL617857,BAO_0000019,,
2789,,,,B,,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,H,,1,,CHEMBL617858,BAO_0000249,,
2790,,,,B,,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617859,BAO_0000357,,
2791,,,,B,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617860,BAO_0000357,,
2792,,,,B,,,,Binding activity radioligand.,H,,1,,CHEMBL617861,BAO_0000357,,
2793,,,,B,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,H,,1,,CHEMBL617862,BAO_0000019,,
2794,,,,B,,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,H,,1,,CHEMBL617863,BAO_0000019,,
2795,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,H,,1,,CHEMBL617864,BAO_0000249,,
2796,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,H,,1,,CHEMBL617649,BAO_0000249,,
2797,,,,F,,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,H,,1,,CHEMBL617650,BAO_0000019,,
2798,,,,F,,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,H,,1,,CHEMBL617651,BAO_0000019,,
2799,,,,B,,,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,H,,1,,CHEMBL617652,BAO_0000357,,
2800,,,,B,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,H,,1,,CHEMBL857072,BAO_0000019,,
2801,,,,B,,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617653,BAO_0000357,,
2802,,,,B,,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,H,,1,,CHEMBL617654,BAO_0000019,,
2803,,,,F,,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617655,BAO_0000019,,
2804,,,,B,,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,H,,1,,CHEMBL617656,BAO_0000357,,
2805,,,,B,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,H,,1,,CHEMBL617657,BAO_0000357,,
2806,,,,B,,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,H,,1,,CHEMBL617658,BAO_0000357,,
2807,,,,B,,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,D,,1,,CHEMBL617659,BAO_0000357,,
2808,,,,B,,,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,D,,1,,CHEMBL617838,BAO_0000357,,
2809,Brain membranes,,,B,,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,D,,1,,CHEMBL617839,BAO_0000249,,
2810,,,,B,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,H,,1,,CHEMBL617840,BAO_0000357,,
2811,,,,B,,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,H,,1,,CHEMBL617841,BAO_0000019,,
2812,,,,B,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,H,,1,,CHEMBL875915,BAO_0000019,,
2813,,In vitro,,B,,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,H,,1,,CHEMBL617842,BAO_0000219,,
2814,,,,B,NIH3T3,723.0,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,H,,1,,CHEMBL617843,BAO_0000219,,
2815,,,,B,,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,H,,1,,CHEMBL617844,BAO_0000357,,
2816,,,,B,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617845,BAO_0000357,,
2817,,,,B,NIH3T3,723.0,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617846,BAO_0000219,,
2818,,,,B,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,H,,1,,CHEMBL617847,BAO_0000357,,
2819,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617848,BAO_0000357,,
2820,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,H,,1,,CHEMBL617849,BAO_0000357,,
2821,,,,B,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,,1,,CHEMBL621507,BAO_0000357,,
2822,,,,B,,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,H,,1,,CHEMBL621508,BAO_0000357,,
2823,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,H,,1,,CHEMBL621509,BAO_0000019,,
2824,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,H,,1,,CHEMBL621510,BAO_0000019,,
2825,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,H,,1,,CHEMBL621511,BAO_0000019,,
2826,,,,B,A9,625.0,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL621512,BAO_0000219,,
2827,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,H,,1,,CHEMBL621513,BAO_0000357,,
2828,,,,B,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,H,,1,,CHEMBL621514,BAO_0000357,,
2829,,In vitro,,B,,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,H,,1,,CHEMBL621515,BAO_0000219,,
2830,,,,B,,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,H,,1,,CHEMBL621516,BAO_0000219,,
2831,,,Caudate-putamen,B,,,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,H,,1,,CHEMBL621517,BAO_0000019,5383.0,
2832,,,,B,,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,H,,1,,CHEMBL621518,BAO_0000357,,
2833,,,,B,,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,H,,1,,CHEMBL621519,BAO_0000019,,
2834,,,,B,,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL621520,BAO_0000357,,
2835,,,,B,,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL621521,BAO_0000357,,
2836,,,,B,,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL621522,BAO_0000357,,
2837,,,,B,,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,H,,1,,CHEMBL621523,BAO_0000219,,
2838,,,,B,,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL621524,BAO_0000357,,
2839,,,,B,,,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,D,,1,,CHEMBL621525,BAO_0000357,,
2840,,,,B,,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,H,,1,,CHEMBL872921,BAO_0000357,,
2841,,,,B,,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL621526,BAO_0000357,,
2842,,,,B,,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,H,,1,,CHEMBL621527,BAO_0000219,,
2843,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,D,,1,,CHEMBL617865,BAO_0000019,,
2844,,,,B,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617866,BAO_0000357,,
2845,,,,B,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,H,,1,,CHEMBL617867,BAO_0000019,,
2846,,,,B,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,H,,1,,CHEMBL617487,BAO_0000357,,
2847,,,,B,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617488,BAO_0000357,,
2848,,,,B,,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,H,,1,,CHEMBL617489,BAO_0000357,,
2849,,,,B,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,H,,1,,CHEMBL617490,BAO_0000019,,
2850,,,,B,,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,H,,1,,CHEMBL617491,BAO_0000019,,
2851,,,,B,,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,H,,1,,CHEMBL617492,BAO_0000019,,
2852,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,H,,1,,CHEMBL617493,BAO_0000019,,
2853,,,,B,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,H,,1,,CHEMBL617494,BAO_0000357,,
2854,,,,B,,,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,D,,1,,CHEMBL617495,BAO_0000019,,
2855,,,,B,,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,H,,1,,CHEMBL617496,BAO_0000357,,
2856,,,,B,CHO-K1,485.0,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,H,,1,,CHEMBL617497,BAO_0000219,,
2857,,,,B,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,,1,,CHEMBL617498,BAO_0000357,,
2858,,,,B,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,H,,1,,CHEMBL617499,BAO_0000357,,
2859,,,,F,,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617500,BAO_0000019,,
2860,,,,B,,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617501,BAO_0000357,,
2861,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617502,BAO_0000357,,
2862,,,,B,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,H,,1,,CHEMBL617503,BAO_0000357,,
2863,,,,B,,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,H,,1,,CHEMBL617504,BAO_0000357,,
2864,,,,B,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,H,,1,,CHEMBL617406,BAO_0000357,,
2865,,,,B,,,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,D,,1,,CHEMBL617407,BAO_0000019,,
2866,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,H,,1,,CHEMBL617408,BAO_0000357,,
2867,,,,B,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,H,,1,,CHEMBL617409,BAO_0000357,,
2868,,,,B,,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,H,,1,,CHEMBL617410,BAO_0000357,,
2869,,,,B,,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,H,,1,,CHEMBL617411,BAO_0000357,,
2870,,,,B,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,H,,1,,CHEMBL617412,BAO_0000019,,
2871,,,,B,,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,D,,1,,CHEMBL617774,BAO_0000357,,
2872,,,,B,HEK293,722.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,D,,1,,CHEMBL617775,BAO_0000219,,
2873,,,,B,HEK293,722.0,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,D,,1,,CHEMBL617776,BAO_0000219,,
2874,,,,F,CHO,449.0,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,,1,,CHEMBL617777,BAO_0000219,,
2875,,,,F,CHO,449.0,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,,1,,CHEMBL617778,BAO_0000219,,
2876,,,,B,HEK293,722.0,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",H,,1,,CHEMBL617779,BAO_0000219,,
2877,,,,B,HEK293,722.0,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,H,,1,,CHEMBL617780,BAO_0000219,,
2878,,,,B,HEK293,722.0,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",H,,1,,CHEMBL617781,BAO_0000219,,
2879,,,,B,HEK293,722.0,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,D,,1,,CHEMBL617782,BAO_0000219,,
2880,,,,B,HEK293,722.0,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,D,,1,,CHEMBL617783,BAO_0000219,,
2881,,,,B,,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,H,,1,,CHEMBL617784,BAO_0000357,,
2882,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,H,,1,,CHEMBL617785,BAO_0000219,,
2883,,,,B,HEK293,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,H,,1,,CHEMBL857984,BAO_0000219,,
2884,,,,B,HEK293,722.0,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,H,,1,,CHEMBL617786,BAO_0000219,,
2885,,,,B,HEK293,722.0,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,H,,1,,CHEMBL617787,BAO_0000219,,
2886,,,,B,HEK293,722.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,D,,1,,CHEMBL617788,BAO_0000219,,
2887,,,,B,HEK293,722.0,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,D,,1,,CHEMBL617789,BAO_0000219,,
2888,,,,B,HEK293,722.0,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,H,,1,,CHEMBL617790,BAO_0000219,,
2889,,,,B,CHO-K1,485.0,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,H,,1,,CHEMBL617791,BAO_0000219,,
2890,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2B receptor,H,,1,,CHEMBL617608,BAO_0000357,,
2891,,,,B,HEK293,722.0,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,H,,1,,CHEMBL617609,BAO_0000219,,
2892,,,,B,HEK293,722.0,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,H,,1,,CHEMBL617610,BAO_0000219,,
2893,,,,B,HEK293,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,H,,1,,CHEMBL617611,BAO_0000219,,
2894,,,,B,HEK293,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",H,,1,,CHEMBL617612,BAO_0000219,,
2895,,,,B,HEK293,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",H,,1,,CHEMBL617613,BAO_0000219,,
2896,,,,B,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,H,,1,,CHEMBL617614,BAO_0000019,,
2897,,,Stomach,B,,,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,H,,1,,CHEMBL617615,BAO_0000019,945.0,
2898,,,Stomach,B,,,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,H,,1,,CHEMBL858114,BAO_0000357,945.0,
2899,,,Stomach,B,,,,Affinity against serotonergic receptor in the isolated rat stomach fundus,H,,1,,CHEMBL617616,BAO_0000357,945.0,
2900,,,Stomach,F,,,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,D,,1,,CHEMBL617617,BAO_0000019,945.0,
2901,,,,F,,,,Antagonistic against 5-hydroxytryptamine 2B receptor,D,,1,,CHEMBL875914,BAO_0000019,,
2902,,,Stomach,F,,,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,H,,1,,CHEMBL617618,BAO_0000019,945.0,
2903,,,Stomach,B,,,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,D,,1,,CHEMBL617619,BAO_0000357,945.0,
2904,,,,F,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,H,,1,,CHEMBL617620,BAO_0000019,,
2905,,,,F,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,H,,1,,CHEMBL617621,BAO_0000019,,
2906,,,,F,,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,H,,1,,CHEMBL617622,BAO_0000019,,
2907,,,Stomach,B,,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,,1,,CHEMBL617623,BAO_0000357,945.0,
2908,,,Stomach,B,,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,,1,,CHEMBL617624,BAO_0000357,945.0,
2909,,,Stomach,B,,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,,1,,CHEMBL617625,BAO_0000357,945.0,
2910,,,Stomach,B,,,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,,1,,CHEMBL617626,BAO_0000357,945.0,
2911,,,Stomach,F,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,H,,1,,CHEMBL617627,BAO_0000019,945.0,
2912,,,Stomach,F,,,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,H,,1,,CHEMBL617628,BAO_0000019,945.0,
2913,,,Stomach,F,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,H,,1,,CHEMBL617629,BAO_0000019,945.0,
2914,,,Stomach,F,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,H,,1,,CHEMBL858115,BAO_0000019,945.0,
2915,,,Stomach,F,,,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,D,,1,,CHEMBL617630,BAO_0000019,945.0,
2916,,,Thoracic aorta,F,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,H,,1,,CHEMBL617631,BAO_0000019,1515.0,
2917,,,,B,,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,H,,1,,CHEMBL617632,BAO_0000357,,
2918,,,,B,,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,H,,1,,CHEMBL617633,BAO_0000357,,
2919,,,,B,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,H,,1,,CHEMBL617634,BAO_0000357,,
2920,,,,B,,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,H,,1,,CHEMBL617635,BAO_0000357,,
2922,,,Stomach,F,,,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,D,,1,,CHEMBL617637,BAO_0000019,945.0,
2923,,,,B,,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,,1,,CHEMBL617638,BAO_0000357,,
2924,,,,B,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,H,,1,,CHEMBL617639,BAO_0000357,,
2925,,,,B,,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,H,,1,,CHEMBL617640,BAO_0000357,,
2926,,,,B,,,,Evaluated for the binding affinity to 5-HT 2B receptor,H,,1,,CHEMBL617641,BAO_0000357,,
2927,,,,B,,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,H,,1,,CHEMBL617642,BAO_0000357,,
2928,,,,B,,,,Binding affinities against 5-hydroxytryptamine 2B receptor,H,,1,,CHEMBL617643,BAO_0000357,,
2929,,,,B,,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,H,,1,,CHEMBL617644,BAO_0000357,,
2930,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,H,,1,,CHEMBL617645,BAO_0000357,,
2931,,,,B,,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,H,,1,,CHEMBL617646,BAO_0000357,,
2932,,,,B,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,H,,1,,CHEMBL617647,BAO_0000357,,
2933,,,,B,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,H,,1,,CHEMBL617648,BAO_0000357,,
2934,,,,B,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,H,,1,,CHEMBL617875,BAO_0000357,,
2935,,,,B,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,H,,1,,CHEMBL617876,BAO_0000357,,
2936,,,,B,,,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,H,,1,,CHEMBL617877,BAO_0000357,,
2937,,,,B,,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,H,,1,,CHEMBL617878,BAO_0000357,,
2938,,,,B,,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,H,,1,,CHEMBL617879,BAO_0000357,,
2939,,,,B,,,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,H,,1,,CHEMBL617880,BAO_0000019,,
2940,,,Striatum,B,,,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,D,,1,,CHEMBL617881,BAO_0000357,2435.0,
2941,,,,B,,,,Binding affinity against 5-HT1A receptor,H,,1,,CHEMBL857073,BAO_0000357,,
2942,,,,F,CHO,449.0,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,H,,1,,CHEMBL617882,BAO_0000219,,
2943,,,,F,CHO,449.0,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,D,,1,,CHEMBL617883,BAO_0000219,,
2944,,,,F,,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,H,,1,,CHEMBL617884,BAO_0000219,,
2945,,,,B,CHO,449.0,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,H,,1,,CHEMBL617885,BAO_0000219,,
2946,,,,B,CHO,449.0,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",H,,1,,CHEMBL617886,BAO_0000219,,
2947,,,,B,,,,Inhibition of human 5-hydroxytryptamine 2C receptor,D,,1,,CHEMBL617887,BAO_0000357,,
2948,,,,B,,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),H,,1,,CHEMBL617888,BAO_0000357,,
2949,,,,B,,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,H,,1,,CHEMBL617889,BAO_0000019,,
2950,,,,B,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617890,BAO_0000357,,
2951,,,,B,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,H,,1,,CHEMBL617891,BAO_0000357,,
2952,,,,B,,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,H,,1,,CHEMBL617892,BAO_0000357,,
2953,,,,B,CHO,449.0,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,H,,1,,CHEMBL617893,BAO_0000219,,
2954,,,,B,CHO,449.0,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,H,,1,,CHEMBL617894,BAO_0000219,,
2955,,,,B,CHO,449.0,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,H,,1,,CHEMBL617895,BAO_0000219,,
2956,,,,B,CHO,449.0,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL617896,BAO_0000219,,
2957,,,,B,,,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,D,,1,,CHEMBL617897,BAO_0000357,,
2958,,,,F,,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,H,,1,,CHEMBL617898,BAO_0000019,,
2959,,,,F,,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,H,,1,,CHEMBL617899,BAO_0000019,,
2960,,,,B,CHO,449.0,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,H,,1,,CHEMBL617900,BAO_0000219,,
2961,,,,F,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,H,,1,,CHEMBL617901,BAO_0000019,,
2962,,,,F,,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,H,,1,,CHEMBL617902,BAO_0000019,,
2963,,,,F,,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,,1,,CHEMBL617903,BAO_0000019,,
2964,,,,B,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,H,,1,,CHEMBL617904,BAO_0000357,,
2965,,,,B,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,H,,1,,CHEMBL617905,BAO_0000357,,
2966,,,,B,,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,H,,1,,CHEMBL617906,BAO_0000357,,
2967,,,,B,,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,H,,1,,CHEMBL617907,BAO_0000357,,
2968,,,,B,,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,H,,1,,CHEMBL617908,BAO_0000357,,
2969,,,,B,CHO,449.0,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,H,,1,,CHEMBL620617,BAO_0000219,,
2970,,,,B,,,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,D,,1,,CHEMBL620618,BAO_0000019,,
2971,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,H,,1,,CHEMBL620619,BAO_0000357,,
2972,,,,B,,,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,D,,1,,CHEMBL620620,BAO_0000357,,
2973,,,,B,,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,H,,1,,CHEMBL620621,BAO_0000357,,
2974,Membranes,,,B,,,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,D,,1,,CHEMBL872920,BAO_0000249,,
2975,,,,B,,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,H,,1,,CHEMBL620622,BAO_0000223,,
2976,,,,B,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,D,,1,,CHEMBL620623,BAO_0000019,,
2977,,,,B,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,H,,1,,CHEMBL620624,BAO_0000019,,
2978,,,,B,,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,H,,1,,CHEMBL620625,BAO_0000019,,
2979,,,,B,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,H,,1,,CHEMBL620626,BAO_0000219,,
2980,,,,B,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,H,,1,,CHEMBL621307,BAO_0000019,,
2981,,,,B,,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,H,,1,,CHEMBL621308,BAO_0000019,,
2982,,,,B,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,H,,1,,CHEMBL621309,BAO_0000223,,
2983,,,,B,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,H,,1,,CHEMBL621310,BAO_0000223,,
2984,,,,B,,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,H,,1,,CHEMBL621311,BAO_0000223,,
2985,,,,B,,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",H,,1,,CHEMBL621502,BAO_0000249,,
2986,,,,B,,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",H,,1,,CHEMBL621503,BAO_0000249,,
2987,Membranes,,,B,,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,H,,1,,CHEMBL621504,BAO_0000249,,
2988,,,,B,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL621505,BAO_0000223,,
2989,,,,B,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,H,,1,,CHEMBL621506,BAO_0000019,,
2990,,,,B,,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,H,,1,,CHEMBL619781,BAO_0000223,,
2991,,,,B,,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,H,,1,,CHEMBL619782,BAO_0000223,,
2992,,,,B,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,H,,1,,CHEMBL619783,BAO_0000019,,
2993,,,,B,,,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,D,,1,,CHEMBL619784,BAO_0000019,,
2994,,,,B,,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,H,,1,,CHEMBL619785,BAO_0000249,,
2995,,,,B,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL619786,BAO_0000223,,
2996,,,,B,,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,H,,1,,CHEMBL619787,BAO_0000019,,
2997,,,,B,,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,H,,1,,CHEMBL872925,BAO_0000019,,
2998,,,,B,,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,H,,1,,CHEMBL619788,BAO_0000019,,
2999,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,H,,1,,CHEMBL619789,BAO_0000249,,
3000,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,H,,1,,CHEMBL619790,BAO_0000249,,
3001,,,,B,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,H,,1,,CHEMBL619791,BAO_0000019,,
3002,,,,B,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,H,,1,,CHEMBL619792,BAO_0000019,,
3003,Membranes,,,B,,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,H,,1,,CHEMBL619793,BAO_0000249,,
3004,,,,B,,,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,D,,1,,CHEMBL619794,BAO_0000223,,
3005,,,Brain,B,,,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,H,,1,,CHEMBL619795,BAO_0000221,955.0,
3006,,,,B,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,H,,1,,CHEMBL619796,BAO_0000019,,
3007,,,,B,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,H,,1,,CHEMBL620448,BAO_0000223,,
3008,,,,B,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,H,,1,,CHEMBL620449,BAO_0000223,,
3009,,,,B,,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,H,,1,,CHEMBL620450,BAO_0000223,,
3010,,,,B,,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,H,,1,,CHEMBL620451,BAO_0000223,,
3011,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,H,,1,,CHEMBL620631,BAO_0000223,,
3012,,,,B,,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,H,,1,,CHEMBL620632,BAO_0000019,,
3013,,,,B,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,H,,1,,CHEMBL620633,BAO_0000019,,
3014,,,,B,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,H,,1,,CHEMBL620634,BAO_0000223,,
3015,,,,B,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,H,,1,,CHEMBL620635,BAO_0000019,,
3016,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,H,,1,,CHEMBL620636,BAO_0000218,,
3017,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,H,,1,,CHEMBL620637,BAO_0000218,,
3018,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,H,,1,,CHEMBL620638,BAO_0000218,,
3019,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,H,,1,,CHEMBL620639,BAO_0000218,,
3020,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,H,,1,,CHEMBL620640,BAO_0000218,,
3021,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,H,,1,,CHEMBL620641,BAO_0000218,,
3022,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,H,,1,,CHEMBL620642,BAO_0000218,,
3023,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,H,,1,,CHEMBL620643,BAO_0000218,,
3024,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,H,,1,,CHEMBL620644,BAO_0000218,,
3025,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,H,,1,,CHEMBL620645,BAO_0000218,,
3026,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,H,,1,,CHEMBL620646,BAO_0000218,,
3027,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,H,,1,,CHEMBL620647,BAO_0000218,,
3028,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,H,,1,,CHEMBL620648,BAO_0000218,,
3029,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,H,,1,,CHEMBL620649,BAO_0000218,,
3030,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,H,,1,,CHEMBL620650,BAO_0000218,,
3031,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,H,,1,,CHEMBL620651,BAO_0000218,,
3032,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,H,,1,,CHEMBL872875,BAO_0000218,,
3033,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,H,,1,,CHEMBL620652,BAO_0000218,,
3034,,,,F,,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,H,,1,,CHEMBL620653,BAO_0000019,,
3035,,,,B,,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,H,,1,,CHEMBL857076,BAO_0000019,,
3036,,,,B,,,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,D,,1,,CHEMBL620654,BAO_0000019,,
3037,,,,B,,,,Binding activity radioligand.,H,,1,,CHEMBL620655,BAO_0000223,,
3038,Brain membranes,,,B,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,H,,1,,CHEMBL620656,BAO_0000249,,
3039,Brain membranes,,,B,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,H,,1,,CHEMBL620657,BAO_0000249,,
3040,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,H,,1,,CHEMBL620658,BAO_0000357,,
3041,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,H,,1,,CHEMBL620659,BAO_0000357,,
3042,,,,B,,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,H,,1,,CHEMBL620660,BAO_0000357,,
3043,,,,B,,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL620661,BAO_0000357,,
3044,,,,B,,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL620662,BAO_0000357,,
3045,,,,B,,,,Affinity for 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL620663,BAO_0000357,,
3046,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,,1,,CHEMBL620664,BAO_0000357,,
3047,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,H,,1,,CHEMBL620665,BAO_0000357,,
3048,,,,B,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,H,,1,,CHEMBL620666,BAO_0000357,,
3049,,,,B,,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,H,,1,,CHEMBL620667,BAO_0000357,,
3050,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,H,,1,,CHEMBL620668,BAO_0000357,,
3051,,,,B,,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,H,,1,,CHEMBL620669,BAO_0000357,,
3052,,,,B,,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL620670,BAO_0000357,,
3053,,,,B,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL620671,BAO_0000357,,
3054,,,,B,,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,H,,1,,CHEMBL620672,BAO_0000357,,
3055,,,,B,,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,H,,1,,CHEMBL620673,BAO_0000357,,
3056,,,,B,,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL620674,BAO_0000357,,
3057,,,,B,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL620675,BAO_0000357,,
3058,,,,B,,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,H,,1,,CHEMBL620676,BAO_0000357,,
3059,,,,B,,,,Affinity against 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL621382,BAO_0000357,,
3060,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2C receptor,D,,1,,CHEMBL621383,BAO_0000357,,
3061,,,,B,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,H,,1,,CHEMBL621384,BAO_0000357,,
3062,,,,B,,,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,H,,1,,CHEMBL621385,BAO_0000357,,
3063,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,H,,1,,CHEMBL617989,BAO_0000357,,
3064,,,,F,,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,H,,1,,CHEMBL617990,BAO_0000019,,
3065,,,Ileum,B,,,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,H,,1,,CHEMBL875085,BAO_0000221,2116.0,
3066,,,,F,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,H,,1,,CHEMBL617991,BAO_0000019,,
3067,,,,F,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,H,,1,,CHEMBL617992,BAO_0000019,,
3068,,,Ileum,B,,,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,H,,1,,CHEMBL617993,BAO_0000221,2116.0,
3069,,,Ileum,B,,,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,H,,1,,CHEMBL617994,BAO_0000221,2116.0,
3070,,,,F,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,H,,1,,CHEMBL617995,BAO_0000019,,
3071,,,,F,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,H,,1,,CHEMBL617996,BAO_0000019,,
3072,,,,F,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,H,,1,,CHEMBL617997,BAO_0000019,,
3073,,,,F,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,H,,1,,CHEMBL617998,BAO_0000019,,
3074,,,,F,,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,H,,1,,CHEMBL617999,BAO_0000019,,
3075,,,,F,,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,H,,1,,CHEMBL618000,BAO_0000019,,
3076,,,Ileum,F,,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",H,,1,,CHEMBL617815,BAO_0000221,2116.0,
3077,,,Ileum,F,,,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",H,,1,,CHEMBL617816,BAO_0000221,2116.0,
3078,,,Ileum,F,,,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,H,,1,,CHEMBL617817,BAO_0000221,2116.0,
3079,,,Ileum,B,,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,H,,1,,CHEMBL617818,BAO_0000221,2116.0,
3080,,,Ileum,B,,,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,H,,1,,CHEMBL617819,BAO_0000221,2116.0,
3081,,,,B,,,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,H,,1,,CHEMBL617820,BAO_0000223,,
3082,,,Ileum,B,,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,H,,1,,CHEMBL617821,BAO_0000221,2116.0,
3083,,,Ileum,F,,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),H,,1,,CHEMBL617822,BAO_0000221,2116.0,
3084,,,Ileum,F,,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),H,,1,,CHEMBL617823,BAO_0000221,2116.0,
3085,,,Ileum,F,,,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,H,,1,,CHEMBL617824,BAO_0000221,2116.0,
3086,,,Ileum,F,,,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,H,,1,,CHEMBL617825,BAO_0000221,2116.0,
3087,,,Ileum,F,,,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,H,,1,,CHEMBL617826,BAO_0000221,2116.0,
3088,,,Ileum,B,,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,H,,1,,CHEMBL617827,BAO_0000221,2116.0,
3089,,,Ileum,F,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),H,,1,,CHEMBL617828,BAO_0000221,2116.0,
3090,,,Ileum,B,,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,H,,1,,CHEMBL617829,BAO_0000221,2116.0,
3091,,,Ileum,B,,,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,H,,1,,CHEMBL617830,BAO_0000221,2116.0,
3092,,,Ileum,B,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,H,,1,,CHEMBL617831,BAO_0000221,2116.0,
3093,,,Ileum,B,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,H,,1,,CHEMBL617832,BAO_0000221,2116.0,
3094,,,,B,,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,U,,1,,CHEMBL617833,BAO_0000019,,
3095,,,,B,,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,H,,1,,CHEMBL617834,BAO_0000357,,
3096,,,,B,,,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,D,,1,,CHEMBL617835,BAO_0000223,,
3097,,,,B,,,,Binding affinity towards 5-HT3 receptor,H,,1,,CHEMBL617836,BAO_0000223,,
3098,,,,B,,,,Binding activity radioligand.,H,,1,,CHEMBL617837,BAO_0000223,,
3099,,,,B,,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,H,,1,,CHEMBL620392,BAO_0000019,,
3100,,,,B,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL620393,BAO_0000223,,
3101,,,,B,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL620394,BAO_0000223,,
3102,,,,B,,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,H,,1,,CHEMBL620395,BAO_0000223,,
3103,,,,B,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,U,,1,,CHEMBL620396,BAO_0000019,,
3104,,,,B,NG108-15,433.0,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,H,,1,,CHEMBL620582,BAO_0000219,,
3105,,In vivo,,B,,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",H,,1,,CHEMBL620583,BAO_0000218,,
3106,,,,B,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),H,,1,,CHEMBL620584,BAO_0000019,,
3107,,,,B,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,H,,1,,CHEMBL620585,BAO_0000224,,
3108,,,,B,,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,H,,1,,CHEMBL620586,BAO_0000224,,
3109,,,,B,,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),H,,1,,CHEMBL620587,BAO_0000019,,
3110,,,,B,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,H,,1,,CHEMBL620588,BAO_0000019,,
3111,,,,F,,,,5-hydroxytryptamine 3 receptor agonism in mouse,H,,1,,CHEMBL620589,BAO_0000218,,
3112,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,H,,1,,CHEMBL620590,BAO_0000219,,
3113,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,H,,1,,CHEMBL617956,BAO_0000019,,
3114,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,H,,1,,CHEMBL617957,BAO_0000019,,
3115,,,,B,,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,H,,1,,CHEMBL617958,BAO_0000224,,
3116,,,,B,,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,H,,1,,CHEMBL617959,BAO_0000219,,
3117,,,,B,,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,H,,1,,CHEMBL617960,BAO_0000219,,
3118,,,,B,,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,H,,1,,CHEMBL617961,BAO_0000224,,
3119,,In vitro,,B,,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,H,,1,,CHEMBL617962,BAO_0000219,,
3120,,,,B,N1E-115,339.0,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,H,,1,,CHEMBL617963,BAO_0000219,,
3121,,,,B,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,H,,1,,CHEMBL617964,BAO_0000019,,
3122,,,,B,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,H,,1,,CHEMBL617965,BAO_0000219,,
3123,,,,B,,,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,D,,1,,CHEMBL617966,BAO_0000357,,
3124,,,,B,,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,,1,,CHEMBL857074,BAO_0000019,,
3125,,,,B,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL617967,BAO_0000357,,
3126,,,,B,,,,Binding activity radioligand.,H,,1,,CHEMBL617968,BAO_0000357,,
3127,,,,B,,,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,H,,1,,CHEMBL617969,BAO_0000223,,
3128,,,,B,,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,H,,1,,CHEMBL617970,BAO_0000223,,
3129,,,,B,,,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,H,,1,,CHEMBL617971,BAO_0000223,,
3130,,,,B,,,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,H,,1,,CHEMBL617972,BAO_0000019,,
3131,,,,F,,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),H,,1,,CHEMBL617973,BAO_0000019,,
3132,,,,F,,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),H,,1,,CHEMBL617974,BAO_0000019,,
3133,,,Ileum,F,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),H,,1,,CHEMBL617975,BAO_0000221,2116.0,
3134,,,,F,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),H,,1,,CHEMBL617976,BAO_0000019,,
3135,,,,F,,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),H,,1,,CHEMBL617977,BAO_0000019,,
3136,,,,F,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),H,,1,,CHEMBL617978,BAO_0000019,,
3137,,,,F,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),H,,1,,CHEMBL617979,BAO_0000019,,
3138,,,,B,CHO,449.0,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,H,,1,,CHEMBL617980,BAO_0000219,,
3139,,,,B,,,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,D,,1,,CHEMBL617981,BAO_0000019,,
3140,,,,B,,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),H,,1,,CHEMBL617982,BAO_0000019,,
3141,,,,B,,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),H,,1,,CHEMBL617983,BAO_0000357,,
3142,,,,B,,,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,D,,1,,CHEMBL617984,BAO_0000019,,
3143,,,,B,,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",H,,1,,CHEMBL617985,BAO_0000019,,
3144,,In vivo,Heart,F,,,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",H,,1,,CHEMBL617986,BAO_0000218,948.0,
3145,,,Heart,F,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",H,,1,,CHEMBL617987,BAO_0000019,948.0,
3146,,,Heart,F,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",H,,1,,CHEMBL617988,BAO_0000019,948.0,
3147,,,Heart,F,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",H,,1,,CHEMBL617792,BAO_0000019,948.0,
3148,,,Heart,F,,,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",H,,1,,CHEMBL617793,BAO_0000019,948.0,
3149,,,,F,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",H,,1,,CHEMBL617794,BAO_0000019,,
3150,,,,F,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",H,,1,,CHEMBL617795,BAO_0000019,,
3151,,,,F,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",H,,1,,CHEMBL617796,BAO_0000019,,
3152,,,,F,,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",H,,1,,CHEMBL617797,BAO_0000019,,
3153,,In vivo,,F,,,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),D,,1,,CHEMBL617798,BAO_0000218,,
3154,,In vivo,,F,,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),H,,1,,CHEMBL617799,BAO_0000218,,
3155,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,D,,1,,CHEMBL617800,BAO_0000218,,
3156,,,,F,,,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,D,,1,,CHEMBL617801,BAO_0000019,,
3157,,In vivo,,F,,,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,D,,1,,CHEMBL617802,BAO_0000218,,
3158,,,,F,,,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),D,,1,,CHEMBL617803,BAO_0000019,,
3159,,,,B,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,H,,1,,CHEMBL617804,BAO_0000019,,
3160,,,,B,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,D,,1,,CHEMBL617805,BAO_0000019,,
3161,,,,B,,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL617806,BAO_0000223,,
3162,,,,B,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,H,,1,,CHEMBL617807,BAO_0000019,,
3163,,,,B,,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,H,,1,,CHEMBL617808,BAO_0000019,,
3164,,,,B,,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,H,,1,,CHEMBL617809,BAO_0000249,,
3165,,,,B,,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,H,,1,,CHEMBL617810,BAO_0000019,,
3166,,,Brain,B,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,H,,1,,CHEMBL617811,BAO_0000249,955.0,
3167,,,Brain,B,,,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,H,,1,,CHEMBL617812,BAO_0000221,955.0,
3168,,,,B,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,H,,1,,CHEMBL617813,BAO_0000249,,
3169,,,,B,,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,H,,1,,CHEMBL617814,BAO_0000249,,
3170,,,,B,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,H,,1,,CHEMBL617698,BAO_0000019,,
3171,,,,B,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,D,,1,,CHEMBL617699,BAO_0000019,,
3172,,,,B,,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,D,,1,,CHEMBL617700,BAO_0000019,,
3173,,,,B,,,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,D,,1,,CHEMBL617701,BAO_0000223,,
3174,,,,B,,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,H,,1,,CHEMBL617702,BAO_0000019,,
3175,Membranes,,,B,,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",H,,1,,CHEMBL617703,BAO_0000249,,
3176,,,,B,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,D,,1,,CHEMBL617704,BAO_0000019,,
3177,,,,B,,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,H,,1,,CHEMBL617705,BAO_0000223,,
3178,,,,B,,,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,D,,1,,CHEMBL617706,BAO_0000223,,
3179,,,,B,NG108-15,433.0,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),H,,1,,CHEMBL617707,BAO_0000219,,
3180,,,,B,NG108-15,433.0,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,H,,1,,CHEMBL617708,BAO_0000219,,
3181,,,,B,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,H,,1,,CHEMBL617709,BAO_0000019,,
3182,,,,B,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,H,,1,,CHEMBL617710,BAO_0000019,,
3183,,,,B,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,H,,1,,CHEMBL882925,BAO_0000019,,
3184,,,,B,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,H,,1,,CHEMBL617711,BAO_0000019,,
3185,,,,F,,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,H,,1,,CHEMBL617712,BAO_0000019,,
3186,,,,F,,,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,D,,1,,CHEMBL617713,BAO_0000019,,
3187,,,,F,,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",H,,1,,CHEMBL617714,BAO_0000019,,
3188,,,,F,,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,H,,1,,CHEMBL617715,BAO_0000218,,
3189,,In vivo,,F,,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,H,,1,,CHEMBL617716,BAO_0000218,,
3190,,,,F,,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,H,,1,,CHEMBL617717,BAO_0000218,,
3191,,In vivo,,F,,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617718,BAO_0000218,,
3192,,In vivo,,F,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617719,BAO_0000218,,
3193,,In vivo,,F,,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),H,,1,,CHEMBL617720,BAO_0000218,,
3194,,In vivo,,F,,,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,D,,1,,CHEMBL617721,BAO_0000218,,
3195,,In vivo,,F,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617722,BAO_0000218,,
3196,,In vivo,,F,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,H,,1,,CHEMBL617723,BAO_0000218,,
3197,,In vivo,,F,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617724,BAO_0000218,,
3198,,In vivo,,F,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617725,BAO_0000218,,
3199,,In vivo,,F,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617726,BAO_0000218,,
3200,,In vivo,,F,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617727,BAO_0000218,,
3201,,In vivo,,F,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617728,BAO_0000218,,
3202,,In vivo,,F,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617729,BAO_0000218,,
3203,,In vivo,,F,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617730,BAO_0000218,,
3204,,In vivo,,F,,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617731,BAO_0000218,,
3205,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617732,BAO_0000218,,
3206,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617733,BAO_0000218,,
3207,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617734,BAO_0000218,,
3208,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,H,,1,,CHEMBL872874,BAO_0000218,,
3209,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,H,,1,,CHEMBL617735,BAO_0000218,,
3210,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,H,,1,,CHEMBL617736,BAO_0000218,,
3211,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,H,,1,,CHEMBL617737,BAO_0000218,,
3212,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,H,,1,,CHEMBL617738,BAO_0000218,,
3213,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617739,BAO_0000218,,
3214,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617740,BAO_0000218,,
3215,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617741,BAO_0000218,,
3216,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617742,BAO_0000218,,
3217,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617743,BAO_0000218,,
3218,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617744,BAO_0000218,,
3219,,In vivo,,F,,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,H,,1,,CHEMBL617745,BAO_0000218,,
3220,,,,F,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",H,,1,,CHEMBL617746,BAO_0000218,,
3221,,,,F,,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",H,,1,,CHEMBL617747,BAO_0000218,,
3222,,In vivo,,F,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,H,,1,,CHEMBL617748,BAO_0000218,,
3223,,In vivo,,F,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,H,,1,,CHEMBL618909,BAO_0000218,,
3224,,In vivo,,F,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,H,,1,,CHEMBL618910,BAO_0000218,,
3225,,In vivo,,F,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,H,,1,,CHEMBL618911,BAO_0000218,,
3226,,In vivo,,F,,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,H,,1,,CHEMBL618912,BAO_0000218,,
3227,,In vivo,,F,,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),H,,1,,CHEMBL618913,BAO_0000218,,
3228,,,,F,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,H,,1,,CHEMBL618914,BAO_0000019,,
3229,,,,F,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,H,,1,,CHEMBL618915,BAO_0000019,,
3230,,,,B,,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,D,,1,,CHEMBL618916,BAO_0000223,,
3231,,,,F,,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,H,,1,,CHEMBL618917,BAO_0000019,,
3232,,,Hippocampus,B,,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,D,,1,,CHEMBL618918,BAO_0000221,10000000.0,
3233,,,,B,,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,D,,1,,CHEMBL618919,BAO_0000019,,
3234,,,,B,,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,D,,1,,CHEMBL618920,BAO_0000019,,
3235,,,,B,,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL618921,BAO_0000223,,
3236,,,,B,,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL618922,BAO_0000019,,
3237,,,,B,,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,H,,1,,CHEMBL618923,BAO_0000019,,
3238,,,,B,,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,H,,1,,CHEMBL618924,BAO_0000019,,
3239,,,,B,,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,H,,1,,CHEMBL618925,BAO_0000019,,
3240,,,,B,,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,H,,1,,CHEMBL618926,BAO_0000019,,
3241,,,Ileum,F,,,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,D,,1,,CHEMBL618927,BAO_0000221,2116.0,
3242,,,Ileum,F,,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,D,,1,,CHEMBL618928,BAO_0000221,2116.0,
3243,,,Ileum,F,,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",D,,1,,CHEMBL618929,BAO_0000221,2116.0,
3244,,,Ileum,F,,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",D,,1,,CHEMBL618930,BAO_0000221,2116.0,
3245,,,Ileum,F,,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",D,,1,,CHEMBL618931,BAO_0000221,2116.0,
3246,,,Ileum,F,,,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",D,,1,,CHEMBL619594,BAO_0000221,2116.0,
3247,,,Ileum,F,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",D,,1,,CHEMBL619595,BAO_0000221,2116.0,
3248,,,Ileum,F,,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,D,,1,,CHEMBL619596,BAO_0000221,2116.0,
3249,,,Ileum,F,,,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,D,,1,,CHEMBL619755,BAO_0000221,2116.0,
3250,,,Ileum,F,,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,D,,1,,CHEMBL619756,BAO_0000221,2116.0,
3251,,,Ileum,F,,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,D,,1,,CHEMBL619757,BAO_0000221,2116.0,
3252,,,Ileum,F,,,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,D,,1,,CHEMBL619758,BAO_0000221,2116.0,
3253,,,Ileum,F,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",D,,1,,CHEMBL619759,BAO_0000221,2116.0,
3254,,,Ileum,F,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",D,,1,,CHEMBL619760,BAO_0000221,2116.0,
3255,,,Ileum,F,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",D,,1,,CHEMBL619761,BAO_0000221,2116.0,
3256,,,Ileum,F,,,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,D,,1,,CHEMBL619762,BAO_0000221,2116.0,
3257,,,Ileum,F,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",D,,1,,CHEMBL619763,BAO_0000221,2116.0,
3258,,,Ileum,F,,,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",D,,1,,CHEMBL617868,BAO_0000221,2116.0,
3259,,,,B,,,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,D,,1,,CHEMBL617869,BAO_0000357,,
3260,,,Striatum,B,,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,D,,1,,CHEMBL882926,BAO_0000249,2435.0,
3261,,,Striatum,B,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,D,,1,,CHEMBL617870,BAO_0000249,2435.0,
3262,,,Striatum,B,,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,D,,1,,CHEMBL617871,BAO_0000357,2435.0,
3263,,,Striatum,B,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,D,,1,,CHEMBL617872,BAO_0000357,2435.0,
3264,,,Striatum,B,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,D,,1,,CHEMBL617873,BAO_0000357,2435.0,
3265,,,Striatum,B,,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,D,,1,,CHEMBL617874,BAO_0000357,2435.0,
3266,,,Ileum,F,,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,D,,1,,CHEMBL619067,BAO_0000221,2116.0,
3267,,,Ileum,F,,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,D,,1,,CHEMBL619068,BAO_0000221,2116.0,
3268,,,Ileum,F,,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,D,,1,,CHEMBL619069,BAO_0000221,2116.0,
3269,,,,B,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,D,,1,,CHEMBL619070,BAO_0000357,,
3270,,,,B,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,D,,1,,CHEMBL619071,BAO_0000357,,
3271,,,,F,,,,Agonistic activity against 5-hydroxytryptamine 4 receptor,D,,1,,CHEMBL619072,BAO_0000019,,
3272,,,,F,,,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,D,,1,,CHEMBL619073,BAO_0000019,,
3273,,,,F,,,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,D,,1,,CHEMBL619074,BAO_0000019,,
3274,,,,B,,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,D,,1,,CHEMBL619075,BAO_0000357,,
3275,,,Striatum,B,,,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,D,,1,,CHEMBL619076,BAO_0000357,2435.0,
3276,,,Striatum,B,,,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,D,,1,,CHEMBL619077,BAO_0000357,2435.0,
3277,,,Striatum,B,,,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,D,,1,,CHEMBL619078,BAO_0000249,2435.0,
3278,,,Striatum,B,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,D,,1,,CHEMBL619079,BAO_0000249,2435.0,
3279,,,Ileum,B,,,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,D,,1,,CHEMBL619080,BAO_0000221,2116.0,
3280,,,,B,,,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,D,,1,,CHEMBL619081,BAO_0000357,,
3281,,,,B,,,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,D,,1,,CHEMBL619082,BAO_0000357,,
3282,,,,B,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,D,,1,,CHEMBL619083,BAO_0000357,,
3283,,,,B,,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,D,,1,,CHEMBL619084,BAO_0000357,,
3284,,,Ileum,F,,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,D,,1,,CHEMBL859397,BAO_0000221,2116.0,
3285,,,Ileum,F,,,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,D,,1,,CHEMBL619085,BAO_0000221,2116.0,
3286,,,Ileum,F,,,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,D,,1,,CHEMBL619086,BAO_0000221,2116.0,
3287,,,Ileum,F,,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,D,,1,,CHEMBL619087,BAO_0000221,2116.0,
3288,,,Ileum,F,,,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,D,,1,,CHEMBL619088,BAO_0000221,2116.0,
3289,,,,B,,,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,D,,1,,CHEMBL619089,BAO_0000357,,
3290,,,,B,,,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL619090,BAO_0000357,,
3291,,,,F,,,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,D,,1,,CHEMBL619091,BAO_0000019,,
3292,,,,B,,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,D,,1,,CHEMBL619092,BAO_0000357,,
3293,,,,B,,,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,D,,1,,CHEMBL619093,BAO_0000019,,
3294,,,,B,HEK293,722.0,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,H,,1,,CHEMBL619094,BAO_0000219,,
3295,,,,B,,,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,D,,1,,CHEMBL619095,BAO_0000019,,
3296,,,,B,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,D,,1,,CHEMBL857988,BAO_0000357,,
3297,,,,B,,,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,D,,1,,CHEMBL619096,BAO_0000357,,
3298,,,Striatum,B,,,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,D,,1,,CHEMBL619097,BAO_0000357,2435.0,
3299,,,Hippocampus,B,,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,D,,1,,CHEMBL619098,BAO_0000221,10000000.0,
3300,,,,B,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,D,,1,,CHEMBL619751,BAO_0000357,,
3301,,,,B,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,D,,1,,CHEMBL619752,BAO_0000357,,
3302,,,Ileum,F,,,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,D,,1,,CHEMBL875096,BAO_0000221,2116.0,
3303,,,,B,,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,H,,1,,CHEMBL619004,BAO_0000357,,
3304,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,H,,1,,CHEMBL619005,BAO_0000357,,
3305,,,,B,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,H,,1,,CHEMBL619006,BAO_0000019,,
3306,,,,B,HeLa,308.0,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,H,,1,,CHEMBL619007,BAO_0000219,,
3307,,,,B,,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,H,,1,,CHEMBL619008,BAO_0000357,,
3308,,,,B,,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,H,,1,,CHEMBL619009,BAO_0000357,,
3309,,,,B,HeLa,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",H,,1,,CHEMBL619010,BAO_0000219,,
3310,,,,B,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,H,,1,,CHEMBL619011,BAO_0000357,,
3311,,,,B,,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,H,,1,,CHEMBL619012,BAO_0000357,,
3312,,,,B,,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,H,,1,,CHEMBL619013,BAO_0000219,,
3313,,,,B,,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,H,,1,,CHEMBL619014,BAO_0000357,,
3314,,,Cardiac atrium,F,,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,H,,1,,CHEMBL857503,BAO_0000019,2081.0,
3315,,,Cardiac atrium,F,,,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,H,,1,,CHEMBL619015,BAO_0000019,2081.0,
3316,,,,B,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,H,,1,,CHEMBL619016,BAO_0000357,,
3317,,,Hippocampus,B,,,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,H,,1,,CHEMBL619017,BAO_0000221,10000000.0,
3318,,,Hippocampus,B,,,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,H,,1,,CHEMBL619018,BAO_0000221,10000000.0,
3319,,,,B,,,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,H,,1,,CHEMBL619019,BAO_0000019,,
3320,,,,B,,,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,D,,1,,CHEMBL619020,BAO_0000357,,
3321,,,,F,,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,H,,1,,CHEMBL619021,BAO_0000019,,
3322,,,,B,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,H,,1,,CHEMBL619022,BAO_0000357,,
3323,,,,B,,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,H,,1,,CHEMBL619023,BAO_0000357,,
3324,,,,F,,,,lntrinsic activity relative to 5-HT receptor,H,,1,,CHEMBL619024,BAO_0000019,,
3325,,,,F,,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,H,,1,,CHEMBL619025,BAO_0000019,,
3326,,,,F,,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,H,,1,,CHEMBL619026,BAO_0000019,,
3327,,,,F,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,H,,1,,CHEMBL619027,BAO_0000019,,
3328,,,,F,,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,H,,1,,CHEMBL619028,BAO_0000019,,
3329,,,,F,,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,H,,1,,CHEMBL619029,BAO_0000019,,
3330,,,,F,,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,H,,1,,CHEMBL619030,BAO_0000019,,
3331,,,,B,,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,H,,1,,CHEMBL619031,BAO_0000357,,
3332,,,,F,,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,H,,1,,CHEMBL619032,BAO_0000019,,
3333,,,,B,,,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,D,,1,,CHEMBL619033,BAO_0000357,,
3334,,,,B,,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,H,,1,,CHEMBL619034,BAO_0000357,,
3335,,,,B,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,H,,1,,CHEMBL619035,BAO_0000357,,
3336,,,,B,,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,H,,1,,CHEMBL619036,BAO_0000357,,
3337,,,,B,,,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,D,,1,,CHEMBL619037,BAO_0000019,,
3338,,,Striatum,B,,,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,H,,1,,CHEMBL619038,BAO_0000249,2435.0,
3339,,,,B,,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,H,,1,,CHEMBL619039,BAO_0000249,,
3340,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,H,,1,,CHEMBL619040,BAO_0000249,,
3341,,,Striatum,B,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,D,,1,,CHEMBL619041,BAO_0000019,2435.0,
3342,,,Striatum,B,,,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,H,,1,,CHEMBL619042,BAO_0000019,2435.0,
3343,,,Striatum,B,,,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,H,,1,,CHEMBL619043,BAO_0000249,2435.0,
3344,,,Striatum,B,,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,H,,1,,CHEMBL619044,BAO_0000019,2435.0,
3345,,,Striatum,B,,,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,H,,1,,CHEMBL619045,BAO_0000249,2435.0,
3346,,,Striatum,B,,,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,H,,1,,CHEMBL619046,BAO_0000249,2435.0,
3347,,,,B,,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,H,,1,,CHEMBL619047,BAO_0000249,,
3348,,,Brain,F,,,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,H,,1,,CHEMBL619048,BAO_0000221,955.0,
3349,,,,F,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,H,,1,,CHEMBL859398,BAO_0000019,,
3350,,,,F,,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,H,,1,,CHEMBL619049,BAO_0000019,,
3351,,,,F,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,H,,1,,CHEMBL857886,BAO_0000019,,
3352,,,,F,,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,H,,1,,CHEMBL619050,BAO_0000019,,
3353,,,,F,,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,H,,1,,CHEMBL620591,BAO_0000019,,
3354,,,,B,,,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,D,,1,,CHEMBL620592,BAO_0000357,,
3355,,,Striatum,B,,,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,H,,1,,CHEMBL620593,BAO_0000249,2435.0,
3356,,,,F,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,D,,1,,CHEMBL620594,BAO_0000019,,
3357,,,,F,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,H,,1,,CHEMBL875079,BAO_0000019,,
3358,,,,F,,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,H,,1,,CHEMBL620595,BAO_0000019,,
3359,,,,F,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,D,,1,,CHEMBL620596,BAO_0000019,,
3360,,,,F,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,H,,1,,CHEMBL620597,BAO_0000019,,
3361,,,,F,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,H,,1,,CHEMBL620598,BAO_0000019,,
3362,,,,F,,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),H,,1,,CHEMBL620599,BAO_0000218,,
3363,,,,F,,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,H,,1,,CHEMBL620600,BAO_0000019,,
3364,,,,F,,,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,H,,1,,CHEMBL620601,BAO_0000019,,
3365,,,,F,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,H,,1,,CHEMBL620602,BAO_0000019,,
3366,,,,B,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,H,,1,,CHEMBL620603,BAO_0000357,,
3367,,,,B,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,H,,1,,CHEMBL620604,BAO_0000357,,
3368,,,,B,,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,H,,1,,CHEMBL620605,BAO_0000357,,
3369,,,,B,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,H,,1,,CHEMBL620606,BAO_0000357,,
3370,,,,F,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,H,,1,,CHEMBL620607,BAO_0000019,,
3371,,,,B,,,,In vitro binding affinity towards 5-HT4 receptor was determined,H,,1,,CHEMBL620608,BAO_0000357,,
3372,,,,F,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,H,,1,,CHEMBL620609,BAO_0000019,,
3373,,,,F,,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,H,,1,,CHEMBL620610,BAO_0000019,,
3374,,,,B,,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,H,,1,,CHEMBL620611,BAO_0000357,,
3375,,,,B,,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,H,,1,,CHEMBL620612,BAO_0000357,,
3376,,,,B,,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,H,,1,,CHEMBL620613,BAO_0000357,,
3377,,,,B,,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,H,,1,,CHEMBL620614,BAO_0000357,,
3378,,,,B,,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,H,,1,,CHEMBL620615,BAO_0000357,,
3379,Brain membranes,,,B,,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,H,,1,,CHEMBL857075,BAO_0000249,,
3380,Brain membranes,,,B,,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,H,,1,,CHEMBL620616,BAO_0000249,,
3381,Brain membranes,,,B,,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,H,,1,,CHEMBL619411,BAO_0000249,,
3382,,,,B,,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,H,,1,,CHEMBL619412,BAO_0000019,,
3383,,,,B,,,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,D,,1,,CHEMBL619413,BAO_0000019,,
3384,,,Hippocampus,B,,,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,H,,1,,CHEMBL619414,BAO_0000221,10000000.0,
3385,,,,B,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,H,,1,,CHEMBL619415,BAO_0000019,,
3386,,,,B,,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,H,,1,,CHEMBL619416,BAO_0000019,,
3387,,,,F,,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,H,,1,,CHEMBL619417,BAO_0000019,,
3388,,,,B,,,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,D,,1,,CHEMBL619418,BAO_0000223,,
3389,,,,B,,,,Binding affinity against 5-Hydroxytryptamine 3 receptor,D,,1,,CHEMBL619419,BAO_0000223,,
3390,,,,B,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,H,,1,,CHEMBL619420,BAO_0000019,,
3391,,,,B,,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,H,,1,,CHEMBL619421,BAO_0000249,,
3392,,,,B,,,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,D,,1,,CHEMBL619422,BAO_0000019,,
3393,,,,B,,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,H,,1,,CHEMBL619423,BAO_0000019,,
3394,,,,B,,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,H,,1,,CHEMBL875080,BAO_0000019,,
3395,,,,B,,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,H,,1,,CHEMBL619424,BAO_0000019,,
3396,,,,B,,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,H,,1,,CHEMBL619425,BAO_0000249,,
3397,,,,B,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,H,,1,,CHEMBL619426,BAO_0000223,,
3398,,,,B,,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,H,,1,,CHEMBL619427,BAO_0000223,,
3399,,,,B,,,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,D,,1,,CHEMBL619645,BAO_0000223,,
3400,,,,B,,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",D,,1,,CHEMBL619646,BAO_0000249,,
3401,,,Brain,F,,,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,H,,1,,CHEMBL619647,BAO_0000221,955.0,
3402,,,,F,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL619648,BAO_0000019,,
3403,,,,F,,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,H,,1,,CHEMBL619165,BAO_0000019,,
3404,,In vivo,,F,,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL620719,BAO_0000218,,
3405,,,,B,,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,H,,1,,CHEMBL872924,BAO_0000019,,
3406,,,,B,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL620720,BAO_0000357,,
3407,,,,B,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,H,,1,,CHEMBL620721,BAO_0000019,,
3408,,,,B,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,H,,1,,CHEMBL620722,BAO_0000019,,
3409,,,,B,,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",H,,1,,CHEMBL620723,BAO_0000019,,
3410,,,,B,,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,H,,1,,CHEMBL620724,BAO_0000019,,
3411,,,,B,,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,H,,1,,CHEMBL620725,BAO_0000249,,
3412,,,,F,,,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,D,,1,,CHEMBL620726,BAO_0000019,,
3413,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL620727,BAO_0000357,,
3414,,,,B,,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,H,,1,,CHEMBL620728,BAO_0000223,,
3415,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,U,,1,,CHEMBL620729,BAO_0000019,,
3416,,,,F,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,H,,1,,CHEMBL858288,BAO_0000019,,
3417,,,,B,,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL620730,BAO_0000223,,
3418,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL620731,BAO_0000223,,
3419,,,,F,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,H,,1,,CHEMBL620732,BAO_0000019,,
3420,,,,F,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,H,,1,,CHEMBL618042,BAO_0000019,,
3421,,,,F,,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,H,,1,,CHEMBL618043,BAO_0000019,,
3422,,,,B,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL618044,BAO_0000223,,
3423,,,,F,,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,H,,1,,CHEMBL618045,BAO_0000019,,
3424,,,,B,,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,H,,1,,CHEMBL618046,BAO_0000223,,
3425,,,,F,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,H,,1,,CHEMBL618047,BAO_0000019,,
3426,,,,F,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,H,,1,,CHEMBL875084,BAO_0000019,,
3427,,,,F,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,H,,1,,CHEMBL618048,BAO_0000019,,
3428,,,,B,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,H,,1,,CHEMBL618049,BAO_0000223,,
3429,,,,F,,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,H,,1,,CHEMBL619764,BAO_0000019,,
3430,,,,F,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,H,,1,,CHEMBL619765,BAO_0000019,,
3431,,,,F,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,H,,1,,CHEMBL619766,BAO_0000019,,
3432,,,,B,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,H,,1,,CHEMBL619767,BAO_0000223,,
3433,,,,B,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,H,,1,,CHEMBL619768,BAO_0000223,,
3434,,,,F,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,H,,1,,CHEMBL619769,BAO_0000019,,
3435,,,,B,,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,H,,1,,CHEMBL619770,BAO_0000223,,
3436,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL619771,BAO_0000223,,
3437,,,,B,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,H,,1,,CHEMBL619772,BAO_0000219,,
3438,,,,B,,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,H,,1,,CHEMBL619773,BAO_0000223,,
3439,,,,B,NG108-15,433.0,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,H,,1,,CHEMBL619774,BAO_0000219,,
3440,,,,B,,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,H,,1,,CHEMBL875083,BAO_0000019,,
3441,,,,B,NG108-15,433.0,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,H,,1,,CHEMBL620718,BAO_0000219,,
3442,,,,B,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,H,,1,,CHEMBL618127,BAO_0000223,,
3443,,,,B,,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,H,,1,,CHEMBL618128,BAO_0000223,,
3444,,In vitro,,B,,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,H,,1,,CHEMBL618129,BAO_0000219,,
3445,,,,B,,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,H,,1,,CHEMBL618130,BAO_0000223,,
3446,,,,F,,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,H,,1,,CHEMBL618131,BAO_0000019,,
3447,,,,F,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,H,,1,,CHEMBL618132,BAO_0000019,,
3448,,,,F,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,H,,1,,CHEMBL618133,BAO_0000019,,
3449,,,,F,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,H,,1,,CHEMBL618134,BAO_0000019,,
3450,,,,F,,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,H,,1,,CHEMBL618135,BAO_0000019,,
3451,,,,B,,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,H,,1,,CHEMBL618136,BAO_0000223,,
3452,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL618137,BAO_0000223,,
3453,,,,B,,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,H,,1,,CHEMBL618138,BAO_0000223,,
3454,,,,B,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,H,,1,,CHEMBL618139,BAO_0000223,,
3455,,,,B,,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,H,,1,,CHEMBL618140,BAO_0000223,,
3456,,,,B,,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,H,,1,,CHEMBL618141,BAO_0000223,,
3457,,,,B,,,,Binding affinity for 5-hydroxytryptamine 2C receptor,H,,1,,CHEMBL873478,BAO_0000357,,
3458,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL618142,BAO_0000223,,
3459,,,,B,,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL618143,BAO_0000357,,
3460,,,,B,,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL618144,BAO_0000357,,
3461,,,,B,,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL618145,BAO_0000357,,
3462,,,,B,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,H,,1,,CHEMBL618146,BAO_0000223,,
3463,,,,B,,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,H,,1,,CHEMBL618147,BAO_0000223,,
3464,,,,B,,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,H,,1,,CHEMBL618148,BAO_0000223,,
3465,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,H,,1,,CHEMBL618149,BAO_0000019,,
3466,,,,B,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL872927,BAO_0000357,,
3467,,,,B,,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL618150,BAO_0000357,,
3468,,,,B,,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,H,,1,,CHEMBL618151,BAO_0000357,,
3469,,,,B,,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL875094,BAO_0000357,,
3470,,,,B,,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,H,,1,,CHEMBL618152,BAO_0000019,,
3471,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,H,,1,,CHEMBL618153,BAO_0000357,,
3472,,,,B,,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,H,,1,,CHEMBL618888,BAO_0000357,,
3473,,,,F,,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,H,,1,,CHEMBL618889,BAO_0000019,,
3474,,,,B,,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,H,,1,,CHEMBL618890,BAO_0000357,,
3475,,,,B,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,H,,1,,CHEMBL618891,BAO_0000019,,
3476,,,,B,,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,H,,1,,CHEMBL619054,BAO_0000019,,
3477,,,,B,,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,H,,1,,CHEMBL619055,BAO_0000223,,
3478,,,,B,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,H,,1,,CHEMBL619056,BAO_0000357,,
3479,,,,F,,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,H,,1,,CHEMBL619057,BAO_0000019,,
3480,,,,B,,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,H,,1,,CHEMBL619058,BAO_0000357,,
3481,,,,F,Oocytes,,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,D,,1,,CHEMBL619059,BAO_0000219,,
3482,,,,F,Oocytes,,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,D,,1,,CHEMBL619060,BAO_0000219,,
3483,,,,F,Oocytes,,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,D,,1,,CHEMBL875095,BAO_0000219,,
3484,,,Ileum,F,,,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,D,,1,,CHEMBL619061,BAO_0000221,2116.0,
3485,,,Ileum,F,,,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,D,,1,,CHEMBL619062,BAO_0000221,2116.0,
3486,,,,F,,,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,D,,1,,CHEMBL619063,BAO_0000019,,
3487,,,Ileum,B,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,D,,1,,CHEMBL619064,BAO_0000221,2116.0,
3488,,,,B,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,D,,1,,CHEMBL619065,BAO_0000357,,
3489,,,Ileum,B,,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,D,,1,,CHEMBL619066,BAO_0000221,2116.0,
3490,,,Ileum,B,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,H,,1,,CHEMBL619775,BAO_0000221,2116.0,
3491,,,,B,,,,Affinity against 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL619776,BAO_0000357,,
3492,,,,B,,,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,H,,1,,CHEMBL619777,BAO_0000224,,
3493,,,,B,,,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,H,,1,,CHEMBL619778,BAO_0000224,,
3494,,,Ileum,B,,,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,H,,1,,CHEMBL619779,BAO_0000221,2116.0,
3495,,,,B,,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",H,,1,,CHEMBL619780,BAO_0000224,,
3496,,,,B,,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",H,,1,,CHEMBL619166,BAO_0000224,,
3497,,,,F,,,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,H,,1,,CHEMBL619167,BAO_0000019,,
3498,,,,F,,,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,H,,1,,CHEMBL619168,BAO_0000019,,
3499,,,Cardiac atrium,B,,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,D,,1,,CHEMBL619169,BAO_0000219,2081.0,
3500,,,Cardiac atrium,B,,,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,D,,1,,CHEMBL619170,BAO_0000219,2081.0,
3501,,,,F,,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",D,,1,,CHEMBL619171,BAO_0000019,,
3502,,,Cardiac atrium,F,,,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",D,,1,,CHEMBL619172,BAO_0000219,2081.0,
3503,,,,B,,,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,U,,1,,CHEMBL619173,BAO_0000019,,
3504,,,,B,,,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,U,,1,,CHEMBL619174,BAO_0000019,,
3505,,,,B,,,,5-hydroxytryptamine receptor binding affinity was determined in rats,H,,1,,CHEMBL619175,BAO_0000019,,
3506,,,,B,,,,Binding affinity at rat 5-hydroxytryptamine receptor.,H,,1,,CHEMBL619176,BAO_0000224,,
3507,,,,B,,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,H,,1,,CHEMBL619177,BAO_0000019,,
3508,,,,B,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,H,,1,,CHEMBL619178,BAO_0000224,,
3509,,,,B,,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,H,,1,,CHEMBL619179,BAO_0000224,,
3510,,,Stomach,F,,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,H,,1,,CHEMBL619180,BAO_0000019,945.0,
3511,,,Stomach,F,,,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,H,,1,,CHEMBL619181,BAO_0000019,945.0,
3512,,,,F,,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,H,,1,,CHEMBL619182,BAO_0000019,,
3513,,,,B,,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,H,,1,,CHEMBL619183,BAO_0000224,,
3514,,,,B,,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",H,,1,,CHEMBL619184,BAO_0000224,,
3515,,,Hippocampus,B,,,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,H,,1,,CHEMBL619185,BAO_0000221,10000000.0,
3516,,,,B,,,,Binding affinity for rat 5-hydroxytryptamine transporter.,H,,1,,CHEMBL619186,BAO_0000357,,
3517,,,,B,,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,H,,1,,CHEMBL619187,BAO_0000019,,
3518,,,,B,,,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,D,,1,,CHEMBL619188,BAO_0000019,,
3519,,,,B,,,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,D,,1,,CHEMBL619189,BAO_0000224,,
3520,,,Brain,F,,,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,D,,1,,CHEMBL619190,BAO_0000019,955.0,
3521,,,Cerebellum,F,,,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,D,,1,,CHEMBL619191,BAO_0000221,2037.0,
3522,,,,B,,,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,D,,1,,CHEMBL619192,BAO_0000019,,
3523,,,,B,,,,Percent binding affinity against 5-hydroxytryptamine receptor,D,,1,,CHEMBL619193,BAO_0000224,,
3524,,,,B,,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,U,,1,,CHEMBL619194,BAO_0000019,,
3525,,,,B,,,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,D,,1,,CHEMBL619195,BAO_0000224,,
3526,,,,B,,,,Affinity against 5-hydroxytryptamine receptor was determined,D,,1,,CHEMBL619196,BAO_0000224,,
3527,,,Stomach,B,,,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,D,,1,,CHEMBL619197,BAO_0000019,945.0,
3528,,In vitro,,B,,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,D,,1,,CHEMBL619198,BAO_0000219,,
3529,,In vitro,,B,,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,D,,1,,CHEMBL875081,BAO_0000219,,
3530,,,,B,,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,H,,1,,CHEMBL884712,BAO_0000357,,
3531,,,,B,,,,Inhibition of 5-hydroxytryptamine reuptake,H,,1,,CHEMBL884710,BAO_0000357,,
3532,,,,F,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",H,,1,,CHEMBL619199,BAO_0000019,,
3533,,,,F,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",H,,1,,CHEMBL619200,BAO_0000019,,
3534,,,,F,,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",H,,1,,CHEMBL619201,BAO_0000019,,
3535,,,,F,,,,Tested for 5-hydroxytryptamine receptor uptake,H,,1,,CHEMBL619202,BAO_0000019,,
3536,,,,B,CHO,449.0,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,D,,1,,CHEMBL619203,BAO_0000219,,
3537,,,,F,,,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,D,,1,,CHEMBL619204,BAO_0000019,,
3538,,,,B,,,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,H,,1,,CHEMBL619205,BAO_0000249,,
3539,,,,B,,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,H,,1,,CHEMBL619206,BAO_0000357,,
3540,,,,B,,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,H,,1,,CHEMBL619207,BAO_0000249,,
3541,,,Striatum,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,H,,1,,CHEMBL619208,BAO_0000019,2435.0,
3542,,,Striatum,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,H,,1,,CHEMBL619209,BAO_0000019,2435.0,
3543,,,Striatum,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,H,,1,,CHEMBL619210,BAO_0000019,2435.0,
3544,,,Striatum,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,H,,1,,CHEMBL619211,BAO_0000019,2435.0,
3545,,,Striatum,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,H,,1,,CHEMBL619212,BAO_0000019,2435.0,
3546,,,Striatum,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,H,,1,,CHEMBL620681,BAO_0000019,2435.0,
3547,,,Striatum,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,H,,1,,CHEMBL620682,BAO_0000019,2435.0,
3548,,,Striatum,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,H,,1,,CHEMBL620683,BAO_0000019,2435.0,
3549,,,Striatum,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,H,,1,,CHEMBL620684,BAO_0000019,2435.0,
3550,,,Striatum,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,H,,1,,CHEMBL620685,BAO_0000019,2435.0,
3551,,,Striatum,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,H,,1,,CHEMBL620686,BAO_0000019,2435.0,
3552,,,Limbic system,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,H,,1,,CHEMBL620687,BAO_0000019,349.0,
3553,,,Limbic system,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,H,,1,,CHEMBL620688,BAO_0000019,349.0,
3554,,,Limbic system,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,H,,1,,CHEMBL620689,BAO_0000019,349.0,
3555,,,Limbic system,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,H,,1,,CHEMBL620690,BAO_0000019,349.0,
3556,,,Limbic system,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,H,,1,,CHEMBL620691,BAO_0000019,349.0,
3557,,,Limbic system,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,H,,1,,CHEMBL620692,BAO_0000019,349.0,
3558,,,Limbic system,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,H,,1,,CHEMBL620693,BAO_0000019,349.0,
3559,,,,B,,,,Binding affinity against 5-hydroxytryptamine 4 receptor,H,,1,,CHEMBL620694,BAO_0000357,,
3560,,,,F,,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,H,,1,,CHEMBL857986,BAO_0000019,,
3561,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,H,,1,,CHEMBL620695,BAO_0000357,,
3562,,,,B,,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,H,,1,,CHEMBL620696,BAO_0000357,,
3563,,,,B,,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,H,,1,,CHEMBL620697,BAO_0000357,,
3564,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,H,,1,,CHEMBL620698,BAO_0000357,,
3565,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,H,,1,,CHEMBL620699,BAO_0000357,,
3566,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,H,,1,,CHEMBL620700,BAO_0000357,,
3567,,,,B,COS-7,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,H,,1,,CHEMBL620701,BAO_0000219,,
3568,,,,B,COS-7,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,H,,1,,CHEMBL875082,BAO_0000219,,
3569,,,,B,COS-7,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,H,,1,,CHEMBL620702,BAO_0000219,,
3570,,,,B,COS-7,643.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,H,,1,,CHEMBL620703,BAO_0000219,,
3571,,,,B,C6,673.0,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,H,,1,,CHEMBL620704,BAO_0000219,,
3572,,,,B,C6,673.0,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,H,,1,,CHEMBL620705,BAO_0000219,,
3573,,,,B,C6,673.0,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,H,,1,,CHEMBL620706,BAO_0000219,,
3574,,,,B,C6,673.0,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,H,,1,,CHEMBL620707,BAO_0000219,,
3575,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,H,,1,,CHEMBL620708,BAO_0000357,,
3576,,,,B,,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,H,,1,,CHEMBL620709,BAO_0000357,,
3577,,,,B,,,,Binding affinity against 5-hydroxytryptamine 5A receptor,D,,1,,CHEMBL620710,BAO_0000357,,
3578,,,,B,CHO,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,H,,1,,CHEMBL620711,BAO_0000219,,
3579,,,,B,,,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,D,,1,,CHEMBL620712,BAO_0000357,,
3580,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,D,,1,,CHEMBL620713,BAO_0000357,,
3581,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,D,,1,,CHEMBL620714,BAO_0000357,,
3582,,,,B,,,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,D,,1,,CHEMBL620715,BAO_0000357,,
3583,,,,B,,,,Binding affinity towards 5-HT5A receptor,H,,1,,CHEMBL620716,BAO_0000357,,
3584,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,H,,1,,CHEMBL620717,BAO_0000357,,
3585,,,,B,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,H,,1,,CHEMBL618072,BAO_0000357,,
3586,,,,B,,,,Binding affinity towards cloned human 5-HT5A receptor was determined,H,,1,,CHEMBL857987,BAO_0000357,,
3587,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,,1,,CHEMBL618073,BAO_0000219,,
3588,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,H,,1,,CHEMBL618074,BAO_0000219,,
3589,,,,B,HEK293,722.0,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),H,,1,,CHEMBL618075,BAO_0000219,,
3590,,,,B,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,D,,1,,CHEMBL618076,BAO_0000357,,
3591,,,,B,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,D,,1,,CHEMBL618077,BAO_0000357,,
3592,,,,B,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,D,,1,,CHEMBL618078,BAO_0000357,,
3593,,,,B,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,D,,1,,CHEMBL881821,BAO_0000357,,
3594,,,,B,,,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,D,,1,,CHEMBL618079,BAO_0000357,,
3595,,,,B,,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,H,,1,,CHEMBL618080,BAO_0000357,,
3596,,,,B,HEK293,722.0,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,H,,1,,CHEMBL618081,BAO_0000219,,
3597,,,,B,HEK293,722.0,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,H,,1,,CHEMBL618082,BAO_0000219,,
3598,,,,B,,,,Binding affinity towards 5-HT5a receptor,H,,1,,CHEMBL618083,BAO_0000357,,
3599,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor,D,,1,,CHEMBL618084,BAO_0000357,,
3600,,,,B,,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,H,,1,,CHEMBL618085,BAO_0000357,,
3601,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,H,,1,,CHEMBL618086,BAO_0000357,,
3602,,,,B,,,,Binding affinities against 5-hydroxytryptamine 5A receptor,H,,1,,CHEMBL875092,BAO_0000357,,
3603,,,,B,,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,H,,1,,CHEMBL618087,BAO_0000357,,
3604,,,,B,,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,H,,1,,CHEMBL872926,BAO_0000357,,
3605,,,,F,,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,H,,1,,CHEMBL618088,BAO_0000019,,
3606,,,,B,,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,H,,1,,CHEMBL618089,BAO_0000223,,
3607,,,,B,,,,Inhibition of human 5-hydroxytryptamine 6 receptor,D,,1,,CHEMBL618090,BAO_0000357,,
3608,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,D,,1,,CHEMBL618091,BAO_0000357,,
3609,,,,B,,,,Inhibition against human 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL618092,BAO_0000357,,
3610,,,,B,,,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,D,,1,,CHEMBL618093,BAO_0000357,,
3611,,,,B,HeLa,308.0,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,H,,1,,CHEMBL618094,BAO_0000219,,
3612,,,,B,,,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,D,,1,,CHEMBL618095,BAO_0000357,,
3613,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,D,,1,,CHEMBL875093,BAO_0000357,,
3614,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,D,,1,,CHEMBL618096,BAO_0000357,,
3615,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,D,,1,,CHEMBL618118,BAO_0000357,,
3616,,,,B,,,,Binding affinity against 5-hydroxytryptamine 6 receptor,D,,1,,CHEMBL618119,BAO_0000357,,
3617,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL618120,BAO_0000357,,
3618,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL618121,BAO_0000357,,
3619,,,,B,HEK293,722.0,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",H,,1,,CHEMBL618122,BAO_0000219,,
3620,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,H,,1,,CHEMBL618123,BAO_0000357,,
3621,,,,B,HEK293,722.0,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,H,,1,,CHEMBL618124,BAO_0000219,,
3622,,,,B,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL618125,BAO_0000357,,
3623,,,,B,HEK293,722.0,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,D,,1,,CHEMBL618126,BAO_0000219,,
3624,,,,B,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,H,,1,,CHEMBL618236,BAO_0000019,,
3625,,,,B,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,H,,1,,CHEMBL618237,BAO_0000019,,
3626,,,,B,COS-7,643.0,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,H,,1,,CHEMBL618238,BAO_0000219,,
3627,,,,B,,,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,D,,1,,CHEMBL618239,BAO_0000357,,
3628,,,,B,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL618240,BAO_0000019,,
3629,,,,B,,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,H,,1,,CHEMBL618241,BAO_0000357,,
3630,,,,B,HEK293,722.0,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,H,,1,,CHEMBL859399,BAO_0000219,,
3631,,,,F,,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,H,,1,,CHEMBL618242,BAO_0000019,,
3632,,,,B,,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL857991,BAO_0000357,,
3633,,,,B,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL619951,BAO_0000357,,
3634,,,,B,HeLa,308.0,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,D,,1,,CHEMBL619952,BAO_0000219,,
3635,,,,B,HeLa,308.0,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,D,,1,,CHEMBL619953,BAO_0000219,,
3636,,,,B,HeLa,308.0,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,H,,1,,CHEMBL619954,BAO_0000219,,
3637,,,,B,HeLa,308.0,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,H,,1,,CHEMBL619955,BAO_0000219,,
3638,,,,B,HeLa,308.0,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,H,,1,,CHEMBL619956,BAO_0000219,,
3639,,,,B,CHO,449.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,H,,1,,CHEMBL619957,BAO_0000219,,
3640,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,,1,,CHEMBL619958,BAO_0000219,,
3641,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,H,,1,,CHEMBL620627,BAO_0000219,,
3642,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,H,,1,,CHEMBL620628,BAO_0000219,,
3643,,,,B,HeLa,308.0,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,H,,1,,CHEMBL620629,BAO_0000219,,
3644,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL620630,BAO_0000357,,
3645,,,,B,HeLa,308.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,H,,1,,CHEMBL620782,BAO_0000219,,
3646,,,,B,,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL620783,BAO_0000357,,
3647,,,,B,,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL620784,BAO_0000357,,
3648,,,,B,HeLa,308.0,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,H,,1,,CHEMBL620785,BAO_0000219,,
3649,,,,B,,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),H,,1,,CHEMBL857992,BAO_0000357,,
3650,,,,B,,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,H,,1,,CHEMBL620786,BAO_0000219,,
3651,,,,B,HeLa,308.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,H,,1,,CHEMBL620787,BAO_0000219,,
3652,,,,B,HeLa,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",H,,1,,CHEMBL620788,BAO_0000219,,
3653,,,,B,HeLa,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",H,,1,,CHEMBL620789,BAO_0000219,,
3654,,,,B,HeLa,308.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",H,,1,,CHEMBL620790,BAO_0000219,,
3655,,,,B,CHO,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,H,,1,,CHEMBL620791,BAO_0000219,,
3656,,,,B,,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,H,,1,,CHEMBL620792,BAO_0000019,,
3657,,,,B,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL620793,BAO_0000357,,
3658,,,,B,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,H,,1,,CHEMBL620794,BAO_0000357,,
3659,,,,B,HeLa,308.0,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,D,,1,,CHEMBL620795,BAO_0000219,,
3660,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL620796,BAO_0000357,,
3661,,,,B,,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,H,,1,,CHEMBL620797,BAO_0000357,,
3662,,,,F,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,D,,1,,CHEMBL620798,BAO_0000019,,
3663,,,,B,,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,H,,1,,CHEMBL620799,BAO_0000357,,
3664,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL620800,BAO_0000357,,
3665,,,,B,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,H,,1,,CHEMBL620801,BAO_0000357,,
3666,,,,B,,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL875100,BAO_0000357,,
3667,,,,B,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,H,,1,,CHEMBL620802,BAO_0000357,,
3668,,,,F,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL620803,BAO_0000019,,
3669,,,,F,,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,H,,1,,CHEMBL620804,BAO_0000019,,
3670,,,,B,,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,H,,1,,CHEMBL620805,BAO_0000357,,
3671,,,,B,,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL620806,BAO_0000357,,
3672,,,,B,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,H,,1,,CHEMBL620807,BAO_0000357,,
3673,,,,B,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,H,,1,,CHEMBL620808,BAO_0000357,,
3674,,,,B,,,,Binding affinities against 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL620809,BAO_0000357,,
3675,,,,B,,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL620810,BAO_0000357,,
3676,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 6 receptor,D,,1,,CHEMBL620811,BAO_0000357,,
3677,,,,B,,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,H,,1,,CHEMBL620812,BAO_0000357,,
3678,,,,B,,,,Affinity against 5-hydroxytryptamine 6 receptor,H,,1,,CHEMBL620813,BAO_0000357,,
3679,,,,B,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],H,,1,,CHEMBL620814,BAO_0000357,,
3680,,,,B,,,,Inhibition of human 5-hydroxytryptamine 7 receptor,D,,1,,CHEMBL620815,BAO_0000357,,
3681,,,,B,HEK293,722.0,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,H,,1,,CHEMBL620816,BAO_0000219,,
3682,,,,B,,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL620817,BAO_0000357,,
3683,,,,B,,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),H,,1,,CHEMBL620818,BAO_0000357,,
3684,,,,B,HEK293,722.0,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,H,,1,,CHEMBL620819,BAO_0000219,,
3685,,,,B,,,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,D,,1,,CHEMBL620820,BAO_0000357,,
3686,,,,B,CHO,449.0,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,H,,1,,CHEMBL620821,BAO_0000219,,
3687,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,D,,1,,CHEMBL620822,BAO_0000357,,
3688,,,,B,,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,D,,1,,CHEMBL620823,BAO_0000357,,
3689,,,,B,,,,Binding affinity against 5-hydroxytryptamine 7 receptor,D,,1,,CHEMBL620824,BAO_0000357,,
3690,,,,B,CHO,449.0,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,H,,1,,CHEMBL620825,BAO_0000219,,
3691,,,,B,,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,H,,1,,CHEMBL872930,BAO_0000357,,
3692,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL620826,BAO_0000357,,
3693,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,H,,1,,CHEMBL620827,BAO_0000357,,
3694,,,,B,,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL620828,BAO_0000357,,
3695,,,,B,,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL620829,BAO_0000357,,
3696,,,,B,HEK293,722.0,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,H,,1,,CHEMBL620830,BAO_0000219,,
3697,,,,B,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,H,,1,,CHEMBL620831,BAO_0000019,,
3698,,,,B,,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,H,,1,,CHEMBL620832,BAO_0000019,,
3699,,,,B,,,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,D,,1,,CHEMBL621548,BAO_0000357,,
3700,,,,B,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL621549,BAO_0000019,,
3701,,,,B,,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,H,,1,,CHEMBL621550,BAO_0000357,,
3702,,,,B,CHO,449.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,H,,1,,CHEMBL621551,BAO_0000219,,
3703,,,,B,,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,H,,1,,CHEMBL621552,BAO_0000019,,
3704,,,,B,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL857077,BAO_0000357,,
3705,,,,B,,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,H,,1,,CHEMBL618158,BAO_0000357,,
3706,,,,B,COS-7,643.0,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,D,,1,,CHEMBL618159,BAO_0000219,,
3707,,,,B,COS-7,643.0,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,H,,1,,CHEMBL875101,BAO_0000219,,
3708,,,,B,HEK293,722.0,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,D,,1,,CHEMBL618160,BAO_0000219,,
3709,,,,B,,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,H,,1,,CHEMBL618161,BAO_0000357,,
3710,,,,B,HEK293,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,H,,1,,CHEMBL618162,BAO_0000219,,
3711,,,,B,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,H,,1,,CHEMBL618163,BAO_0000357,,
3712,,,,B,,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,H,,1,,CHEMBL618164,BAO_0000357,,
3713,,,,B,,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,H,,1,,CHEMBL618165,BAO_0000219,,
3714,,,,B,HEK293,722.0,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,H,,1,,CHEMBL618166,BAO_0000219,,
3715,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,H,,1,,CHEMBL857989,BAO_0000219,,
3716,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,H,,1,,CHEMBL619888,BAO_0000219,,
3717,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,H,,1,,CHEMBL619889,BAO_0000219,,
3718,,,,B,HEK293,722.0,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,H,,1,,CHEMBL619890,BAO_0000219,,
3719,,,,B,CHO,449.0,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,H,,1,,CHEMBL619891,BAO_0000219,,
3720,,,,B,HEK293,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),H,,1,,CHEMBL619892,BAO_0000219,,
3721,,,,B,HEK293,722.0,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,D,,1,,CHEMBL619893,BAO_0000219,,
3722,,,,B,HEK293,722.0,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),H,,1,,CHEMBL619894,BAO_0000219,,
3723,,,,B,HEK293,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,D,,1,,CHEMBL619895,BAO_0000219,,
3724,,,,B,,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,D,,1,,CHEMBL619896,BAO_0000357,,
3725,,,,B,COS-7,643.0,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,H,,1,,CHEMBL619897,BAO_0000219,,
3726,,,,B,HEK293,722.0,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,H,,1,,CHEMBL619898,BAO_0000219,,
3727,,,,B,HEK293,722.0,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,H,,1,,CHEMBL619899,BAO_0000219,,
3728,,,,B,HEK293,722.0,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),H,,1,,CHEMBL619900,BAO_0000219,,
3729,,,,B,HEK293,722.0,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,D,,1,,CHEMBL619901,BAO_0000219,,
3730,,,,B,HEK293,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,H,,1,,CHEMBL620580,BAO_0000219,,
3731,,,,B,HEK293,722.0,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,H,,1,,CHEMBL620581,BAO_0000219,,
3732,,,,B,HEK293,722.0,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",H,,1,,CHEMBL620733,BAO_0000219,,
3733,,,,B,,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,D,,1,,CHEMBL620734,BAO_0000357,,
3734,,,,B,,,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,D,,1,,CHEMBL620735,BAO_0000357,,
3735,,,,B,,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,H,,1,,CHEMBL620736,BAO_0000019,,
3736,,,,B,CHO,449.0,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,H,,1,,CHEMBL620737,BAO_0000219,,
3737,,,,B,CHO,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,H,,1,,CHEMBL620738,BAO_0000219,,
3738,,,,B,CHO,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,H,,1,,CHEMBL620739,BAO_0000219,,
3739,,,,B,CHO,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,H,,1,,CHEMBL620740,BAO_0000219,,
3740,,,,B,CHO,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,H,,1,,CHEMBL620741,BAO_0000219,,
3741,,,,B,CHO,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,H,,1,,CHEMBL620742,BAO_0000219,,
3742,,,,B,CHO,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,H,,1,,CHEMBL620743,BAO_0000219,,
3743,,,,B,CHO,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,H,,1,,CHEMBL620744,BAO_0000219,,
3744,,,,B,CHO,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,H,,1,,CHEMBL620745,BAO_0000219,,
3745,,,,B,CHO,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,H,,1,,CHEMBL620746,BAO_0000219,,
3746,,,,B,CHO,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,H,,1,,CHEMBL620747,BAO_0000219,,
3747,,,,B,CHO,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,H,,1,,CHEMBL620748,BAO_0000219,,
3748,,,,B,CHO,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,H,,1,,CHEMBL620749,BAO_0000219,,
3749,,,,B,,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL620750,BAO_0000357,,
3750,,,,B,,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,D,,1,,CHEMBL620751,BAO_0000357,,
3751,,,,B,,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL620752,BAO_0000357,,
3752,,,,B,,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,H,,1,,CHEMBL872929,BAO_0000019,,
3753,,,,B,,,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,D,,1,,CHEMBL620753,BAO_0000357,,
3754,,,,B,,,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,D,,1,,CHEMBL620754,BAO_0000357,,
3755,,,,B,CHO,449.0,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,D,,1,,CHEMBL620755,BAO_0000219,,
3756,,,,B,,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,H,,1,,CHEMBL620756,BAO_0000357,,
3757,,,,B,,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL620757,BAO_0000357,,
3758,,,,B,CHO,449.0,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",H,,1,,CHEMBL620758,BAO_0000219,,
3759,,,,B,CHO,449.0,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",H,,1,,CHEMBL620759,BAO_0000219,,
3760,,,,B,CHO,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,H,,1,,CHEMBL620760,BAO_0000219,,
3761,,,,B,CHO,449.0,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,H,,1,,CHEMBL620761,BAO_0000219,,
3762,,,Ileum,F,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,H,,1,,CHEMBL620762,BAO_0000221,2116.0,
3763,,,Ileum,F,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,H,,1,,CHEMBL620763,BAO_0000221,2116.0,
3764,,,Ileum,F,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,H,,1,,CHEMBL620764,BAO_0000221,2116.0,
3765,Membranes,,,B,,,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,D,,1,,CHEMBL857990,BAO_0000249,,
3766,,,,B,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,H,,1,,CHEMBL620765,BAO_0000357,,
3767,,,,B,,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,H,,1,,CHEMBL620766,BAO_0000357,,
3768,,,Hypothalamus,B,,,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,H,,1,,CHEMBL620767,BAO_0000019,1898.0,
3769,,,,B,,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,H,,1,,CHEMBL620768,BAO_0000357,,
3770,,,Hypothalamus,B,,,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,H,,1,,CHEMBL619051,BAO_0000249,1898.0,
3771,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL619052,BAO_0000357,,
3772,,,,F,HEK293,722.0,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,D,,1,,CHEMBL619053,BAO_0000219,,
3773,,,,F,HEK293,722.0,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,D,,1,,CHEMBL619703,BAO_0000219,,
3774,,,,F,HEK293,722.0,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,D,,1,,CHEMBL619704,BAO_0000219,,
3775,,,,B,,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL619851,BAO_0000357,,
3776,,,,B,,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,H,,1,,CHEMBL619852,BAO_0000357,,
3777,,,,B,,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,H,,1,,CHEMBL619853,BAO_0000357,,
3778,,,,B,,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,D,,1,,CHEMBL619854,BAO_0000357,,
3779,,,,B,,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL619855,BAO_0000357,,
3780,,,,B,,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,H,,1,,CHEMBL619856,BAO_0000357,,
3781,,,,B,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,H,,1,,CHEMBL619857,BAO_0000357,,
3782,,,,F,,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,H,,1,,CHEMBL619858,BAO_0000019,,
3783,,,,B,,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,H,,1,,CHEMBL619859,BAO_0000357,,
3784,,,,B,,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,H,,1,,CHEMBL619860,BAO_0000357,,
3785,,,,B,,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL619861,BAO_0000357,,
3786,,,,B,,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL619862,BAO_0000357,,
3787,,,,B,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,H,,1,,CHEMBL619863,BAO_0000357,,
3788,,,,B,,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,H,,1,,CHEMBL619864,BAO_0000357,,
3789,,,,B,,,,Binding affinities against 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL872928,BAO_0000357,,
3790,,,,B,,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL619865,BAO_0000357,,
3791,,,,B,,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,H,,1,,CHEMBL619866,BAO_0000357,,
3792,,,,B,,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,H,,1,,CHEMBL619867,BAO_0000357,,
3793,,,Ileum,B,,,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,H,,1,,CHEMBL619868,BAO_0000221,2116.0,
3794,,,,F,,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,H,,1,,CHEMBL619869,BAO_0000019,,
3795,,,,F,,,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,D,,1,,CHEMBL619870,BAO_0000019,,
3796,,,,B,,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,H,,1,,CHEMBL619871,BAO_0000357,,
3797,,,,B,,,,In vitro inhibition of human recombinant lipoxygenase enzyme,H,,1,,CHEMBL619872,BAO_0000357,,
3798,,,,B,,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,H,,1,,CHEMBL619873,BAO_0000357,,
3799,,,Blood,B,,,,Inhibition of 5-lipoxygenase in human whole blood.,H,,1,,CHEMBL619874,BAO_0000357,178.0,
3800,,,Blood,B,,,,Inhibition of 5-lipoxygenase in human whole blood.,H,,1,,CHEMBL619875,BAO_0000357,178.0,
3801,,,,B,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,H,,1,,CHEMBL619876,BAO_0000357,,
3802,,,,B,,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),H,,1,,CHEMBL619877,BAO_0000357,,
3803,,,,F,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,H,,1,,CHEMBL619878,BAO_0000219,,
3804,,,Blood,F,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,H,,1,,CHEMBL619879,BAO_0000019,178.0,
3805,,,,B,,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,H,,1,,CHEMBL619880,BAO_0000357,,
3806,,,,B,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),H,,1,,CHEMBL619881,BAO_0000357,,
3807,,,,B,,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,H,,1,,CHEMBL619882,BAO_0000357,,
3808,,,,B,,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,H,,1,,CHEMBL619883,BAO_0000357,,
3809,,,Blood,B,,,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),D,,1,,CHEMBL619884,BAO_0000357,178.0,
3810,,,,B,,,,In vitro potency against human 5-Lipoxygenase,H,,1,,CHEMBL619885,BAO_0000357,,
3811,,,,F,,,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,D,,1,,CHEMBL619886,BAO_0000019,,
3812,,,Blood,F,,,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,H,,1,,CHEMBL619887,BAO_0000019,178.0,
3813,,,,F,,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,H,,1,,CHEMBL875097,BAO_0000019,,
3814,,,,B,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,H,,1,,CHEMBL618001,BAO_0000219,,
3815,,,,B,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,H,,1,,CHEMBL618002,BAO_0000219,,
3816,,,,B,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,H,,1,,CHEMBL618003,BAO_0000219,,
3817,,,,B,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,H,,1,,CHEMBL618004,BAO_0000219,,
3818,,,,B,,,,Inhibition of human 5-lipoxygenase in human cells,H,,1,,CHEMBL618005,BAO_0000219,,
3819,,,,B,,,,Inhibition of human neutrophil 5-lipoxygenase,H,,1,,CHEMBL618006,BAO_0000357,,
3820,,,,B,,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,H,,1,,CHEMBL875086,BAO_0000019,,
3821,,,Blood,B,,,,Inhibition of 5-lipoxygenase from human whole blood,H,,1,,CHEMBL618007,BAO_0000357,178.0,
3822,,,,B,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,H,,1,,CHEMBL618008,BAO_0000357,,
3823,,,,B,,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,H,,1,,CHEMBL618009,BAO_0000219,,
3824,,,,B,,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,H,,1,,CHEMBL618010,BAO_0000357,,
3825,,,,B,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,H,,1,,CHEMBL618011,BAO_0000357,,
3826,,,,B,,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,H,,1,,CHEMBL618012,BAO_0000357,,
3827,,,,B,,,,Tested against 5-lipoxygenase,H,,1,,CHEMBL882927,BAO_0000357,,
3828,,,,B,,,,Tested for activity against 5-Lipoxygenase (5-LO),H,,1,,CHEMBL618013,BAO_0000357,,
3829,,,,B,,,,Tested for activity against 5-lipoxygenase,H,,1,,CHEMBL618014,BAO_0000357,,
3830,,,,B,,,,Tested for inhibition of 5-HPETE production by human 5-LO,H,,1,,CHEMBL618015,BAO_0000357,,
3831,,,,F,,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,H,,1,,CHEMBL618016,BAO_0000019,,
3832,,,,B,,,,Inhibition of Human 5-lipoxygenase,H,,1,,CHEMBL618017,BAO_0000357,,
3833,,,,B,,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,H,,1,,CHEMBL618018,BAO_0000019,,
3834,,,,B,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],H,,1,,CHEMBL875087,BAO_0000219,,
3835,,,,B,,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],H,,1,,CHEMBL618019,BAO_0000219,,
3836,,,,B,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,H,,1,,CHEMBL618020,BAO_0000019,,
3837,,,,B,,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,H,,1,,CHEMBL618021,BAO_0000019,,
3838,,,Blood,B,,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),H,,1,,CHEMBL618022,BAO_0000357,178.0,
3839,,,,B,,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,H,,1,,CHEMBL618023,BAO_0000357,,
3840,,,,B,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),H,,1,,CHEMBL618024,BAO_0000357,,
3841,,,,B,,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,H,,1,,CHEMBL873950,BAO_0000019,,
3842,,,,B,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,H,,1,,CHEMBL618025,BAO_0000357,,
3843,,,,B,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,H,,1,,CHEMBL618026,BAO_0000219,,
3844,,,,B,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,H,,1,,CHEMBL618027,BAO_0000219,,
3845,,,,B,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,H,,1,,CHEMBL618028,BAO_0000219,,
3846,,,,B,,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,H,,1,,CHEMBL618029,BAO_0000219,,
3847,,,,B,,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,H,,1,,CHEMBL618030,BAO_0000357,,
3848,,,,B,,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,H,,1,,CHEMBL618031,BAO_0000357,,
3849,,,,B,,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,H,,1,,CHEMBL618032,BAO_0000357,,
3850,,,,B,,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,H,,1,,CHEMBL618033,BAO_0000357,,
3851,,,,B,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,H,,1,,CHEMBL618034,BAO_0000357,,
3852,,,,B,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,H,,1,,CHEMBL875088,BAO_0000357,,
3853,,,,B,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,H,,1,,CHEMBL618035,BAO_0000019,,
3854,,,,B,,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,H,,1,,CHEMBL618036,BAO_0000019,,
3855,,,,B,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,H,,1,,CHEMBL618037,BAO_0000357,,
3856,,,,B,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,H,,1,,CHEMBL618038,BAO_0000357,,
3857,,,,F,,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,H,,1,,CHEMBL618761,BAO_0000019,,
3858,,,,B,,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,H,,1,,CHEMBL618762,BAO_0000357,,
3859,,,,B,,,,Inhibition of lipoxygenase at the concentration of 1 uM,H,,1,,CHEMBL618763,BAO_0000357,,
3860,,,,B,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,H,,1,,CHEMBL618764,BAO_0000357,,
3861,,,,B,,,,Inhibition of 5-Lipoxygenase (5-LOX),D,,1,,CHEMBL618765,BAO_0000357,,
3862,,,,B,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,H,,1,,CHEMBL618766,BAO_0000357,,
3863,,,,B,,,,Inhibition of 5-lipoxygenase in mouse macrophages.,H,,1,,CHEMBL618767,BAO_0000357,,
3864,,,,B,,,,Inhibitory activity against lipoxygenase-2 in mice,H,,1,,CHEMBL619380,BAO_0000357,,
3865,,,,B,,,,Inhibitory activity against murine lipoxygenase-2.,H,,1,,CHEMBL619381,BAO_0000357,,
3866,,,,B,,,,Inhibition of 5-lipoxygenase from mouse macrophage,D,,1,,CHEMBL619382,BAO_0000357,,
3867,,,,B,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,H,,1,,CHEMBL619383,BAO_0000357,,
3868,,,,B,,,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,H,,1,,CHEMBL619384,BAO_0000019,,
3869,,,,B,,,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,H,,1,,CHEMBL619385,BAO_0000019,,
3870,,,,B,,,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,H,,1,,CHEMBL882928,BAO_0000019,,
3871,,,,B,,,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,D,,1,,CHEMBL619386,BAO_0000019,,
3872,,,,B,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",H,,1,,CHEMBL619387,BAO_0000019,,
3873,,,,B,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",H,,1,,CHEMBL619388,BAO_0000019,,
3874,,,,B,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",H,,1,,CHEMBL619389,BAO_0000019,,
3875,,,,B,,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),H,,1,,CHEMBL619390,BAO_0000019,,
3876,,,,B,,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",H,,1,,CHEMBL619391,BAO_0000019,,
3877,,,,B,,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,H,,1,,CHEMBL619392,BAO_0000019,,
3878,,,,B,,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),H,,1,,CHEMBL619393,BAO_0000019,,
3879,,,,B,,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,H,,1,,CHEMBL619394,BAO_0000019,,
3880,,,,B,RBL-1,702.0,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",H,,1,,CHEMBL619395,BAO_0000219,,
3881,,,,B,RBL-1,702.0,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",H,,1,,CHEMBL619396,BAO_0000219,,
3882,,,,B,,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),H,,1,,CHEMBL619397,BAO_0000357,,
3883,,,,B,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",H,,1,,CHEMBL619398,BAO_0000357,,
3884,,,,B,,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",H,,1,,CHEMBL619399,BAO_0000357,,
3885,,,,B,,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,H,,1,,CHEMBL619400,BAO_0000357,,
3886,,,,B,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",H,,1,,CHEMBL619401,BAO_0000019,,
3887,,,,B,,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",H,,1,,CHEMBL619402,BAO_0000019,,
3888,,,,B,RBL-2H3,663.0,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,D,,1,,CHEMBL619403,BAO_0000219,,
3889,,,,B,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,H,,1,,CHEMBL619404,BAO_0000357,,
3890,,,,B,,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,H,,1,,CHEMBL619405,BAO_0000357,,
3891,,,,B,RBL-1,702.0,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,H,,1,,CHEMBL619406,BAO_0000219,,
3892,,,,B,RBL-1,702.0,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,D,,1,,CHEMBL619407,BAO_0000219,,
3893,,,,B,,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),H,,1,,CHEMBL619408,BAO_0000357,,
3894,,,,B,RBL-1,702.0,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,H,,1,,CHEMBL619409,BAO_0000219,,
3895,,,,B,RBL-1,702.0,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,H,,1,,CHEMBL619410,BAO_0000219,,
3896,,,,B,RBL-1,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,H,,1,,CHEMBL619753,BAO_0000219,,
3897,,,,B,RBL-1,702.0,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,H,,1,,CHEMBL619754,BAO_0000219,,
3898,,,,B,,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,H,,1,,CHEMBL619903,BAO_0000357,,
3899,,,,B,,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",H,,1,,CHEMBL619904,BAO_0000357,,
3900,,,,B,,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,H,,1,,CHEMBL619905,BAO_0000357,,
3901,,,,B,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,H,,1,,CHEMBL619906,BAO_0000019,,
3902,,,,B,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,H,,1,,CHEMBL619907,BAO_0000019,,
3903,,,,B,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,H,,1,,CHEMBL619908,BAO_0000019,,
3904,,,,B,,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,H,,1,,CHEMBL619909,BAO_0000019,,
3905,,,,F,RBL-1,702.0,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,H,,1,,CHEMBL619910,BAO_0000219,,
3906,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,H,,1,,CHEMBL882929,BAO_0000219,,
3907,,,,B,RBL-1,702.0,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,H,,1,,CHEMBL619911,BAO_0000219,,
3908,,,,B,,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,H,,1,,CHEMBL619912,BAO_0000019,,
3909,,,,B,,,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,D,,1,,CHEMBL619913,BAO_0000357,,
3910,,,,B,RBL-1,702.0,,In vitro inhibitory activity against RBL-1 5-LO,H,,1,,CHEMBL619914,BAO_0000219,,
3911,,,,B,RBL-1,702.0,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),H,,1,,CHEMBL619915,BAO_0000219,,
3912,,,,B,RBL-1,702.0,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),H,,1,,CHEMBL619916,BAO_0000219,,
3913,,,,B,,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,H,,1,,CHEMBL619917,BAO_0000218,,
3914,,,,B,,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,H,,1,,CHEMBL619918,BAO_0000357,,
3915,,,,B,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,H,,1,,CHEMBL619919,BAO_0000218,,
3916,,,,B,RBL-1,702.0,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,H,,1,,CHEMBL883710,BAO_0000219,,
3917,,,Blood,B,,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,H,,1,,CHEMBL619920,BAO_0000019,178.0,
3918,,,,B,,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,H,,1,,CHEMBL619921,BAO_0000357,,
3919,,,,F,,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,H,,1,,CHEMBL619922,BAO_0000019,,
3920,,,,F,,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,H,,1,,CHEMBL619923,BAO_0000219,,
3921,,,,B,RBL-1,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,H,,1,,CHEMBL619924,BAO_0000219,,
3922,,,,B,,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,H,,1,,CHEMBL619925,BAO_0000357,,
3923,,,,B,RBL-1,702.0,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,H,,1,,CHEMBL619926,BAO_0000219,,
3924,,,,B,RBL-1,702.0,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,H,,1,,CHEMBL619927,BAO_0000219,,
3925,,,,B,RBL-1,702.0,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,H,,1,,CHEMBL619928,BAO_0000219,,
3926,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase,H,,1,,CHEMBL619929,BAO_0000219,,
3927,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,H,,1,,CHEMBL875089,BAO_0000219,,
3928,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,H,,1,,CHEMBL619930,BAO_0000219,,
3929,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,H,,1,,CHEMBL619931,BAO_0000219,,
3930,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,H,,1,,CHEMBL619932,BAO_0000219,,
3931,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,H,,1,,CHEMBL619933,BAO_0000219,,
3932,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,H,,1,,CHEMBL619934,BAO_0000219,,
3933,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,H,,1,,CHEMBL619935,BAO_0000219,,
3934,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,H,,1,,CHEMBL619936,BAO_0000219,,
3935,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,H,,1,,CHEMBL619937,BAO_0000219,,
3936,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,H,,1,,CHEMBL619938,BAO_0000219,,
3937,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,H,,1,,CHEMBL619939,BAO_0000219,,
3938,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,H,,1,,CHEMBL619940,BAO_0000219,,
3939,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,H,,1,,CHEMBL875090,BAO_0000219,,
3940,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,H,,1,,CHEMBL619941,BAO_0000219,,
3941,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,H,,1,,CHEMBL619942,BAO_0000219,,
3942,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,H,,1,,CHEMBL883711,BAO_0000219,,
3943,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,H,,1,,CHEMBL619943,BAO_0000219,,
3944,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,H,,1,,CHEMBL619944,BAO_0000219,,
3945,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,H,,1,,CHEMBL619945,BAO_0000219,,
3946,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,H,,1,,CHEMBL619946,BAO_0000219,,
3947,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,H,,1,,CHEMBL619947,BAO_0000219,,
3948,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,H,,1,,CHEMBL619948,BAO_0000219,,
3949,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,H,,1,,CHEMBL619949,BAO_0000219,,
3950,,,,B,,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,H,,1,,CHEMBL619950,BAO_0000019,,
3951,,,,B,,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,H,,1,,CHEMBL618050,BAO_0000019,,
3952,,,,F,RBL-2H3,663.0,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,H,,1,,CHEMBL875091,BAO_0000219,,
3953,,,,F,RBL-2H3,663.0,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,H,,1,,CHEMBL618051,BAO_0000219,,
3954,,,,B,RBL-1,702.0,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,D,,1,,CHEMBL618052,BAO_0000219,,
3955,,,,B,,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,H,,1,,CHEMBL618053,BAO_0000019,,
3956,,,,B,,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),H,,1,,CHEMBL618054,BAO_0000019,,
3957,,,,B,RBL-1,702.0,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,D,,1,,CHEMBL618055,BAO_0000219,,
3958,,,,B,RBL-1,702.0,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,H,,1,,CHEMBL618056,BAO_0000219,,
3959,,,,B,,,,In vitro inhibitory activity against 5-lipoxygenase was determined,H,,1,,CHEMBL618057,BAO_0000357,,
3960,,,,B,RBL-1,702.0,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,H,,1,,CHEMBL618058,BAO_0000219,,
3961,,,,B,RBL-1,702.0,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,H,,1,,CHEMBL618059,BAO_0000219,,
3962,,,,F,,,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,D,,1,,CHEMBL618060,BAO_0000019,,
3963,,,,B,RBL-1,702.0,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,H,,1,,CHEMBL618061,BAO_0000219,,
3964,,,,B,,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,H,,1,,CHEMBL618062,BAO_0000019,,
3965,,,,B,RBL-1,702.0,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,H,,1,,CHEMBL618063,BAO_0000219,,
3966,,,,B,,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,H,,1,,CHEMBL618064,BAO_0000357,,
3967,,,,B,RBL-1,702.0,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,D,,1,,CHEMBL618065,BAO_0000219,,
3968,,,,B,RBL-1,702.0,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,D,,1,,CHEMBL618066,BAO_0000219,,
3969,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),H,,1,,CHEMBL618067,BAO_0000219,,
3970,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),H,,1,,CHEMBL618068,BAO_0000219,,
3971,,,,B,RBL-1,702.0,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,D,,1,,CHEMBL618069,BAO_0000219,,
3972,,,,B,RBL-1,702.0,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,,1,,CHEMBL618070,BAO_0000219,,
3973,,,Limbic system,F,,,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,H,,1,,CHEMBL618071,BAO_0000019,349.0,
3974,,,Limbic system,F,,,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,H,,1,,CHEMBL619247,BAO_0000019,349.0,
3975,,,,F,,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,H,,1,,CHEMBL619248,BAO_0000019,,
3976,,,Hippocampus,B,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,H,,1,,CHEMBL619249,BAO_0000221,10000000.0,
3977,,,Hippocampus,B,,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,H,,1,,CHEMBL619250,BAO_0000221,10000000.0,
3978,,,,B,,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,H,,1,,CHEMBL619251,BAO_0000019,,
3979,,,Blood,F,,,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,H,,1,,CHEMBL619252,BAO_0000019,178.0,
3980,,,Blood,F,,,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,H,,1,,CHEMBL619253,BAO_0000019,178.0,
3981,,,,B,,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],H,,1,,CHEMBL619254,BAO_0000219,,
3982,,,,B,,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,H,,1,,CHEMBL619255,BAO_0000219,,
3983,,,,B,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,H,,1,,CHEMBL619256,BAO_0000219,,
3984,,,,B,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),H,,1,,CHEMBL875418,BAO_0000219,,
3985,,,,B,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,H,,1,,CHEMBL619257,BAO_0000219,,
3986,,,,B,,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,H,,1,,CHEMBL619258,BAO_0000219,,
3987,,,,B,,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,H,,1,,CHEMBL619259,BAO_0000357,,
3988,,,,B,,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,H,,1,,CHEMBL619260,BAO_0000357,,
3989,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL619261,BAO_0000218,178.0,
3990,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL619263,BAO_0000218,178.0,
3991,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL619264,BAO_0000218,178.0,
3992,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL619265,BAO_0000218,178.0,
3993,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL619266,BAO_0000218,178.0,
3994,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL619902,BAO_0000218,178.0,
3995,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620058,BAO_0000218,178.0,
3996,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620059,BAO_0000218,178.0,
3997,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620060,BAO_0000218,178.0,
3998,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620061,BAO_0000218,178.0,
3999,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",H,,1,,CHEMBL620062,BAO_0000218,178.0,
4000,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620063,BAO_0000218,178.0,
4001,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",H,,1,,CHEMBL620064,BAO_0000218,178.0,
4002,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620065,BAO_0000218,178.0,
4003,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",H,,1,,CHEMBL620066,BAO_0000218,178.0,
4004,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620067,BAO_0000218,178.0,
4005,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",H,,1,,CHEMBL620068,BAO_0000218,178.0,
4006,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620069,BAO_0000218,178.0,
4007,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",H,,1,,CHEMBL620070,BAO_0000218,178.0,
4008,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620071,BAO_0000218,178.0,
4009,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",H,,1,,CHEMBL620072,BAO_0000218,178.0,
4010,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620036,BAO_0000218,178.0,
4011,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",H,,1,,CHEMBL857702,BAO_0000218,178.0,
4012,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620037,BAO_0000218,178.0,
4013,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",H,,1,,CHEMBL620038,BAO_0000218,178.0,
4014,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620039,BAO_0000218,178.0,
4015,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",H,,1,,CHEMBL620040,BAO_0000218,178.0,
4016,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620041,BAO_0000218,178.0,
4017,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",H,,1,,CHEMBL620042,BAO_0000218,178.0,
4018,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620043,BAO_0000218,178.0,
4019,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",H,,1,,CHEMBL620044,BAO_0000218,178.0,
4020,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620045,BAO_0000218,178.0,
4021,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",H,,1,,CHEMBL620046,BAO_0000218,178.0,
4022,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620047,BAO_0000218,178.0,
4023,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",H,,1,,CHEMBL620048,BAO_0000218,178.0,
4024,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL857703,BAO_0000218,178.0,
4025,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",H,,1,,CHEMBL620049,BAO_0000218,178.0,
4026,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620050,BAO_0000218,178.0,
4027,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620051,BAO_0000218,178.0,
4028,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL619213,BAO_0000218,178.0,
4029,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL619214,BAO_0000218,178.0,
4030,,In vivo,Blood,F,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL619804,BAO_0000218,178.0,
4031,,In vivo,Blood,F,,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL619805,BAO_0000218,178.0,
4032,,In vivo,Blood,F,,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL619806,BAO_0000218,178.0,
4033,,In vivo,Blood,F,,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL619807,BAO_0000218,178.0,
4034,,In vivo,Blood,F,,,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL619808,BAO_0000218,178.0,
4035,,,,B,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,H,,1,,CHEMBL619809,BAO_0000218,,
4036,,,,B,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,H,,1,,CHEMBL619810,BAO_0000218,,
4037,,,,B,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,H,,1,,CHEMBL619811,BAO_0000218,,
4038,,,,B,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,H,,1,,CHEMBL620769,BAO_0000218,,
4039,,,,B,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,H,,1,,CHEMBL620770,BAO_0000218,,
4040,,,,B,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,H,,1,,CHEMBL620771,BAO_0000218,,
4041,,,,B,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,H,,1,,CHEMBL620772,BAO_0000218,,
4042,,,,B,,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,H,,1,,CHEMBL620773,BAO_0000218,,
4043,,,,B,,,,Ability to inhibit 5-lipoxygenase in guinea pig,H,,1,,CHEMBL620774,BAO_0000357,,
4044,,,,B,,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),H,,1,,CHEMBL620775,BAO_0000357,,
4045,,,,B,,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,H,,1,,CHEMBL620776,BAO_0000357,,
4046,,,Blood,B,,,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",H,,1,,CHEMBL620777,BAO_0000218,178.0,
4047,,,,B,,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,H,,1,,CHEMBL620778,BAO_0000357,,
4048,,,,B,,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,H,,1,,CHEMBL620779,BAO_0000357,,
4049,,,,B,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,H,,1,,CHEMBL621500,BAO_0000019,,
4050,,,,B,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,H,,1,,CHEMBL621501,BAO_0000019,,
4051,,,,B,,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,H,,1,,CHEMBL618098,BAO_0000019,,
4052,,,,B,,,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,H,,1,,CHEMBL618099,BAO_0000019,,
4053,,,,B,,,,Inhibitory activity against 5-lipoxygenase,H,,1,,CHEMBL618100,BAO_0000357,,
4054,,,,B,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,H,,1,,CHEMBL618101,BAO_0000357,,
4055,,,,B,,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,H,,1,,CHEMBL618102,BAO_0000357,,
4056,,,,B,,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,H,,1,,CHEMBL618103,BAO_0000357,,
4057,,,,B,,,,Inhibitory activity uM,H,,1,,CHEMBL618104,BAO_0000357,,
4058,,,,B,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,H,,1,,CHEMBL883712,BAO_0000219,,
4059,,,,B,,,,Inhibitory activity against 5-lipoxygenase at 10 uM,H,,1,,CHEMBL618105,BAO_0000357,,
4060,,,,B,,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,H,,1,,CHEMBL618106,BAO_0000357,,
4061,,,,B,,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,H,,1,,CHEMBL618107,BAO_0000357,,
4062,,,,B,,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,H,,1,,CHEMBL618108,BAO_0000357,,
4063,,,,B,,,,Inhibitory activity uM,H,,1,,CHEMBL618109,BAO_0000357,,
4064,,,,B,,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,H,,1,,CHEMBL618110,BAO_0000357,,
4065,,,,B,,,,Inhibitory activity uM,H,,1,,CHEMBL618111,BAO_0000357,,
4066,,,,F,,,,Inhibitory activity uM,H,,1,,CHEMBL618112,BAO_0000019,,
4067,,,,B,,,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,H,,1,,CHEMBL618113,BAO_0000019,,
4068,,,,B,,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,H,,1,,CHEMBL618114,BAO_0000357,,
4069,,,Ileum,F,,,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,H,,1,,CHEMBL620871,BAO_0000221,2116.0,
4070,,,,B,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),H,,1,,CHEMBL620872,BAO_0000357,,
4071,,,,B,,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),H,,1,,CHEMBL620873,BAO_0000357,,
4072,,,,B,,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),H,,1,,CHEMBL620874,BAO_0000357,,
4073,,,,B,,,,In vitro inhibition of human 5-Lipoxygenase.,H,,1,,CHEMBL620875,BAO_0000357,,
4074,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,U,,1,,CHEMBL620876,BAO_0000251,2107.0,
4075,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,U,,1,,CHEMBL620877,BAO_0000251,2107.0,
4076,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,U,,1,,CHEMBL857854,BAO_0000251,2107.0,
4077,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,U,,1,,CHEMBL620878,BAO_0000251,2107.0,
4078,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,U,,1,,CHEMBL620879,BAO_0000251,2107.0,
4079,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,U,,1,,CHEMBL620880,BAO_0000251,2107.0,
4080,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,U,,1,,CHEMBL620881,BAO_0000251,2107.0,
4081,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,U,,1,,CHEMBL620882,BAO_0000251,2107.0,
4082,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,U,,1,,CHEMBL620883,BAO_0000251,2107.0,
4083,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,U,,1,,CHEMBL620884,BAO_0000251,2107.0,
4084,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,U,,1,,CHEMBL620885,BAO_0000251,2107.0,
4085,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,U,,1,,CHEMBL620886,BAO_0000251,2107.0,
4086,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,U,,1,,CHEMBL620887,BAO_0000251,2107.0,
4087,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,U,,1,,CHEMBL618039,BAO_0000251,2107.0,
4088,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,U,,1,,CHEMBL618040,BAO_0000251,2107.0,
4089,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,U,,1,,CHEMBL618041,BAO_0000251,2107.0,
4090,Microsomes,,Liver,B,,,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",U,,1,,CHEMBL618216,BAO_0000251,2107.0,
4091,Microsomes,,Liver,B,,,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",U,,1,,CHEMBL618217,BAO_0000251,2107.0,
4092,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,U,,1,,CHEMBL618218,BAO_0000251,2107.0,
4093,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,U,,1,,CHEMBL618219,BAO_0000251,2107.0,
4094,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,U,,1,,CHEMBL618220,BAO_0000251,2107.0,
4095,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,U,,1,,CHEMBL618221,BAO_0000251,2107.0,
4096,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,U,,1,,CHEMBL618222,BAO_0000251,2107.0,
4097,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,U,,1,,CHEMBL618223,BAO_0000251,2107.0,
4098,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,U,,1,,CHEMBL618224,BAO_0000251,2107.0,
4099,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,U,,1,,CHEMBL618225,BAO_0000251,2107.0,
4100,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,U,,1,,CHEMBL618226,BAO_0000251,2107.0,
4101,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,U,,1,,CHEMBL618227,BAO_0000251,2107.0,
4102,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,U,,1,,CHEMBL618228,BAO_0000251,2107.0,
4103,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,U,,1,,CHEMBL618229,BAO_0000251,2107.0,
4104,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,U,,1,,CHEMBL618230,BAO_0000251,2107.0,
4105,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,U,,1,,CHEMBL618231,BAO_0000251,2107.0,
4106,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,U,,1,,CHEMBL618232,BAO_0000251,2107.0,
4107,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,U,,1,,CHEMBL618233,BAO_0000251,2107.0,
4108,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,U,,1,,CHEMBL618234,BAO_0000251,2107.0,
4109,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,U,,1,,CHEMBL618235,BAO_0000251,2107.0,
4110,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,U,,1,,CHEMBL618115,BAO_0000251,2107.0,
4111,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,U,,1,,CHEMBL618116,BAO_0000251,2107.0,
4112,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,U,,1,,CHEMBL618117,BAO_0000251,2107.0,
4113,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,U,,1,,CHEMBL619968,BAO_0000251,2107.0,
4114,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,U,,1,,CHEMBL619969,BAO_0000251,2107.0,
4115,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,U,,1,,CHEMBL619970,BAO_0000251,2107.0,
4116,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,U,,1,,CHEMBL619971,BAO_0000251,2107.0,
4117,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,U,,1,,CHEMBL619972,BAO_0000251,2107.0,
4118,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,U,,1,,CHEMBL619973,BAO_0000251,2107.0,
4119,Microsomes,,Liver,B,,,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,U,,1,,CHEMBL619974,BAO_0000251,2107.0,
4120,Microsomes,,Liver,B,,,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,U,,1,,CHEMBL619975,BAO_0000251,2107.0,
4121,Microsomes,,,B,,,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,U,,1,,CHEMBL619976,BAO_0000251,,
4122,Microsomes,,Liver,B,,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",U,,1,,CHEMBL619977,BAO_0000251,2107.0,
4123,Microsomes,,Liver,B,,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",U,,1,,CHEMBL619978,BAO_0000251,2107.0,
4124,Microsomes,,Liver,B,,,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",U,,1,,CHEMBL619979,BAO_0000251,2107.0,
4125,Microsomes,,Liver,B,,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",U,,1,,CHEMBL619980,BAO_0000251,2107.0,
4126,Microsomes,,Liver,B,,,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",U,,1,,CHEMBL619981,BAO_0000251,2107.0,
4127,,,,F,RPMI-8226,741.0,,In vitro inhibition of 7226/S myeloma cancer cell line,N,,1,,CHEMBL619982,BAO_0000219,,
4128,,,,F,BEL-7404 tumor cell line,993.0,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),N,,1,,CHEMBL619983,BAO_0000219,,
4129,,,,F,786-0,391.0,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,N,,1,,CHEMBL620031,BAO_0000219,,
4130,,,,F,786-0,391.0,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,N,,1,,CHEMBL620032,BAO_0000219,,
4131,,,,F,V79,505.0,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,N,,1,,CHEMBL620033,BAO_0000219,,
4132,,,,F,V79,505.0,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,N,,1,,CHEMBL620034,BAO_0000219,,
4133,,,,F,7800C1 cell line,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,N,,1,,CHEMBL620035,BAO_0000219,,
4134,,,,F,7800C1 cell line,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,N,,1,,CHEMBL618318,BAO_0000219,,
4135,,,,F,7800C1 cell line,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,N,,1,,CHEMBL618319,BAO_0000219,,
4136,,,,F,7800C1 cell line,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,N,,1,,CHEMBL618320,BAO_0000219,,
4137,,,,F,7800C1 cell line,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,N,,1,,CHEMBL618321,BAO_0000219,,
4138,,,,F,7800C1 cell line,1119.0,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,N,,1,,CHEMBL883118,BAO_0000219,,
4139,,,,F,786-0,391.0,,In vitro antitumor activity against renal 786-0 tumor cell lines,N,,1,,CHEMBL883795,BAO_0000219,,
4140,,,,F,786-0,391.0,,Cytotoxic activity against 786-0 Renal cancer cell line,N,,1,,CHEMBL618322,BAO_0000219,,
4141,,,,F,786-0,391.0,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,N,,1,,CHEMBL618323,BAO_0000219,,
4142,,,,F,786-0,391.0,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,N,,1,,CHEMBL618324,BAO_0000219,,
4143,,,,F,786-0,391.0,,In vitro antitumor activity against human renal 786-0 cell line,N,,1,,CHEMBL618325,BAO_0000219,,
4144,,,,F,786-0,391.0,,Inhibition of Renal cancer in 786-0 cancer cell lines,N,,1,,CHEMBL875416,BAO_0000219,,
4145,,,,F,786-0,391.0,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,N,,1,,CHEMBL618326,BAO_0000219,,
4146,,,,F,786-0,391.0,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,N,,1,,CHEMBL618327,BAO_0000219,,
4147,,,,F,786-0,391.0,,inhibition of the growth of renal cancer(786-0) cell line,N,,1,,CHEMBL619215,BAO_0000219,,
4148,,,,F,786-0,391.0,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),N,,1,,CHEMBL619216,BAO_0000219,,
4149,,,,F,786-0,391.0,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,N,,1,,CHEMBL619217,BAO_0000219,,
4150,,,,F,786-0,391.0,,The IC50 value was measured on 786-0 cell line in ovarian tumor,N,,1,,CHEMBL619218,BAO_0000219,,
4151,,,,F,786-0,391.0,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,N,,1,,CHEMBL619219,BAO_0000219,,
4152,,,,F,786-0,391.0,,The IC50 value was measured on 786-0 cell line in renal tumor type.,N,,1,,CHEMBL619220,BAO_0000219,,
4153,,,,F,786-0,391.0,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,N,,1,,CHEMBL619221,BAO_0000219,,
4154,,,,F,786-0,391.0,,Tested for cytotoxic activity against renal cancer 786-0 cell line,N,,1,,CHEMBL619222,BAO_0000219,,
4155,,,,F,786-0,391.0,,Compound was tested for growth inhibitory activity against 786-0 cell line,N,,1,,CHEMBL857454,BAO_0000219,,
4156,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,H,,1,,CHEMBL619223,BAO_0000219,,
4157,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,H,,1,,CHEMBL619224,BAO_0000219,,
4158,,,,B,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,H,,1,,CHEMBL619225,BAO_0000019,,
4159,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),H,,1,,CHEMBL619226,BAO_0000219,,
4160,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),H,,1,,CHEMBL619227,BAO_0000219,,
4161,,,,B,,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,H,,1,,CHEMBL619228,BAO_0000357,,
4162,,,,B,,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,H,,1,,CHEMBL619229,BAO_0000219,,
4163,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,H,,1,,CHEMBL619230,BAO_0000219,,
4164,,,,B,,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,H,,1,,CHEMBL619231,BAO_0000357,,
4165,,,,B,,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",H,,1,,CHEMBL619232,BAO_0000357,,
4166,,,,B,,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,H,,1,,CHEMBL619233,BAO_0000357,,
4167,,,,B,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,H,,1,,CHEMBL619234,BAO_0000357,,
4168,,,,B,,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),H,,1,,CHEMBL619235,BAO_0000357,,
4169,,,,B,,,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",D,,1,,CHEMBL619236,BAO_0000019,,
4170,,,,B,RBL-1,702.0,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,H,,1,,CHEMBL619237,BAO_0000219,,
4171,,,,B,,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,H,,1,,CHEMBL619238,BAO_0000357,,
4172,,,,B,,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,H,,1,,CHEMBL619239,BAO_0000357,,
4173,,,,B,,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,H,,1,,CHEMBL619240,BAO_0000357,,
4174,,,,B,,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,H,,1,,CHEMBL875417,BAO_0000019,,
4175,,,,B,RBL-1,702.0,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),H,,1,,CHEMBL619241,BAO_0000219,,
4176,,,,F,,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,H,,1,,CHEMBL619242,BAO_0000019,,
4177,,,,B,RBL-1,702.0,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,H,,1,,CHEMBL883796,BAO_0000219,,
4178,,,,B,,,,Tested for its inhibitory activity against 5-lipoxygenase,H,,1,,CHEMBL619243,BAO_0000357,,
4179,,,,B,,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,H,,1,,CHEMBL619244,BAO_0000357,,
4180,,,,B,,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",H,,1,,CHEMBL619245,BAO_0000019,,
4181,,,,B,,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,H,,1,,CHEMBL619246,BAO_0000019,,
4182,,,,B,RBL-1,702.0,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,H,,1,,CHEMBL619984,BAO_0000219,,
4183,,,,B,RBL-1,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,H,,1,,CHEMBL619985,BAO_0000219,,
4184,,,,B,RBL-1,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,H,,1,,CHEMBL619986,BAO_0000219,,
4185,,,,B,RBL-1,702.0,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,H,,1,,CHEMBL619987,BAO_0000219,,
4186,,,,B,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,H,,1,,CHEMBL619988,BAO_0000218,,
4187,,,,B,RBL-1,702.0,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,H,,1,,CHEMBL619989,BAO_0000219,,
4188,,,,B,RBL-1,702.0,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,H,,1,,CHEMBL619990,BAO_0000219,,
4189,,,,B,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],H,,1,,CHEMBL619991,BAO_0000219,,
4190,,,,B,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),H,,1,,CHEMBL619992,BAO_0000219,,
4191,,In vivo,,B,,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),H,,1,,CHEMBL619993,BAO_0000218,,
4192,,,,F,RBL-2H3,663.0,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,H,,1,,CHEMBL619994,BAO_0000219,,
4193,,,,F,RBL-2H3,663.0,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,H,,1,,CHEMBL619995,BAO_0000219,,
4194,,,,B,,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],H,,1,,CHEMBL619996,BAO_0000019,,
4195,,,,B,,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,H,,1,,CHEMBL619997,BAO_0000019,,
4196,,,,B,,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,H,,1,,CHEMBL619998,BAO_0000019,,
4197,,,,B,,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,H,,1,,CHEMBL619999,BAO_0000019,,
4198,,,,B,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,H,,1,,CHEMBL620000,BAO_0000019,,
4199,,,,B,RBL-1,702.0,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,H,,1,,CHEMBL620001,BAO_0000219,,
4200,,,,B,,,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,D,,1,,CHEMBL620002,BAO_0000357,,
4201,,,,B,RBL-1,702.0,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,H,,1,,CHEMBL620003,BAO_0000219,,
4202,,,,F,RBL-1,702.0,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,H,,1,,CHEMBL620004,BAO_0000219,,
4203,,,,B,,,,Compound was evaluated for the inhibition of 5-lipoxygenase,H,,1,,CHEMBL874063,BAO_0000357,,
4204,,,,B,RBL-1,702.0,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,H,,1,,CHEMBL620005,BAO_0000219,,
4205,,,,B,RBL-1,702.0,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,H,,1,,CHEMBL620006,BAO_0000219,,
4206,,,,B,RBL-1,702.0,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,H,,1,,CHEMBL620007,BAO_0000219,,
4207,,,,B,RBL-1,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,H,,1,,CHEMBL620008,BAO_0000219,,
4208,,,,B,RBL-1,702.0,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,D,,1,,CHEMBL620009,BAO_0000219,,
4209,,,,B,RBL-1,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,H,,1,,CHEMBL620010,BAO_0000219,,
4210,,,,B,RBL-1,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,H,,1,,CHEMBL620011,BAO_0000219,,
4211,,,,B,RBL-1,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,H,,1,,CHEMBL620677,BAO_0000219,,
4212,,,,B,RBL-1,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,H,,1,,CHEMBL620678,BAO_0000219,,
4213,,,,B,RBL-1,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,H,,1,,CHEMBL620679,BAO_0000219,,
4214,,,,B,RBL-1,702.0,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,H,,1,,CHEMBL620680,BAO_0000219,,
4215,,,,B,,,,Inhibitory activity against 5-lipoxygenase at 10 uM,D,,1,,CHEMBL620838,BAO_0000357,,
4216,,,,B,,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,H,,1,,CHEMBL620839,BAO_0000357,,
4217,,,,B,,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,H,,1,,CHEMBL620840,BAO_0000357,,
4218,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,H,,1,,CHEMBL620841,BAO_0000219,,
4219,,,,B,RBL-1,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,H,,1,,CHEMBL620842,BAO_0000219,,
4220,,,,B,RBL-1,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,H,,1,,CHEMBL620843,BAO_0000219,,
4221,,,,B,RBL-1,702.0,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,H,,1,,CHEMBL620844,BAO_0000219,,
4222,,,,B,RBL-1,702.0,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,H,,1,,CHEMBL620845,BAO_0000219,,
4223,,,,B,,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,H,,1,,CHEMBL620846,BAO_0000019,,
4224,,,,B,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,H,,1,,CHEMBL873951,BAO_0000357,,
4225,,,,B,,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,H,,1,,CHEMBL620847,BAO_0000357,,
4226,,,,B,RBL-1,702.0,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,H,,1,,CHEMBL620848,BAO_0000219,,
4227,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,H,,1,,CHEMBL620849,BAO_0000219,,
4228,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,H,,1,,CHEMBL620850,BAO_0000219,,
4229,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,H,,1,,CHEMBL620851,BAO_0000219,,
4230,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,H,,1,,CHEMBL620852,BAO_0000219,,
4231,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,,1,,CHEMBL875098,BAO_0000219,,
4232,,,,B,RBL-1,702.0,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,D,,1,,CHEMBL620853,BAO_0000219,,
4233,,,,B,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,H,,1,,CHEMBL620854,BAO_0000019,,
4234,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,H,,1,,CHEMBL620855,BAO_0000219,,
4235,,,,B,RBL-1,702.0,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,H,,1,,CHEMBL839884,BAO_0000219,,
4236,,,,B,RBL-1,702.0,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,,1,,CHEMBL620856,BAO_0000219,,
4237,,,,B,RBL-1,702.0,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,,1,,CHEMBL620857,BAO_0000219,,
4238,,,,B,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,H,,1,,CHEMBL620858,BAO_0000019,,
4239,,,,B,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,H,,1,,CHEMBL620859,BAO_0000019,,
4240,,,,B,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,H,,1,,CHEMBL620860,BAO_0000019,,
4241,,,,B,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,H,,1,,CHEMBL620861,BAO_0000019,,
4242,,,,B,,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),H,,1,,CHEMBL620862,BAO_0000357,,
4243,,,,B,,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,H,,1,,CHEMBL620863,BAO_0000357,,
4244,,,,B,,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,H,,1,,CHEMBL620864,BAO_0000019,,
4245,,,,B,RBL-1,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,H,,1,,CHEMBL620865,BAO_0000219,,
4246,,,,B,RBL-1,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,H,,1,,CHEMBL620866,BAO_0000219,,
4247,,,,B,RBL-2H3,663.0,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,H,,1,,CHEMBL620867,BAO_0000219,,
4248,,,,B,RBL-2H3,663.0,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,H,,1,,CHEMBL620868,BAO_0000219,,
4249,,,,F,RBL-2H3,663.0,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,H,,1,,CHEMBL620869,BAO_0000219,,
4250,,,,F,,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,H,,1,,CHEMBL873952,BAO_0000019,,
4251,,,,B,,,,The compound was tested for inhibition of isolated 5-lipoxygenase,H,,1,,CHEMBL875099,BAO_0000357,,
4252,,,,F,RBL-2H3,663.0,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,H,,1,,CHEMBL620870,BAO_0000219,,
4253,,,,B,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,H,,1,,CHEMBL618261,BAO_0000019,,
4254,,,,B,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,H,,1,,CHEMBL618262,BAO_0000019,,
4255,,,,B,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,H,,1,,CHEMBL619428,BAO_0000019,,
4256,,,,B,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,H,,1,,CHEMBL619429,BAO_0000019,,
4257,,,,B,,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,H,,1,,CHEMBL619430,BAO_0000019,,
4258,,,,B,RBL-1,702.0,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,H,,1,,CHEMBL620017,BAO_0000219,,
4259,,,,B,RBL-1,702.0,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,H,,1,,CHEMBL620018,BAO_0000219,,
4260,,,,F,RBL-1,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,H,,1,,CHEMBL620019,BAO_0000219,,
4261,,,,F,RBL-1,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,H,,1,,CHEMBL620020,BAO_0000219,,
4262,,,,F,RBL-1,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,H,,1,,CHEMBL620021,BAO_0000219,,
4263,,,,F,RBL-1,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,H,,1,,CHEMBL620022,BAO_0000219,,
4264,,,,F,RBL-1,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,H,,1,,CHEMBL620023,BAO_0000219,,
4265,,,,F,RBL-1,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,H,,1,,CHEMBL620024,BAO_0000219,,
4266,,,,F,RBL-1,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,H,,1,,CHEMBL620025,BAO_0000219,,
4267,,,,F,RBL-1,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,H,,1,,CHEMBL620026,BAO_0000219,,
4268,,,,F,RBL-1,702.0,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,H,,1,,CHEMBL620027,BAO_0000219,,
4269,,,,F,,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,D,,1,,CHEMBL620028,BAO_0000019,,
4270,,,,B,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,H,,1,,CHEMBL620029,BAO_0000357,,
4271,,,,B,,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,H,,1,,CHEMBL620030,BAO_0000357,,
4272,,,,B,RBL-1,702.0,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,H,,1,,CHEMBL875415,BAO_0000219,,
4273,,,,B,RBL-1,702.0,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,H,,1,,CHEMBL618256,BAO_0000219,,
4274,,,,B,RBL-1,702.0,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,H,,1,,CHEMBL618257,BAO_0000219,,
4275,,,,B,RBL-1,702.0,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,H,,1,,CHEMBL618258,BAO_0000219,,
4276,,,,B,RBL-1,702.0,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,H,,1,,CHEMBL618259,BAO_0000219,,
4277,,,,B,,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,H,,1,,CHEMBL618260,BAO_0000019,,
4278,,,,B,RBL-1,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,H,,1,,CHEMBL618215,BAO_0000219,,
4279,,,,B,RBL-1,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,H,,1,,CHEMBL618390,BAO_0000219,,
4280,,,,B,RBL-1,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,H,,1,,CHEMBL618391,BAO_0000219,,
4281,,,,B,RBL-1,702.0,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,H,,1,,CHEMBL618392,BAO_0000219,,
4282,,,,B,RBL-1,702.0,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,H,,1,,CHEMBL618393,BAO_0000219,,
4283,,,,B,,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,H,,1,,CHEMBL618394,BAO_0000219,,
4284,,,,B,RBL-1,702.0,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),H,,1,,CHEMBL618395,BAO_0000219,,
4285,,,,B,RBL-1,702.0,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),D,,1,,CHEMBL618396,BAO_0000219,,
4286,,,,B,RBL-1,702.0,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),D,,1,,CHEMBL858253,BAO_0000219,,
4287,,,,B,,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,D,,1,,CHEMBL618397,BAO_0000019,,
4288,,,,B,,,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),H,,1,,CHEMBL618398,BAO_0000357,,
4289,,,,B,,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",U,,1,,CHEMBL618399,BAO_0000019,,
4290,,,,B,,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,H,,1,,CHEMBL618400,BAO_0000357,,
4291,,,,B,,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,H,,1,,CHEMBL618401,BAO_0000357,,
4292,,,,B,,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,H,,1,,CHEMBL618402,BAO_0000357,,
4293,,,,B,RBL-1,702.0,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,H,,1,,CHEMBL876400,BAO_0000219,,
4294,,,,B,,,,Inhibitory activity against 5-lipoxygenase.,H,,1,,CHEMBL618403,BAO_0000357,,
4295,,,,B,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,H,,1,,CHEMBL618404,BAO_0000357,,
4296,,,,B,,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,H,,1,,CHEMBL618405,BAO_0000357,,
4297,,,,B,,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,H,,1,,CHEMBL618406,BAO_0000357,,
4298,,,,F,,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,H,,1,,CHEMBL618407,BAO_0000019,,
4299,,,,B,,,,Tested for the inhibitory activity against 5-lipoxygenase,H,,1,,CHEMBL618408,BAO_0000357,,
4300,,,,B,,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,H,,1,,CHEMBL618409,BAO_0000357,,
4301,,,,B,,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,H,,1,,CHEMBL618410,BAO_0000357,,
4302,,,,B,,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,H,,1,,CHEMBL618411,BAO_0000357,,
4303,,,,B,,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,H,,1,,CHEMBL618412,BAO_0000357,,
4304,,,,B,RBL-1,702.0,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,H,,1,,CHEMBL618413,BAO_0000219,,
4305,,,,B,,,,,H,,1,,CHEMBL618414,BAO_0000357,,
4306,,,,B,,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),H,,1,,CHEMBL618415,BAO_0000357,,
4307,,,,B,,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,H,,1,,CHEMBL618416,BAO_0000019,,
4308,,,,B,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,H,,1,,CHEMBL876401,BAO_0000357,,
4309,,,,B,,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,H,,1,,CHEMBL618417,BAO_0000357,,
4310,,,,B,,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,H,,1,,CHEMBL618418,BAO_0000357,,
4311,,,,B,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",H,,1,,CHEMBL618419,BAO_0000357,,
4312,,,,B,,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",H,,1,,CHEMBL618420,BAO_0000357,,
4313,,,,B,,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,H,,1,,CHEMBL618421,BAO_0000357,,
4314,,,,B,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,H,,1,,CHEMBL618422,BAO_0000019,,
4315,,,,B,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),H,,1,,CHEMBL618423,BAO_0000019,,
4316,,,,B,,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),H,,1,,CHEMBL618424,BAO_0000019,,
4317,,,,B,,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,S,,1,,CHEMBL618425,BAO_0000220,,
4318,,,,F,,,,The dark toxicity against 543 human galactophore carcinoma cells,U,,1,,CHEMBL618426,BAO_0000019,,
4319,,,,F,Panel (56 tumour cell lines),390.0,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,N,,1,,CHEMBL618427,BAO_0000219,,
4320,,,,F,5637,345.0,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,N,,1,,CHEMBL618428,BAO_0000219,,
4321,,,,F,5637,345.0,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,N,,1,,CHEMBL618429,BAO_0000219,,
4322,,,,F,5637,345.0,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",N,,1,,CHEMBL618430,BAO_0000219,,
4323,,,,F,5637,345.0,,Growth inhibition against human 5637 cell lines,N,,1,,CHEMBL618431,BAO_0000219,,
4324,,,,F,5637,345.0,,Antitumor activity against human bladder carcinoma 5637 cells.,N,,1,,CHEMBL883799,BAO_0000219,,
4325,,,,F,5637,345.0,,Antitumor activity against human bladder carcinoma 5637 cells,N,,1,,CHEMBL618432,BAO_0000219,,
4326,,,,F,5637,345.0,,Antitumor activity against human bladder carcinoma 5637 cells,N,,1,,CHEMBL618433,BAO_0000219,,
4327,,,,B,,,,In vitro inhibition of bovine trypsin(Trp).,D,,1,,CHEMBL618434,BAO_0000357,,
4328,,,,B,CV-1,407.0,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,H,,1,,CHEMBL618435,BAO_0000219,,
4329,,,,B,,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,H,,1,,CHEMBL876402,BAO_0000357,,
4330,,,,F,,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,H,,1,,CHEMBL618436,BAO_0000019,,
4331,,In vivo,,F,,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,U,,1,,CHEMBL618437,BAO_0000218,,
4332,,,,B,,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,D,,1,,CHEMBL618438,BAO_0000357,,
4333,Microsomes,,,A,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,H,,1,,CHEMBL883800,BAO_0000251,,
4334,Microsomes,,,A,,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,H,,1,,CHEMBL618439,BAO_0000251,,
4335,,,,F,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,U,,1,,CHEMBL618440,BAO_0000019,,
4336,,,,F,,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,U,,1,,CHEMBL618441,BAO_0000019,,
4337,,,,B,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,H,,1,,CHEMBL618442,BAO_0000019,,
4338,,,,B,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,H,,1,,CHEMBL618443,BAO_0000019,,
4339,,,,B,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,H,,1,,CHEMBL619158,BAO_0000019,,
4340,,,,B,,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,H,,1,,CHEMBL620974,BAO_0000019,,
4341,,,,B,,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,H,,1,,CHEMBL620975,BAO_0000357,,
4342,,,,F,,,,Average inhibitory concentration against 60 human cell lines was reported,U,,1,,CHEMBL620976,BAO_0000019,,
4343,,,,F,,,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,U,,1,,CHEMBL620977,BAO_0000019,,
4344,,,,F,Panel NCI-60 (60 carcinoma cell lines),542.0,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,N,,1,,CHEMBL620978,BAO_0000219,,
4345,,,,F,Panel NCI-60 (60 carcinoma cell lines),542.0,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,N,,1,,CHEMBL620979,BAO_0000219,,
4346,,,,F,Panel NCI-60 (60 carcinoma cell lines),542.0,,In vitro mean growth inhibitory activity against 60-cell panel,N,,1,,CHEMBL620980,BAO_0000219,,
4347,,,,F,Panel NCI-60 (60 carcinoma cell lines),542.0,,In vitro mean growth lethal concentration against 60-cell panel,N,,1,,CHEMBL620981,BAO_0000219,,
4348,,,,F,Panel NCI-60 (60 carcinoma cell lines),542.0,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,N,,1,,CHEMBL620982,BAO_0000219,,
4349,,,,F,Panel NCI-60 (60 carcinoma cell lines),542.0,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,N,,1,,CHEMBL620983,BAO_0000219,,
4350,,,,F,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,H,,1,,CHEMBL620984,BAO_0000019,,
4351,,,,F,,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,H,,1,,CHEMBL620985,BAO_0000019,,
4352,,,,B,,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,H,,1,,CHEMBL620986,BAO_0000357,,
4353,,,,F,,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,N,,1,,CHEMBL620987,BAO_0000218,,
4354,,,,F,,,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,N,,1,,CHEMBL620988,BAO_0000218,,
4355,,,,F,,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,N,,1,,CHEMBL620989,BAO_0000218,,
4356,,,,F,,,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,N,,1,,CHEMBL620990,BAO_0000218,,
4357,,,,F,,,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,N,,1,,CHEMBL620991,BAO_0000218,,
4358,,,,F,6C3HED,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,N,,1,,CHEMBL620992,BAO_0000218,,
4359,,,,F,6C3HED,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,N,,1,,CHEMBL620993,BAO_0000218,,
4360,,,,F,6C3HED,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,N,,1,,CHEMBL620994,BAO_0000218,,
4361,,,,F,6C3HED,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,N,,1,,CHEMBL620995,BAO_0000218,,
4362,,,,F,6C3HED,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,N,,1,,CHEMBL620996,BAO_0000218,,
4363,,,,F,6C3HED,850.0,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,N,,1,,CHEMBL875581,BAO_0000218,,
4364,,In vivo,,F,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,U,,1,,CHEMBL620997,BAO_0000218,,
4365,,In vivo,,F,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,U,,1,,CHEMBL620998,BAO_0000218,,
4366,,In vivo,,F,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),U,,1,,CHEMBL620999,BAO_0000218,,
4367,,In vivo,,F,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,U,,1,,CHEMBL621000,BAO_0000218,,
4368,,In vivo,,F,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,U,,1,,CHEMBL621001,BAO_0000218,,
4369,,In vivo,,F,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,U,,1,,CHEMBL621002,BAO_0000218,,
4370,,In vivo,,F,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,U,,1,,CHEMBL621003,BAO_0000218,,
4371,,In vivo,,F,,,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",U,,1,,CHEMBL621004,BAO_0000218,,
4372,,In vivo,,F,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),U,,1,,CHEMBL621005,BAO_0000218,,
4373,,In vivo,,F,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),U,,1,,CHEMBL621006,BAO_0000218,,
4374,,In vivo,,F,,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,U,,1,,CHEMBL621007,BAO_0000218,,
4375,,,,F,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,U,,1,,CHEMBL621008,BAO_0000218,,
4376,,,,F,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,U,,1,,CHEMBL621009,BAO_0000218,,
4377,,,,F,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,U,,1,,CHEMBL857705,BAO_0000218,,
4378,,,,F,,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,U,,1,,CHEMBL619828,BAO_0000218,,
4379,,,,F,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,U,,1,,CHEMBL619829,BAO_0000218,,
4380,,,,F,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,U,,1,,CHEMBL619830,BAO_0000218,,
4381,,,,F,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,U,,1,,CHEMBL619831,BAO_0000218,,
4382,,,,F,,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,U,,1,,CHEMBL619832,BAO_0000218,,
4383,,,,A,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,U,,1,,CHEMBL619833,BAO_0000218,,
4384,,,,A,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,U,,1,,CHEMBL619834,BAO_0000218,,
4385,,,,A,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,U,,1,,CHEMBL619835,BAO_0000218,,
4386,,,,A,,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,U,,1,,CHEMBL619836,BAO_0000218,,
4387,,,,F,6C3HED,850.0,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",N,,1,,CHEMBL619837,BAO_0000218,,
4388,,In vivo,,F,,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,U,,1,,CHEMBL619838,BAO_0000218,,
4389,,,,A,,,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,N,,1,,CHEMBL619839,BAO_0000218,,
4390,,In vivo,,F,6C3HED,850.0,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,N,,1,,CHEMBL619840,BAO_0000218,,
4391,,In vivo,,F,6C3HED,850.0,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,N,,1,,CHEMBL619841,BAO_0000218,,
4392,,,,F,6C3HED,850.0,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),N,,1,,CHEMBL857704,BAO_0000218,,
4393,,,,F,6C3HED,850.0,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),N,,1,,CHEMBL619842,BAO_0000218,,
4394,,,,F,6C3HED,850.0,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),N,,1,,CHEMBL619843,BAO_0000218,,
4395,,,,B,,,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",U,,1,,CHEMBL619844,BAO_0000019,,
4396,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,U,,1,,CHEMBL857855,BAO_0000251,2107.0,
4397,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,U,,1,,CHEMBL619845,BAO_0000251,2107.0,
4398,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,U,,1,,CHEMBL619846,BAO_0000251,2107.0,
4399,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,U,,1,,CHEMBL619847,BAO_0000251,2107.0,
4400,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,U,,1,,CHEMBL619848,BAO_0000251,2107.0,
4401,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,U,,1,,CHEMBL620893,BAO_0000251,2107.0,
4402,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,U,,1,,CHEMBL620894,BAO_0000251,2107.0,
4403,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,U,,1,,CHEMBL620895,BAO_0000251,2107.0,
4404,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,U,,1,,CHEMBL620896,BAO_0000251,2107.0,
4405,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,U,,1,,CHEMBL620897,BAO_0000251,2107.0,
4406,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,U,,1,,CHEMBL620898,BAO_0000251,2107.0,
4407,Microsomes,,Liver,B,,,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,U,,1,,CHEMBL620899,BAO_0000251,2107.0,
4408,,In vivo,Plasma,A,,,,The apparent total plasma clearance in monkey,U,,1,,CHEMBL620900,BAO_0000218,1969.0,
4409,,In vivo,,A,,,,Compound was evaluated for Hepatic clearance in monkey,U,,1,,CHEMBL620901,BAO_0000218,,
4410,,In vivo,,A,,,,Lower clearance in monkey (i.v.) at 0.5 mpk,U,,1,,CHEMBL620902,BAO_0000218,,
4411,,In vivo,,A,,,,Plasma clearance in rhesus monkey,U,,1,,CHEMBL620903,BAO_0000218,,
4412,,In vivo,,A,,,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,U,,1,,CHEMBL620904,BAO_0000218,,
4413,,In vivo,,A,,,,Plasma clearance of compound was determined in monkey,U,,1,,CHEMBL620905,BAO_0000218,,
4414,,In vivo,,A,,,,Plasma clearance was calculated in rhesus monkey,U,,1,,CHEMBL620906,BAO_0000218,,
4415,,In vivo,,A,,,,Plasma clearance in rhesus monkey,U,,1,,CHEMBL875420,BAO_0000218,,
4416,,In vivo,,A,,,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,,1,,CHEMBL620907,BAO_0000218,,
4417,,In vivo,,A,,,,Plasma clearance was evaluated in rhesus,U,,1,,CHEMBL620908,BAO_0000218,,
4418,,In vivo,,A,,,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,U,,1,,CHEMBL620909,BAO_0000218,,
4419,,In vivo,,A,,,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,U,,1,,CHEMBL620910,BAO_0000218,,
4420,,In vivo,,A,,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,,1,,CHEMBL620911,BAO_0000218,,
4421,,In vivo,,A,,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,,1,,CHEMBL620912,BAO_0000218,,
4422,,In vivo,,A,,,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,U,,1,,CHEMBL620913,BAO_0000218,,
4423,,In vivo,,A,,,,Cmax in monkey after administration of 1 mg/kg iv,U,,1,,CHEMBL620914,BAO_0000218,,
4424,,In vivo,,A,,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,U,,1,,CHEMBL620915,BAO_0000218,,
4425,,In vivo,,A,,,,Cmax in cynomolgus monkey by iv administration,U,,1,,CHEMBL620916,BAO_0000218,,
4426,,In vivo,,A,,,,Cmax in cynomolgus monkey by po administration,U,,1,,CHEMBL620917,BAO_0000218,,
4427,,In vivo,,A,,,,Cmax value evaluated in monkey,U,,1,,CHEMBL620918,BAO_0000218,,
4428,,In vivo,,A,,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,,1,,CHEMBL620919,BAO_0000218,,
4429,,In vivo,Plasma,A,,,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,U,,1,,CHEMBL620920,BAO_0000218,1969.0,
4430,,In vivo,Plasma,A,,,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,U,,1,,CHEMBL620921,BAO_0000218,1969.0,
4431,,In vivo,Plasma,A,,,,Maximal plasma concentration in squirrel monkeys,U,,1,,CHEMBL620922,BAO_0000218,1969.0,
4432,,In vivo,,A,,,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,,1,,CHEMBL620923,BAO_0000218,,
4433,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,U,,1,,CHEMBL620924,BAO_0000218,1969.0,
4434,,In vivo,,A,,,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,,1,,CHEMBL620925,BAO_0000218,,
4435,,In vivo,,A,,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,U,,1,,CHEMBL620926,BAO_0000218,,
4436,,In vivo,,A,,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,U,,1,,CHEMBL620927,BAO_0000218,,
4437,,In vivo,,A,,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,U,,1,,CHEMBL620928,BAO_0000218,,
4438,,In vivo,,A,,,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,U,,1,,CHEMBL620929,BAO_0000218,,
4439,,In vivo,Plasma,A,,,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,U,,1,,CHEMBL620930,BAO_0000218,1969.0,
4440,,,,A,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,U,,1,,CHEMBL620931,BAO_0000218,,
4441,,,,A,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,U,,1,,CHEMBL620932,BAO_0000218,,
4442,,In vivo,,A,,,,Absolute bioavailability was evaluated in monkey,U,,1,,CHEMBL620933,BAO_0000218,,
4443,,In vivo,,A,,,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,U,,1,,CHEMBL620934,BAO_0000218,,
4444,,In vivo,,A,,,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,U,,1,,CHEMBL620935,BAO_0000218,,
4445,,In vivo,,A,,,,Bioavailability of compound was determined in rhesus monkey,U,,1,,CHEMBL620936,BAO_0000218,,
4446,,In vivo,,A,,,,Bioavailability determined after oral administration in marmoset,U,,1,,CHEMBL620937,BAO_0000218,,
4447,,In vivo,,A,,,,Oral bioavailability in cynomolgus monkey,U,,1,,CHEMBL620938,BAO_0000218,,
4448,,In vivo,,A,,,,Bioavailability in monkey (p.o.) at 2.0 mpk,U,,1,,CHEMBL620939,BAO_0000218,,
4449,,In vivo,,A,,,,Bioavailability was evaluated after oral administration in monkey,U,,1,,CHEMBL620940,BAO_0000218,,
4450,,In vivo,,A,,,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,,1,,CHEMBL620941,BAO_0000218,,
4451,,In vivo,,A,,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,,1,,CHEMBL620942,BAO_0000218,,
4452,,In vivo,,A,,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,,1,,CHEMBL620943,BAO_0000218,,
4453,,In vivo,,A,,,,Bioavailability of the compound was determined in monkey,U,,1,,CHEMBL620944,BAO_0000218,,
4454,,In vivo,,A,,,,Bioavailability in squirrel monkey (dose 5 mg/kg),U,,1,,CHEMBL620945,BAO_0000218,,
4455,,In vivo,,A,,,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,,1,,CHEMBL620946,BAO_0000218,,
4456,,In vivo,,A,,,,Oral bioavailability in monkey,U,,1,,CHEMBL620947,BAO_0000218,,
4457,,In vivo,,A,,,,Compound was tested for bioavailability in squirrel monkey,U,,1,,CHEMBL620948,BAO_0000218,,
4458,,In vivo,,A,,,,Oral bioavailability in Rhesus monkey,U,,1,,CHEMBL620949,BAO_0000218,,
4459,,In vivo,,A,,,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),U,,1,,CHEMBL620950,BAO_0000218,,
4460,,In vivo,,A,,,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,U,,1,,CHEMBL620951,BAO_0000218,,
4461,,In vivo,,A,,,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,U,,1,,CHEMBL620952,BAO_0000218,,
4462,,In vivo,,A,,,,Oral bioavailability in monkey (dose 5 mg/kg),U,,1,,CHEMBL875421,BAO_0000218,,
4463,,In vivo,,A,,,,Oral bioavailability of compound at 5 mg/kg in monkey,U,,1,,CHEMBL620953,BAO_0000218,,
4464,,In vivo,,A,,,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,N,,1,,CHEMBL873491,BAO_0000218,,
4465,,In vivo,,A,,,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,N,,1,,CHEMBL620954,BAO_0000218,,
4466,,,Plasma,A,,,,Plasma half life determined,N,,1,,CHEMBL620955,BAO_0000218,1969.0,
4467,,,Plasma,A,,,,Plasma half life in dog,N,,1,,CHEMBL618097,BAO_0000218,1969.0,
4468,,,Plasma,A,,,,Plasma half-life in Beagle dogs,N,,1,,CHEMBL618268,BAO_0000218,1969.0,
4469,,In vivo,Plasma,A,,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),N,,1,,CHEMBL618269,BAO_0000218,1969.0,
4470,,In vivo,Plasma,A,,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),N,,1,,CHEMBL618270,BAO_0000218,1969.0,
4471,,In vivo,,A,,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,N,,1,,CHEMBL618271,BAO_0000218,,
4472,,In vivo,,A,,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,N,,1,,CHEMBL873493,BAO_0000218,,
4473,,,,A,,,,Tested for the half life period in dog,N,,1,,CHEMBL621031,BAO_0000218,,
4474,,In vivo,,A,,,,Tested for the half life period in dog at dosage of 10 mpk,N,,1,,CHEMBL621032,BAO_0000218,,
4475,,,,A,,,,The compound was tested for half life in dog,N,,1,,CHEMBL621033,BAO_0000218,,
4476,,,Plasma,A,,,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",N,,1,,CHEMBL621034,BAO_0000218,1969.0,
4477,,,,A,,,,The half life was determined,N,,1,,CHEMBL621035,BAO_0000218,,
4478,,,Plasma,A,,,,The plasma half-life in dogs,N,,1,,CHEMBL621036,BAO_0000218,1969.0,
4479,,,Plasma,A,,,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,N,,1,,CHEMBL621037,BAO_0000218,1969.0,
4480,,,,A,,,,Half life in dog,N,,1,,CHEMBL619812,BAO_0000218,,
4481,,In vivo,,A,,,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,N,,1,,CHEMBL619813,BAO_0000218,,
4482,,In vivo,,A,,,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,N,,1,,CHEMBL873335,BAO_0000218,,
4483,,In vivo,,A,,,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,,1,,CHEMBL619814,BAO_0000218,,
4484,,In vivo,,A,,,,Cmax in ferrets after 30 mg/kg oral dose,N,,1,,CHEMBL619815,BAO_0000218,,
4485,,In vivo,,F,,,,Emesis in ferrets at 30 mg/kg oral dose,N,,1,,CHEMBL619816,BAO_0000218,,
4486,,In vivo,,A,,,,Bioavailability in cynomolgus monkey,U,,1,,CHEMBL619817,BAO_0000218,,
4487,,In vivo,,A,,,,Volume of distribution in cynomolgus,N,,1,,CHEMBL619818,BAO_0000218,,
4488,,,Plasma,A,,,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,U,,1,,CHEMBL619819,BAO_0000218,1969.0,
4489,,,,A,,,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,U,,1,,CHEMBL619820,BAO_0000218,,
4490,,,,A,,,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",U,,1,,CHEMBL875419,BAO_0000218,,
4491,,In vivo,Plasma,A,,,,AUC in guinea pig after 3mg/kg oral dose,U,,1,,CHEMBL619821,BAO_0000218,1969.0,
4492,,In vivo,,A,,,,Bioavailability in guinea pig was tested,U,,1,,CHEMBL619822,BAO_0000218,,
4493,,In vivo,,A,,,,Tested for oral bioavailability in guinea pig at 5 mg/kg,U,,1,,CHEMBL619823,BAO_0000218,,
4494,,In vivo,,A,,,,Tested for the oral bioavailability of the compound,U,,1,,CHEMBL619824,BAO_0000218,,
4495,,In vivo,,A,,,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,U,,1,,CHEMBL619825,BAO_0000218,,
4496,,In vivo,,A,,,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,U,,1,,CHEMBL619826,BAO_0000218,,
4497,,In vivo,Lung,A,,,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,U,,1,,CHEMBL619827,BAO_0000218,2048.0,
4498,,In vivo,,A,,,,Cmax in guinea pig after 3mg/kg oral dose,U,,1,,CHEMBL618167,BAO_0000218,,
4499,,,Blood,A,,,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,U,,1,,CHEMBL618168,BAO_0000019,178.0,
4500,,,Brain,A,,,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,U,,1,,CHEMBL618169,BAO_0000019,955.0,
4501,,,,A,,,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,U,,1,,CHEMBL618170,BAO_0000019,,
4502,,,Intestine,A,,,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,U,,1,,CHEMBL618171,BAO_0000019,160.0,
4503,,,Kidney,A,,,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,U,,1,,CHEMBL618172,BAO_0000019,2113.0,
4504,,,Liver,A,,,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,U,,1,,CHEMBL618173,BAO_0000019,2107.0,
4505,,,,A,,,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,U,,1,,CHEMBL618174,BAO_0000019,,
4506,,,Spleen,A,,,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,U,,1,,CHEMBL875408,BAO_0000019,2106.0,
4507,,In vivo,,A,,,,Elimination T1/2 in Guinea pig (PO dose),U,,1,,CHEMBL839827,BAO_0000218,,
4508,,,,A,,,,Partition coefficient was measured as -log (counts per min ),U,,1,,CHEMBL618175,BAO_0000019,,
4509,,In vivo,,A,,,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,U,,1,,CHEMBL618176,BAO_0000218,,
4510,,In vivo,,A,,,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,U,,1,,CHEMBL618177,BAO_0000218,,
4511,,In vivo,,A,,,,Elimination T1/2 in Guinea pig (PO dose),U,,1,,CHEMBL618178,BAO_0000218,,
4512,,In vivo,,A,,,,"Tested for the half life period of the compound, intravenously",U,,1,,CHEMBL618179,BAO_0000218,,
4513,,,,A,,,,Half-life was measured,U,,1,,CHEMBL873489,BAO_0000019,,
4514,,,,A,,,,The time required for onset of inotropy after addition of a single dose of delta F75,U,,1,,CHEMBL618180,BAO_0000019,,
4515,,In vivo,,A,,,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,U,,1,,CHEMBL618181,BAO_0000218,,
4516,,In vivo,,A,,,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,U,,1,,CHEMBL618182,BAO_0000218,,
4517,,In vivo,,A,,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,U,,1,,CHEMBL618183,BAO_0000218,,
4518,,In vivo,,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,1,,CHEMBL618184,BAO_0000218,,
4519,,In vivo,,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,1,,CHEMBL618185,BAO_0000218,,
4520,,In vivo,,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,1,,CHEMBL618186,BAO_0000218,,
4521,,In vivo,,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,1,,CHEMBL618187,BAO_0000218,,
4522,,In vivo,,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,N,,1,,CHEMBL618188,BAO_0000218,,
4523,,In vivo,,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,1,,CHEMBL875409,BAO_0000218,,
4524,,In vivo,,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,1,,CHEMBL618189,BAO_0000218,,
4525,,In vivo,Blood,A,,,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,N,,1,,CHEMBL618190,BAO_0000218,178.0,
4526,,In vivo,Blood,A,,,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,N,,1,,CHEMBL618191,BAO_0000218,178.0,
4527,,In vivo,Blood,A,,,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,N,,1,,CHEMBL618192,BAO_0000218,178.0,
4528,,In vivo,Bone,A,,,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,N,,1,,CHEMBL618193,BAO_0000218,10000001.0,
4529,,In vivo,Bone,A,,,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,N,,1,,CHEMBL618194,BAO_0000218,10000001.0,
4530,,In vivo,Bone,A,,,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,N,,1,,CHEMBL618195,BAO_0000218,10000001.0,
4531,,In vivo,Brain,A,,,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,N,,1,,CHEMBL618196,BAO_0000218,955.0,
4532,,In vivo,Brain,A,,,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,N,,1,,CHEMBL618197,BAO_0000218,955.0,
4533,,In vivo,Brain,A,,,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,N,,1,,CHEMBL618198,BAO_0000218,955.0,
4534,,In vivo,Heart,A,,,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,N,,1,,CHEMBL618199,BAO_0000218,948.0,
4535,,In vivo,Heart,A,,,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,N,,1,,CHEMBL618200,BAO_0000218,948.0,
4536,,In vivo,Heart,A,,,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,N,,1,,CHEMBL618201,BAO_0000218,948.0,
4537,,In vivo,Intestine,A,,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,N,,1,,CHEMBL618202,BAO_0000218,160.0,
4538,,In vivo,Intestine,A,,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,N,,1,,CHEMBL618203,BAO_0000218,160.0,
4539,,In vivo,Intestine,A,,,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,N,,1,,CHEMBL618204,BAO_0000218,160.0,
4540,,In vivo,Kidney,A,,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,N,,1,,CHEMBL618205,BAO_0000218,2113.0,
4541,,In vivo,Kidney,A,,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,N,,1,,CHEMBL618206,BAO_0000218,2113.0,
4542,,In vivo,Kidney,A,,,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,N,,1,,CHEMBL618207,BAO_0000218,2113.0,
4543,,In vivo,Liver,A,,,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,N,,1,,CHEMBL618208,BAO_0000218,2107.0,
4544,,In vivo,Liver,A,,,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,N,,1,,CHEMBL618932,BAO_0000218,2107.0,
4545,,In vivo,Liver,A,,,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,N,,1,,CHEMBL618933,BAO_0000218,2107.0,
4546,,In vivo,Lung,A,,,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,N,,1,,CHEMBL618934,BAO_0000218,2048.0,
4547,,In vivo,Lung,A,,,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,N,,1,,CHEMBL618935,BAO_0000218,2048.0,
4548,,In vivo,Lung,A,,,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,N,,1,,CHEMBL618936,BAO_0000218,2048.0,
4549,,In vivo,Muscle tissue,A,,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,N,,1,,CHEMBL618937,BAO_0000218,2385.0,
4550,,In vivo,Muscle tissue,A,,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,N,,1,,CHEMBL618938,BAO_0000218,2385.0,
4551,,In vivo,Muscle tissue,A,,,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,N,,1,,CHEMBL619104,BAO_0000218,2385.0,
4552,,In vivo,Spleen,A,,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,N,,1,,CHEMBL619105,BAO_0000218,2106.0,
4553,,In vivo,Spleen,A,,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,N,,1,,CHEMBL619106,BAO_0000218,2106.0,
4554,,In vivo,Spleen,A,,,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,N,,1,,CHEMBL619107,BAO_0000218,2106.0,
4555,,In vivo,Stomach,A,,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,N,,1,,CHEMBL875410,BAO_0000218,945.0,
4556,,In vivo,Stomach,A,,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,N,,1,,CHEMBL619108,BAO_0000218,945.0,
4557,,In vivo,Stomach,A,,,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,N,,1,,CHEMBL619109,BAO_0000218,945.0,
4558,,In vivo,,A,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,N,,1,,CHEMBL619110,BAO_0000218,,
4559,,In vivo,,F,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,N,,1,,CHEMBL619111,BAO_0000218,,
4560,,In vivo,,A,,,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,N,,1,,CHEMBL619112,BAO_0000218,,
4561,,In vivo,,A,,,,MRT value at a dose of 10 mg/kg peroral administration in mice.,N,,1,,CHEMBL619113,BAO_0000218,,
4562,,In vivo,,A,,,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,N,,1,,CHEMBL619114,BAO_0000218,,
4563,,In vivo,,F,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,N,,1,,CHEMBL619115,BAO_0000218,,
4564,,,,F,A2780,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,N,,1,,CHEMBL619116,BAO_0000219,,
4565,,,,F,A2780,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,N,,1,,CHEMBL619117,BAO_0000219,,
4566,,,,F,A2780,478.0,,Compound was evaluated for cytotoxicity against A2780 cell lines.,N,,1,,CHEMBL619118,BAO_0000219,,
4567,,,,F,A2780,478.0,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,N,,1,,CHEMBL619119,BAO_0000219,,
4568,,,,F,A2780,478.0,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,N,,1,,CHEMBL619120,BAO_0000219,,
4569,,,,F,A2780,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,N,,1,,CHEMBL619121,BAO_0000219,,
4570,,,,F,A2780,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,N,,1,,CHEMBL619122,BAO_0000219,,
4571,,,,F,A2780,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,N,,1,,CHEMBL619123,BAO_0000219,,
4572,,,,F,A2780,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,N,,1,,CHEMBL619124,BAO_0000219,,
4573,,,,F,A2780,478.0,,Compound was evaluated for cytotoxicity against A2780 cell line,N,,1,,CHEMBL619125,BAO_0000219,,
4574,,,,F,A2780,478.0,,In vitro inhibitory activity against human tumor cell line A2780,N,,1,,CHEMBL875411,BAO_0000219,,
4575,,,,F,A2780,478.0,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,N,,1,,CHEMBL619126,BAO_0000219,,
4576,,,,F,A2780,478.0,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,N,,1,,CHEMBL619127,BAO_0000219,,
4577,,,,F,A2780,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,N,,1,,CHEMBL619128,BAO_0000219,,
4578,,,,F,A2780,478.0,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,N,,1,,CHEMBL619129,BAO_0000219,,
4579,,,,F,A2780,478.0,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,N,,1,,CHEMBL619130,BAO_0000219,,
4580,,,,F,A2780,478.0,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,N,,1,,CHEMBL619131,BAO_0000219,,
4581,,,,F,A2780,478.0,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,N,,1,,CHEMBL619132,BAO_0000219,,
4582,,,,F,A2780,478.0,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,N,,1,,CHEMBL619133,BAO_0000218,,
4583,,,,F,A2780,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,N,,1,,CHEMBL619134,BAO_0000219,,
4584,,,,F,A2780,478.0,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,N,,1,,CHEMBL619135,BAO_0000219,,
4585,,,,F,A2780,478.0,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,N,,1,,CHEMBL619136,BAO_0000219,,
4586,,,,F,A2780,478.0,,Relative resistance factor in A2780 cisplatin-resistant line,N,,1,,CHEMBL619137,BAO_0000219,,
4587,,,,F,A2780,478.0,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,N,,1,,CHEMBL883713,BAO_0000219,,
4588,,,,F,A2780,478.0,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,N,,1,,CHEMBL875412,BAO_0000219,,
4589,,,,F,A2780,478.0,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,N,,1,,CHEMBL619138,BAO_0000218,,
4590,,,,F,A2780,478.0,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,N,,1,,CHEMBL619262,BAO_0000218,,
4591,,,,F,A2780,478.0,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,N,,1,,CHEMBL619139,BAO_0000219,,
4592,,,,F,A2780,478.0,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,N,,1,,CHEMBL619140,BAO_0000219,,
4593,,,,F,A2780,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,N,,1,,CHEMBL619141,BAO_0000219,,
4594,,,,F,A2780,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,N,,1,,CHEMBL619142,BAO_0000219,,
4595,,,,F,A2780,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,N,,1,,CHEMBL619143,BAO_0000219,,
4596,,,,F,A2780,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,N,,1,,CHEMBL619144,BAO_0000219,,
4597,,,,F,A2780,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,N,,1,,CHEMBL619145,BAO_0000219,,
4598,,,,F,A2780,478.0,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,N,,1,,CHEMBL619146,BAO_0000219,,
4599,,,,F,A2780,478.0,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,N,,1,,CHEMBL619147,BAO_0000219,,
4600,,,,F,A2780,478.0,,Antiproliferative effect of compound on A2780/DX cell line,N,,1,,CHEMBL619148,BAO_0000219,,
4601,,,,F,A2780,478.0,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,N,,1,,CHEMBL619149,BAO_0000219,,
4602,,,,F,A2780,478.0,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),N,,1,,CHEMBL619150,BAO_0000219,,
4603,,,,F,A2780,478.0,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),N,,1,,CHEMBL619151,BAO_0000219,,
4604,,,,F,A2780,478.0,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,N,,1,,CHEMBL883794,BAO_0000219,,
4605,,,,F,A2780,478.0,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,N,,1,,CHEMBL619152,BAO_0000219,,
4606,,,,F,A2780,478.0,,In vitro cytotoxicity against A2780ADR cell line,N,,1,,CHEMBL619153,BAO_0000219,,
4607,,,,F,A2780,478.0,,In vitro cytotoxicity against A2780CIS cell line,N,,1,,CHEMBL619154,BAO_0000219,,
4608,,,,F,A2780,478.0,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,N,,1,,CHEMBL619155,BAO_0000219,,
4609,,,,F,A2780,478.0,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,N,,1,,CHEMBL619156,BAO_0000219,,
4610,,,,F,A2780,478.0,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",N,,1,,CHEMBL619157,BAO_0000219,,
4611,,,,F,A2780,478.0,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",N,,1,,CHEMBL619797,BAO_0000219,,
4612,,In vivo,,A,,,,Oral bioavailability of compound in rhesus macaques,U,,1,,CHEMBL619798,BAO_0000218,,
4613,,In vivo,,A,,,,Oral bioavailability in monkey,U,,1,,CHEMBL619799,BAO_0000218,,
4614,,In vivo,,A,,,,Oral bioavailability evaluated in monkey,U,,1,,CHEMBL619800,BAO_0000218,,
4615,,In vivo,,A,,,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),U,,1,,CHEMBL619801,BAO_0000218,,
4616,,In vivo,,A,,,,Oral bioavailability in Rhesus monkey,U,,1,,CHEMBL619802,BAO_0000218,,
4617,,In vivo,,A,,,,Oral bioavailability was calculated in rhesus monkey,U,,1,,CHEMBL619803,BAO_0000218,,
4618,,In vivo,,A,,,,Oral bioavailability in cynomolgus monkey,U,,1,,CHEMBL619965,BAO_0000218,,
4619,,In vivo,,A,,,,Oral bioavailability in monkey,U,,1,,CHEMBL619966,BAO_0000218,,
4620,,In vivo,,A,,,,Oral bioavailability in monkey,U,,1,,CHEMBL619967,BAO_0000218,,
4621,,In vivo,,A,,,,Oral bioavailability in monkey (dose 1 mg/kg),U,,1,,CHEMBL620073,BAO_0000218,,
4622,,In vivo,,A,,,,Oral bioavailability in monkey (dose 5 mg/kg),U,,1,,CHEMBL620074,BAO_0000218,,
4623,,In vivo,,A,,,,Oral bioavailability in monkey,U,,1,,CHEMBL620075,BAO_0000218,,
4624,,In vivo,,A,,,,Oral bioavailability in monkey,U,,1,,CHEMBL620076,BAO_0000218,,
4625,,In vivo,,A,,,,Oral bioavailability in rhesus monkey,U,,1,,CHEMBL620077,BAO_0000218,,
4626,,In vivo,,A,,,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,U,,1,,CHEMBL620078,BAO_0000218,,
4627,,In vivo,,A,,,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,U,,1,,CHEMBL620079,BAO_0000218,,
4628,,In vivo,,A,,,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,,1,,CHEMBL620080,BAO_0000218,,
4629,,In vivo,,A,,,,Oral bioavailability in Rhesus monkey,U,,1,,CHEMBL620081,BAO_0000218,,
4630,,In vivo,,A,,,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),U,,1,,CHEMBL620082,BAO_0000218,,
4631,,In vivo,,A,,,,Oral bioavailability in monkey at 10 mg/kg of the compound,U,,1,,CHEMBL620083,BAO_0000218,,
4632,,In vivo,,A,,,,Bioavailability in Rhesus monkey,U,,1,,CHEMBL620084,BAO_0000218,,
4633,,,,A,,,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,1,,CHEMBL620085,BAO_0000218,,
4634,,,,A,,,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,1,,CHEMBL874595,BAO_0000218,,
4635,,In vivo,,A,,,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,U,,1,,CHEMBL873352,BAO_0000218,,
4636,,In vivo,,A,,,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,U,,1,,CHEMBL620086,BAO_0000218,,
4637,,In vivo,,A,,,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,U,,1,,CHEMBL620087,BAO_0000218,,
4638,,In vivo,,A,,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,U,,1,,CHEMBL620088,BAO_0000218,,
4639,,In vivo,,A,,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,U,,1,,CHEMBL620089,BAO_0000218,,
4640,,In vivo,,A,,,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,,1,,CHEMBL620090,BAO_0000218,,
4641,,In vivo,,A,,,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,,1,,CHEMBL620091,BAO_0000218,,
4642,Microsomes,,,A,,,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),U,,1,,CHEMBL620092,BAO_0000251,,
4643,Microsomes,,,A,,,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),U,,1,,CHEMBL620093,BAO_0000251,,
4644,Microsomes,,,A,,,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),U,,1,,CHEMBL620094,BAO_0000251,,
4645,Microsomes,,,A,,,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),U,,1,,CHEMBL620095,BAO_0000251,,
4646,,In vivo,,A,,,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,1,,CHEMBL620096,BAO_0000218,,
4647,,In vivo,,A,,,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,1,,CHEMBL620097,BAO_0000218,,
4648,,,,A,,,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,U,,1,,CHEMBL620098,BAO_0000019,,
4649,,,,A,,,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,1,,CHEMBL620099,BAO_0000218,,
4650,,,,A,,,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,1,,CHEMBL620100,BAO_0000218,,
4651,,,,A,,,,Elimination Half-life of compound was determined in monkey,U,,1,,CHEMBL620101,BAO_0000019,,
4652,,,,A,,,,Half life of compound was determined in rhesus monkey,U,,1,,CHEMBL620102,BAO_0000019,,
4653,,,Plasma,A,,,,Half life in monkey plasma,U,,1,,CHEMBL620103,BAO_0000366,1969.0,
4654,,,Plasma,A,,,,Half life in monkey plasma; Not detected,U,,1,,CHEMBL620104,BAO_0000366,1969.0,
4655,,In vivo,,A,,,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,,1,,CHEMBL874596,BAO_0000218,,
4656,,In vivo,,A,,,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,U,,1,,CHEMBL873490,BAO_0000218,,
4657,,,,A,,,,Terminal half life of the compound.,U,,1,,CHEMBL620105,BAO_0000019,,
4658,,In vivo,,A,,,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,,1,,CHEMBL620780,BAO_0000218,,
4659,,In vivo,,A,,,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,,1,,CHEMBL620781,BAO_0000218,,
4660,,,,A,,,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,U,,1,,CHEMBL620956,BAO_0000218,,
4661,,,Urine,A,,,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,1,,CHEMBL620957,BAO_0000218,1088.0,
4662,,,Urine,A,,,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,1,,CHEMBL620958,BAO_0000218,1088.0,
4663,,In vivo,,A,,,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,U,,1,,CHEMBL620959,BAO_0000218,,
4664,,In vivo,,A,,,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,U,,1,,CHEMBL620960,BAO_0000218,,
4665,,In vivo,,A,,,,Volume of distribution was evaluated in rhesus,U,,1,,CHEMBL620961,BAO_0000218,,
4666,,In vivo,,A,,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,U,,1,,CHEMBL620962,BAO_0000218,,
4667,,In vivo,,A,,,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,U,,1,,CHEMBL620963,BAO_0000218,,
4668,,In vivo,,A,,,,Bioavailability in hamster was determined,U,,1,,CHEMBL620964,BAO_0000218,,
4669,,In vivo,,A,,,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,U,,1,,CHEMBL620965,BAO_0000218,,
4670,,In vivo,,A,,,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,U,,1,,CHEMBL620966,BAO_0000218,,
4671,,,Blood,A,,,,Half life of compound was determined in hamster blood,U,,1,,CHEMBL620967,BAO_0000221,178.0,
4672,,,,A,,,,Michaelis-Menten constant of the compound.,U,,1,,CHEMBL620968,BAO_0000019,,
4673,,,,A,,,,Vmax value was measured at 0 uM concentration of silyl ether.,U,,1,,CHEMBL874597,BAO_0000019,,
4674,,,,A,,,,Vmax value was measured at 10 uM concentration of silyl ether.,U,,1,,CHEMBL620969,BAO_0000019,,
4675,,,,A,,,,Vmax value was measured at 5 uM concentration of silyl ether.,U,,1,,CHEMBL620970,BAO_0000019,,
4676,,,,B,,,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,D,,1,,CHEMBL620971,BAO_0000357,,
4677,,,,A,,,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,U,,1,,CHEMBL620972,BAO_0000218,,
4678,,,,A,,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),U,,1,,CHEMBL620973,BAO_0000019,,
4679,,,,A,,,,Active metabolite of ifosfamide determined in humans; A-Active,U,,1,,CHEMBL618243,BAO_0000019,,
4680,,,,A,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,U,,1,,CHEMBL618244,BAO_0000019,,
4681,,,,A,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,U,,1,,CHEMBL618245,BAO_0000019,,
4682,,,,A,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,U,,1,,CHEMBL618246,BAO_0000019,,
4683,,,,A,,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,U,,1,,CHEMBL618247,BAO_0000019,,
4684,,,,A,,,,Compound was evaluated for oral bioavailability in human,U,,1,,CHEMBL618248,BAO_0000218,,
4685,,,Urine,A,,,,Metabolite of ifosfamide determined in urine; NF-Not found,U,,1,,CHEMBL618249,BAO_0000019,1088.0,
4686,,,,A,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),U,,1,,CHEMBL618250,BAO_0000019,,
4687,,,,A,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,U,,1,,CHEMBL874598,BAO_0000019,,
4688,,,,A,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,U,,1,,CHEMBL618251,BAO_0000019,,
4689,,,,A,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,U,,1,,CHEMBL618252,BAO_0000019,,
4690,,,,A,,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,U,,1,,CHEMBL618253,BAO_0000019,,
4691,,,,A,,,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),U,,1,,CHEMBL618254,BAO_0000019,,
4692,,,,A,,,,Percent of compound in healthy individuals (Group D),U,,1,,CHEMBL618255,BAO_0000019,,
4693,Microsomes,,Liver,A,,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,U,,1,,CHEMBL618983,BAO_0000251,2107.0,
4694,,,,A,,,,Binding towards human plasma protein at 10 uM,U,,1,,CHEMBL618984,BAO_0000019,,
4695,,,,A,,,,Binding towards human plasma protein at 100 uM,U,,1,,CHEMBL618985,BAO_0000019,,
4696,,,,A,,,,Human plasma protein binding activity was determined,U,,1,,CHEMBL618986,BAO_0000019,,
4697,,,,A,,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),U,,1,,CHEMBL618987,BAO_0000019,,
4698,,,,A,,,,Percent binding of compound towards human plasma protein was determined,U,,1,,CHEMBL618988,BAO_0000019,,
4699,Microsomes,In vitro,Liver,A,,,,Plasma clearance in human liver microsomes,U,,1,,CHEMBL618989,BAO_0000251,2107.0,
4700,Microsomes,In vitro,Liver,A,,,,In vitro intrinsic clearance in human liver microsome,U,,1,,CHEMBL618990,BAO_0000251,2107.0,
4701,Microsomes,In vitro,Liver,A,,,,In vitro intrinsic clearance in human liver microsome,U,,1,,CHEMBL618991,BAO_0000251,2107.0,
4702,Microsomes,In vitro,,A,,,,In vitro microsome metabolism clearance in human was determined,U,,1,,CHEMBL876725,BAO_0000251,,
4703,Microsomes,In vitro,,A,,,,In vitro microsome metabolism clearance in human was determined; High,U,,1,,CHEMBL618992,BAO_0000251,,
4704,Microsomes,In vitro,,A,,,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,U,,1,,CHEMBL618993,BAO_0000251,,
4705,Microsomes,In vitro,Liver,A,,,,Pharmacokinetic property (clearance) in human liver microsome,U,,1,,CHEMBL618994,BAO_0000251,2107.0,
4706,Microsomes,In vitro,Liver,A,,,,Plasma clearance in human liver microsomes,U,,1,,CHEMBL618995,BAO_0000251,2107.0,
4707,Microsomes,In vitro,Liver,A,,,,In vitro clearance in human liver microsomes,U,,1,,CHEMBL618996,BAO_0000251,2107.0,
4708,Microsomes,In vitro,Liver,A,,,,Intrinsic clearance in human liver microsomes was determined,U,,1,,CHEMBL618997,BAO_0000251,2107.0,
4709,Microsomes,In vitro,Liver,A,,,,Intrinsic clearance in human liver microsomes was determined,U,,1,,CHEMBL618998,BAO_0000251,2107.0,
4710,,In vivo,,A,,,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,U,,1,,CHEMBL618999,BAO_0000218,,
4711,,In vivo,,A,,,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,U,,1,,CHEMBL620223,BAO_0000218,,
4712,,,,A,,,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,U,,1,,CHEMBL620224,BAO_0000218,,
4713,,,,A,,,,Stability in human plasma 2 hr after incubation expressed as percent concentration,U,,1,,CHEMBL620225,BAO_0000019,,
4714,,,,A,,,,Stability in human plasma 4 hr after incubation expressed as percent concentration,U,,1,,CHEMBL620226,BAO_0000019,,
4715,,,Urine,A,,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,1,,CHEMBL620227,BAO_0000019,1088.0,
4716,,,Urine,A,,,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,1,,CHEMBL876726,BAO_0000019,1088.0,
4717,,,Urine,A,,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,1,,CHEMBL620228,BAO_0000019,1088.0,
4718,,,Urine,A,,,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,1,,CHEMBL620229,BAO_0000019,1088.0,
4719,,In vivo,,F,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,N,,1,,CHEMBL620230,BAO_0000218,,
4720,,In vivo,,F,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,N,,1,,CHEMBL620231,BAO_0000218,,
4721,,In vivo,,F,,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,N,,1,,CHEMBL620232,BAO_0000218,,
4722,,In vivo,,F,,,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,N,,1,,CHEMBL620233,BAO_0000218,,
4723,,,,A,,,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),N,,1,,CHEMBL620234,BAO_0000218,,
4724,,,,A,,,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),N,,1,,CHEMBL620235,BAO_0000218,,
4725,,,,A,,,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),N,,1,,CHEMBL620236,BAO_0000218,,
4726,,,Liver,A,,,,In vitro metabolic potential in mouse liver microsomes,N,,1,,CHEMBL620237,BAO_0000218,2107.0,
4727,,,,A,,,,Ability of compound to bind to plasma protein was evaluated in HSA cells,N,,1,,CHEMBL620238,BAO_0000218,,
4728,,,Adrenal gland,A,,,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),N,,1,,CHEMBL620239,BAO_0000218,2369.0,
4729,,,Brain,A,,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,N,,1,,CHEMBL620240,BAO_0000218,955.0,
4730,,,Brain,A,,,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,N,,1,,CHEMBL620241,BAO_0000218,955.0,
4731,,,,A,,,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),N,,1,,CHEMBL876727,BAO_0000218,,
4732,,,Kidney,A,,,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),N,,1,,CHEMBL620242,BAO_0000218,2113.0,
4733,,,,A,,,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),N,,1,,CHEMBL620243,BAO_0000218,,
4734,,,,A,,,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,N,,1,,CHEMBL620244,BAO_0000218,,
4735,,,Serum,A,,,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,N,,1,,CHEMBL620245,BAO_0000218,1977.0,
4736,,,Serum,A,,,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,N,,1,,CHEMBL620246,BAO_0000218,1977.0,
4737,,,Serum,A,,,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,N,,1,,CHEMBL620247,BAO_0000218,1977.0,
4738,,In vivo,Plasma,A,,,,Half life of compound was determined in plasma of mice at 24 mg/Kg,N,,1,,CHEMBL620248,BAO_0000218,1969.0,
4739,,In vivo,Plasma,A,,,,Half life of compound was determined in plasma of mice at 40 mg/Kg,N,,1,,CHEMBL873497,BAO_0000218,1969.0,
4740,,In vivo,Plasma,A,,,,Half life of compound was determined in plasma of mice at 5 mg/Kg,N,,1,,CHEMBL620249,BAO_0000218,1969.0,
4741,,In vivo,,F,,,,Half life after intraperitoneal administration in mice at 18 uM/kg,N,,1,,CHEMBL620250,BAO_0000218,,
4742,,In vivo,,F,,,,Half life after intraperitoneal administration in mice at 23 uM/kg,N,,1,,CHEMBL620251,BAO_0000218,,
4743,,In vivo,,F,,,,Half life after intraperitoneal administration in mice at 25 uM/kg,N,,1,,CHEMBL620252,BAO_0000218,,
4744,,In vivo,,F,,,,Half life after intraperitoneal administration in mice at 26 uM/kg,N,,1,,CHEMBL620253,BAO_0000218,,
4745,,In vivo,,F,,,,Half life after intravenous administration in mice at 23 uM/kg,N,,1,,CHEMBL620254,BAO_0000218,,
4746,,In vivo,,A,,,,Half life after intravenous administration in mice at 24 uM/kg,N,,1,,CHEMBL620255,BAO_0000218,,
4747,,In vivo,,A,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,N,,1,,CHEMBL620256,BAO_0000218,,
4748,,In vivo,,A,,,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,N,,1,,CHEMBL876728,BAO_0000218,,
4749,,In vivo,,A,,,,Maximum time required to reach Cp max was evaluated in mice after oral administration,N,,1,,CHEMBL620257,BAO_0000218,,
4750,,In vivo,,A,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),N,,1,,CHEMBL620258,BAO_0000218,,
4751,,In vivo,,A,,,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",N,,1,,CHEMBL620259,BAO_0000218,,
4752,,In vivo,,A,,,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,N,,1,,CHEMBL620260,BAO_0000218,,
4753,,In vivo,Blood,A,,,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,N,,1,,CHEMBL620261,BAO_0000218,178.0,
4754,,In vivo,,A,,,,Half life at a dose of 10 mg/kg intravenous administration in mice.,N,,1,,CHEMBL620262,BAO_0000218,,
4755,,In vivo,,A,,,,Half life at a dose of 10 mg/kg peroral administration in mice.,N,,1,,CHEMBL620263,BAO_0000218,,
4756,,,,A,,,,Half life in ob/ob mice,N,,1,,CHEMBL620264,BAO_0000218,,
4757,,In vivo,,A,,,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,N,,1,,CHEMBL620265,BAO_0000218,,
4758,,,,A,,,,Half-life was measured in mouse,N,,1,,CHEMBL620266,BAO_0000218,,
4759,,In vivo,,A,,,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,N,,1,,CHEMBL620267,BAO_0000218,,
4760,,,,A,,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,N,,1,,CHEMBL619364,BAO_0000218,,
4761,,,,A,,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,N,,1,,CHEMBL619365,BAO_0000218,,
4762,,,Brain,A,,,,T2 in brain of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL619366,BAO_0000218,955.0,
4763,,,Kidney,A,,,,T2 in kidney of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL619367,BAO_0000218,2113.0,
4764,,,Liver,A,,,,T2 in liver of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL619368,BAO_0000218,2107.0,
4765,,,Lung,A,,,,T2 in lungs of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL619369,BAO_0000218,2048.0,
4766,,,Spleen,A,,,,T2 in spleen of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL876729,BAO_0000218,2106.0,
4767,,In vivo,,A,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,N,,1,,CHEMBL619370,BAO_0000218,,
4768,,In vivo,,A,,,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",N,,1,,CHEMBL619371,BAO_0000218,,
4769,,In vivo,,A,,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,N,,1,,CHEMBL619372,BAO_0000218,,
4770,,In vivo,,A,,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,N,,1,,CHEMBL620012,BAO_0000218,,
4771,,In vivo,,A,,,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,N,,1,,CHEMBL620013,BAO_0000218,,
4772,,,,F,A2780,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",N,,1,,CHEMBL620014,BAO_0000219,,
4773,,,,F,A2780,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",N,,1,,CHEMBL620015,BAO_0000219,,
4774,,,,F,A2780,478.0,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,,1,,CHEMBL621010,BAO_0000219,,
4775,,,,F,A2780,478.0,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,,1,,CHEMBL621011,BAO_0000219,,
4776,,,,F,A2780,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,,1,,CHEMBL621012,BAO_0000219,,
4777,,,,F,A2780,478.0,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,,1,,CHEMBL621013,BAO_0000219,,
4778,,,,F,A2780,478.0,,In vitro cytotoxicity against A2780TAX cell line,N,,1,,CHEMBL621014,BAO_0000219,,
4779,,,,F,A2780cisR,481.0,,In vitro inhibitory activity against human tumor cell line A2780cis,N,,1,,CHEMBL618154,BAO_0000219,,
4780,,,,F,A2780,478.0,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,N,,1,,CHEMBL618155,BAO_0000219,,
4781,,,,F,A2780cisR,481.0,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,N,,1,,CHEMBL618156,BAO_0000219,,
4782,,,,F,A2780cisR,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),N,,1,,CHEMBL618157,BAO_0000219,,
4783,,,,F,A2780,478.0,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,N,,1,,CHEMBL618328,BAO_0000219,,
4784,,,,F,A2780,478.0,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,N,,1,,CHEMBL618329,BAO_0000219,,
4785,,,,F,A2780,478.0,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,N,,1,,CHEMBL618330,BAO_0000219,,
4786,,,,F,A2780,478.0,,In vitro antitumor activity against A2780cisR cell line.,N,,1,,CHEMBL618331,BAO_0000219,,
4787,,,,F,A2780,478.0,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),N,,1,,CHEMBL618332,BAO_0000219,,
4788,,,,F,A2780,478.0,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,N,,1,,CHEMBL618333,BAO_0000219,,
4789,,,,F,A2780cisR,481.0,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,N,,1,,CHEMBL618334,BAO_0000219,,
4790,,,,F,A2780,478.0,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,N,,1,,CHEMBL618335,BAO_0000219,,
4791,,,,B,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,D,,1,,CHEMBL618336,BAO_0000019,,
4792,,,,F,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),H,,1,,CHEMBL618337,BAO_0000019,,
4793,,,,F,,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),D,,1,,CHEMBL618338,BAO_0000019,,
4794,,,,F,HEK293,722.0,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,D,,1,,CHEMBL618339,BAO_0000219,,
4795,,,,F,HEK293,722.0,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,D,,1,,CHEMBL618340,BAO_0000219,,
4796,,,,B,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,D,,1,,CHEMBL618341,BAO_0000019,,
4797,,,,F,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),H,,1,,CHEMBL618342,BAO_0000019,,
4798,,,,F,,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),D,,1,,CHEMBL618343,BAO_0000019,,
4799,,,,B,,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,H,,1,,CHEMBL621038,BAO_0000357,,
4800,,,,F,T-cells,574.0,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),U,,1,,CHEMBL621039,BAO_0000219,,
4801,,,,F,T-cells,574.0,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,U,,1,,CHEMBL621040,BAO_0000219,,
4802,,,,F,A-375,455.0,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,N,,1,,CHEMBL621041,BAO_0000219,,
4803,,,,F,A-375,455.0,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,N,,1,,CHEMBL621042,BAO_0000219,,
4804,,,,F,A-375,455.0,,In vitro antitumor activity against A375cell line extracted form melanoma,N,,1,,CHEMBL621043,BAO_0000219,,
4805,,,,F,A-375,455.0,,Inhibition of cell growth in (A375) melan cell line,N,,1,,CHEMBL621044,BAO_0000219,,
4806,,,,F,A-375,455.0,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,N,,1,,CHEMBL621045,BAO_0000219,,
4807,,,,F,A-375,455.0,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,N,,1,,CHEMBL621046,BAO_0000219,,
4808,,,,F,A-375,455.0,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,N,,1,,CHEMBL621047,BAO_0000219,,
4809,,,,F,A-427,797.0,,Antiproliferative activity measured against A427 human lung carcinoma,N,,1,,CHEMBL621048,BAO_0000219,,
4810,,,,F,A-427,797.0,,Antiproliferative activity measured against A427 human lung carcinoma,N,,1,,CHEMBL883798,BAO_0000219,,
4811,,,,F,A-427,797.0,,Cytotoxicity against lung carcinoma A427 tumor cell lines,N,,1,,CHEMBL621049,BAO_0000219,,
4812,,,,F,A-427,797.0,,Inhibition of large cell lung carcinoma (A427),N,,1,,CHEMBL621050,BAO_0000219,,
4813,,,,F,A-427,797.0,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,N,,1,,CHEMBL621051,BAO_0000219,,
4814,,,,F,A-427,797.0,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,N,,1,,CHEMBL621052,BAO_0000219,,
4815,,,,F,A-427,797.0,,Inhibitory concentration in human lung carcinoma A427 cell line,N,,1,,CHEMBL621053,BAO_0000219,,
4816,,,,F,A-427,797.0,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,N,,1,,CHEMBL621054,BAO_0000219,,
4817,,In vivo,,A,,,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,U,,1,,CHEMBL621055,BAO_0000218,,
4818,,In vivo,,A,,,,Tested for volume of distribution upon iv administration to african green monkey,U,,1,,CHEMBL876398,BAO_0000218,,
4819,,In vivo,,A,,,,Volume of distribution in monkey,U,,1,,CHEMBL621056,BAO_0000218,,
4820,,In vivo,,A,,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,,1,,CHEMBL621057,BAO_0000218,,
4821,,In vivo,,A,,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,U,,1,,CHEMBL621058,BAO_0000218,,
4822,,In vivo,,A,,,,Pharmacokinetic property(Vdss) in cynomolgus monkey,U,,1,,CHEMBL621059,BAO_0000218,,
4823,,In vivo,,A,,,,The distribution volume after intravenous administration in cynomolgus monkeys,U,,1,,CHEMBL621060,BAO_0000218,,
4824,,In vivo,,A,,,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,U,,1,,CHEMBL621061,BAO_0000218,,
4825,,In vivo,,A,,,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,U,,1,,CHEMBL621062,BAO_0000218,,
4826,,In vivo,,A,,,,Volume displacement was calculated in rhesus monkey,U,,1,,CHEMBL621063,BAO_0000218,,
4827,,In vivo,,A,,,,Volume of distribution in steady state was determined in rhesus monkey,U,,1,,CHEMBL621064,BAO_0000218,,
4828,,In vivo,,A,,,,Volume of distribution of compound was determined in monkey,U,,1,,CHEMBL621065,BAO_0000218,,
4829,,In vivo,,A,,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,,1,,CHEMBL621066,BAO_0000218,,
4830,,In vivo,,A,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,,1,,CHEMBL621067,BAO_0000218,,
4831,,In vivo,,A,,,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,,1,,CHEMBL621068,BAO_0000218,,
4832,,In vivo,,A,,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,,1,,CHEMBL876399,BAO_0000218,,
4833,,In vivo,,A,,,,Volume distribution in monkey after administration of 1 mg/kg iv,U,,1,,CHEMBL621069,BAO_0000218,,
4834,,In vivo,,A,,,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,,1,,CHEMBL621070,BAO_0000218,,
4835,,In vivo,,A,,,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,U,,1,,CHEMBL621071,BAO_0000218,,
4836,,In vivo,,A,,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,1,,CHEMBL621072,BAO_0000218,,
4837,,In vivo,,A,,,,Oral systemic bioavailability upon iv administration to african green monkey,U,,1,,CHEMBL618209,BAO_0000218,,
4838,,In vivo,,A,,,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,,1,,CHEMBL618210,BAO_0000218,,
4839,,,,A,,,,Baboon plasma free fraction. ,U,,1,,CHEMBL618211,BAO_0000019,,
4840,,,,A,,,,Area under the curve was calculated in rhesus monkey after iv administration,U,,1,,CHEMBL618212,BAO_0000218,,
4841,,,,A,,,,Area under the curve was calculated in rhesus monkey after peroral administration,U,,1,,CHEMBL618213,BAO_0000019,,
4842,,,,A,,,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,U,,1,,CHEMBL618214,BAO_0000019,,
4843,,In vivo,,A,,,,Half life period in monkey after 5 mg/kg dose,U,,1,,CHEMBL873492,BAO_0000218,,
4844,,In vivo,,A,,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,U,,1,,CHEMBL618272,BAO_0000218,,
4845,,In vivo,,A,,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,U,,1,,CHEMBL618273,BAO_0000218,,
4846,,In vivo,Plasma,A,,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,U,,1,,CHEMBL618274,BAO_0000218,1969.0,
4847,,In vivo,,A,,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,U,,1,,CHEMBL618275,BAO_0000218,,
4848,,In vivo,,A,,,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,,1,,CHEMBL618276,BAO_0000218,,
4849,,,,A,,,,Compound was evaluated for terminal half life in monkey,U,,1,,CHEMBL618277,BAO_0000019,,
4850,,In vivo,,A,,,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,U,,1,,CHEMBL618278,BAO_0000218,,
4851,,In vivo,Plasma,A,,,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,,1,,CHEMBL618279,BAO_0000218,1969.0,
4852,,,,A,,,,Half life of compound was determined in squirrel monkey,U,,1,,CHEMBL618280,BAO_0000019,,
4853,,In vivo,,A,,,,Half life after iv administration in cynomolgus monkey,U,,1,,CHEMBL618281,BAO_0000218,,
4854,,In vivo,Plasma,A,,,,Half life in monkey plasma after administration of 1 mg/kg iv,U,,1,,CHEMBL618282,BAO_0000218,1969.0,
4855,,,,A,,,,Half life was calculated in rhesus monkey,U,,1,,CHEMBL618283,BAO_0000019,,
4856,,,,A,,,,Half life in monkey,U,,1,,CHEMBL618284,BAO_0000019,,
4857,,In vivo,,A,,,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,,1,,CHEMBL618285,BAO_0000218,,
4858,,,,A,,,,Half life was evaluated in rhesus,U,,1,,CHEMBL618286,BAO_0000019,,
4859,,In vivo,,A,,,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,U,,1,,CHEMBL618287,BAO_0000218,,
4860,,In vivo,,A,,,,Half life period was determine after peroral administration at 10 mpk in Rhesus,U,,1,,CHEMBL618288,BAO_0000218,,
4861,,In vivo,,A,,,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,,1,,CHEMBL876393,BAO_0000218,,
4862,,In vivo,,A,,,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,U,,1,,CHEMBL618289,BAO_0000218,,
4863,,In vivo,,A,,,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,U,,1,,CHEMBL618290,BAO_0000218,,
4864,,,,A,,,,Half-life was calculated in monkey,U,,1,,CHEMBL618291,BAO_0000019,,
4865,,,,A,,,,Half-life in Squirrel monkey,U,,1,,CHEMBL618292,BAO_0000019,,
4866,,,,A,,,,Half-life in rhesus monkey,U,,1,,CHEMBL618293,BAO_0000019,,
4867,,In vivo,,A,,,,Half-life was measured in monkey after an iv dose of 1 mg/kg,U,,1,,CHEMBL618294,BAO_0000218,,
4868,,In vivo,,A,,,,Half-life period after intravenous administration in cynomolgus monkeys,U,,1,,CHEMBL618295,BAO_0000218,,
4869,,In vivo,,A,,,,Half-life period after oral administration in cynomolgus monkeys,U,,1,,CHEMBL618296,BAO_0000218,,
4870,,In vivo,,A,,,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,U,,1,,CHEMBL618297,BAO_0000218,,
4871,,,Urine,A,,,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,1,,CHEMBL618298,BAO_0000019,1088.0,
4872,,,Urine,A,,,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,1,,CHEMBL618299,BAO_0000019,1088.0,
4873,,,Urine,A,,,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,1,,CHEMBL618300,BAO_0000019,1088.0,
4874,,,Urine,A,,,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,1,,CHEMBL618301,BAO_0000019,1088.0,
4875,,,Urine,A,,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,U,,1,,CHEMBL618302,BAO_0000019,1088.0,
4876,,,Urine,A,,,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,U,,1,,CHEMBL876394,BAO_0000019,1088.0,
4877,,,Urine,A,,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,U,,1,,CHEMBL618303,BAO_0000019,1088.0,
4878,,,Urine,A,,,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,U,,1,,CHEMBL618304,BAO_0000019,1088.0,
4879,,In vivo,,A,,,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,U,,1,,CHEMBL618305,BAO_0000218,,
4880,,In vivo,,A,,,,Oral bioavailability in human,U,,1,,CHEMBL618306,BAO_0000218,,
4881,,,,A,,,,Compound was tested for human plasma protein binding,U,,1,,CHEMBL618307,BAO_0000019,,
4882,,,,A,,,,Compound was tested for human plasma protein binding; Not determined,U,,1,,CHEMBL618308,BAO_0000019,,
4883,,,,A,,,,Protein binding activity of compound in human plasma; % Free,U,,1,,CHEMBL618309,BAO_0000019,,
4884,,,,A,,,,Unbound fraction (plasma),U,,1,,CHEMBL618310,BAO_0000019,,
4885,,,Plasma,A,,,,Half life for the hydrolysis of compound in human blood serum,U,,1,,CHEMBL873353,BAO_0000366,1969.0,
4886,,,Plasma,A,,,,Half life period in human plasma using phosphate buffer (0.08 M),U,,1,,CHEMBL618311,BAO_0000366,1969.0,
4887,,,Plasma,A,,,,Half life period in human plasma using phosphate buffer (0.1 M),U,,1,,CHEMBL618312,BAO_0000366,1969.0,
4888,,,Plasma,A,,,,Half-life in human plasma was determined,U,,1,,CHEMBL618313,BAO_0000366,1969.0,
4889,,,,A,,,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,U,,1,,CHEMBL618314,BAO_0000019,,
4890,,,,A,,,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),U,,1,,CHEMBL618315,BAO_0000019,,
4891,,,,A,,,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",U,,1,,CHEMBL618316,BAO_0000019,,
4892,,,,A,,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",U,,1,,CHEMBL618317,BAO_0000019,,
4893,,,,A,,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",U,,1,,CHEMBL620138,BAO_0000019,,
4894,,,,A,,,,Partition coefficient (logP),U,,1,,CHEMBL858280,BAO_0000019,,
4895,,,,A,,,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,U,,1,,CHEMBL620139,BAO_0000019,,
4896,Microsomes,,,A,,,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,U,,1,,CHEMBL620140,BAO_0000251,,
4897,,,,A,,,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),U,,1,,CHEMBL620141,BAO_0000019,,
4898,,,,A,,,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),U,,1,,CHEMBL620142,BAO_0000019,,
4899,,,,A,,,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),U,,1,,CHEMBL620143,BAO_0000019,,
4900,Microsomes,,,A,,,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),U,,1,,CHEMBL620144,BAO_0000251,,
4901,Microsomes,,,A,,,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),U,,1,,CHEMBL620145,BAO_0000251,,
4902,Microsomes,,,A,,,,Metabolism of compound in human microsomes; Trace,U,,1,,CHEMBL620146,BAO_0000251,,
4903,Microsomes,,Liver,A,,,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,U,,1,,CHEMBL620147,BAO_0000251,2107.0,
4904,Microsomes,,,A,,,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,U,,1,,CHEMBL620148,BAO_0000251,,
4905,Microsomes,,Liver,A,,,,In vitro metabolic potential in human liver microsomes,U,,1,,CHEMBL620149,BAO_0000251,2107.0,
4906,,,,A,,,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,U,,1,,CHEMBL876412,BAO_0000019,,
4907,,,,A,,,,Tested for human plasma protein binding of the compound; Not tested,U,,1,,CHEMBL619352,BAO_0000019,,
4908,,,,A,,,,Compound was tested for percent protein binding (PB) in human,U,,1,,CHEMBL619353,BAO_0000019,,
4909,,,Plasma,A,,,,Protein binding in human plasma,U,,1,,CHEMBL619354,BAO_0000019,1969.0,
4910,,,,A,,,,Permeability coefficient (B to A) in Caco-2 cell,U,,1,,CHEMBL619355,BAO_0000019,,
4911,,,,A,,,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,U,,1,,CHEMBL619356,BAO_0000019,,
4912,,,,A,,,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),U,,1,,CHEMBL619357,BAO_0000019,,
4913,,,,A,,,,In vitro rate of absorption observed as Caco-2 permeability in humans,U,,1,,CHEMBL619358,BAO_0000019,,
4914,,,,A,Caco-2,495.0,,Cellular permeability of compound was determined in Caco-2 cells; High,U,,1,,CHEMBL619359,BAO_0000219,,
4915,,,,A,Caco-2,495.0,,Permeability in Caco-2 cells of compound,U,,1,,CHEMBL619360,BAO_0000219,,
4916,,,,A,,,,Permeability coefficient (A to B) in Caco-2 cell,U,,1,,CHEMBL619361,BAO_0000019,,
4917,,,,A,,,,Permeability coefficient (B to A) in Caco-2 cell,U,,1,,CHEMBL619362,BAO_0000019,,
4918,,,,A,,,,Permeability coefficient (Papp) (Caco-2 cell monolayer),U,,1,,CHEMBL619363,BAO_0000019,,
4919,,,,A,,,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,U,,1,,CHEMBL618942,BAO_0000019,,
4920,,,,A,,,,Compound was tested for protein binding in human plasma,U,,1,,CHEMBL618943,BAO_0000019,,
4921,,,,A,,,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,U,,1,,CHEMBL618944,BAO_0000019,,
4922,,,Urine,A,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,U,,1,,CHEMBL618945,BAO_0000019,1088.0,
4923,,In vivo,,A,,,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,N,,1,,CHEMBL618946,BAO_0000218,,
4924,,In vivo,,A,,,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),N,,1,,CHEMBL876413,BAO_0000218,,
4925,,In vivo,,A,,,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,N,,1,,CHEMBL618947,BAO_0000218,,
4926,,In vivo,Plasma,A,,,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,N,,1,,CHEMBL618948,BAO_0000218,1969.0,
4927,,In vivo,Plasma,A,,,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,,1,,CHEMBL618949,BAO_0000218,1969.0,
4928,,In vivo,,F,,,,Tmax after intraperitoneal administration in mice at 23 uM/kg,N,,1,,CHEMBL618950,BAO_0000218,,
4929,,In vivo,,A,,,,Tmax after oral administration at 30 mg/kg in ICR mouse,N,,1,,CHEMBL618951,BAO_0000218,,
4930,,In vivo,,A,,,,Tmax after peroral administration in mice at 2.4 uM/kg,N,,1,,CHEMBL618952,BAO_0000218,,
4931,,In vivo,,A,,,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,N,,1,,CHEMBL618953,BAO_0000218,,
4932,,In vivo,Brain,A,,,,Tmax in brain of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL618954,BAO_0000218,955.0,
4933,,In vivo,Kidney,A,,,,Tmax in kidney of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL618955,BAO_0000218,2113.0,
4934,,In vivo,Liver,A,,,,Tmax in liver of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL618956,BAO_0000218,2107.0,
4935,,In vivo,Lung,A,,,,Tmax in lungs of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL618957,BAO_0000218,2048.0,
4936,,In vivo,,F,,,,Tmax in mice at 18 uM/kg i.p. administration,N,,1,,CHEMBL618958,BAO_0000218,,
4937,,In vivo,,F,,,,Tmax in mice at 23 uM/kg i.v. administration,N,,1,,CHEMBL618959,BAO_0000218,,
4938,,In vivo,,F,,,,Tmax in mice at 25 uM/kg i.p. administration,N,,1,,CHEMBL618960,BAO_0000218,,
4939,,In vivo,,F,,,,Tmax in mice at 26 uM/kg i.p. administration,N,,1,,CHEMBL876723,BAO_0000218,,
4940,,In vivo,Spleen,A,,,,Tmax in spleen of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL618961,BAO_0000218,2106.0,
4941,,In vivo,,A,,,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,N,,1,,CHEMBL618962,BAO_0000218,,
4942,,In vivo,,A,,,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,N,,1,,CHEMBL618963,BAO_0000218,,
4943,,,,A,,,,Tmax value in IRC mice,N,,1,,CHEMBL618964,BAO_0000218,,
4944,,In vivo,,A,,,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,N,,1,,CHEMBL618965,BAO_0000218,,
4945,,In vivo,,A,,,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,N,,1,,CHEMBL618966,BAO_0000218,,
4946,,,Urine,A,,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),N,,1,,CHEMBL618967,BAO_0000218,1088.0,
4947,,,Urine,A,,,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),N,,1,,CHEMBL618968,BAO_0000218,1088.0,
4948,,,Urine,A,,,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),N,,1,,CHEMBL618969,BAO_0000218,1088.0,
4949,,,,A,,,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,N,,1,,CHEMBL618970,BAO_0000218,,
4950,,,,A,,,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,N,,1,,CHEMBL618971,BAO_0000218,,
4951,,In vivo,,A,,,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,N,,1,,CHEMBL618972,BAO_0000218,,
4952,,In vivo,,A,,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,N,,1,,CHEMBL618973,BAO_0000218,,
4953,,In vivo,,A,,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,N,,1,,CHEMBL618974,BAO_0000218,,
4954,,In vivo,,A,,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,N,,1,,CHEMBL618975,BAO_0000218,,
4955,,In vivo,,A,,,,Vd in mice,N,,1,,CHEMBL618976,BAO_0000218,,
4956,,In vivo,,A,,,,Volume of distribution in mouse,N,,1,,CHEMBL618977,BAO_0000218,,
4957,,In vivo,,A,,,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,,1,,CHEMBL876724,BAO_0000218,,
4958,,In vivo,,A,,,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,N,,1,,CHEMBL618978,BAO_0000218,,
4959,,In vivo,,A,,,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,N,,1,,CHEMBL618979,BAO_0000218,,
4960,,In vivo,,A,,,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,N,,1,,CHEMBL618980,BAO_0000218,,
4961,,In vivo,,A,,,,Pharmacokinetic property (vdss) was measured in mouse,N,,1,,CHEMBL618981,BAO_0000218,,
4962,,In vivo,,A,,,,Value distribution upon iv administration in mouse,N,,1,,CHEMBL618982,BAO_0000218,,
4963,,In vivo,,A,,,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,N,,1,,CHEMBL620150,BAO_0000218,,
4964,,In vivo,,A,,,,Volume of distribution was evaluated in mice after intravenous administration,N,,1,,CHEMBL620151,BAO_0000218,,
4965,,In vivo,,A,,,,Volume of distribution was evaluated in mice after oral administration,N,,1,,CHEMBL620152,BAO_0000218,,
4966,,In vivo,,A,,,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,N,,1,,CHEMBL620153,BAO_0000218,,
4967,,In vivo,,A,,,,Steady state volume of distribution was determined in mice,N,,1,,CHEMBL876395,BAO_0000218,,
4968,,In vivo,,A,,,,Volume distribution (steady state) of compound was determined in mouse,N,,1,,CHEMBL620154,BAO_0000218,,
4969,,In vivo,,A,,,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,N,,1,,CHEMBL620155,BAO_0000218,,
4970,,In vivo,,A,,,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,N,,1,,CHEMBL620156,BAO_0000218,,
4971,,In vivo,,A,,,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,N,,1,,CHEMBL620157,BAO_0000218,,
4972,,In vivo,Kidney,A,,,,Biodistribution of compound (oxidized form) in in kidney tissue,N,,1,,CHEMBL620158,BAO_0000218,2113.0,
4973,,In vivo,Blood,A,,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,N,,1,,CHEMBL620159,BAO_0000218,178.0,
4974,,In vivo,Blood,A,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",N,,1,,CHEMBL620160,BAO_0000218,178.0,
4975,,In vivo,Blood,A,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL620161,BAO_0000218,178.0,
4976,,,,F,A-427,797.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,N,,1,,CHEMBL620162,BAO_0000219,,
4977,,,,F,A-431,500.0,,Inhibition of A431 human squamous cell carcinoma cell proliferation,N,,1,,CHEMBL620163,BAO_0000219,,
4978,,,,F,A-431,500.0,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,N,,1,,CHEMBL620833,BAO_0000219,,
4979,,,,F,A-431,500.0,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,N,,1,,CHEMBL876396,BAO_0000219,,
4980,,,,F,A-431,500.0,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,N,,1,,CHEMBL620834,BAO_0000219,,
4981,,,,F,A-431,500.0,,Inhibition of A431 human carcinoma cell proliferation,N,,1,,CHEMBL620835,BAO_0000219,,
4982,,,,F,A-431,500.0,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,N,,1,,CHEMBL620836,BAO_0000219,,
4983,,,,F,A-431,500.0,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,N,,1,,CHEMBL620837,BAO_0000219,,
4984,,,,F,A-431,500.0,,In vitro cytotoxicity against epidermoid carcinoma cell line,N,,1,,CHEMBL621017,BAO_0000219,,
4985,,,,F,A-431,500.0,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",D,,1,,CHEMBL621018,BAO_0000218,,
4986,,,,F,A-431,500.0,,Antiproliferative activity of compound was measured on human tumor cell line A431.,N,,1,,CHEMBL621019,BAO_0000219,,
4987,,,,F,A-431,500.0,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,N,,1,,CHEMBL621020,BAO_0000219,,
4988,,,,F,A-431,500.0,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,N,,1,,CHEMBL621021,BAO_0000219,,
4989,,,,F,A-431,500.0,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,H,,1,,CHEMBL621022,BAO_0000219,,
4990,,,,F,A-431,500.0,,Tested for antiproliferative activity against human A431 cells,N,,1,,CHEMBL621023,BAO_0000219,,
4991,,,,F,A-431,500.0,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,D,,1,,CHEMBL621024,BAO_0000219,,
4992,,,,F,A-431,500.0,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,N,,1,,CHEMBL621025,BAO_0000219,,
4993,,,,F,A-431,500.0,,Inhibition of A431 cell proliferation,N,,1,,CHEMBL621026,BAO_0000219,,
4994,,,,F,A-431,500.0,,Cytotoxic effect on A431 human epidermoid carcinoma cells,N,,1,,CHEMBL621027,BAO_0000219,,
4995,,,,F,A-431,500.0,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),N,,1,,CHEMBL876397,BAO_0000219,,
4996,,,,F,A-431,500.0,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,N,,1,,CHEMBL883797,BAO_0000219,,
4997,,,,F,A-431,500.0,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,N,,1,,CHEMBL621028,BAO_0000219,,
4998,,,,F,A-431,500.0,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,N,,1,,CHEMBL621029,BAO_0000219,,
4999,,,,F,A-431,500.0,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,N,,1,,CHEMBL621030,BAO_0000219,,
5000,,,,F,A-431,500.0,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,H,,1,,CHEMBL621147,BAO_0000219,,
5001,,,,F,A-431,500.0,,In vivo antiproliferative activity against A431 cell line,N,,1,,CHEMBL621148,BAO_0000218,,
5002,,,,F,A-431,500.0,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,D,,1,,CHEMBL621149,BAO_0000219,,
5003,,,,F,A-431,500.0,,Inhibition of A431 human epidermoid carcinoma cell proliferation,N,,1,,CHEMBL621150,BAO_0000219,,
5004,,,,F,A-431,500.0,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,D,,1,,CHEMBL621151,BAO_0000219,,
5005,,,,F,A-431,500.0,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),N,,1,,CHEMBL621152,BAO_0000219,,
5006,,,,F,A-431,500.0,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),N,,1,,CHEMBL621153,BAO_0000219,,
5007,,,,F,A-431,500.0,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),N,,1,,CHEMBL884000,BAO_0000219,,
5008,,,,F,,,,Inhibition of EGFR overexpressing A431 cell proliferation,D,,1,,CHEMBL621154,BAO_0000019,,
5009,,,,F,A-431,500.0,,Inhibition of A431 cell proliferation,N,,1,,CHEMBL621155,BAO_0000219,,
5010,,,,F,A-431,500.0,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,D,,1,,CHEMBL621156,BAO_0000219,,
5011,,,,F,A-431,500.0,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",D,,1,,CHEMBL621157,BAO_0000219,,
5012,,,,F,A-431,500.0,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),H,,1,,CHEMBL621158,BAO_0000219,,
5013,,,,F,A-431,500.0,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,N,,1,,CHEMBL621159,BAO_0000219,,
5014,,,,F,A-431,500.0,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,N,,1,,CHEMBL621160,BAO_0000219,,
5015,,,,F,A-431,500.0,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,N,,1,,CHEMBL621161,BAO_0000219,,
5016,,,,F,A-431,500.0,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,N,,1,,CHEMBL621162,BAO_0000219,,
5017,,,,F,A-431,500.0,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,N,,1,,CHEMBL621163,BAO_0000219,,
5018,,,,F,A-431,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,N,,1,,CHEMBL621164,BAO_0000219,,
5019,,,,F,A-431,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,N,,1,,CHEMBL621165,BAO_0000219,,
5020,,,,A,,,,Half-life period in cynomolgus monkey,U,,1,,CHEMBL619159,BAO_0000019,,
5021,,In vitro,Plasma,A,,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",U,,1,,CHEMBL619160,BAO_0000366,1969.0,
5022,,In vivo,,A,,,,Longer half-life in monkey (i.v.) at 0.5 mpk,U,,1,,CHEMBL619161,BAO_0000218,,
5023,,,Plasma,A,,,,Plasma half life in monkey,U,,1,,CHEMBL619162,BAO_0000366,1969.0,
5024,,,Plasma,A,,,,Plasma half-life in rhesus monkey,U,,1,,CHEMBL619163,BAO_0000366,1969.0,
5025,,In vivo,Plasma,A,,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,,1,,CHEMBL619164,BAO_0000218,1969.0,
5026,,In vivo,Plasma,A,,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,,1,,CHEMBL619320,BAO_0000218,1969.0,
5027,,In vivo,,A,,,,Tested for half life upon iv administration to african green monkey,U,,1,,CHEMBL619321,BAO_0000218,,
5028,,In vivo,,A,,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,,1,,CHEMBL873336,BAO_0000218,,
5029,,In vivo,,A,,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,U,,1,,CHEMBL619322,BAO_0000218,,
5030,,In vivo,,A,,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,U,,1,,CHEMBL619323,BAO_0000218,,
5031,,In vivo,,A,,,,The time for peak concentration value after oral administration in cynomolgus monkeys,U,,1,,CHEMBL619324,BAO_0000218,,
5032,,,,A,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,U,,1,,CHEMBL619325,BAO_0000019,,
5033,,,,A,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,U,,1,,CHEMBL876411,BAO_0000019,,
5034,,,,A,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,U,,1,,CHEMBL619326,BAO_0000019,,
5035,,,,A,,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,U,,1,,CHEMBL619327,BAO_0000019,,
5036,,,,A,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,U,,1,,CHEMBL619328,BAO_0000019,,
5037,,,,A,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,U,,1,,CHEMBL619329,BAO_0000019,,
5038,,,,A,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,U,,1,,CHEMBL619330,BAO_0000019,,
5039,,,,A,,,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,U,,1,,CHEMBL619331,BAO_0000019,,
5040,,,,A,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,U,,1,,CHEMBL619332,BAO_0000019,,
5041,,,,A,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,U,,1,,CHEMBL619333,BAO_0000019,,
5042,,,,A,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,U,,1,,CHEMBL619334,BAO_0000019,,
5043,,,,A,,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,U,,1,,CHEMBL619335,BAO_0000019,,
5044,,,,A,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,U,,1,,CHEMBL619336,BAO_0000019,,
5045,,,,A,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,U,,1,,CHEMBL619337,BAO_0000019,,
5046,,,,A,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,U,,1,,CHEMBL619338,BAO_0000019,,
5047,,,,A,,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,U,,1,,CHEMBL619339,BAO_0000019,,
5048,,In vivo,,A,,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),N,,1,,CHEMBL619340,BAO_0000218,,
5049,,In vivo,Plasma,A,,,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,N,,1,,CHEMBL873496,BAO_0000218,1969.0,
5050,,,Plasma,A,,,,AUC value in rat after IV administration at a dose of 10 mg/kg,N,,1,,CHEMBL619341,BAO_0000218,1969.0,
5051,,,Plasma,A,,,,AUC value in rat after oral administration at a dose of 10 mg/kg,N,,1,,CHEMBL619342,BAO_0000218,1969.0,
5052,,In vivo,,A,,,,Cmax value in rat after oral administration at a dose of 10 mg/kg,N,,1,,CHEMBL619343,BAO_0000218,,
5053,,In vivo,,A,,,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,N,,1,,CHEMBL619344,BAO_0000218,,
5054,,In vivo,,A,,,,Tmax value in rat after oral administration at a dose of 10 mg/kg,N,,1,,CHEMBL619345,BAO_0000218,,
5055,,,,A,,,,Vc value in rat after IV administration at a dose of 10 mg/kg,N,,1,,CHEMBL619346,BAO_0000218,,
5056,,In vivo,,A,,,,Half life period in rat after IV administration at a dose of 10 mg/kg,N,,1,,CHEMBL619347,BAO_0000218,,
5057,,,,A,,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,U,,1,,CHEMBL619348,BAO_0000019,,
5058,,,,A,,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),U,,1,,CHEMBL619349,BAO_0000019,,
5059,,,,A,,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),U,,1,,CHEMBL619350,BAO_0000019,,
5060,,,,A,,,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,U,,1,,CHEMBL619351,BAO_0000019,,
5061,,,,A,,,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,U,,1,,CHEMBL875953,BAO_0000019,,
5062,,,,A,,,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,U,,1,,CHEMBL621716,BAO_0000019,,
5063,,,,A,,,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,U,,1,,CHEMBL621717,BAO_0000019,,
5064,,,,A,,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,U,,1,,CHEMBL621718,BAO_0000019,,
5065,,,,A,,,,Area under curve after 1 mpk peroral administration to beagles,U,,1,,CHEMBL621719,BAO_0000019,,
5066,,,,A,,,,Area under curve after 2 mpk peroral administration to beagles,U,,1,,CHEMBL621720,BAO_0000019,,
5067,,In vivo,,A,,,,Cmax value after 1 mpk peroral administration to beagles,U,,1,,CHEMBL621721,BAO_0000218,,
5068,,,Urine,A,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,U,,1,,CHEMBL621722,BAO_0000019,1088.0,
5069,,,Urine,A,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,U,,1,,CHEMBL621723,BAO_0000019,1088.0,
5070,,,Urine,A,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,U,,1,,CHEMBL621724,BAO_0000019,1088.0,
5071,,,Urine,A,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,U,,1,,CHEMBL623443,BAO_0000019,1088.0,
5072,,,Urine,A,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,U,,1,,CHEMBL623444,BAO_0000019,1088.0,
5073,,,Urine,A,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,U,,1,,CHEMBL623445,BAO_0000019,1088.0,
5074,,,Urine,A,,,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,U,,1,,CHEMBL623446,BAO_0000019,1088.0,
5075,Microsomes,,Liver,A,,,,Metabolic stability observed at 30 min after administration in human liver microsomes,U,,1,,CHEMBL623447,BAO_0000251,2107.0,
5076,,,,A,,,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,U,,1,,CHEMBL623448,BAO_0000019,,
5077,,,,A,,,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,U,,1,,CHEMBL623449,BAO_0000019,,
5078,,,,A,,,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,U,,1,,CHEMBL623450,BAO_0000019,,
5079,Microsomes,,Liver,A,,,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",U,,1,,CHEMBL623451,BAO_0000251,2107.0,
5080,,,,A,,,,Metabolic stability (% remaining at 30 mins) in human S9.,U,,1,,CHEMBL623452,BAO_0000019,,
5081,,,,A,,,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,U,,1,,CHEMBL623453,BAO_0000019,,
5082,Microsomes,,Liver,A,,,,Percent parent compound remaining after 20 min incubation with human liver microsomes,U,,1,,CHEMBL623454,BAO_0000251,2107.0,
5083,Microsomes,,Liver,A,,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,U,,1,,CHEMBL623455,BAO_0000251,2107.0,
5084,Microsomes,,Liver,A,,,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,U,,1,,CHEMBL624371,BAO_0000251,2107.0,
5085,,,,A,,,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,U,,1,,CHEMBL624372,BAO_0000218,,
5086,,,,A,,,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,U,,1,,CHEMBL624373,BAO_0000019,,
5087,,,,A,,,,Percent remaining in human plasma after incubation for 60 min at 37 C.,U,,1,,CHEMBL624374,BAO_0000019,,
5088,,,,A,,,,The percent remaining in human plasma after 30 min was determined,U,,1,,CHEMBL624556,BAO_0000019,,
5089,,,Plasma,A,,,,Conversion rate of the prodrug in human plasma,U,,1,,CHEMBL624557,BAO_0000366,1969.0,
5090,,,Plasma,A,,,,Conversion rate of the prodrug in human plasma; ND means no data,U,,1,,CHEMBL624558,BAO_0000366,1969.0,
5091,,,Blood,A,,,,Half life of compound was determined in human blood,U,,1,,CHEMBL624559,BAO_0000221,178.0,
5092,,,,A,,,,Half life of compound was determined in man with once daily dosing,U,,1,,CHEMBL624560,BAO_0000019,,
5093,Microsomes,In vitro,,A,,,,Half life in human microsomes,U,,1,,CHEMBL624561,BAO_0000251,,
5094,,,Plasma,A,,,,Half life in human plasma,U,,1,,CHEMBL624562,BAO_0000366,1969.0,
5095,,,Plasma,A,,,,Half life in human plasma; Not detected,U,,1,,CHEMBL624563,BAO_0000366,1969.0,
5096,,In vivo,,A,,,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,U,,1,,CHEMBL624564,BAO_0000218,,
5097,Microsomes,In vitro,Liver,A,,,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,U,,1,,CHEMBL624565,BAO_0000251,2107.0,
5098,,,Plasma,A,,,,Half-life in human plasma,U,,1,,CHEMBL875152,BAO_0000366,1969.0,
5099,,,Plasma,A,,,,Half-life of the parent prodrug in plasma,U,,1,,CHEMBL624566,BAO_0000366,1969.0,
5100,,In vitro,Plasma,A,,,,In vitro half life in human plasma was determined,U,,1,,CHEMBL873805,BAO_0000366,1969.0,
5101,Microsomes,In vitro,Liver,A,,,,The compound was tested In Vitro for half life in human liver microsomes.,U,,1,,CHEMBL624567,BAO_0000251,2107.0,
5102,,In vivo,,A,,,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,U,,1,,CHEMBL624568,BAO_0000218,,
5103,,In vivo,,A,,,,Observed volume of distribution,U,,1,,CHEMBL624569,BAO_0000218,,
5104,,In vivo,,A,,,,Oral bioavailability in human,U,,1,,CHEMBL624570,BAO_0000218,,
5105,,,,A,,,,Tested for human plasma protein binding of the compound,U,,1,,CHEMBL624571,BAO_0000019,,
5106,,,,A,,,,"First order rate constant, k was determined in human plasma",U,,1,,CHEMBL624572,BAO_0000019,,
5107,,,,A,,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,U,,1,,CHEMBL624573,BAO_0000019,,
5108,,,,A,,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,U,,1,,CHEMBL875153,BAO_0000019,,
5109,Microsomes,,Liver,A,,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,U,,1,,CHEMBL624574,BAO_0000251,2107.0,
5110,,,,A,,,,The compound was tested for the plasma binding in human,U,,1,,CHEMBL624575,BAO_0000019,,
5111,,,,A,,,,Plasma protein binding (human),U,,1,,CHEMBL624576,BAO_0000019,,
5112,Microsomes,In vitro,Liver,A,,,,Compound was evaluated for half-life in human liver microsomes,U,,1,,CHEMBL624577,BAO_0000251,2107.0,
5113,,In vitro,Blood,A,,,,Half life measured in vitro for its stability in human blood,U,,1,,CHEMBL624578,BAO_0000221,178.0,
5114,,,Serum,A,,,,Half life in human serum,U,,1,,CHEMBL622796,BAO_0000019,1977.0,
5115,,,Serum,A,,,,Half life in human serum; ND=not determined,U,,1,,CHEMBL622797,BAO_0000019,1977.0,
5116,,,,A,,,,Half life were determined in CEM-SS cell extract in decomposition step 1,U,,1,,CHEMBL622798,BAO_0000019,,
5117,,,,A,,,,Half life were determined in CEM-SS cell extract in decomposition step 2,U,,1,,CHEMBL622799,BAO_0000019,,
5118,,,Plasma,A,,,,Half life of the in human plasma,U,,1,,CHEMBL622800,BAO_0000366,1969.0,
5119,S9,In vitro,,A,,,,Half life period in human hepatic S9 fraction was determined,U,,1,,CHEMBL622801,BAO_0000220,,
5120,Microsomes,In vitro,Liver,A,,,,Half life period in human liver microsome was determined,U,,1,,CHEMBL622802,BAO_0000251,2107.0,
5121,,,,A,,,,Half life period was determined; 6-7,U,,1,,CHEMBL622803,BAO_0000019,,
5122,,,,A,,,,Half life period was evaluated in human,U,,1,,CHEMBL875154,BAO_0000019,,
5123,,,Plasma,A,,,,Half life time in human plasma,U,,1,,CHEMBL622804,BAO_0000366,1969.0,
5124,,In vivo,Brain,A,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL622805,BAO_0000218,955.0,
5125,,In vivo,Heart,A,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL622611,BAO_0000218,948.0,
5126,,In vivo,Heart,A,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL622612,BAO_0000218,948.0,
5127,,In vivo,Kidney,A,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL875160,BAO_0000218,2113.0,
5128,,In vivo,Kidney,A,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",N,,1,,CHEMBL622613,BAO_0000218,2113.0,
5129,,In vivo,Kidney,A,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL622614,BAO_0000218,2113.0,
5130,,In vivo,Liver,A,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL622615,BAO_0000218,2107.0,
5131,,In vivo,Liver,A,,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,N,,1,,CHEMBL622616,BAO_0000218,2107.0,
5132,,In vivo,Liver,A,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL622617,BAO_0000218,2107.0,
5133,,In vivo,Spleen,A,,,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,N,,1,,CHEMBL622618,BAO_0000218,2106.0,
5134,,In vivo,Spleen,A,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",N,,1,,CHEMBL622619,BAO_0000218,2106.0,
5135,,In vivo,Spleen,A,,,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL622620,BAO_0000218,2106.0,
5136,,In vivo,Brain,A,,,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,1,,CHEMBL622621,BAO_0000218,955.0,
5137,,In vivo,Blood,A,,,,Biodistribution of compound (oxidized form) in blood tissue,N,,1,,CHEMBL622622,BAO_0000218,178.0,
5138,,In vivo,Blood,A,,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL622623,BAO_0000218,178.0,
5139,,In vivo,Blood,A,,,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",N,,1,,CHEMBL622624,BAO_0000218,178.0,
5140,,In vivo,Blood,A,,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,1,,CHEMBL622625,BAO_0000218,178.0,
5141,,In vivo,Blood,A,,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL622626,BAO_0000218,178.0,
5142,,In vivo,Blood,A,,,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,,1,,CHEMBL622627,BAO_0000218,178.0,
5143,,In vivo,Brain,A,,,,Biodistribution of compound (oxidized form) in brain tissue of mice,N,,1,,CHEMBL622628,BAO_0000218,955.0,
5144,,In vivo,Brain,A,,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL622629,BAO_0000218,955.0,
5145,,In vivo,Brain,A,,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",N,,1,,CHEMBL622630,BAO_0000218,955.0,
5146,,In vivo,Brain,A,,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL622631,BAO_0000218,955.0,
5147,,In vivo,Brain,A,,,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,,1,,CHEMBL622632,BAO_0000218,955.0,
5148,,In vivo,Brain,A,,,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",N,,1,,CHEMBL622633,BAO_0000218,955.0,
5149,,In vivo,Heart,A,,,,Biodistribution of compound (oxidized form) in heart tissue of mice,N,,1,,CHEMBL622634,BAO_0000218,948.0,
5150,,In vivo,Heart,A,,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL622635,BAO_0000218,948.0,
5151,,In vivo,Heart,A,,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL875161,BAO_0000218,948.0,
5152,,In vivo,Heart,A,,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",N,,1,,CHEMBL622636,BAO_0000218,948.0,
5153,,In vivo,Heart,A,,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL623335,BAO_0000218,948.0,
5154,,In vivo,Heart,A,,,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,,1,,CHEMBL623336,BAO_0000218,948.0,
5155,,In vivo,Kidney,A,,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL623337,BAO_0000218,2113.0,
5156,,In vivo,Kidney,A,,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",N,,1,,CHEMBL623338,BAO_0000218,2113.0,
5157,,In vivo,Kidney,A,,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",N,,1,,CHEMBL623339,BAO_0000218,2113.0,
5158,,In vivo,Kidney,A,,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL623524,BAO_0000218,2113.0,
5159,,In vivo,Kidney,A,,,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,,1,,CHEMBL623525,BAO_0000218,2113.0,
5160,,In vivo,Liver,A,,,,Biodistribution of compound (oxidized form) in liver tissue,N,,1,,CHEMBL623526,BAO_0000218,2107.0,
5161,,In vivo,Liver,A,,,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL623527,BAO_0000218,2107.0,
5162,,In vivo,Liver,A,,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,1,,CHEMBL623528,BAO_0000218,2107.0,
5163,,,,F,A-431,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,N,,1,,CHEMBL624615,BAO_0000219,,
5164,,,,F,A-431,500.0,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,N,,1,,CHEMBL621672,BAO_0000219,,
5165,,,,F,A-431,500.0,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",N,,1,,CHEMBL621673,BAO_0000218,,
5166,,,,F,A-431,500.0,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",N,,1,,CHEMBL621674,BAO_0000218,,
5167,,,,F,A-431,500.0,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,D,,1,,CHEMBL884002,BAO_0000219,,
5168,,,,F,A-431,500.0,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",N,,1,,CHEMBL621850,BAO_0000219,,
5169,,,,F,A-431,500.0,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,N,,1,,CHEMBL621851,BAO_0000219,,
5170,,,,F,A-431,500.0,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,D,,1,,CHEMBL621852,BAO_0000219,,
5171,,,,F,A-431,500.0,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,D,,1,,CHEMBL621853,BAO_0000219,,
5172,,,,F,A-431,500.0,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",N,,1,,CHEMBL621854,BAO_0000218,,
5173,,,,F,A-431,500.0,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",N,,1,,CHEMBL621855,BAO_0000218,,
5174,,,,F,A-431,500.0,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",N,,1,,CHEMBL623724,BAO_0000218,,
5175,,,,F,A-431,500.0,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",N,,1,,CHEMBL623725,BAO_0000218,,
5176,,,,F,A-431,500.0,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",N,,1,,CHEMBL623726,BAO_0000218,,
5177,,,,F,A-431,500.0,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",D,,1,,CHEMBL623727,BAO_0000219,,
5178,,,,F,A-431,500.0,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,H,,1,,CHEMBL623728,BAO_0000219,,
5179,,,,F,A-431,500.0,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",N,,1,,CHEMBL623729,BAO_0000218,,
5180,,,,F,A-431,500.0,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",N,,1,,CHEMBL623730,BAO_0000218,,
5181,,,,F,A-431,500.0,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",N,,1,,CHEMBL623731,BAO_0000218,,
5182,,,,F,A-431,500.0,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",N,,1,,CHEMBL623732,BAO_0000218,,
5183,,,,F,A-431,500.0,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",N,,1,,CHEMBL623733,BAO_0000218,,
5184,,,,F,A-431,500.0,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",N,,1,,CHEMBL623734,BAO_0000218,,
5185,,,,F,A-431,500.0,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",N,,1,,CHEMBL623735,BAO_0000218,,
5186,,,,F,A-431,500.0,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,N,,1,,CHEMBL623736,BAO_0000219,,
5187,,,,F,A-431,500.0,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,N,,1,,CHEMBL623737,BAO_0000219,,
5188,,,,F,A-431,500.0,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,N,,1,,CHEMBL623738,BAO_0000219,,
5189,,,,F,A-431,500.0,,Dose giving a 50% decrease in the living cell number (A437 cells),N,,1,,CHEMBL875168,BAO_0000219,,
5190,,,,F,A549,646.0,,In vitro inhibitory concentration against proliferation of A459 cell line.,N,,1,,CHEMBL623739,BAO_0000219,,
5191,,,,F,A549,646.0,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,N,,1,,CHEMBL623740,BAO_0000219,,
5192,,,,F,A549,646.0,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,N,,1,,CHEMBL624424,BAO_0000219,,
5193,,,,F,A498,624.0,,In vitro antitumor activity against renal A498 tumor cell lines,N,,1,,CHEMBL624425,BAO_0000219,,
5194,,,,F,A498,624.0,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",N,,1,,CHEMBL624426,BAO_0000219,,
5195,,,,F,A498,624.0,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",N,,1,,CHEMBL624427,BAO_0000219,,
5196,,,,F,A498,624.0,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,N,,1,,CHEMBL624428,BAO_0000219,,
5197,,,,F,A498,624.0,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,N,,1,,CHEMBL624429,BAO_0000219,,
5198,,,,F,A498,624.0,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,N,,1,,CHEMBL624620,BAO_0000219,,
5199,,,,F,A498,624.0,,Cytotoxicity on kidney carcinoma (A-498) cell line,N,,1,,CHEMBL624621,BAO_0000219,,
5200,,,,F,A498,624.0,,Compound was evaluated against Human cell line renal A498,N,,1,,CHEMBL624622,BAO_0000219,,
5201,,,,F,A498,624.0,,Compound was tested for inhibition of A498 human renal cancer cell line,N,,1,,CHEMBL624623,BAO_0000219,,
5202,,,,F,A498,624.0,,Growth inhibitory activity against A498 human cancer cell line,N,,1,,CHEMBL874365,BAO_0000219,,
5203,,,,F,A498,624.0,,In vitro antitumor activity against human renal A498 cell line,N,,1,,CHEMBL624624,BAO_0000219,,
5204,,,,F,A498,624.0,,In vitro cytotoxic activity against renal (A498) cell line,N,,1,,CHEMBL624625,BAO_0000219,,
5205,,,,F,A498,624.0,,In vitro cytotoxic activity against human renal cancer (A498) cell line,N,,1,,CHEMBL624626,BAO_0000219,,
5206,,,,F,A498,624.0,,Tested for cytostatic activity against renal A498 cell line,N,,1,,CHEMBL624627,BAO_0000219,,
5207,,,,F,A498,624.0,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,N,,1,,CHEMBL883157,BAO_0000219,,
5208,,,,F,A498,624.0,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,N,,1,,CHEMBL624628,BAO_0000219,,
5209,,In vivo,,A,,,,Cmax value after 2 mpk peroral administration to beagles,U,,1,,CHEMBL624629,BAO_0000218,,
5210,,In vivo,,A,,,,Bioavailability,U,beagle,1,,CHEMBL623551,BAO_0000218,,
5211,,In vivo,,A,,,,Bioavailability after 1 mpk peroral administration to beagles,U,beagle,1,,CHEMBL623552,BAO_0000218,,
5212,,In vivo,,A,,,,Bioavailability after 2 mpk peroral administration to beagles,U,beagle,1,,CHEMBL623553,BAO_0000218,,
5213,,,,A,,,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,U,,1,,CHEMBL623554,BAO_0000019,,
5214,,,,A,,,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,U,,1,,CHEMBL623555,BAO_0000019,,
5215,,,,A,,,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,U,,1,,CHEMBL623556,BAO_0000019,,
5216,,,,A,,,,Solubility against bovine alpha-chymotrypsin,U,,1,,CHEMBL623557,BAO_0000019,,
5217,,,,A,,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,U,,1,,CHEMBL623558,BAO_0000019,,
5218,,,,A,,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,U,,1,,CHEMBL623559,BAO_0000019,,
5219,,,Spleen,A,,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,U,,1,,CHEMBL623560,BAO_0000221,2106.0,
5220,,,,A,,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,U,,1,,CHEMBL623561,BAO_0000019,,
5221,,,,A,,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,U,,1,,CHEMBL623562,BAO_0000019,,
5222,,,,A,,,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,U,,1,,CHEMBL623563,BAO_0000019,,
5223,,,Spleen,A,,,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,U,,1,,CHEMBL623564,BAO_0000221,2106.0,
5224,,,,A,,,,Half life in presence of 2 mg/mL BSA at pH 8.8,U,,1,,CHEMBL873806,BAO_0000019,,
5225,,,,A,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,U,,1,,CHEMBL623565,BAO_0000019,,
5226,,,,A,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,U,,1,,CHEMBL623566,BAO_0000019,,
5227,,,,A,,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,U,,1,,CHEMBL623567,BAO_0000019,,
5228,,,,A,,,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),U,,1,,CHEMBL623568,BAO_0000019,,
5229,,,Plasma,A,,,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,N,,1,,CHEMBL623569,BAO_0000218,1969.0,
5230,,,Plasma,A,,,,AUC after administration at 100 mg/kg/day in dogs,N,,1,,CHEMBL623570,BAO_0000218,1969.0,
5231,,,Plasma,A,,,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,N,,1,,CHEMBL624254,BAO_0000218,1969.0,
5232,,,Plasma,A,,,,AUC value after 15 mg/kg iv dose in Dogs,N,,1,,CHEMBL624255,BAO_0000218,1969.0,
5233,,,Plasma,A,,,,AUC value after 30 mg/kg po dose in Dogs,N,,1,,CHEMBL624256,BAO_0000218,1969.0,
5234,,,Plasma,A,,,,AUC value after administration of 4 mg/Kg oral dose in dog,N,,1,,CHEMBL624257,BAO_0000218,1969.0,
5235,,,Plasma,A,,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,N,,1,,CHEMBL624258,BAO_0000218,1969.0,
5236,,,,A,,,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,N,,1,,CHEMBL875277,BAO_0000218,,
5237,,,,A,,,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,N,,1,,CHEMBL622667,BAO_0000218,,
5238,,,,A,,,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,N,,1,,CHEMBL622668,BAO_0000218,,
5239,,,,A,,,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,N,,1,,CHEMBL622669,BAO_0000218,,
5240,,,,A,,,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,N,,1,,CHEMBL622670,BAO_0000218,,
5241,,,,A,,,,Area under curve determined in dogs after oral administration of 10 mg/kg,N,,1,,CHEMBL622671,BAO_0000218,,
5242,,,,A,,,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,,1,,CHEMBL622672,BAO_0000218,,
5243,,,,A,,,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,N,,1,,CHEMBL622673,BAO_0000218,,
5244,,,,A,,,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,N,,1,,CHEMBL622674,BAO_0000218,,
5245,,,,A,,,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),N,,1,,CHEMBL622675,BAO_0000218,,
5246,,,,A,,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,N,,1,,CHEMBL622676,BAO_0000218,,
5247,,,,A,,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),N,,1,,CHEMBL622677,BAO_0000218,,
5248,,,,A,,,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,N,,1,,CHEMBL622678,BAO_0000218,,
5249,,,,A,,,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,N,,1,,CHEMBL622679,BAO_0000218,,
5250,,,,A,,,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,,1,,CHEMBL622680,BAO_0000218,,
5251,,,,A,,,,Area under curve was determine after peroral administration at 10 mpk in dog,N,,1,,CHEMBL622681,BAO_0000218,,
5252,,,,A,,,,Area under curve was determine after peroral administration at 5 mpk in dog,N,,1,,CHEMBL875278,BAO_0000218,,
5253,,,,A,,,,Area under curve was determined,N,,1,,CHEMBL622682,BAO_0000218,,
5254,,,,A,,,,Area under curve in dogs,N,,1,,CHEMBL622683,BAO_0000218,,
5255,,,,A,,,,Area under curve in dogs at 10 mg/kg dose fo oral administration,N,,1,,CHEMBL622684,BAO_0000218,,
5256,,,,A,,,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),N,,1,,CHEMBL622685,BAO_0000218,,
5257,,,,A,,,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,N,,1,,CHEMBL622686,BAO_0000218,,
5258,,,,A,,,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,,1,,CHEMBL618344,BAO_0000218,,
5259,,,,A,,,,Area under curve value in dog at a dose of 5 mg/kg,N,,1,,CHEMBL875582,BAO_0000218,,
5260,,,,A,,,,Area under curve was determined after 0.1 mg/kg iv administration in dog,N,,1,,CHEMBL618345,BAO_0000218,,
5261,,,,A,,,,Area under curve was determined after 0.3 mg/kg po administration in dog,N,,1,,CHEMBL618346,BAO_0000218,,
5262,,,,A,,,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,N,,1,,CHEMBL618347,BAO_0000218,,
5263,,,,A,,,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,N,,1,,CHEMBL618348,BAO_0000218,,
5264,,,,A,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,U,,1,,CHEMBL618349,BAO_0000019,,
5265,,,,A,,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,U,,1,,CHEMBL618350,BAO_0000019,,
5266,,,,A,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,U,,1,,CHEMBL618351,BAO_0000019,,
5267,,,,A,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,U,,1,,CHEMBL618352,BAO_0000019,,
5268,,,Blood,A,,,,Time taken to reduce 50% of the concentration of compound in blood plasma,U,,1,,CHEMBL873494,BAO_0000221,178.0,
5269,,,Plasma,A,,,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",U,,1,,CHEMBL618353,BAO_0000366,1969.0,
5270,,,Plasma,A,,,,Half life in human plasma,U,,1,,CHEMBL618354,BAO_0000366,1969.0,
5271,,,Plasma,A,,,,Half life in human plasma was reported,U,,1,,CHEMBL875583,BAO_0000366,1969.0,
5272,,,Serum,A,,,,Half life in human serum,U,,1,,CHEMBL618355,BAO_0000019,1977.0,
5273,,,Plasma,A,,,,Half life upon exposure to human plasma,U,,1,,CHEMBL618356,BAO_0000366,1969.0,
5274,Microsomes,In vitro,,A,,,,t1/2 in human microsomes,U,,1,,CHEMBL618357,BAO_0000251,,
5275,,,Plasma,A,,,,Half life period in 80% human plasma at 37 degree Centigrade,U,,1,,CHEMBL618358,BAO_0000366,1969.0,
5276,,,Zone of skin,A,,,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),U,,1,,CHEMBL618359,BAO_0000221,14.0,
5277,,In vitro,Plasma,A,,,,Half-life measured in in vitro Cathepsin B assay in human plasma,U,,1,,CHEMBL618360,BAO_0000366,1969.0,
5278,,,,A,,,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,U,,1,,CHEMBL618361,BAO_0000019,,
5279,Microsomes,In vitro,Liver,A,,,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,U,,1,,CHEMBL618362,BAO_0000251,2107.0,
5280,,,Plasma,A,,,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",U,,1,,CHEMBL618363,BAO_0000366,1969.0,
5281,,,Plasma,A,,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",U,,1,,CHEMBL618364,BAO_0000366,1969.0,
5282,,,Plasma,A,,,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",U,,1,,CHEMBL875584,BAO_0000366,1969.0,
5283,,,,A,,,,Half-life in the CEM cell extracts,U,,1,,CHEMBL618365,BAO_0000019,,
5284,,,Plasma,A,,,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,U,,1,,CHEMBL873495,BAO_0000366,1969.0,
5285,,,Plasma,A,,,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,U,,1,,CHEMBL618366,BAO_0000366,1969.0,
5286,,,,A,,,,Half-life was determined,U,,1,,CHEMBL618367,BAO_0000019,,
5287,,,Blood,A,,,,Half-life (human blood stability),U,,1,,CHEMBL618368,BAO_0000221,178.0,
5288,,,Blood,A,,,,Half-life (human blood stability); no data,U,,1,,CHEMBL618369,BAO_0000221,178.0,
5289,,,Plasma,A,,,,Half-life in human plasma,U,,1,,CHEMBL618370,BAO_0000366,1969.0,
5290,,,,A,,,,CYP3A4 metabolism half-life (t1/2),U,,1,,CHEMBL618371,BAO_0000019,,
5291,,,Blood,A,,,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),U,,1,,CHEMBL618372,BAO_0000221,178.0,
5292,,In vitro,Plasma,A,,,,In vitro half life in human plasma,U,,1,,CHEMBL618373,BAO_0000366,1969.0,
5293,,In vitro,Plasma,A,,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",U,,1,,CHEMBL618374,BAO_0000366,1969.0,
5294,,In vitro,Plasma,A,,,,In vitro hydrolysis in human plasma,U,,1,,CHEMBL618375,BAO_0000366,1969.0,
5295,,In vitro,Plasma,A,,,,In vitro hydrolysis in human plasma; no data,U,,1,,CHEMBL618376,BAO_0000366,1969.0,
5296,Microsomes,In vitro,Liver,A,,,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,U,,1,,CHEMBL618377,BAO_0000251,2107.0,
5297,,,Plasma,A,,,,Plasma half life in human,U,,1,,CHEMBL618378,BAO_0000366,1969.0,
5298,,,Plasma,A,,,,Stability after incubation with human plasma (at 37 degree C),U,,1,,CHEMBL618379,BAO_0000366,1969.0,
5299,,,Plasma,A,,,,T1/2 was evaluated in human plasma,U,,1,,CHEMBL618380,BAO_0000366,1969.0,
5300,,,Plasma,A,,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",U,,1,,CHEMBL618381,BAO_0000366,1969.0,
5301,,,Plasma,A,,,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",U,,1,,CHEMBL618382,BAO_0000366,1969.0,
5302,,,,A,,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,U,,1,,CHEMBL618383,BAO_0000019,,
5303,,In vitro,,A,,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,U,,1,,CHEMBL618384,BAO_0000019,,
5304,,In vitro,,A,,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,U,,1,,CHEMBL618385,BAO_0000019,,
5305,,,Plasma,A,,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,U,,1,,CHEMBL619099,BAO_0000366,1969.0,
5306,,,Plasma,A,,,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,U,,1,,CHEMBL619100,BAO_0000366,1969.0,
5307,,,,A,,,,Time taken for 50% to be consumed by serum PON1 was determined,U,,1,,CHEMBL619101,BAO_0000019,,
5308,,,,A,,,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,U,,1,,CHEMBL619102,BAO_0000019,,
5309,Microsomes,,Liver,A,,,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,U,,1,,CHEMBL619103,BAO_0000251,2107.0,
5310,,,,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,1,,CHEMBL619268,BAO_0000218,,
5311,,,,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,1,,CHEMBL619269,BAO_0000218,,
5312,,,,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,1,,CHEMBL619270,BAO_0000218,,
5313,,,,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,1,,CHEMBL619271,BAO_0000218,,
5314,,,,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,1,,CHEMBL875585,BAO_0000218,,
5315,,,,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,,1,,CHEMBL619272,BAO_0000218,,
5316,,,,F,786-0,391.0,,Compound tested for growth inhibition of renal cancer cell line 786-0,N,,1,,CHEMBL619273,BAO_0000219,,
5317,,,,F,786-0,391.0,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,N,,1,,CHEMBL619274,BAO_0000219,,
5318,,,,F,786-0,391.0,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,N,,1,,CHEMBL619275,BAO_0000219,,
5319,,,,F,786-0,391.0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",N,,1,,CHEMBL619276,BAO_0000219,,
5320,,,,F,786-0,391.0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",N,,1,,CHEMBL619277,BAO_0000219,,
5321,,,,F,786-0,391.0,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",N,,1,,CHEMBL619278,BAO_0000219,,
5322,,,,F,786-0,391.0,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,N,,1,,CHEMBL619279,BAO_0000219,,
5323,,,,F,786-0,391.0,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,N,,1,,CHEMBL858458,BAO_0000219,,
5324,,,,F,786-0,391.0,,Cytotoxic effect on renal cancer line 786-0,N,,1,,CHEMBL619280,BAO_0000219,,
5325,,,,F,786-0,391.0,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,N,,1,,CHEMBL619281,BAO_0000219,,
5326,,,,F,786-0,391.0,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),N,,1,,CHEMBL619282,BAO_0000219,,
5327,,,,F,786-0,391.0,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",N,,1,,CHEMBL619283,BAO_0000219,,
5328,,,,F,786-0,391.0,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,N,,1,,CHEMBL619284,BAO_0000219,,
5329,,,,F,786-0,391.0,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,N,,1,,CHEMBL619285,BAO_0000219,,
5330,,,,F,786-0,391.0,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),N,,1,,CHEMBL619286,BAO_0000219,,
5331,,,,F,786-0,391.0,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,N,,1,,CHEMBL619287,BAO_0000219,,
5332,,,,F,786-0,391.0,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,N,,1,,CHEMBL857455,BAO_0000219,,
5333,,,,F,786-0,391.0,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),N,,1,,CHEMBL883801,BAO_0000219,,
5334,,,,F,791T cell line,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,N,,1,,CHEMBL619288,BAO_0000219,,
5335,,,,F,791T cell line,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),N,,1,,CHEMBL619289,BAO_0000219,,
5336,,,,F,791T cell line,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,N,,1,,CHEMBL619290,BAO_0000219,,
5337,,,,F,791T cell line,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),N,,1,,CHEMBL619291,BAO_0000219,,
5338,,,,F,791T cell line,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),N,,1,,CHEMBL619292,BAO_0000219,,
5339,,,,F,791T cell line,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,N,,1,,CHEMBL619293,BAO_0000219,,
5340,,,,F,791T cell line,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),N,,1,,CHEMBL619294,BAO_0000219,,
5341,,,,F,791T cell line,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),N,,1,,CHEMBL619295,BAO_0000219,,
5342,,,,F,791T cell line,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),N,,1,,CHEMBL619296,BAO_0000219,,
5343,,,,F,791T cell line,972.0,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,N,,1,,CHEMBL619297,BAO_0000219,,
5344,,,,F,786-0,391.0,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,N,,1,,CHEMBL619298,BAO_0000219,,
5345,,,,F,,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,U,,1,,CHEMBL619299,BAO_0000019,,
5346,,,,F,RPMI-8226,741.0,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,N,,1,,CHEMBL619300,BAO_0000219,,
5347,,,,F,RPMI-8226,741.0,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,N,,1,,CHEMBL619301,BAO_0000219,,
5348,,,,F,RPMI-8226,741.0,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,N,,1,,CHEMBL619302,BAO_0000219,,
5349,,,,F,RPMI-8226,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,N,,1,,CHEMBL619303,BAO_0000219,,
5350,,,,F,RPMI-8226,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,N,,1,,CHEMBL619304,BAO_0000219,,
5351,,,,F,RPMI-8226,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),N,,1,,CHEMBL857706,BAO_0000219,,
5352,,,,F,RPMI-8226,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),N,,1,,CHEMBL619305,BAO_0000219,,
5353,,,,F,RPMI-8226,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),N,,1,,CHEMBL619306,BAO_0000219,,
5354,,,,F,RPMI-8226,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,,1,,CHEMBL619307,BAO_0000219,,
5355,,,,F,RPMI-8226,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,,1,,CHEMBL619308,BAO_0000219,,
5356,,,,F,RPMI-8226,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),N,,1,,CHEMBL619309,BAO_0000219,,
5357,,,,F,RPMI-8226,741.0,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),N,,1,,CHEMBL619310,BAO_0000219,,
5358,,,,F,A498,624.0,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),N,,1,,CHEMBL619311,BAO_0000219,,
5359,,,,F,A498,624.0,,Compound was tested for the growth inhibition of A498 renal tumor cell line,N,,1,,CHEMBL619312,BAO_0000219,,
5360,,,,F,A498,624.0,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),N,,1,,CHEMBL619313,BAO_0000219,,
5361,,,,F,A498,624.0,,In vitro inhibitory concentration against renal cancer cell line A498,N,,1,,CHEMBL619314,BAO_0000219,,
5362,,,,F,A498,624.0,,Cytotoxicity against A 498 tumor cell line,N,,1,,CHEMBL619959,BAO_0000219,,
5363,,,,F,A498,624.0,,In vitro antitumor activity against A498 human cancer cell line,N,,1,,CHEMBL619960,BAO_0000219,,
5364,,,,F,A498,624.0,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),N,,1,,CHEMBL619961,BAO_0000219,,
5365,,,,F,A498,624.0,,Inhibitory dose required against A498 human tumor cell lines,N,,1,,CHEMBL619962,BAO_0000219,,
5366,,,,F,A498,624.0,,Anticancer activity against one renal cancer (A498 cell line),N,,1,,CHEMBL875586,BAO_0000219,,
5367,,,,F,A498,624.0,,In vitro cytotoxicity against melanoma A498 cell line,N,,1,,CHEMBL619963,BAO_0000219,,
5368,,,,F,A498,624.0,,Compound was tested for growth inhibitory activity against A498 cell line,N,,1,,CHEMBL619964,BAO_0000219,,
5369,,,,F,A498,624.0,,Compound tested for growth inhibition of renal cancer cell line A498,N,,1,,CHEMBL620108,BAO_0000219,,
5370,,,,F,A498,624.0,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,N,,1,,CHEMBL620109,BAO_0000219,,
5371,,,,F,A498,624.0,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,N,,1,,CHEMBL620110,BAO_0000219,,
5372,,,,F,A498,624.0,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,N,,1,,CHEMBL620111,BAO_0000219,,
5373,,,,F,A498,624.0,,Tested for cytotoxicity against A498 cell lines in renal cancer,N,,1,,CHEMBL620112,BAO_0000219,,
5374,,,,F,A498,624.0,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,N,,1,,CHEMBL620113,BAO_0000219,,
5375,,,,F,A498,624.0,,Cytotoxic effect on renal cancer lines A498,N,,1,,CHEMBL620114,BAO_0000219,,
5376,,,,F,A498,624.0,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,N,,1,,CHEMBL620115,BAO_0000219,,
5377,,,,F,A498,624.0,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),N,,1,,CHEMBL620116,BAO_0000219,,
5378,,,,F,A498,624.0,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,N,,1,,CHEMBL620117,BAO_0000219,,
5379,,,,F,A498,624.0,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,N,,1,,CHEMBL620118,BAO_0000219,,
5380,,,,F,A498,624.0,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,N,,1,,CHEMBL620119,BAO_0000219,,
5381,,,,F,A498,624.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,N,,1,,CHEMBL620120,BAO_0000219,,
5382,,,,F,A549,646.0,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,N,,1,,CHEMBL620121,BAO_0000219,,
5383,,,,F,A549,646.0,,Antitumor activity against A549 human lung carcinoma cell line,N,,1,,CHEMBL620122,BAO_0000219,,
5384,,,,F,A549,646.0,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,N,,1,,CHEMBL620123,BAO_0000219,,
5385,,,,F,A549,646.0,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,N,,1,,CHEMBL620124,BAO_0000219,,
5386,,,,F,A549,646.0,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",N,,1,,CHEMBL620125,BAO_0000219,,
5387,,,,F,A549,646.0,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,N,,1,,CHEMBL620126,BAO_0000219,,
5388,,,,F,A549,646.0,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,,1,,CHEMBL883027,BAO_0000219,,
5389,,,,F,A549,646.0,,In vitro cytotoxic activity against human lung A549 cell line,N,,1,,CHEMBL620127,BAO_0000219,,
5390,,,,F,A549,646.0,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),N,,1,,CHEMBL620128,BAO_0000219,,
5391,,,,F,A549,646.0,,In vitro cytotoxic activity against human lung A549 cell line),N,,1,,CHEMBL620129,BAO_0000219,,
5392,,,,F,A549,646.0,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,N,,1,,CHEMBL620130,BAO_0000219,,
5393,,,,F,A549,646.0,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,N,,1,,CHEMBL620131,BAO_0000219,,
5394,,,,F,A549,646.0,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",N,,1,,CHEMBL620132,BAO_0000219,,
5395,,,,F,A549,646.0,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",N,,1,,CHEMBL620133,BAO_0000219,,
5396,,,,F,A549,646.0,,Inhibition of A549 human lung carcinoma cell proliferation,N,,1,,CHEMBL620134,BAO_0000219,,
5397,,,,F,A549,646.0,,Inhibitory activity against A549 lung adenocarcinoma cell line,N,,1,,CHEMBL620135,BAO_0000219,,
5398,,,,F,A549,646.0,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,N,,1,,CHEMBL620136,BAO_0000219,,
5399,,,,F,A549,646.0,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,N,,1,,CHEMBL620137,BAO_0000219,,
5400,,,,F,A549,646.0,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,N,,1,,CHEMBL620268,BAO_0000219,,
5401,,,,F,A549,646.0,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,,1,,CHEMBL620269,BAO_0000219,,
5402,,,,F,A549,646.0,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,N,,1,,CHEMBL620270,BAO_0000219,,
5403,,,,F,A549,646.0,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,N,,1,,CHEMBL620271,BAO_0000219,,
5404,,,,F,A549,646.0,,Inhibition of A549 cancer cell proliferation,N,,1,,CHEMBL620272,BAO_0000219,,
5405,,,,F,A549,646.0,,Inhibition of A549 cancer cell proliferation (Not tested),N,,1,,CHEMBL620273,BAO_0000219,,
5406,,,,F,A549,646.0,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,N,,1,,CHEMBL620274,BAO_0000219,,
5407,,,,F,A549,646.0,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,N,,1,,CHEMBL620275,BAO_0000219,,
5408,,,,F,A549,646.0,,Antiproliferative potency determined as inhibitory concentration against A549 cells,N,,1,,CHEMBL620276,BAO_0000219,,
5409,,,,F,A549,646.0,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,N,,1,,CHEMBL620277,BAO_0000219,,
5410,,,,F,A549,646.0,,Cytotoxicity against Renal cell lines A549 was determined,N,,1,,CHEMBL620278,BAO_0000219,,
5411,,,,A,,,,Area under curve was determined in dog after a 3 mg/kg of oral dose,N,,1,,CHEMBL620279,BAO_0000218,,
5412,,,,A,,,,Area under curve was determined in dog after oral administration at 1 mg/kg,N,,1,,CHEMBL620280,BAO_0000218,,
5413,,,,A,,,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,,1,,CHEMBL620281,BAO_0000218,,
5414,,,,A,,,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,,1,,CHEMBL620282,BAO_0000218,,
5415,,,,A,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),N,,1,,CHEMBL621134,BAO_0000218,,
5416,,,,A,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),N,,1,,CHEMBL621135,BAO_0000218,,
5417,,,,A,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),N,,1,,CHEMBL621136,BAO_0000218,,
5418,,,,A,,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),N,,1,,CHEMBL621137,BAO_0000218,,
5419,,,Plasma,A,,,,Area under plasma concentration time curve in dog upon oral administration,N,,1,,CHEMBL621138,BAO_0000218,1969.0,
5420,,,Plasma,A,,,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,N,,1,,CHEMBL875587,BAO_0000218,1969.0,
5421,,,,A,,,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,N,,1,,CHEMBL621139,BAO_0000218,,
5422,,,,A,,,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,N,,1,,CHEMBL621140,BAO_0000218,,
5423,,,,A,,,,Area under the curve for the compound was obtained when tested in dog,N,,1,,CHEMBL621141,BAO_0000218,,
5424,,,,A,,,,Area under the curve at a dose of 1 mg/kg,N,,1,,CHEMBL621142,BAO_0000218,,
5425,,,,A,,,,Area under the curve at a dose of 1 mg/kg (oral),N,,1,,CHEMBL621143,BAO_0000218,,
5426,,,,A,,,,Area under the curve at i.v. dose of 0.2 mg/kg,N,,1,,CHEMBL621144,BAO_0000218,,
5427,,,,A,,,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,N,,1,,CHEMBL621145,BAO_0000218,,
5428,,,,A,,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,N,,1,,CHEMBL621146,BAO_0000218,,
5429,,,,A,,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,N,,1,,CHEMBL622567,BAO_0000218,,
5430,,,,A,,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,N,,1,,CHEMBL622568,BAO_0000218,,
5431,,,,A,,,,Compound was evaluated for area under the curve in dog blood.,N,,1,,CHEMBL622569,BAO_0000218,,
5432,,,,A,,,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,N,,1,,CHEMBL622570,BAO_0000218,,
5433,,,Plasma,A,,,,AUC in dog after oral dose (1 mg/kg),N,,1,,CHEMBL622571,BAO_0000218,1969.0,
5434,,,,A,,,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,N,,1,,CHEMBL622572,BAO_0000218,,
5435,,,,A,,,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",N,,1,,CHEMBL622573,BAO_0000218,,
5436,,,,A,,,,Pharmacokinetic parameter AUC after intravenous administration to dogs,N,,1,,CHEMBL622574,BAO_0000218,,
5437,,,,A,,,,Pharmacokinetic parameter AUC after oral administration to dogs,N,,1,,CHEMBL622575,BAO_0000218,,
5438,,,,A,,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,N,,1,,CHEMBL622576,BAO_0000218,,
5439,,,,A,,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,N,,1,,CHEMBL622577,BAO_0000218,,
5440,,,,A,,,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,N,,1,,CHEMBL622578,BAO_0000218,,
5441,,,,A,,,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,N,,1,,CHEMBL622579,BAO_0000218,,
5442,,,,A,,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",N,,1,,CHEMBL622580,BAO_0000218,,
5443,,,,A,,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",N,,1,,CHEMBL622581,BAO_0000218,,
5444,,,,A,,,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,,1,,CHEMBL622582,BAO_0000218,,
5445,,,,A,,,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,,1,,CHEMBL622583,BAO_0000218,,
5446,,,,A,,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),N,,1,,CHEMBL622584,BAO_0000218,,
5447,,,,A,,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),N,,1,,CHEMBL622585,BAO_0000218,,
5448,,,,A,,,,Compound was evaluated for oral bioavailability in dog; 90-100,N,,1,,CHEMBL622586,BAO_0000218,,
5449,,,,A,,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,N,,1,,CHEMBL623281,BAO_0000218,,
5450,,,,A,,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,N,,1,,CHEMBL623282,BAO_0000218,,
5451,,,,A,,,,PAPP (membrane permeability) in dog kidney cell monolayer assay,N,,1,,CHEMBL623283,BAO_0000218,,
5452,,,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL623284,BAO_0000218,,
5453,,,,A,,,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,N,,1,,CHEMBL623285,BAO_0000218,,
5454,,,Plasma,A,,,,Plasma protein binding towards dog plasma at 10 uM,N,,1,,CHEMBL623463,BAO_0000218,1969.0,
5455,,,Plasma,A,,,,Plasma protein binding towards dog plasma at 100 uM,N,,1,,CHEMBL875952,BAO_0000218,1969.0,
5456,,In vivo,,A,,,,Bioavailability in dog (dose 4 mg/kg p.o.),N,,1,,CHEMBL621705,BAO_0000218,,
5457,,In vivo,,A,,,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,N,,1,,CHEMBL621706,BAO_0000218,,
5458,,In vivo,,A,,,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,N,,1,,CHEMBL621707,BAO_0000218,,
5459,,In vivo,,A,,,,Bioavailability in dogs,N,,1,,CHEMBL621708,BAO_0000218,,
5460,,In vivo,,A,,,,Bioavailability,N,,1,,CHEMBL621709,BAO_0000218,,
5461,,In vivo,,A,,,,Oral bioavailability in dog (dose 10 mg/kg),N,,1,,CHEMBL621710,BAO_0000218,,
5462,,In vivo,,A,,,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,N,,1,,CHEMBL621711,BAO_0000218,,
5463,,In vivo,,A,,,,Bioavailability in dog (dose 10.0 mg/kg p.o.),N,,1,,CHEMBL621712,BAO_0000218,,
5464,,In vivo,,A,,,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,N,,1,,CHEMBL621713,BAO_0000218,,
5465,,In vivo,,A,,,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,N,,1,,CHEMBL621714,BAO_0000218,,
5466,,,,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,1,,CHEMBL621715,BAO_0000218,,
5467,,,Liver,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,1,,CHEMBL623717,BAO_0000218,2107.0,
5468,,,Liver,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,,1,,CHEMBL623718,BAO_0000218,2107.0,
5469,,,Liver,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,1,,CHEMBL623719,BAO_0000218,2107.0,
5470,,,,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,1,,CHEMBL623720,BAO_0000218,,
5471,,,,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,1,,CHEMBL623721,BAO_0000218,,
5472,,,Muscle tissue,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,1,,CHEMBL623722,BAO_0000218,2385.0,
5473,,,Muscle tissue,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,,1,,CHEMBL623723,BAO_0000218,2385.0,
5474,,,Muscle tissue,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,1,,CHEMBL618543,BAO_0000218,2385.0,
5475,,,Spleen,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,1,,CHEMBL618544,BAO_0000218,2106.0,
5476,,,Spleen,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,1,,CHEMBL875155,BAO_0000218,2106.0,
5477,,,,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,1,,CHEMBL618545,BAO_0000218,,
5478,,,,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,,1,,CHEMBL618546,BAO_0000218,,
5479,,,,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,1,,CHEMBL623529,BAO_0000218,,
5480,,,,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,,1,,CHEMBL623530,BAO_0000218,,
5481,,,,A,,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,1,,CHEMBL621764,BAO_0000218,,
5482,,,,A,,,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),U,,1,,CHEMBL621765,BAO_0000019,,
5483,,,Cerebellum,A,,,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),U,,1,,CHEMBL621766,BAO_0000019,2037.0,
5484,,,Frontal cortex,A,,,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),U,,1,,CHEMBL621767,BAO_0000019,1870.0,
5485,,,,A,,,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),U,,1,,CHEMBL621768,BAO_0000019,,
5486,,,Striatum,A,,,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),U,,1,,CHEMBL621769,BAO_0000019,2435.0,
5487,,,,A,,,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),U,,1,,CHEMBL621770,BAO_0000019,,
5488,,,Cerebellum,A,,,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),U,,1,,CHEMBL621771,BAO_0000019,2037.0,
5489,,,Frontal cortex,A,,,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),U,,1,,CHEMBL621772,BAO_0000019,1870.0,
5490,,,,A,,,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),U,,1,,CHEMBL621773,BAO_0000019,,
5491,,,Striatum,A,,,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),U,,1,,CHEMBL621774,BAO_0000019,2435.0,
5492,,,,A,,,,Compound was evaluated for oral bioavailability in rats,U,,1,,CHEMBL621775,BAO_0000218,,
5493,,In vivo,Plasma,A,,,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,U,,1,,CHEMBL621776,BAO_0000218,1969.0,
5494,,,,A,,,,Half life period was evaluated in monkey,U,,1,,CHEMBL621777,BAO_0000019,,
5495,,In vivo,,A,,,,Half-life in rhesus monkeys by intravenous administration of dose,U,,1,,CHEMBL875162,BAO_0000218,,
5496,,,Plasma,A,,,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,N,,1,,CHEMBL621778,BAO_0000218,1969.0,
5497,,,Plasma,A,,,,AUC after intraperitoneal administration of 100 mg/kg in mice,N,,1,,CHEMBL621779,BAO_0000218,1969.0,
5498,,,Plasma,A,,,,AUC value was determined after oral administration,N,,1,,CHEMBL622479,BAO_0000218,1969.0,
5499,,,,A,,,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,N,,1,,CHEMBL622480,BAO_0000218,,
5500,,,,A,,,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),N,,1,,CHEMBL622481,BAO_0000218,,
5501,,,,A,,,,Area under curve by ioral administration in mouse,N,,1,,CHEMBL622482,BAO_0000218,,
5502,,,,A,,,,Area under curve by iv administration in mouse,N,,1,,CHEMBL622483,BAO_0000218,,
5503,,,,A,,,,Area under curve at 0-8 hr in IRC mice after peroral administration,N,,1,,CHEMBL622484,BAO_0000218,,
5504,,,,A,,,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,N,,1,,CHEMBL622641,BAO_0000218,,
5505,,,,A,,,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,N,,1,,CHEMBL622642,BAO_0000218,,
5506,,,,A,,,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,N,,1,,CHEMBL622643,BAO_0000218,,
5507,,,,A,,,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,N,,1,,CHEMBL622644,BAO_0000218,,
5508,,,,F,RPMI-8226,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,N,,1,,CHEMBL622645,BAO_0000219,,
5509,,,,F,RPMI-8226,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,N,,1,,CHEMBL622646,BAO_0000219,,
5510,,,,F,RPMI-8226,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),N,,1,,CHEMBL621238,BAO_0000219,,
5511,,,,F,RPMI-8226,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),N,,1,,CHEMBL621239,BAO_0000219,,
5512,,,,F,RPMI-8226,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),N,,1,,CHEMBL621240,BAO_0000219,,
5513,,,,F,RPMI-8226,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,,1,,CHEMBL621241,BAO_0000219,,
5514,,,,F,RPMI-8226,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),N,,1,,CHEMBL621242,BAO_0000219,,
5515,,,,F,RPMI-8226,741.0,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),N,,1,,CHEMBL620350,BAO_0000219,,
5516,,,,F,RPMI-8226,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,N,,1,,CHEMBL620351,BAO_0000219,,
5517,,,,F,RPMI-8226,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,N,,1,,CHEMBL620352,BAO_0000219,,
5518,,,,F,RPMI-8226,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),N,,1,,CHEMBL620353,BAO_0000219,,
5519,,,,F,RPMI-8226,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),N,,1,,CHEMBL620354,BAO_0000219,,
5520,,,,F,RPMI-8226,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),N,,1,,CHEMBL620355,BAO_0000219,,
5521,,,,F,RPMI-8226,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,,1,,CHEMBL620356,BAO_0000219,,
5522,,,,F,RPMI-8226,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),N,,1,,CHEMBL620357,BAO_0000219,,
5523,,,,F,RPMI-8226,741.0,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),N,,1,,CHEMBL620358,BAO_0000219,,
5524,,,,F,RPMI-8226,741.0,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,N,,1,,CHEMBL620359,BAO_0000219,,
5525,,,,F,RPMI-8226,741.0,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,N,,1,,CHEMBL620360,BAO_0000219,,
5526,,,,F,RPMI-8226,741.0,,Cytotoxicity of compound against 8226/DOX1V cells,N,,1,,CHEMBL620361,BAO_0000219,,
5527,,,,F,RPMI-8226,741.0,,Cytotoxicity of compound against 8226/S cells,N,,1,,CHEMBL620362,BAO_0000219,,
5528,,,,F,RPMI-8226,741.0,,Inhibitory concentration against 8226 myeloma cancer cell line,N,,1,,CHEMBL620363,BAO_0000219,,
5529,,,,F,RPMI-8226,741.0,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,N,,1,,CHEMBL620364,BAO_0000219,,
5530,,,,F,833K,854.0,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,N,,1,,CHEMBL620365,BAO_0000219,,
5531,,,,F,833K,854.0,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',N,,1,,CHEMBL620366,BAO_0000219,,
5532,,,,F,833K,854.0,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,N,,1,,CHEMBL620367,BAO_0000219,,
5533,,,,F,833K,854.0,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,N,,1,,CHEMBL620368,BAO_0000219,,
5534,,,,B,,,,Inhibitory activity against caspase-1,U,,1,,CHEMBL620369,BAO_0000019,,
5535,,,,B,,,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,H,,1,,CHEMBL620370,BAO_0000357,,
5536,,,,F,8701-BC,705.0,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,N,,1,,CHEMBL620371,BAO_0000219,,
5537,,,,F,8701-BC,705.0,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,N,,1,,CHEMBL620372,BAO_0000219,,
5538,,,,F,,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,U,,1,,CHEMBL876492,BAO_0000019,,
5539,,,,F,,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,U,,1,,CHEMBL620373,BAO_0000019,,
5540,,,,F,,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,U,,1,,CHEMBL620374,BAO_0000019,,
5541,,,,B,,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,U,,1,,CHEMBL620375,BAO_0000019,,
5542,,,,F,,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,U,,1,,CHEMBL857902,BAO_0000019,,
5543,,,,F,,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,U,,1,,CHEMBL620376,BAO_0000019,,
5544,,,,B,,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,H,,1,,CHEMBL620377,BAO_0000357,,
5545,,,,F,KB ,324.0,,Tested for in vitro cytotoxic potency of compound in 9KB assay,N,,1,,CHEMBL620378,BAO_0000219,,
5546,,,,A,KB ,324.0,,Tested for in vitro cytotoxic potency of compound in 9KB assay,N,,1,,CHEMBL620379,BAO_0000219,,
5547,,,,F,,,,In vitro cytotoxicity of compound was tested against 9KB cells.,U,,1,,CHEMBL620380,BAO_0000219,,
5548,,,,F,9L,392.0,,Cytotoxic concentration against 9L cells was determined on day 3,N,,1,,CHEMBL884006,BAO_0000219,,
5549,,,,F,9L,392.0,,Tested in vitro for anticancer activity against 9L cells,N,,1,,CHEMBL620381,BAO_0000219,,
5550,,,,F,9L,392.0,,Tested in vitro for anticancer activity against 9L cells; Not determined,N,,1,,CHEMBL620382,BAO_0000219,,
5551,,,,F,A549,646.0,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,N,,1,,CHEMBL620383,BAO_0000219,,
5552,,,,F,A549,646.0,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,N,,1,,CHEMBL876493,BAO_0000219,,
5553,,,,F,A549,646.0,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,N,,1,,CHEMBL620384,BAO_0000219,,
5554,,,,F,A549,646.0,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,N,,1,,CHEMBL620385,BAO_0000219,,
5555,,,,F,A549,646.0,,Cytotoxicity against human lung carcinoma A549 cell line,N,,1,,CHEMBL620386,BAO_0000219,,
5556,,,,F,A549,646.0,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,D,,1,,CHEMBL620387,BAO_0000219,,
5557,,,,F,A549,646.0,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",D,,1,,CHEMBL621404,BAO_0000219,,
5558,,,,F,A549,646.0,,"In vitro growth inhibition of A549, lung carcinoma",N,,1,,CHEMBL621405,BAO_0000219,,
5559,,,,F,A549,646.0,,"In vitro growth inhibition of A549, lung carcinoma.",N,,1,,CHEMBL621406,BAO_0000219,,
5560,,,,F,A549,646.0,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,N,,1,,CHEMBL621407,BAO_0000219,,
5561,,,,F,A549,646.0,,Cytotoxic activity against human lung cancer A549 cell line was determined,N,,1,,CHEMBL621408,BAO_0000219,,
5562,,,,F,A549,646.0,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,N,,1,,CHEMBL885345,BAO_0000219,,
5563,,,,F,A549,646.0,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,N,,1,,CHEMBL621409,BAO_0000219,,
5564,,,,F,A549,646.0,,Cytotoxicity in A549 (human carcinoma) cell line.,N,,1,,CHEMBL876034,BAO_0000219,,
5565,,,,F,A549,646.0,,Cytotoxicity on lung carcinoma (A-549) cell line,N,,1,,CHEMBL621410,BAO_0000219,,
5566,,,,F,A549,646.0,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,N,,1,,CHEMBL621411,BAO_0000219,,
5567,,,,F,A549,646.0,,Effective dose of compound against replication of A549 cell line was evaluated,N,,1,,CHEMBL621412,BAO_0000219,,
5568,,,,F,A549,646.0,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,N,,1,,CHEMBL621413,BAO_0000219,,
5569,,,,F,A549,646.0,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),N,,1,,CHEMBL621414,BAO_0000219,,
5570,,,,F,A549,646.0,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,N,,1,,CHEMBL621415,BAO_0000219,,
5571,,,,F,A549,646.0,,The compound was evaluated for antiproliferative activity against A549 cell line,N,,1,,CHEMBL621416,BAO_0000219,,
5572,,,,F,A549,646.0,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,N,,1,,CHEMBL621417,BAO_0000219,,
5573,,,,F,A549,646.0,,Concentration required for growth inhibition of human lung carcinoma cell line A549,N,,1,,CHEMBL621418,BAO_0000219,,
5574,,,,F,A549,646.0,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,N,,1,,CHEMBL621419,BAO_0000219,,
5575,,,,F,A549,646.0,,Growth inhibition against A549 cell line was evaluated,N,,1,,CHEMBL621420,BAO_0000219,,
5576,,,,F,A549,646.0,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,N,,1,,CHEMBL875823,BAO_0000219,,
5577,,,,F,A549,646.0,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,N,,1,,CHEMBL621421,BAO_0000219,,
5578,,,,F,A549,646.0,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,N,,1,,CHEMBL621422,BAO_0000219,,
5579,,,,F,A549,646.0,,Chemosensitivity against DT-diaphorase rich A549 cell lines,N,,1,,CHEMBL884014,BAO_0000219,,
5580,,,,F,A549,646.0,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,N,,1,,CHEMBL621423,BAO_0000219,,
5581,,,,F,A549,646.0,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,N,,1,,CHEMBL621424,BAO_0000219,,
5582,,,,F,A549,646.0,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,N,,1,,CHEMBL621425,BAO_0000219,,
5583,,,,F,A549,646.0,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,N,,1,,CHEMBL621426,BAO_0000219,,
5584,,,,F,A549,646.0,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,N,,1,,CHEMBL621427,BAO_0000219,,
5585,,,,F,A549,646.0,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,N,,1,,CHEMBL621428,BAO_0000219,,
5586,,,,F,A549,646.0,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,N,,1,,CHEMBL621429,BAO_0000219,,
5587,,,,F,A549,646.0,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),N,,1,,CHEMBL621430,BAO_0000219,,
5588,,,,F,A549,646.0,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,N,,1,,CHEMBL621431,BAO_0000219,,
5589,,,,F,A549,646.0,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,N,,1,,CHEMBL621432,BAO_0000219,,
5590,,,,F,A549,646.0,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,N,,1,,CHEMBL621433,BAO_0000219,,
5591,,,,F,A549,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,N,,1,,CHEMBL875824,BAO_0000219,,
5592,,,,F,A549,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,N,,1,,CHEMBL621434,BAO_0000219,,
5593,,,,F,A549,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,N,,1,,CHEMBL621435,BAO_0000219,,
5594,,,,F,A549,646.0,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,N,,1,,CHEMBL621436,BAO_0000219,,
5595,,,,F,A549,646.0,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,N,,1,,CHEMBL621437,BAO_0000219,,
5596,,,,F,A549,646.0,,Compound was tested for the growth inhibition of A549 lung tumor cell line,N,,1,,CHEMBL621438,BAO_0000219,,
5597,,,,F,A549,646.0,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,N,,1,,CHEMBL621439,BAO_0000219,,
5598,,,,F,A549,646.0,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,N,,1,,CHEMBL621440,BAO_0000219,,
5599,,In vivo,,A,,,,Oral bioavailability in dog (conscious),N,,1,,CHEMBL621441,BAO_0000218,,
5600,,In vivo,,A,,,,Compound was evaluated for the oral bioavailability after oral administration in dog.,N,,1,,CHEMBL621442,BAO_0000218,,
5601,,In vivo,,A,,,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,N,,1,,CHEMBL621443,BAO_0000218,,
5602,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL621444,BAO_0000218,,
5603,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL625133,BAO_0000218,,
5604,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL625134,BAO_0000218,,
5605,,In vivo,,A,,,,Oral bioavailability in dog (fasted),N,,1,,CHEMBL625135,BAO_0000218,,
5606,,In vivo,,A,,,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,N,,1,,CHEMBL625136,BAO_0000218,,
5607,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL625137,BAO_0000218,,
5608,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL625138,BAO_0000218,,
5609,,In vivo,,A,,,,Percent bioavailability in dog,N,,1,,CHEMBL625139,BAO_0000218,,
5610,,In vivo,,A,,,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,N,,1,,CHEMBL872264,BAO_0000218,,
5611,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL625140,BAO_0000218,,
5612,,In vivo,,A,,,,The compound was evaluated for bioavailability in dogs; 34-44,N,,1,,CHEMBL624436,BAO_0000218,,
5613,,In vivo,,A,,,,Bioavailability in dog (dose 4 mg/kg p.o.),N,,1,,CHEMBL624437,BAO_0000218,,
5614,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL872261,BAO_0000218,,
5615,,,,A,,,,8 hour trough Blood level in dog was measured after administration of compound,N,,1,,CHEMBL624438,BAO_0000218,,
5616,,In vivo,Plasma,A,,,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,N,,1,,CHEMBL624439,BAO_0000218,1969.0,
5617,,,,A,,,,C24 after oral administration at 5 mg/kg,N,,1,,CHEMBL624440,BAO_0000218,,
5618,,,,A,,,,Clearance after oral and iv dosing in dogs,N,,1,,CHEMBL624441,BAO_0000218,,
5619,,,Plasma,A,,,,Clearance of the drug was measured in the plasma of dog,N,,1,,CHEMBL624442,BAO_0000218,1969.0,
5620,,,,A,,,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,N,,1,,CHEMBL624443,BAO_0000218,,
5621,,In vivo,,A,,,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,N,,1,,CHEMBL624444,BAO_0000218,,
5622,,In vivo,,A,,,,Clearance of compound was determined in dogs,N,,1,,CHEMBL624445,BAO_0000218,,
5623,,In vivo,,A,,,,Clearance on i.v. administration of 2 mg/kg was measured in dog,N,,1,,CHEMBL624446,BAO_0000218,,
5624,,In vivo,,A,,,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,,1,,CHEMBL624447,BAO_0000218,,
5625,,In vivo,,A,,,,Plasma clearance in dog was determined,N,,1,,CHEMBL624448,BAO_0000218,,
5626,,In vivo,,A,,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,,1,,CHEMBL624449,BAO_0000218,,
5627,,In vivo,,A,,,,Plasma clearance in dog after administration of 0.25 mg/kg iv,N,,1,,CHEMBL624450,BAO_0000218,,
5628,,In vivo,,A,,,,Plasma clearance in dog after administration of 1 mg/kg iv,N,,1,,CHEMBL875942,BAO_0000218,,
5629,,In vivo,,A,,,,Plasma clearance in dogs,N,,1,,CHEMBL624451,BAO_0000218,,
5630,,In vivo,,A,,,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,N,,1,,CHEMBL624452,BAO_0000218,,
5631,,In vivo,,A,,,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,N,,1,,CHEMBL624453,BAO_0000218,,
5632,,In vivo,,A,,,,Plasma clearance after 15 mg/kg iv dose in Dogs,N,,1,,CHEMBL624454,BAO_0000218,,
5633,,In vivo,,A,,,,Plasma clearance after 30 mg/kg po dose in Dogs,N,,1,,CHEMBL624455,BAO_0000218,,
5634,,In vivo,,A,,,,Plasma administration to dogs,N,,1,,CHEMBL624456,BAO_0000218,,
5635,,In vivo,,A,,,,Plasma clearance was determined,N,,1,,CHEMBL624457,BAO_0000218,,
5636,,In vivo,,A,,,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,N,,1,,CHEMBL624458,BAO_0000218,,
5637,,In vivo,,A,,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,N,,1,,CHEMBL624459,BAO_0000218,,
5638,Microsomes,In vitro,Liver,A,,,,Intrinsic clearance in human liver microsomes,S,,1,,CHEMBL624460,BAO_0000251,2107.0,
5639,Microsomes,In vitro,Liver,A,,,,Intrinsic clearance in human liver microsomes,S,,1,,CHEMBL624461,BAO_0000251,2107.0,
5640,,In vivo,,A,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,N,,1,,CHEMBL875943,BAO_0000218,,
5641,,In vivo,,A,,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,N,,1,,CHEMBL624462,BAO_0000218,,
5642,,In vivo,,A,,,,Clearance in dog (dose 1 mg/kg i.v.),N,,1,,CHEMBL624463,BAO_0000218,,
5643,,In vivo,,A,,,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,N,,1,,CHEMBL624464,BAO_0000218,,
5644,,In vivo,,A,,,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,,1,,CHEMBL624465,BAO_0000218,,
5645,,In vivo,,A,,,,Plasma clearance after peroral administration at 10 mpk in dog,N,,1,,CHEMBL624466,BAO_0000218,,
5646,,In vivo,,A,,,,Plasma clearance after peroral administration at 5 mpk in dog,N,,1,,CHEMBL624467,BAO_0000218,,
5647,,In vivo,,A,,,,Plasma clearance after peroral administration at 5 mg/kg in dog,N,,1,,CHEMBL624468,BAO_0000218,,
5648,,In vivo,,A,,,,Plasma clearance was measured in dog,N,,1,,CHEMBL624469,BAO_0000218,,
5649,,In vivo,,A,,,,Plasma clearance was measured in dog,N,,1,,CHEMBL624470,BAO_0000218,,
5650,,In vivo,,A,,,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,N,,1,,CHEMBL624471,BAO_0000218,,
5651,,In vivo,,A,,,,Total clearance was determined after 0.1 mg/kg iv administration in dog,N,,1,,CHEMBL624472,BAO_0000218,,
5652,,In vivo,,A,,,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,N,,1,,CHEMBL622775,BAO_0000218,,
5653,,In vivo,,A,,,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,N,,1,,CHEMBL622776,BAO_0000218,,
5654,,In vivo,,A,,,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,N,,1,,CHEMBL622777,BAO_0000218,,
5655,,In vivo,,A,,,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,N,,1,,CHEMBL622778,BAO_0000218,,
5656,,In vivo,,A,,,,Clearance by intravenous administration of 1.2 mg/kg in dog,N,,1,,CHEMBL622779,BAO_0000218,,
5657,,In vivo,,A,,,,Clearance by iv administration in dogs at a dose of 1 mg/kg,N,,1,,CHEMBL622780,BAO_0000218,,
5658,,In vivo,Plasma,A,,,,Clearance value was evaluated in dog plasma,N,,1,,CHEMBL622781,BAO_0000218,1969.0,
5659,,In vivo,,A,,,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,N,,1,,CHEMBL622782,BAO_0000218,,
5660,,In vivo,Plasma,A,,,,Compound was tested for plasma clearance in dog,N,,1,,CHEMBL622783,BAO_0000218,1969.0,
5661,,In vivo,,A,,,,Pharmacokinetic property (Plasma clearance) was measured in dog,N,,1,,CHEMBL622784,BAO_0000218,,
5662,,,,A,,,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,N,,1,,CHEMBL622785,BAO_0000218,,
5663,,,,A,,,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,N,,1,,CHEMBL622786,BAO_0000218,,
5664,,,,A,,,,Area under curve value in mouse at a dose of 10 mg/kg,N,,1,,CHEMBL622787,BAO_0000218,,
5665,,,,A,,,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,N,,1,,CHEMBL875949,BAO_0000218,,
5666,,,,A,,,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,N,,1,,CHEMBL622788,BAO_0000218,,
5667,,,,F,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,N,,1,,CHEMBL622789,BAO_0000218,,
5668,,,,F,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,N,,1,,CHEMBL622790,BAO_0000218,,
5669,,,,F,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,N,,1,,CHEMBL622791,BAO_0000218,,
5670,,,,F,,,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,N,,1,,CHEMBL622792,BAO_0000218,,
5671,,,,A,,,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,N,,1,,CHEMBL622793,BAO_0000218,,
5672,,,,A,,,,Area under curve was determined for the compound at 24 mg/Kg,N,,1,,CHEMBL622794,BAO_0000218,,
5673,,,,A,,,,Area under curve was determined for the compound at 40 mg/Kg,N,,1,,CHEMBL622795,BAO_0000218,,
5674,,,,A,,,,Area under curve was determined for the compound at 5 mg/Kg,N,,1,,CHEMBL621803,BAO_0000218,,
5675,,,,A,,,,Area under the curve for the compound is obtained at dose 25 mg/kg,N,,1,,CHEMBL621804,BAO_0000218,,
5676,,,,A,,,,Area under the curve for the compound was obtained when tested in mouse,N,,1,,CHEMBL621805,BAO_0000218,,
5677,,,,A,,,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,N,,1,,CHEMBL621806,BAO_0000218,,
5678,,,,A,,,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,N,,1,,CHEMBL621807,BAO_0000218,,
5679,,,,A,,,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,N,,1,,CHEMBL621808,BAO_0000218,,
5680,,,,A,,,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,N,,1,,CHEMBL621809,BAO_0000218,,
5681,,,,A,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),N,,1,,CHEMBL621810,BAO_0000218,,
5682,,,,A,,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,N,,1,,CHEMBL875164,BAO_0000218,,
5683,,,,A,,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,N,,1,,CHEMBL621811,BAO_0000218,,
5684,,,,A,,,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",N,,1,,CHEMBL621812,BAO_0000218,,
5685,,,,A,,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),N,,1,,CHEMBL621813,BAO_0000218,,
5686,,,,A,,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),N,,1,,CHEMBL621814,BAO_0000218,,
5687,,,,A,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,N,,1,,CHEMBL621815,BAO_0000218,,
5688,,,,A,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,N,,1,,CHEMBL621816,BAO_0000218,,
5689,,,,A,,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,N,,1,,CHEMBL621817,BAO_0000218,,
5690,,,,A,,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,N,,1,,CHEMBL621818,BAO_0000218,,
5691,,,,A,,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,N,,1,,CHEMBL621819,BAO_0000218,,
5692,,,,A,,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,N,,1,,CHEMBL621820,BAO_0000218,,
5693,,,,A,,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,N,,1,,CHEMBL621821,BAO_0000218,,
5694,,,,A,,,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,N,,1,,CHEMBL621822,BAO_0000218,,
5695,,,,A,,,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,N,,1,,CHEMBL619474,BAO_0000218,,
5696,,,,A,,,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",N,,1,,CHEMBL619475,BAO_0000218,,
5697,,,,A,,,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",N,,1,,CHEMBL619476,BAO_0000218,,
5698,,,,A,,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",N,,1,,CHEMBL619477,BAO_0000218,,
5699,,,,A,,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",N,,1,,CHEMBL619478,BAO_0000218,,
5700,,,,A,,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",N,,1,,CHEMBL619479,BAO_0000218,,
5701,,,,A,,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",N,,1,,CHEMBL619480,BAO_0000218,,
5702,,,,A,,,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,N,,1,,CHEMBL619481,BAO_0000218,,
5703,,,,A,,,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,N,,1,,CHEMBL619482,BAO_0000218,,
5704,,,,A,,,,Area under the curve was evaluated in mice after intravenous administration,N,,1,,CHEMBL619483,BAO_0000218,,
5705,,,,A,,,,Area under the curve was evaluated in mice after oral administration,N,,1,,CHEMBL619484,BAO_0000218,,
5706,,,Plasma,A,,,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,N,,1,,CHEMBL619485,BAO_0000218,1969.0,
5707,,,Plasma,A,,,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,N,,1,,CHEMBL619486,BAO_0000218,1969.0,
5708,,,,A,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),N,,1,,CHEMBL619487,BAO_0000218,,
5709,,,,A,,,,AUMC after intraperitoneal administration of 100 mg/kg in mice,N,,1,,CHEMBL619488,BAO_0000218,,
5710,,In vivo,Blood,A,,,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,N,,1,,CHEMBL620106,BAO_0000218,178.0,
5711,,,,F,9L,392.0,,The compound was tested in vitro for anticancer activity against 9L cells,N,,1,,CHEMBL620107,BAO_0000219,,
5712,,,,F,,,,Anti proliferation activity determined; Weak effect,U,,1,,CHEMBL620283,BAO_0000019,,
5713,,,,F,,,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,U,,1,,CHEMBL875176,BAO_0000219,,
5714,,,,F,,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,U,,1,,CHEMBL620284,BAO_0000219,,
5715,,,,F,,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,U,,1,,CHEMBL623515,BAO_0000219,,
5716,,,,F,,,,The cytotoxic activity was in vitro tested by 9PS assay method,U,,1,,CHEMBL623516,BAO_0000019,,
5717,,,,F,,,,The cytotoxic activity was in vitro tested by 9PS assay method.,U,,1,,CHEMBL623517,BAO_0000019,,
5718,,,,A,,,,Partition coefficient (logD6.5),U,,1,,CHEMBL857878,BAO_0000019,,
5719,,,,F,A2780,478.0,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,N,,1,,CHEMBL623518,BAO_0000219,,
5720,,,,F,A-375,455.0,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),N,,1,,CHEMBL624195,BAO_0000219,,
5721,,,,F,A-431,500.0,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,N,,1,,CHEMBL624196,BAO_0000219,,
5722,,,,F,A-431,500.0,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,D,,1,,CHEMBL624197,BAO_0000219,,
5723,,,,F,A498,624.0,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,N,,1,,CHEMBL624198,BAO_0000219,,
5724,,,,F,A498,624.0,,in vitro cytotoxicity against A 498 cancer cell line,N,,1,,CHEMBL621287,BAO_0000219,,
5725,,,,F,A498,624.0,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,N,,1,,CHEMBL621288,BAO_0000219,,
5726,,,,F,A498,624.0,,Cytotoxic activity against A 498 renal cancer cell lines.,N,,1,,CHEMBL876496,BAO_0000219,,
5727,,,,F,A498,624.0,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,N,,1,,CHEMBL621289,BAO_0000219,,
5728,,,,F,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,U,,1,,CHEMBL621290,BAO_0000019,,
5729,,,,F,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,U,,1,,CHEMBL621291,BAO_0000019,,
5730,,,,F,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,U,,1,,CHEMBL621292,BAO_0000019,,
5731,,,,F,,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,U,,1,,CHEMBL621293,BAO_0000019,,
5732,,,,F,A549,646.0,,Inhibitory concentration required against A 549 lung cancer cell line,N,,1,,CHEMBL621294,BAO_0000219,,
5733,,,,F,A549,646.0,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,N,,1,,CHEMBL621295,BAO_0000219,,
5734,,,,F,A549,646.0,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,N,,1,,CHEMBL884007,BAO_0000219,,
5735,,,,F,A549,646.0,,In vitro cytotoxicity against lung cancer A 549 cell lines,N,,1,,CHEMBL621296,BAO_0000219,,
5736,,,,F,A549,646.0,,Compound was tested for its cytotoxicity against A 549 cell line,N,,1,,CHEMBL621297,BAO_0000219,,
5737,,,,F,A549,646.0,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",N,,1,,CHEMBL839828,BAO_0000219,,
5738,,,,F,A549,646.0,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",N,,1,,CHEMBL620397,BAO_0000219,,
5739,,,,F,A549,646.0,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,N,,1,,CHEMBL620398,BAO_0000219,,
5740,,,,F,A549,646.0,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,N,,1,,CHEMBL620399,BAO_0000219,,
5741,,,,F,A549,646.0,,In vitro inhibition of A549 (human lung cancer) cell growth.,N,,1,,CHEMBL620400,BAO_0000219,,
5742,,,,F,A549,646.0,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,N,,1,,CHEMBL620401,BAO_0000219,,
5743,,,,F,A549,646.0,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,N,,1,,CHEMBL620402,BAO_0000219,,
5744,,,,F,A549,646.0,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),N,,1,,CHEMBL620403,BAO_0000219,,
5745,,,,F,,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,U,,1,,CHEMBL620404,BAO_0000218,,
5746,,In vivo,,F,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,H,,1,,CHEMBL620405,BAO_0000218,,
5747,,In vivo,,F,,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,H,,1,,CHEMBL620406,BAO_0000218,,
5748,,In vivo,,F,,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,H,,1,,CHEMBL620407,BAO_0000218,,
5749,,In vivo,,F,,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,H,,1,,CHEMBL620408,BAO_0000218,,
5750,,In vivo,,F,,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,H,,1,,CHEMBL620409,BAO_0000218,,
5751,,,,F,A498,624.0,,Inhibition of A-498 human Renal cell proliferation,N,,1,,CHEMBL620410,BAO_0000219,,
5752,,,,F,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",U,,1,,CHEMBL620411,BAO_0000019,,
5753,,,,F,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",U,,1,,CHEMBL620412,BAO_0000019,,
5754,,,,F,,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",U,,1,,CHEMBL876596,BAO_0000019,,
5755,,,,F,A 172,622.0,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,N,,1,,CHEMBL620413,BAO_0000219,,
5756,,,,F,A 172,622.0,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,,1,,CHEMBL620414,BAO_0000219,,
5757,,,,F,A 172,622.0,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,,1,,CHEMBL620415,BAO_0000219,,
5758,,,,F,A549,646.0,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,N,,1,,CHEMBL620416,BAO_0000219,,
5759,,,,F,A549,646.0,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,N,,1,,CHEMBL620417,BAO_0000219,,
5760,,,,F,A549,646.0,,Cytotoxic activity evaluated against A549 tumor cells,N,,1,,CHEMBL620418,BAO_0000219,,
5761,,,,F,A549,646.0,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,N,,1,,CHEMBL620419,BAO_0000219,,
5762,,,,F,A549,646.0,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,N,,1,,CHEMBL620420,BAO_0000219,,
5763,,,,F,A549,646.0,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,N,,1,,CHEMBL620421,BAO_0000219,,
5764,,,,F,A549,646.0,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,N,,1,,CHEMBL620422,BAO_0000219,,
5765,,,,F,A549,646.0,,Cytotoxicity of compound against A549 cell line,N,,1,,CHEMBL620423,BAO_0000219,,
5766,,,,F,A549,646.0,,Cytotoxicity against human lung cell carcinoma A549 cell line,N,,1,,CHEMBL620424,BAO_0000219,,
5767,,,,F,A549,646.0,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,N,,1,,CHEMBL620425,BAO_0000219,,
5768,,,,F,A549,646.0,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,N,,1,,CHEMBL620426,BAO_0000219,,
5769,,,,F,A549,646.0,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,N,,1,,CHEMBL620427,BAO_0000219,,
5770,,,,F,A549,646.0,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,N,,1,,CHEMBL620428,BAO_0000219,,
5771,,,,F,A549,646.0,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,N,,1,,CHEMBL620429,BAO_0000219,,
5772,,,,F,A549,646.0,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,N,,1,,CHEMBL620430,BAO_0000219,,
5773,,,,F,A549,646.0,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,N,,1,,CHEMBL839887,BAO_0000219,,
5774,,,,F,A549,646.0,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,N,,1,,CHEMBL620431,BAO_0000219,,
5775,,,,F,A549,646.0,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,N,,1,,CHEMBL884010,BAO_0000219,,
5776,,,,F,A549,646.0,,In vitro cytotoxicity against A549 (human lung cancer),N,,1,,CHEMBL620538,BAO_0000219,,
5777,,,,F,A549,646.0,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,N,,1,,CHEMBL620539,BAO_0000219,,
5778,,,,F,A549,646.0,,In vivo antiproliferative activity against A549 cell line,N,,1,,CHEMBL623373,BAO_0000218,,
5779,,,,F,A549,646.0,,Inhibition of non-small-cell lung adenocarcinoma (A549),N,,1,,CHEMBL623374,BAO_0000219,,
5780,,,,F,A549,646.0,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,N,,1,,CHEMBL623375,BAO_0000219,,
5781,,,,F,A549,646.0,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,N,,1,,CHEMBL623376,BAO_0000219,,
5782,,,,F,A549,646.0,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),N,,1,,CHEMBL623377,BAO_0000219,,
5783,,,,F,A549,646.0,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,N,,1,,CHEMBL623378,BAO_0000219,,
5784,,,,F,A549,646.0,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,N,,1,,CHEMBL623379,BAO_0000219,,
5785,,,,F,A549,646.0,,Inhibitory activity against A549 lung cancer cell line,N,,1,,CHEMBL623380,BAO_0000219,,
5786,,,,F,A549,646.0,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,N,,1,,CHEMBL623381,BAO_0000219,,
5787,,,,F,A549,646.0,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,N,,1,,CHEMBL623382,BAO_0000219,,
5788,,,,F,A549,646.0,,Inhibitory concentration against A549 (lung cancer) cell line,N,,1,,CHEMBL623383,BAO_0000219,,
5789,,,,F,A549,646.0,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,N,,1,,CHEMBL623384,BAO_0000219,,
5790,,,,F,A549,646.0,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,N,,1,,CHEMBL623385,BAO_0000219,,
5791,,,,F,A549,646.0,,Activity against A549 cancer cell line.,N,,1,,CHEMBL623386,BAO_0000219,,
5792,,,,F,A549,646.0,,The compound was evaluated for cytotoxicity against A549 cell line,N,,1,,CHEMBL884105,BAO_0000219,,
5793,,,,F,A549,646.0,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,N,,1,,CHEMBL623387,BAO_0000219,,
5794,,,,F,A549,646.0,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,N,,1,,CHEMBL621568,BAO_0000219,,
5795,,,,F,A549,646.0,,Growth inhibitory activity was measured for human A549 tumor cell line.,N,,1,,CHEMBL621569,BAO_0000219,,
5796,,,,F,A549,646.0,,Inhibitory activity against A549 lung cancer cell line,N,,1,,CHEMBL621570,BAO_0000219,,
5797,,,,F,A549,646.0,,Inhibitory activity against A549 cell line; inactive,N,,1,,CHEMBL621571,BAO_0000219,,
5798,,,,F,A549,646.0,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,N,,1,,CHEMBL621572,BAO_0000219,,
5799,,,,F,A549,646.0,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,N,,1,,CHEMBL621573,BAO_0000219,,
5800,,,,F,A549,646.0,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,N,,1,,CHEMBL621574,BAO_0000219,,
5801,,,,F,A549,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),N,,1,,CHEMBL621575,BAO_0000219,,
5802,,,,F,A549,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),N,,1,,CHEMBL621576,BAO_0000219,,
5803,,,,F,A549,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),N,,1,,CHEMBL621577,BAO_0000219,,
5804,,,,F,A549,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),N,,1,,CHEMBL621578,BAO_0000219,,
5805,,,,F,A549,646.0,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),N,,1,,CHEMBL621579,BAO_0000219,,
5806,,,,F,A549,646.0,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,N,,1,,CHEMBL621580,BAO_0000219,,
5807,,In vivo,,A,,,,Plasma clearance (in vivo) in mongrel dogs was determined,N,,1,,CHEMBL621581,BAO_0000218,,
5808,,In vivo,,A,,,,Plasma clearance was measured in dog,N,,1,,CHEMBL621582,BAO_0000218,,
5809,,In vivo,,A,,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,N,,1,,CHEMBL621583,BAO_0000218,,
5810,,In vivo,,A,,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,N,,1,,CHEMBL621584,BAO_0000218,,
5811,,In vivo,Plasma,A,,,,Tested for plasma clearance in dog,N,,1,,CHEMBL621585,BAO_0000218,1969.0,
5812,,In vivo,,A,,,,The compound was tested for clearance in dog plasma.,N,,1,,CHEMBL621586,BAO_0000218,,
5813,,In vivo,,A,,,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",N,,1,,CHEMBL875835,BAO_0000218,,
5814,,In vivo,,A,,,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,N,,1,,CHEMBL621587,BAO_0000218,,
5815,,In vivo,Plasma,A,,,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),N,,1,,CHEMBL621588,BAO_0000218,1969.0,
5816,Microsomes,In vitro,Liver,A,,,,In vitro clearance in dog liver microsomes,N,,1,,CHEMBL621589,BAO_0000218,2107.0,
5817,,In vivo,,A,,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,N,,1,,CHEMBL621590,BAO_0000218,,
5818,,In vivo,,A,,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,N,,1,,CHEMBL621591,BAO_0000218,,
5819,,In vivo,,A,,,,Plasma clearance in dog,N,,1,,CHEMBL621592,BAO_0000218,,
5820,,In vivo,,A,,,,Clearance rate in dog,N,,1,,CHEMBL621593,BAO_0000218,,
5821,,In vivo,Plasma,A,,,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,N,,1,,CHEMBL621594,BAO_0000218,1969.0,
5822,,In vivo,,A,,,,Clearance in dogs,N,,1,,CHEMBL621595,BAO_0000218,,
5823,,In vivo,,A,,,,Plasma clearance in dogs,N,,1,,CHEMBL621596,BAO_0000218,,
5824,,In vivo,,A,,,,Plasma clearance was determined,N,,1,,CHEMBL621597,BAO_0000218,,
5825,,In vivo,,A,,,,Lower clearance in dog (i.v.) at 0.5 mpk,N,,1,,CHEMBL621598,BAO_0000218,,
5826,,In vivo,,A,,,,Plasma clearance in Beagle dogs,N,,1,,CHEMBL621599,BAO_0000218,,
5827,,In vivo,,A,,,,Plasma clearance (Clp) in dog,N,,1,,CHEMBL875836,BAO_0000218,,
5828,,In vivo,,A,,,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,N,,1,,CHEMBL621600,BAO_0000218,,
5829,,In vivo,,A,,,,Plasma clearance (pharmacokinetic parameter) in dog was determined,N,,1,,CHEMBL621601,BAO_0000218,,
5830,,In vivo,,A,,,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,N,,1,,CHEMBL618474,BAO_0000218,,
5831,,In vivo,,A,,,,Plasma clearance of compound was determined in dog,N,,1,,CHEMBL618475,BAO_0000218,,
5832,,In vivo,,A,,,,Plasma clearance after intravenous administration of 1 mg/kg in dog,N,,1,,CHEMBL624524,BAO_0000218,,
5833,,In vivo,,A,,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,N,,1,,CHEMBL624525,BAO_0000218,,
5834,,In vivo,,A,,,,Plasma clearance in dog was determined,N,,1,,CHEMBL624526,BAO_0000218,,
5835,,In vivo,,A,,,,Plasma clearance was calculated in dog,N,,1,,CHEMBL624527,BAO_0000218,,
5836,,In vivo,,A,,,,Plasma clearance at the dose of 2 mg/kg in dog,N,,1,,CHEMBL624528,BAO_0000218,,
5837,,In vivo,,A,,,,Plasma clearance in dog,N,,1,,CHEMBL624529,BAO_0000218,,
5838,,In vivo,,A,,,,Plasma clearance in dog,N,,1,,CHEMBL624530,BAO_0000218,,
5839,,In vivo,,A,,,,Plasma clearance in dog; Unable to calculate,N,,1,,CHEMBL624531,BAO_0000218,,
5840,,In vivo,,A,,,,Plasma clearance in rhesus monkey,N,,1,,CHEMBL624532,BAO_0000218,,
5841,,In vivo,,A,,,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,,1,,CHEMBL624533,BAO_0000218,,
5842,,In vivo,,A,,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,,1,,CHEMBL624534,BAO_0000218,,
5843,,In vivo,,A,,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,,1,,CHEMBL624535,BAO_0000218,,
5844,,In vivo,,A,,,,Plasma clearance was evaluated in dog,N,,1,,CHEMBL624536,BAO_0000218,,
5845,,In vivo,,A,,,,Plasma clearance was evaluated in dog; Not tested,N,,1,,CHEMBL624537,BAO_0000218,,
5846,,In vivo,,A,,,,Plasma clearance was evaluated in rhesus,N,,1,,CHEMBL624538,BAO_0000218,,
5847,,In vivo,,A,,,,Plasma clearance was evaluated in rhesus; Not tested,N,,1,,CHEMBL624539,BAO_0000218,,
5848,,In vivo,,A,,,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,N,,1,,CHEMBL624540,BAO_0000218,,
5849,,In vivo,,A,,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,1,,CHEMBL624541,BAO_0000218,,
5850,,In vivo,,A,,,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,N,,1,,CHEMBL624542,BAO_0000218,,
5851,,In vivo,,A,,,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,,1,,CHEMBL624543,BAO_0000218,,
5852,,In vivo,,A,,,,Clearance value at a dose of 0.2 mg/kg i.v.,N,,1,,CHEMBL624544,BAO_0000218,,
5853,,In vivo,Plasma,A,,,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,N,,1,,CHEMBL624545,BAO_0000218,1969.0,
5854,,In vivo,,A,,,,Cmax after oral dose of compound at 3 mg/kg in dogs,N,,1,,CHEMBL624546,BAO_0000218,,
5855,,In vivo,,A,,,,Cmax after single intravenous bolus of 1 mg/kg in dogs,N,,1,,CHEMBL875957,BAO_0000218,,
5856,,In vivo,,A,,,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,,1,,CHEMBL624547,BAO_0000218,,
5857,,In vivo,,A,,,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,N,,1,,CHEMBL624548,BAO_0000218,,
5858,,In vivo,,A,,,,Cmax in dog after administration of 1 mg/kg iv,N,,1,,CHEMBL624549,BAO_0000218,,
5859,,In vivo,Plasma,A,,,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,N,,1,,CHEMBL624550,BAO_0000218,1969.0,
5860,,In vivo,,A,,,,Cmax on p.o. administration of 10 mg/kg was measured in dog,N,,1,,CHEMBL621613,BAO_0000218,,
5861,,In vivo,,A,,,,Cmax was determine after peroral administration at 10 mpk in dog,N,,1,,CHEMBL621614,BAO_0000218,,
5862,,In vivo,,A,,,,Cmax was determine after peroral administration at 5 mpk in dog,N,,1,,CHEMBL623431,BAO_0000218,,
5863,,In vivo,,A,,,,Cmax was determine after peroral administration at 5 mg/kg in dog,N,,1,,CHEMBL623432,BAO_0000218,,
5864,,In vivo,,A,,,,Cmax after 0.3 mg/kg po administration in dog,N,,1,,CHEMBL623433,BAO_0000218,,
5865,,In vivo,,A,,,,Cmax after peroral administration in dogs at 2.4 uM/kg,N,,1,,CHEMBL623434,BAO_0000218,,
5866,,In vivo,,A,,,,Cmax in dog after oral administration at 1 mg/kg,N,,1,,CHEMBL623435,BAO_0000218,,
5867,,In vivo,,A,,,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,N,,1,,CHEMBL623436,BAO_0000218,,
5868,,In vivo,,A,,,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,N,,1,,CHEMBL875958,BAO_0000218,,
5869,,In vivo,,A,,,,Cmax value after 15 mg/kg iv dose in Dogs,N,,1,,CHEMBL623437,BAO_0000218,,
5870,,In vivo,Blood,A,,,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL623438,BAO_0000218,178.0,
5871,,In vivo,Blood,A,,,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL623439,BAO_0000218,178.0,
5872,,In vivo,Bone,A,,,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,1,,CHEMBL623440,BAO_0000218,10000001.0,
5873,,In vivo,Bone,A,,,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL623441,BAO_0000218,10000001.0,
5874,,In vivo,Bone,A,,,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL623442,BAO_0000218,10000001.0,
5875,,In vivo,,A,,,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,1,,CHEMBL623469,BAO_0000218,,
5876,,In vivo,,A,,,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL623470,BAO_0000218,,
5877,,In vivo,,A,,,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL623471,BAO_0000218,,
5878,,In vivo,Heart,A,,,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,1,,CHEMBL623472,BAO_0000218,948.0,
5879,,In vivo,Heart,A,,,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL623473,BAO_0000218,948.0,
5880,,In vivo,Heart,A,,,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL623474,BAO_0000218,948.0,
5881,,In vivo,Kidney,A,,,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,1,,CHEMBL623475,BAO_0000218,2113.0,
5882,,In vivo,Kidney,A,,,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL623476,BAO_0000218,2113.0,
5883,,In vivo,Kidney,A,,,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL623477,BAO_0000218,2113.0,
5884,,In vivo,Intestine,A,,,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL621896,BAO_0000218,160.0,
5885,,In vivo,Intestine,A,,,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,1,,CHEMBL621897,BAO_0000218,160.0,
5886,,In vivo,Intestine,A,,,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL621898,BAO_0000218,160.0,
5887,,In vivo,Liver,A,,,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,1,,CHEMBL621899,BAO_0000218,2107.0,
5888,,In vivo,Liver,A,,,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL621900,BAO_0000218,2107.0,
5889,,In vivo,Liver,A,,,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL621901,BAO_0000218,2107.0,
5890,,In vivo,Lung,A,,,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,1,,CHEMBL621902,BAO_0000218,2048.0,
5891,,In vivo,Lung,A,,,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL621903,BAO_0000218,2048.0,
5892,,In vivo,Lung,A,,,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL622587,BAO_0000218,2048.0,
5893,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,1,,CHEMBL620285,BAO_0000218,2385.0,
5894,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL875285,BAO_0000218,2385.0,
5895,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL620286,BAO_0000218,2385.0,
5896,,In vivo,,A,,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,1,,CHEMBL620287,BAO_0000218,,
5897,,In vivo,,A,,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL620288,BAO_0000218,,
5898,,In vivo,,A,,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL620289,BAO_0000218,,
5899,,In vivo,Intestine,A,,,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,1,,CHEMBL620290,BAO_0000218,160.0,
5900,,In vivo,Intestine,A,,,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL620291,BAO_0000218,160.0,
5901,,In vivo,Intestine,A,,,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL620292,BAO_0000218,160.0,
5902,,In vivo,Spleen,A,,,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,1,,CHEMBL620293,BAO_0000218,2106.0,
5903,,In vivo,Spleen,A,,,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL620294,BAO_0000218,2106.0,
5904,,In vivo,Spleen,A,,,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL618614,BAO_0000218,2106.0,
5905,,In vivo,Stomach,A,,,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,1,,CHEMBL618615,BAO_0000218,945.0,
5906,,In vivo,Stomach,A,,,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL618616,BAO_0000218,945.0,
5907,,,,F,A 172,622.0,,Cytotoxicity against A-172 human tumor cell lines,N,,1,,CHEMBL618617,BAO_0000219,,
5908,,,,F,A 172,622.0,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,N,,1,,CHEMBL618618,BAO_0000219,,
5909,,,,F,A204,623.0,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,N,,1,,CHEMBL618619,BAO_0000219,,
5910,,,,F,A2780,478.0,,Tested for antiproliferative activity against A-2780 tumoral cell line,N,,1,,CHEMBL618620,BAO_0000219,,
5911,,,,F,A-375,455.0,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,N,,1,,CHEMBL618621,BAO_0000219,,
5912,,,,F,A-375,455.0,,Tested in vitro against A-375 cell line human melanoma,N,,1,,CHEMBL618622,BAO_0000219,,
5913,,,,F,A-427,797.0,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,N,,1,,CHEMBL618623,BAO_0000219,,
5914,,,,F,A-427,797.0,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,,1,,CHEMBL618624,BAO_0000219,,
5915,,,,F,A-427,797.0,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,N,,1,,CHEMBL618625,BAO_0000219,,
5916,,,,F,A-427,797.0,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,,1,,CHEMBL618626,BAO_0000219,,
5917,,,,F,A-427,797.0,,Antitumor activity on A-427 lung carcinoma cell lines,N,,1,,CHEMBL618627,BAO_0000219,,
5918,,,,F,A-427,797.0,,Cytotoxic activity against human A-427 lung tumor cell line,N,,1,,CHEMBL618628,BAO_0000219,,
5919,,,,F,A-427,797.0,,In vitro antitumor effects against human A-427 cell lines.,N,,1,,CHEMBL618629,BAO_0000219,,
5920,,,,F,A-427,797.0,,In vitro inhibition of A-427 (human lung cancer) cell growth.,N,,1,,CHEMBL618630,BAO_0000219,,
5921,,,,F,A-427,797.0,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,N,,1,,CHEMBL618631,BAO_0000219,,
5922,,,,F,A-427,797.0,,Cytotoxic activity of compound against A-427 lung human tumor cell line,N,,1,,CHEMBL618632,BAO_0000219,,
5923,,,,F,A-431,500.0,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,N,,1,,CHEMBL618633,BAO_0000219,,
5924,,,,F,A498,624.0,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,N,,1,,CHEMBL619315,BAO_0000219,,
5925,,,,F,A498,624.0,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,N,,1,,CHEMBL619316,BAO_0000219,,
5926,,,,F,A498,624.0,,Cytotoxicity against human kidney carcinoma A-498cell lines,N,,1,,CHEMBL619317,BAO_0000219,,
5927,,,,F,A498,624.0,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,N,,1,,CHEMBL619318,BAO_0000219,,
5928,,,,F,A498,624.0,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,N,,1,,CHEMBL619319,BAO_0000219,,
5929,,,,F,A498,624.0,,Antitumor cytotoxic activity against A-498 cell line was determined,N,,1,,CHEMBL619739,BAO_0000219,,
5930,,,,F,A498,624.0,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,N,,1,,CHEMBL619740,BAO_0000219,,
5931,,,,F,A498,624.0,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,N,,1,,CHEMBL883158,BAO_0000219,,
5932,,,,F,A498,624.0,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,N,,1,,CHEMBL884012,BAO_0000219,,
5933,,,,F,A498,624.0,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,N,,1,,CHEMBL619741,BAO_0000219,,
5934,,,,F,A498,624.0,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",N,,1,,CHEMBL619742,BAO_0000219,,
5935,,,,F,A549,646.0,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,N,,1,,CHEMBL876610,BAO_0000219,,
5936,,,,F,A549,646.0,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,N,,1,,CHEMBL619743,BAO_0000219,,
5937,,,,F,A549,646.0,,In vitro antiproliferative activity against human A-549 NSCL cell line,N,,1,,CHEMBL619744,BAO_0000219,,
5938,,,,F,A549,646.0,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,N,,1,,CHEMBL619745,BAO_0000219,,
5939,,,,F,A549,646.0,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,N,,1,,CHEMBL619746,BAO_0000219,,
5940,,,,F,A549,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,N,,1,,CHEMBL619747,BAO_0000219,,
5941,,,,F,A549,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,N,,1,,CHEMBL619748,BAO_0000219,,
5942,,,,F,A549,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,N,,1,,CHEMBL619749,BAO_0000219,,
5943,,,,F,A549,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,N,,1,,CHEMBL619750,BAO_0000219,,
5944,,,,F,A549,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,N,,1,,CHEMBL624014,BAO_0000219,,
5945,,,,F,A549,646.0,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,N,,1,,CHEMBL624015,BAO_0000219,,
5946,,,,F,A549,646.0,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,N,,1,,CHEMBL885344,BAO_0000219,,
5947,,,,F,A549,646.0,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,N,,1,,CHEMBL623224,BAO_0000219,,
5948,,,,F,A549,646.0,,Cytotoxic activity against A-549 cell line,N,,1,,CHEMBL623225,BAO_0000219,,
5949,,,,F,A549,646.0,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,N,,1,,CHEMBL622698,BAO_0000219,,
5950,,,,F,A549,646.0,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,N,,1,,CHEMBL622699,BAO_0000219,,
5951,,,,F,A549,646.0,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",N,,1,,CHEMBL622700,BAO_0000219,,
5952,,,,F,A549,646.0,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),N,,1,,CHEMBL622701,BAO_0000219,,
5953,,,,F,A549,646.0,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),N,,1,,CHEMBL622702,BAO_0000219,,
5954,,,,F,A549,646.0,,Cytotoxic activity against human lung carcinoma (A-549) cell line,N,,1,,CHEMBL622703,BAO_0000219,,
5955,,,,F,A549,646.0,,Cytotoxic activity towards A-549 cells,N,,1,,CHEMBL622704,BAO_0000219,,
5956,,,,F,A549,646.0,,"In vitro percent inhibition of A549, lung carcinoma.",N,,1,,CHEMBL622705,BAO_0000219,,
5957,,,,F,A549,646.0,,"In vitro percent inhibition of A549, lung carcinoma",N,,1,,CHEMBL622706,BAO_0000219,,
5958,,,,F,A549,646.0,,"In vitro percent inhibition of A549, lung carcinoma.",N,,1,,CHEMBL622707,BAO_0000219,,
5959,,,,F,A549,646.0,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",N,,1,,CHEMBL622708,BAO_0000219,,
5960,,,,F,A549,646.0,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,N,,1,,CHEMBL622709,BAO_0000219,,
5961,,,,F,A549,646.0,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,N,,1,,CHEMBL622710,BAO_0000219,,
5962,,,,F,A549,646.0,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,N,,1,,CHEMBL622711,BAO_0000219,,
5963,,,,F,A549,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,,1,,CHEMBL622712,BAO_0000218,,
5964,,,,F,A549,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,,1,,CHEMBL622713,BAO_0000218,,
5965,,,,F,A549,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,,1,,CHEMBL622714,BAO_0000218,,
5966,,,,F,A549,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,,1,,CHEMBL622715,BAO_0000218,,
5967,,,,F,A549,646.0,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,,1,,CHEMBL622716,BAO_0000218,,
5968,,,,F,A549,646.0,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",N,,1,,CHEMBL622717,BAO_0000219,,
5969,,,,F,A549,646.0,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),N,,1,,CHEMBL622718,BAO_0000218,,
5970,,,,F,A549,646.0,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,N,,1,,CHEMBL622719,BAO_0000219,,
5971,,,,F,A549,646.0,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,N,,1,,CHEMBL622720,BAO_0000219,,
5972,,,,F,A549,646.0,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,N,,1,,CHEMBL622721,BAO_0000219,,
5973,,,,F,A549,646.0,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,N,,1,,CHEMBL622722,BAO_0000219,,
5974,,,,F,A549,646.0,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,N,,1,,CHEMBL876030,BAO_0000219,,
5975,,,,F,A549,646.0,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",N,,1,,CHEMBL620206,BAO_0000219,,
5976,,,,F,A549,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,N,,1,,CHEMBL620207,BAO_0000219,,
5977,,,,F,A549,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,N,,1,,CHEMBL620208,BAO_0000219,,
5978,,,,F,A549,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,N,,1,,CHEMBL620209,BAO_0000219,,
5979,,,,F,A549,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,N,,1,,CHEMBL620210,BAO_0000219,,
5980,,,,F,A549,646.0,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,N,,1,,CHEMBL621639,BAO_0000219,,
5981,,,,F,A549,646.0,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,N,,1,,CHEMBL621640,BAO_0000219,,
5982,,,,F,A549,646.0,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,N,,1,,CHEMBL621641,BAO_0000219,,
5983,,,,F,A549,646.0,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,N,,1,,CHEMBL621642,BAO_0000219,,
5984,,,,F,A549,646.0,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,N,,1,,CHEMBL621643,BAO_0000219,,
5985,,,,F,A549,646.0,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,N,,1,,CHEMBL621644,BAO_0000219,,
5986,,,,F,A549,646.0,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,N,,1,,CHEMBL621645,BAO_0000219,,
5987,,,,F,A549,646.0,,In vitro antiproliferative activity against A549 cell line,N,,1,,CHEMBL621646,BAO_0000219,,
5988,,,,F,A549,646.0,,Synergism with indomethacin in A549 cells,N,,1,,CHEMBL621647,BAO_0000219,,
5989,,,,F,A549,646.0,,Synergism with tolmetin in A549 cells,N,,1,,CHEMBL621648,BAO_0000219,,
5990,,,,F,A549,646.0,,Synergism with sulindac in A549 cells,N,,1,,CHEMBL621649,BAO_0000219,,
5991,,,,F,A549,646.0,,Antagonism of indomethacin in A549 cells,N,,1,,CHEMBL621650,BAO_0000219,,
5992,,,,F,A549,646.0,,Antagonism of sulindac in A549 cells,N,,1,,CHEMBL621651,BAO_0000219,,
5993,,,,F,A549,646.0,,Antagonism of tolmetin in A549 cells,N,,1,,CHEMBL621652,BAO_0000219,,
5994,,,,F,A549,646.0,,Synergism with indomethacin in A549 cells,N,,1,,CHEMBL621653,BAO_0000219,,
5995,,,,F,A549,646.0,,Synergism with sulindac in A549 cells,N,,1,,CHEMBL621654,BAO_0000219,,
5996,,,,F,A549,646.0,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,N,,1,,CHEMBL621655,BAO_0000219,,
5997,,In vivo,,A,,,,Cmax value after 30 mg/kg po dose in Dogs,N,,1,,CHEMBL621656,BAO_0000218,,
5998,,In vivo,,A,,,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),N,,1,,CHEMBL621657,BAO_0000218,,
5999,,In vivo,,A,,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,N,,1,,CHEMBL621658,BAO_0000218,,
6000,,In vivo,,A,,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),N,,1,,CHEMBL621659,BAO_0000218,,
6001,,In vivo,,A,,,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,N,,1,,CHEMBL621660,BAO_0000218,,
6002,,In vivo,,A,,,,Cmax value after administration of 4 mg/Kg oral dose in dog,N,,1,,CHEMBL621661,BAO_0000218,,
6003,,In vivo,,A,,,,Cmax value in dog,N,,1,,CHEMBL621662,BAO_0000218,,
6004,,In vivo,,A,,,,Cmax value in dogs after oral administration at 1 mg/kg,N,,1,,CHEMBL621663,BAO_0000218,,
6005,,In vivo,,A,,,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,N,,1,,CHEMBL621664,BAO_0000218,,
6006,,In vivo,Plasma,A,,,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,N,,1,,CHEMBL621665,BAO_0000218,1969.0,
6007,,In vivo,Plasma,A,,,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,N,,1,,CHEMBL621666,BAO_0000218,1969.0,
6008,,In vivo,,A,,,,Concentration maxima after oral dosing in dogs,N,,1,,CHEMBL621667,BAO_0000218,,
6009,,In vivo,,A,,,,Concentration maxima after oral dosing in dogs; not available,N,,1,,CHEMBL876738,BAO_0000218,,
6010,,In vivo,,A,,,,Concentration maxima after oral dosing in dogs; not available,N,,1,,CHEMBL621668,BAO_0000218,,
6011,,In vivo,,A,,,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,N,,1,,CHEMBL621669,BAO_0000218,,
6012,,In vivo,,A,,,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,N,,1,,CHEMBL621670,BAO_0000218,,
6013,,In vivo,,A,,,,In vivo maximal concentration was calculated at 1 mg/kg in dog,N,,1,,CHEMBL621671,BAO_0000218,,
6014,,In vivo,,A,,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,N,,1,,CHEMBL622360,BAO_0000218,,
6015,,In vivo,,A,,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,N,,1,,CHEMBL622361,BAO_0000218,,
6016,,In vivo,Plasma,A,,,,Cmax in dog plasma after oral dose (1 mg/kg),N,,1,,CHEMBL622362,BAO_0000218,1969.0,
6017,,In vivo,Plasma,A,,,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,N,,1,,CHEMBL622363,BAO_0000218,1969.0,
6018,,In vivo,Plasma,A,,,,Maximal plasma concentration at a dose of 1 mg/kg,N,,1,,CHEMBL622364,BAO_0000218,1969.0,
6019,,In vivo,Plasma,A,,,,Maximal plasma concentration at a dose of 1 mg/kg (oral),N,,1,,CHEMBL622365,BAO_0000218,1969.0,
6020,,In vivo,Plasma,A,,,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,N,,1,,CHEMBL622533,BAO_0000218,1969.0,
6021,,In vivo,,A,,,,Maximum concentration of compound in dog was evaluated.,N,,1,,CHEMBL622534,BAO_0000218,,
6022,,In vivo,,A,,,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,N,,1,,CHEMBL622535,BAO_0000218,,
6023,,In vivo,,A,,,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,N,,1,,CHEMBL876739,BAO_0000218,,
6024,,In vivo,,A,,,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,,1,,CHEMBL622536,BAO_0000218,,
6025,,In vivo,Plasma,A,,,,Maximum concentration obtained in dog plasma was determined,N,,1,,CHEMBL622537,BAO_0000218,1969.0,
6026,,In vivo,,A,,,,Maximum concentration was determined,N,,1,,CHEMBL622538,BAO_0000218,,
6027,,In vivo,,A,,,,Maximum concentration at the dose of 2 mg/kg in dog,N,,1,,CHEMBL627867,BAO_0000218,,
6028,,In vivo,,A,,,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,,1,,CHEMBL627868,BAO_0000218,,
6029,,In vivo,Plasma,A,,,,Maximum concentration was evaluated in dog plasma,N,,1,,CHEMBL627869,BAO_0000218,1969.0,
6030,,In vivo,,A,,,,Maximum concentration was evaluated after 75 min after administration in dog,N,,1,,CHEMBL627870,BAO_0000218,,
6031,,In vivo,Plasma,A,,,,Maximum plasma concentration determined in dog after oral administration of 17b,N,,1,,CHEMBL627871,BAO_0000218,1969.0,
6032,,In vivo,Plasma,A,,,,Maximum plasma concentration determined in dog after oral administration of 2b,N,,1,,CHEMBL627872,BAO_0000218,1969.0,
6033,,In vivo,Plasma,A,,,,Maximum plasma concentration in dog,N,,1,,CHEMBL627873,BAO_0000218,1969.0,
6034,,In vivo,Plasma,A,,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,N,,1,,CHEMBL627874,BAO_0000218,1969.0,
6035,,In vivo,Plasma,A,,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,N,,1,,CHEMBL627875,BAO_0000218,1969.0,
6036,,In vivo,Plasma,A,,,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,N,,1,,CHEMBL627876,BAO_0000218,1969.0,
6037,,In vivo,Plasma,A,,,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,N,,1,,CHEMBL627877,BAO_0000218,1969.0,
6038,,In vivo,Plasma,A,,,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,,1,,CHEMBL627878,BAO_0000218,1969.0,
6039,,In vivo,Plasma,A,,,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,N,,1,,CHEMBL627879,BAO_0000218,1969.0,
6040,,In vivo,Plasma,A,,,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,,1,,CHEMBL875355,BAO_0000218,1969.0,
6041,,In vivo,Plasma,A,,,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,,1,,CHEMBL627880,BAO_0000218,1969.0,
6042,,In vivo,Plasma,A,,,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,N,,1,,CHEMBL627881,BAO_0000218,1969.0,
6043,,In vivo,Plasma,A,,,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,N,,1,,CHEMBL627882,BAO_0000218,1969.0,
6044,,In vivo,Plasma,A,,,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,N,,1,,CHEMBL627883,BAO_0000218,1969.0,
6045,,In vivo,Plasma,A,,,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,N,,1,,CHEMBL628526,BAO_0000218,1969.0,
6046,,In vivo,Plasma,A,,,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,N,,1,,CHEMBL628527,BAO_0000218,1969.0,
6047,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,N,,1,,CHEMBL628528,BAO_0000218,1969.0,
6048,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,N,,1,,CHEMBL628529,BAO_0000218,1969.0,
6049,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,N,,1,,CHEMBL628530,BAO_0000218,1969.0,
6050,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,N,,1,,CHEMBL625243,BAO_0000218,1969.0,
6051,,In vivo,Plasma,A,,,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,N,,1,,CHEMBL625244,BAO_0000218,1969.0,
6052,,In vivo,,A,,,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,N,,1,,CHEMBL625245,BAO_0000218,,
6053,,In vivo,,A,,,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,N,,1,,CHEMBL625246,BAO_0000218,,
6054,,In vivo,Stomach,A,,,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,1,,CHEMBL625247,BAO_0000218,945.0,
6055,,In vivo,Urine,A,,,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,1,,CHEMBL625248,BAO_0000218,1088.0,
6056,,In vivo,Urine,A,,,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,N,,1,,CHEMBL625249,BAO_0000218,1088.0,
6057,,In vivo,Urine,A,,,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,N,,1,,CHEMBL625250,BAO_0000218,1088.0,
6058,,,,A,,,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,N,,1,,CHEMBL625251,BAO_0000218,,
6059,,,,A,,,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,N,,1,,CHEMBL875356,BAO_0000218,,
6060,,,,A,,,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),N,,1,,CHEMBL625252,BAO_0000218,,
6061,,,Blood,A,,,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),N,,1,,CHEMBL625253,BAO_0000218,178.0,
6062,,,,A,,,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),N,,1,,CHEMBL625254,BAO_0000218,,
6063,,,,A,,,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),N,,1,,CHEMBL625255,BAO_0000218,,
6064,,,,A,,,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),N,,1,,CHEMBL625256,BAO_0000218,,
6065,,,Blood,A,,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),N,,1,,CHEMBL625257,BAO_0000218,178.0,
6066,,,Blood,A,,,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),N,,1,,CHEMBL625258,BAO_0000218,178.0,
6067,,,,A,,,,Compound was evaluated for washout rate in mice (Radiolabeled compound),N,,1,,CHEMBL625259,BAO_0000218,,
6068,,,,A,,,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,N,,1,,CHEMBL625260,BAO_0000218,,
6069,,,,A,,,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",N,,1,,CHEMBL625261,BAO_0000218,,
6070,,,,A,,,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",N,,1,,CHEMBL625262,BAO_0000218,,
6071,,,,A,,,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",N,,1,,CHEMBL622639,BAO_0000218,,
6072,,,,A,,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,N,,1,,CHEMBL622640,BAO_0000218,,
6073,,,,A,,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,N,,1,,CHEMBL622812,BAO_0000218,,
6074,,,,A,,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,N,,1,,CHEMBL622813,BAO_0000218,,
6075,,,,A,,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,N,,1,,CHEMBL622814,BAO_0000218,,
6076,,,,A,,,,Time at maximum activity in mice (Radiolabeled compound),N,,1,,CHEMBL622815,BAO_0000218,,
6077,,,,A,,,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,N,,1,,CHEMBL625342,BAO_0000218,,
6078,,,,A,,,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,N,,1,,CHEMBL625343,BAO_0000218,,
6079,,,,A,,,,Binding towards mouse plasma protein at 10 uM,N,,1,,CHEMBL877591,BAO_0000218,,
6080,,,,A,,,,Binding towards mouse plasma protein at 100 uM,N,,1,,CHEMBL625344,BAO_0000218,,
6081,,In vivo,,A,,,,Bioavailability was evaluated in mice after intravenous administration,N,,1,,CHEMBL625345,BAO_0000218,,
6082,,In vivo,,A,,,,Bioavailability was evaluated in mice after oral administration,N,,1,,CHEMBL625346,BAO_0000218,,
6083,,In vivo,,A,,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,N,,1,,CHEMBL625347,BAO_0000218,,
6084,,In vivo,,A,,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,N,,1,,CHEMBL625348,BAO_0000218,,
6085,,In vivo,,A,,,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,N,,1,,CHEMBL625349,BAO_0000218,,
6086,,In vivo,,A,,,,Oral bioavailability in mouse,N,,1,,CHEMBL625350,BAO_0000218,,
6087,,In vivo,,A,,,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,N,,1,,CHEMBL882952,BAO_0000218,,
6088,,In vivo,Brain,A,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL625351,BAO_0000218,955.0,
6089,,In vivo,Brain,A,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL625352,BAO_0000218,955.0,
6090,,In vivo,Brain,A,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL877592,BAO_0000218,955.0,
6091,,In vivo,Brain,A,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL625353,BAO_0000218,955.0,
6092,,In vivo,Brain,A,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL625354,BAO_0000218,955.0,
6093,,In vivo,Brain,A,,,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL626019,BAO_0000218,955.0,
6094,,In vivo,Heart,A,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL626020,BAO_0000218,948.0,
6095,,In vivo,Heart,A,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL626021,BAO_0000218,948.0,
6096,,In vivo,Heart,A,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL626022,BAO_0000218,948.0,
6097,,In vivo,Heart,A,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL626192,BAO_0000218,948.0,
6098,,,,F,A549,646.0,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),N,,1,,CHEMBL626193,BAO_0000219,,
6099,,,,F,A549,646.0,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,N,,1,,CHEMBL626194,BAO_0000219,,
6100,,,,F,A549,646.0,,Cytotoxicity against human lung carcinoma A-549 cell lines,N,,1,,CHEMBL626195,BAO_0000219,,
6101,,,,F,A549,646.0,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,N,,1,,CHEMBL626196,BAO_0000219,,
6102,,,,F,A549,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549,N,,1,,CHEMBL626197,BAO_0000219,,
6103,,,,F,A549,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,N,,1,,CHEMBL626198,BAO_0000219,,
6104,,,,F,A549,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,N,,1,,CHEMBL626199,BAO_0000219,,
6105,,,,F,A549,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,N,,1,,CHEMBL626200,BAO_0000219,,
6106,,,,F,A549,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,N,,1,,CHEMBL626201,BAO_0000219,,
6107,,,,F,A549,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,N,,1,,CHEMBL626202,BAO_0000219,,
6108,,,,F,A549,646.0,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,N,,1,,CHEMBL626203,BAO_0000219,,
6109,,,,F,A549,646.0,,In vitro cytotoxicity against A-549 human lung cancer cells,N,,1,,CHEMBL626204,BAO_0000219,,
6110,,,,F,A549,646.0,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,N,,1,,CHEMBL624701,BAO_0000219,,
6111,,,,F,A549,646.0,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,N,,1,,CHEMBL624702,BAO_0000219,,
6112,,,,F,A549,646.0,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,N,,1,,CHEMBL624703,BAO_0000219,,
6113,,,,F,A549,646.0,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,N,,1,,CHEMBL624704,BAO_0000219,,
6114,,,,F,A549,646.0,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,N,,1,,CHEMBL624705,BAO_0000219,,
6115,,,,F,A549,646.0,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,N,,1,,CHEMBL624706,BAO_0000219,,
6116,,,,F,A549,646.0,,Antitumor cytotoxic activity against A-549 cell line was determined,N,,1,,CHEMBL624707,BAO_0000219,,
6117,,,,F,A549,646.0,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",N,,1,,CHEMBL624708,BAO_0000219,,
6118,,,,F,A549,646.0,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,N,,1,,CHEMBL624709,BAO_0000219,,
6119,,,,F,A549,646.0,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,N,,1,,CHEMBL884107,BAO_0000219,,
6120,,,,F,A549,646.0,,Antitumoral activity was assayed against A-549 cell line,N,,1,,CHEMBL624710,BAO_0000219,,
6121,,,,F,A549,646.0,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,N,,1,,CHEMBL624711,BAO_0000219,,
6122,,,,F,A549,646.0,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,N,,1,,CHEMBL624712,BAO_0000219,,
6123,,,,F,A549,646.0,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,N,,1,,CHEMBL624713,BAO_0000219,,
6124,,,,F,A549,646.0,,Compound was tested for inhibition of cell growth of A-549 cells,N,,1,,CHEMBL624714,BAO_0000219,,
6125,,,,F,A549,646.0,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,N,,1,,CHEMBL624715,BAO_0000219,,
6126,,,,F,A549,646.0,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,N,,1,,CHEMBL624716,BAO_0000219,,
6127,,,,F,A549,646.0,,In vitro cytotoxicity against A549-human lung carcinoma cells.,N,,1,,CHEMBL619505,BAO_0000219,,
6128,,,,F,A549,646.0,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,N,,1,,CHEMBL619506,BAO_0000219,,
6129,,,,F,A549,646.0,,Cytotoxic activity against A-549 cell lines.,N,,1,,CHEMBL619507,BAO_0000219,,
6130,,,,F,A549,646.0,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,N,,1,,CHEMBL619508,BAO_0000219,,
6131,,,,F,A549,646.0,,Cytotoxicity against human A549 non small cell lung cell lines,N,,1,,CHEMBL619509,BAO_0000219,,
6132,,,,F,A549,646.0,,Inhibition of cell growth in (A-549) lung cell line,N,,1,,CHEMBL619510,BAO_0000219,,
6133,,,,F,A549,646.0,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,N,,1,,CHEMBL619511,BAO_0000219,,
6134,,,,F,A549,646.0,,In vitro antitumor activity against A-549 tumor cells.,N,,1,,CHEMBL619512,BAO_0000219,,
6135,,,,F,A549,646.0,,In vitro antitumor effects against human A-549 cell lines.,N,,1,,CHEMBL619513,BAO_0000219,,
6136,,,,F,A549,646.0,,In vitro cytotoxic activity of compound against A-549 cell line,N,,1,,CHEMBL619514,BAO_0000219,,
6137,,,,F,A549,646.0,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,N,,1,,CHEMBL619515,BAO_0000219,,
6138,,,,F,A549,646.0,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,N,,1,,CHEMBL619516,BAO_0000219,,
6139,,,,F,A549,646.0,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,N,,1,,CHEMBL884005,BAO_0000219,,
6140,,,,F,A549,646.0,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,N,,1,,CHEMBL619517,BAO_0000219,,
6141,,,,F,A549,646.0,,Inhibitory concentration of compound against A-549 cell line,N,,1,,CHEMBL619518,BAO_0000219,,
6142,,,,F,A549,646.0,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,N,,1,,CHEMBL619519,BAO_0000219,,
6143,,,,F,A549,646.0,,cytotoxic activity against leukemia (A-549) cancer cell line,N,,1,,CHEMBL876489,BAO_0000219,,
6144,,,,F,A549,646.0,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,N,,1,,CHEMBL619520,BAO_0000219,,
6145,,,,F,A549,646.0,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,N,,1,,CHEMBL619521,BAO_0000219,,
6146,,,,F,A549,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),N,,1,,CHEMBL619522,BAO_0000219,,
6147,,,,F,A549,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),N,,1,,CHEMBL619523,BAO_0000219,,
6148,,,,F,A549,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),N,,1,,CHEMBL619524,BAO_0000219,,
6149,,,,F,A549,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),N,,1,,CHEMBL619525,BAO_0000219,,
6150,,,,F,A549,646.0,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,N,,1,,CHEMBL619526,BAO_0000219,,
6151,,,,F,A549,646.0,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,N,,1,,CHEMBL619527,BAO_0000219,,
6152,,,,F,A549,646.0,,Cytotoxicity against A549 cells; No cytotoxicity,N,,1,,CHEMBL619528,BAO_0000219,,
6153,,,,F,A549,646.0,,Cytotoxicity against human lung carcinoma (A549) cell lines,N,,1,,CHEMBL619529,BAO_0000219,,
6154,,,,F,A549,646.0,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,N,,1,,CHEMBL619530,BAO_0000219,,
6155,,,,F,A549,646.0,,In vitro anticancer activity against human lung (A549) cell line,N,,1,,CHEMBL876490,BAO_0000219,,
6156,,,,F,A549,646.0,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,N,,1,,CHEMBL619531,BAO_0000219,,
6157,,,,F,A549,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,N,,1,,CHEMBL619532,BAO_0000219,,
6158,,,,F,A549,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,N,,1,,CHEMBL619533,BAO_0000219,,
6159,,,,F,A549,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,N,,1,,CHEMBL619534,BAO_0000219,,
6160,,,,F,A549,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,N,,1,,CHEMBL620164,BAO_0000219,,
6161,,,,F,A549,646.0,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,N,,1,,CHEMBL620165,BAO_0000219,,
6162,,,,F,A549,646.0,,Inhibition of A549 human lung tumor cell proliferation,N,,1,,CHEMBL620166,BAO_0000219,,
6163,,,,F,A549,646.0,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",N,,1,,CHEMBL620167,BAO_0000219,,
6164,,,,F,A549,646.0,,In vitro cytotoxicity against human tumor cell line A549,N,,1,,CHEMBL620168,BAO_0000219,,
6165,,,,F,A549,646.0,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,N,,1,,CHEMBL620338,BAO_0000219,,
6166,,,,F,A549,646.0,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,N,,1,,CHEMBL620339,BAO_0000219,,
6167,,,,F,A549,646.0,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,N,,1,,CHEMBL620340,BAO_0000219,,
6168,,,,F,A549,646.0,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,N,,1,,CHEMBL620341,BAO_0000219,,
6169,,,,F,A549,646.0,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,N,,1,,CHEMBL876491,BAO_0000219,,
6170,,,,F,A549,646.0,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,N,,1,,CHEMBL620342,BAO_0000219,,
6171,,,,F,A549,646.0,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,N,,1,,CHEMBL620343,BAO_0000219,,
6172,,,,F,A549,646.0,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,N,,1,,CHEMBL620344,BAO_0000219,,
6173,,,,F,A549,646.0,,In vitro anticancer activity against human lung (A549) cell line,N,,1,,CHEMBL620345,BAO_0000219,,
6174,,,,F,A549,646.0,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,N,,1,,CHEMBL620346,BAO_0000219,,
6175,,,,F,A549,646.0,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,N,,1,,CHEMBL620347,BAO_0000219,,
6176,,,,F,A549,646.0,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,N,,1,,CHEMBL620348,BAO_0000219,,
6177,,,,F,A549,646.0,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,N,,1,,CHEMBL620349,BAO_0000219,,
6178,,,,F,A549,646.0,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,N,,1,,CHEMBL618667,BAO_0000219,,
6179,,,,F,A549,646.0,,Percentage inhibition of human lung carcinoma (A549) cell lines,N,,1,,CHEMBL618668,BAO_0000219,,
6180,,,,F,A549,646.0,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,N,,1,,CHEMBL876031,BAO_0000219,,
6181,,,,F,A549,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",N,,1,,CHEMBL618759,BAO_0000219,,
6182,,,,F,A549,646.0,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,N,,1,,CHEMBL618760,BAO_0000219,,
6183,,,,F,A549,646.0,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,N,,1,,CHEMBL619000,BAO_0000219,,
6184,,,,F,A549,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",N,,1,,CHEMBL619001,BAO_0000219,,
6185,,,,F,A549,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",N,,1,,CHEMBL619002,BAO_0000219,,
6186,,,,F,A549,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",N,,1,,CHEMBL619003,BAO_0000219,,
6187,,,,F,A549,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",N,,1,,CHEMBL619597,BAO_0000219,,
6188,,,,F,A549,646.0,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",N,,1,,CHEMBL619598,BAO_0000219,,
6189,,,,F,A549,646.0,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,N,,1,,CHEMBL619599,BAO_0000219,,
6190,,,,F,A549,646.0,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,N,,1,,CHEMBL619600,BAO_0000219,,
6191,,,,F,A549,646.0,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,N,,1,,CHEMBL619601,BAO_0000219,,
6192,,,,F,A549,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,N,,1,,CHEMBL619602,BAO_0000219,,
6193,,,,F,A549,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,N,,1,,CHEMBL619603,BAO_0000219,,
6194,,,,F,A549,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,N,,1,,CHEMBL619604,BAO_0000219,,
6195,,,,F,A549,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,N,,1,,CHEMBL619605,BAO_0000219,,
6196,,In vivo,,A,,,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,N,,1,,CHEMBL619606,BAO_0000218,,
6197,,In vivo,,A,,,,Pharmacokinetic activity (Cmax) in dog,N,,1,,CHEMBL876032,BAO_0000218,,
6198,,In vivo,,A,,,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),N,,1,,CHEMBL619607,BAO_0000218,,
6199,,In vivo,,A,,,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,N,,1,,CHEMBL619608,BAO_0000218,,
6200,,In vivo,,A,,,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,N,,1,,CHEMBL619609,BAO_0000218,,
6201,,In vivo,Plasma,A,,,,Cmax in dog plasma after 30mg/kg oral dose,N,,1,,CHEMBL619610,BAO_0000218,1969.0,
6202,,In vivo,Blood,A,,,,Tested for the peak blood level in dog,N,,1,,CHEMBL619611,BAO_0000218,178.0,
6203,,In vivo,,A,,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",N,,1,,CHEMBL619612,BAO_0000218,,
6204,,In vivo,,A,,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",N,,1,,CHEMBL619613,BAO_0000218,,
6205,,In vivo,Blood,A,,,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,N,,1,,CHEMBL619614,BAO_0000218,178.0,
6206,,,,A,,,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,N,,1,,CHEMBL619615,BAO_0000218,,
6207,,,,A,,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,N,,1,,CHEMBL619616,BAO_0000218,,
6208,,,Plasma,A,,,,Final plasma concentration in dogs after oral administration at 1 mg/kg,N,,1,,CHEMBL619617,BAO_0000218,1969.0,
6209,,,,A,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,N,,1,,CHEMBL619618,BAO_0000218,,
6210,,,,A,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,N,,1,,CHEMBL876033,BAO_0000218,,
6211,,,,A,,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,N,,1,,CHEMBL619619,BAO_0000218,,
6212,,,,A,,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,N,,1,,CHEMBL619620,BAO_0000218,,
6213,,,Urine,A,,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,N,,1,,CHEMBL619621,BAO_0000218,1088.0,
6214,,,Urine,A,,,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,N,,1,,CHEMBL619622,BAO_0000218,1088.0,
6215,,,Urine,A,,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,N,,1,,CHEMBL618874,BAO_0000218,1088.0,
6216,,In vivo,,A,,,,Absolute bioavailability was evaluated in dog,N,,1,,CHEMBL618875,BAO_0000218,,
6217,,In vivo,,A,,,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,N,,1,,CHEMBL618876,BAO_0000218,,
6218,,In vivo,,A,,,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,N,,1,,CHEMBL618877,BAO_0000218,,
6219,,In vivo,,A,,,,Bioavailability in dog,N,,1,,CHEMBL618878,BAO_0000218,,
6220,,In vivo,,A,,,,Bioavailability in dog,N,,1,,CHEMBL618879,BAO_0000218,,
6221,,In vivo,,A,,,,Bioavailability after intravenous administration in dogs,N,,1,,CHEMBL618880,BAO_0000218,,
6222,,In vivo,,A,,,,Bioavailability after peroral administration in dogs,N,,1,,CHEMBL618881,BAO_0000218,,
6223,,In vivo,,A,,,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),N,,1,,CHEMBL618882,BAO_0000218,,
6224,,In vivo,,A,,,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,N,,1,,CHEMBL624226,BAO_0000218,,
6225,,In vivo,Plasma,A,,,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,N,,1,,CHEMBL624227,BAO_0000218,1969.0,
6226,,In vivo,,A,,,,Bioavailability,N,,1,,CHEMBL624228,BAO_0000218,,
6227,,In vivo,,A,,,,Bioavailability,N,,1,,CHEMBL624229,BAO_0000218,,
6228,,In vivo,,A,,,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,N,,1,,CHEMBL624230,BAO_0000218,,
6229,,In vivo,,A,,,,Bioavailability in dog,N,,1,,CHEMBL624231,BAO_0000218,,
6230,,In vivo,,A,,,,Bioavailability in dog,N,,1,,CHEMBL624232,BAO_0000218,,
6231,,In vivo,,A,,,,Bioavailability in dog,N,,1,,CHEMBL625127,BAO_0000218,,
6232,,In vivo,,A,,,,Bioavailability in dog,N,,1,,CHEMBL625128,BAO_0000218,,
6233,,In vivo,,A,,,,Bioavailability in dog,N,,1,,CHEMBL621675,BAO_0000218,,
6234,,In vivo,,A,,,,Bioavailability in dog (p.o.) at 2.0 mpk,N,,1,,CHEMBL621676,BAO_0000218,,
6235,,In vivo,,A,,,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),N,,1,,CHEMBL621677,BAO_0000218,,
6236,,In vivo,,A,,,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,,1,,CHEMBL621678,BAO_0000218,,
6237,,In vivo,,A,,,,Bioavailability in dog,N,,1,,CHEMBL621679,BAO_0000218,,
6238,,In vivo,,A,,,,Bioavailability was evaluated after oral administration in dog,N,,1,,CHEMBL621680,BAO_0000218,,
6239,,In vivo,,A,,,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,,1,,CHEMBL621681,BAO_0000218,,
6240,,In vivo,,A,,,,Bioavailability was evaluated in dog,N,,1,,CHEMBL876740,BAO_0000218,,
6241,,In vivo,,A,,,,Bioavailability in dog,N,,1,,CHEMBL621682,BAO_0000218,,
6242,,In vivo,,A,,,,Bioavailability in dog,N,,1,,CHEMBL621683,BAO_0000218,,
6243,,In vivo,,A,,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),N,,1,,CHEMBL621684,BAO_0000218,,
6244,,In vivo,,A,,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),N,,1,,CHEMBL621685,BAO_0000218,,
6245,,In vivo,,A,,,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),N,,1,,CHEMBL621686,BAO_0000218,,
6246,,In vivo,,A,,,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,,1,,CHEMBL621687,BAO_0000218,,
6247,,In vivo,,A,,,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,N,,1,,CHEMBL621688,BAO_0000218,,
6248,,In vivo,,A,,,,Bioavailability of compound in dog was determined after peroral administration,N,,1,,CHEMBL621689,BAO_0000218,,
6249,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL621690,BAO_0000218,,
6250,,In vivo,,A,,,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,N,,1,,CHEMBL621691,BAO_0000218,,
6251,,In vivo,,A,,,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,N,,1,,CHEMBL875941,BAO_0000218,,
6252,,In vivo,,A,,,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,N,,1,,CHEMBL621692,BAO_0000218,,
6253,,In vivo,,A,,,,Bioavailability in dog,N,,1,,CHEMBL621693,BAO_0000218,,
6254,,In vivo,,A,,,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),N,,1,,CHEMBL621694,BAO_0000218,,
6255,,In vivo,Heart,A,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL621695,BAO_0000218,948.0,
6256,,In vivo,Heart,A,,,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL621696,BAO_0000218,948.0,
6257,,In vivo,Kidney,A,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL621697,BAO_0000218,2113.0,
6258,,In vivo,Kidney,A,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL621698,BAO_0000218,2113.0,
6259,,In vivo,Kidney,A,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL623420,BAO_0000218,2113.0,
6260,,In vivo,Kidney,A,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL623421,BAO_0000218,2113.0,
6261,,In vivo,Kidney,A,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL623422,BAO_0000218,2113.0,
6262,,In vivo,Kidney,A,,,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL623423,BAO_0000218,2113.0,
6263,,In vivo,Liver,A,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL623424,BAO_0000218,2107.0,
6264,,In vivo,Liver,A,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL623425,BAO_0000218,2107.0,
6265,,In vivo,Liver,A,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL623426,BAO_0000218,2107.0,
6266,,In vivo,Liver,A,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL623427,BAO_0000218,2107.0,
6267,,In vivo,Liver,A,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL623428,BAO_0000218,2107.0,
6268,,In vivo,Liver,A,,,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL875947,BAO_0000218,2107.0,
6269,,In vivo,Lung,A,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL623429,BAO_0000218,2048.0,
6270,,In vivo,Lung,A,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL623430,BAO_0000218,2048.0,
6271,,In vivo,Lung,A,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL622588,BAO_0000218,2048.0,
6272,,In vivo,Lung,A,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL622589,BAO_0000218,2048.0,
6273,,In vivo,Lung,A,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL622751,BAO_0000218,2048.0,
6274,,In vivo,Lung,A,,,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,,1,,CHEMBL622752,BAO_0000218,2048.0,
6275,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,N,,1,,CHEMBL622753,BAO_0000218,,
6276,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,N,,1,,CHEMBL622647,BAO_0000218,,
6277,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,N,,1,,CHEMBL875163,BAO_0000218,,
6278,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,N,,1,,CHEMBL622648,BAO_0000218,,
6279,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,N,,1,,CHEMBL622649,BAO_0000218,,
6280,,,Brain,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,N,,1,,CHEMBL622650,BAO_0000218,955.0,
6281,,,Brain,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,N,,1,,CHEMBL622651,BAO_0000218,955.0,
6282,,,Brain,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,N,,1,,CHEMBL622652,BAO_0000218,955.0,
6283,,,Brain,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,N,,1,,CHEMBL622653,BAO_0000218,955.0,
6284,,,Brain,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,N,,1,,CHEMBL622654,BAO_0000218,955.0,
6285,,,Heart,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,N,,1,,CHEMBL622655,BAO_0000218,948.0,
6286,,,Heart,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,N,,1,,CHEMBL622656,BAO_0000218,948.0,
6287,,,Heart,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,N,,1,,CHEMBL622657,BAO_0000218,948.0,
6288,,,Heart,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,N,,1,,CHEMBL622658,BAO_0000218,948.0,
6289,,,Heart,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,N,,1,,CHEMBL622659,BAO_0000218,948.0,
6290,,,Kidney,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,N,,1,,CHEMBL624630,BAO_0000218,2113.0,
6291,,,Kidney,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,N,,1,,CHEMBL624631,BAO_0000218,2113.0,
6292,,,Kidney,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,N,,1,,CHEMBL624632,BAO_0000218,2113.0,
6293,,,,F,A549,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,N,,1,,CHEMBL624633,BAO_0000219,,
6294,,,,F,A549,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,N,,1,,CHEMBL624634,BAO_0000219,,
6295,,,,F,A549,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),N,,1,,CHEMBL624635,BAO_0000219,,
6296,,,,F,A549,646.0,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),N,,1,,CHEMBL624636,BAO_0000219,,
6297,,,,F,A549,646.0,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,N,,1,,CHEMBL857055,BAO_0000219,,
6298,,,,F,A549,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,N,,1,,CHEMBL624637,BAO_0000219,,
6299,,,,F,A549,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,N,,1,,CHEMBL624638,BAO_0000219,,
6300,,,,F,A549,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,N,,1,,CHEMBL874366,BAO_0000219,,
6301,,,,F,A549,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,N,,1,,CHEMBL624639,BAO_0000219,,
6302,,,,F,A549,646.0,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,N,,1,,CHEMBL624640,BAO_0000219,,
6303,,,,F,A549,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,N,,1,,CHEMBL624641,BAO_0000219,,
6304,,,,F,A549,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,N,,1,,CHEMBL624642,BAO_0000219,,
6305,,,,F,A549,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,N,,1,,CHEMBL624643,BAO_0000219,,
6306,,,,F,A549,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,N,,1,,CHEMBL624644,BAO_0000219,,
6307,,,,F,A549,646.0,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,N,,1,,CHEMBL624645,BAO_0000219,,
6308,,,,F,A549,646.0,,The compound was evaluated for its cytotoxic potency against A-549 cell line,N,,1,,CHEMBL619445,BAO_0000219,,
6309,,,,F,A549,646.0,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,N,,1,,CHEMBL839886,BAO_0000219,,
6310,,,,F,A549,646.0,,Cytotoxic activity of compound against A-549 tumor cell line.,N,,1,,CHEMBL619446,BAO_0000219,,
6311,,,,F,A549,646.0,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,N,,1,,CHEMBL619447,BAO_0000219,,
6312,,,,F,A549,646.0,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,N,,1,,CHEMBL619448,BAO_0000219,,
6313,,,,F,A549,646.0,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,N,,1,,CHEMBL619449,BAO_0000219,,
6314,,,,F,A549,646.0,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,N,,1,,CHEMBL619450,BAO_0000219,,
6315,,,,F,A549,646.0,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),N,,1,,CHEMBL619451,BAO_0000219,,
6316,,,,F,A549,646.0,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,N,,1,,CHEMBL619452,BAO_0000219,,
6317,,,,F,A549,646.0,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,N,,1,,CHEMBL619453,BAO_0000219,,
6318,,,,F,A549,646.0,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,N,,1,,CHEMBL874367,BAO_0000219,,
6319,,,,F,A549,646.0,,Cytotoxic concentration against A-549 tumor cells.,N,,1,,CHEMBL619454,BAO_0000219,,
6320,,,,F,A549,646.0,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,N,,1,,CHEMBL619455,BAO_0000219,,
6321,,,,F,A549,646.0,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",N,,1,,CHEMBL619456,BAO_0000219,,
6322,,,,F,,,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,N,,1,,CHEMBL619457,BAO_0000218,,
6323,,,,F,,,,Activity against Acinetobacter calcoaceticus (AC54),N,,1,,CHEMBL619458,BAO_0000218,,
6324,,,,F,,,,In vitro antifungal activity against Aspergillus flavus CM74,N,,1,,CHEMBL619459,BAO_0000218,,
6325,,,,F,,,,In vitro antifungal activity against Aspergillus flavus CM74,N,,1,,CHEMBL619460,BAO_0000218,,
6326,,,,F,,,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,N,,1,,CHEMBL619461,BAO_0000218,,
6327,,,,F,,,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),N,,1,,CHEMBL619462,BAO_0000218,,
6328,,,,F,,,,Antimicrobial activity against Aspergillus fumigatus (MIC),N,,1,,CHEMBL620388,BAO_0000218,,
6329,,,,F,,,,Antimicrobial activity against Aspergillus fumigatus (MIC),N,,1,,CHEMBL620389,BAO_0000218,,
6330,,,,F,,,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),N,,1,,CHEMBL620390,BAO_0000218,,
6331,,,,F,,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,N,,1,,CHEMBL620391,BAO_0000218,,
6332,,,,F,,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,N,,1,,CHEMBL621073,BAO_0000218,,
6333,,,,F,,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,N,,1,,CHEMBL621074,BAO_0000218,,
6334,,,,F,,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,N,,1,,CHEMBL621075,BAO_0000218,,
6335,,,,F,,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),N,,1,,CHEMBL619554,BAO_0000218,,
6336,,,,F,,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),N,,1,,CHEMBL619555,BAO_0000218,,
6337,,,,F,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,N,,1,,CHEMBL619556,BAO_0000218,,
6338,,,,F,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,N,,1,,CHEMBL619557,BAO_0000218,,
6339,,,,F,,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,N,,1,,CHEMBL619558,BAO_0000218,,
6340,,,,F,A549,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,N,,1,,CHEMBL619559,BAO_0000219,,
6341,,,,F,A549,646.0,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,N,,1,,CHEMBL619560,BAO_0000219,,
6342,,,,F,A549,646.0,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,N,,1,,CHEMBL619561,BAO_0000219,,
6343,,,,F,A549,646.0,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,N,,1,,CHEMBL619562,BAO_0000219,,
6344,,,,F,A549,646.0,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,N,,1,,CHEMBL619563,BAO_0000219,,
6345,,,,F,A549,646.0,,GI values against A549 cells (lung cancer),N,,1,,CHEMBL857457,BAO_0000219,,
6346,,,,F,A549,646.0,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,N,,1,,CHEMBL619564,BAO_0000219,,
6347,,,,F,A549,646.0,,Inhibitory activity against A549 human adenocarcinoma,N,,1,,CHEMBL619565,BAO_0000219,,
6348,,,,F,A549,646.0,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,N,,1,,CHEMBL619566,BAO_0000218,,
6349,,,,F,A549,646.0,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,N,,1,,CHEMBL619567,BAO_0000218,,
6350,,,,F,A549,646.0,,Inhibitory activity against A549 lung adenocarcinoma cell line,N,,1,,CHEMBL619568,BAO_0000219,,
6351,,,,F,A549,646.0,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,N,,1,,CHEMBL619569,BAO_0000219,,
6352,,,,F,A549,646.0,,Cytotoxicity against human A549 lung cells,N,,1,,CHEMBL619570,BAO_0000219,,
6353,,,,F,A549,646.0,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,N,,1,,CHEMBL619571,BAO_0000218,,
6354,,,,F,A549,646.0,,Growth inhibition of A549 (human lung carcinoma) cell line.,N,,1,,CHEMBL619572,BAO_0000219,,
6355,,,,F,A549,646.0,,Effective dose required for inhibitory activity against A549 human tumor cell line.,N,,1,,CHEMBL619573,BAO_0000219,,
6356,,,,F,A549,646.0,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,N,,1,,CHEMBL619574,BAO_0000219,,
6357,,,,F,A549,646.0,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,N,,1,,CHEMBL619575,BAO_0000219,,
6358,,,,F,A549,646.0,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,N,,1,,CHEMBL619576,BAO_0000219,,
6359,,,,F,A549,646.0,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,N,,1,,CHEMBL619577,BAO_0000219,,
6360,,,,F,A549,646.0,,In vitro inhibitory activity against A549 tumor cell culture,N,,1,,CHEMBL619578,BAO_0000219,,
6361,,,,F,A549,646.0,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,N,,1,,CHEMBL884009,BAO_0000219,,
6362,,,,F,A549,646.0,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),N,,1,,CHEMBL619579,BAO_0000219,,
6363,,,,F,A549,646.0,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,N,,1,,CHEMBL619580,BAO_0000219,,
6364,,,,F,A549,646.0,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,N,,1,,CHEMBL619581,BAO_0000219,,
6365,,,,F,A549,646.0,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,N,,1,,CHEMBL619582,BAO_0000219,,
6366,,,,F,A549,646.0,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,N,,1,,CHEMBL619583,BAO_0000219,,
6367,,,,F,A549,646.0,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,N,,1,,CHEMBL876502,BAO_0000219,,
6368,,,,F,A549,646.0,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,N,,1,,CHEMBL619584,BAO_0000219,,
6369,,,,F,A549,646.0,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,N,,1,,CHEMBL619585,BAO_0000219,,
6370,,,,F,A549,646.0,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,N,,1,,CHEMBL619586,BAO_0000219,,
6371,,,,F,A549,646.0,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,N,,1,,CHEMBL619587,BAO_0000219,,
6372,,,,F,A549,646.0,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,N,,1,,CHEMBL619588,BAO_0000219,,
6373,,,,F,A549,646.0,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,N,,1,,CHEMBL619589,BAO_0000219,,
6374,,,,F,A549,646.0,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,N,,1,,CHEMBL619590,BAO_0000219,,
6375,,,,F,A549,646.0,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),N,,1,,CHEMBL619591,BAO_0000219,,
6376,,,,F,A549,646.0,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,N,,1,,CHEMBL619592,BAO_0000219,,
6377,,,,F,A549,646.0,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,N,,1,,CHEMBL619593,BAO_0000219,,
6378,,,,F,A549,646.0,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,N,,1,,CHEMBL620217,BAO_0000219,,
6379,,,,F,A549,646.0,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,N,,1,,CHEMBL620218,BAO_0000219,,
6380,,,,F,A549,646.0,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,N,,1,,CHEMBL620219,BAO_0000219,,
6381,,,,F,A549,646.0,,Antitumor activity against A549/ATCC cell line,N,,1,,CHEMBL620220,BAO_0000219,,
6382,,,,F,A549,646.0,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,N,,1,,CHEMBL625141,BAO_0000219,,
6383,,,,F,A549,646.0,,In vitro cytotoxicity against A549/ATCC cell line.,N,,1,,CHEMBL625142,BAO_0000219,,
6384,,,,F,A549,646.0,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,N,,1,,CHEMBL625143,BAO_0000219,,
6385,,,,F,A549,646.0,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,N,,1,,CHEMBL625144,BAO_0000219,,
6386,,,,F,A549,646.0,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,N,,1,,CHEMBL622474,BAO_0000219,,
6387,,,,F,A549,646.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,N,,1,,CHEMBL884104,BAO_0000219,,
6388,,,,F,,,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,U,,1,,CHEMBL622475,BAO_0000219,,
6389,,In vivo,,A,,,,Compound was tested for oral bioavailability in dogs,U,,1,,CHEMBL622476,BAO_0000218,,
6390,,In vivo,,A,,,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,N,,1,,CHEMBL875831,BAO_0000218,,
6391,,In vivo,,A,,,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,N,,1,,CHEMBL622477,BAO_0000218,,
6392,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL622478,BAO_0000218,,
6393,,In vivo,,A,,,,Compound was tested for the oral bioavailability in dog; No availability,N,,1,,CHEMBL623172,BAO_0000218,,
6394,,In vivo,,A,,,,Oral bioavailability in dog (dose 5 mg/kg),N,,1,,CHEMBL623173,BAO_0000218,,
6395,,In vivo,,A,,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,N,,1,,CHEMBL623174,BAO_0000218,,
6396,,In vivo,,A,,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,N,,1,,CHEMBL623175,BAO_0000218,,
6397,,In vivo,,A,,,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),N,,1,,CHEMBL623340,BAO_0000218,,
6398,,In vivo,,A,,,,Oral bioavailability in dog (dose 5 mg/kg),N,,1,,CHEMBL623341,BAO_0000218,,
6399,,In vivo,,A,,,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),N,,1,,CHEMBL623342,BAO_0000218,,
6400,,In vivo,,A,,,,Oral bioavailability of active FTIs in dogs,N,,1,,CHEMBL623343,BAO_0000218,,
6401,,In vivo,,A,,,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),N,,1,,CHEMBL623344,BAO_0000218,,
6402,,In vivo,,A,,,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,N,,1,,CHEMBL623345,BAO_0000218,,
6403,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL875832,BAO_0000218,,
6404,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL623346,BAO_0000218,,
6405,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL623347,BAO_0000218,,
6406,,In vivo,,A,,,,Oral bioavailability of compound was determined in dog; Not tested,N,,1,,CHEMBL623348,BAO_0000218,,
6407,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL623349,BAO_0000218,,
6408,,In vivo,,A,,,,Oral bioavailability (10 mg/kg) was determined in dog,N,,1,,CHEMBL623350,BAO_0000218,,
6409,,In vivo,,A,,,,Oral bioavailability,N,,1,,CHEMBL623351,BAO_0000218,,
6410,,In vivo,,A,,,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),N,,1,,CHEMBL623352,BAO_0000218,,
6411,,In vivo,,A,,,,Oral bioavailability administered in solution in rats,N,,1,,CHEMBL623353,BAO_0000218,,
6412,,In vivo,,A,,,,Oral bioavailability after 30 mg/kg po dose in Dogs,N,,1,,CHEMBL875833,BAO_0000218,,
6413,,In vivo,,A,,,,Oral bioavailability at a dose of 1 mg/kg in dogs,N,,1,,CHEMBL623354,BAO_0000218,,
6414,,In vivo,,A,,,,Oral bioavailability in dog (dose 1 mg/kg p.o.),N,,1,,CHEMBL623355,BAO_0000218,,
6415,,In vivo,,A,,,,Oral bioavailability in Dog; ND = not determined,N,,1,,CHEMBL623356,BAO_0000218,,
6416,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL623357,BAO_0000218,,
6417,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL623358,BAO_0000218,,
6418,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL623359,BAO_0000218,,
6419,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL623360,BAO_0000218,,
6420,,In vivo,,A,,,,Oral bioavailability in dogs; No data,N,,1,,CHEMBL623361,BAO_0000218,,
6421,,In vivo,,A,,,,Oral bioavailability measured in dogs,N,,1,,CHEMBL623362,BAO_0000218,,
6422,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL623363,BAO_0000218,,
6423,,In vivo,,A,,,,Oral bioavailability was calculated in dog,N,,1,,CHEMBL623364,BAO_0000218,,
6424,,In vivo,,A,,,,Oral bioavailability after 0.3 mg/kg po administration in dog,N,,1,,CHEMBL875834,BAO_0000218,,
6425,,In vivo,,A,,,,Oral bioavailability in dog (i.v. dosing),N,,1,,CHEMBL623365,BAO_0000218,,
6426,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL623366,BAO_0000218,,
6427,,In vivo,,A,,,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,N,,1,,CHEMBL623367,BAO_0000218,,
6428,,In vivo,,A,,,,Oral bioavailability in Beagle dogs,N,,1,,CHEMBL623368,BAO_0000218,,
6429,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL623369,BAO_0000218,,
6430,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL623370,BAO_0000218,,
6431,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL623371,BAO_0000218,,
6432,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL623372,BAO_0000218,,
6433,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL621351,BAO_0000218,,
6434,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL621352,BAO_0000218,,
6435,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL621353,BAO_0000218,,
6436,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL621354,BAO_0000218,,
6437,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL621355,BAO_0000218,,
6438,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL621356,BAO_0000218,,
6439,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL621357,BAO_0000218,,
6440,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL621358,BAO_0000218,,
6441,,In vivo,,A,,,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),N,,1,,CHEMBL621359,BAO_0000218,,
6442,,In vivo,,A,,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),N,,1,,CHEMBL621360,BAO_0000218,,
6443,,In vivo,,A,,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),N,,1,,CHEMBL621361,BAO_0000218,,
6444,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL621362,BAO_0000218,,
6445,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL621363,BAO_0000218,,
6446,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL621364,BAO_0000218,,
6447,,In vivo,,A,,,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),N,,1,,CHEMBL621166,BAO_0000218,,
6448,,In vivo,,A,,,,Oral bioavailability in dog (dose 1 mg/kg i.v.),N,,1,,CHEMBL621167,BAO_0000218,,
6449,,In vivo,,A,,,,Oral bioavailability (F) in dogs,N,,1,,CHEMBL621168,BAO_0000218,,
6450,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL621169,BAO_0000218,,
6451,,In vivo,,A,,,,Bioavailability in dog,N,,1,,CHEMBL875950,BAO_0000218,,
6452,,In vivo,,A,,,,Oral bioavailability in dog (dose 10 mg/kg),N,,1,,CHEMBL621170,BAO_0000218,,
6453,,In vivo,,A,,,,Oral bioavailability after peroral administration at 5 mpk in Dog,N,,1,,CHEMBL621171,BAO_0000218,,
6454,,In vivo,,A,,,,Oral bioavailability in dog (dose 5 mg/kg),N,,1,,CHEMBL621172,BAO_0000218,,
6455,,In vivo,,A,,,,Oral bioavailability in dog (dose 10 mg/kg),N,,1,,CHEMBL621173,BAO_0000218,,
6456,,,Kidney,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,N,,1,,CHEMBL621174,BAO_0000218,2113.0,
6457,,,Kidney,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,N,,1,,CHEMBL621175,BAO_0000218,2113.0,
6458,,,Liver,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,N,,1,,CHEMBL621176,BAO_0000218,2107.0,
6459,,,Liver,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,N,,1,,CHEMBL621177,BAO_0000218,2107.0,
6460,,,Liver,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,N,,1,,CHEMBL621178,BAO_0000218,2107.0,
6461,,,Liver,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,N,,1,,CHEMBL621179,BAO_0000218,2107.0,
6462,,,Liver,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,N,,1,,CHEMBL621180,BAO_0000218,2107.0,
6463,,,Lung,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,N,,1,,CHEMBL875951,BAO_0000218,2048.0,
6464,,,Lung,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,N,,1,,CHEMBL621181,BAO_0000218,2048.0,
6465,,,Lung,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,N,,1,,CHEMBL621182,BAO_0000218,2048.0,
6466,,,Lung,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,N,,1,,CHEMBL621183,BAO_0000218,2048.0,
6467,,,Lung,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,N,,1,,CHEMBL621184,BAO_0000218,2048.0,
6468,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,N,,1,,CHEMBL621185,BAO_0000218,,
6469,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,N,,1,,CHEMBL621186,BAO_0000218,,
6470,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,N,,1,,CHEMBL621187,BAO_0000218,,
6471,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,N,,1,,CHEMBL621188,BAO_0000218,,
6472,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,N,,1,,CHEMBL621189,BAO_0000218,,
6473,,,Spleen,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,N,,1,,CHEMBL621190,BAO_0000218,2106.0,
6474,,,Spleen,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,N,,1,,CHEMBL618520,BAO_0000218,2106.0,
6475,,,Spleen,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,N,,1,,CHEMBL621739,BAO_0000218,2106.0,
6476,,,Spleen,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,N,,1,,CHEMBL621740,BAO_0000218,2106.0,
6477,,,Spleen,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,N,,1,,CHEMBL621741,BAO_0000218,2106.0,
6478,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,N,,1,,CHEMBL621742,BAO_0000218,,
6479,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,N,,1,,CHEMBL621743,BAO_0000218,,
6480,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,N,,1,,CHEMBL621744,BAO_0000218,,
6481,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,N,,1,,CHEMBL621745,BAO_0000218,,
6482,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,N,,1,,CHEMBL621746,BAO_0000218,,
6483,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,N,,1,,CHEMBL621747,BAO_0000218,,
6484,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,N,,1,,CHEMBL621748,BAO_0000218,,
6485,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,N,,1,,CHEMBL621749,BAO_0000218,,
6486,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,N,,1,,CHEMBL621750,BAO_0000218,,
6487,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,N,,1,,CHEMBL621751,BAO_0000218,,
6488,,,Heart,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,N,,1,,CHEMBL621752,BAO_0000218,948.0,
6489,,,Heart,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,N,,1,,CHEMBL621753,BAO_0000218,948.0,
6490,,,Heart,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,N,,1,,CHEMBL875955,BAO_0000218,948.0,
6491,,,Heart,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,N,,1,,CHEMBL621754,BAO_0000218,948.0,
6492,,,Heart,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,N,,1,,CHEMBL621755,BAO_0000218,948.0,
6493,,,Liver,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,N,,1,,CHEMBL621756,BAO_0000218,2107.0,
6494,,,Liver,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,N,,1,,CHEMBL624199,BAO_0000218,2107.0,
6495,,,Liver,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,N,,1,,CHEMBL624200,BAO_0000218,2107.0,
6496,,,Liver,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,N,,1,,CHEMBL624375,BAO_0000218,2107.0,
6497,,,Liver,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,N,,1,,CHEMBL624376,BAO_0000218,2107.0,
6498,,,Lung,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,N,,1,,CHEMBL624377,BAO_0000218,2048.0,
6499,,,Lung,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,N,,1,,CHEMBL624378,BAO_0000218,2048.0,
6500,,,,F,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,,1,,CHEMBL857901,BAO_0000218,,
6501,,,,F,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,,1,,CHEMBL875274,BAO_0000218,,
6502,,,,F,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,,1,,CHEMBL624379,BAO_0000218,,
6503,,,,F,,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,,1,,CHEMBL624380,BAO_0000218,,
6504,,,,F,,,,Activity against Acinetobacter calcoaceticus (AC54),N,,1,,CHEMBL624381,BAO_0000218,,
6505,,,,F,,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,N,,1,,CHEMBL624382,BAO_0000218,,
6506,,,,F,,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,N,,1,,CHEMBL624383,BAO_0000218,,
6507,,,,F,,,,Chlorohexidine coefficient for Actinomyces naeslundii 631,N,,1,,CHEMBL624384,BAO_0000218,,
6508,,,,F,,,,Chlorohexidine coefficient for Actinomyces naeslundii B74,N,,1,,CHEMBL624385,BAO_0000218,,
6509,,,,F,,,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,N,,1,,CHEMBL624386,BAO_0000218,,
6510,,,,F,,,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,N,,1,,CHEMBL624387,BAO_0000218,,
6511,,,,F,,,,Plaque bactericidal index against Actinomyces naeslundii 631,N,,1,,CHEMBL624388,BAO_0000218,,
6512,,,,F,,,,Plaque bactericidal index against Actinomyces naeslundii N/9,N,,1,,CHEMBL624389,BAO_0000218,,
6513,,,,F,,,,Plaque bactericidal index against Actinomyces naeslundii B74,N,,1,,CHEMBL624390,BAO_0000218,,
6514,,,,F,,,,Plaque bactericidal index against Actinomyces naeslundii N/3,N,,1,,CHEMBL875275,BAO_0000218,,
6515,,,,F,,,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,N,,1,,CHEMBL624391,BAO_0000218,,
6516,,,,F,,,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",N,,1,,CHEMBL623636,BAO_0000218,,
6517,,,,F,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,N,,1,,CHEMBL623637,BAO_0000218,,
6518,,,,F,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,N,,1,,CHEMBL623638,BAO_0000218,,
6519,,,,F,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,N,,1,,CHEMBL623639,BAO_0000218,,
6520,,,,F,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,N,,1,,CHEMBL623640,BAO_0000218,,
6521,,,,F,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,N,,1,,CHEMBL623641,BAO_0000218,,
6522,,,,F,,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,N,,1,,CHEMBL623642,BAO_0000218,,
6523,,,,F,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,N,,1,,CHEMBL623643,BAO_0000218,,
6524,,,,F,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,N,,1,,CHEMBL623644,BAO_0000218,,
6525,,,,F,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,N,,1,,CHEMBL623645,BAO_0000218,,
6526,,,,F,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,N,,1,,CHEMBL623646,BAO_0000218,,
6527,,,,F,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,N,,1,,CHEMBL623647,BAO_0000218,,
6528,,,,F,,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,N,,1,,CHEMBL623648,BAO_0000218,,
6529,,,,F,,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,N,,1,,CHEMBL623649,BAO_0000218,,
6530,,,,F,,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,N,,1,,CHEMBL623650,BAO_0000218,,
6531,,,,F,,,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,N,,1,,CHEMBL623651,BAO_0000218,,
6532,,,,F,,,,Chlorohexidine coefficient for Actinomyces viscosus M-100,N,,1,,CHEMBL623652,BAO_0000218,,
6533,,,,F,,,,Chlorohexidine coefficient for Actinomyces viscosus M-626,N,,1,,CHEMBL623653,BAO_0000218,,
6534,,,,F,,,,Chlorohexidine coefficient for Actinomyces viscosus T14V,N,,1,,CHEMBL623654,BAO_0000218,,
6535,,,,F,,,,Plaque bactericidal index against Actinomyces viscosus 8A06,N,,1,,CHEMBL623655,BAO_0000218,,
6536,,,,F,,,,Plaque bactericidal index against Actinomyces viscosus M-100,N,,1,,CHEMBL623656,BAO_0000218,,
6537,,,,F,,,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,N,,1,,CHEMBL623657,BAO_0000218,,
6538,,,,F,,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",N,,1,,CHEMBL623658,BAO_0000218,,
6539,,,,F,,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",N,,1,,CHEMBL623659,BAO_0000218,,
6540,,,,F,,,,Plaque bactericidal index against Actinomyces viscosus 626,N,,1,,CHEMBL623660,BAO_0000218,,
6541,,,,F,,,,Plaque bactericidal index against Actinomyces viscosus T14V,N,,1,,CHEMBL623661,BAO_0000218,,
6542,,,,F,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,N,,1,,CHEMBL875281,BAO_0000218,,
6543,,,,F,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,N,,1,,CHEMBL623662,BAO_0000218,,
6544,,,,F,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,N,,1,,CHEMBL623663,BAO_0000218,,
6545,,,,F,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,N,,1,,CHEMBL623664,BAO_0000218,,
6546,,,,F,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,N,,1,,CHEMBL623665,BAO_0000218,,
6547,,,,F,A673,165.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,N,,1,,CHEMBL621856,BAO_0000219,,
6548,,,,F,A704,645.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,N,,1,,CHEMBL620432,BAO_0000219,,
6549,,,,F,,,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,U,,1,,CHEMBL620433,BAO_0000219,,
6550,,,,F,A9,625.0,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,N,,1,,CHEMBL620434,BAO_0000219,,
6551,,,,F,A9,625.0,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,N,,1,,CHEMBL620435,BAO_0000219,,
6552,,,,F,A9,625.0,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,N,,1,,CHEMBL620436,BAO_0000219,,
6553,,,,F,A9,625.0,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,N,,1,,CHEMBL876597,BAO_0000219,,
6554,,,,F,Human ovarian carcinoma cell line,874.0,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,N,,1,,CHEMBL620437,BAO_0000219,,
6555,,,,F,A9,625.0,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",N,,1,,CHEMBL620438,BAO_0000219,,
6556,,,,F,A9,625.0,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,N,,1,,CHEMBL620439,BAO_0000219,,
6557,,,,F,A9,625.0,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,N,,1,,CHEMBL619657,BAO_0000219,,
6558,,,,F,A9,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,N,,1,,CHEMBL619658,BAO_0000219,,
6559,,,,F,A9,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,N,,1,,CHEMBL619659,BAO_0000219,,
6560,,,,F,,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",H,,1,,CHEMBL619660,BAO_0000019,,
6561,,,,F,A9,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,N,,1,,CHEMBL619661,BAO_0000219,,
6562,,,,F,A9,625.0,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,N,,1,,CHEMBL619662,BAO_0000219,,
6563,,,,F,AA6,975.0,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,N,,1,,CHEMBL619663,BAO_0000219,,
6564,,,,F,,,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,U,,1,,CHEMBL619664,BAO_0000219,,
6565,,,,F,,,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",U,,1,,CHEMBL619665,BAO_0000219,,
6566,,,,F,AA5,974.0,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),N,,1,,CHEMBL883244,BAO_0000219,,
6567,,,,F,AA5,974.0,,Cytotoxicity was measured against AA5/HIV-1(IIIB),N,,1,,CHEMBL884011,BAO_0000219,,
6568,,,,F,AA5,974.0,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,N,,1,,CHEMBL619666,BAO_0000219,,
6569,,,,F,U-937,379.0,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,N,,1,,CHEMBL619667,BAO_0000219,,
6570,,,,F,UV4,274.0,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,N,,1,,CHEMBL619668,BAO_0000219,,
6571,,,,F,CHO-AA8,185.0,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",N,,1,,CHEMBL619669,BAO_0000219,,
6572,,,,F,CHO-AA8,185.0,,Average intracellular compound concentration when the hypoxic SER=1.6,N,,1,,CHEMBL876608,BAO_0000219,,
6573,,,,F,CHO-AA8,185.0,,Average intracellular compound concentration when the hypoxic SER=1.6.,N,,1,,CHEMBL619670,BAO_0000219,,
6574,,,,F,CHO-AA8,185.0,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,N,,1,,CHEMBL619671,BAO_0000219,,
6575,,,,F,CHO-AA8,185.0,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,N,,1,,CHEMBL619672,BAO_0000219,,
6576,,,,F,CHO-AA8,185.0,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,N,,1,,CHEMBL619673,BAO_0000219,,
6577,,,,F,CHO-AA8,185.0,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",N,,1,,CHEMBL619674,BAO_0000219,,
6578,,,,F,CHO-AA8,185.0,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",N,,1,,CHEMBL619675,BAO_0000219,,
6579,,,,F,CHO-AA8,185.0,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,N,,1,,CHEMBL619676,BAO_0000219,,
6580,,,,F,CHO-AA8,185.0,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,N,,1,,CHEMBL619677,BAO_0000219,,
6581,,,,A,CHO-AA8,185.0,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,N,,1,,CHEMBL619678,BAO_0000219,,
6582,,,,A,CHO-AA8,185.0,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,N,,1,,CHEMBL619679,BAO_0000219,,
6583,,,,A,CHO-AA8,185.0,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,N,,1,,CHEMBL619680,BAO_0000219,,
6584,,,,A,CHO-AA8,185.0,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,N,,1,,CHEMBL621457,BAO_0000219,,
6585,,,,F,CHO-AA8,185.0,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,N,,1,,CHEMBL876609,BAO_0000219,,
6586,,,,F,CHO-AA8,185.0,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,N,,1,,CHEMBL621458,BAO_0000219,,
6587,,,,F,CHO-AA8,185.0,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,N,,1,,CHEMBL621459,BAO_0000219,,
6588,,,,F,CHO-AA8,185.0,,Aerobic growth inhibition in Chinese hamster cell line AA8,N,,1,,CHEMBL621460,BAO_0000219,,
6589,,,,F,CHO-AA8,185.0,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,N,,1,,CHEMBL621461,BAO_0000219,,
6590,,,,F,CHO-AA8,185.0,,Inhibition of growth under aerobic conditions in AA8 cells,N,,1,,CHEMBL621462,BAO_0000219,,
6591,,In vivo,,A,,,,Oral bioavailability in dog (dose 10 mg/kg),N,,1,,CHEMBL621463,BAO_0000218,,
6592,,In vivo,,A,,,,Oral bioavailability in dog at 10 mg/kg of the compound,N,,1,,CHEMBL621464,BAO_0000218,,
6593,,In vivo,,A,,,,Oral bioavailability in dog (dose 5 uM/kg),N,,1,,CHEMBL621465,BAO_0000218,,
6594,,In vivo,,A,,,,Oral bioavailability in dog (dose 5 uM/kg),N,,1,,CHEMBL621466,BAO_0000218,,
6595,,In vivo,,A,,,,Oral bioavailability in dog (mongrel),N,,1,,CHEMBL621467,BAO_0000218,,
6596,,In vivo,,A,,,,Oral bioavailability in dog (dose 10 mg/kg),N,,1,,CHEMBL621468,BAO_0000218,,
6597,,In vivo,,F,,,,Oral bioavailability in dog (dose 10 mg/kg),N,,1,,CHEMBL876734,BAO_0000218,,
6598,,In vivo,,A,,,,Bioavailability in dog,N,,1,,CHEMBL618476,BAO_0000218,,
6599,,In vivo,,A,,,,Bioavailability in dog (dose 1 mg/kg i.v.),N,,1,,CHEMBL618477,BAO_0000218,,
6600,,In vivo,,A,,,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),N,,1,,CHEMBL618478,BAO_0000218,,
6601,,In vivo,,A,,,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,N,,1,,CHEMBL618479,BAO_0000218,,
6602,,In vivo,,A,,,,Bioavailability in dog,N,,1,,CHEMBL618480,BAO_0000218,,
6603,,In vivo,,A,,,,Bioavailability in dog (dose 3-10 mg/kg),N,,1,,CHEMBL618481,BAO_0000218,,
6604,,In vivo,Plasma,A,,,,The compound was tested for bioavailability of compound in plasma of dog; Complete,N,,1,,CHEMBL618482,BAO_0000218,1969.0,
6605,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL618483,BAO_0000218,,
6606,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL618484,BAO_0000218,,
6607,,In vivo,,A,,,,Bioavailability in dog,N,,1,,CHEMBL618485,BAO_0000218,,
6608,,In vivo,,A,,,,oral bioavailability was measured in dogs,N,,1,,CHEMBL618486,BAO_0000218,,
6609,,,,A,,,,Compound was tested for plasma protein binding in dog; Not determined,N,,1,,CHEMBL618487,BAO_0000218,,
6610,,,,A,,,,Compound was tested for plasma protein binding of dog,N,,1,,CHEMBL618488,BAO_0000218,,
6611,,,,A,,,,Compound was tested for plasma protein binding of dog; Not determined,N,,1,,CHEMBL876735,BAO_0000218,,
6612,,,,A,,,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,N,,1,,CHEMBL618489,BAO_0000218,,
6613,,In vivo,,A,,,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,N,,1,,CHEMBL618490,BAO_0000218,,
6614,,,,A,,,,Half life was determined,N,,1,,CHEMBL618491,BAO_0000218,,
6615,,In vivo,,A,,,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,N,,1,,CHEMBL618492,BAO_0000218,,
6616,,,,A,,,,Half life was evaluated in dog,N,,1,,CHEMBL873354,BAO_0000218,,
6617,,,,A,,,,Half life was determined,N,,1,,CHEMBL618493,BAO_0000218,,
6618,,In vivo,,A,,,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,,1,,CHEMBL618494,BAO_0000218,,
6619,,In vivo,Heart,A,,,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,,1,,CHEMBL618495,BAO_0000218,948.0,
6620,,In vivo,Kidney,A,,,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,,1,,CHEMBL618496,BAO_0000218,2113.0,
6621,,In vivo,Liver,A,,,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,,1,,CHEMBL618497,BAO_0000218,2107.0,
6622,,In vivo,Lung,A,,,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,,1,,CHEMBL618498,BAO_0000218,2048.0,
6623,,In vivo,Spleen,A,,,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,,1,,CHEMBL618499,BAO_0000218,2106.0,
6624,,,,A,,,,LogP in dog,N,,1,,CHEMBL876736,BAO_0000218,,
6625,,,,A,,,,Partition coefficient (logP),N,,1,,CHEMBL618500,BAO_0000218,,
6626,,,,A,,,,Partition coefficient in dog,N,,1,,CHEMBL857831,BAO_0000218,,
6627,,In vivo,,A,,,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,N,,1,,CHEMBL618501,BAO_0000218,,
6628,,In vivo,,A,,,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),N,,1,,CHEMBL618502,BAO_0000218,,
6629,,,,A,,,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,N,,1,,CHEMBL618503,BAO_0000218,,
6630,,,,A,,,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),N,,1,,CHEMBL618504,BAO_0000218,,
6631,,,,A,,,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),N,,1,,CHEMBL618505,BAO_0000218,,
6632,,,,A,,,,Metabolism of compound in dog S9 microsomes; Trace,N,,1,,CHEMBL618506,BAO_0000218,,
6633,,,Liver,A,,,,In vitro metabolic potential in dog liver microsomes,N,,1,,CHEMBL618507,BAO_0000218,2107.0,
6634,,In vivo,,A,,,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,N,,1,,CHEMBL876737,BAO_0000218,,
6635,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL618508,BAO_0000218,,
6636,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL618509,BAO_0000218,,
6637,,In vivo,,A,,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,1,,CHEMBL618510,BAO_0000218,,
6638,,In vivo,,A,,,,The compound was tested for bioavailability in dogs,N,,1,,CHEMBL618511,BAO_0000218,,
6639,,In vivo,,A,,,,The compound was tested for oral bioavailability in dogs,N,,1,,CHEMBL618512,BAO_0000218,,
6640,,In vivo,,A,,,,Oral bioavailability in dog,N,,1,,CHEMBL618513,BAO_0000218,,
6641,,,,A,,,,Compound was tested for percent protein binding (PB) in dog,N,,1,,CHEMBL618514,BAO_0000218,,
6642,,,,A,,,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,N,,1,,CHEMBL620052,BAO_0000218,,
6643,,In vivo,Plasma,A,,,,Compound was evaluated for plasma clearance.,N,,1,,CHEMBL620053,BAO_0000218,1969.0,
6644,,In vivo,Plasma,A,,,,The compound was tested for plasma clearance in dog,N,,1,,CHEMBL620054,BAO_0000218,1969.0,
6645,,In vivo,Plasma,A,,,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,N,,1,,CHEMBL620055,BAO_0000218,1969.0,
6646,,,,A,,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,N,,1,,CHEMBL620056,BAO_0000218,,
6647,,,Liver,A,,,,In vitro relative rate of metabolism was determined in dog liver microsomes,N,,1,,CHEMBL620057,BAO_0000218,2107.0,
6648,,In vivo,,A,,,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,N,,1,,CHEMBL618939,BAO_0000218,,
6649,,In vivo,,A,,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,N,,1,,CHEMBL618940,BAO_0000218,,
6650,,In vivo,,A,,,,Half life after intravenous administration in dogs at 1.2 uM/kg,N,,1,,CHEMBL618941,BAO_0000218,,
6651,,,Lung,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,N,,1,,CHEMBL624473,BAO_0000218,2048.0,
6652,,,Lung,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,N,,1,,CHEMBL624474,BAO_0000218,2048.0,
6653,,,Lung,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,N,,1,,CHEMBL624475,BAO_0000218,2048.0,
6654,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,N,,1,,CHEMBL624476,BAO_0000218,,
6655,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,N,,1,,CHEMBL623478,BAO_0000218,,
6656,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,N,,1,,CHEMBL623479,BAO_0000218,,
6657,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,N,,1,,CHEMBL623480,BAO_0000218,,
6658,,,,A,CCRF S-180,42.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,N,,1,,CHEMBL623481,BAO_0000218,,
6659,,,Brain,A,,,,C2 in brain of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL623482,BAO_0000218,955.0,
6660,,,Kidney,A,,,,C2 in kidney of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL623483,BAO_0000218,2113.0,
6661,,,Liver,A,,,,C2 in liver of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL623484,BAO_0000218,2107.0,
6662,,,Lung,A,,,,C2 in lungs of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL623485,BAO_0000218,2048.0,
6663,,,Spleen,A,,,,C2 in spleen of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL623486,BAO_0000218,2106.0,
6664,,In vivo,,A,,,,Plasma clearance in mouse,N,,1,,CHEMBL623487,BAO_0000218,,
6665,,In vivo,,A,,,,Clearance of compound after intravenous administration in mice at 24 uM/kg,N,,1,,CHEMBL623488,BAO_0000218,,
6666,,In vivo,,A,,,,Clearance from mouse blood following i.v. administration of 10 mg/kg,N,,1,,CHEMBL623489,BAO_0000218,,
6667,,In vivo,,A,,,,Clearance was evaluated in mice after intravenous administration,N,,1,,CHEMBL875157,BAO_0000218,,
6668,,In vivo,,A,,,,Clearance was evaluated in mice after oral administration,N,,1,,CHEMBL623490,BAO_0000218,,
6669,,In vivo,,A,,,,Pharmacokinetic property (Plasma clearance) was measured in mouse,N,,1,,CHEMBL623491,BAO_0000218,,
6670,,In vivo,,A,,,,Plasma clearance of compound was determined at 40 mg/Kg,N,,1,,CHEMBL623492,BAO_0000218,,
6671,,In vivo,,A,,,,Plasma clearance of at 24 mg/Kg,N,,1,,CHEMBL623493,BAO_0000218,,
6672,,In vivo,,A,,,,Plasma clearance at 24 mg/Kg,N,,1,,CHEMBL623494,BAO_0000218,,
6673,,In vivo,,A,,,,Plasma clearance at 5 mg/Kg,N,,1,,CHEMBL623495,BAO_0000218,,
6674,,In vivo,,A,,,,Plasma clearance in mice,N,,1,,CHEMBL623496,BAO_0000218,,
6675,,In vivo,,A,,,,Plasma clearance value upon iv administration in mouse,N,,1,,CHEMBL623497,BAO_0000218,,
6676,,In vivo,Plasma,A,,,,Total plasma clearance in mice,N,,1,,CHEMBL623498,BAO_0000218,1969.0,
6677,,In vivo,,A,,,,Clearance in mouse,N,,1,,CHEMBL623499,BAO_0000218,,
6678,,In vivo,,A,,,,Clearance value was determined,N,,1,,CHEMBL623500,BAO_0000218,,
6679,,In vivo,,A,,,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,N,,1,,CHEMBL623501,BAO_0000218,,
6680,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL875158,BAO_0000100,,
6681,,In vivo,,A,,,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,N,,1,,CHEMBL623502,BAO_0000218,,
6682,,In vivo,,A,,,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,N,,1,,CHEMBL623503,BAO_0000218,,
6683,,In vivo,,A,,,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,,1,,CHEMBL623504,BAO_0000218,,
6684,,In vivo,,A,,,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,N,,1,,CHEMBL623505,BAO_0000218,,
6685,,In vivo,,A,,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,N,,1,,CHEMBL623506,BAO_0000218,,
6686,,In vivo,,A,,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,N,,1,,CHEMBL623507,BAO_0000218,,
6687,,In vivo,,A,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,N,,1,,CHEMBL623508,BAO_0000218,,
6688,,In vivo,,A,,,,Cmax after oral administration at 30 mg/kg in ICR mouse,N,,1,,CHEMBL623509,BAO_0000218,,
6689,,In vivo,,A,,,,Cmax after peroral administration in mice at 2.4 uM/kg,N,,1,,CHEMBL875159,BAO_0000218,,
6690,,In vivo,Brain,A,,,,Cmax in brain of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL623510,BAO_0000218,955.0,
6691,,In vivo,Kidney,A,,,,Cmax in kidney of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL623511,BAO_0000218,2113.0,
6692,,In vivo,Liver,A,,,,Cmax in liver of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL623512,BAO_0000218,2107.0,
6693,,In vivo,Lung,A,,,,Cmax in lungs of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL623513,BAO_0000218,2048.0,
6694,,In vivo,,F,,,,Cmax in mice at 18 uM/kg i.p. administration,N,,1,,CHEMBL623514,BAO_0000218,,
6695,,In vivo,,F,,,,Cmax in mice at 23 uM/kg i.v. administration,N,,1,,CHEMBL622609,BAO_0000218,,
6696,,In vivo,,F,,,,Cmax in mice at 24 uM/kg i.p. administration,N,,1,,CHEMBL622610,BAO_0000218,,
6697,,In vivo,,F,,,,Cmax in mice at 25 uM/kg i.p. administration,N,,1,,CHEMBL621823,BAO_0000218,,
6698,,In vivo,,F,,,,Cmax in mice at 26 uM/kg i.p. administration,N,,1,,CHEMBL621824,BAO_0000218,,
6699,,In vivo,Spleen,A,,,,Cmax in spleen of mice at the oral dose of 50 mg/kg,N,,1,,CHEMBL621825,BAO_0000218,2106.0,
6700,,In vivo,,A,,,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,N,,1,,CHEMBL621826,BAO_0000218,,
6701,,In vivo,,A,,,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,N,,1,,CHEMBL621827,BAO_0000218,,
6702,,In vivo,,A,,,,Cmax value was determined,N,,1,,CHEMBL621828,BAO_0000218,,
6703,,In vivo,,A,,,,Cmax value in IRC mice,N,,1,,CHEMBL621829,BAO_0000218,,
6704,,In vivo,,A,,,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,N,,1,,CHEMBL621830,BAO_0000218,,
6705,,In vivo,,A,,,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,N,,1,,CHEMBL621831,BAO_0000218,,
6706,,In vivo,Plasma,A,,,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,N,,1,,CHEMBL621832,BAO_0000218,1969.0,
6707,,In vivo,Plasma,A,,,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",N,,1,,CHEMBL624579,BAO_0000218,1969.0,
6708,,In vivo,,A,,,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,N,,1,,CHEMBL624580,BAO_0000218,,
6709,,,,F,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,N,,1,,CHEMBL624581,BAO_0000218,,
6710,,,,F,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,N,,1,,CHEMBL624582,BAO_0000218,,
6711,,,,F,,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,N,,1,,CHEMBL624583,BAO_0000218,,
6712,,,,F,A-375,455.0,,Inhibitory activity against human tumor cell line A0375 melanoma.,N,,1,,CHEMBL624584,BAO_0000219,,
6713,Brain membranes,,,B,,,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,D,,1,,CHEMBL624585,BAO_0000249,,
6714,,,,F,,,,Forskolin-induced cAMP production at human A1 adenosine receptor,D,,1,,CHEMBL875165,BAO_0000019,,
6715,,,,F,CHO,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,H,,1,,CHEMBL619490,BAO_0000219,,
6716,,,,F,CHO,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,H,,1,,CHEMBL619491,BAO_0000219,,
6717,,,,F,CHO,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,H,,1,,CHEMBL619492,BAO_0000219,,
6718,,,,F,CHO,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,H,,1,,CHEMBL619493,BAO_0000219,,
6719,,,,F,CHO,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,H,,1,,CHEMBL619494,BAO_0000219,,
6720,,,,F,CHO,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,H,,1,,CHEMBL619495,BAO_0000219,,
6721,,,,F,CHO,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,H,,1,,CHEMBL619496,BAO_0000219,,
6722,,,,F,CHO,449.0,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,D,,1,,CHEMBL619497,BAO_0000219,,
6723,,,,F,CHO,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,H,,1,,CHEMBL619498,BAO_0000219,,
6724,,,,F,CHO,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,H,,1,,CHEMBL619499,BAO_0000219,,
6725,,,,F,CHO,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,H,,1,,CHEMBL619500,BAO_0000219,,
6726,,,,F,CHO,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,H,,1,,CHEMBL619501,BAO_0000219,,
6727,,,,F,CHO,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,H,,1,,CHEMBL619502,BAO_0000219,,
6728,,,,F,CHO,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,H,,1,,CHEMBL619503,BAO_0000219,,
6729,,,,F,CHO,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,H,,1,,CHEMBL619504,BAO_0000219,,
6730,,,,F,CHO,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,H,,1,,CHEMBL621298,BAO_0000219,,
6731,,,,F,CHO,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,H,,1,,CHEMBL621299,BAO_0000219,,
6732,,,,F,CHO,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,H,,1,,CHEMBL621300,BAO_0000219,,
6733,,,,F,CHO,449.0,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,H,,1,,CHEMBL621301,BAO_0000219,,
6734,,,,F,CHO,449.0,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,H,,1,,CHEMBL621302,BAO_0000219,,
6735,,,,F,A10,164.0,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,N,,1,,CHEMBL621303,BAO_0000219,,
6736,,,,F,A10,164.0,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,U,,1,,CHEMBL621304,BAO_0000219,,
6737,,,,F,A10,164.0,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,U,,1,,CHEMBL621305,BAO_0000219,,
6738,,,,F,A10,164.0,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,N,,1,,CHEMBL621306,BAO_0000219,,
6739,,,,F,A10,164.0,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,N,,1,,CHEMBL618444,BAO_0000219,,
6740,,,,F,A10,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,N,,1,,CHEMBL618445,BAO_0000219,,
6741,,,,F,CHO-AA8,185.0,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,N,,1,,CHEMBL618446,BAO_0000219,,
6742,,,,F,CHO-AA8,185.0,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,N,,1,,CHEMBL618447,BAO_0000219,,
6743,,,,F,CHO-AA8,185.0,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,N,,1,,CHEMBL618448,BAO_0000219,,
6744,,,,F,CHO-AA8,185.0,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,N,,1,,CHEMBL618449,BAO_0000219,,
6745,,,,F,CHO-AA8,185.0,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,N,,1,,CHEMBL618637,BAO_0000219,,
6746,,,,F,CHO-AA8,185.0,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",N,,1,,CHEMBL618638,BAO_0000219,,
6747,,,,F,CHO-AA8,185.0,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),N,,1,,CHEMBL618639,BAO_0000219,,
6748,,,,F,CHO-AA8,185.0,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",N,,1,,CHEMBL618640,BAO_0000219,,
6749,,,,F,CHO-AA8,185.0,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,N,,1,,CHEMBL618641,BAO_0000219,,
6750,,,,F,CHO-AA8,185.0,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,N,,1,,CHEMBL618642,BAO_0000219,,
6751,,,,F,CHO-AA8,185.0,,Inhibitory activity against aerobic growth of AA8 cells.,N,,1,,CHEMBL618643,BAO_0000219,,
6752,,,,A,CHO-AA8,185.0,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,N,,1,,CHEMBL884013,BAO_0000219,,
6753,,,,F,CHO-AA8,185.0,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,N,,1,,CHEMBL622723,BAO_0000219,,
6754,,,,F,CHO-AA8,185.0,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,N,,1,,CHEMBL622724,BAO_0000219,,
6755,,,,F,CHO-AA8,185.0,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,N,,1,,CHEMBL622725,BAO_0000219,,
6756,,,,F,CHO-AA8,185.0,,Cytotoxicity against AA8 cell line,N,,1,,CHEMBL622726,BAO_0000219,,
6757,,,,F,CHO-AA8,185.0,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),N,,1,,CHEMBL622727,BAO_0000219,,
6758,,,,A,CHO-AA8,185.0,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),N,,1,,CHEMBL622728,BAO_0000219,,
6759,,,,F,CHO-AA8,185.0,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),N,,1,,CHEMBL622729,BAO_0000219,,
6760,,,,A,CHO-AA8,185.0,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),N,,1,,CHEMBL622730,BAO_0000219,,
6761,,,,F,CHO-AA8,185.0,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,N,,1,,CHEMBL622731,BAO_0000219,,
6762,,,,F,CHO-AA8,185.0,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,N,,1,,CHEMBL622732,BAO_0000219,,
6763,,,,F,CHO-AA8,185.0,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,N,,1,,CHEMBL622733,BAO_0000219,,
6764,,,,F,,,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),U,,1,,CHEMBL622734,BAO_0000218,,
6765,,,,F,CHO-AA8,185.0,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,N,,1,,CHEMBL622735,BAO_0000219,,
6766,,,,F,CHO-AA8,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,U,,1,,CHEMBL618746,BAO_0000219,,
6767,,,,F,CHO-AA8,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,U,,1,,CHEMBL618747,BAO_0000219,,
6768,,,,F,CHO-AA8,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,U,,1,,CHEMBL620540,BAO_0000219,,
6769,,,,F,CHO-AA8,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,U,,1,,CHEMBL620541,BAO_0000219,,
6770,,,,F,CHO-AA8,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,U,,1,,CHEMBL620542,BAO_0000219,,
6771,,,,F,CHO-AA8,185.0,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,U,,1,,CHEMBL620543,BAO_0000219,,
6772,,,,F,CHO-AA8,185.0,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,U,,1,,CHEMBL618832,BAO_0000219,,
6773,,,,F,CHO-AA8,185.0,,Concentration required to reduce AA8 cell survival by 10%,N,,1,,CHEMBL618833,BAO_0000219,,
6774,,,,F,CHO-AA8,185.0,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",U,,1,,CHEMBL618834,BAO_0000219,,
6775,,,,F,CHO-AA8,185.0,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,U,,1,,CHEMBL618835,BAO_0000219,,
6776,,,,F,CHO-AA8,185.0,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,U,,1,,CHEMBL618836,BAO_0000219,,
6777,,,,F,CHO-AA8,185.0,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,U,,1,,CHEMBL618837,BAO_0000219,,
6778,,,,F,CHO-AA8,185.0,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,U,,1,,CHEMBL618838,BAO_0000219,,
6779,,,,F,CHO-AA8,185.0,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,U,,1,,CHEMBL618839,BAO_0000219,,
6780,,,,F,CHO-AA8,185.0,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,U,,1,,CHEMBL618840,BAO_0000219,,
6781,,,,F,,,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",U,,1,,CHEMBL618841,BAO_0000019,,
6782,,,,F,CHO-AA8,185.0,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,U,,1,,CHEMBL618842,BAO_0000219,,
6783,,,,F,CHO-AA8,185.0,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,U,,1,,CHEMBL618843,BAO_0000219,,
6784,,In vivo,,A,,,,Half life period after 15 mg/kg iv dose in Dogs,N,,1,,CHEMBL618844,BAO_0000218,,
6785,,In vivo,,A,,,,Half life period after 30 mg/kg po dose in Dogs,N,,1,,CHEMBL618845,BAO_0000218,,
6786,,In vivo,,A,,,,Half life was measured after oral 2b administration (tested in 6 dogs),N,,1,,CHEMBL618846,BAO_0000218,,
6787,,In vivo,,A,,,,Half life was measured in dog after oral 17b administration,N,,1,,CHEMBL618847,BAO_0000218,,
6788,,In vivo,,A,,,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,N,,1,,CHEMBL618848,BAO_0000218,,
6789,,In vivo,,A,,,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,N,,1,,CHEMBL618849,BAO_0000218,,
6790,,In vivo,,A,,,,Tmax value after 15 mg/kg iv dose in Dogs,N,,1,,CHEMBL618850,BAO_0000218,,
6791,,In vivo,,A,,,,Tmax value after 30 mg/kg po dose in Dogs,N,,1,,CHEMBL618851,BAO_0000218,,
6792,,In vivo,,A,,,,Compound was evaluated for its half life when administered intravenously in dog,N,,1,,CHEMBL873815,BAO_0000218,,
6793,,In vivo,Plasma,A,,,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),N,,1,,CHEMBL618852,BAO_0000218,1969.0,
6794,,,,A,,,,Elimination Half-life of compound was determined in dog,N,,1,,CHEMBL618853,BAO_0000218,,
6795,,In vivo,,A,,,,Half life of compound in dog following oral administration,N,,1,,CHEMBL618854,BAO_0000218,,
6796,,,,A,,,,Half life of compound was determined in dog,N,,1,,CHEMBL618855,BAO_0000218,,
6797,,,Blood,A,,,,Half life of compound was determined in dog blood,N,,1,,CHEMBL618856,BAO_0000218,178.0,
6798,,In vivo,,A,,,,Half life after oral and iv dosing in dogs,N,,1,,CHEMBL875827,BAO_0000218,,
6799,,,,A,,,,Half life in dogs in hours,N,,1,,CHEMBL618857,BAO_0000218,,
6800,,In vivo,,A,,,,Half life on i.v. administration of 2 mg/kg was measured in dog,N,,1,,CHEMBL618858,BAO_0000218,,
6801,,In vivo,,A,,,,t1/2 in dog after oral dose (1 mg/kg),N,,1,,CHEMBL618859,BAO_0000218,,
6802,,,,A,,,,Half life was evaluated in dog,N,,1,,CHEMBL618860,BAO_0000218,,
6803,,In vivo,,A,,,,Half life period of compound was determined after intravenous administration at 2 mg/kg,N,,1,,CHEMBL618861,BAO_0000218,,
6804,,In vivo,,A,,,,Half life period of compound was determined after peroral administration at 2 mg/kg,N,,1,,CHEMBL622539,BAO_0000218,,
6805,,In vivo,,A,,,,Half life period (10 mg/kg) was determined in dog,N,,1,,CHEMBL622540,BAO_0000218,,
6806,,In vivo,,A,,,,Half life period (10 mg/kg) was determined in dog,N,,1,,CHEMBL873803,BAO_0000218,,
6807,,In vivo,,A,,,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,N,,1,,CHEMBL873804,BAO_0000218,,
6808,,In vivo,,A,,,,Half life period by po administration in dog at a dose of 0.3 mg/kg,N,,1,,CHEMBL624311,BAO_0000218,,
6809,,,,A,,,,Half life period in dog,N,,1,,CHEMBL624312,BAO_0000218,,
6810,,In vivo,,A,,,,Half life period in dogs after oral administration at 1 mg/kg,N,,1,,CHEMBL624313,BAO_0000218,,
6811,,In vivo,,A,,,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,,1,,CHEMBL624314,BAO_0000218,,
6812,,,,A,,,,Half-life of compound was determined in dogs,N,,1,,CHEMBL624315,BAO_0000218,,
6813,,,Plasma,A,,,,Half-life in dog plasma,N,,1,,CHEMBL624316,BAO_0000218,1969.0,
6814,,,,A,,,,Half-life in mongrel dogs was determined,N,,1,,CHEMBL624317,BAO_0000218,,
6815,,In vivo,,A,,,,Half-life in dog upon oral administration,N,,1,,CHEMBL624318,BAO_0000218,,
6816,,In vivo,,A,,,,Half-life in dog upon oral administration; Unable to calculate,N,,1,,CHEMBL624319,BAO_0000218,,
6817,,,,A,,,,Half-life was measured in dog,N,,1,,CHEMBL624496,BAO_0000218,,
6818,,,,A,,,,Half-life was measured in dog,N,,1,,CHEMBL624497,BAO_0000218,,
6819,,,,A,,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,N,,1,,CHEMBL624498,BAO_0000218,,
6820,,In vivo,,A,,,,Oral half life was determined,N,,1,,CHEMBL624499,BAO_0000218,,
6821,,In vivo,Plasma,A,,,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,N,,1,,CHEMBL624500,BAO_0000218,1969.0,
6822,,,Plasma,A,,,,Plasma half life was evaluated,N,,1,,CHEMBL624501,BAO_0000218,1969.0,
6823,,,Plasma,A,,,,Plasma half life was evaluated in Dog,N,,1,,CHEMBL623666,BAO_0000218,1969.0,
6824,,,Plasma,A,,,,Plasma half life was evaluated in dog,N,,1,,CHEMBL623667,BAO_0000218,1969.0,
6825,,In vivo,,A,,,,T1/2 (Half-life) was after oral administration at 5 mg/kg,N,,1,,CHEMBL623668,BAO_0000218,,
6826,,,,A,,,,Tested for the half life value in dog,N,,1,,CHEMBL623669,BAO_0000218,,
6827,,In vivo,,A,,,,Maximum time at the dose of 2 mg/kg in dog,N,,1,,CHEMBL623670,BAO_0000218,,
6828,,In vivo,,A,,,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,,1,,CHEMBL623671,BAO_0000218,,
6829,,In vivo,Blood,A,,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,,1,,CHEMBL875945,BAO_0000218,178.0,
6830,,In vivo,Blood,A,,,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,,1,,CHEMBL623672,BAO_0000218,178.0,
6831,,In vivo,,A,,,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,N,,1,,CHEMBL623673,BAO_0000218,,
6832,,In vivo,,A,,,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),N,,1,,CHEMBL623674,BAO_0000218,,
6833,,In vivo,,A,,,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,N,,1,,CHEMBL623675,BAO_0000218,,
6834,,,,A,,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",N,,1,,CHEMBL872526,BAO_0000218,,
6835,,In vivo,,A,,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",N,,1,,CHEMBL623676,BAO_0000218,,
6836,,In vivo,Plasma,A,,,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,N,,1,,CHEMBL623677,BAO_0000218,1969.0,
6837,,In vivo,Plasma,A,,,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,N,,1,,CHEMBL623678,BAO_0000218,1969.0,
6838,,,Plasma,A,,,,Time taken for maximum plasma concentration in dog,N,,1,,CHEMBL623679,BAO_0000218,1969.0,
6839,,In vivo,,A,,,,Time to reach Cmax after oral administration to dogs,N,,1,,CHEMBL623680,BAO_0000218,,
6840,,In vivo,Plasma,A,,,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,,1,,CHEMBL623681,BAO_0000218,1969.0,
6841,,In vivo,,A,,,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,N,,1,,CHEMBL623682,BAO_0000218,,
6842,,In vivo,,A,,,,Tmax after peroral administration (1 mg/kg) was determined in dog,N,,1,,CHEMBL623683,BAO_0000218,,
6843,,In vivo,,A,,,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,N,,1,,CHEMBL623684,BAO_0000218,,
6844,,In vivo,,A,,,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,N,,1,,CHEMBL622745,BAO_0000218,,
6845,,In vivo,,A,,,,Tmax after peroral administration in dogs at 2.4 uM/kg,N,,1,,CHEMBL622746,BAO_0000218,,
6846,,In vivo,,A,,,,In vivo Cmax in mice at dose of 100 mg/kg,N,,1,,CHEMBL622747,BAO_0000218,,
6847,,In vivo,,A,,,,In vivo Cmax in mice at dose of 50 mg/kg,N,,1,,CHEMBL622748,BAO_0000218,,
6848,,In vivo,,A,,,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,N,,1,,CHEMBL622749,BAO_0000218,,
6849,,In vivo,Plasma,A,,,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),N,,1,,CHEMBL622750,BAO_0000218,1969.0,
6850,,In vivo,Plasma,A,,,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,N,,1,,CHEMBL623411,BAO_0000218,1969.0,
6851,,In vivo,Plasma,A,,,,Maximum concentration obtained in mouse plasma was determined,N,,1,,CHEMBL875946,BAO_0000218,1969.0,
6852,,In vivo,Plasma,A,,,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,N,,1,,CHEMBL623412,BAO_0000218,1969.0,
6853,,In vivo,Plasma,A,,,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,,1,,CHEMBL623413,BAO_0000218,1969.0,
6854,,In vivo,Plasma,A,,,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,N,,1,,CHEMBL623414,BAO_0000218,1969.0,
6855,,In vivo,Plasma,A,,,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,N,,1,,CHEMBL623415,BAO_0000218,1969.0,
6856,,In vivo,Plasma,A,,,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,N,,1,,CHEMBL623416,BAO_0000218,1969.0,
6857,,In vivo,Plasma,A,,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,N,,1,,CHEMBL623417,BAO_0000218,1969.0,
6858,,In vivo,Plasma,A,,,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,N,,1,,CHEMBL623418,BAO_0000218,1969.0,
6859,,In vivo,Plasma,A,,,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,N,,1,,CHEMBL623419,BAO_0000218,1969.0,
6860,,In vivo,,A,,,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,N,,1,,CHEMBL622816,BAO_0000218,,
6861,,In vivo,,A,,,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,N,,1,,CHEMBL623313,BAO_0000218,,
6862,,In vivo,,A,,,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,N,,1,,CHEMBL623314,BAO_0000218,,
6863,,In vivo,,A,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,N,,1,,CHEMBL876788,BAO_0000218,,
6864,,In vivo,,A,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,N,,1,,CHEMBL623315,BAO_0000218,,
6865,,In vivo,,A,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,N,,1,,CHEMBL623316,BAO_0000218,,
6866,,In vivo,,A,,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,N,,1,,CHEMBL623317,BAO_0000218,,
6868,,In vivo,,A,,,,Cmax in male mice after 2 mg/kg oral dose,N,,1,,CHEMBL623319,BAO_0000218,,
6869,,In vivo,,A,,,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,N,,1,,CHEMBL623320,BAO_0000218,,
6870,,In vivo,,A,,,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,N,,1,,CHEMBL623321,BAO_0000218,,
6871,,,,A,,,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,N,,1,,CHEMBL623322,BAO_0000218,,
6872,,,,A,,,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,N,,1,,CHEMBL623323,BAO_0000218,,
6873,,,,A,,,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,N,,1,,CHEMBL623324,BAO_0000218,,
6874,,,,A,,,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,N,,1,,CHEMBL623325,BAO_0000218,,
6875,,,,A,,,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,N,,1,,CHEMBL623326,BAO_0000218,,
6876,,,,A,,,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,N,,1,,CHEMBL623327,BAO_0000218,,
6877,,,Plasma,A,,,,Maximum concentration in plasma upon oral administration in mouse,N,,1,,CHEMBL623328,BAO_0000218,1969.0,
6878,,,Plasma,A,,,,Maximum plasma concentration was evaluated in mice after oral administration,N,,1,,CHEMBL623329,BAO_0000218,1969.0,
6879,,In vivo,Plasma,A,,,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,N,,1,,CHEMBL623330,BAO_0000218,1969.0,
6880,,,,A,,,,Dose at which the compound induced fecal excretion in mice,N,,1,,CHEMBL876789,BAO_0000218,,
6893,,,,F,A10,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,N,,1,,CHEMBL623333,BAO_0000219,,
6894,,,,F,A10,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,N,,1,,CHEMBL623334,BAO_0000219,,
6895,,,,F,A10,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,N,,1,,CHEMBL627536,BAO_0000219,,
6896,,,,F,A10,164.0,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,N,,1,,CHEMBL627537,BAO_0000219,,
6897,,,,F,A10,164.0,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),N,,1,,CHEMBL627538,BAO_0000219,,
6898,,,,F,A121,393.0,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,N,,1,,CHEMBL884106,BAO_0000219,,
6899,,,,F,A121,393.0,,Anticancer activity against human ovarian carcinoma A121 cells,N,,1,,CHEMBL625294,BAO_0000219,,
6900,,,,F,A121,393.0,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,N,,1,,CHEMBL625295,BAO_0000219,,
6901,,,,F,A121,393.0,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,N,,1,,CHEMBL625296,BAO_0000219,,
6902,,,,F,A121,393.0,,Growth inhibition of human ovarian carcinoma (A121) cell line,N,,1,,CHEMBL625297,BAO_0000219,,
6903,,,,F,A121,393.0,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,N,,1,,CHEMBL625298,BAO_0000219,,
6904,,,,F,A121,393.0,,Cytotoxicity against human A121 ovarian cells,N,,1,,CHEMBL625960,BAO_0000219,,
6905,,,,F,A121,393.0,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,N,,1,,CHEMBL625961,BAO_0000219,,
6906,,,,F,A121,393.0,,In vitro cytotoxicity against human ovarian carcinoma A21,N,,1,,CHEMBL625962,BAO_0000219,,
6907,,,,F,A121,393.0,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,N,,1,,CHEMBL624717,BAO_0000219,,
6908,,,,F,A121,393.0,,Inhibitory activity of compound against human A121 ovarian cell line.,N,,1,,CHEMBL624718,BAO_0000219,,
6909,,,,F,A121,393.0,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,N,,1,,CHEMBL624719,BAO_0000219,,
6910,,,,F,A121,393.0,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,N,,1,,CHEMBL624720,BAO_0000219,,
6911,,,,F,A 172,622.0,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,N,,1,,CHEMBL624721,BAO_0000219,,
6912,,,,F,A 172,622.0,,In vitro cytotoxicity against A172 human tumor cell lines.,N,,1,,CHEMBL624722,BAO_0000219,,
6913,,,,F,A 172,622.0,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,N,,1,,CHEMBL877597,BAO_0000219,,
6914,,,,F,A 172,622.0,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,N,,1,,CHEMBL624723,BAO_0000219,,
6915,,,,F,A 172,622.0,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,N,,1,,CHEMBL624724,BAO_0000219,,
6916,,,,B,,,,Association constant against A2 adenosine receptor,H,,1,,CHEMBL624725,BAO_0000224,,
6917,,,,F,A2,1085.0,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,N,,1,,CHEMBL624726,BAO_0000219,,
6918,,,,B,,,,Ratio of Ki for adenosine A2 and A1 receptor binding,D,,1,,CHEMBL857535,BAO_0000224,,
6919,,,,F,A204,623.0,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,N,,1,,CHEMBL624727,BAO_0000219,,
6920,,,,F,A204,623.0,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,N,,1,,CHEMBL624728,BAO_0000219,,
6921,,,,F,A2058,404.0,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,N,,1,,CHEMBL624729,BAO_0000219,,
6922,,,,F,A253 cell line,973.0,,Growth inhibition against Human squamous cell line(A 253),N,,1,,CHEMBL624730,BAO_0000219,,
6923,,,,F,A253 cell line,973.0,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,N,,1,,CHEMBL624731,BAO_0000219,,
6924,,,,F,A253 cell line,973.0,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,N,,1,,CHEMBL624732,BAO_0000219,,
6925,,,,F,A253 cell line,973.0,,Growth inhibition of A253 cell lines.,N,,1,,CHEMBL883245,BAO_0000219,,
6926,,,,F,A253 cell line,973.0,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),N,,1,,CHEMBL624733,BAO_0000219,,
6927,,,,F,A253 cell line,973.0,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,N,,1,,CHEMBL624734,BAO_0000219,,
6928,,,,F,A253 cell line,973.0,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,N,,1,,CHEMBL624735,BAO_0000219,,
6929,,,,F,A2780,478.0,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,N,,1,,CHEMBL621780,BAO_0000219,,
6930,,,,F,A2780,478.0,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,N,,1,,CHEMBL877598,BAO_0000219,,
6931,,,,F,A2780,478.0,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,N,,1,,CHEMBL621781,BAO_0000219,,
6932,,,,F,A2780,478.0,,Cytotoxicity against human cancer cell lines A2780 (ovarian),N,,1,,CHEMBL621782,BAO_0000219,,
6933,,,,F,A2780,478.0,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,N,,1,,CHEMBL621783,BAO_0000219,,
6934,,,,F,A2780,478.0,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,N,,1,,CHEMBL621784,BAO_0000219,,
6935,,,,F,A2780,478.0,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),N,,1,,CHEMBL621785,BAO_0000219,,
6936,,,,F,A2780,478.0,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,N,,1,,CHEMBL621968,BAO_0000219,,
6937,,,,F,A2780,478.0,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,N,,1,,CHEMBL621969,BAO_0000219,,
6938,,,,F,A2780,478.0,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,N,,1,,CHEMBL621970,BAO_0000219,,
6939,,,,F,A2780,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,N,,1,,CHEMBL621971,BAO_0000219,,
6940,,,,F,A2780,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,N,,1,,CHEMBL621972,BAO_0000219,,
6941,,,,F,A2780,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,N,,1,,CHEMBL884108,BAO_0000219,,
6942,,,,F,,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,U,,1,,CHEMBL623826,BAO_0000019,,
6943,,,,A,CHO-AA8,185.0,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,U,,1,,CHEMBL623827,BAO_0000219,,
6944,,,,F,CHO-AA8,185.0,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,U,,1,,CHEMBL623828,BAO_0000219,,
6945,,,,F,CHO-AA8,185.0,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,U,,1,,CHEMBL623829,BAO_0000219,,
6946,,,,F,CHO-AA8,185.0,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),U,,1,,CHEMBL623830,BAO_0000219,,
6947,,,,F,,,,Growth inhibition against CHO-derived cell line AA8,U,,1,,CHEMBL623831,BAO_0000019,,
6948,,,,F,CHO-AA8,185.0,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],U,,1,,CHEMBL623832,BAO_0000219,,
6949,,,,F,CHO-AA8,185.0,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,N,,1,,CHEMBL623833,BAO_0000219,,
6950,,,,F,CHO-AA8,185.0,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,N,,1,,CHEMBL623834,BAO_0000219,,
6951,,,,F,CHO-AA8,185.0,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,U,,1,,CHEMBL623835,BAO_0000219,,
6952,,,,F,CHO-AA8,185.0,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,U,,1,,CHEMBL623836,BAO_0000219,,
6953,,,,F,CHO-AA8,185.0,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,U,,1,,CHEMBL623837,BAO_0000219,,
6954,,,,F,CHO-AA8,185.0,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,N,,1,,CHEMBL623838,BAO_0000219,,
6955,,,,F,,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,H,,1,,CHEMBL623839,BAO_0000019,,
6956,,,,F,,,,Number of binding sites (n) of isolated serum protein AAG,H,,1,,CHEMBL623840,BAO_0000019,,
6957,,,,B,,,,Association constant for binding to AATT duplex,M,,1,,CHEMBL623841,BAO_0000225,,
6958,,,,F,ABAE,416.0,,Inhibition of ABAE human fibroblast cell proliferation,N,,1,,CHEMBL623842,BAO_0000219,,
6959,,,,F,AC755,1064.0,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",N,,1,,CHEMBL623843,BAO_0000218,,
6960,,,,F,,,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,D,,1,,CHEMBL618669,BAO_0000218,,
6961,,In vivo,,F,,,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,D,,1,,CHEMBL618670,BAO_0000218,,
6962,,,,B,,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,H,,1,,CHEMBL618671,BAO_0000357,,
6963,,,,B,,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,H,,1,,CHEMBL618672,BAO_0000357,,
6964,,,,F,ACH-2 cell line,978.0,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,N,,1,,CHEMBL618673,BAO_0000219,,
6965,,,,F,ACH-2 cell line,978.0,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),N,,1,,CHEMBL618674,BAO_0000219,,
6966,,,,F,T cell line,998.0,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,U,,1,,CHEMBL618675,BAO_0000219,,
6967,,,,F,T cell line,998.0,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),U,,1,,CHEMBL618676,BAO_0000219,,
6968,,,,F,T cell line,998.0,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),U,,1,,CHEMBL618677,BAO_0000219,,
6969,,,,F,ACHN,626.0,,Inhibition of growth of renal cancer ACHN cell line,N,,1,,CHEMBL618678,BAO_0000219,,
6970,,,,F,ACHN,626.0,,Inhibition of growth of ACHN renal cancer cell line,N,,1,,CHEMBL618679,BAO_0000219,,
6971,,,,F,ACHN,626.0,,Inhibitory concentration required against ACHN renal cancer cell line,N,,1,,CHEMBL618680,BAO_0000219,,
6972,,,,F,ACHN,626.0,,Concentration required to inhibit growth of human renal (ACHN) cell line,N,,1,,CHEMBL618681,BAO_0000219,,
6973,,,,F,ACHN,626.0,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,N,,1,,CHEMBL618682,BAO_0000219,,
6974,,,,F,ACHN,626.0,,Cytotoxic activity against ACHN Renal cancer cell line,N,,1,,CHEMBL618683,BAO_0000219,,
6975,,,,F,ACHN,626.0,,Cytotoxicity evaluation against ACHN renal cancer cells,N,,1,,CHEMBL618684,BAO_0000219,,
6976,,,,F,ACHN,626.0,,In vitro antitumor activity against human renal ACHN cell line,N,,1,,CHEMBL618685,BAO_0000219,,
6977,,,,F,ACHN,626.0,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,N,,1,,CHEMBL876499,BAO_0000219,,
6978,,,,F,ACHN,626.0,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,N,,1,,CHEMBL618686,BAO_0000219,,
6979,,,,F,ACHN,626.0,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",N,,1,,CHEMBL618687,BAO_0000219,,
6980,,,,F,ACHN,626.0,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,N,,1,,CHEMBL618688,BAO_0000219,,
6981,,,,F,ACHN,626.0,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,N,,1,,CHEMBL618689,BAO_0000219,,
6982,,,,F,ACHN,626.0,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,N,,1,,CHEMBL618690,BAO_0000219,,
6983,,,,F,ACHN,626.0,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,N,,1,,CHEMBL618691,BAO_0000219,,
6984,,,,F,ACHN,626.0,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),N,,1,,CHEMBL619373,BAO_0000219,,
6985,,,,F,ACHN,626.0,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",N,,1,,CHEMBL884008,BAO_0000219,,
6986,,,,F,ACHN,626.0,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,N,,1,,CHEMBL619374,BAO_0000219,,
6987,,,,F,ACHN,626.0,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,N,,1,,CHEMBL619375,BAO_0000219,,
6988,,,,F,ACHN,626.0,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,N,,1,,CHEMBL619376,BAO_0000219,,
6989,,,,F,ACHN,626.0,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,N,,1,,CHEMBL619377,BAO_0000219,,
6990,,,,F,ACHN,626.0,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,N,,1,,CHEMBL619378,BAO_0000219,,
6991,,In vivo,,A,,,,Tmax value after administration of 4 mg/Kg oral dose in dog,N,,1,,CHEMBL872527,BAO_0000218,,
6992,,,,A,,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",N,,1,,CHEMBL876500,BAO_0000218,,
6993,,,,A,,,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,N,,1,,CHEMBL619379,BAO_0000218,,
6994,,In vivo,,A,,,,Volume distribution after 15 mg/kg iv dose in Dogs,N,,1,,CHEMBL619538,BAO_0000218,,
6995,,In vivo,,A,,,,Volume distribution after 30 mg/kg po dose in Dogs,N,,1,,CHEMBL619539,BAO_0000218,,
6996,,In vivo,,A,,,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,N,,1,,CHEMBL619540,BAO_0000218,,
6997,,In vivo,,A,,,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,N,,1,,CHEMBL619541,BAO_0000218,,
6998,,In vivo,,A,,,,Volume of distribution was evaluated in dog,N,,1,,CHEMBL619542,BAO_0000218,,
6999,,In vivo,,A,,,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,N,,1,,CHEMBL619543,BAO_0000218,,
7000,,,,A,,,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,N,,1,,CHEMBL619544,BAO_0000218,,
7001,,In vivo,,A,,,,The compound was tested for volume of distribution in dog,N,,1,,CHEMBL619545,BAO_0000218,,
7002,,In vivo,,A,,,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,N,,1,,CHEMBL619546,BAO_0000218,,
7003,,In vivo,,A,,,,Vd (1 mg/kg) was determined in dog (in vivo),N,,1,,CHEMBL619547,BAO_0000218,,
7004,,In vivo,,A,,,,Vd in dog,N,,1,,CHEMBL619548,BAO_0000218,,
7005,,In vivo,,A,,,,Volume distribution was determined,N,,1,,CHEMBL619549,BAO_0000218,,
7006,,In vivo,,A,,,,Volume of distribution in dog,N,,1,,CHEMBL619550,BAO_0000218,,
7007,,In vivo,,A,,,,Volume of distribution by as 4 fold increase by iv administration in dogs,N,,1,,CHEMBL876501,BAO_0000218,,
7008,,In vivo,,A,,,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,N,,1,,CHEMBL619551,BAO_0000218,,
7009,,In vivo,,A,,,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,,1,,CHEMBL619552,BAO_0000218,,
7010,,In vivo,,A,,,,Volume distribution at the dose of 2 mg/kg in dog,N,,1,,CHEMBL619553,BAO_0000218,,
7011,,In vivo,,A,,,,Steady state volume of distribution was determined,N,,1,,CHEMBL618722,BAO_0000218,,
7012,,In vivo,,A,,,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,N,,1,,CHEMBL618723,BAO_0000218,,
7013,,In vivo,,A,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,N,,1,,CHEMBL618724,BAO_0000218,,
7014,,In vivo,,A,,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,N,,1,,CHEMBL618725,BAO_0000218,,
7015,,In vivo,,A,,,,Bioavailability in dog (dose 1 mg/kg i.v.),N,,1,,CHEMBL618726,BAO_0000218,,
7016,,In vivo,,A,,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),N,,1,,CHEMBL618727,BAO_0000218,,
7017,,In vivo,,A,,,,Pharmacokinetic property (vdss) was measured in dog,N,,1,,CHEMBL624233,BAO_0000218,,
7018,,In vivo,,A,,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,N,,1,,CHEMBL624234,BAO_0000218,,
7019,,In vivo,,A,,,,Vdss was determined after iv 0.1 mg/kg administration in dog,N,,1,,CHEMBL624235,BAO_0000218,,
7020,,In vivo,,A,,,,Volume displacement was calculated in dog,N,,1,,CHEMBL624236,BAO_0000218,,
7021,,In vivo,,A,,,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,N,,1,,CHEMBL624237,BAO_0000218,,
7022,,In vivo,,A,,,,Volume distribution constant was determined,N,,1,,CHEMBL624238,BAO_0000218,,
7023,,In vivo,,A,,,,Volume distribution at a dose of 1 uM/kg in dog was determined,N,,1,,CHEMBL624239,BAO_0000218,,
7024,,In vivo,,A,,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,N,,1,,CHEMBL875829,BAO_0000218,,
7025,,In vivo,,A,,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,,1,,CHEMBL624240,BAO_0000218,,
7026,,In vivo,,A,,,,Volume distribution (Vdss) was measured in dog,N,,1,,CHEMBL624241,BAO_0000218,,
7027,,In vivo,,A,,,,Volume distribution (Vdss) was measured in dog,N,,1,,CHEMBL624242,BAO_0000218,,
7028,,In vivo,,A,,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,1,,CHEMBL624243,BAO_0000218,,
7029,,In vivo,,A,,,,Volume of distribution in steady state was determined in dog,N,,1,,CHEMBL624244,BAO_0000218,,
7030,,In vivo,,A,,,,Volume of distribution of compound was determined in dog,N,,1,,CHEMBL624245,BAO_0000218,,
7031,,In vivo,,A,,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,N,,1,,CHEMBL624246,BAO_0000218,,
7032,,In vivo,,A,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),N,,1,,CHEMBL624247,BAO_0000218,,
7033,,In vivo,,A,,,,Volume of distribution (Vdss) was measured in dog,N,,1,,CHEMBL624248,BAO_0000218,,
7034,,In vivo,,A,,,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,,1,,CHEMBL624249,BAO_0000218,,
7035,,In vivo,,A,,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,,1,,CHEMBL624250,BAO_0000218,,
7036,,In vivo,,A,,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,,1,,CHEMBL624251,BAO_0000218,,
7037,,,,A,,,,Maximum rate of depolarization of the upstroke of the action potential,N,,1,,CHEMBL624252,BAO_0000218,,
7038,,In vivo,,A,,,,Steady state volume distribution in dog,N,,1,,CHEMBL624253,BAO_0000218,,
7039,,In vivo,,A,,,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,N,,1,,CHEMBL624950,BAO_0000218,,
7040,,In vivo,,A,,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,N,,1,,CHEMBL624951,BAO_0000218,,
7041,,In vivo,,A,,,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,N,,1,,CHEMBL875830,BAO_0000218,,
7042,,In vivo,,A,,,,Volume distribution in dog after administration of 1 mg/kg iv,N,,1,,CHEMBL624952,BAO_0000218,,
7043,,In vivo,,A,,,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,N,,1,,CHEMBL624953,BAO_0000218,,
7044,,In vivo,,A,,,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,N,,1,,CHEMBL624954,BAO_0000218,,
7045,,In vivo,,A,,,,Vss on i.v. administration of 2 mg/kg was measured in dog,N,,1,,CHEMBL624955,BAO_0000218,,
7046,,,,A,,,,Vss was determined,N,,1,,CHEMBL624956,BAO_0000218,,
7047,,,,A,,,,Vss in dog,N,,1,,CHEMBL625129,BAO_0000218,,
7048,,In vivo,,A,,,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,N,,1,,CHEMBL625130,BAO_0000218,,
7049,,In vivo,,A,,,,Volume distribution in dogs,N,,1,,CHEMBL625131,BAO_0000218,,
7050,,In vivo,,A,,,,Volume of distribution in dog,N,,1,,CHEMBL625132,BAO_0000218,,
7051,,In vivo,,A,,,,Tested for the oral bioavailability in dog,N,,1,,CHEMBL872263,BAO_0000218,,
7060,,In vivo,,A,,,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,N,,1,,CHEMBL624336,BAO_0000218,,
7061,,In vivo,,A,,,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,N,,1,,CHEMBL624337,BAO_0000218,,
7062,,In vivo,,A,,,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,N,,1,,CHEMBL624338,BAO_0000218,,
7063,,In vivo,,A,,,,Bioavailability was measured in mouse,N,,1,,CHEMBL624339,BAO_0000218,,
7064,,In vivo,,A,,,,Bioavailability in mouse,N,,1,,CHEMBL624340,BAO_0000218,,
7065,,In vivo,,A,,,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,,1,,CHEMBL624341,BAO_0000218,,
7066,,In vivo,,A,,,,Bioavailability in mouse,N,,1,,CHEMBL624342,BAO_0000218,,
7067,,In vivo,,A,,,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,N,,1,,CHEMBL624343,BAO_0000218,,
7068,,In vivo,,A,,,,Oral bioavailability in mouse,N,,1,,CHEMBL624344,BAO_0000218,,
7069,,In vivo,,A,,,,Oral availability at 50 mg/kg po in male mice,N,,1,,CHEMBL624345,BAO_0000218,,
7070,,In vivo,,A,,,,Oral bioavailability in mouse (dose 10 mg/kg),N,,1,,CHEMBL624346,BAO_0000218,,
7071,,In vivo,,A,,,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,N,,1,,CHEMBL624347,BAO_0000218,,
7072,,In vivo,,A,,,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",N,,1,,CHEMBL624348,BAO_0000218,,
7074,,In vivo,,A,,,,Oral bioavailability in mouse,N,,1,,CHEMBL622754,BAO_0000218,,
7075,,In vivo,,A,,,,Oral bioavailability in vivo in mice;ND=Not determined,N,,1,,CHEMBL622755,BAO_0000218,,
7076,,In vivo,,A,,,,Oral bioavailability in mouse at 10 mg/kg of the compound,N,,1,,CHEMBL622756,BAO_0000218,,
7077,,In vivo,,A,,,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),N,,1,,CHEMBL622757,BAO_0000218,,
7078,,In vivo,,A,,,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),N,,1,,CHEMBL622758,BAO_0000218,,
7079,,In vivo,,A,,,,Tested for bioavailability of the compound,N,,1,,CHEMBL622759,BAO_0000218,,
7080,,In vivo,,A,,,,Tested for half life at the dose of 10 mg/kg when administered intravenously,N,,1,,CHEMBL622760,BAO_0000218,,
7081,,,Plasma,A,,,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,N,,1,,CHEMBL622761,BAO_0000218,1969.0,
7082,,,Plasma,A,,,,The plasma half life of compound was determined on heparin prepared by human plasma. ,N,,1,,CHEMBL622762,BAO_0000218,1969.0,
7083,,,Plasma,A,,,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,N,,1,,CHEMBL622763,BAO_0000218,1969.0,
7084,,,Plasma,A,,,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,N,,1,,CHEMBL622764,BAO_0000218,1969.0,
7085,,,Plasma,A,,,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,N,,1,,CHEMBL622765,BAO_0000218,1969.0,
7086,,,,F,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,N,,1,,CHEMBL622766,BAO_0000218,,
7087,,,,A,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,N,,1,,CHEMBL622767,BAO_0000218,,
7088,,,,A,,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,N,,1,,CHEMBL622768,BAO_0000218,,
7089,,In vivo,Blood,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,1,,CHEMBL875948,BAO_0000218,178.0,
7090,,In vivo,Blood,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,1,,CHEMBL622769,BAO_0000218,178.0,
7091,,In vivo,Blood,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,1,,CHEMBL622770,BAO_0000218,178.0,
7092,,In vivo,Blood,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,1,,CHEMBL622771,BAO_0000218,178.0,
7093,,In vivo,Blood,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,1,,CHEMBL622772,BAO_0000218,178.0,
7094,,In vivo,Blood,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,1,,CHEMBL622773,BAO_0000218,178.0,
7095,,In vivo,Blood,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,1,,CHEMBL622774,BAO_0000218,178.0,
7096,,In vivo,Bone,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,1,,CHEMBL621725,BAO_0000218,10000001.0,
7097,,In vivo,Bone,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,,1,,CHEMBL621726,BAO_0000218,10000001.0,
7098,,,,F,A2780,478.0,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,N,,1,,CHEMBL621727,BAO_0000219,,
7099,,,,F,A2780,478.0,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,N,,1,,CHEMBL622413,BAO_0000219,,
7100,,,,F,A2780,478.0,,Compound was evaluated for cytotoxicity against A2780 cell line,N,,1,,CHEMBL622414,BAO_0000219,,
7101,,,,F,A2780,478.0,,Inhibition of A2780 cell clonogenic assay,N,,1,,CHEMBL622415,BAO_0000219,,
7102,,,,F,A2780,478.0,,Cytotoxic effect on ovarian cancer cell line (A2780),N,,1,,CHEMBL884001,BAO_0000219,,
7103,,,,F,A2780,478.0,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,N,,1,,CHEMBL622416,BAO_0000219,,
7104,,,,F,A2780,478.0,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",N,,1,,CHEMBL622417,BAO_0000219,,
7105,,,,F,A2780,478.0,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,N,,1,,CHEMBL622590,BAO_0000219,,
7106,,,,F,A2780,478.0,,Antiproliferative activity against human A2780 cells,N,,1,,CHEMBL622591,BAO_0000219,,
7107,,,,F,A2780,478.0,,Inhibition of human A2780 cell proliferation,N,,1,,CHEMBL622592,BAO_0000219,,
7108,,,,F,A2780,478.0,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,N,,1,,CHEMBL622593,BAO_0000219,,
7109,,,,F,A2780,478.0,,Inhibition of human A2780 cell proliferation (No data),N,,1,,CHEMBL622594,BAO_0000219,,
7110,,,,F,A2780,478.0,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,N,,1,,CHEMBL622595,BAO_0000219,,
7111,,,,F,A2780,478.0,,Compound was evaluated against human Ovarian carcinoma cell line A2780,N,,1,,CHEMBL622596,BAO_0000219,,
7112,,,,F,A2780,478.0,,Growth inhibition against A2780 wild-type ovarian cell lines,N,,1,,CHEMBL622597,BAO_0000219,,
7113,,,,F,A2780,478.0,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,N,,1,,CHEMBL622598,BAO_0000219,,
7114,,,,F,,,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,D,,1,,CHEMBL622599,BAO_0000019,,
7115,,,,F,A2780,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,N,,1,,CHEMBL622600,BAO_0000219,,
7116,,,,F,A2780,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,N,,1,,CHEMBL622601,BAO_0000219,,
7117,,,,F,A2780,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,N,,1,,CHEMBL622602,BAO_0000219,,
7118,,,,F,A2780,478.0,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,N,,1,,CHEMBL622603,BAO_0000219,,
7119,,,,F,A2780,478.0,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,N,,1,,CHEMBL622604,BAO_0000219,,
7120,,,,F,A2780,478.0,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,N,,1,,CHEMBL622605,BAO_0000219,,
7121,,,,F,A2780,478.0,,In vitro inhibition of human ovarian cell line A2780,N,,1,,CHEMBL622606,BAO_0000219,,
7122,,,,F,A2780,478.0,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",N,,1,,CHEMBL619463,BAO_0000219,,
7123,,,,F,A2780,478.0,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),N,,1,,CHEMBL619464,BAO_0000219,,
7124,,,,F,A2780,478.0,,Concentration required to inhibit A2780-cell growth by 50%,N,,1,,CHEMBL619465,BAO_0000219,,
7125,,,,F,A2780,478.0,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,N,,1,,CHEMBL619466,BAO_0000219,,
7126,,,,F,A2780,478.0,,Cytotoxic effect on human ovarian (A2780) cancer cell line,N,,1,,CHEMBL619467,BAO_0000219,,
7127,,,,F,A2780,478.0,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,N,,1,,CHEMBL619468,BAO_0000219,,
7128,,,,F,A2780,478.0,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,N,,1,,CHEMBL619469,BAO_0000219,,
7129,,,,F,A2780,478.0,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,N,,1,,CHEMBL619470,BAO_0000219,,
7130,,,,F,A2780,478.0,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,N,,1,,CHEMBL619471,BAO_0000219,,
7131,,,,F,A2780,478.0,,Cytotoxicity against human ovarian carcinoma A2780 cell line,N,,1,,CHEMBL619472,BAO_0000219,,
7132,,,,F,A2780,478.0,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",N,,1,,CHEMBL619473,BAO_0000219,,
7133,,,,F,A2780,478.0,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",N,,1,,CHEMBL874368,BAO_0000219,,
7134,,,,F,A2780,478.0,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",N,,1,,CHEMBL884003,BAO_0000219,,
7135,,,,F,A2780,478.0,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",N,,1,,CHEMBL622690,BAO_0000219,,
7136,,,,F,A2780,478.0,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,N,,1,,CHEMBL622691,BAO_0000219,,
7137,,,,F,A2780,478.0,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,N,,1,,CHEMBL622692,BAO_0000219,,
7138,,,,F,A2780,478.0,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,N,,1,,CHEMBL623406,BAO_0000219,,
7139,,,,F,A2780,478.0,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",N,,1,,CHEMBL884004,BAO_0000219,,
7140,,,,F,A2780,478.0,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,N,,1,,CHEMBL623407,BAO_0000219,,
7141,,,,F,A2780,478.0,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,N,,1,,CHEMBL623408,BAO_0000219,,
7142,,,,F,A2780,478.0,,In vitro antitumor activity against A2780 cell line.,N,,1,,CHEMBL623409,BAO_0000219,,
7143,,,,F,A2780,478.0,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,N,,1,,CHEMBL623410,BAO_0000219,,
7144,,,,F,A2780,478.0,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,N,,1,,CHEMBL623576,BAO_0000219,,
7145,,,,F,ACHN,626.0,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,N,,1,,CHEMBL623577,BAO_0000219,,
7146,,,,F,ACHN,626.0,,The IC50 value was measured on ACHN cell line in renal tumor type.,N,,1,,CHEMBL623578,BAO_0000219,,
7147,,,,F,ACHN,626.0,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,N,,1,,CHEMBL623579,BAO_0000219,,
7148,,,,F,ACHN,626.0,,In vitro lethal concentration against most sensitive ACHN cell line,N,,1,,CHEMBL623580,BAO_0000219,,
7149,,,,F,ACHN,626.0,,Tested for cytotoxic activity against renal cancer ACHN cell line,N,,1,,CHEMBL623581,BAO_0000219,,
7150,,,,F,ACHN,626.0,,Compound tested for growth inhibition of renal cancer cell line ACHN,N,,1,,CHEMBL857456,BAO_0000219,,
7151,,,,F,ACHN,626.0,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,N,,1,,CHEMBL623582,BAO_0000219,,
7152,,,,F,ACHN,626.0,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,N,,1,,CHEMBL623583,BAO_0000219,,
7153,,,,F,ACHN,626.0,,In vitro anticancer activity against ACHN renal cancer cell line,N,,1,,CHEMBL623584,BAO_0000219,,
7154,,,,F,ACHN,626.0,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,N,,1,,CHEMBL623585,BAO_0000219,,
7155,,,,F,ACHN,626.0,,Percent selectivity was evaluated in renal ACHN cell lines,N,,1,,CHEMBL623586,BAO_0000219,,
7156,,,,F,ACHN,626.0,,In vitro inhibitory activity against renal ACHN cancer cell line,N,,1,,CHEMBL623587,BAO_0000219,,
7157,,,,F,ACHN,626.0,,Tested for cytotoxicity against ACHN cell lines in renal cancer,N,,1,,CHEMBL875279,BAO_0000219,,
7158,,,,F,ACHN,626.0,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,N,,1,,CHEMBL623588,BAO_0000219,,
7159,,,,F,ACHN,626.0,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,N,,1,,CHEMBL623589,BAO_0000219,,
7160,,,,F,ACHN,626.0,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,N,,1,,CHEMBL623590,BAO_0000219,,
7161,,,,F,ACHN,626.0,,Cytotoxic effect on renal cancer line ACHN,N,,1,,CHEMBL623591,BAO_0000219,,
7162,,,,F,ACHN,626.0,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,N,,1,,CHEMBL623592,BAO_0000219,,
7163,,,,F,ACHN,626.0,,In vitro inhibition of Renal Cancer ACHN cell lines,N,,1,,CHEMBL623593,BAO_0000219,,
7164,,,,F,ACHN,626.0,,Antitumor activity against human renal adenocarcinoma ACHN cells,N,,1,,CHEMBL623594,BAO_0000219,,
7165,,,,F,ACHN,626.0,,Antitumor activity against human renal adenocarcinoma ACHN cells.,N,,1,,CHEMBL621833,BAO_0000219,,
7166,,,,F,ACHN,626.0,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,N,,1,,CHEMBL621834,BAO_0000219,,
7167,,,,F,ACHN,626.0,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),N,,1,,CHEMBL621835,BAO_0000219,,
7168,,,,F,ACHN,626.0,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",N,,1,,CHEMBL621836,BAO_0000219,,
7169,,,,F,ACHN,626.0,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,N,,1,,CHEMBL621837,BAO_0000219,,
7170,,,,F,ACHN,626.0,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,N,,1,,CHEMBL875280,BAO_0000219,,
7171,,,,F,ACHN,626.0,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,N,,1,,CHEMBL621838,BAO_0000219,,
7172,,,,F,ACHN,626.0,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,N,,1,,CHEMBL621839,BAO_0000219,,
7173,,,,A,,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,U,,1,,CHEMBL621840,BAO_0000019,,
7174,,,,F,,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,H,,1,,CHEMBL621841,BAO_0000019,,
7175,,,,F,HEL,468.0,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,N,,1,,CHEMBL622979,BAO_0000218,,
7176,,,,F,,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,N,,1,,CHEMBL876595,BAO_0000218,,
7177,,,,B,,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),H,,1,,CHEMBL620221,BAO_0000357,,
7178,,,,B,,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),H,,1,,CHEMBL620222,BAO_0000357,,
7179,,,,F,ADDP cell line,979.0,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,N,,1,,CHEMBL620506,BAO_0000219,,
7180,,,,F,ADJ/PC6,980.0,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,N,,1,,CHEMBL620507,BAO_0000219,,
7181,,,,F,ADJ/PC6,980.0,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,N,,1,,CHEMBL620508,BAO_0000219,,
7182,,,,F,ADJ/PC6,980.0,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",N,,1,,CHEMBL620509,BAO_0000219,,
7183,,,,F,ADJ/PC6,980.0,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,N,,1,,CHEMBL620510,BAO_0000219,,
7184,,,,A,ADJ/PC6,980.0,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,N,,1,,CHEMBL620511,BAO_0000219,,
7185,,,,F,ADJ/PC6,980.0,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,N,,1,,CHEMBL620512,BAO_0000219,,
7186,,,,F,,,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,U,,1,,CHEMBL620513,BAO_0000019,,
7187,,,,F,,,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,U,,1,,CHEMBL620514,BAO_0000019,,
7188,,,,F,,,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,U,,1,,CHEMBL620515,BAO_0000019,,
7189,,In vivo,,A,,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),U,,1,,CHEMBL620516,BAO_0000218,,
7190,,,Plasma,A,,,,AUC value in dog after IV administration at a dose of 5 mg/kg,N,,1,,CHEMBL620517,BAO_0000218,1969.0,
7191,,,Plasma,A,,,,AUC value in dog after oral administration at a dose of 5 mg/kg,N,,1,,CHEMBL620518,BAO_0000218,1969.0,
7192,,In vivo,,A,,,,Cmax value in dog after oral administration at a dose of 5 mg/kg,N,,1,,CHEMBL620519,BAO_0000218,,
7193,,In vivo,,A,,,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,N,,1,,CHEMBL621386,BAO_0000218,,
7194,,In vivo,,A,,,,Tmax value in dog after oral administration at a dose of 5 mg/kg,N,,1,,CHEMBL621387,BAO_0000218,,
7195,,In vivo,,A,,,,Compound was evaluated for its clearance when administered intravenously in dog,N,,1,,CHEMBL621388,BAO_0000218,,
7196,,In vivo,,A,,,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,,1,,CHEMBL621389,BAO_0000218,,
7197,,In vivo,,A,,,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),N,,1,,CHEMBL621390,BAO_0000218,,
7198,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL621391,BAO_0000100,,
7199,,,,A,,,,Half life in dog,N,,1,,CHEMBL621392,BAO_0000218,,
7200,,,,A,,,,Time taken for EC90 was determined when tested in dog,N,,1,,CHEMBL621393,BAO_0000218,,
7201,,,,A,,,,Half life (iv) was determined,N,,1,,CHEMBL621394,BAO_0000218,,
7202,,,Liver,A,,,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,N,,1,,CHEMBL621395,BAO_0000218,2107.0,
7203,,,,A,,,,Area under the curve was calculated in dog after iv administration,N,,1,,CHEMBL621396,BAO_0000218,,
7204,,,,A,,,,Area under the curve was calculated in dog after peroral administration,N,,1,,CHEMBL621397,BAO_0000218,,
7205,,,,A,,,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,N,,1,,CHEMBL621398,BAO_0000218,,
7206,,,,A,,,,pKa was evaluated in dog,N,,1,,CHEMBL618818,BAO_0000218,,
7207,,,,A,,,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,N,,1,,CHEMBL618819,BAO_0000218,,
7208,,In vivo,,A,,,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,,1,,CHEMBL618820,BAO_0000218,,
7209,,In vivo,,A,,,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,,1,,CHEMBL873810,BAO_0000218,,
7210,,In vivo,,A,,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,N,,1,,CHEMBL876606,BAO_0000218,,
7211,,,,A,,,,Compound was evaluated for the half-life (t 1/2) in hours,N,,1,,CHEMBL618821,BAO_0000218,,
7212,,In vivo,Blood,A,,,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,,1,,CHEMBL618822,BAO_0000218,178.0,
7213,,In vivo,Blood,A,,,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,,1,,CHEMBL618823,BAO_0000218,178.0,
7214,,In vivo,,A,,,,Half life after intravenous administration of 1 mg/kg in dog,N,,1,,CHEMBL618824,BAO_0000218,,
7215,,,,A,,,,Half life was measured in dog,N,,1,,CHEMBL618825,BAO_0000218,,
7216,,In vivo,,A,,,,Half life period in dog after 5 mg/kg dose,N,,1,,CHEMBL618826,BAO_0000218,,
7217,,,,A,,,,Half life period was evaluated in dog; 4-4.8,N,,1,,CHEMBL618827,BAO_0000218,,
7218,,In vivo,,A,,,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,,1,,CHEMBL618828,BAO_0000218,,
7219,,In vivo,,A,,,,Half-life was determined in dog after a3 mg/kg of iv dose,N,,1,,CHEMBL618829,BAO_0000218,,
7220,,,,A,,,,Half-life was determined,N,,1,,CHEMBL618830,BAO_0000218,,
7221,,,,A,,,,Half life in dogs,N,,1,,CHEMBL618831,BAO_0000218,,
7222,,In vivo,Plasma,A,,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,N,,1,,CHEMBL619489,BAO_0000218,1969.0,
7223,,In vivo,,A,,,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,N,,1,,CHEMBL619649,BAO_0000218,,
7224,,In vivo,,A,,,,Compound was evaluated for the half life period after iv administration in Beagle dog.,N,,1,,CHEMBL876607,BAO_0000218,,
7225,,In vivo,,A,,,,Compound was evaluated for the half life period after oral administration in conscious dog.,N,,1,,CHEMBL619650,BAO_0000218,,
7226,,,,A,,,,Compound was tested for half life in dog,N,,1,,CHEMBL619651,BAO_0000218,,
7227,,,,A,,,,Compound was tested for its half life in dog,N,,1,,CHEMBL619652,BAO_0000218,,
7228,,In vivo,,A,,,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,,1,,CHEMBL619653,BAO_0000218,,
7229,,,,A,,,,Half life of compound in dog was determined,N,,1,,CHEMBL619654,BAO_0000218,,
7230,,In vivo,,A,,,,Half life (iv) was determined,N,,1,,CHEMBL619655,BAO_0000218,,
7231,,,Blood,A,,,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),N,,1,,CHEMBL619656,BAO_0000218,178.0,
7232,,In vivo,Plasma,A,,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,N,,1,,CHEMBL873812,BAO_0000218,1969.0,
7233,,In vivo,Plasma,F,,,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,N,,1,,CHEMBL621365,BAO_0000218,1969.0,
7234,,,,A,,,,Half life in dog,N,,1,,CHEMBL621366,BAO_0000218,,
7235,,,Plasma,A,,,,Half life in dog plasma,N,,1,,CHEMBL621367,BAO_0000218,1969.0,
7236,,In vivo,Plasma,A,,,,Half life in dog plasma after administration of 0.25 mg/kg iv,N,,1,,CHEMBL621368,BAO_0000218,1969.0,
7237,,In vivo,Plasma,A,,,,Half life in dog plasma after administration of 1 mg/kg iv,N,,1,,CHEMBL621369,BAO_0000218,1969.0,
7238,,In vivo,Plasma,A,,,,Half life in dog plasma was determined at dose 10 mg/kg,N,,1,,CHEMBL621370,BAO_0000218,1969.0,
7239,,,,A,,,,Half life in dog was determined,N,,1,,CHEMBL621371,BAO_0000218,,
7240,,In vivo,,A,,,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,,1,,CHEMBL621372,BAO_0000218,,
7241,,,Plasma,A,,,,Half life upon exposure to human plasma,N,,1,,CHEMBL621373,BAO_0000218,1969.0,
7242,,,,A,,,,Half life was calculated in dog,N,,1,,CHEMBL621374,BAO_0000218,,
7243,,,,A,,,,Half life was determined,N,,1,,CHEMBL621375,BAO_0000218,,
7244,,,,A,,,,Half life was determined,N,,1,,CHEMBL621376,BAO_0000218,,
7245,,In vivo,,A,,,,Half life by intravenous administration of 1.2 mg/kg in dog,N,,1,,CHEMBL619624,BAO_0000218,,
7246,,,,A,,,,Half life in dog,N,,1,,CHEMBL875840,BAO_0000218,,
7247,,,,A,,,,Half life in dog after intra venous administration of the compound,N,,1,,CHEMBL619625,BAO_0000218,,
7248,,,,A,,,,Half life in dog after intra venous administration of the compound; ND means Not determined,N,,1,,CHEMBL619626,BAO_0000218,,
7249,,In vivo,,A,,,,Half life in dog after po administration of the compound,N,,1,,CHEMBL619627,BAO_0000218,,
7250,,In vivo,,A,,,,Half life in dog after po administration of the compound; ND means Not determined,N,,1,,CHEMBL873817,BAO_0000218,,
7251,,In vivo,,A,,,,Half life in dog at the single oral dose of 1 mg/kg,N,,1,,CHEMBL619628,BAO_0000218,,
7252,,,,A,,,,Half life in dogs,N,,1,,CHEMBL619629,BAO_0000218,,
7253,,In vivo,,A,,,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,N,,1,,CHEMBL619630,BAO_0000218,,
7254,,,,A,,,,Half life in rat,N,,1,,CHEMBL619631,BAO_0000218,,
7255,,In vivo,,A,,,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,,1,,CHEMBL619632,BAO_0000218,,
7256,,In vivo,Bone,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,1,,CHEMBL619633,BAO_0000218,10000001.0,
7257,,In vivo,Bone,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,1,,CHEMBL875841,BAO_0000218,10000001.0,
7258,,In vivo,Bone,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,1,,CHEMBL619634,BAO_0000218,10000001.0,
7259,,In vivo,Bone,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,1,,CHEMBL619635,BAO_0000218,10000001.0,
7260,,In vivo,Bone,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,1,,CHEMBL619636,BAO_0000218,10000001.0,
7261,,In vivo,Gut,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,1,,CHEMBL619637,BAO_0000218,10000004.0,
7262,,In vivo,Gut,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,1,,CHEMBL619638,BAO_0000218,10000004.0,
7263,,In vivo,Gut,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,1,,CHEMBL619639,BAO_0000218,10000004.0,
7264,,In vivo,Gut,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,1,,CHEMBL619640,BAO_0000218,10000004.0,
7265,,In vivo,Gut,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,1,,CHEMBL619641,BAO_0000218,10000004.0,
7266,,In vivo,Gut,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,1,,CHEMBL619642,BAO_0000218,10000004.0,
7267,,In vivo,Gut,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,1,,CHEMBL619643,BAO_0000218,10000004.0,
7268,,In vivo,Heart,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,1,,CHEMBL619644,BAO_0000218,948.0,
7269,,In vivo,Heart,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,1,,CHEMBL621112,BAO_0000218,948.0,
7270,,In vivo,Heart,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,1,,CHEMBL621113,BAO_0000218,948.0,
7271,,In vivo,Heart,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,1,,CHEMBL621114,BAO_0000218,948.0,
7272,,In vivo,Heart,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,1,,CHEMBL621115,BAO_0000218,948.0,
7273,,In vivo,Heart,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,1,,CHEMBL621116,BAO_0000218,948.0,
7274,,In vivo,Heart,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,1,,CHEMBL621117,BAO_0000218,948.0,
7275,,In vivo,Kidney,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,1,,CHEMBL621118,BAO_0000218,2113.0,
7276,,In vivo,Kidney,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,,1,,CHEMBL621119,BAO_0000218,2113.0,
7277,,In vivo,Kidney,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,1,,CHEMBL621120,BAO_0000218,2113.0,
7278,,In vivo,Kidney,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,1,,CHEMBL621757,BAO_0000218,2113.0,
7279,,In vivo,Kidney,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,1,,CHEMBL621758,BAO_0000218,2113.0,
7280,,In vivo,Kidney,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,1,,CHEMBL621759,BAO_0000218,2113.0,
7281,,In vivo,Kidney,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,1,,CHEMBL621760,BAO_0000218,2113.0,
7282,,In vivo,Liver,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,1,,CHEMBL621761,BAO_0000218,2107.0,
7283,,In vivo,Liver,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,1,,CHEMBL621762,BAO_0000218,2107.0,
7284,,In vivo,Liver,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,1,,CHEMBL621763,BAO_0000218,2107.0,
7285,,In vivo,Liver,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,1,,CHEMBL624502,BAO_0000218,2107.0,
7286,,In vivo,Liver,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,1,,CHEMBL624503,BAO_0000218,2107.0,
7287,,In vivo,Liver,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,1,,CHEMBL624504,BAO_0000218,2107.0,
7288,,In vivo,Liver,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,1,,CHEMBL624505,BAO_0000218,2107.0,
7289,,In vivo,Lung,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,1,,CHEMBL624506,BAO_0000218,2048.0,
7290,,,,F,A2780,478.0,,In vitro cytotoxicity against A2780 (human ovarian cancer),N,,1,,CHEMBL624507,BAO_0000219,,
7291,,,,F,A2780,478.0,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,N,,1,,CHEMBL624508,BAO_0000219,,
7292,,,,F,A2780,478.0,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,N,,1,,CHEMBL624509,BAO_0000219,,
7293,,,,F,A2780,478.0,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,N,,1,,CHEMBL624510,BAO_0000219,,
7294,,,,F,A2780,478.0,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,N,,1,,CHEMBL875956,BAO_0000219,,
7295,,,,F,A2780,478.0,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,N,,1,,CHEMBL839885,BAO_0000219,,
7296,,,,F,A2780,478.0,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,N,,1,,CHEMBL624511,BAO_0000219,,
7297,,,,F,A2780,478.0,,In vitro cytotoxicity against A2780 cell line,N,,1,,CHEMBL624512,BAO_0000219,,
7298,,,,F,A2780,478.0,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,N,,1,,CHEMBL624513,BAO_0000219,,
7299,,,,F,A2780,478.0,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,N,,1,,CHEMBL624514,BAO_0000219,,
7300,,,,F,A2780,478.0,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,N,,1,,CHEMBL618547,BAO_0000218,,
7301,,,,F,A2780,478.0,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",N,,1,,CHEMBL618548,BAO_0000219,,
7302,,,,F,A2780,478.0,,Inhibition of tubulin polymerization in analogy of ca.,N,,1,,CHEMBL618549,BAO_0000219,,
7303,,,,F,A2780,478.0,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,N,,1,,CHEMBL618550,BAO_0000219,,
7304,,,,F,A2780,478.0,,Cytotoxic effect in ovarian cancer cell line (A2780),N,,1,,CHEMBL618551,BAO_0000219,,
7305,,,,F,A2780,478.0,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,N,,1,,CHEMBL618552,BAO_0000219,,
7306,,,,F,A2780,478.0,,Tested for the cytotoxicity in A2780 ovarian cell line,N,,1,,CHEMBL618553,BAO_0000219,,
7307,,,,F,A2780,478.0,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),N,,1,,CHEMBL618554,BAO_0000219,,
7308,,,,F,A2780,478.0,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,N,,1,,CHEMBL618555,BAO_0000219,,
7309,,,,F,A2780cisR,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,N,,1,,CHEMBL618556,BAO_0000219,,
7310,,,,F,A2780cisR,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),N,,1,,CHEMBL618557,BAO_0000219,,
7311,,,,F,A2780cisR,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,N,,1,,CHEMBL618558,BAO_0000219,,
7312,,,,F,A2780cisR,481.0,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),N,,1,,CHEMBL618559,BAO_0000219,,
7313,,,,F,A2780,478.0,,In vivo log of cells killed after administration of compound in A2780 cell line,N,,1,,CHEMBL618560,BAO_0000218,,
7314,,In vivo,,F,A2780,478.0,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,N,,1,,CHEMBL618561,BAO_0000218,,
7315,,,,F,A2780,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,N,,1,,CHEMBL618562,BAO_0000219,,
7316,,,,F,A2780,478.0,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,N,,1,,CHEMBL618563,BAO_0000219,,
7317,,,,F,A2780,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,N,,1,,CHEMBL618564,BAO_0000219,,
7318,,,,F,A2780,478.0,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,N,,1,,CHEMBL618565,BAO_0000219,,
7319,,,,F,A2780,478.0,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),N,,1,,CHEMBL618566,BAO_0000218,,
7320,,,,F,A2780,478.0,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,N,,1,,CHEMBL618567,BAO_0000219,,
7321,,,,F,A2780,478.0,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,N,,1,,CHEMBL618568,BAO_0000219,,
7322,,,,F,A2780,478.0,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,N,,1,,CHEMBL618569,BAO_0000219,,
7323,,,,F,A2780,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,N,,1,,CHEMBL621857,BAO_0000219,,
7324,,,,F,A2780,478.0,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,N,,1,,CHEMBL621858,BAO_0000219,,
7325,,,,F,A2780,478.0,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,N,,1,,CHEMBL621859,BAO_0000219,,
7326,,,,F,A2780,478.0,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",N,,1,,CHEMBL621860,BAO_0000219,,
7327,,,,F,A2780,478.0,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),N,,1,,CHEMBL621861,BAO_0000219,,
7328,,,,F,A2780,478.0,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",N,,1,,CHEMBL621862,BAO_0000219,,
7329,,,,F,A2780,478.0,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),N,,1,,CHEMBL621863,BAO_0000219,,
7330,,,,F,A2780,478.0,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),N,,1,,CHEMBL621864,BAO_0000219,,
7331,,,,F,A2780,478.0,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),N,,1,,CHEMBL621865,BAO_0000219,,
7332,,,,F,A2780,478.0,,In vitro antiproliferative activity against A2780 cell line,N,,1,,CHEMBL621866,BAO_0000219,,
7333,,,,F,A2780,478.0,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,N,,1,,CHEMBL621867,BAO_0000219,,
7334,,,,F,A2780,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,N,,1,,CHEMBL621868,BAO_0000219,,
7335,,,,F,A2780,478.0,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,N,,1,,CHEMBL875282,BAO_0000219,,
7336,,,,A,,,,Vc value in dog after IV administration at a dose of 5 mg/kg,N,,1,,CHEMBL621869,BAO_0000218,,
7337,,In vivo,,A,,,,Half life period in dog after IV administration at a dose of 5 mg/kg,N,,1,,CHEMBL621870,BAO_0000218,,
7338,,,,A,,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,U,,1,,CHEMBL621871,BAO_0000019,,
7339,,,Plasma,A,,,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,1,,CHEMBL621243,BAO_0000218,1969.0,
7340,,,Plasma,A,,,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,1,,CHEMBL621244,BAO_0000218,1969.0,
7341,,In vivo,,A,,,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,U,,1,,CHEMBL621245,BAO_0000218,,
7342,,In vivo,,A,,,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,U,,1,,CHEMBL621246,BAO_0000218,,
7343,,In vivo,,A,,,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,U,,1,,CHEMBL621247,BAO_0000218,,
7344,,In vivo,,A,,,,Oral Bioavailability in rat,U,,1,,CHEMBL618386,BAO_0000218,,
7345,,,,A,,,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,,1,,CHEMBL618387,BAO_0000218,,
7346,,,,A,,,,Area under curve value in monkey at a dose of 5 mg/kg,U,,1,,CHEMBL618388,BAO_0000218,,
7347,,,,A,,,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,U,,1,,CHEMBL618389,BAO_0000218,,
7348,,,,A,,,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,U,,1,,CHEMBL618574,BAO_0000019,,
7349,,,,A,,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,U,,1,,CHEMBL618575,BAO_0000019,,
7350,,,,A,,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,U,,1,,CHEMBL618576,BAO_0000019,,
7351,,,,A,,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,U,,1,,CHEMBL618577,BAO_0000218,,
7352,,,,A,,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,U,,1,,CHEMBL876487,BAO_0000218,,
7353,,,,A,,,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,U,,1,,CHEMBL618578,BAO_0000218,,
7354,,,,A,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,,1,,CHEMBL618579,BAO_0000218,,
7355,,,,A,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,,1,,CHEMBL618580,BAO_0000019,,
7356,,,,A,,,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,U,,1,,CHEMBL618581,BAO_0000218,,
7357,,,,A,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,U,,1,,CHEMBL618582,BAO_0000218,,
7358,,,,A,,,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,U,,1,,CHEMBL618583,BAO_0000218,,
7359,,,,A,,,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,U,,1,,CHEMBL618584,BAO_0000218,,
7360,,In vivo,,A,,,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),U,,1,,CHEMBL618585,BAO_0000218,,
7361,,,,A,,,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),U,,1,,CHEMBL618586,BAO_0000218,,
7362,,In vivo,,A,,,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,1,,CHEMBL618587,BAO_0000218,,
7363,,In vivo,,A,,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,1,,CHEMBL618588,BAO_0000218,,
7364,,,,A,,,,Binding towards monkey plasma protein at 10 uM,U,,1,,CHEMBL618589,BAO_0000019,,
7365,,,,A,,,,Binding towards monkey plasma protein at 100 uM,U,,1,,CHEMBL618590,BAO_0000019,,
7366,,In vivo,,A,,,,Apparent bioavailability in squirrel monkey was determined,U,,1,,CHEMBL872262,BAO_0000218,,
7367,,In vivo,,A,,,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,U,,1,,CHEMBL618591,BAO_0000218,,
7368,,In vivo,,A,,,,Bioavailability in monkey (dose 2 mg/kg),U,,1,,CHEMBL618592,BAO_0000218,,
7369,,In vivo,,A,,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,U,,1,,CHEMBL876488,BAO_0000218,,
7370,,In vivo,,A,,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,,1,,CHEMBL618593,BAO_0000218,,
7371,,In vivo,,A,,,,Bioavailability in monkey (i.d. dosing),U,,1,,CHEMBL618594,BAO_0000218,,
7372,,In vivo,,A,,,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,U,,1,,CHEMBL618595,BAO_0000218,,
7373,,,,A,,,,Clearance of the drug was measured in cynomolgus,U,,1,,CHEMBL621469,BAO_0000019,,
7374,,In vivo,,A,,,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,U,,1,,CHEMBL621470,BAO_0000218,,
7375,,In vivo,,A,,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,,1,,CHEMBL621471,BAO_0000218,,
7376,,In vivo,Plasma,A,,,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,,1,,CHEMBL621472,BAO_0000218,1969.0,
7377,,In vivo,,A,,,,Plasma clearance in rhesus monkey was determined,U,,1,,CHEMBL621473,BAO_0000218,,
7378,,In vivo,,A,,,,Plasma clearance in monkey after administration of 1 mg/kg iv,U,,1,,CHEMBL621474,BAO_0000218,,
7379,,In vivo,,A,,,,Plasma clearance in cynomolgus monkey,U,,1,,CHEMBL621475,BAO_0000218,,
7380,,In vivo,,A,,,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,U,,1,,CHEMBL621476,BAO_0000218,,
7381,,In vivo,,A,,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,U,,1,,CHEMBL624290,BAO_0000218,,
7382,,In vivo,,A,,,,The total clearance was determined after intravenous administration in cynomolgus monkeys,U,,1,,CHEMBL624291,BAO_0000218,,
7383,,In vivo,,A,,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,U,,1,,CHEMBL624292,BAO_0000218,,
7384,,In vivo,,A,,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,U,,1,,CHEMBL624293,BAO_0000218,,
7385,,In vivo,,A,,,,Tested for Clearance upon iv administration to african green monkey,U,,1,,CHEMBL624294,BAO_0000218,,
7386,,In vivo,,A,,,,Clearance in monkey,U,,1,,CHEMBL624295,BAO_0000218,,
7387,,In vivo,,A,,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,,1,,CHEMBL624296,BAO_0000218,,
7388,,In vivo,,A,,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,,1,,CHEMBL624297,BAO_0000218,,
7389,,In vivo,,A,,,,Half life was evaluated after intravenous administration to dogs,N,,1,,CHEMBL624298,BAO_0000218,,
7390,,,,A,,,,Half life was evaluated in dog,N,,1,,CHEMBL624299,BAO_0000218,,
7391,,,,A,,,,Half life was evaluated in dog,N,,1,,CHEMBL624300,BAO_0000218,,
7392,,In vivo,,A,,,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,N,,1,,CHEMBL624301,BAO_0000218,,
7393,,In vivo,,A,,,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),N,,1,,CHEMBL624302,BAO_0000218,,
7394,,In vivo,,A,,,,Half life period after intravenous administration in dog,N,,1,,CHEMBL876026,BAO_0000218,,
7395,,In vivo,,A,,,,Half life period after oral administration (2.5 mg/kg) in dog was determined,N,,1,,CHEMBL624303,BAO_0000218,,
7396,,,,A,,,,Half life period at a dose of 1 uM/kg in dog was determined,N,,1,,CHEMBL624304,BAO_0000218,,
7397,,In vivo,,A,,,,Half life period was determine after peroral administration at 10 mpk in dog,N,,1,,CHEMBL624305,BAO_0000218,,
7398,,In vivo,,A,,,,Half life period was determine after peroral administration at 5 mpk in dog,N,,1,,CHEMBL624306,BAO_0000218,,
7399,,,,A,,,,Half life period was determined,N,,1,,CHEMBL624307,BAO_0000218,,
7400,,,,A,,,,Half life period was determined,N,,1,,CHEMBL624308,BAO_0000218,,
7401,,In vivo,,A,,,,Half life period by iv administration in dog at a dose of 6 mg/kg,N,,1,,CHEMBL624309,BAO_0000218,,
7402,,,,A,,,,Half life period was evaluated in dog,N,,1,,CHEMBL624310,BAO_0000218,,
7403,,In vivo,,A,,,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,N,,1,,CHEMBL625003,BAO_0000218,,
7404,,In vivo,,A,,,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),N,,1,,CHEMBL625004,BAO_0000218,,
7405,,In vivo,,A,,,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,N,,1,,CHEMBL625005,BAO_0000218,,
7406,,In vivo,,A,,,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,N,,1,,CHEMBL873813,BAO_0000218,,
7407,,In vivo,,A,,,,Half-life after oral dose of compound at 3 mg/kg in dogs,N,,1,,CHEMBL625006,BAO_0000218,,
7408,,In vivo,,A,,,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,N,,1,,CHEMBL625007,BAO_0000218,,
7409,,In vivo,,A,,,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,N,,1,,CHEMBL876027,BAO_0000218,,
7410,,In vivo,,A,,,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,N,,1,,CHEMBL625008,BAO_0000218,,
7411,,In vivo,,A,,,,Half-life of compound in dog following p.o. administration of 1 mg/kg,N,,1,,CHEMBL625009,BAO_0000218,,
7412,,,Plasma,A,,,,Half-life of compound in plasma of dog was determined,N,,1,,CHEMBL625010,BAO_0000218,1969.0,
7413,,,,A,,,,Half-life of compound was determined in dogs,N,,1,,CHEMBL625011,BAO_0000218,,
7414,,In vivo,,A,,,,Half-life after administration of 4 mg/Kg oral dose in dog,N,,1,,CHEMBL621553,BAO_0000218,,
7415,,In vivo,,A,,,,Half-life after intravenous administration of 1 mg/kg/h in dog,N,,1,,CHEMBL621554,BAO_0000218,,
7416,,,,A,,,,Half-life in Dog,N,,1,,CHEMBL621555,BAO_0000218,,
7417,,,,A,,,,Half-life in Dog,N,,1,,CHEMBL621556,BAO_0000218,,
7418,,,,A,,,,Half-life in dog,N,,1,,CHEMBL621557,BAO_0000218,,
7419,,In vivo,,A,,,,Half-life in dog after oral administration at 1 mg/kg,N,,1,,CHEMBL621558,BAO_0000218,,
7420,,In vivo,,A,,,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,N,,1,,CHEMBL621559,BAO_0000218,,
7421,,,,A,,,,Half-life in dogs,N,,1,,CHEMBL621560,BAO_0000218,,
7422,,,,A,,,,Half-life in dogs; ND indicates not determined,N,,1,,CHEMBL876028,BAO_0000218,,
7423,,,Plasma,A,,,,Half-life in plasma of dog,N,,1,,CHEMBL621561,BAO_0000218,1969.0,
7424,,,Plasma,A,,,,Half-life in plasma of dog at dose of 3-10 mgkg,N,,1,,CHEMBL621562,BAO_0000218,1969.0,
7425,,In vivo,,A,,,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,N,,1,,CHEMBL621563,BAO_0000218,,
7426,,In vivo,,A,,,,Half-life was measured in dog after an iv dose of 1 mg/kg,N,,1,,CHEMBL621564,BAO_0000218,,
7427,,In vivo,,A,,,,Half-life was measured in dogs after an oral dose of 10 uM/kg,N,,1,,CHEMBL621565,BAO_0000218,,
7428,,In vivo,,A,,,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,N,,1,,CHEMBL621566,BAO_0000218,,
7429,,In vivo,,A,,,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,N,,1,,CHEMBL621567,BAO_0000218,,
7430,,In vivo,,A,,,,Half-life of the compound after 0.3 mg/kg po administration in dog,N,,1,,CHEMBL622978,BAO_0000218,,
7431,,In vivo,,A,,,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,N,,1,,CHEMBL873814,BAO_0000218,,
7432,,In vivo,,A,,,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,N,,1,,CHEMBL623219,BAO_0000218,,
7433,,In vivo,,A,,,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,N,,1,,CHEMBL624477,BAO_0000218,,
7434,,,,A,,,,t1/2 in dog,N,,1,,CHEMBL624478,BAO_0000218,,
7435,,,,A,,,,Half-life period measured in dogs,N,,1,,CHEMBL624479,BAO_0000218,,
7436,,In vivo,,A,,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,N,,1,,CHEMBL624480,BAO_0000218,,
7437,,In vivo,,A,,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,,1,,CHEMBL623595,BAO_0000218,,
7438,,In vivo,,A,,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,1,,CHEMBL623596,BAO_0000218,,
7439,,In vitro,Plasma,A,,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",N,,1,,CHEMBL623597,BAO_0000218,1969.0,
7440,,In vivo,,A,,,,In vivo half life period was calculated at 1 mg/kg in dog,N,,1,,CHEMBL623598,BAO_0000218,,
7441,,In vivo,,A,,,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,N,,1,,CHEMBL623599,BAO_0000218,,
7442,,In vivo,,A,,,,Longer half-life in dog (i.v.) at 0.5 mpk,N,,1,,CHEMBL623600,BAO_0000218,,
7443,,In vivo,,A,,,,Oral bioavailability in dog (dose 5 uM/kg),N,,1,,CHEMBL623601,BAO_0000218,,
7444,,In vivo,,A,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,N,,1,,CHEMBL623602,BAO_0000218,,
7445,,In vivo,,A,,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,N,,1,,CHEMBL623603,BAO_0000218,,
7446,,In vivo,,A,,,,Bioavailability in dog (dose 1 mg/kg i.v.),N,,1,,CHEMBL623604,BAO_0000218,,
7447,,In vivo,Lung,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,,1,,CHEMBL623605,BAO_0000218,2048.0,
7448,,In vivo,Lung,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,1,,CHEMBL623606,BAO_0000218,2048.0,
7449,,In vivo,Lung,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,1,,CHEMBL623607,BAO_0000218,2048.0,
7450,,In vivo,Lung,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,1,,CHEMBL623608,BAO_0000218,2048.0,
7451,,In vivo,Lung,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,1,,CHEMBL623609,BAO_0000218,2048.0,
7452,,In vivo,Lung,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,1,,CHEMBL623610,BAO_0000218,2048.0,
7453,,In vivo,Muscle tissue,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,1,,CHEMBL623611,BAO_0000218,2385.0,
7454,,In vivo,Muscle tissue,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,,1,,CHEMBL623612,BAO_0000218,2385.0,
7455,,In vivo,Muscle tissue,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,1,,CHEMBL623613,BAO_0000218,2385.0,
7456,,In vivo,Muscle tissue,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,1,,CHEMBL623614,BAO_0000218,2385.0,
7457,,In vivo,Muscle tissue,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,1,,CHEMBL623615,BAO_0000218,2385.0,
7458,,In vivo,Muscle tissue,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,1,,CHEMBL623616,BAO_0000218,2385.0,
7459,,In vivo,Muscle tissue,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,1,,CHEMBL623617,BAO_0000218,2385.0,
7460,,In vivo,Zone of skin,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,1,,CHEMBL875944,BAO_0000218,14.0,
7461,,In vivo,Zone of skin,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,1,,CHEMBL623618,BAO_0000218,14.0,
7462,,In vivo,Zone of skin,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,1,,CHEMBL623619,BAO_0000218,14.0,
7463,,In vivo,Zone of skin,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,1,,CHEMBL623620,BAO_0000218,14.0,
7464,,In vivo,Zone of skin,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,1,,CHEMBL623621,BAO_0000218,14.0,
7465,,In vivo,Zone of skin,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,1,,CHEMBL623622,BAO_0000218,14.0,
7466,,In vivo,Zone of skin,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,1,,CHEMBL623623,BAO_0000218,14.0,
7467,,In vivo,Spleen,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,1,,CHEMBL623624,BAO_0000218,2106.0,
7468,,In vivo,Spleen,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,1,,CHEMBL618521,BAO_0000218,2106.0,
7469,,In vivo,Spleen,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,1,,CHEMBL618522,BAO_0000218,2106.0,
7470,,In vivo,Spleen,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,1,,CHEMBL618523,BAO_0000218,2106.0,
7471,,In vivo,Spleen,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,1,,CHEMBL618524,BAO_0000218,2106.0,
7472,,In vivo,Spleen,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,1,,CHEMBL618525,BAO_0000218,2106.0,
7473,,In vivo,Spleen,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,1,,CHEMBL624586,BAO_0000218,2106.0,
7474,,In vivo,Stomach,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,1,,CHEMBL624587,BAO_0000218,945.0,
7475,,In vivo,Stomach,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,1,,CHEMBL624588,BAO_0000218,945.0,
7476,,In vivo,Stomach,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,1,,CHEMBL624589,BAO_0000218,945.0,
7477,,In vivo,Stomach,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,1,,CHEMBL624590,BAO_0000218,945.0,
7478,,In vivo,Stomach,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,1,,CHEMBL624591,BAO_0000218,945.0,
7479,,In vivo,Stomach,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,1,,CHEMBL624592,BAO_0000218,945.0,
7480,,In vivo,Stomach,A,,,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,1,,CHEMBL624593,BAO_0000218,945.0,
7481,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL624594,BAO_0000218,,
7482,,In vivo,,A,,,,Tested for the bioavailability in rat,N,,1,,CHEMBL624595,BAO_0000218,,
7483,,In vivo,,A,,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),N,,1,,CHEMBL624596,BAO_0000218,,
7484,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL624597,BAO_0000218,,
7485,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL624598,BAO_0000218,,
7486,,In vivo,,A,,,,Bioavailability in rat (dose 3-10 mg/kg),N,,1,,CHEMBL624599,BAO_0000218,,
7487,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL875166,BAO_0000218,,
7488,,In vivo,Plasma,A,,,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,,1,,CHEMBL624600,BAO_0000218,1969.0,
7489,,In vivo,Plasma,A,,,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,N,,1,,CHEMBL624601,BAO_0000218,1969.0,
7490,,In vivo,,A,,,,Half life after oral administration was determined in rats at 6 mg/kg,N,,1,,CHEMBL624602,BAO_0000218,,
7491,,,,A,,,,Half life was determined,N,,1,,CHEMBL624603,BAO_0000218,,
7492,,In vivo,,A,,,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,N,,1,,CHEMBL624604,BAO_0000218,,
7493,,In vivo,Plasma,A,,,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,N,,1,,CHEMBL624605,BAO_0000218,1969.0,
7494,,,,A,,,,Half life in rats,N,,1,,CHEMBL624606,BAO_0000218,,
7495,,In vivo,Blood,A,,,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,N,,1,,CHEMBL624607,BAO_0000218,178.0,
7496,,,,A,,,,Hill coefficient of the compound,N,,1,,CHEMBL624608,BAO_0000218,,
7497,,,Blood,A,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,N,,1,,CHEMBL624609,BAO_0000218,178.0,
7498,,,Blood,A,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,N,,1,,CHEMBL624610,BAO_0000218,178.0,
7499,,,Blood,A,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,N,,1,,CHEMBL624611,BAO_0000218,178.0,
7500,,,Blood,A,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,N,,1,,CHEMBL624612,BAO_0000218,178.0,
7501,,,Blood,A,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,N,,1,,CHEMBL875167,BAO_0000218,178.0,
7502,,,Blood,A,,,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,N,,1,,CHEMBL624613,BAO_0000218,178.0,
7503,,,Blood,A,,,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",N,,1,,CHEMBL624614,BAO_0000218,178.0,
7504,,,,A,,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,N,,1,,CHEMBL624392,BAO_0000218,,
7505,,In vivo,Brain,A,,,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,N,,1,,CHEMBL624393,BAO_0000218,955.0,
7506,,In vivo,Brain,A,,,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,N,,1,,CHEMBL624394,BAO_0000218,955.0,
7507,,In vivo,Brain,A,,,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,N,,1,,CHEMBL624395,BAO_0000218,955.0,
7508,,In vivo,Brain,A,,,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,N,,1,,CHEMBL624396,BAO_0000218,955.0,
7509,,In vivo,Brain,A,,,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,N,,1,,CHEMBL624397,BAO_0000218,955.0,
7510,,In vivo,Thyroid gland,A,,,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,N,,1,,CHEMBL624398,BAO_0000218,2046.0,
7511,,In vivo,Thyroid gland,A,,,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,N,,1,,CHEMBL624399,BAO_0000218,2046.0,
7512,,In vivo,Thyroid gland,A,,,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,N,,1,,CHEMBL624400,BAO_0000218,2046.0,
7513,,In vivo,Thyroid gland,A,,,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,N,,1,,CHEMBL624401,BAO_0000218,2046.0,
7514,,In vivo,Thyroid gland,A,,,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,N,,1,,CHEMBL624402,BAO_0000218,2046.0,
7515,,In vivo,Blood,A,,,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,1,,CHEMBL624403,BAO_0000218,178.0,
7516,,In vivo,Blood,A,,,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,N,,1,,CHEMBL624404,BAO_0000218,178.0,
7517,,In vivo,Blood,A,,,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,N,,1,,CHEMBL624405,BAO_0000218,178.0,
7518,,In vivo,Bone,A,,,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,1,,CHEMBL624406,BAO_0000218,10000001.0,
7519,,In vivo,Bone,A,,,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,N,,1,,CHEMBL624407,BAO_0000218,10000001.0,
7520,,In vivo,Bone,A,,,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,N,,1,,CHEMBL624408,BAO_0000218,10000001.0,
7521,,In vivo,Heart,A,,,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,1,,CHEMBL618644,BAO_0000218,948.0,
7522,,In vivo,Heart,A,,,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,N,,1,,CHEMBL618645,BAO_0000218,948.0,
7523,,In vivo,Heart,A,,,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,N,,1,,CHEMBL618646,BAO_0000218,948.0,
7524,,In vivo,Kidney,A,,,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,1,,CHEMBL618647,BAO_0000218,2113.0,
7525,,In vivo,Kidney,A,,,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,N,,1,,CHEMBL618648,BAO_0000218,2113.0,
7526,,In vivo,Kidney,A,,,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,N,,1,,CHEMBL618649,BAO_0000218,2113.0,
7527,,In vivo,Liver,A,,,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,1,,CHEMBL618650,BAO_0000218,2107.0,
7528,,In vivo,Liver,A,,,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,N,,1,,CHEMBL618651,BAO_0000218,2107.0,
7529,,In vivo,Liver,A,,,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,N,,1,,CHEMBL876497,BAO_0000218,2107.0,
7530,,In vivo,Lung,A,,,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,1,,CHEMBL618652,BAO_0000218,2048.0,
7531,,In vivo,Lung,A,,,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,N,,1,,CHEMBL618653,BAO_0000218,2048.0,
7532,,In vivo,Lung,A,,,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,N,,1,,CHEMBL618654,BAO_0000218,2048.0,
7533,,,,A,,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,N,,1,,CHEMBL618655,BAO_0000218,,
7534,,,,A,,,,Compound was tested for solubility in water,N,,1,,CHEMBL618656,BAO_0000218,,
7535,,,,P,,,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),U,,1,,CHEMBL618657,BAO_0000100,,
7536,,,,A,,,,Solubility was determined,N,,1,,CHEMBL618658,BAO_0000218,,
7537,,,,A,,,,solubility in water (ug/mL) at 37 degree C.,N,,1,,CHEMBL618659,BAO_0000218,,
7538,,,,A,,,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,N,,1,,CHEMBL618660,BAO_0000218,,
7539,,,,A,,,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,N,,1,,CHEMBL618661,BAO_0000218,,
7540,,,,A,,,,Half life in rats,N,,1,,CHEMBL873807,BAO_0000218,,
7541,,,,A,,,,Half life in Dawley rat,N,,1,,CHEMBL618662,BAO_0000218,,
7542,,In vivo,,A,,,,Half life period after 3 mg/kg iv administration,N,,1,,CHEMBL618663,BAO_0000218,,
7543,,In vivo,,A,,,,Half life period after 3 mg/kg iv administration in rat,N,,1,,CHEMBL618664,BAO_0000218,,
7544,,In vivo,,A,,,,Half life period after 3 mg/kg iv administration in the rat,N,,1,,CHEMBL618665,BAO_0000218,,
7545,,,,A,,,,Half life period in female Sprague-Dawley rats,N,,1,,CHEMBL876498,BAO_0000218,,
7546,,,,A,,,,Half life period in rat,N,,1,,CHEMBL618666,BAO_0000218,,
7547,,,,A,,,,Half-life in rats was determined,N,,1,,CHEMBL620440,BAO_0000218,,
7548,,,,A,,,,Half-life in rats with metabolic oxidation,N,,1,,CHEMBL620441,BAO_0000218,,
7549,,,,A,,,,Half-life in rats,N,,1,,CHEMBL620442,BAO_0000218,,
7550,,In vivo,,A,,,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,N,,1,,CHEMBL620443,BAO_0000218,,
7551,,In vivo,,A,,,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,N,,1,,CHEMBL620444,BAO_0000218,,
7552,,In vivo,,A,,,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,N,,1,,CHEMBL620445,BAO_0000218,,
7553,,In vivo,,A,,,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,N,,1,,CHEMBL620446,BAO_0000218,,
7554,,,Plasma,A,,,,Biological half-life measured in plasma of rat,N,,1,,CHEMBL620447,BAO_0000218,1969.0,
7555,,,Plasma,A,,,,Biological half-life measured in plasma of rat; 22-25,N,,1,,CHEMBL621129,BAO_0000218,1969.0,
7556,,,Plasma,A,,,,Biological half-life measured in plasma of rat; 9-16,N,,1,,CHEMBL621130,BAO_0000218,1969.0,
7557,,In vivo,,A,,,,Compound was evaluated for its half life when administered intravenously in rat,N,,1,,CHEMBL873808,BAO_0000218,,
7558,,In vivo,,A,,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,N,,1,,CHEMBL876598,BAO_0000218,,
7559,,In vivo,,A,,,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,N,,1,,CHEMBL621131,BAO_0000218,,
7560,,In vivo,,A,,,,Half life (T1/2) after oral administration in rat,N,,1,,CHEMBL621132,BAO_0000218,,
7561,,In vivo,,A,,,,Half life of compound after iv administration of 20 mg/kg dose in rat,N,,1,,CHEMBL621133,BAO_0000218,,
7562,,In vivo,,A,,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,N,,1,,CHEMBL621312,BAO_0000218,,
7563,,,,A,,,,Half life of compound was determined in rat,N,,1,,CHEMBL621313,BAO_0000218,,
7564,,,Blood,A,,,,Half life of compound was determined in rat blood,N,,1,,CHEMBL621314,BAO_0000218,178.0,
7565,,In vivo,,A,,,,Half life at 1 mg/kg was determined in rat,N,,1,,CHEMBL621315,BAO_0000218,,
7566,,In vivo,,A,,,,Half life at 10 mg/kg was determined in rat,N,,1,,CHEMBL621316,BAO_0000218,,
7567,,,,A,,,,Half life in rats,N,,1,,CHEMBL621317,BAO_0000218,,
7568,,,,A,,,,Half life in rats in hours,N,,1,,CHEMBL621318,BAO_0000218,,
7569,,In vivo,,A,,,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,N,,1,,CHEMBL621319,BAO_0000218,,
7570,,In vivo,,A,,,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,N,,1,,CHEMBL621377,BAO_0000218,,
7571,,,,A,,,,Half life was determined,N,,1,,CHEMBL621378,BAO_0000218,,
7572,,In vivo,,A,,,,Half life after i.v. administration,N,,1,,CHEMBL876599,BAO_0000218,,
7573,,In vivo,,A,,,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,N,,1,,CHEMBL621379,BAO_0000218,,
7574,,,Plasma,A,,,,Half life in rat plasma,N,,1,,CHEMBL621380,BAO_0000218,1969.0,
7575,,,Plasma,A,,,,Half life in rat plasma; Not detected,N,,1,,CHEMBL621381,BAO_0000218,1969.0,
7576,,,,A,,,,Half life in rats,N,,1,,CHEMBL618515,BAO_0000218,,
7577,,In vivo,,A,,,,Half life period of compound was determined after peroral administration,N,,1,,CHEMBL618516,BAO_0000218,,
7578,,In vivo,,A,,,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,N,,1,,CHEMBL618517,BAO_0000218,,
7579,,,,A,,,,Half life period in rat,N,,1,,CHEMBL618518,BAO_0000218,,
7580,,In vivo,,A,,,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,N,,1,,CHEMBL618519,BAO_0000218,,
7581,,In vivo,,A,,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,N,,1,,CHEMBL618698,BAO_0000218,,
7582,,In vivo,,A,,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,N,,1,,CHEMBL618862,BAO_0000218,,
7583,,In vivo,,A,,,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,N,,1,,CHEMBL618863,BAO_0000218,,
7584,,In vivo,,A,,,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,N,,1,,CHEMBL618864,BAO_0000218,,
7585,,In vivo,,A,,,,Half life time in rat the dose of 2 mg/kg,N,,1,,CHEMBL618865,BAO_0000218,,
7586,,In vivo,,A,,,,Half-life 24 hr after 10 mg/kg iv administration in rats,N,,1,,CHEMBL618866,BAO_0000218,,
7587,,In vivo,,A,,,,Half-life 24 hr after 2 mg/kg iv administration in rats,N,,1,,CHEMBL618867,BAO_0000218,,
7588,,,,A,,,,Half-life consistent with the observed metabolic steady state in rats,N,,1,,CHEMBL875828,BAO_0000218,,
7589,,In vivo,,A,,,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,N,,1,,CHEMBL618868,BAO_0000218,,
7590,,,,A,,,,Half-life for oxidative metabolic stability was determined using male human,N,,1,,CHEMBL618869,BAO_0000218,,
7591,,In vivo,,A,,,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",N,,1,,CHEMBL618870,BAO_0000218,,
7592,,,Plasma,A,,,,Half-life in rat plasma,N,,1,,CHEMBL618871,BAO_0000218,1969.0,
7593,,,Plasma,A,,,,Half-life in rat plasma was determined,N,,1,,CHEMBL618872,BAO_0000218,1969.0,
7594,,,,A,,,,Half-life in rats was determined,N,,1,,CHEMBL873816,BAO_0000218,,
7595,,,,A,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,U,,1,,CHEMBL618873,BAO_0000218,,
7596,,,,A,,,,Area under curve after oral dose of 0.1 mg//kg,U,,1,,CHEMBL621602,BAO_0000019,,
7597,,,,A,,,,Area under curve after oral dose of 0.3 mg/kg,U,,1,,CHEMBL621603,BAO_0000218,,
7598,,,,A,,,,Area under curve after oral dose of 1 mg/kg,U,,1,,CHEMBL621604,BAO_0000218,,
7599,,,,A,,,,Area under curve after oral dose of 10 mg/kg,U,,1,,CHEMBL621605,BAO_0000218,,
7600,,,,A,,,,Area under curve after oral dose of 23.4 mg/kg,U,,1,,CHEMBL621606,BAO_0000218,,
7601,,,,A,,,,Area under curve after oral dose of 3 mg/kg,U,,1,,CHEMBL621607,BAO_0000218,,
7602,,,,A,,,,Area under curve after oral dose of 3.87 mg/kg,U,,1,,CHEMBL621608,BAO_0000218,,
7603,,,,A,,,,Area under curve was determined,U,,1,,CHEMBL621609,BAO_0000019,,
7604,,,,A,,,,Area under curve at a dose of 10 mg/kg,U,,1,,CHEMBL621610,BAO_0000218,,
7605,,,,A,,,,Area under curve was determined; ND=No data,N,,1,,CHEMBL621611,BAO_0000218,,
7606,,,,A,,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,N,,1,,CHEMBL621612,BAO_0000218,,
7607,,,,A,,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,N,,1,,CHEMBL622308,BAO_0000218,,
7608,,,,A,,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,N,,1,,CHEMBL622309,BAO_0000218,,
7609,,,,A,,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,N,,1,,CHEMBL622310,BAO_0000218,,
7610,,,,A,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,N,,1,,CHEMBL622311,BAO_0000218,,
7611,,,,A,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,N,,1,,CHEMBL622312,BAO_0000218,,
7612,,,,A,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,N,,1,,CHEMBL622931,BAO_0000218,,
7613,,,,A,,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,N,,1,,CHEMBL622932,BAO_0000218,,
7614,,,Plasma,A,,,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,N,,1,,CHEMBL622736,BAO_0000218,1969.0,
7615,,,Plasma,A,,,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,N,,1,,CHEMBL622737,BAO_0000218,1969.0,
7616,,,Plasma,A,,,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,N,,1,,CHEMBL622738,BAO_0000218,1969.0,
7617,,,Plasma,A,,,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,N,,1,,CHEMBL622739,BAO_0000218,1969.0,
7618,,,Plasma,A,,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,N,,1,,CHEMBL622740,BAO_0000218,1969.0,
7619,,,Plasma,A,,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,N,,1,,CHEMBL622741,BAO_0000218,1969.0,
7620,,,Plasma,A,,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,N,,1,,CHEMBL622742,BAO_0000218,1969.0,
7621,,,Plasma,A,,,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,N,,1,,CHEMBL622743,BAO_0000218,1969.0,
7622,,,Plasma,A,,,,AUC in mice,N,,1,,CHEMBL622744,BAO_0000218,1969.0,
7623,,,,A,,,,Area under curve was measured from the graph obtained from concentration Vs time,U,,1,,CHEMBL624134,BAO_0000019,,
7624,,,,A,,,,Area under curve value of compound per hour after oral administration,U,,1,,CHEMBL624135,BAO_0000019,,
7625,,,,A,,,,Area under curve was determined after oral administration in rats,N,,1,,CHEMBL624136,BAO_0000218,,
7626,,,,A,,,,Area under curve was determined after oral administration in rats; No data,N,,1,,CHEMBL624137,BAO_0000218,,
7627,,,,A,,,,Area under curve was determined after oral administration in rats;No data,N,,1,,CHEMBL624320,BAO_0000218,,
7628,,,,A,,,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,N,,1,,CHEMBL624321,BAO_0000218,,
7629,,,,A,,,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,N,,1,,CHEMBL624322,BAO_0000218,,
7630,,,,A,,,,Area under curve was determined for the compound after iv dose of 5.06 in rats,N,,1,,CHEMBL624323,BAO_0000218,,
7631,,,,A,,,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,N,,1,,CHEMBL624324,BAO_0000218,,
7632,,,,A,,,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,N,,1,,CHEMBL624325,BAO_0000218,,
7633,,,,A,,,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,N,,1,,CHEMBL624326,BAO_0000218,,
7634,,,,A,,,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,N,,1,,CHEMBL624327,BAO_0000218,,
7635,,,,A,,,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,N,,1,,CHEMBL624328,BAO_0000218,,
7636,,,,A,,,,Area under curve was determined in Dogs after peroral administration,N,,1,,CHEMBL627848,BAO_0000218,,
7637,,,,A,,,,Area under curve was determined in Rats after peroral administration,N,,1,,CHEMBL627849,BAO_0000218,,
7638,,,,A,,,,Area under curve was determined in carotid blood of rat when administered intradermally,N,,1,,CHEMBL627850,BAO_0000218,,
7639,,,,A,,,,Area under curve was determined in portal blood of rat when administered intradermally,N,,1,,CHEMBL627851,BAO_0000218,,
7640,,,,A,,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,N,,1,,CHEMBL627852,BAO_0000218,,
7641,,,,A,,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,N,,1,,CHEMBL627853,BAO_0000218,,
7642,,,,A,,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),N,,1,,CHEMBL627854,BAO_0000218,,
7643,,,,A,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,N,,1,,CHEMBL627855,BAO_0000218,,
7644,,,,A,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),N,,1,,CHEMBL627856,BAO_0000218,,
7645,,,,A,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,N,,1,,CHEMBL875339,BAO_0000218,,
7646,,,,A,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),N,,1,,CHEMBL627857,BAO_0000218,,
7647,,In vivo,Spleen,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,N,,1,,CHEMBL627858,BAO_0000218,2106.0,
7648,,,Blood,A,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,N,,1,,CHEMBL627859,BAO_0000218,178.0,
7649,,,Brain,A,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,N,,1,,CHEMBL627860,BAO_0000218,955.0,
7650,,,Heart,A,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,N,,1,,CHEMBL627019,BAO_0000218,948.0,
7651,,,Liver,A,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,N,,1,,CHEMBL627020,BAO_0000218,2107.0,
7652,,,Lung,A,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,N,,1,,CHEMBL627021,BAO_0000218,2048.0,
7653,,,Muscle tissue,A,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,N,,1,,CHEMBL627022,BAO_0000218,2385.0,
7654,,,,A,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,N,,1,,CHEMBL627023,BAO_0000218,,
7655,,,Spleen,A,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,N,,1,,CHEMBL627024,BAO_0000218,2106.0,
7656,,,Thyroid gland,A,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,N,,1,,CHEMBL627025,BAO_0000218,2046.0,
7657,,,Kidney,A,,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,N,,1,,CHEMBL627026,BAO_0000218,2113.0,
7658,,,Blood,A,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,N,,1,,CHEMBL627027,BAO_0000218,178.0,
7659,,,Brain,A,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,N,,1,,CHEMBL627028,BAO_0000218,955.0,
7660,,,Heart,A,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,N,,1,,CHEMBL627029,BAO_0000218,948.0,
7661,,,Kidney,A,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,N,,1,,CHEMBL627030,BAO_0000218,2113.0,
7662,,,Liver,A,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,N,,1,,CHEMBL627031,BAO_0000218,2107.0,
7663,,,Lung,A,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,N,,1,,CHEMBL627032,BAO_0000218,2048.0,
7664,,,Muscle tissue,A,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,N,,1,,CHEMBL627033,BAO_0000218,2385.0,
7665,,,,A,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,N,,1,,CHEMBL627034,BAO_0000218,,
7666,,,Spleen,A,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,N,,1,,CHEMBL627035,BAO_0000218,2106.0,
7667,,,Thyroid gland,A,,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,N,,1,,CHEMBL627036,BAO_0000218,2046.0,
7668,,,Blood,A,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,N,,1,,CHEMBL875340,BAO_0000218,178.0,
7669,,,Heart,A,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,N,,1,,CHEMBL627037,BAO_0000218,948.0,
7670,,,Kidney,A,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,N,,1,,CHEMBL627038,BAO_0000218,2113.0,
7671,,,Liver,A,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,N,,1,,CHEMBL627039,BAO_0000218,2107.0,
7672,,,Muscle tissue,A,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,N,,1,,CHEMBL627040,BAO_0000218,2385.0,
7673,,,Spleen,A,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,N,,1,,CHEMBL624663,BAO_0000218,2106.0,
7674,,,Thyroid gland,A,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,N,,1,,CHEMBL625963,BAO_0000218,2046.0,
7675,,,Brain,A,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,N,,1,,CHEMBL876799,BAO_0000218,955.0,
7676,,,Lung,A,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,N,,1,,CHEMBL626133,BAO_0000218,2048.0,
7677,,,,A,,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,N,,1,,CHEMBL626134,BAO_0000218,,
7678,,,,A,,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,N,,1,,CHEMBL626135,BAO_0000218,,
7679,,,,A,,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,N,,1,,CHEMBL626136,BAO_0000218,,
7680,,,,A,,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,N,,1,,CHEMBL626137,BAO_0000218,,
7681,,,,A,,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,N,,1,,CHEMBL626138,BAO_0000218,,
7682,,,,A,,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,N,,1,,CHEMBL626139,BAO_0000218,,
7683,,In vivo,,A,,,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,N,,1,,CHEMBL626140,BAO_0000218,,
7684,,In vivo,,A,,,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,N,,1,,CHEMBL626141,BAO_0000218,,
7685,,,,A,,,,C24h in rat p.o. at 20 mg/kg concentration,N,,1,,CHEMBL626142,BAO_0000218,,
7686,,In vivo,Muscle tissue,A,,,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,1,,CHEMBL627930,BAO_0000218,2385.0,
7687,,In vivo,Muscle tissue,A,,,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,N,,1,,CHEMBL627931,BAO_0000218,2385.0,
7688,,In vivo,Muscle tissue,A,,,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,N,,1,,CHEMBL627932,BAO_0000218,2385.0,
7689,,In vivo,Spleen,A,,,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,1,,CHEMBL627933,BAO_0000218,2106.0,
7690,,In vivo,Spleen,A,,,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,N,,1,,CHEMBL627934,BAO_0000218,2106.0,
7691,,In vivo,Spleen,A,,,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,N,,1,,CHEMBL627935,BAO_0000218,2106.0,
7692,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,N,,1,,CHEMBL627936,BAO_0000218,178.0,
7693,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,N,,1,,CHEMBL627937,BAO_0000218,178.0,
7694,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,N,,1,,CHEMBL627938,BAO_0000218,178.0,
7695,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,N,,1,,CHEMBL627939,BAO_0000218,178.0,
7696,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,N,,1,,CHEMBL627940,BAO_0000218,178.0,
7697,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,N,,1,,CHEMBL627941,BAO_0000218,178.0,
7698,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,N,,1,,CHEMBL876800,BAO_0000218,178.0,
7699,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,N,,1,,CHEMBL627942,BAO_0000218,178.0,
7700,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,N,,1,,CHEMBL627943,BAO_0000218,178.0,
7701,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,N,,1,,CHEMBL627944,BAO_0000218,178.0,
7702,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,N,,1,,CHEMBL627945,BAO_0000218,178.0,
7703,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,N,,1,,CHEMBL628584,BAO_0000218,178.0,
7704,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,N,,1,,CHEMBL628585,BAO_0000218,178.0,
7705,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,N,,1,,CHEMBL628586,BAO_0000218,178.0,
7706,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,N,,1,,CHEMBL628587,BAO_0000218,178.0,
7707,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,N,,1,,CHEMBL628588,BAO_0000218,178.0,
7708,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,N,,1,,CHEMBL628589,BAO_0000218,178.0,
7709,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,N,,1,,CHEMBL625304,BAO_0000218,178.0,
7710,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,N,,1,,CHEMBL625305,BAO_0000218,178.0,
7711,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,N,,1,,CHEMBL625306,BAO_0000218,178.0,
7712,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,N,,1,,CHEMBL625307,BAO_0000218,178.0,
7713,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,N,,1,,CHEMBL625308,BAO_0000218,178.0,
7714,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,N,,1,,CHEMBL627740,BAO_0000218,178.0,
7715,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,N,,1,,CHEMBL627741,BAO_0000218,178.0,
7716,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,N,,1,,CHEMBL627742,BAO_0000218,178.0,
7717,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,N,,1,,CHEMBL627743,BAO_0000218,178.0,
7718,,In vivo,Blood,A,,,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,N,,1,,CHEMBL627744,BAO_0000218,178.0,
7719,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,N,,1,,CHEMBL627745,BAO_0000218,10000001.0,
7720,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,N,,1,,CHEMBL627746,BAO_0000218,10000001.0,
7721,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,N,,1,,CHEMBL627747,BAO_0000218,10000001.0,
7722,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,N,,1,,CHEMBL876810,BAO_0000218,10000001.0,
7723,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,N,,1,,CHEMBL627748,BAO_0000218,10000001.0,
7724,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,N,,1,,CHEMBL627749,BAO_0000218,10000001.0,
7725,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,N,,1,,CHEMBL627750,BAO_0000218,10000001.0,
7726,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,N,,1,,CHEMBL618728,BAO_0000218,10000001.0,
7727,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,N,,1,,CHEMBL618729,BAO_0000218,10000001.0,
7728,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,N,,1,,CHEMBL618730,BAO_0000218,10000001.0,
7729,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,N,,1,,CHEMBL618731,BAO_0000218,10000001.0,
7730,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,N,,1,,CHEMBL618732,BAO_0000218,10000001.0,
7731,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,N,,1,,CHEMBL618733,BAO_0000218,10000001.0,
7732,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,N,,1,,CHEMBL618734,BAO_0000218,10000001.0,
7733,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,N,,1,,CHEMBL618735,BAO_0000218,10000001.0,
7734,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,N,,1,,CHEMBL876602,BAO_0000218,10000001.0,
7735,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,N,,1,,CHEMBL618736,BAO_0000218,10000001.0,
7736,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,N,,1,,CHEMBL618737,BAO_0000218,10000001.0,
7737,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,N,,1,,CHEMBL618738,BAO_0000218,10000001.0,
7738,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,N,,1,,CHEMBL618739,BAO_0000218,10000001.0,
7739,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,N,,1,,CHEMBL618740,BAO_0000218,10000001.0,
7740,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,N,,1,,CHEMBL618741,BAO_0000218,10000001.0,
7741,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,N,,1,,CHEMBL618742,BAO_0000218,10000001.0,
7742,,In vivo,Bone,A,,,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,N,,1,,CHEMBL618743,BAO_0000218,10000001.0,
7743,,In vivo,Plasma,A,,,,Half-life from rat plasma at a single oral dose of 25 mg/kg,N,,1,,CHEMBL618744,BAO_0000218,1969.0,
7744,,,,A,,,,Half-life in male rat,N,,1,,CHEMBL618745,BAO_0000218,,
7745,,In vivo,,A,,,,Half-life in rat after peroral administration at 10 mg/kg concentration,N,,1,,CHEMBL620479,BAO_0000218,,
7746,,In vivo,,A,,,,Half-life in rat after peroral administration at 5 mg/kg concentration,N,,1,,CHEMBL620480,BAO_0000218,,
7747,,In vivo,,A,,,,Half-life in rat at a dose of 3 mg/kg,N,,1,,CHEMBL620481,BAO_0000218,,
7748,,,,A,,,,Half-life was evaluated in rats,N,,1,,CHEMBL620482,BAO_0000218,,
7749,,,,A,,,,Half-life was measured in rat,N,,1,,CHEMBL876603,BAO_0000218,,
7750,,In vivo,,A,,,,Half-life period for the compound was determined in rats at 50 mg/kg dose,N,,1,,CHEMBL620483,BAO_0000218,,
7751,,In vivo,,A,,,,Half-life period in rats after intravenous administration at 5 mg/kg,N,,1,,CHEMBL620484,BAO_0000218,,
7752,,In vivo,,A,,,,Half-life period in rat at 10 mg/kg,N,,1,,CHEMBL620485,BAO_0000218,,
7753,,In vivo,,A,,,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",N,,1,,CHEMBL620486,BAO_0000218,,
7754,,In vivo,,A,,,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",N,,1,,CHEMBL620487,BAO_0000218,,
7755,,In vivo,,A,,,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",N,,1,,CHEMBL620488,BAO_0000218,,
7756,,In vivo,,A,,,,Half-life time in rat the dose of 2 mg/kg,N,,1,,CHEMBL620489,BAO_0000218,,
7757,,In vivo,,A,,,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,N,,1,,CHEMBL620490,BAO_0000218,,
7758,,In vivo,,A,,,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,N,,1,,CHEMBL620491,BAO_0000218,,
7759,,In vivo,Plasma,A,,,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",N,,1,,CHEMBL876604,BAO_0000218,1969.0,
7760,,In vivo,,A,,,,Oral half life was determined,N,,1,,CHEMBL620492,BAO_0000218,,
7761,,In vivo,,A,,,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",N,,1,,CHEMBL620493,BAO_0000218,,
7762,,In vivo,,A,,,,Pharmacokinetic property (t1/2) in rat,N,,1,,CHEMBL620494,BAO_0000218,,
7763,,,Plasma,A,,,,Plasma elimination half-life was determined,N,,1,,CHEMBL620495,BAO_0000218,1969.0,
7764,,In vivo,Plasma,A,,,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,N,,1,,CHEMBL620496,BAO_0000218,1969.0,
7765,,In vivo,Plasma,A,,,,Plasma half life was observed after intravenous administration in rat,N,,1,,CHEMBL620497,BAO_0000218,1969.0,
7766,,,Plasma,A,,,,Plasma half-life was determined,N,,1,,CHEMBL620498,BAO_0000218,1969.0,
7767,,In vivo,Plasma,A,,,,Plasma half-life following oral administration in Fisher rats,N,,1,,CHEMBL620499,BAO_0000218,1969.0,
7768,,,Plasma,A,,,,Plasma half-life in rat,N,,1,,CHEMBL620500,BAO_0000218,1969.0,
7769,,In vivo,Plasma,A,,,,Plasmatic Half-life after intravenous administration to rat,N,,1,,CHEMBL873809,BAO_0000218,1969.0,
7770,,In vivo,,A,,,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,N,,1,,CHEMBL620501,BAO_0000218,,
7771,,In vivo,,A,,,,Terminal half life after intravenous administration (1 mg/kg) in rat,N,,1,,CHEMBL620502,BAO_0000218,,
7772,,In vivo,,A,,,,Terminal half life in Rat at a oral dose of 5 mg/kg,N,,1,,CHEMBL620503,BAO_0000218,,
7773,,In vivo,,A,,,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,N,,1,,CHEMBL620504,BAO_0000218,,
7774,,In vivo,,A,,,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,N,,1,,CHEMBL876605,BAO_0000218,,
7775,,In vivo,,A,,,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,N,,1,,CHEMBL620505,BAO_0000218,,
7776,,In vivo,Plasma,A,,,,plasma half life was observed after intravenous administration in rat,N,,1,,CHEMBL873811,BAO_0000218,1969.0,
7777,,In vivo,,A,,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,N,,1,,CHEMBL624016,BAO_0000218,,
7778,,,,A,,,,Half life of compound determined in rat,N,,1,,CHEMBL624017,BAO_0000218,,
7779,,,,A,,,,Mean residence time determined in rat,N,,1,,CHEMBL624018,BAO_0000218,,
7780,,,,A,,,,Plasma half life determined in rat,N,,1,,CHEMBL624019,BAO_0000218,,
7781,,In vivo,Brain,A,,,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,N,,1,,CHEMBL624020,BAO_0000218,955.0,
7782,,In vivo,,A,,,,Compound was evaluated for pharmacokinetic parameter maximum time period,N,,1,,CHEMBL624201,BAO_0000218,,
7783,,In vivo,,A,,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,N,,1,,CHEMBL872528,BAO_0000218,,
7784,,In vivo,,A,,,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL624202,BAO_0000218,,
7785,,In vivo,,A,,,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL624203,BAO_0000218,,
7786,,In vivo,,A,,,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL624350,BAO_0000218,,
7787,,In vivo,,A,,,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL621320,BAO_0000218,,
7788,,In vivo,,A,,,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,N,,1,,CHEMBL621321,BAO_0000218,,
7789,,,,A,,,,Maximum time (Tmax) required to reach Cmax in rats,N,,1,,CHEMBL621322,BAO_0000218,,
7790,,In vivo,,A,,,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,N,,1,,CHEMBL621323,BAO_0000218,,
7791,,In vivo,,A,,,,Maximum time of clearance of compound in rats after peroral administration,N,,1,,CHEMBL621324,BAO_0000218,,
7792,,,,A,,,,Maximum time at the dose of 2 mg/kg in rat,N,,1,,CHEMBL621325,BAO_0000218,,
7793,,In vivo,Plasma,A,,,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,N,,1,,CHEMBL875837,BAO_0000218,1969.0,
7794,,In vivo,Plasma,A,,,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,N,,1,,CHEMBL621326,BAO_0000218,1969.0,
7795,,In vivo,,A,,,,Tmax in Guinea pig (PO dose),N,,1,,CHEMBL621327,BAO_0000218,,
7796,,In vivo,,A,,,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",N,,1,,CHEMBL621328,BAO_0000218,,
7797,,In vivo,,A,,,,Pharmacokinetic parameter (Tmax) in rat,N,,1,,CHEMBL621329,BAO_0000218,,
7798,,In vivo,,A,,,,Pharmacokinetic parameter (Tmax) was estimated,N,,1,,CHEMBL621330,BAO_0000218,,
7799,,In vivo,,A,,,,Pharmacokinetic property (Tmax) in rat,N,,1,,CHEMBL621331,BAO_0000218,,
7800,,In vivo,,A,,,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,N,,1,,CHEMBL621332,BAO_0000218,,
7801,,In vivo,,A,,,,T max in Rat at a oral dose of 5 mg/kg,N,,1,,CHEMBL621333,BAO_0000218,,
7802,,In vivo,,A,,,,T max was determined at 10 mg/kg po dose in rats,N,,1,,CHEMBL621334,BAO_0000218,,
7803,,,,A,,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),N,,1,,CHEMBL621335,BAO_0000218,,
7804,,,,A,,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,N,,1,,CHEMBL621336,BAO_0000218,,
7805,,,,A,,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,N,,1,,CHEMBL621337,BAO_0000218,,
7806,,,,A,,,,Area under curve was measured after i.v. administration into Beagle dog.,N,,1,,CHEMBL621338,BAO_0000218,,
7807,,,,A,,,,Area under curve was measured after iv administration into Beagle dog,N,,1,,CHEMBL875838,BAO_0000218,,
7808,,,,A,,,,Area under curve was measured after po administration into Beagle dog,N,,1,,CHEMBL621339,BAO_0000218,,
7809,,,,A,,,,Area under curve was measured after po administration into Beagle dog.,N,,1,,CHEMBL621340,BAO_0000218,,
7810,,,,A,,,,Area under curve was measured at peroral dose of 3 mg/kg,U,,1,,CHEMBL621341,BAO_0000218,,
7811,,,,A,,,,Area under curve was measured by using concentration Vs time,U,,1,,CHEMBL621342,BAO_0000019,,
7812,,,,A,,,,Area under curve was measured by using concentration Vs time; not tested,U,,1,,CHEMBL621343,BAO_0000019,,
7813,,,,A,,,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),N,,1,,CHEMBL621344,BAO_0000218,,
7814,,,,A,,,,Area under curve(AUC) was measured in mice after oral administration.,N,,1,,CHEMBL621345,BAO_0000218,,
7815,,,,A,,,,Area under curve(AUC) value of the compound,U,,1,,CHEMBL621346,BAO_0000019,,
7816,,,,A,,,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,U,,1,,CHEMBL621347,BAO_0000218,,
7817,,,,A,,,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,N,,1,,CHEMBL621348,BAO_0000218,,
7818,,,Blood,A,,,,Area under curve(carotid artery) was determined by the availability in blood,U,,1,,CHEMBL621349,BAO_0000019,178.0,
7819,,,Blood,A,,,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,U,,1,,CHEMBL621350,BAO_0000019,178.0,
7820,,,Blood,A,,,,Area under curve(carotid artery) was determined by the availability in blood; No data,U,,1,,CHEMBL875839,BAO_0000019,178.0,
7821,,,Blood,A,,,,Area under curve(portal vein) was determined by the availability in blood,U,,1,,CHEMBL620211,BAO_0000019,178.0,
7822,,,Blood,A,,,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,U,,1,,CHEMBL620212,BAO_0000019,178.0,
7823,,,Blood,A,,,,Area under curve(portal vein) was determined by the availability in blood; No data,U,,1,,CHEMBL620213,BAO_0000019,178.0,
7824,,,Plasma,A,,,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",N,,1,,CHEMBL620214,BAO_0000218,1969.0,
7825,,,Plasma,A,,,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",N,,1,,CHEMBL620215,BAO_0000218,1969.0,
7826,,,Plasma,A,,,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,N,,1,,CHEMBL620216,BAO_0000218,1969.0,
7827,,,Plasma,A,,,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",N,,1,,CHEMBL620888,BAO_0000218,1969.0,
7828,,,Plasma,A,,,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",N,,1,,CHEMBL620889,BAO_0000218,1969.0,
7829,,,Plasma,A,,,,Area under plasma concentration vs time curve observed in rats for 0-3 h,U,,1,,CHEMBL620890,BAO_0000019,1969.0,
7830,,,Plasma,A,,,,Area under plasma time curve determined in male rat,N,,1,,CHEMBL620891,BAO_0000218,1969.0,
7831,,,,A,,,,Area under the MAP curve measured over 5 min.,U,,1,,CHEMBL620892,BAO_0000019,,
7832,,,,A,,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,N,,1,,CHEMBL621079,BAO_0000218,,
7833,,,,A,,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,N,,1,,CHEMBL621080,BAO_0000218,,
7834,,,,A,,,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,N,,1,,CHEMBL621081,BAO_0000218,,
7835,,,,A,,,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,N,,1,,CHEMBL621082,BAO_0000218,,
7836,,,,A,,,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,N,,1,,CHEMBL621083,BAO_0000218,,
7837,,,,A,,,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,N,,1,,CHEMBL621084,BAO_0000218,,
7838,,,,A,,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,N,,1,,CHEMBL621085,BAO_0000218,,
7839,,,,A,,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,N,,1,,CHEMBL621086,BAO_0000218,,
7840,,,,A,,,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),N,,1,,CHEMBL621087,BAO_0000218,,
7841,,,,A,,,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),N,,1,,CHEMBL622607,BAO_0000218,,
7842,,,,A,,,,Serum AUC in marmosets (IV dose),N,,1,,CHEMBL622608,BAO_0000218,,
7843,,,,A,,,,Area under the curve after intravenous administration at a dose of 10 umol/kg,U,,1,,CHEMBL624481,BAO_0000019,,
7844,,,,A,,,,Area under the curve after intravenous administration at a dose of 2 umol/kg,U,,1,,CHEMBL624482,BAO_0000019,,
7845,,,,A,,,,Area under the curve after intravenous administration at a dose of 4 umol/kg,U,,1,,CHEMBL624483,BAO_0000019,,
7846,,,,A,,,,Area under the curve after intravenous administration at a dose of 40 umol/kg,U,,1,,CHEMBL624484,BAO_0000019,,
7847,,,,A,,,,Area under the curve after intravenous administration at a dose of 5 umol/kg,U,,1,,CHEMBL624485,BAO_0000019,,
7848,,,,A,,,,Area under the curve for fumarate salt was evaluated in F344 Rats.,N,,1,,CHEMBL624486,BAO_0000218,,
7849,,,,A,,,,Area under the curve for the compound was calculated.,U,,1,,CHEMBL624487,BAO_0000019,,
7850,,,,A,,,,Area under the curve in concentration/ time,U,,1,,CHEMBL624488,BAO_0000019,,
7851,,,,A,,,,Area under the curve administered intraintestinal in rats.,N,,1,,CHEMBL624489,BAO_0000218,,
7852,,,,A,,,,Area under the curve administered intravenously in rats.,N,,1,,CHEMBL625184,BAO_0000218,,
7853,,,,A,,,,Area under the curve during intravenous administration,U,,1,,CHEMBL625185,BAO_0000019,,
7854,,,,A,,,,Area under the curve during intravenous administration; Not determined,U,,1,,CHEMBL875954,BAO_0000019,,
7855,,,,A,,,,Area under the curve during systemic administration,U,,1,,CHEMBL625186,BAO_0000019,,
7856,,,,A,,,,Area under the curve during systemic administration; Not determined,U,,1,,CHEMBL625187,BAO_0000019,,
7857,,,,A,,,,Area under the curve was calculated for the compound.,U,,1,,CHEMBL625188,BAO_0000019,,
7858,,,,A,,,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,N,,1,,CHEMBL625189,BAO_0000218,,
7859,,,,A,,,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,N,,1,,CHEMBL625190,BAO_0000218,,
7860,,,,A,,,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,N,,1,,CHEMBL621733,BAO_0000218,,
7861,,,,A,,,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,N,,1,,CHEMBL621734,BAO_0000218,,
7862,,,,A,,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,N,,1,,CHEMBL621735,BAO_0000218,,
7863,,,Plasma,A,,,,Clearance of the drug was measured in the plasma of rat; No data,N,,1,,CHEMBL621736,BAO_0000218,1969.0,
7864,,,Plasma,A,,,,The pharmacokinetic parameter plasma clearance in vivo in rats,N,,1,,CHEMBL621737,BAO_0000218,1969.0,
7865,,,,A,,,,Plasma clearance at the dose of 2 mg/kg in rat,N,,1,,CHEMBL621738,BAO_0000218,,
7866,,In vivo,,A,,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,N,,1,,CHEMBL622806,BAO_0000218,,
7867,,In vivo,,A,,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,N,,1,,CHEMBL623519,BAO_0000218,,
7868,,In vivo,,A,,,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,N,,1,,CHEMBL623520,BAO_0000218,,
7869,,In vivo,,A,,,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,N,,1,,CHEMBL623521,BAO_0000218,,
7870,,In vivo,,A,,,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,N,,1,,CHEMBL623522,BAO_0000218,,
7871,,In vivo,,A,,,,Clearance rate in rat,N,,1,,CHEMBL623523,BAO_0000218,,
7872,,In vivo,,A,,,,Clearance rate in rat,N,,1,,CHEMBL623690,BAO_0000218,,
7873,,In vivo,,A,,,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL623691,BAO_0000218,,
7874,,In vivo,,A,,,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL623692,BAO_0000218,,
7875,,In vivo,,A,,,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL623693,BAO_0000218,,
7876,,In vivo,,A,,,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL623694,BAO_0000218,,
7877,,In vivo,,A,,,,Clearance of compound after iv administration of 20 mg/kg dose in rat,N,,1,,CHEMBL623695,BAO_0000218,,
7878,,In vivo,,A,,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,N,,1,,CHEMBL623696,BAO_0000218,,
7879,,In vivo,,A,,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,N,,1,,CHEMBL623697,BAO_0000218,,
7880,,In vivo,Plasma,A,,,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,,1,,CHEMBL623698,BAO_0000218,1969.0,
7881,,In vivo,Plasma,A,,,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,U,,1,,CHEMBL623699,BAO_0000218,1969.0,
7882,,In vivo,,A,,,,Mean (%CV) PK parameters for CL(mL/min/kg).,N,,1,,CHEMBL623700,BAO_0000218,,
7883,,In vivo,,A,,,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,N,,1,,CHEMBL623701,BAO_0000218,,
7884,,In vivo,Plasma,A,,,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,N,,1,,CHEMBL623702,BAO_0000218,1969.0,
7885,,In vivo,,A,,,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,N,,1,,CHEMBL623703,BAO_0000218,,
7886,,In vivo,,A,,,,Plasma clearance in rat was determined,N,,1,,CHEMBL623704,BAO_0000218,,
7887,,In vivo,,A,,,,Plasma clearance in rat after administration of 2 mg/kg iv,N,,1,,CHEMBL623705,BAO_0000218,,
7888,,In vivo,,A,,,,Plasma clearance in rat after administration of 2 mg/kg iv,N,,1,,CHEMBL623706,BAO_0000218,,
7889,,In vivo,,A,,,,Plasma clearance was determined,N,,1,,CHEMBL623707,BAO_0000218,,
7890,,In vivo,,A,,,,Plasma clearance in rat,N,,1,,CHEMBL623708,BAO_0000218,,
7891,,In vivo,,A,,,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,N,,1,,CHEMBL623709,BAO_0000218,,
7892,,In vivo,,A,,,,Plasma clearance in rat by iv administration,N,,1,,CHEMBL623710,BAO_0000218,,
7893,,In vivo,,A,,,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,N,,1,,CHEMBL623711,BAO_0000218,,
7894,,In vivo,,A,,,,Plasma clearance in rat p.o.,N,,1,,CHEMBL623712,BAO_0000218,,
7895,,In vivo,,A,,,,Plasma clearance in rats,N,,1,,CHEMBL623713,BAO_0000218,,
7896,,In vivo,,A,,,,Plasma clearance was determined; ND denotes no data,N,,1,,CHEMBL623714,BAO_0000218,,
7897,,In vivo,,A,,,,Plasma clearance was determined; ND denotes not determined,N,,1,,CHEMBL623715,BAO_0000218,,
7898,,In vivo,,A,,,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,N,,1,,CHEMBL623716,BAO_0000218,,
7899,,In vivo,,A,,,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,N,,1,,CHEMBL622980,BAO_0000218,,
7900,,In vivo,,A,,,,Plasma administration to rats,N,,1,,CHEMBL622981,BAO_0000218,,
7901,,In vivo,,A,,,,Plasma clearance of the compound in female Sprague-Dawley rats,N,,1,,CHEMBL622982,BAO_0000218,,
7902,,In vivo,,A,,,,Plasma clearance was observed after intravenous administration in rat,N,,1,,CHEMBL622983,BAO_0000218,,
7903,,In vivo,,A,,,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,N,,1,,CHEMBL622984,BAO_0000218,,
7904,,In vivo,,A,,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,N,,1,,CHEMBL622985,BAO_0000218,,
7905,,In vivo,Plasma,A,,,,plasma clearance was observed after intravenous administration in rat,N,,1,,CHEMBL623631,BAO_0000218,1969.0,
7906,,In vivo,,A,,,,In vivo CL/F determined,N,,1,,CHEMBL623632,BAO_0000218,,
7907,,In vivo,Plasma,A,,,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,N,,1,,CHEMBL623633,BAO_0000218,1969.0,
7908,,In vivo,Plasma,A,,,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,N,,1,,CHEMBL623634,BAO_0000218,1969.0,
7909,,In vivo,,A,,,,Compound was tested for the lower blood clearance in rat,N,,1,,CHEMBL623635,BAO_0000218,,
7910,,In vivo,,A,,,,Evaluated for the low clearance in rat (in vivo),N,,1,,CHEMBL621195,BAO_0000218,,
7911,,In vivo,,A,,,,Pharmacokinetic property (CLb)of the compound was determined in rat,N,,1,,CHEMBL621196,BAO_0000218,,
7912,,In vivo,,A,,,,Rapid clearance after intravenous administration in rat was determined,N,,1,,CHEMBL875287,BAO_0000218,,
7913,,In vivo,,A,,,,Clearance measured in rat,N,,1,,CHEMBL621197,BAO_0000218,,
7914,,In vivo,Plasma,A,,,,Compound was evaluated for plasma clearance in rat,N,,1,,CHEMBL621198,BAO_0000218,1969.0,
7915,,In vivo,Plasma,A,,,,Low plasma clearance was calculated in rat,N,,1,,CHEMBL621199,BAO_0000218,1969.0,
7916,,In vivo,,A,,,,Pharmacokinetic property (Clp) in rat,N,,1,,CHEMBL621200,BAO_0000218,,
7917,,In vivo,,A,,,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,N,,1,,CHEMBL621201,BAO_0000218,,
7918,,In vivo,,A,,,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,N,,1,,CHEMBL621202,BAO_0000218,,
7919,,In vivo,,A,,,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,N,,1,,CHEMBL621203,BAO_0000218,,
7920,,In vivo,,A,,,,Plasma clearance after IV dosing at 1 mg/kg in rat,N,,1,,CHEMBL621204,BAO_0000218,,
7921,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,N,,1,,CHEMBL621205,BAO_0000218,948.0,
7922,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,N,,1,,CHEMBL621206,BAO_0000218,948.0,
7923,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,N,,1,,CHEMBL621207,BAO_0000218,948.0,
7924,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,N,,1,,CHEMBL621208,BAO_0000218,948.0,
7925,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,N,,1,,CHEMBL621209,BAO_0000218,948.0,
7926,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,N,,1,,CHEMBL876484,BAO_0000218,948.0,
7927,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,N,,1,,CHEMBL621210,BAO_0000218,948.0,
7928,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,N,,1,,CHEMBL621211,BAO_0000218,948.0,
7929,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,N,,1,,CHEMBL621212,BAO_0000218,948.0,
7930,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,N,,1,,CHEMBL621213,BAO_0000218,948.0,
7931,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,N,,1,,CHEMBL621214,BAO_0000218,948.0,
7932,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,N,,1,,CHEMBL621215,BAO_0000218,948.0,
7933,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,N,,1,,CHEMBL621216,BAO_0000218,948.0,
7934,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,N,,1,,CHEMBL621217,BAO_0000218,948.0,
7935,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,N,,1,,CHEMBL621218,BAO_0000218,948.0,
7936,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,N,,1,,CHEMBL621219,BAO_0000218,948.0,
7937,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,N,,1,,CHEMBL621220,BAO_0000218,948.0,
7938,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,N,,1,,CHEMBL621221,BAO_0000218,948.0,
7939,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,N,,1,,CHEMBL621222,BAO_0000218,948.0,
7940,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,N,,1,,CHEMBL621223,BAO_0000218,948.0,
7941,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,N,,1,,CHEMBL876485,BAO_0000218,948.0,
7942,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,N,,1,,CHEMBL621224,BAO_0000218,948.0,
7943,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,N,,1,,CHEMBL621225,BAO_0000218,948.0,
7944,,In vivo,Heart,A,,,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,N,,1,,CHEMBL621226,BAO_0000218,948.0,
7945,,In vivo,Kidney,A,,,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,N,,1,,CHEMBL621227,BAO_0000218,2113.0,
7946,,In vivo,Kidney,A,,,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,N,,1,,CHEMBL621228,BAO_0000218,2113.0,
7947,,In vivo,Kidney,A,,,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,N,,1,,CHEMBL621229,BAO_0000218,2113.0,
7948,,In vivo,Kidney,A,,,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,N,,1,,CHEMBL621230,BAO_0000218,2113.0,
7949,,In vivo,Kidney,A,,,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,N,,1,,CHEMBL621231,BAO_0000218,2113.0,
7950,,In vivo,Kidney,A,,,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,N,,1,,CHEMBL621232,BAO_0000218,2113.0,
7951,,In vivo,Kidney,A,,,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,N,,1,,CHEMBL621233,BAO_0000218,2113.0,
7952,,In vivo,Kidney,A,,,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,N,,1,,CHEMBL621234,BAO_0000218,2113.0,
7953,,In vivo,Kidney,A,,,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,N,,1,,CHEMBL621235,BAO_0000218,2113.0,
7954,,In vivo,Kidney,A,,,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,N,,1,,CHEMBL621236,BAO_0000218,2113.0,
7955,,In vivo,Kidney,A,,,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,N,,1,,CHEMBL621237,BAO_0000218,2113.0,
7956,,In vivo,Kidney,A,,,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,N,,1,,CHEMBL876486,BAO_0000218,2113.0,
7957,,In vivo,Intestine,A,,,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,N,,1,,CHEMBL622436,BAO_0000218,160.0,
7958,,In vivo,Intestine,A,,,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,N,,1,,CHEMBL622437,BAO_0000218,160.0,
7959,,In vivo,Intestine,A,,,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,N,,1,,CHEMBL622438,BAO_0000218,160.0,
7960,,In vivo,Liver,A,,,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,N,,1,,CHEMBL622439,BAO_0000218,2107.0,
7961,,In vivo,Liver,A,,,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,N,,1,,CHEMBL622440,BAO_0000218,2107.0,
7962,,In vivo,Liver,A,,,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,N,,1,,CHEMBL622441,BAO_0000218,2107.0,
7963,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,N,,1,,CHEMBL622442,BAO_0000218,2107.0,
7964,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,N,,1,,CHEMBL622443,BAO_0000218,2107.0,
7965,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,N,,1,,CHEMBL622444,BAO_0000218,2107.0,
7966,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,N,,1,,CHEMBL622445,BAO_0000218,2107.0,
7967,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,N,,1,,CHEMBL622446,BAO_0000218,2107.0,
7968,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,N,,1,,CHEMBL622447,BAO_0000218,2107.0,
7969,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,N,,1,,CHEMBL622448,BAO_0000218,2107.0,
7970,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,N,,1,,CHEMBL622449,BAO_0000218,2107.0,
7971,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,N,,1,,CHEMBL622450,BAO_0000218,2107.0,
7972,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,N,,1,,CHEMBL622451,BAO_0000218,2107.0,
7973,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,N,,1,,CHEMBL622452,BAO_0000218,2107.0,
7974,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,N,,1,,CHEMBL622453,BAO_0000218,2107.0,
7975,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,N,,1,,CHEMBL622454,BAO_0000218,2107.0,
7976,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,N,,1,,CHEMBL622455,BAO_0000218,2107.0,
7977,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,N,,1,,CHEMBL876024,BAO_0000218,2107.0,
7978,,In vivo,,A,,,,T max was determined at 3 mg/kg po dose in rats,N,,1,,CHEMBL622456,BAO_0000218,,
7979,,In vivo,,A,,,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL622457,BAO_0000218,,
7980,,In vivo,,A,,,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL622458,BAO_0000218,,
7981,,,,A,,,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,N,,1,,CHEMBL622459,BAO_0000218,,
7982,,,,A,,,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,N,,1,,CHEMBL873343,BAO_0000218,,
7983,,,,A,,,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,N,,1,,CHEMBL622460,BAO_0000218,,
7984,,,Plasma,A,,,,Time for maximum plasma concentration determined in rat,N,,1,,CHEMBL622461,BAO_0000218,1969.0,
7985,,In vivo,Plasma,A,,,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,N,,1,,CHEMBL622462,BAO_0000218,1969.0,
7986,,In vivo,,A,,,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,N,,1,,CHEMBL622463,BAO_0000218,,
7987,,In vivo,,A,,,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,N,,1,,CHEMBL622464,BAO_0000218,,
7988,,In vivo,,A,,,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,N,,1,,CHEMBL622465,BAO_0000218,,
7989,,In vivo,,A,,,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,N,,1,,CHEMBL622466,BAO_0000218,,
7990,,In vivo,,A,,,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,N,,1,,CHEMBL622467,BAO_0000218,,
7991,,,Plasma,A,,,,Time of maximum plasma concentration in rat,N,,1,,CHEMBL622468,BAO_0000218,1969.0,
7992,,,Plasma,A,,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",N,,1,,CHEMBL876025,BAO_0000218,1969.0,
7993,,,Plasma,A,,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",N,,1,,CHEMBL622469,BAO_0000218,1969.0,
7994,,,Plasma,A,,,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",N,,1,,CHEMBL622470,BAO_0000218,1969.0,
7995,,In vivo,,A,,,,Time required to reach maximum concentration (Cmax) after oral administration in rat,N,,1,,CHEMBL622471,BAO_0000218,,
7996,,,Plasma,A,,,,Time required to reach maximum concentration in rat plasma,N,,1,,CHEMBL622472,BAO_0000218,1969.0,
7997,,In vivo,Plasma,A,,,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,N,,1,,CHEMBL622473,BAO_0000218,1969.0,
7998,,In vivo,Plasma,A,,,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,N,,1,,CHEMBL624282,BAO_0000218,1969.0,
7999,,In vivo,Plasma,A,,,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,N,,1,,CHEMBL624283,BAO_0000218,1969.0,
8000,,In vivo,Plasma,A,,,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,N,,1,,CHEMBL624284,BAO_0000218,1969.0,
8001,,In vivo,Plasma,A,,,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,N,,1,,CHEMBL624285,BAO_0000218,1969.0,
8002,,In vivo,,A,,,,Time to reach Cmax after oral administration to rats,N,,1,,CHEMBL624286,BAO_0000218,,
8003,,In vivo,,A,,,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,N,,1,,CHEMBL624287,BAO_0000218,,
8004,,,,A,,,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,N,,1,,CHEMBL624288,BAO_0000218,,
8005,,In vivo,Plasma,A,,,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,N,,1,,CHEMBL624289,BAO_0000218,1969.0,
8006,,In vivo,Plasma,A,,,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,N,,1,,CHEMBL873344,BAO_0000218,1969.0,
8007,,In vivo,,A,,,,Tmax after peroral administration (10 mg/kg) was determined in rat,N,,1,,CHEMBL619623,BAO_0000218,,
8008,,In vivo,,A,,,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,N,,1,,CHEMBL621399,BAO_0000218,,
8009,,In vivo,,A,,,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,N,,1,,CHEMBL621400,BAO_0000218,,
8010,,In vivo,,A,,,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",N,,1,,CHEMBL621401,BAO_0000218,,
8011,,,,A,,,,Tmax was determined,N,,1,,CHEMBL621402,BAO_0000218,,
8012,,,,A,,,,Tmax was determined,N,,1,,CHEMBL621403,BAO_0000218,,
8013,,In vivo,,A,,,,Tmax after oral administration in rat,N,,1,,CHEMBL621121,BAO_0000218,,
8014,,In vivo,,A,,,,Tmax after peroral administration in rats at 2.4 uM/kg,N,,1,,CHEMBL872525,BAO_0000218,,
8015,,,,A,,,,Tmax in male rat,N,,1,,CHEMBL621122,BAO_0000218,,
8016,,In vivo,,A,,,,Tmax in rat at 10 mg/kg,N,,1,,CHEMBL621123,BAO_0000218,,
8017,,In vivo,,A,,,,Tmax in rat by po administration at a dose of 40 mg/kg,N,,1,,CHEMBL621124,BAO_0000218,,
8018,,,,A,,,,Tmax in rats,N,,1,,CHEMBL621125,BAO_0000218,,
8019,,In vivo,,A,,,,Tmax was measured in rats after peroral administration at 5 mg/kg,N,,1,,CHEMBL621126,BAO_0000218,,
8020,,In vivo,,A,,,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,N,,1,,CHEMBL621127,BAO_0000218,,
8021,,In vivo,,A,,,,Tmax value after administration of 20 mg/Kg oral dose in rat,N,,1,,CHEMBL621128,BAO_0000218,,
8022,,In vivo,,A,,,,Tmax value at a dose of 10 mg/kg in male SD rats,N,,1,,CHEMBL618263,BAO_0000218,,
8023,,In vivo,,A,,,,Tmax value at a dose of 100 mg/kg in male SD rats,N,,1,,CHEMBL618264,BAO_0000218,,
8024,,In vivo,,A,,,,Tmax value at a dose of 50 mg/kg in male SD rats,N,,1,,CHEMBL618265,BAO_0000218,,
8025,,In vivo,Plasma,A,,,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,,1,,CHEMBL618266,BAO_0000218,1969.0,
8026,,In vivo,,A,,,,time required to reach maximum concentration (Cmax) after oral administration in rat,N,,1,,CHEMBL618267,BAO_0000218,,
8027,,,Urine,A,,,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),N,,1,,CHEMBL618450,BAO_0000218,1088.0,
8028,,,Urine,A,,,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),N,,1,,CHEMBL618451,BAO_0000218,1088.0,
8029,,,,A,,,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,N,,1,,CHEMBL618452,BAO_0000218,,
8030,,,Urine,A,,,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,N,,1,,CHEMBL618453,BAO_0000218,1088.0,
8031,,,Urine,A,,,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,N,,1,,CHEMBL618454,BAO_0000218,1088.0,
8032,,,Urine,A,,,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,N,,1,,CHEMBL618455,BAO_0000218,1088.0,
8033,,In vivo,,A,,,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,N,,1,,CHEMBL618456,BAO_0000218,,
8034,,In vivo,,A,,,,Compound distribution in rat tissues was determined,N,,1,,CHEMBL618457,BAO_0000218,,
8035,,In vivo,,A,,,,Volume of distribution was evaluated in rat,N,,1,,CHEMBL618458,BAO_0000218,,
8036,,,,A,,,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,N,,1,,CHEMBL618459,BAO_0000218,,
8037,,,,A,,,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,N,,1,,CHEMBL876733,BAO_0000218,,
8038,,,,A,,,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,N,,1,,CHEMBL618460,BAO_0000218,,
8039,,,,A,,,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,N,,1,,CHEMBL618461,BAO_0000218,,
8040,,,,A,,,,Area under the curve was determined after oral administration (300 uM/Kg),U,,1,,CHEMBL618462,BAO_0000019,,
8041,,,,A,,,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,N,,1,,CHEMBL618463,BAO_0000218,,
8042,,,,A,,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,N,,1,,CHEMBL618464,BAO_0000218,,
8043,,,,A,,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,N,,1,,CHEMBL618465,BAO_0000218,,
8044,,,,A,,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,N,,1,,CHEMBL618466,BAO_0000218,,
8045,,,,A,,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,N,,1,,CHEMBL618467,BAO_0000218,,
8046,,,,A,,,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,N,,1,,CHEMBL618468,BAO_0000218,,
8047,,,Plasma,A,,,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,N,,1,,CHEMBL618469,BAO_0000218,1969.0,
8048,,,Plasma,A,,,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,N,,1,,CHEMBL618470,BAO_0000218,1969.0,
8049,,,,A,,,,Plasma drug AUC in rat (PO dose),U,,1,,CHEMBL618471,BAO_0000218,,
8050,,,,A,,,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,N,,1,,CHEMBL618472,BAO_0000218,,
8051,,,,A,,,,Area under was determined at a dose of 30 mg/kg,U,,1,,CHEMBL618473,BAO_0000218,,
8052,,,,A,,,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,N,,1,,CHEMBL621699,BAO_0000218,,
8053,,,,A,,,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,N,,1,,CHEMBL621700,BAO_0000218,,
8054,,,,A,,,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,N,,1,,CHEMBL621701,BAO_0000218,,
8055,,,,A,,,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,N,,1,,CHEMBL621702,BAO_0000218,,
8056,,,,A,,,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,N,,1,,CHEMBL621703,BAO_0000218,,
8057,,,,A,,,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,N,,1,,CHEMBL621704,BAO_0000218,,
8058,,,,A,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",N,,1,,CHEMBL624259,BAO_0000218,,
8059,,,,A,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",N,,1,,CHEMBL624260,BAO_0000218,,
8060,,,,A,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",N,,1,,CHEMBL624430,BAO_0000218,,
8061,,,,A,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",N,,1,,CHEMBL624431,BAO_0000218,,
8062,,,,A,,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",N,,1,,CHEMBL624432,BAO_0000218,,
8063,,,,A,,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",N,,1,,CHEMBL624433,BAO_0000218,,
8064,,,,A,,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",N,,1,,CHEMBL624434,BAO_0000218,,
8065,,,,A,,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",N,,1,,CHEMBL624435,BAO_0000218,,
8066,,,,A,,,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,N,,1,,CHEMBL618570,BAO_0000218,,
8067,,,,A,,,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),N,,1,,CHEMBL618571,BAO_0000218,,
8068,,,,A,,,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,N,,1,,CHEMBL618572,BAO_0000218,,
8069,,,,A,,,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),N,,1,,CHEMBL618573,BAO_0000218,,
8070,,,,A,,,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,N,,1,,CHEMBL619267,BAO_0000218,,
8071,,,,A,,,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),N,,1,,CHEMBL619431,BAO_0000218,,
8072,,,,A,,,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,N,,1,,CHEMBL619432,BAO_0000218,,
8073,,,,A,,,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),N,,1,,CHEMBL619433,BAO_0000218,,
8074,,,Plasma,A,,,,AUC in mice after oral dose (50 mg/kg),U,,1,,CHEMBL619434,BAO_0000218,1969.0,
8075,,,Serum,A,,,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,N,,1,,CHEMBL619435,BAO_0000218,1977.0,
8076,,,Plasma,A,,,,AUC (0-4 hr) ug/ml/h,U,,1,,CHEMBL619436,BAO_0000019,1969.0,
8077,,,,A,,,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,N,,1,,CHEMBL619437,BAO_0000218,,
8078,,,,A,,,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,U,,1,,CHEMBL619438,BAO_0000218,,
8079,,,,A,,,,Compound was evaluated for Area under curve in mice,N,,1,,CHEMBL619439,BAO_0000218,,
8080,,,,A,,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,N,,1,,CHEMBL619440,BAO_0000218,,
8081,,,,F,,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,U,,1,,CHEMBL619441,BAO_0000218,,
8082,,,,A,,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,N,,1,,CHEMBL619442,BAO_0000218,,
8083,,,,A,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,U,,1,,CHEMBL875156,BAO_0000019,,
8084,,,,A,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,U,,1,,CHEMBL619443,BAO_0000019,,
8085,,,,A,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,U,,1,,CHEMBL619444,BAO_0000019,,
8086,,,,A,,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,U,,1,,CHEMBL623464,BAO_0000019,,
8087,,,,A,,,,Compound was evaluated for area under curve when administered through oral route in mouse,N,,1,,CHEMBL623465,BAO_0000218,,
8088,,In vivo,,A,,,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,N,,1,,CHEMBL623466,BAO_0000218,,
8089,,In vivo,,A,,,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,N,,1,,CHEMBL623467,BAO_0000218,,
8090,,In vivo,,A,,,,Plasma clearance in rat,N,,1,,CHEMBL623468,BAO_0000218,,
8091,,In vivo,,A,,,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,N,,1,,CHEMBL622660,BAO_0000218,,
8092,,In vivo,,A,,,,Plasma clearance rate in Sprague-Dawley rats,N,,1,,CHEMBL622661,BAO_0000218,,
8093,,In vivo,,F,,,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,N,,1,,CHEMBL622662,BAO_0000218,,
8094,,In vivo,,A,,,,Pharmacokinetic property (total body clearance) in rat,N,,1,,CHEMBL622663,BAO_0000218,,
8095,,In vivo,,A,,,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,N,,1,,CHEMBL622664,BAO_0000218,,
8096,,,,A,,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,N,,1,,CHEMBL622665,BAO_0000218,,
8097,,,,A,,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,N,,1,,CHEMBL622666,BAO_0000218,,
8098,,In vivo,,A,,,,Cl in rat i.v. at 2 mg/kg concentration,N,,1,,CHEMBL621615,BAO_0000218,,
8099,,In vivo,,A,,,,Clearance of compound after intravenous administration in rats at 24 uM/kg,N,,1,,CHEMBL621616,BAO_0000218,,
8100,,In vivo,,A,,,,Clearance was determined,N,,1,,CHEMBL621617,BAO_0000218,,
8101,,In vivo,,A,,,,Clearance by intravenous administration of 3.4 mg/kg in rat,N,,1,,CHEMBL621618,BAO_0000218,,
8102,,In vivo,,A,,,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,N,,1,,CHEMBL621619,BAO_0000218,,
8103,,In vivo,,A,,,,Clearance rate after i.v. administration in rats,N,,1,,CHEMBL621620,BAO_0000218,,
8104,,In vivo,,A,,,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,N,,1,,CHEMBL621786,BAO_0000218,,
8105,,In vivo,,A,,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,N,,1,,CHEMBL621787,BAO_0000218,,
8106,,In vivo,,A,,,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,N,,1,,CHEMBL621788,BAO_0000218,,
8107,,In vivo,,A,,,,Clearance (Cl) after oral administration in rat,N,,1,,CHEMBL621789,BAO_0000218,,
8108,,In vivo,,A,,,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,N,,1,,CHEMBL621790,BAO_0000218,,
8109,,In vivo,Plasma,A,,,,Compound was tested for plasma clearance in rat,N,,1,,CHEMBL621791,BAO_0000218,1969.0,
8110,Microsomes,In vitro,,A,,,,In vitro microsome metabolism clearance in rat was determined,N,,1,,CHEMBL621792,BAO_0000218,,
8111,Microsomes,In vitro,,A,,,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,N,,1,,CHEMBL621793,BAO_0000218,,
8112,,In vivo,,A,,,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL621794,BAO_0000218,,
8113,,In vivo,Plasma,A,,,,In vivo plasma clearance was determined,N,,1,,CHEMBL621795,BAO_0000218,1969.0,
8114,,In vivo,,A,,,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,N,,1,,CHEMBL621796,BAO_0000218,,
8115,,In vivo,Liver,A,Hepatocyte,401.0,,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,N,,1,,CHEMBL621797,BAO_0000218,2107.0,
8116,,In vivo,,A,,,,Pharmacokinetic property (Plasma clearance) was measured in rat,N,,1,,CHEMBL621798,BAO_0000218,,
8117,,In vivo,,A,,,,Pharmacokinetic property (clearance) in rat i.v.,N,,1,,CHEMBL621799,BAO_0000218,,
8118,,In vivo,,A,,,,"Plasma Clearance was evaluated in rats, iv",N,,1,,CHEMBL621800,BAO_0000218,,
8119,,In vivo,,A,,,,Plasma clearance (in vivo) in rats was determined,N,,1,,CHEMBL621801,BAO_0000218,,
8120,,In vivo,,A,,,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,N,,1,,CHEMBL621802,BAO_0000218,,
8121,,In vivo,,A,,,,Plasma clearance was determined,N,,1,,CHEMBL618596,BAO_0000218,,
8122,,In vivo,,A,,,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,N,,1,,CHEMBL618597,BAO_0000218,,
8123,,In vivo,,A,,,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,N,,1,,CHEMBL618598,BAO_0000218,,
8124,,In vivo,,A,,,,Plasma clearance in rats,N,,1,,CHEMBL618599,BAO_0000218,,
8125,,In vivo,,A,,,,Plasma clearance rate determined in rat,N,,1,,CHEMBL618600,BAO_0000218,,
8126,,In vivo,,A,,,,Plasma clearance was determined in rat,N,,1,,CHEMBL618601,BAO_0000218,,
8127,,In vivo,,A,,,,Plasma clearance was determined,N,,1,,CHEMBL618602,BAO_0000218,,
8128,,In vivo,,A,,,,Plasma clearance value in rat,N,,1,,CHEMBL618603,BAO_0000218,,
8129,,Ex vivo,Liver,A,,,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,N,,1,,CHEMBL618604,BAO_0000218,2107.0,
8130,,In vivo,,A,,,,Clearance in rat,N,,1,,CHEMBL618605,BAO_0000218,,
8131,,In vivo,,A,,,,Total body clearance in rat i.v. at 2 mg/kg concentration,N,,1,,CHEMBL618606,BAO_0000218,,
8132,,In vivo,,A,,,,Clearance of compound in rats after intravenous administration,N,,1,,CHEMBL618607,BAO_0000218,,
8133,,In vivo,,A,,,,Clearance after iv administration to rats,N,,1,,CHEMBL618608,BAO_0000218,,
8134,,In vivo,,A,,,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,N,,1,,CHEMBL618609,BAO_0000218,,
8135,,In vivo,,A,,,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,N,,1,,CHEMBL618610,BAO_0000218,,
8136,,In vivo,,A,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,N,,1,,CHEMBL618611,BAO_0000218,,
8137,,In vivo,,A,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,N,,1,,CHEMBL618612,BAO_0000218,,
8138,,In vivo,,A,,,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,N,,1,,CHEMBL618613,BAO_0000218,,
8139,,In vivo,,A,,,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,N,,1,,CHEMBL621076,BAO_0000218,,
8140,,In vivo,,A,,,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,N,,1,,CHEMBL621077,BAO_0000218,,
8141,,In vivo,,A,,,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",N,,1,,CHEMBL621078,BAO_0000218,,
8142,,In vivo,,A,,,,Clearance in rat,N,,1,,CHEMBL621251,BAO_0000218,,
8143,,In vivo,,A,,,,Clearance in rat after oral administration at 10 mg/kg,N,,1,,CHEMBL621252,BAO_0000218,,
8144,,In vivo,,A,,,,Clearance in rat.,N,,1,,CHEMBL621253,BAO_0000218,,
8145,,In vivo,,A,,,,Clearance rate following an oral dose of 20 mg/kg in rats,N,,1,,CHEMBL621254,BAO_0000218,,
8146,,In vivo,,A,,,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,N,,1,,CHEMBL621255,BAO_0000218,,
8147,,In vivo,Plasma,A,,,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,N,,1,,CHEMBL621256,BAO_0000218,1969.0,
8148,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,N,,1,,CHEMBL621257,BAO_0000218,2107.0,
8149,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,N,,1,,CHEMBL621258,BAO_0000218,2107.0,
8150,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,N,,1,,CHEMBL621259,BAO_0000218,2107.0,
8151,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,N,,1,,CHEMBL621260,BAO_0000218,2107.0,
8152,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,N,,1,,CHEMBL876494,BAO_0000218,2107.0,
8153,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,N,,1,,CHEMBL621261,BAO_0000218,2107.0,
8154,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,N,,1,,CHEMBL621262,BAO_0000218,2107.0,
8155,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,N,,1,,CHEMBL621263,BAO_0000218,2107.0,
8156,,In vivo,Liver,A,,,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,N,,1,,CHEMBL621264,BAO_0000218,2107.0,
8157,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,N,,1,,CHEMBL621265,BAO_0000218,2385.0,
8158,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,N,,1,,CHEMBL621266,BAO_0000218,2385.0,
8159,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,N,,1,,CHEMBL621267,BAO_0000218,2385.0,
8160,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,N,,1,,CHEMBL621268,BAO_0000218,2385.0,
8161,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,N,,1,,CHEMBL621269,BAO_0000218,2385.0,
8162,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,N,,1,,CHEMBL621270,BAO_0000218,2385.0,
8163,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,N,,1,,CHEMBL621271,BAO_0000218,2385.0,
8164,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,N,,1,,CHEMBL621272,BAO_0000218,2385.0,
8165,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,N,,1,,CHEMBL621273,BAO_0000218,2385.0,
8166,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,N,,1,,CHEMBL621274,BAO_0000218,2385.0,
8167,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,N,,1,,CHEMBL876495,BAO_0000218,2385.0,
8168,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,N,,1,,CHEMBL621275,BAO_0000218,2385.0,
8169,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,N,,1,,CHEMBL621276,BAO_0000218,2385.0,
8170,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,N,,1,,CHEMBL621277,BAO_0000218,2385.0,
8171,,In vivo,Intestine,A,,,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,N,,1,,CHEMBL621278,BAO_0000218,160.0,
8172,,In vivo,Intestine,A,,,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,N,,1,,CHEMBL621279,BAO_0000218,160.0,
8173,,In vivo,Intestine,A,,,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),N,,1,,CHEMBL621280,BAO_0000218,160.0,
8174,,In vivo,Spleen,A,,,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,N,,1,,CHEMBL621281,BAO_0000218,2106.0,
8175,,In vivo,Spleen,A,,,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,N,,1,,CHEMBL621282,BAO_0000218,2106.0,
8176,,In vivo,Spleen,A,,,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,N,,1,,CHEMBL621283,BAO_0000218,2106.0,
8177,,In vivo,Spleen,A,,,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,N,,1,,CHEMBL621284,BAO_0000218,2106.0,
8178,,In vivo,Spleen,A,,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,N,,1,,CHEMBL621285,BAO_0000218,2106.0,
8179,,In vivo,Spleen,A,,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,N,,1,,CHEMBL621286,BAO_0000218,2106.0,
8180,,In vivo,Spleen,A,,,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,N,,1,,CHEMBL623220,BAO_0000218,2106.0,
8181,,In vivo,Spleen,A,,,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,N,,1,,CHEMBL623221,BAO_0000218,2106.0,
8182,,In vivo,Spleen,A,,,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,N,,1,,CHEMBL876029,BAO_0000218,2106.0,
8183,,In vivo,Stomach,A,,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,N,,1,,CHEMBL623222,BAO_0000218,945.0,
8184,,In vivo,Stomach,A,,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,N,,1,,CHEMBL623223,BAO_0000218,945.0,
8185,,In vivo,Stomach,A,,,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,N,,1,,CHEMBL621445,BAO_0000218,945.0,
8186,,In vivo,Blood,A,,,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621446,BAO_0000218,178.0,
8187,,In vivo,Blood,A,,,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621447,BAO_0000218,178.0,
8188,,In vivo,Blood,A,,,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL619681,BAO_0000218,178.0,
8189,,In vivo,Blood,A,,,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL619682,BAO_0000218,178.0,
8190,,In vivo,Blood,A,,,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL619683,BAO_0000218,178.0,
8191,,In vivo,Brain,A,,,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL619684,BAO_0000218,955.0,
8192,,In vivo,Brain,A,,,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL619685,BAO_0000218,955.0,
8193,,In vivo,Brain,A,,,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL619686,BAO_0000218,955.0,
8194,,In vivo,Brain,A,,,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL619687,BAO_0000218,955.0,
8195,,In vivo,Brain,A,,,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL619688,BAO_0000218,955.0,
8196,,In vivo,Heart,A,,,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL619689,BAO_0000218,948.0,
8197,,In vivo,Heart,A,,,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL619690,BAO_0000218,948.0,
8198,,In vivo,Heart,A,,,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL619691,BAO_0000218,948.0,
8199,,In vivo,,A,,,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,N,,1,,CHEMBL619692,BAO_0000218,,
8200,,,,A,,,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,N,,1,,CHEMBL619693,BAO_0000218,,
8201,,In vivo,,A,,,,Vc value after IV dose at a dose of 5 mg/kg in rats.,N,,1,,CHEMBL619694,BAO_0000218,,
8202,,In vivo,,A,,,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,N,,1,,CHEMBL619695,BAO_0000218,,
8203,,In vivo,,A,,,,Compound was evaluated for pharmacokinetic parameter volume of distribution,N,,1,,CHEMBL619696,BAO_0000218,,
8204,,In vivo,,A,,,,Compound was evaluated for volume of distribution in rat,N,,1,,CHEMBL619697,BAO_0000218,,
8205,,In vivo,,A,,,,Steady state volume distribution was determined; steady state(ss),N,,1,,CHEMBL619698,BAO_0000218,,
8206,,In vivo,,A,,,,Steady state volume of distribution after iv administration to rats,N,,1,,CHEMBL619699,BAO_0000218,,
8207,,In vivo,,A,,,,Steady state volume of distribution dosing at 3 mg/kg iv,N,,1,,CHEMBL619700,BAO_0000218,,
8208,,In vivo,,A,,,,The compound was evaluated for volume of distribution in rat,N,,1,,CHEMBL619701,BAO_0000218,,
8209,,In vivo,,A,,,,The compound was tested for volume of distribution in rat,N,,1,,CHEMBL619702,BAO_0000218,,
8210,,In vivo,,A,,,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,N,,1,,CHEMBL620335,BAO_0000218,,
8211,,In vivo,,A,,,,Volume distribution (VD) after oral administration in rat,N,,1,,CHEMBL620336,BAO_0000218,,
8212,,In vivo,,A,,,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,N,,1,,CHEMBL620337,BAO_0000218,,
8213,,In vivo,,A,,,,Volume distribution in rat,N,,1,,CHEMBL620520,BAO_0000218,,
8214,,In vivo,,A,,,,Volume distribution in rat,N,,1,,CHEMBL620521,BAO_0000218,,
8215,,In vivo,,A,,,,Volume distribution in rat after peroral administration at 10 mg/kg,N,,1,,CHEMBL875825,BAO_0000218,,
8216,,In vivo,,A,,,,Volume distribution in rat after peroral administration at 5 mg/kg,N,,1,,CHEMBL620522,BAO_0000218,,
8217,,In vivo,,A,,,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,N,,1,,CHEMBL620523,BAO_0000218,,
8218,,In vivo,,A,,,,Volume of distribution in rat.,N,,1,,CHEMBL620524,BAO_0000218,,
8219,,In vivo,,A,,,,Volume of distribution in rat,N,,1,,CHEMBL620525,BAO_0000218,,
8220,,In vivo,,A,,,,Volume of distribution in rat,N,,1,,CHEMBL620526,BAO_0000218,,
8221,,In vivo,,A,,,,Volume of distribution in rat by iv administration,N,,1,,CHEMBL620527,BAO_0000218,,
8222,,In vivo,,A,,,,Volume of distribution in rats,N,,1,,CHEMBL620528,BAO_0000218,,
8223,,In vivo,,A,,,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,N,,1,,CHEMBL620529,BAO_0000218,,
8224,,,,A,,,,Volume distribution at the dose of 2 mg/kg in rat,N,,1,,CHEMBL620530,BAO_0000218,,
8225,,In vivo,,A,,,,Steady state volume of distribution was determined,N,,1,,CHEMBL620531,BAO_0000218,,
8226,,In vivo,,A,,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,,1,,CHEMBL620532,BAO_0000218,,
8227,,In vivo,,A,,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,U,,1,,CHEMBL620533,BAO_0000218,,
8228,,In vivo,,A,,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,U,,1,,CHEMBL620534,BAO_0000218,,
8229,,In vivo,,A,,,,Mean (%CV) PK parameters for Vdss(mL/kg).,N,,1,,CHEMBL620535,BAO_0000218,,
8230,,In vivo,,A,,,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,N,,1,,CHEMBL875826,BAO_0000218,,
8231,,In vivo,,A,,,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,N,,1,,CHEMBL620536,BAO_0000218,,
8232,,In vivo,,A,,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,N,,1,,CHEMBL620537,BAO_0000218,,
8233,,In vivo,,A,,,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,N,,1,,CHEMBL618526,BAO_0000218,,
8234,,In vivo,,A,,,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,N,,1,,CHEMBL618527,BAO_0000218,,
8235,,In vivo,,A,,,,Pharmacokinetic property (Vdss) in rat,N,,1,,CHEMBL618528,BAO_0000218,,
8236,,In vivo,,A,,,,Pharmacokinetic property (vdss) was measured in rat,N,,1,,CHEMBL618529,BAO_0000218,,
8237,,In vivo,,A,,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,N,,1,,CHEMBL618530,BAO_0000218,,
8238,,In vivo,,A,,,,Volume of distribution in rat,N,,1,,CHEMBL618531,BAO_0000218,,
8239,,In vivo,,A,,,,The pharmacokinetic parameter volume of distribution in vivo in rats,N,,1,,CHEMBL618532,BAO_0000218,,
8240,,In vivo,,F,,,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,N,,1,,CHEMBL618533,BAO_0000218,,
8241,,In vivo,,A,,,,Vdss in rat i.v. at 2 mg/kg concentration,N,,1,,CHEMBL618534,BAO_0000218,,
8242,,In vivo,,A,,,,Volume distribution after intravenous administration (1 mg/kg) in rat,N,,1,,CHEMBL618535,BAO_0000218,,
8243,,In vivo,,A,,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,N,,1,,CHEMBL618536,BAO_0000218,,
8244,,In vivo,,A,,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,N,,1,,CHEMBL618537,BAO_0000218,,
8245,,In vivo,,A,,,,Volume distribution at a dose of 10 uM/kg in rat was determined,N,,1,,CHEMBL618538,BAO_0000218,,
8246,,In vivo,,A,,,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,N,,1,,CHEMBL618539,BAO_0000218,,
8247,,In vivo,,A,,,,Volume distribution was calculated in rat,N,,1,,CHEMBL618540,BAO_0000218,,
8248,,In vivo,,A,,,,Volume distribution was determined,N,,1,,CHEMBL618541,BAO_0000218,,
8249,,In vivo,,A,,,,Volume of distribution after intravenous administration was evaluated in rat,N,,1,,CHEMBL618542,BAO_0000218,,
8250,,In vivo,,A,,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,1,,CHEMBL622544,BAO_0000218,,
8251,,In vivo,,A,,,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",N,,1,,CHEMBL622545,BAO_0000218,,
8252,,In vivo,,A,,,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",N,,1,,CHEMBL622546,BAO_0000218,,
8253,,In vivo,,A,,,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",N,,1,,CHEMBL622547,BAO_0000218,,
8254,,In vivo,,A,,,,Volume of distribution in steady state was determined in rat,N,,1,,CHEMBL622548,BAO_0000218,,
8255,,In vivo,,A,,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,N,,1,,CHEMBL622549,BAO_0000218,,
8256,,In vivo,,A,,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,N,,1,,CHEMBL622550,BAO_0000218,,
8257,,,,A,,,,Compound was evaluated for area under curve when administered through oral route to mouse,N,,1,,CHEMBL622551,BAO_0000218,,
8258,,,,A,,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,N,,1,,CHEMBL622552,BAO_0000218,,
8259,,,,A,,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,N,,1,,CHEMBL622553,BAO_0000218,,
8260,,In vivo,,F,,,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,U,,1,,CHEMBL622554,BAO_0000218,,
8261,,,,A,,,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,N,,1,,CHEMBL622555,BAO_0000218,,
8262,,,,A,,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,N,,1,,CHEMBL622556,BAO_0000218,,
8263,,,,A,,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,N,,1,,CHEMBL622557,BAO_0000218,,
8264,,,Blood,A,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,N,,1,,CHEMBL622558,BAO_0000218,178.0,
8265,,,Blood,A,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,N,,1,,CHEMBL622559,BAO_0000218,178.0,
8266,,,,A,,,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,N,,1,,CHEMBL622560,BAO_0000218,,
8267,,,,A,,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,N,,1,,CHEMBL622561,BAO_0000218,,
8268,,,,A,,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,N,,1,,CHEMBL622562,BAO_0000218,,
8269,,,,A,,,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,N,,1,,CHEMBL622563,BAO_0000218,,
8270,,,,A,,,,Concentration of compound in Central nervous system,U,,1,,CHEMBL622564,BAO_0000019,,
8271,,,,A,,,,Concentration of compound in Central nervous system; Not detectable,U,,1,,CHEMBL622565,BAO_0000019,,
8272,,,,A,,,,"Concentration of diester in the blood, following oral administration in mice",N,,1,,CHEMBL622566,BAO_0000218,,
8273,,,,A,,,,"Concentration of monoester in the blood, following oral administration in mice",N,,1,,CHEMBL624515,BAO_0000218,,
8274,,,,A,,,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,N,,1,,CHEMBL624516,BAO_0000218,,
8275,,,,A,,,,Evaluated for Pharmacokinetic property: Area under the curve,U,,1,,CHEMBL624517,BAO_0000019,,
8276,,,,A,,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,N,,1,,CHEMBL624518,BAO_0000218,,
8277,,,,A,,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,N,,1,,CHEMBL624519,BAO_0000218,,
8278,,,,A,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,N,,1,,CHEMBL624520,BAO_0000218,,
8279,,,,A,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,N,,1,,CHEMBL624521,BAO_0000218,,
8280,,,,A,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,N,,1,,CHEMBL624522,BAO_0000218,,
8281,,,,A,,,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,N,,1,,CHEMBL624523,BAO_0000218,,
8282,,,,A,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",N,,1,,CHEMBL624409,BAO_0000218,,
8283,,,,A,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",N,,1,,CHEMBL624410,BAO_0000218,,
8284,,,,A,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",N,,1,,CHEMBL624411,BAO_0000218,,
8285,,,,A,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",N,,1,,CHEMBL623531,BAO_0000218,,
8286,,,,A,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",N,,1,,CHEMBL623532,BAO_0000218,,
8287,,,,A,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",N,,1,,CHEMBL623533,BAO_0000218,,
8288,,,,A,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",N,,1,,CHEMBL623534,BAO_0000218,,
8289,,,,A,,,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,N,,1,,CHEMBL623535,BAO_0000218,,
8290,,,,A,,,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,N,,1,,CHEMBL623536,BAO_0000218,,
8291,,,,A,,,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,N,,1,,CHEMBL623537,BAO_0000218,,
8292,,,,A,,,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,N,,1,,CHEMBL623538,BAO_0000218,,
8293,,,,A,,,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,N,,1,,CHEMBL623539,BAO_0000218,,
8294,,,,A,,,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,N,,1,,CHEMBL623540,BAO_0000218,,
8295,,,,A,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",N,,1,,CHEMBL623541,BAO_0000218,,
8296,,,,A,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",N,,1,,CHEMBL623542,BAO_0000218,,
8297,,,,A,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",N,,1,,CHEMBL623543,BAO_0000218,,
8298,,,,A,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",N,,1,,CHEMBL623544,BAO_0000218,,
8299,,,,A,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",N,,1,,CHEMBL623545,BAO_0000218,,
8300,,,,A,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",N,,1,,CHEMBL623546,BAO_0000218,,
8301,,In vivo,Plasma,A,,,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,N,,1,,CHEMBL623547,BAO_0000218,1969.0,
8302,,In vivo,,A,,,,High i.v. clearance in Dawley rats,N,,1,,CHEMBL623548,BAO_0000218,,
8303,Microsomes,In vitro,Liver,A,,,,In vitro clearance in rat liver microsomes,N,,1,,CHEMBL623549,BAO_0000218,2107.0,
8304,Microsomes,In vitro,Liver,A,,,,Intrinsic clearance in rat liver microsomes was determined,N,,1,,CHEMBL623550,BAO_0000218,2107.0,
8305,,In vitro,Liver,A,Hepatocyte,401.0,,Intrinsic clearance in rat hepatocytes was determined,N,,1,,CHEMBL875276,BAO_0000218,2107.0,
8306,,In vivo,,A,,,,Plasma Clearance was determined,N,,1,,CHEMBL621872,BAO_0000218,,
8307,,In vivo,,A,,,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,N,,1,,CHEMBL621873,BAO_0000218,,
8308,,In vivo,,A,,,,Plasma clearance in rat.,N,,1,,CHEMBL621874,BAO_0000218,,
8309,,In vivo,,A,,,,Plasma clearance in rats,N,,1,,CHEMBL621875,BAO_0000218,,
8310,,In vivo,,A,,,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,N,,1,,CHEMBL621876,BAO_0000218,,
8311,,In vivo,,A,,,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,N,,1,,CHEMBL621877,BAO_0000218,,
8312,,In vivo,,A,,,,Plasma clearance was measured in rat,N,,1,,CHEMBL621878,BAO_0000218,,
8313,,In vivo,,A,,,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,N,,1,,CHEMBL621879,BAO_0000218,,
8314,,In vivo,Plasma,A,,,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",N,,1,,CHEMBL621880,BAO_0000218,1969.0,
8315,,In vivo,,A,,,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,N,,1,,CHEMBL621881,BAO_0000218,,
8316,,In vivo,,A,,,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,N,,1,,CHEMBL621882,BAO_0000218,,
8317,,In vivo,,A,,,,Total clearance at 1 mg/kg was determined in rat,N,,1,,CHEMBL875283,BAO_0000218,,
8318,,In vivo,,A,,,,Total clearance at 10 mg/kg was determined in rat,N,,1,,CHEMBL621883,BAO_0000218,,
8319,,In vivo,,A,,,,Clearance in rat,N,,1,,CHEMBL621884,BAO_0000218,,
8320,,In vivo,,A,,,,Plasma clearance rate determined in rats,N,,1,,CHEMBL621885,BAO_0000218,,
8321,,In vivo,,A,,,,Clearance of compound in rat was evaluated,N,,1,,CHEMBL621886,BAO_0000218,,
8322,,In vivo,Plasma,A,,,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,N,,1,,CHEMBL621887,BAO_0000218,1969.0,
8323,,In vivo,,A,,,,Pharmacokinetic property (blood clearance) in rat,N,,1,,CHEMBL621888,BAO_0000218,,
8324,,In vivo,,A,,,,Plasma clearance in rat,N,,1,,CHEMBL621889,BAO_0000218,,
8325,,In vivo,,A,,,,Plasma clearance in rats,N,,1,,CHEMBL621890,BAO_0000218,,
8326,Microsomes,In vitro,Liver,A,,,,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,N,,1,,CHEMBL621891,BAO_0000218,2107.0,
8327,,In vivo,,A,,,,Clearance in Dawley rat,N,,1,,CHEMBL621892,BAO_0000218,,
8328,,In vivo,,A,,,,Clearance rat,N,,1,,CHEMBL621893,BAO_0000218,,
8329,,In vivo,,A,,,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),N,,1,,CHEMBL621894,BAO_0000218,,
8330,,In vivo,,A,,,,Clearance rat; Not determined,N,,1,,CHEMBL621895,BAO_0000218,,
8331,,In vivo,,A,,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,N,,1,,CHEMBL875284,BAO_0000218,,
8332,,In vivo,,A,,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,N,,1,,CHEMBL618699,BAO_0000218,,
8333,,In vivo,,A,,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,N,,1,,CHEMBL618700,BAO_0000218,,
8334,,In vivo,,A,,,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,N,,1,,CHEMBL618701,BAO_0000218,,
8335,,In vivo,Plasma,A,,,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",N,,1,,CHEMBL876600,BAO_0000218,1969.0,
8336,,In vivo,,A,,,,Clearance of compound in rat after 1 mg/kg i.v. administration,N,,1,,CHEMBL618702,BAO_0000218,,
8337,,In vivo,,A,,,,Compound was evaluated for Hepatic clearance in rat,N,,1,,CHEMBL618703,BAO_0000218,,
8338,,In vivo,,A,,,,In vivo clearance after 5 mg/kg dose,N,,1,,CHEMBL618704,BAO_0000218,,
8339,,In vivo,Plasma,A,,,,Compound was tested for plasma clearance in rats,N,,1,,CHEMBL618705,BAO_0000218,1969.0,
8340,,In vivo,,A,,,,Hepatic clearance after intravenous administration was evaluated in rat,N,,1,,CHEMBL618706,BAO_0000218,,
8341,,In vivo,,A,,,,Lower clearance in rat (i.v.) at 0.5 mpk,N,,1,,CHEMBL618707,BAO_0000218,,
8342,,In vivo,Plasma,A,,,,Pharmacokinetic parameter expressed as plasma clearance in rat,N,,1,,CHEMBL618708,BAO_0000218,1969.0,
8343,,In vivo,,A,,,,Pharmacokinetic property (Clp) in rat,N,,1,,CHEMBL618709,BAO_0000218,,
8344,,In vivo,,A,,,,Plasma clearance in Sprague-Dawley rats,N,,1,,CHEMBL618710,BAO_0000218,,
8345,,In vivo,,A,,,,Plasma clearance (Clp) in rat,N,,1,,CHEMBL618711,BAO_0000218,,
8346,,In vivo,,A,,,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,N,,1,,CHEMBL618712,BAO_0000218,,
8347,,In vivo,,A,,,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,N,,1,,CHEMBL618713,BAO_0000218,,
8348,,In vivo,,A,,,,Plasma clearance after intravenous administration of 1 mg/kg in rat,N,,1,,CHEMBL618714,BAO_0000218,,
8349,,In vivo,,A,,,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,N,,1,,CHEMBL618715,BAO_0000218,,
8350,,In vivo,,A,,,,Plasma clearance in rat was determined,N,,1,,CHEMBL618716,BAO_0000218,,
8351,,In vivo,,A,,,,Plasma clearance measured in rat,N,,1,,CHEMBL876601,BAO_0000218,,
8352,,In vivo,,A,,,,Plasma clearance was calculated in rat,N,,1,,CHEMBL618717,BAO_0000218,,
8353,,In vivo,,A,,,,Plasma clearance in rat,N,,1,,CHEMBL618718,BAO_0000218,,
8354,,In vivo,,A,,,,Plasma clearance in rat,N,,1,,CHEMBL618719,BAO_0000218,,
8355,,In vivo,,A,,,,Plasma clearance in rat,N,,1,,CHEMBL618720,BAO_0000218,,
8356,,In vivo,,A,,,,Plasma clearance in rat,N,,1,,CHEMBL618721,BAO_0000218,,
8357,,In vivo,,A,,,,Plasma clearance in rats,N,,1,,CHEMBL621477,BAO_0000218,,
8358,,In vivo,,A,,,,Plasma clearance in rat,N,,1,,CHEMBL621478,BAO_0000218,,
8359,,In vivo,,A,,,,Plasma clearance was evaluated in rat,N,,1,,CHEMBL621479,BAO_0000218,,
8360,,In vivo,,A,,,,Plasma clearance was evaluated in rat; Not tested,N,,1,,CHEMBL621480,BAO_0000218,,
8361,,In vivo,,A,,,,Plasma clearance rate was determined for the compound in rat,N,,1,,CHEMBL621481,BAO_0000218,,
8362,,In vivo,,A,,,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",N,,1,,CHEMBL621482,BAO_0000218,,
8363,,In vivo,,A,,,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",N,,1,,CHEMBL621483,BAO_0000218,,
8364,,In vivo,,A,,,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",N,,1,,CHEMBL621484,BAO_0000218,,
8365,,In vivo,Heart,A,,,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621485,BAO_0000218,948.0,
8366,,In vivo,Heart,A,,,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621486,BAO_0000218,948.0,
8367,,In vivo,Intestine,A,,,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621487,BAO_0000218,160.0,
8368,,In vivo,Intestine,A,,,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621488,BAO_0000218,160.0,
8369,,In vivo,Intestine,A,,,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621489,BAO_0000218,160.0,
8370,,In vivo,Intestine,A,,,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621490,BAO_0000218,160.0,
8371,,In vivo,Intestine,A,,,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621491,BAO_0000218,160.0,
8372,,In vivo,Kidney,A,,,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621492,BAO_0000218,2113.0,
8373,,In vivo,Kidney,A,,,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621493,BAO_0000218,2113.0,
8374,,In vivo,Kidney,A,,,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621494,BAO_0000218,2113.0,
8375,,In vivo,Kidney,A,,,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621495,BAO_0000218,2113.0,
8376,,In vivo,Kidney,A,,,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621496,BAO_0000218,2113.0,
8377,,In vivo,Liver,A,,,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621497,BAO_0000218,2107.0,
8378,,In vivo,Liver,A,,,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621498,BAO_0000218,2107.0,
8379,,In vivo,Liver,A,,,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL621499,BAO_0000218,2107.0,
8380,,In vivo,Liver,A,,,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL618634,BAO_0000218,2107.0,
8381,,In vivo,Liver,A,,,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL618635,BAO_0000218,2107.0,
8382,,In vivo,Lung,A,,,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL618636,BAO_0000218,2048.0,
8383,,In vivo,Lung,A,,,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL619737,BAO_0000218,2048.0,
8384,,In vivo,Lung,A,,,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL619738,BAO_0000218,2048.0,
8385,,In vivo,Lung,A,,,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL624329,BAO_0000218,2048.0,
8386,,In vivo,Lung,A,,,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL624330,BAO_0000218,2048.0,
8387,,In vivo,Muscle tissue,A,,,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL624331,BAO_0000218,2385.0,
8388,,In vivo,Muscle tissue,A,,,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL624332,BAO_0000218,2385.0,
8389,,In vivo,Muscle tissue,A,,,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL624333,BAO_0000218,2385.0,
8390,,In vivo,Muscle tissue,A,,,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL624334,BAO_0000218,2385.0,
8391,,In vivo,Muscle tissue,A,,,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL624335,BAO_0000218,2385.0,
8392,,In vivo,Spleen,A,,,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620016,BAO_0000218,2106.0,
8393,,In vivo,Spleen,A,,,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620169,BAO_0000218,2106.0,
8394,,In vivo,Spleen,A,,,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620170,BAO_0000218,2106.0,
8395,,In vivo,Spleen,A,,,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620171,BAO_0000218,2106.0,
8396,,In vivo,Spleen,A,,,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620172,BAO_0000218,2106.0,
8397,,In vivo,Stomach,A,,,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620173,BAO_0000218,945.0,
8398,,In vivo,Stomach,A,,,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620174,BAO_0000218,945.0,
8399,,In vivo,Stomach,A,,,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620175,BAO_0000218,945.0,
8400,,In vivo,Stomach,A,,,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620176,BAO_0000218,945.0,
8401,,In vivo,Stomach,A,,,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620177,BAO_0000218,945.0,
8402,,,Cerebellum,A,,,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620178,BAO_0000218,2037.0,
8403,,,Cerebellum,A,,,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620179,BAO_0000218,2037.0,
8404,,,,A,,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620180,BAO_0000218,,
8405,,In vivo,,A,,,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,N,,1,,CHEMBL620181,BAO_0000218,,
8406,,In vivo,,A,,,,Volume of distribution of compound in rats after intravenous administration,N,,1,,CHEMBL620182,BAO_0000218,,
8407,,In vivo,,A,,,,Volume of distribution in rat,N,,1,,CHEMBL620183,BAO_0000218,,
8408,,In vivo,,A,,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,N,,1,,CHEMBL620184,BAO_0000218,,
8409,,In vivo,,A,,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,N,,1,,CHEMBL620185,BAO_0000218,,
8410,,In vivo,,A,,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,N,,1,,CHEMBL620186,BAO_0000218,,
8411,,In vivo,,A,,,,Volume of distribution was determined in Dawley rat,N,,1,,CHEMBL620187,BAO_0000218,,
8412,,In vivo,,A,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,N,,1,,CHEMBL620188,BAO_0000218,,
8413,,In vivo,,A,,,,Volume of distribution was reported in Sprague-Dawley rat,N,,1,,CHEMBL620189,BAO_0000218,,
8414,,In vivo,,A,,,,Volumes of distribution in rat after peroral administration,N,,1,,CHEMBL620190,BAO_0000218,,
8415,,In vivo,,A,,,,Volumes of distribution in rat after po administration,N,,1,,CHEMBL620191,BAO_0000218,,
8416,,In vivo,,A,,,,Volumes of distribution in rat after po administration; Not determined,N,,1,,CHEMBL620192,BAO_0000218,,
8417,,In vivo,,A,,,,Pharmacokinetic property (Volume) in rat i.v.,N,,1,,CHEMBL620193,BAO_0000218,,
8418,,In vivo,,A,,,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,N,,1,,CHEMBL620194,BAO_0000218,,
8419,,In vivo,,A,,,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",N,,1,,CHEMBL876730,BAO_0000218,,
8420,,In vivo,,A,,,,Volume distribution in rat after oral administration at 10 mg/kg,N,,1,,CHEMBL620195,BAO_0000218,,
8421,,In vivo,,A,,,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,N,,1,,CHEMBL620196,BAO_0000218,,
8422,,In vivo,,A,,,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,N,,1,,CHEMBL620197,BAO_0000218,,
8423,,In vivo,,A,,,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,N,,1,,CHEMBL620198,BAO_0000218,,
8424,,In vivo,,A,,,,Volume of distribution in rats,N,,1,,CHEMBL620199,BAO_0000218,,
8425,,In vivo,,A,,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,N,,1,,CHEMBL620200,BAO_0000218,,
8426,,In vivo,,A,,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,N,,1,,CHEMBL620201,BAO_0000218,,
8427,,In vivo,,A,,,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL620202,BAO_0000218,,
8428,,In vivo,,A,,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL620203,BAO_0000218,,
8429,,In vivo,,A,,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,N,,1,,CHEMBL620204,BAO_0000218,,
8430,,In vivo,,A,,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL620205,BAO_0000218,,
8431,,In vivo,,A,,,,Pharmacokinetic parameter (Vss) in rat,N,,1,,CHEMBL624664,BAO_0000218,,
8432,,In vivo,,A,,,,Pharmacokinetic property (Volume) in rat i.v.,N,,1,,CHEMBL624665,BAO_0000218,,
8433,,,,A,,,,Pharmacokinetic property (Vss) in rat,N,,1,,CHEMBL624666,BAO_0000218,,
8434,,In vivo,,A,,,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,N,,1,,CHEMBL624667,BAO_0000218,,
8435,,In vivo,,A,,,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL624668,BAO_0000218,,
8436,,In vivo,,A,,,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL624669,BAO_0000218,,
8437,,In vivo,,A,,,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL624670,BAO_0000218,,
8438,,In vivo,,A,,,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL624671,BAO_0000218,,
8439,,In vivo,,A,,,,Steady state volume distribution in rat,N,,1,,CHEMBL624672,BAO_0000218,,
8440,,In vivo,Plasma,A,,,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",N,,1,,CHEMBL624673,BAO_0000218,1969.0,
8441,,In vivo,,A,,,,Steady state volume of distribution determined in rat,N,,1,,CHEMBL624674,BAO_0000218,,
8442,,In vivo,,A,,,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,N,,1,,CHEMBL624675,BAO_0000218,,
8443,,In vivo,,A,,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,N,,1,,CHEMBL621728,BAO_0000218,,
8444,,,,A,,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,N,,1,,CHEMBL621729,BAO_0000218,,
8445,,,,A,,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,N,,1,,CHEMBL621730,BAO_0000218,,
8446,,In vivo,,A,,,,Volume distribution in rat after administration of 2 mg/kg iv,N,,1,,CHEMBL621731,BAO_0000218,,
8447,,In vivo,,A,,,,Volume distribution in rat after administration of 2 mg/kg iv,N,,1,,CHEMBL621732,BAO_0000218,,
8448,,In vivo,,A,,,,Volume in steady state distribution value was determined,N,,1,,CHEMBL621908,BAO_0000218,,
8449,,In vivo,,A,,,,Volume in steady state distribution value was determined; ND denotes no data,N,,1,,CHEMBL875347,BAO_0000218,,
8450,,In vivo,,A,,,,Volume in steady state distribution value was determined; ND denotes not determined,N,,1,,CHEMBL621909,BAO_0000218,,
8451,,In vivo,,A,,,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,N,,1,,CHEMBL621910,BAO_0000218,,
8452,,In vivo,,A,,,,Volume of distribution at steady state was evaluated in rats,N,,1,,CHEMBL621911,BAO_0000218,,
8453,,In vivo,,A,,,,Volume of distribution at steady state was observed after intravenous administration in rat,N,,1,,CHEMBL621912,BAO_0000218,,
8454,,In vivo,,A,,,,Volume of distribution in steady state was determined in rat,N,,1,,CHEMBL621913,BAO_0000218,,
8455,,In vivo,,A,,,,Volume of distribution in steady state was determined in rat,N,,1,,CHEMBL621914,BAO_0000218,,
8456,,In vivo,,A,,,,Volume of distribution after i.v. administration,N,,1,,CHEMBL621915,BAO_0000218,,
8457,,In vivo,,A,,,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,N,,1,,CHEMBL621916,BAO_0000218,,
8458,,In vivo,Liver,A,,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,,1,,CHEMBL621917,BAO_0000218,2107.0,
8459,,In vivo,Liver,A,,,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL621918,BAO_0000218,2107.0,
8460,,In vivo,Spleen,A,,,,Biodistribution of compound (oxidized form) in spleen tissue,N,,1,,CHEMBL621919,BAO_0000218,2106.0,
8461,,In vivo,Spleen,A,,,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL621920,BAO_0000218,2106.0,
8462,,In vivo,Spleen,A,,,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",N,,1,,CHEMBL621921,BAO_0000218,2106.0,
8463,,In vivo,Spleen,A,,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,1,,CHEMBL622401,BAO_0000218,2106.0,
8464,,In vivo,Spleen,A,,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,1,,CHEMBL875348,BAO_0000218,2106.0,
8465,,In vivo,Spleen,A,,,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,,1,,CHEMBL622402,BAO_0000218,2106.0,
8466,,In vivo,Blood,A,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,N,,1,,CHEMBL622403,BAO_0000218,178.0,
8467,,In vivo,Blood,A,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,1,,CHEMBL622404,BAO_0000218,178.0,
8468,,In vivo,Brain,A,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,N,,1,,CHEMBL622405,BAO_0000218,955.0,
8469,,In vivo,Brain,A,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",N,,1,,CHEMBL622406,BAO_0000218,955.0,
8470,,In vivo,Brain,A,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,1,,CHEMBL622407,BAO_0000218,955.0,
8471,,In vivo,Heart,A,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,N,,1,,CHEMBL622408,BAO_0000218,948.0,
8472,,In vivo,Heart,A,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",N,,1,,CHEMBL622409,BAO_0000218,948.0,
8473,,In vivo,Heart,A,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,1,,CHEMBL622410,BAO_0000218,948.0,
8474,,In vivo,Kidney,A,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,N,,1,,CHEMBL622411,BAO_0000218,2113.0,
8475,,In vivo,Kidney,A,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",N,,1,,CHEMBL627864,BAO_0000218,2113.0,
8476,,In vivo,Kidney,A,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,1,,CHEMBL627865,BAO_0000218,2113.0,
8477,,In vivo,Liver,A,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,N,,1,,CHEMBL627866,BAO_0000218,2107.0,
8478,,In vivo,Liver,A,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,1,,CHEMBL627751,BAO_0000218,2107.0,
8479,,In vivo,Spleen,A,,,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,N,,1,,CHEMBL627752,BAO_0000218,2106.0,
8480,,In vivo,Spleen,A,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",N,,1,,CHEMBL627753,BAO_0000218,2106.0,
8481,,In vivo,Spleen,A,,,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,1,,CHEMBL627754,BAO_0000218,2106.0,
8482,,,,A,,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,N,,1,,CHEMBL627755,BAO_0000218,,
8483,,In vivo,Brain,A,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL627756,BAO_0000218,955.0,
8484,,In vivo,Brain,A,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL627757,BAO_0000218,955.0,
8485,,In vivo,Brain,A,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL627758,BAO_0000218,955.0,
8486,,In vivo,Brain,A,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL627759,BAO_0000218,955.0,
8487,,In vivo,Brain,A,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL627760,BAO_0000218,955.0,
8488,,In vivo,Brain,A,,,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL627761,BAO_0000218,955.0,
8489,,In vivo,Heart,A,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL876811,BAO_0000218,948.0,
8490,,In vivo,Heart,A,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL627762,BAO_0000218,948.0,
8491,,In vivo,Heart,A,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL627763,BAO_0000218,948.0,
8492,,In vivo,Heart,A,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL627764,BAO_0000218,948.0,
8493,,In vivo,Heart,A,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL627765,BAO_0000218,948.0,
8494,,In vivo,Heart,A,,,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL627766,BAO_0000218,948.0,
8495,,In vivo,Kidney,A,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL627767,BAO_0000218,2113.0,
8496,,In vivo,Kidney,A,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL627768,BAO_0000218,2113.0,
8497,,In vivo,Kidney,A,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL628422,BAO_0000218,2113.0,
8498,,In vivo,Kidney,A,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL628423,BAO_0000218,2113.0,
8499,,In vivo,,A,,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,N,,1,,CHEMBL628424,BAO_0000218,,
8500,,In vivo,,A,,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,N,,1,,CHEMBL628425,BAO_0000218,,
8501,,In vivo,,A,,,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,N,,1,,CHEMBL628426,BAO_0000218,,
8502,,In vivo,,A,,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,1,,CHEMBL628427,BAO_0000218,,
8503,,In vivo,,A,,,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,N,,1,,CHEMBL626938,BAO_0000218,,
8504,,In vivo,,A,,,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,N,,1,,CHEMBL626939,BAO_0000218,,
8505,,In vivo,,A,,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,N,,1,,CHEMBL626940,BAO_0000218,,
8506,,In vivo,,A,,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,N,,1,,CHEMBL626941,BAO_0000218,,
8507,,In vivo,,A,,,,Plasma clearance was reported in Sprague-Dawley rat,N,,1,,CHEMBL626942,BAO_0000218,,
8508,,In vivo,,A,,,,Plasma clearance after intravenous administration (1 mg/kg) in rat,N,,1,,CHEMBL876812,BAO_0000218,,
8509,,In vivo,,A,,,,Plasma clearance of compound in rats was evaluated,N,,1,,CHEMBL626943,BAO_0000218,,
8510,,In vivo,,A,,,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,N,,1,,CHEMBL626944,BAO_0000218,,
8511,,In vivo,,A,,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,N,,1,,CHEMBL626945,BAO_0000218,,
8512,,In vivo,,A,,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,N,,1,,CHEMBL626946,BAO_0000218,,
8513,,In vivo,,A,,,,Plasma clearance rate in Sprague-Dawley rats,N,,1,,CHEMBL626856,BAO_0000218,,
8514,,In vivo,,A,,,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),N,,1,,CHEMBL626857,BAO_0000218,,
8515,,In vivo,Plasma,A,,,,The compound was evaluated for plasma clearance in rat,N,,1,,CHEMBL626858,BAO_0000218,1969.0,
8516,,In vivo,Plasma,A,,,,Total plasma clearance in rat,N,,1,,CHEMBL627018,BAO_0000218,1969.0,
8517,,In vivo,Blood,A,,,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,N,,1,,CHEMBL625331,BAO_0000218,178.0,
8518,,In vivo,Blood,A,,,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,N,,1,,CHEMBL625332,BAO_0000218,178.0,
8519,,In vivo,,A,,,,C max was determined at 10 mg/kg po dose in rats,N,,1,,CHEMBL877590,BAO_0000218,,
8520,,In vivo,,A,,,,C max was determined at 3 mg/kg po dose in rats,N,,1,,CHEMBL625333,BAO_0000218,,
8521,,In vivo,,A,,,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,N,,1,,CHEMBL625334,BAO_0000218,,
8522,,In vivo,,A,,,,Cmax after single intravenous bolus of 1 mg/kg in rats,N,,1,,CHEMBL625335,BAO_0000218,,
8523,,In vivo,,A,,,,Cmax of compound at 5 mg/kg after po administration was determined in rat,N,,1,,CHEMBL625336,BAO_0000218,,
8524,,In vivo,,A,,,,Cmax 24 hr after 10 mg/kg oral administration in rats,N,,1,,CHEMBL625337,BAO_0000218,,
8525,,In vivo,,A,,,,Cmax 24 hr after 2 mg/kg oral administration in rats,N,,1,,CHEMBL625338,BAO_0000218,,
8526,,In vivo,Plasma,A,,,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,N,,1,,CHEMBL625339,BAO_0000218,1969.0,
8527,,In vivo,,A,,,,Cmax in rat after administration of 2 mg/kg iv,N,,1,,CHEMBL625340,BAO_0000218,,
8528,,In vivo,,A,,,,Cmax in rat after administration of 2 mg/kg iv,N,,1,,CHEMBL625341,BAO_0000218,,
8529,,In vivo,,A,,,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,N,,1,,CHEMBL622687,BAO_0000218,,
8530,,In vivo,Plasma,A,,,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,N,,1,,CHEMBL622688,BAO_0000218,1969.0,
8531,,In vivo,Blood,A,,,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,N,,1,,CHEMBL622689,BAO_0000218,178.0,
8532,,In vivo,Blood,A,,,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,N,,1,,CHEMBL620295,BAO_0000218,178.0,
8533,,In vivo,,A,,,,Cmax after 10 mg/kg oral administration in rat,N,,1,,CHEMBL620296,BAO_0000218,,
8534,,In vivo,,A,,,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,N,,1,,CHEMBL620297,BAO_0000218,,
8535,,In vivo,,A,,,,Cmax after IV dosing at 1 mg/kg in rat; no data,N,,1,,CHEMBL620298,BAO_0000218,,
8536,,In vivo,,A,,,,Cmax after oral administration at 20 mpk in rats,N,,1,,CHEMBL620299,BAO_0000218,,
8537,,In vivo,,A,,,,Cmax after oral administration at 20 mpk in rats; Not performed.,N,,1,,CHEMBL620300,BAO_0000218,,
8538,,In vivo,,A,,,,Cmax after oral administration at 20 mpk in rats d; Not performed.,N,,1,,CHEMBL620301,BAO_0000218,,
8539,,In vivo,,A,,,,Cmax after oral administration in rat,N,,1,,CHEMBL620302,BAO_0000218,,
8540,,In vivo,,A,,,,Cmax after oral administration at a dose of 2 mg/kg in rat,N,,1,,CHEMBL620303,BAO_0000218,,
8541,,In vivo,,A,,,,Cmax after oral administration at a dose of 4 mg/kg in rat,N,,1,,CHEMBL620304,BAO_0000218,,
8542,,In vivo,,A,,,,Cmax in rats after 20 mg/kg oral dose,N,,1,,CHEMBL620305,BAO_0000218,,
8543,,In vivo,,A,,,,Cmax after peroral administration in rats at 2.4 uM/kg,N,,1,,CHEMBL620306,BAO_0000218,,
8544,,In vivo,,A,,,,Cmax at the dose of 2 mg/Kg administered perorally in rats,N,,1,,CHEMBL620307,BAO_0000218,,
8545,,In vivo,,A,,,,Cmax at the dose of 5 mg/Kg administered perorally in rats,N,,1,,CHEMBL620308,BAO_0000218,,
8546,,In vivo,,A,,,,Cmax by administering at 20 mg/kg p.o. in rats,N,,1,,CHEMBL620309,BAO_0000218,,
8547,,In vivo,,A,,,,Cmax in male rat,N,,1,,CHEMBL620310,BAO_0000218,,
8548,,In vivo,,A,,,,Cmax in rat,N,,1,,CHEMBL620311,BAO_0000218,,
8549,,In vivo,,A,,,,Cmax in rat,N,,1,,CHEMBL620312,BAO_0000218,,
8550,,In vivo,,A,,,,Cmax in rat,N,,1,,CHEMBL620313,BAO_0000218,,
8551,,In vivo,,A,,,,Cmax in rat at 10 mg/kg,N,,1,,CHEMBL620314,BAO_0000218,,
8552,,In vivo,,A,,,,Cmax in rat at the dose of 1 mg/kg i.v.,N,,1,,CHEMBL620315,BAO_0000218,,
8553,,In vivo,,A,,,,Cmax in rat by po administration at a dose of 40 mg/kg,N,,1,,CHEMBL620316,BAO_0000218,,
8554,,In vivo,,A,,,,Cmax in rat p.o. at 20 mg/kg concentration,N,,1,,CHEMBL620317,BAO_0000218,,
8555,,In vivo,,A,,,,Cmax in rats,N,,1,,CHEMBL620318,BAO_0000218,,
8556,,In vivo,,A,,,,Cmax in rats,N,,1,,CHEMBL620319,BAO_0000218,,
8557,,In vivo,,A,,,,Cmax was evaluated after 20 uM/kg of peroral administration,N,,1,,CHEMBL620320,BAO_0000218,,
8558,,In vivo,,A,,,,Cmax was measured in rats after peroral administration at 3 mg/kg,N,,1,,CHEMBL620321,BAO_0000218,,
8559,,In vivo,,A,,,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,N,,1,,CHEMBL620322,BAO_0000218,,
8560,,,,A,,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620323,BAO_0000218,,
8561,,,Frontal cortex,A,,,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620324,BAO_0000218,1870.0,
8562,,,Frontal cortex,A,,,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620325,BAO_0000218,1870.0,
8563,,,Hippocampus,A,,,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620326,BAO_0000218,10000000.0,
8564,,,Hippocampus,A,,,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620327,BAO_0000218,10000000.0,
8565,,,,A,,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620328,BAO_0000218,,
8566,,,,A,,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620329,BAO_0000218,,
8567,,,Midbrain,A,,,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620330,BAO_0000218,1891.0,
8568,,,Midbrain,A,,,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL875286,BAO_0000218,1891.0,
8569,,,,A,,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620331,BAO_0000218,,
8570,,,,A,,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620332,BAO_0000218,,
8571,,,Striatum,A,,,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620333,BAO_0000218,2435.0,
8572,,,Striatum,A,,,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,1,,CHEMBL620334,BAO_0000218,2435.0,
8573,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,1,,CHEMBL621015,BAO_0000218,178.0,
8574,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,1,,CHEMBL621016,BAO_0000218,178.0,
8575,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,1,,CHEMBL621191,BAO_0000218,178.0,
8576,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,1,,CHEMBL621192,BAO_0000218,178.0,
8577,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,1,,CHEMBL621193,BAO_0000218,178.0,
8578,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,1,,CHEMBL621194,BAO_0000218,178.0,
8579,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,1,,CHEMBL624204,BAO_0000218,178.0,
8580,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,1,,CHEMBL624205,BAO_0000218,178.0,
8581,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,1,,CHEMBL624206,BAO_0000218,178.0,
8582,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,1,,CHEMBL624207,BAO_0000218,178.0,
8583,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,1,,CHEMBL624208,BAO_0000218,178.0,
8584,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,1,,CHEMBL624209,BAO_0000218,178.0,
8585,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,1,,CHEMBL624210,BAO_0000218,178.0,
8586,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,1,,CHEMBL624211,BAO_0000218,178.0,
8587,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,1,,CHEMBL624212,BAO_0000218,178.0,
8588,,,Blood,A,,,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,1,,CHEMBL624213,BAO_0000218,178.0,
8589,,,Blood,A,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,1,,CHEMBL876611,BAO_0000218,178.0,
8590,,,Blood,A,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,1,,CHEMBL624214,BAO_0000218,178.0,
8591,,,Blood,A,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,1,,CHEMBL624215,BAO_0000218,178.0,
8592,,,Blood,A,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,1,,CHEMBL624216,BAO_0000218,178.0,
8593,,,Blood,A,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,1,,CHEMBL624217,BAO_0000218,178.0,
8594,,,Blood,A,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,1,,CHEMBL624218,BAO_0000218,178.0,
8595,,,Blood,A,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,1,,CHEMBL624219,BAO_0000218,178.0,
8596,,,Blood,A,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,1,,CHEMBL624220,BAO_0000218,178.0,
8597,,,Blood,A,,,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,1,,CHEMBL624221,BAO_0000218,178.0,
8598,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,1,,CHEMBL624222,BAO_0000218,,
8599,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,1,,CHEMBL624223,BAO_0000218,,
8600,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,1,,CHEMBL624224,BAO_0000218,,
8601,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,1,,CHEMBL624225,BAO_0000218,,
8602,,In vivo,,A,,,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,N,,1,,CHEMBL622420,BAO_0000218,,
8603,,In vivo,,A,,,,Volume of steady state distribution after i.v. administration in rats,N,,1,,CHEMBL622421,BAO_0000218,,
8604,,In vivo,,A,,,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,N,,1,,CHEMBL622422,BAO_0000218,,
8605,,In vivo,,A,,,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,N,,1,,CHEMBL622423,BAO_0000218,,
8606,,In vivo,,A,,,,Vss was determined,N,,1,,CHEMBL622424,BAO_0000218,,
8607,,In vivo,,A,,,,Vss in rat,N,,1,,CHEMBL622425,BAO_0000218,,
8608,,In vivo,,A,,,,Vss was evaluated after 10 uM/kg of intra arterial administration,N,,1,,CHEMBL876612,BAO_0000218,,
8609,,In vivo,,A,,,,volume of distribution at steady state was observed after intravenous administration in rat,N,,1,,CHEMBL622426,BAO_0000218,,
8610,,In vivo,,A,,,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,N,,1,,CHEMBL622427,BAO_0000218,,
8611,,In vivo,,A,,,,Pharmacokinetic (PK) parameter Vz in rat,N,,1,,CHEMBL622428,BAO_0000218,,
8612,,In vivo,,A,,,,Volume distribution in rats,N,,1,,CHEMBL622429,BAO_0000218,,
8613,,In vivo,,A,,,,Volume of distribution in rat; No data,N,,1,,CHEMBL622430,BAO_0000218,,
8614,,In vivo,,A,,,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,N,,1,,CHEMBL622431,BAO_0000218,,
8615,,,Ileum,A,,,,% absorption predicted from in vitro rat ileum transport studies,N,,1,,CHEMBL622432,BAO_0000218,2116.0,
8616,,In vivo,,A,,,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,N,,1,,CHEMBL622433,BAO_0000218,,
8617,,In vivo,,A,,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,N,,1,,CHEMBL622434,BAO_0000218,,
8618,,In vivo,,A,,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,N,,1,,CHEMBL622435,BAO_0000218,,
8619,,In vivo,,A,,,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),N,,1,,CHEMBL618748,BAO_0000218,,
8620,,In vivo,,A,,,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,N,,1,,CHEMBL618749,BAO_0000218,,
8621,,In vivo,,A,,,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,N,,1,,CHEMBL618750,BAO_0000218,,
8622,,In vivo,,A,,,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,N,,1,,CHEMBL618751,BAO_0000218,,
8623,,In vivo,,A,,,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,N,,1,,CHEMBL618752,BAO_0000218,,
8624,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL618753,BAO_0000218,,
8625,,In vivo,Plasma,A,,,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,N,,1,,CHEMBL618754,BAO_0000218,1969.0,
8626,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL618755,BAO_0000218,,
8627,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL618756,BAO_0000218,,
8628,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL618757,BAO_0000218,,
8629,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL618758,BAO_0000218,,
8630,,In vivo,,A,,,,Oral bioavailability in rat (dose 30 mg/kg),N,,1,,CHEMBL621088,BAO_0000218,,
8631,,,,A,,,,Pharmacokinetic property (cLogP) in rat,N,,1,,CHEMBL621089,BAO_0000218,,
8632,,,Blood,F,,,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,N,,1,,CHEMBL621090,BAO_0000218,178.0,
8633,,,Blood,F,,,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,N,,1,,CHEMBL621091,BAO_0000218,178.0,
8634,,In vivo,,A,,,,Clearance in rat.,N,,1,,CHEMBL876731,BAO_0000218,,
8635,,In vivo,,A,,,,Compound was evaluated for its clearance when administered intravenously in rat,N,,1,,CHEMBL621092,BAO_0000218,,
8636,,In vivo,,A,,,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,N,,1,,CHEMBL621093,BAO_0000218,,
8637,,,,A,,,,Blood: Brain distribution ratio is determined in rat,N,,1,,CHEMBL621094,BAO_0000218,,
8638,,,,A,,,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,N,,1,,CHEMBL621095,BAO_0000218,,
8639,,,,A,,,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,N,,1,,CHEMBL621096,BAO_0000218,,
8640,,In vivo,Kidney,A,,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL621097,BAO_0000218,2113.0,
8641,,,,F,,,,Percent dose excreted in 0-48 hours administered ip to male rat,N,,1,,CHEMBL621098,BAO_0000218,,
8642,,,Cerebellum,A,,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL621099,BAO_0000218,2037.0,
8643,,,Cerebellum,A,,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL621100,BAO_0000218,2037.0,
8644,,,Cerebellum,A,,,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,1,,CHEMBL621101,BAO_0000218,2037.0,
8645,,,Cerebellum,A,,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL621102,BAO_0000218,2037.0,
8646,,,Cerebellum,A,,,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL876732,BAO_0000218,2037.0,
8647,,,,A,,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL621103,BAO_0000218,,
8648,,,,A,,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL621104,BAO_0000218,,
8649,,,,A,,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,1,,CHEMBL621105,BAO_0000218,,
8650,,,,A,,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL621106,BAO_0000218,,
8651,,,,A,,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL621107,BAO_0000218,,
8652,,,,A,,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL621108,BAO_0000218,,
8653,,,,A,,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL621109,BAO_0000218,,
8654,,In vivo,Kidney,A,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL621110,BAO_0000218,2113.0,
8655,,In vivo,Kidney,A,,,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL621111,BAO_0000218,2113.0,
8656,,In vivo,Liver,A,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL622541,BAO_0000218,2107.0,
8657,,In vivo,Liver,A,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL622542,BAO_0000218,2107.0,
8658,,In vivo,Liver,A,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL622543,BAO_0000218,2107.0,
8659,,In vivo,Liver,A,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL624412,BAO_0000218,2107.0,
8660,,In vivo,Liver,A,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL624413,BAO_0000218,2107.0,
8661,,In vivo,Liver,A,,,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL624414,BAO_0000218,2107.0,
8662,,In vivo,Lung,A,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL624415,BAO_0000218,2048.0,
8663,,In vivo,Lung,A,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL624416,BAO_0000218,2048.0,
8664,,In vivo,Lung,A,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL624417,BAO_0000218,2048.0,
8665,,In vivo,Lung,A,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL624418,BAO_0000218,2048.0,
8666,,In vivo,Lung,A,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL624419,BAO_0000218,2048.0,
8667,,In vivo,Lung,A,,,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL624420,BAO_0000218,2048.0,
8668,,In vivo,Muscle tissue,A,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL624421,BAO_0000218,2385.0,
8669,,In vivo,Muscle tissue,A,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL624422,BAO_0000218,2385.0,
8670,,In vivo,Muscle tissue,A,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL624423,BAO_0000218,2385.0,
8671,,In vivo,Muscle tissue,A,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL625123,BAO_0000218,2385.0,
8672,,In vivo,Muscle tissue,A,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL625124,BAO_0000218,2385.0,
8673,,In vivo,Muscle tissue,A,,,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL625125,BAO_0000218,2385.0,
8674,,In vivo,Zone of skin,A,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL625126,BAO_0000218,14.0,
8675,,In vivo,Zone of skin,A,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL626947,BAO_0000218,14.0,
8676,,In vivo,Zone of skin,A,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL626948,BAO_0000218,14.0,
8677,,In vivo,Zone of skin,A,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL626949,BAO_0000218,14.0,
8678,,In vivo,Zone of skin,A,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL626950,BAO_0000218,14.0,
8679,,In vivo,Zone of skin,A,,,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL626951,BAO_0000218,14.0,
8680,,In vivo,Spleen,A,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL626952,BAO_0000218,2106.0,
8681,,In vivo,Spleen,A,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL626953,BAO_0000218,2106.0,
8682,,In vivo,Spleen,A,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL626954,BAO_0000218,2106.0,
8683,,In vivo,Spleen,A,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL626955,BAO_0000218,2106.0,
8684,,In vivo,Spleen,A,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL626956,BAO_0000218,2106.0,
8685,,In vivo,Spleen,A,,,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL626957,BAO_0000218,2106.0,
8686,,In vivo,Blood,A,,,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL626958,BAO_0000218,178.0,
8687,,In vivo,Blood,A,,,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL626959,BAO_0000218,178.0,
8688,,In vivo,Blood,A,,,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL626960,BAO_0000218,178.0,
8689,,In vivo,Blood,A,,,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL626961,BAO_0000218,178.0,
8690,,In vivo,Blood,A,,,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL627589,BAO_0000218,178.0,
8691,,In vivo,Blood,A,,,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),N,,1,,CHEMBL627590,BAO_0000218,178.0,
8692,,,,A,,,,Time taken for EC90 was determined when tested in mouse,N,,1,,CHEMBL627591,BAO_0000218,,
8693,,,,A,,,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,N,,1,,CHEMBL627592,BAO_0000218,,
8694,,In vivo,,A,,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),N,,1,,CHEMBL627593,BAO_0000218,,
8695,,,,A,,,,Half life in mice,N,,1,,CHEMBL627594,BAO_0000218,,
8696,,In vivo,,A,,,,Half life period in mouse after 10 mg/Kg dose,N,,1,,CHEMBL876813,BAO_0000218,,
8697,,In vivo,,A,,,,Half life period in mouse after 10 mg/kg dose,N,,1,,CHEMBL627595,BAO_0000218,,
8698,,In vivo,,A,,,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,,1,,CHEMBL627596,BAO_0000218,,
8699,,In vivo,,A,,,,Cmax value at 5 mg/kg po was determined in rat,N,,1,,CHEMBL627597,BAO_0000218,,
8700,,In vivo,,A,,,,Cmax value evaluated in rat,N,,1,,CHEMBL627598,BAO_0000218,,
8701,,In vivo,Brain,A,,,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,N,,1,,CHEMBL627599,BAO_0000218,955.0,
8702,,In vivo,,A,,,,Cmax value after administration of 20 mg/Kg oral dose in rat,N,,1,,CHEMBL627600,BAO_0000218,,
8703,,In vivo,,A,,,,Cmax value at 1 mg/kg po in rat,N,,1,,CHEMBL627601,BAO_0000218,,
8704,,In vivo,,A,,,,Cmax value at 5 mg/kg po in rat,N,,1,,CHEMBL627776,BAO_0000218,,
8705,,In vivo,,A,,,,Cmax value at a dose of 10 mg/kg in male SD rats,N,,1,,CHEMBL627777,BAO_0000218,,
8706,,In vivo,,A,,,,Cmax value at a dose of 100 mg/kg in male SD rats,N,,1,,CHEMBL627778,BAO_0000218,,
8707,,In vivo,,A,,,,Cmax value at a dose of 50 mg/kg in male SD rats,N,,1,,CHEMBL627779,BAO_0000218,,
8708,,In vivo,,A,,,,Cmax value in rats at 10 mg/kg,N,,1,,CHEMBL876814,BAO_0000218,,
8709,,In vivo,,A,,,,Cmax value was evaluated in rats at a dose of 20 mg/kg,N,,1,,CHEMBL627780,BAO_0000218,,
8710,,In vivo,,A,,,,Cmax value was determined after peroral administration of 20 mg/kg in rat,N,,1,,CHEMBL627781,BAO_0000218,,
8711,,In vivo,,A,,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,N,,1,,CHEMBL627782,BAO_0000218,,
8712,,In vivo,Plasma,A,,,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,N,,1,,CHEMBL627783,BAO_0000218,1969.0,
8713,,In vivo,Plasma,A,,,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,N,,1,,CHEMBL627784,BAO_0000218,1969.0,
8714,,In vivo,,A,,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,N,,1,,CHEMBL627785,BAO_0000218,,
8715,,In vivo,,A,,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,N,,1,,CHEMBL627786,BAO_0000218,,
8716,,In vivo,Plasma,A,,,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,N,,1,,CHEMBL627787,BAO_0000218,1969.0,
8717,,In vivo,Plasma,A,,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,N,,1,,CHEMBL627788,BAO_0000218,1969.0,
8718,,In vivo,Plasma,A,,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,N,,1,,CHEMBL626579,BAO_0000218,1969.0,
8719,,In vivo,Plasma,A,,,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,N,,1,,CHEMBL626580,BAO_0000218,1969.0,
8720,,In vivo,,A,,,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,N,,1,,CHEMBL876815,BAO_0000218,,
8721,,In vivo,Plasma,A,,,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,N,,1,,CHEMBL626581,BAO_0000218,1969.0,
8722,,In vivo,Plasma,A,,,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,N,,1,,CHEMBL626582,BAO_0000218,1969.0,
8723,,In vivo,,A,,,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,N,,1,,CHEMBL626583,BAO_0000218,,
8724,,In vivo,,A,,,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL626205,BAO_0000218,,
8725,,In vivo,,A,,,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL626206,BAO_0000218,,
8726,,In vivo,,A,,,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL626207,BAO_0000218,,
8727,,In vivo,,A,,,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL623882,BAO_0000218,,
8728,,In vivo,,A,,,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,N,,1,,CHEMBL623883,BAO_0000218,,
8729,,In vivo,,A,,,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,N,,1,,CHEMBL623884,BAO_0000218,,
8730,,In vivo,Plasma,A,,,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",N,,1,,CHEMBL623885,BAO_0000218,1969.0,
8731,,In vivo,Plasma,A,,,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,N,,1,,CHEMBL623886,BAO_0000218,1969.0,
8732,,In vivo,,A,,,,Maximal concentration in rat was determined,N,,1,,CHEMBL623887,BAO_0000218,,
8733,,In vivo,,A,,,,Maximal concentration after i.v. administration,N,,1,,CHEMBL623888,BAO_0000218,,
8734,,In vivo,Plasma,A,,,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,N,,1,,CHEMBL623889,BAO_0000218,1969.0,
8735,,In vivo,Plasma,A,,,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,N,,1,,CHEMBL623890,BAO_0000218,1969.0,
8736,,In vivo,Plasma,A,,,,Cmax in rat plasma after oral dose (50 mg/Kg),N,,1,,CHEMBL623891,BAO_0000218,1969.0,
8737,,In vivo,Plasma,A,,,,Maximal plasma concentration was determined.,N,,1,,CHEMBL623892,BAO_0000218,1969.0,
8738,,In vivo,Plasma,A,,,,Maximal plasma drug concentration was determined,N,,1,,CHEMBL623893,BAO_0000218,1969.0,
8739,,In vivo,,A,,,,Maximal concentration in rats after peroral administration,N,,1,,CHEMBL877616,BAO_0000218,,
8740,,In vivo,,A,,,,Maximum concentration in rat after 2 mg/kg peroral administration,N,,1,,CHEMBL623894,BAO_0000218,,
8741,,In vivo,Plasma,A,,,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,N,,1,,CHEMBL623895,BAO_0000218,1969.0,
8742,,In vivo,,A,,,,Maximum concentration of compound in rat was evaluated.,N,,1,,CHEMBL623896,BAO_0000218,,
8743,,In vivo,,A,,,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,N,,1,,CHEMBL623897,BAO_0000218,,
8744,,In vivo,,A,,,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,N,,1,,CHEMBL623898,BAO_0000218,,
8745,,In vivo,,A,,,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,N,,1,,CHEMBL623899,BAO_0000218,,
8746,,In vivo,,A,,,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,N,,1,,CHEMBL623900,BAO_0000218,,
8747,,In vivo,,A,,,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,N,,1,,CHEMBL623901,BAO_0000218,,
8748,,In vivo,,A,,,,Maximum concentration was evaluated in rats,N,,1,,CHEMBL623902,BAO_0000218,,
8749,,In vivo,Cerebrospinal fluid,A,,,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,N,,1,,CHEMBL623903,BAO_0000218,1359.0,
8750,,In vivo,Plasma,A,,,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,N,,1,,CHEMBL623904,BAO_0000218,1969.0,
8751,,In vivo,Plasma,A,,,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,N,,1,,CHEMBL877617,BAO_0000218,1969.0,
8752,,In vivo,,A,,,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,N,,1,,CHEMBL623905,BAO_0000218,,
8753,,In vivo,,A,,,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,N,,1,,CHEMBL623906,BAO_0000218,,
8754,,In vivo,Plasma,A,,,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,,1,,CHEMBL623907,BAO_0000218,1969.0,
8755,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,1,,CHEMBL623908,BAO_0000218,,
8756,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,N,,1,,CHEMBL623909,BAO_0000218,,
8757,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,1,,CHEMBL623910,BAO_0000218,,
8758,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,1,,CHEMBL623911,BAO_0000218,,
8759,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,1,,CHEMBL623912,BAO_0000218,,
8760,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,1,,CHEMBL624616,BAO_0000218,,
8761,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,1,,CHEMBL624617,BAO_0000218,,
8762,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,1,,CHEMBL624618,BAO_0000218,,
8763,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,1,,CHEMBL624619,BAO_0000218,,
8764,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,1,,CHEMBL624794,BAO_0000218,,
8765,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,1,,CHEMBL624795,BAO_0000218,,
8766,,,,A,,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,1,,CHEMBL623921,BAO_0000218,,
8767,,,,A,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,1,,CHEMBL623922,BAO_0000218,,
8768,,,,A,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,1,,CHEMBL623923,BAO_0000218,,
8769,,,,A,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,1,,CHEMBL623924,BAO_0000218,,
8770,,,,A,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,1,,CHEMBL623925,BAO_0000218,,
8771,,,,A,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,1,,CHEMBL623926,BAO_0000218,,
8772,,,,A,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,1,,CHEMBL623927,BAO_0000218,,
8773,,,,A,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,1,,CHEMBL623928,BAO_0000218,,
8774,,,,A,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,1,,CHEMBL623929,BAO_0000218,,
8775,,,,A,,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,1,,CHEMBL623930,BAO_0000218,,
8776,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,1,,CHEMBL623931,BAO_0000218,955.0,
8777,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,1,,CHEMBL622165,BAO_0000218,955.0,
8778,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,1,,CHEMBL621249,BAO_0000218,955.0,
8779,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,1,,CHEMBL621250,BAO_0000218,955.0,
8780,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,1,,CHEMBL621448,BAO_0000218,955.0,
8781,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,1,,CHEMBL621449,BAO_0000218,955.0,
8782,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,1,,CHEMBL621450,BAO_0000218,955.0,
8783,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,1,,CHEMBL621451,BAO_0000218,955.0,
8784,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,1,,CHEMBL621452,BAO_0000218,955.0,
8785,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,1,,CHEMBL621453,BAO_0000218,955.0,
8786,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,1,,CHEMBL621454,BAO_0000218,955.0,
8787,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,1,,CHEMBL621455,BAO_0000218,955.0,
8788,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,1,,CHEMBL621456,BAO_0000218,955.0,
8789,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,1,,CHEMBL625145,BAO_0000218,955.0,
8790,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,1,,CHEMBL875847,BAO_0000218,955.0,
8791,,,Brain,A,,,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,1,,CHEMBL625146,BAO_0000218,955.0,
8792,,,Brain,A,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,1,,CHEMBL625147,BAO_0000218,955.0,
8793,,,Brain,A,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,1,,CHEMBL625148,BAO_0000218,955.0,
8794,,,Brain,A,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,1,,CHEMBL625149,BAO_0000218,955.0,
8795,,,Brain,A,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,1,,CHEMBL625150,BAO_0000218,955.0,
8796,,,Brain,A,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,1,,CHEMBL625151,BAO_0000218,955.0,
8797,,,Brain,A,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,1,,CHEMBL625152,BAO_0000218,955.0,
8798,,,Brain,A,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,1,,CHEMBL625153,BAO_0000218,955.0,
8799,,,Brain,A,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,1,,CHEMBL625154,BAO_0000218,955.0,
8800,,,Brain,A,,,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,1,,CHEMBL625155,BAO_0000218,955.0,
8801,,,,A,,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,1,,CHEMBL625156,BAO_0000218,,
8802,,,,A,,,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL624354,BAO_0000218,,
8803,,,Hippocampus,A,,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL624355,BAO_0000218,10000000.0,
8804,,,Hippocampus,A,,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL624356,BAO_0000218,10000000.0,
8805,,,Hippocampus,A,,,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL624357,BAO_0000218,10000000.0,
8806,,,Hippocampus,A,,,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL624358,BAO_0000218,10000000.0,
8807,,,Striatum,A,,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL624359,BAO_0000218,2435.0,
8808,,,Striatum,A,,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL624360,BAO_0000218,2435.0,
8809,,,Striatum,A,,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,1,,CHEMBL624361,BAO_0000218,2435.0,
8810,,,Striatum,A,,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL624362,BAO_0000218,2435.0,
8811,,,Striatum,A,,,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL624363,BAO_0000218,2435.0,
8812,,In vivo,Blood,A,,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL624364,BAO_0000218,178.0,
8813,,In vivo,Blood,A,,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL624365,BAO_0000218,178.0,
8814,,In vivo,Blood,A,,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL624366,BAO_0000218,178.0,
8815,,In vivo,Blood,A,,,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL624367,BAO_0000218,178.0,
8816,,In vivo,Brain,A,,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL624368,BAO_0000218,955.0,
8817,,In vivo,Brain,A,,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL624369,BAO_0000218,955.0,
8818,,In vivo,Brain,A,,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,1,,CHEMBL624370,BAO_0000218,955.0,
8819,,In vivo,Brain,A,,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL625069,BAO_0000218,955.0,
8820,,In vivo,Brain,A,,,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL625070,BAO_0000218,955.0,
8821,,In vivo,Heart,A,,,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL626051,BAO_0000218,948.0,
8822,,In vivo,Heart,A,,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL626052,BAO_0000218,948.0,
8823,,In vivo,Heart,A,,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,1,,CHEMBL626053,BAO_0000218,948.0,
8824,,In vivo,Heart,A,,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL626054,BAO_0000218,948.0,
8825,,In vivo,Heart,A,,,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL626055,BAO_0000218,948.0,
8826,,In vivo,Kidney,A,,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL626056,BAO_0000218,2113.0,
8827,,In vivo,Kidney,A,,,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL626057,BAO_0000218,2113.0,
8828,,In vivo,Kidney,A,,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL625193,BAO_0000218,2113.0,
8829,,In vivo,Kidney,A,,,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL625194,BAO_0000218,2113.0,
8830,,In vivo,Liver,A,,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL625195,BAO_0000218,2107.0,
8831,,In vivo,Liver,A,,,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL625196,BAO_0000218,2107.0,
8832,,In vivo,Liver,A,,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,1,,CHEMBL625197,BAO_0000218,2107.0,
8833,,In vivo,Liver,A,,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL625198,BAO_0000218,2107.0,
8834,,In vivo,Liver,A,,,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL627929,BAO_0000218,2107.0,
8835,,In vivo,Lung,A,,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL627074,BAO_0000218,2048.0,
8836,,In vivo,Lung,A,,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL627075,BAO_0000218,2048.0,
8837,,In vivo,Lung,A,,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,1,,CHEMBL627076,BAO_0000218,2048.0,
8838,,In vivo,Lung,A,,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL627077,BAO_0000218,2048.0,
8839,,In vivo,Lung,A,,,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL627078,BAO_0000218,2048.0,
8840,,In vivo,Muscle tissue,A,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),N,,1,,CHEMBL627079,BAO_0000218,2385.0,
8841,,In vivo,,A,,,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,N,,1,,CHEMBL873824,BAO_0000218,,
8842,,In vivo,Plasma,A,,,,Half life in mouse plasma was determined at dose 25 mg/kg,N,,1,,CHEMBL627080,BAO_0000218,1969.0,
8843,,,,A,,,,Half life was determined,N,,1,,CHEMBL627081,BAO_0000218,,
8844,,In vivo,,A,,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,N,,1,,CHEMBL627082,BAO_0000218,,
8845,,In vivo,,A,,,,Half-life in male mice after 1 mg/kg intravenous dose,N,,1,,CHEMBL627083,BAO_0000218,,
8847,,,Plasma,A,,,,Half life in mice plasma,N,,1,,CHEMBL627085,BAO_0000218,1969.0,
8848,,,,A,,,,Half life in mouse,N,,1,,CHEMBL627086,BAO_0000218,,
8849,,In vivo,Plasma,A,,,,Half life in mouse plasma at dose 25 mg/kg,N,,1,,CHEMBL627087,BAO_0000218,1969.0,
8850,,In vivo,,A,,,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,N,,1,,CHEMBL627088,BAO_0000218,,
8851,,In vivo,,A,,,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,N,,1,,CHEMBL627089,BAO_0000218,,
8852,,In vivo,,A,,,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,N,,1,,CHEMBL627090,BAO_0000218,,
8853,,In vivo,,A,,,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),N,,1,,CHEMBL627091,BAO_0000218,,
8854,,In vivo,,A,,,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",N,,1,,CHEMBL627092,BAO_0000218,,
8855,,In vivo,,A,,,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",N,,1,,CHEMBL876785,BAO_0000218,,
8856,,In vivo,,A,,,,Half-life by iv administration in mouse,N,,1,,CHEMBL627093,BAO_0000218,,
8857,,In vivo,,A,,,,Half-life by oral administration in mouse,N,,1,,CHEMBL627094,BAO_0000218,,
8858,,,,A,,,,Half-life in mice,N,,1,,CHEMBL627095,BAO_0000218,,
8859,,,Brain,A,,,,Half-life using mouse brain homogenate,N,,1,,CHEMBL627096,BAO_0000218,955.0,
8860,,,,A,,,,Half-life was measured in mice,N,,1,,CHEMBL627097,BAO_0000218,,
8861,,In vivo,,A,,,,Half-life was measured in mouse after an iv dose of 1 mg/kg,N,,1,,CHEMBL627098,BAO_0000218,,
8862,,,Blood,A,,,,Half-life period was determined in mouse blood,N,,1,,CHEMBL627099,BAO_0000218,178.0,
8863,,,Brain,A,,,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",N,,1,,CHEMBL627100,BAO_0000218,955.0,
8864,,,Plasma,A,,,,Plasma half life in mouse,N,,1,,CHEMBL627101,BAO_0000218,1969.0,
8865,,,,A,,,,Stability of the peptide in the presence of mouse serum,N,,1,,CHEMBL627102,BAO_0000218,,
8866,,,,A,,,,Terminal half life of compound was determined in mouse,N,,1,,CHEMBL627103,BAO_0000218,,
8867,,In vivo,,A,,,,Terminal half life was evaluated in mice after intravenous administration,N,,1,,CHEMBL627104,BAO_0000218,,
8868,,In vivo,,A,,,,Terminal half life was evaluated in mice after oral administration,N,,1,,CHEMBL627105,BAO_0000218,,
8869,,,,A,,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,N,,1,,CHEMBL876786,BAO_0000218,,
8870,,,,A,,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,N,,1,,CHEMBL873825,BAO_0000218,,
8871,,,,A,,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,N,,1,,CHEMBL627106,BAO_0000218,,
8872,,In vivo,,A,,,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,N,,1,,CHEMBL626336,BAO_0000218,,
8873,,In vivo,,A,,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",N,,1,,CHEMBL877462,BAO_0000218,,
8874,,In vivo,,A,,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",N,,1,,CHEMBL626337,BAO_0000218,,
8875,,,,A,,,,Half life after intraperitoneal administration of 100 mg/kg in mice,N,,1,,CHEMBL626338,BAO_0000218,,
8876,,In vivo,,A,,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,N,,1,,CHEMBL626339,BAO_0000218,,
8877,,In vivo,,A,,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,N,,1,,CHEMBL626340,BAO_0000218,,
8878,,In vivo,,A,,,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,N,,1,,CHEMBL625377,BAO_0000218,,
8879,,In vivo,,A,,,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,N,,1,,CHEMBL625378,BAO_0000218,,
8880,,In vivo,,A,,,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,N,,1,,CHEMBL625379,BAO_0000218,,
8881,Microsomes,,,A,,,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),U,,1,,CHEMBL625380,BAO_0000251,,
8882,Microsomes,,,A,,,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),U,,1,,CHEMBL625381,BAO_0000251,,
8883,,,,A,,,,Stability to porcine renal DHP-I,U,,1,,CHEMBL625382,BAO_0000019,,
8884,,In vivo,,A,,,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,U,,1,,CHEMBL873828,BAO_0000218,,
8885,,In vivo,,A,,,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,U,,1,,CHEMBL625383,BAO_0000218,,
8886,,,,A,,,,Half-life of the parent prodrug in porcine esterase solution,U,,1,,CHEMBL625384,BAO_0000019,,
8887,,,,A,,,,"First order rate constant, k was determined in in pig liver Esterase",U,,1,,CHEMBL625385,BAO_0000019,,
8888,,,Liver,A,,,,Half life of the in pig liver Esterase,U,,1,,CHEMBL625386,BAO_0000221,2107.0,
8889,,,Liver,A,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,U,,1,,CHEMBL623571,BAO_0000221,2107.0,
8890,,,Liver,A,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,U,,1,,CHEMBL623572,BAO_0000221,2107.0,
8891,,,Liver,A,,,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,U,,1,,CHEMBL623573,BAO_0000221,2107.0,
8892,,,Liver,A,,,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,U,,1,,CHEMBL623574,BAO_0000221,2107.0,
8893,,,Liver,A,,,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,U,,1,,CHEMBL623575,BAO_0000221,2107.0,
8894,,,Liver,A,,,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,U,,1,,CHEMBL623749,BAO_0000221,2107.0,
8895,,,Liver,A,,,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,U,,1,,CHEMBL623750,BAO_0000221,2107.0,
8896,,In vitro,Liver,A,,,,Half-life in vitro in pig liver,U,,1,,CHEMBL623751,BAO_0000221,2107.0,
8897,,,Liver,A,,,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,U,,1,,CHEMBL623752,BAO_0000221,2107.0,
8898,,In vivo,Plasma,A,,,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,N,,1,,CHEMBL623753,BAO_0000218,1969.0,
8899,,In vivo,Plasma,A,,,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,N,,1,,CHEMBL623754,BAO_0000218,1969.0,
8900,,In vivo,Plasma,A,,,,Maximum concentration in rat plasma was determined,N,,1,,CHEMBL623755,BAO_0000218,1969.0,
8901,,In vivo,,A,,,,Maximum concentration in rats,N,,1,,CHEMBL623756,BAO_0000218,,
8902,,In vivo,,A,,,,Maximum concentration in rats at 1-2 hours,N,,1,,CHEMBL623757,BAO_0000218,,
8903,,In vivo,,A,,,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,N,,1,,CHEMBL623758,BAO_0000218,,
8904,,In vivo,Brain,A,,,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,N,,1,,CHEMBL623759,BAO_0000218,955.0,
8905,,In vivo,,A,,,,Maximum concentration at the dose of 2 mg/kg in rat,N,,1,,CHEMBL623760,BAO_0000218,,
8906,,In vivo,,A,,,,Maximum concentration was evaluated in rats,N,,1,,CHEMBL623761,BAO_0000218,,
8907,,In vivo,Plasma,A,,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,N,,1,,CHEMBL623762,BAO_0000218,1969.0,
8908,,In vivo,Plasma,A,,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,N,,1,,CHEMBL877594,BAO_0000218,1969.0,
8909,,In vivo,Plasma,A,,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,N,,1,,CHEMBL623763,BAO_0000218,1969.0,
8910,,In vivo,Plasma,A,,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,N,,1,,CHEMBL623764,BAO_0000218,1969.0,
8911,,In vivo,Plasma,A,,,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,N,,1,,CHEMBL623765,BAO_0000218,1969.0,
8912,,In vivo,Blood,A,,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,N,,1,,CHEMBL623766,BAO_0000218,178.0,
8913,,In vivo,Blood,A,,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,N,,1,,CHEMBL623767,BAO_0000218,178.0,
8914,,In vivo,Blood,A,,,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,N,,1,,CHEMBL623768,BAO_0000218,178.0,
8915,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,N,,1,,CHEMBL623769,BAO_0000218,1969.0,
8916,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,N,,1,,CHEMBL623770,BAO_0000218,1969.0,
8917,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,N,,1,,CHEMBL623771,BAO_0000218,1969.0,
8918,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,N,,1,,CHEMBL623772,BAO_0000218,1969.0,
8919,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,N,,1,,CHEMBL623773,BAO_0000218,1969.0,
8920,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,N,,1,,CHEMBL623774,BAO_0000218,1969.0,
8921,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,N,,1,,CHEMBL623775,BAO_0000218,1969.0,
8922,,In vivo,,A,,,,Cmax in rat (PO dose),N,,1,,CHEMBL623776,BAO_0000218,,
8923,,In vivo,Plasma,A,,,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,,1,,CHEMBL622191,BAO_0000218,1969.0,
8924,,In vivo,Plasma,A,,,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,,1,,CHEMBL622192,BAO_0000218,1969.0,
8925,,In vivo,Plasma,A,,,,Maximum plasma concentration determined in rat,N,,1,,CHEMBL622193,BAO_0000218,1969.0,
8926,,In vivo,Plasma,A,,,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,N,,1,,CHEMBL622194,BAO_0000218,1969.0,
8927,,In vivo,Plasma,A,,,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,N,,1,,CHEMBL622195,BAO_0000218,1969.0,
8928,,In vivo,Plasma,A,,,,Maximum plasma concentration in rat,N,,1,,CHEMBL622196,BAO_0000218,1969.0,
8929,,In vivo,Plasma,A,,,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,N,,1,,CHEMBL622197,BAO_0000218,1969.0,
8930,,In vivo,Plasma,A,,,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,N,,1,,CHEMBL622198,BAO_0000218,1969.0,
8931,,In vivo,Plasma,A,,,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,N,,1,,CHEMBL622199,BAO_0000218,1969.0,
8932,,In vivo,Plasma,A,,,,Maximum plasma concentration of compound was measured in rat,N,,1,,CHEMBL622200,BAO_0000218,1969.0,
8933,,In vivo,Plasma,A,,,,Maximum plasma concentration after 20 mg/kg oral administration in rat,N,,1,,CHEMBL622201,BAO_0000218,1969.0,
8934,,In vivo,Plasma,A,,,,Maximum plasma concentration after oral administration to rats,N,,1,,CHEMBL623990,BAO_0000218,1969.0,
8935,,In vivo,Plasma,A,,,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,,1,,CHEMBL623991,BAO_0000218,1969.0,
8936,,In vivo,Plasma,A,,,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",N,,1,,CHEMBL623992,BAO_0000218,1969.0,
8937,,In vivo,Plasma,A,,,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,,1,,CHEMBL623993,BAO_0000218,1969.0,
8938,,In vivo,Plasma,A,,,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,N,,1,,CHEMBL623994,BAO_0000218,1969.0,
8939,,In vivo,Plasma,F,,,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,N,,1,,CHEMBL623995,BAO_0000218,1969.0,
8940,,In vivo,Plasma,F,,,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,N,,1,,CHEMBL623996,BAO_0000218,1969.0,
8941,,In vivo,Plasma,F,,,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,N,,1,,CHEMBL623997,BAO_0000218,1969.0,
8942,,In vivo,Plasma,A,,,,Maximum plasma concentration dosed orally in rats,N,,1,,CHEMBL623998,BAO_0000218,1969.0,
8943,,In vivo,Plasma,A,,,,Maximum plasma concentration dosed orally in rats after 6 hours,N,,1,,CHEMBL623999,BAO_0000218,1969.0,
8944,,In vivo,Plasma,A,,,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,N,,1,,CHEMBL624000,BAO_0000218,1969.0,
8945,,In vivo,Plasma,A,,,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,N,,1,,CHEMBL624001,BAO_0000218,1969.0,
8946,,In vivo,Plasma,A,,,,Maximum plasma concentration in rat after po administration,N,,1,,CHEMBL624002,BAO_0000218,1969.0,
8947,,In vivo,Plasma,A,,,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",N,,1,,CHEMBL624003,BAO_0000218,1969.0,
8948,,In vivo,Plasma,A,,,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",N,,1,,CHEMBL624004,BAO_0000218,1969.0,
8949,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,1,,CHEMBL624005,BAO_0000218,948.0,
8950,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,1,,CHEMBL624006,BAO_0000218,948.0,
8951,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,1,,CHEMBL624007,BAO_0000218,948.0,
8952,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,1,,CHEMBL624008,BAO_0000218,948.0,
8953,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,1,,CHEMBL624009,BAO_0000218,948.0,
8954,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,1,,CHEMBL874387,BAO_0000218,948.0,
8955,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,1,,CHEMBL624010,BAO_0000218,948.0,
8956,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,N,,1,,CHEMBL624011,BAO_0000218,948.0,
8957,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,1,,CHEMBL624012,BAO_0000218,948.0,
8958,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,1,,CHEMBL624013,BAO_0000218,948.0,
8959,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,1,,CHEMBL624736,BAO_0000218,948.0,
8960,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,1,,CHEMBL624737,BAO_0000218,948.0,
8961,,,Heart,A,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,1,,CHEMBL624738,BAO_0000218,948.0,
8962,,,Heart,A,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,1,,CHEMBL624739,BAO_0000218,948.0,
8963,,,Heart,A,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,1,,CHEMBL624740,BAO_0000218,948.0,
8964,,,Heart,A,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,1,,CHEMBL624896,BAO_0000218,948.0,
8965,,,Heart,A,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,1,,CHEMBL624897,BAO_0000218,948.0,
8966,,,Heart,A,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,1,,CHEMBL624108,BAO_0000218,948.0,
8967,,,Heart,A,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,1,,CHEMBL624109,BAO_0000218,948.0,
8968,,,Heart,A,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,1,,CHEMBL624110,BAO_0000218,948.0,
8969,,,Heart,A,,,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,1,,CHEMBL624111,BAO_0000218,948.0,
8970,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,1,,CHEMBL624112,BAO_0000218,948.0,
8971,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,1,,CHEMBL624113,BAO_0000218,948.0,
8972,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,1,,CHEMBL619709,BAO_0000218,948.0,
8973,,,Heart,A,,,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,1,,CHEMBL619710,BAO_0000218,948.0,
8974,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,1,,CHEMBL619711,BAO_0000218,2113.0,
8975,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,1,,CHEMBL619712,BAO_0000218,2113.0,
8976,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,1,,CHEMBL619713,BAO_0000218,2113.0,
8977,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,1,,CHEMBL619714,BAO_0000218,2113.0,
8978,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,1,,CHEMBL619715,BAO_0000218,2113.0,
8979,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,1,,CHEMBL619716,BAO_0000218,2113.0,
8980,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,1,,CHEMBL619717,BAO_0000218,2113.0,
8981,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,1,,CHEMBL619718,BAO_0000218,2113.0,
8982,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,1,,CHEMBL619719,BAO_0000218,2113.0,
8983,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,1,,CHEMBL875329,BAO_0000218,2113.0,
8984,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,1,,CHEMBL619720,BAO_0000218,2113.0,
8985,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,1,,CHEMBL619721,BAO_0000218,2113.0,
8986,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,1,,CHEMBL619722,BAO_0000218,2113.0,
8987,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,1,,CHEMBL619723,BAO_0000218,2113.0,
8988,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,1,,CHEMBL619724,BAO_0000218,2113.0,
8989,,,Kidney,A,,,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,1,,CHEMBL619725,BAO_0000218,2113.0,
8990,,,Kidney,A,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,1,,CHEMBL619726,BAO_0000218,2113.0,
8991,,,Kidney,A,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,1,,CHEMBL619727,BAO_0000218,2113.0,
8992,,,Kidney,A,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,1,,CHEMBL619728,BAO_0000218,2113.0,
8993,,,Kidney,A,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,1,,CHEMBL619729,BAO_0000218,2113.0,
8994,,In vivo,Muscle tissue,A,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL619730,BAO_0000218,2385.0,
8995,,In vivo,Muscle tissue,A,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL619731,BAO_0000218,2385.0,
8996,,In vivo,Muscle tissue,A,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,1,,CHEMBL619732,BAO_0000218,2385.0,
8997,,In vivo,Muscle tissue,A,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL619733,BAO_0000218,2385.0,
8998,,In vivo,Muscle tissue,A,,,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL619734,BAO_0000218,2385.0,
8999,,In vivo,Zone of skin,A,,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL619735,BAO_0000218,14.0,
9000,,In vivo,Zone of skin,A,,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL875330,BAO_0000218,14.0,
9001,,In vivo,Zone of skin,A,,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,1,,CHEMBL628465,BAO_0000218,14.0,
9002,,In vivo,Zone of skin,A,,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL628466,BAO_0000218,14.0,
9003,,In vivo,Zone of skin,A,,,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL628467,BAO_0000218,14.0,
9004,,In vivo,Spleen,A,,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL628468,BAO_0000218,2106.0,
9005,,In vivo,Spleen,A,,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL628469,BAO_0000218,2106.0,
9006,,In vivo,Spleen,A,,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,1,,CHEMBL628470,BAO_0000218,2106.0,
9007,,In vivo,Spleen,A,,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL628471,BAO_0000218,2106.0,
9008,,In vivo,Spleen,A,,,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL628472,BAO_0000218,2106.0,
9009,,In vivo,Thyroid gland,A,,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL625191,BAO_0000218,2046.0,
9010,,In vivo,Thyroid gland,A,,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL625192,BAO_0000218,2046.0,
9011,,In vivo,Thyroid gland,A,,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,1,,CHEMBL875337,BAO_0000218,2046.0,
9012,,In vivo,Thyroid gland,A,,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL626341,BAO_0000218,2046.0,
9013,,In vivo,Thyroid gland,A,,,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL626342,BAO_0000218,2046.0,
9014,,In vivo,Liver,A,,,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,1,,CHEMBL621943,BAO_0000218,2107.0,
9015,,,,A,,,,Half life in rats,N,,1,,CHEMBL621944,BAO_0000218,,
9016,,,,A,,,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,N,,1,,CHEMBL621945,BAO_0000218,,
9017,,,,A,,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),N,,1,,CHEMBL621946,BAO_0000218,,
9018,,,,A,,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,N,,1,,CHEMBL621947,BAO_0000218,,
9019,,,,A,,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),N,,1,,CHEMBL621948,BAO_0000218,,
9020,,,,A,,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,N,,1,,CHEMBL621949,BAO_0000218,,
9021,,,,A,,,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),N,,1,,CHEMBL621950,BAO_0000218,,
9022,,,,A,,,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,N,,1,,CHEMBL621951,BAO_0000218,,
9023,,In vivo,Blood,A,,,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,N,,1,,CHEMBL621952,BAO_0000218,178.0,
9024,,,Liver,A,,,,Stability (%) in rat liver microsomes,N,,1,,CHEMBL621953,BAO_0000218,2107.0,
9025,,,,A,,,,Area under curve was calculated after intravenous administration,N,,1,,CHEMBL621954,BAO_0000218,,
9026,,,,A,,,,Area under the curve was calculated after iv administration in rat,N,,1,,CHEMBL621955,BAO_0000218,,
9027,,,,A,,,,Area under the curve was calculated in rat after peroral administration,N,,1,,CHEMBL621956,BAO_0000218,,
9028,,,,A,,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,N,,1,,CHEMBL621957,BAO_0000218,,
9029,,,,A,,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,N,,1,,CHEMBL621958,BAO_0000218,,
9030,,,,A,,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,N,,1,,CHEMBL621959,BAO_0000218,,
9031,,,,A,,,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,N,,1,,CHEMBL621960,BAO_0000218,,
9032,,,,A,,,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,N,,1,,CHEMBL621961,BAO_0000218,,
9033,,,,A,,,,p value of the compound,N,,1,,CHEMBL621962,BAO_0000218,,
9034,,,,F,,,,p value of the compound,N,,1,,CHEMBL876787,BAO_0000218,,
9035,,,,A,,,,p value of the compound,N,,1,,CHEMBL621963,BAO_0000218,,
9036,,,Stomach,A,,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,,1,,CHEMBL622637,BAO_0000218,945.0,
9037,,,Stomach,A,,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,,1,,CHEMBL622638,BAO_0000218,945.0,
9038,,,Stomach,A,,,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,,1,,CHEMBL626561,BAO_0000218,945.0,
9039,,,,F,,,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),U,,1,,CHEMBL626562,BAO_0000019,,
9040,,,,A,,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),U,,1,,CHEMBL626563,BAO_0000218,,
9041,,,,A,,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),U,,1,,CHEMBL626564,BAO_0000218,,
9042,,In vivo,,A,,,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,U,,1,,CHEMBL626565,BAO_0000218,,
9043,,In vivo,,A,,,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,U,,1,,CHEMBL626566,BAO_0000218,,
9044,,In vivo,,A,,,,Clearance rate in rabbits,U,,1,,CHEMBL626567,BAO_0000218,,
9045,,In vivo,,A,,,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,U,,1,,CHEMBL626568,BAO_0000218,,
9046,,In vivo,,A,,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,U,,1,,CHEMBL626569,BAO_0000218,,
9047,,In vivo,,A,,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,U,,1,,CHEMBL626570,BAO_0000218,,
9048,,In vivo,,A,,,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,U,,1,,CHEMBL626571,BAO_0000218,,
9049,,In vivo,,A,,,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,U,,1,,CHEMBL626572,BAO_0000218,,
9050,,In vivo,Plasma,A,,,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,U,,1,,CHEMBL626573,BAO_0000218,1969.0,
9051,Microsomes,,Liver,A,,,,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,U,,1,,CHEMBL626574,BAO_0000251,2107.0,
9052,Microsomes,,Liver,A,,,,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,U,,1,,CHEMBL626575,BAO_0000251,2107.0,
9053,,,,A,,,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,U,,1,,CHEMBL626576,BAO_0000218,,
9054,,,,A,,,,Dose at which bioavailability of perorally administered compound was tested in rabbit,U,,1,,CHEMBL626577,BAO_0000218,,
9055,,In vivo,,A,,,,The compound was tested for its bioavailability in rabbit (by oral dosage).,U,,1,,CHEMBL626578,BAO_0000218,,
9056,,In vivo,,A,,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,U,,1,,CHEMBL625263,BAO_0000218,,
9057,,In vivo,,A,,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,U,,1,,CHEMBL625264,BAO_0000218,,
9058,,In vivo,,A,,,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,U,,1,,CHEMBL625265,BAO_0000218,,
9059,Microsomes,,,A,,,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),U,,1,,CHEMBL625266,BAO_0000251,,
9060,Microsomes,,,A,,,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),U,,1,,CHEMBL876796,BAO_0000251,,
9061,,In vivo,,A,,,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,U,,1,,CHEMBL625267,BAO_0000218,,
9062,,In vivo,Plasma,A,,,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,U,,1,,CHEMBL625268,BAO_0000218,1969.0,
9063,,In vivo,Plasma,A,,,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,U,,1,,CHEMBL625269,BAO_0000218,1969.0,
9064,,In vivo,Plasma,A,,,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,U,,1,,CHEMBL624689,BAO_0000218,1969.0,
9065,,In vivo,,A,,,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,U,,1,,CHEMBL624690,BAO_0000218,,
9066,,,Urine,A,,,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),U,,1,,CHEMBL624691,BAO_0000218,1088.0,
9067,,,Urine,A,,,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),U,,1,,CHEMBL624692,BAO_0000218,1088.0,
9068,,In vivo,,A,,,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,U,,1,,CHEMBL624693,BAO_0000218,,
9069,,In vivo,,A,,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,U,,1,,CHEMBL624694,BAO_0000218,,
9070,,In vitro,,A,,,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,U,,1,,CHEMBL877596,BAO_0000221,,
9071,,,,A,,,,Time within which only 10% of the drug was degraded,U,,1,,CHEMBL624695,BAO_0000019,,
9072,,,Liver,A,,,,Half life period in rabbit liver homogenate,U,,1,,CHEMBL624696,BAO_0000221,2107.0,
9073,,,,A,,,,Half life value in rabbits,U,,1,,CHEMBL624697,BAO_0000019,,
9074,,In vivo,Blood,A,,,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,U,,1,,CHEMBL624698,BAO_0000218,178.0,
9075,,In vivo,Blood,A,,,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,U,,1,,CHEMBL624699,BAO_0000218,178.0,
9076,,In vivo,,A,,,,Half-life period in rabbits following intravenous administration at 2 mg/kg,U,,1,,CHEMBL624700,BAO_0000218,,
9077,,,Plasma,A,,,,AUC 0-8 hr value in rats at 10 mg/kg,N,,1,,CHEMBL622903,BAO_0000218,1969.0,
9078,,,Plasma,A,,,,AUC after administration at 2000 mg/kg/day in rats,N,,1,,CHEMBL622904,BAO_0000218,1969.0,
9079,,,Plasma,A,,,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,N,,1,,CHEMBL622905,BAO_0000218,1969.0,
9080,,,Plasma,A,,,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,N,,1,,CHEMBL622906,BAO_0000218,1969.0,
9081,,,Plasma,A,,,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,N,,1,,CHEMBL622907,BAO_0000218,1969.0,
9082,,,Plasma,A,,,,AUC in rat after oral administration at 10.5 mg/kg dose,N,,1,,CHEMBL622908,BAO_0000218,1969.0,
9083,,,Plasma,A,,,,AUC in rat after oral administration at 11.2 mg/kg dose,N,,1,,CHEMBL622909,BAO_0000218,1969.0,
9084,,,Plasma,A,,,,AUC in rat after oral administration at 9.7 mg/kg dose,N,,1,,CHEMBL622910,BAO_0000218,1969.0,
9085,,,Brain,A,,,,AUC in rat brain after oral administration at 10 mg/kg,N,,1,,CHEMBL622911,BAO_0000218,955.0,
9086,,,Plasma,A,,,,AUC in rat p.o.,N,,1,,CHEMBL622912,BAO_0000218,1969.0,
9087,,,Plasma,A,,,,AUC in rat p.o. at 20 mg/kg concentration,N,,1,,CHEMBL622913,BAO_0000218,1969.0,
9088,,,Plasma,A,,,,AUC in rat plasma after oral administration at 10 mg/kg,N,,1,,CHEMBL622914,BAO_0000218,1969.0,
9089,,,Plasma,A,,,,AUC in rats,N,,1,,CHEMBL622915,BAO_0000218,1969.0,
9090,,,Plasma,A,,,,AUC value after IV dose at a dose of 5 mg/kg in rats.,N,,1,,CHEMBL622916,BAO_0000218,1969.0,
9091,,,Plasma,A,,,,AUC value after oral dose at a dose of 10 mg/kg in rats.,N,,1,,CHEMBL622917,BAO_0000218,1969.0,
9092,,In vivo,Plasma,A,,,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",N,,1,,CHEMBL622918,BAO_0000218,1969.0,
9093,,In vivo,Plasma,A,,,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,N,,1,,CHEMBL622919,BAO_0000218,1969.0,
9094,,In vivo,Plasma,A,,,,Maximum plasma concentration was evaluated in rat,N,,1,,CHEMBL622920,BAO_0000218,1969.0,
9095,,In vivo,Plasma,A,,,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,N,,1,,CHEMBL622921,BAO_0000218,1969.0,
9096,,In vivo,Plasma,A,,,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,N,,1,,CHEMBL622922,BAO_0000218,1969.0,
9097,,In vivo,Plasma,A,,,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,N,,1,,CHEMBL622923,BAO_0000218,1969.0,
9098,,In vivo,Plasma,A,,,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,N,,1,,CHEMBL877604,BAO_0000218,1969.0,
9099,,In vivo,Plasma,A,,,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,N,,1,,CHEMBL622924,BAO_0000218,1969.0,
9100,,In vivo,Plasma,A,,,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,N,,1,,CHEMBL622925,BAO_0000218,1969.0,
9101,,In vivo,Plasma,A,,,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,N,,1,,CHEMBL622926,BAO_0000218,1969.0,
9102,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,N,,1,,CHEMBL623625,BAO_0000218,1969.0,
9103,,In vivo,Plasma,A,,,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,N,,1,,CHEMBL623626,BAO_0000218,1969.0,
9104,,In vivo,Plasma,A,,,,Maximum plasma drug concentration was determined,N,,1,,CHEMBL623627,BAO_0000218,1969.0,
9105,,In vivo,,A,,,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,N,,1,,CHEMBL623628,BAO_0000218,,
9106,,In vivo,Plasma,A,,,,Mean peak plasma concentration was observed after intravenous administration in rat,N,,1,,CHEMBL623629,BAO_0000218,1969.0,
9107,,In vivo,Plasma,A,,,,Mean peak plasma concentration was observed after oral administration in rat,N,,1,,CHEMBL623630,BAO_0000218,1969.0,
9108,,In vivo,,A,,,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,N,,1,,CHEMBL623804,BAO_0000218,,
9109,,In vivo,,A,,,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,N,,1,,CHEMBL623805,BAO_0000218,,
9110,,In vivo,Plasma,A,,,,Peak oral plasma concentration was determined in rats by oral administration,N,,1,,CHEMBL623806,BAO_0000218,1969.0,
9111,,In vivo,Plasma,A,,,,Peak plasma concentration (Cmax) was determined,N,,1,,CHEMBL623807,BAO_0000218,1969.0,
9112,,In vivo,Plasma,A,,,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,N,,1,,CHEMBL623808,BAO_0000218,1969.0,
9113,,In vivo,Plasma,A,,,,Peak plasma concentration (Cmax) in rats,N,,1,,CHEMBL623809,BAO_0000218,1969.0,
9114,,In vivo,Plasma,A,,,,Peak plasma concentration at 1 mg/kg peroral administration,N,,1,,CHEMBL623810,BAO_0000218,1969.0,
9115,,In vivo,Plasma,A,,,,Peak plasma concentration in rat,N,,1,,CHEMBL623811,BAO_0000218,1969.0,
9116,,In vivo,Plasma,A,,,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",N,,1,,CHEMBL623812,BAO_0000218,1969.0,
9117,,In vivo,,A,,,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,N,,1,,CHEMBL877605,BAO_0000218,,
9118,,In vivo,,A,,,,Pharmacokinetic property (Cmax) in rat,N,,1,,CHEMBL623813,BAO_0000218,,
9119,,In vivo,,A,,,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,N,,1,,CHEMBL623814,BAO_0000218,,
9120,,In vivo,,A,,,,Cmax in rat after 3mg/kg oral dose,N,,1,,CHEMBL623815,BAO_0000218,,
9121,,In vivo,,A,,,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,N,Sprague-Dawley,1,,CHEMBL623816,BAO_0000218,,
9122,,In vivo,,A,,,,Cmax in rats after 20 mg/kg oral dose,N,,1,,CHEMBL623145,BAO_0000218,,
9123,,In vivo,Plasma,A,,,,Cmax in rat plasma after 30mg/kg oral dose,N,,1,,CHEMBL623146,BAO_0000218,1969.0,
9124,,In vivo,Plasma,A,,,,Plasma concentration after oral administration of 100 mg/kg to rats,N,,1,,CHEMBL623147,BAO_0000218,1969.0,
9125,,In vivo,Brain,A,,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,N,,1,,CHEMBL623042,BAO_0000218,955.0,
9126,,In vivo,,A,,,,Tested for the Cmax in rat at 10 mg/kg per orally,N,,1,,CHEMBL623043,BAO_0000218,,
9127,,In vivo,,A,,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL623044,BAO_0000218,,
9128,,In vivo,,A,,,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL623045,BAO_0000218,,
9129,,In vivo,,A,,,,Bioavailability as oral Cmax in rats at 30 mins,N,,1,,CHEMBL623046,BAO_0000218,,
9130,,In vivo,,A,,,,Bioavailability as oral Cmax in rats at 6hr,N,,1,,CHEMBL623226,BAO_0000218,,
9131,,In vivo,,A,,,,The maximum concentration of compound was measured at the dose of 100 umol/kg,N,,1,,CHEMBL623227,BAO_0000218,,
9132,,In vivo,,A,,,,The maximum concentration of compound was measured at the dose of 300 umol/kg,N,,1,,CHEMBL623228,BAO_0000218,,
9133,,In vivo,,A,,,,The maximum concentration of compound was measured at the dose of 30 umol/kg,N,,1,,CHEMBL623229,BAO_0000218,,
9134,,In vivo,Plasma,A,,,,The maximum plasma levels for the compounds were determined by LC-MS.,N,,1,,CHEMBL623230,BAO_0000218,1969.0,
9135,,In vivo,Plasma,A,,,,mean peak plasma concentration was observed after intravenous administration in rat,N,,1,,CHEMBL623231,BAO_0000218,1969.0,
9136,,In vivo,Plasma,A,,,,mean peak plasma concentration was observed after oral administration in rat,N,,1,,CHEMBL623232,BAO_0000218,1969.0,
9137,,,,A,,,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,N,,1,,CHEMBL623233,BAO_0000218,,
9138,,,,A,,,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,N,,1,,CHEMBL623234,BAO_0000218,,
9139,,,,A,,,,Concentration in plasma (portal) following oral dose in rats at 1 hr,N,,1,,CHEMBL623235,BAO_0000218,,
9140,,,,A,,,,Concentration in plasma (portal) following oral dose in rats at 2 hr,N,,1,,CHEMBL623236,BAO_0000218,,
9141,,,,A,,,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,N,,1,,CHEMBL623237,BAO_0000218,,
9142,,,,A,,,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,N,,1,,CHEMBL623238,BAO_0000218,,
9143,,,,A,,,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,N,,1,,CHEMBL623239,BAO_0000218,,
9144,,In vivo,Plasma,A,,,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,U,,1,,CHEMBL623240,BAO_0000218,1969.0,
9145,,,Hypothalamus,A,,,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",N,,1,,CHEMBL623241,BAO_0000218,1898.0,
9146,,,Hypothalamus,A,,,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",N,,1,,CHEMBL623242,BAO_0000218,1898.0,
9147,,,,A,,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",N,,1,,CHEMBL874394,BAO_0000218,,
9148,,,,A,,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",N,,1,,CHEMBL623243,BAO_0000218,,
9149,,,,A,,,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,1,,CHEMBL623244,BAO_0000218,,
9150,,,Kidney,A,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,1,,CHEMBL623245,BAO_0000218,2113.0,
9151,,,Kidney,A,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,1,,CHEMBL623246,BAO_0000218,2113.0,
9152,,,Kidney,A,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,1,,CHEMBL623247,BAO_0000218,2113.0,
9153,,,Kidney,A,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,1,,CHEMBL623248,BAO_0000218,2113.0,
9154,,,Kidney,A,,,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,1,,CHEMBL623249,BAO_0000218,2113.0,
9155,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,1,,CHEMBL625072,BAO_0000218,2107.0,
9156,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,1,,CHEMBL625073,BAO_0000218,2107.0,
9157,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,1,,CHEMBL625074,BAO_0000218,2107.0,
9158,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,1,,CHEMBL625075,BAO_0000218,2107.0,
9159,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,N,,1,,CHEMBL625076,BAO_0000218,2107.0,
9160,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,1,,CHEMBL625077,BAO_0000218,2107.0,
9161,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,1,,CHEMBL625078,BAO_0000218,2107.0,
9162,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,1,,CHEMBL874395,BAO_0000218,2107.0,
9163,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,1,,CHEMBL625079,BAO_0000218,2107.0,
9164,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,1,,CHEMBL625080,BAO_0000218,2107.0,
9165,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,1,,CHEMBL625081,BAO_0000218,2107.0,
9166,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,1,,CHEMBL625082,BAO_0000218,2107.0,
9167,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,1,,CHEMBL625083,BAO_0000218,2107.0,
9168,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,1,,CHEMBL625084,BAO_0000218,2107.0,
9169,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,1,,CHEMBL625085,BAO_0000218,2107.0,
9170,,,Liver,A,,,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,1,,CHEMBL625086,BAO_0000218,2107.0,
9171,,,Liver,A,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,1,,CHEMBL625087,BAO_0000218,2107.0,
9172,,,Liver,A,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,1,,CHEMBL625088,BAO_0000218,2107.0,
9173,,,Liver,A,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,1,,CHEMBL622205,BAO_0000218,2107.0,
9174,,,Liver,A,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,1,,CHEMBL622206,BAO_0000218,2107.0,
9175,,,Liver,A,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,1,,CHEMBL622207,BAO_0000218,2107.0,
9176,,,Liver,A,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,1,,CHEMBL622366,BAO_0000218,2107.0,
9177,,,Liver,A,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,1,,CHEMBL622367,BAO_0000218,2107.0,
9178,,,Liver,A,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,1,,CHEMBL875331,BAO_0000218,2107.0,
9179,,,Liver,A,,,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,1,,CHEMBL622368,BAO_0000218,2107.0,
9180,,,Lung,A,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,1,,CHEMBL622369,BAO_0000218,2048.0,
9181,,,Lung,A,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,1,,CHEMBL622370,BAO_0000218,2048.0,
9182,,,Lung,A,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,1,,CHEMBL622371,BAO_0000218,2048.0,
9183,,,Lung,A,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,1,,CHEMBL622372,BAO_0000218,2048.0,
9184,,,Lung,A,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,1,,CHEMBL622373,BAO_0000218,2048.0,
9185,,,Lung,A,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,1,,CHEMBL622374,BAO_0000218,2048.0,
9186,,,Lung,A,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,1,,CHEMBL622375,BAO_0000218,2048.0,
9187,,,Lung,A,,,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,N,,1,,CHEMBL622376,BAO_0000218,2048.0,
9188,,,Lung,A,,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,1,,CHEMBL622377,BAO_0000218,2048.0,
9189,,,Lung,A,,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,1,,CHEMBL622378,BAO_0000218,2048.0,
9190,,,Lung,A,,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,1,,CHEMBL622379,BAO_0000218,2048.0,
9191,,,Lung,A,,,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,1,,CHEMBL622380,BAO_0000218,2048.0,
9192,,,Lung,A,,,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,1,,CHEMBL622381,BAO_0000218,2048.0,
9193,,,Lung,A,,,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,1,,CHEMBL622382,BAO_0000218,2048.0,
9194,,,Lung,A,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,N,,1,,CHEMBL622383,BAO_0000218,2048.0,
9195,,,Stomach,A,,,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,,1,,CHEMBL875332,BAO_0000218,945.0,
9196,,,Stomach,A,,,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,,1,,CHEMBL622384,BAO_0000218,945.0,
9197,,,Stomach,A,,,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,,1,,CHEMBL622385,BAO_0000218,945.0,
9198,,,Stomach,A,,,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,,1,,CHEMBL622386,BAO_0000218,945.0,
9199,,,,A,,,,The compound was tested for the plasma binding in rat,N,,1,,CHEMBL622387,BAO_0000218,,
9200,,,,A,,,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",N,,1,,CHEMBL622388,BAO_0000218,,
9201,,,,A,,,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",N,,1,,CHEMBL622389,BAO_0000218,,
9202,,,,A,,,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",N,,1,,CHEMBL622390,BAO_0000218,,
9203,,,,A,,,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),N,,1,,CHEMBL622391,BAO_0000218,,
9204,,,,A,,,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),N,,1,,CHEMBL622392,BAO_0000218,,
9205,,,,A,,,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),N,,1,,CHEMBL622393,BAO_0000218,,
9206,,,,A,,,,Plasma level at 2 hr after administration of the compound,N,,1,,CHEMBL622394,BAO_0000218,,
9207,,,,A,,,,plasma level at 2 hr after administration of the compound,N,,1,,CHEMBL622395,BAO_0000218,,
9208,,,Serum,A,,,,Stability in rat serum measured as % recovery at 1 min,N,,1,,CHEMBL622396,BAO_0000218,1977.0,
9209,,,Serum,A,,,,Stability in rat serum measured as % recovery at 10 min,N,,1,,CHEMBL624894,BAO_0000218,1977.0,
9210,,,Serum,A,,,,Stability in rat serum measured as % recovery at 10 mins,N,,1,,CHEMBL624895,BAO_0000218,1977.0,
9211,,,Serum,A,,,,Stability in rat serum measured as % recovery at 2 hr,N,,1,,CHEMBL624058,BAO_0000218,1977.0,
9212,,,Serum,A,,,,Stability in rat serum measured as % recovery at 3 min,N,,1,,CHEMBL624059,BAO_0000218,1977.0,
9213,,,Serum,A,,,,Stability in rat serum measured as % recovery at 3 mins,N,,1,,CHEMBL624060,BAO_0000218,1977.0,
9214,,,Serum,A,,,,Stability in rat serum measured as % recovery at 5 min,N,,1,,CHEMBL624061,BAO_0000218,1977.0,
9215,,,Serum,A,,,,Stability in rat serum measured as % recovery at 5 mins,N,,1,,CHEMBL624062,BAO_0000218,1977.0,
9216,,In vivo,,A,,,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,N,,1,,CHEMBL624063,BAO_0000218,,
9217,,In vivo,,A,,,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,N,,1,,CHEMBL624064,BAO_0000218,,
9218,,,Plasma,A,,,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,N,,1,,CHEMBL624065,BAO_0000218,1969.0,
9219,,,Plasma,A,,,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,N,,1,,CHEMBL624066,BAO_0000218,1969.0,
9220,,In vivo,,A,,,,Half life tested in mature male rat at a dose of 30 mg/kg,N,,1,,CHEMBL877490,BAO_0000218,,
9221,,In vivo,,A,,,,Half life after intravenous administration of 1 mg/kg in rat,N,,1,,CHEMBL874442,BAO_0000218,,
9222,,In vivo,,A,,,,Half life period after administration (30 mg/kg) in rat,N,,1,,CHEMBL626890,BAO_0000218,,
9223,,In vivo,,A,,,,Half life period in rat after 5 mg/Kg dose,N,,1,,CHEMBL626891,BAO_0000218,,
9224,,In vivo,,A,,,,Half life period in rat after 5 mg/kg dose,N,,1,,CHEMBL626892,BAO_0000218,,
9225,,,,A,,,,Half life period was determined,N,,1,,CHEMBL626893,BAO_0000218,,
9226,,,,A,,,,Half life period was evaluated in rat,N,,1,,CHEMBL626894,BAO_0000218,,
9227,,,,A,,,,Half life period was evaluated in rat; 0.5-1.0,N,,1,,CHEMBL626895,BAO_0000218,,
9228,,,,A,,,,Half life period was evaluated in rat; 5.9-7.5,N,,1,,CHEMBL626896,BAO_0000218,,
9229,,,Plasma,A,,,,Half-life in rat plasma,N,,1,,CHEMBL626897,BAO_0000218,1969.0,
9230,,,,A,,,,Half-life time in rat was determined,N,,1,,CHEMBL626898,BAO_0000218,,
9231,,In vivo,,A,,,,Terminal half-life after iv administration to rats,N,,1,,CHEMBL626899,BAO_0000218,,
9232,,In vivo,,A,,,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,N,,1,,CHEMBL626900,BAO_0000218,,
9233,,,,A,,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,N,,1,,CHEMBL626901,BAO_0000218,,
9234,,In vivo,,A,,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),N,,1,,CHEMBL626902,BAO_0000218,,
9235,,In vivo,,A,,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),N,,1,,CHEMBL626903,BAO_0000218,,
9236,,In vivo,,A,,,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,N,,1,,CHEMBL874443,BAO_0000218,,
9237,,In vivo,,A,,,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,N,,1,,CHEMBL626904,BAO_0000218,,
9238,,,,A,,,,Half life in rats,N,,1,,CHEMBL626905,BAO_0000218,,
9239,,In vivo,Plasma,A,,,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,N,,1,,CHEMBL873830,BAO_0000218,1969.0,
9240,,In vivo,,A,,,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,N,,1,,CHEMBL626906,BAO_0000218,,
9241,,In vivo,Plasma,A,,,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,,1,,CHEMBL631076,BAO_0000218,1969.0,
9242,,,Plasma,A,,,,Biological half-life was measured in plasma of rats,N,,1,,CHEMBL631077,BAO_0000218,1969.0,
9243,,In vivo,,A,,,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,N,,1,,CHEMBL631078,BAO_0000218,,
9244,,In vivo,,A,,,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,N,,1,,CHEMBL631079,BAO_0000218,,
9245,,In vivo,,A,,,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,N,,1,,CHEMBL631080,BAO_0000218,,
9246,,In vivo,,A,,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,N,,1,,CHEMBL631081,BAO_0000218,,
9247,,In vivo,,A,,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,N,,1,,CHEMBL631239,BAO_0000218,,
9248,,,Plasma,A,,,,Compound was evaluated for plasma half life in rat,N,,1,,CHEMBL631240,BAO_0000218,1969.0,
9249,,,Plasma,A,,,,AUC value at a dose of 5 mg/kg (p.o.) in rats,N,,1,,CHEMBL631241,BAO_0000218,1969.0,
9250,,,Plasma,A,,,,AUC value after administration of 20 mg/Kg oral dose in rat,N,,1,,CHEMBL631242,BAO_0000218,1969.0,
9251,,,Plasma,A,,,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,N,,1,,CHEMBL631243,BAO_0000218,1969.0,
9252,,,Plasma,A,,,,AUC0-96 after administration at 50 mg/kg,N,,1,,CHEMBL874444,BAO_0000218,1969.0,
9253,,,Plasma,A,,,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,N,,1,,CHEMBL631244,BAO_0000218,1969.0,
9254,,,,A,,,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",N,,1,,CHEMBL631245,BAO_0000218,,
9255,,,,A,,,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,N,,1,,CHEMBL627162,BAO_0000218,,
9256,,,,A,,,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,N,,1,,CHEMBL627163,BAO_0000218,,
9257,,,,A,,,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,N,,1,,CHEMBL627164,BAO_0000218,,
9258,,,Kidney,A,,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,N,,1,,CHEMBL627165,BAO_0000218,2113.0,
9259,,,,A,,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,N,,1,,CHEMBL627166,BAO_0000218,,
9260,,,,A,,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,N,,1,,CHEMBL627167,BAO_0000218,,
9261,,,,A,,,,Area under curve (AUC) at a dose of 30 mg/kg in rats,N,,1,,CHEMBL627822,BAO_0000218,,
9262,,,,A,,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,N,,1,,CHEMBL627823,BAO_0000218,,
9263,,,,A,,,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,N,,1,,CHEMBL627824,BAO_0000218,,
9264,,,,A,,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,N,,1,,CHEMBL627825,BAO_0000218,,
9265,,,,A,,,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,N,,1,,CHEMBL627826,BAO_0000218,,
9266,,,,A,,,,Area under curve (Pharmacokinetic property) was determined,N,,1,,CHEMBL627827,BAO_0000218,,
9267,,,,A,,,,Area under curve (Pharmacokinetic property) of the compound; Not determined,N,,1,,CHEMBL627828,BAO_0000218,,
9268,,,,A,,,,Area under curve after intravenous administration (1 mg/kg) in rat,N,,1,,CHEMBL627829,BAO_0000218,,
9269,,,,A,,,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,N,,1,,CHEMBL627830,BAO_0000218,,
9270,,,,A,,,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,N,,1,,CHEMBL627831,BAO_0000218,,
9271,,,,A,,,,Area under curve in male SD rats was observed after oral administration in rat,N,,1,,CHEMBL627832,BAO_0000218,,
9272,,,,A,,,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,N,,1,,CHEMBL627833,BAO_0000218,,
9273,,,,A,,,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,N,,1,,CHEMBL627834,BAO_0000218,,
9274,,,,A,,,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,N,,1,,CHEMBL628004,BAO_0000218,,
9275,,,,A,,,,Area under curve at 5 mg/kg po was determined in rat,N,,1,,CHEMBL628005,BAO_0000218,,
9276,,,,A,,,,Area under curve in Rat at a oral dose of 5 mg/kg,N,,1,,CHEMBL628006,BAO_0000218,,
9277,,,,A,,,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,,1,,CHEMBL628007,BAO_0000218,,
9278,,,,A,,,,Area under curve was determined,N,,1,,CHEMBL625676,BAO_0000218,,
9279,,,,A,,,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,N,,1,,CHEMBL631309,BAO_0000218,,
9280,,,,A,,,,Area under curve after intravenous administration at 3 mg/kg,N,,1,,CHEMBL631310,BAO_0000218,,
9281,,,,A,,,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,N,,1,,CHEMBL631311,BAO_0000218,,
9282,,,,A,,,,Area under curve at 4 hr in rat,N,,1,,CHEMBL631312,BAO_0000218,,
9283,,,,A,,,,Area under curve at a dose of 30 mg/kg,N,,1,,CHEMBL631313,BAO_0000218,,
9284,,,,A,,,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,N,,1,,CHEMBL631314,BAO_0000218,,
9285,,,,A,,,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,N,,1,,CHEMBL631315,BAO_0000218,,
9286,,,,A,,,,Area under curve for a 2-mpk po dose in SD rats,N,,1,,CHEMBL631316,BAO_0000218,,
9287,,,,A,,,,Area under curve in SD rats,N,,1,,CHEMBL631317,BAO_0000218,,
9288,,,,A,,,,Area under curve in rat after oral administration at 13 mg/kg dose,N,,1,,CHEMBL874471,BAO_0000218,,
9289,,,,A,,,,Area under curve in rat by po administration at 0-24 hr,N,,1,,CHEMBL631318,BAO_0000218,,
9290,,,Plasma,A,,,,Area under curve in rat plasma,N,,1,,CHEMBL631319,BAO_0000218,1969.0,
9291,,,,A,,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,N,,1,,CHEMBL631320,BAO_0000218,,
9292,,,,A,,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,N,,1,,CHEMBL631321,BAO_0000218,,
9293,,,,A,,,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,N,,1,,CHEMBL631322,BAO_0000218,,
9294,,,,A,,,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,N,,1,,CHEMBL631323,BAO_0000218,,
9295,,,,A,,,,Area under curve value in rat at a dose of 5 mg/kg,N,,1,,CHEMBL631324,BAO_0000218,,
9296,,,,A,,,,Area under curve was determined after oral administration in rats,N,,1,,CHEMBL631325,BAO_0000218,,
9297,,,,A,,,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,N,,1,,CHEMBL631326,BAO_0000218,,
9298,,,,A,,,,Area under curve was determined after peroral administration in rat,N,,1,,CHEMBL631327,BAO_0000218,,
9299,,,,A,,,,Area under curve was determined at a dose 30 mpk administered orally.,N,,1,,CHEMBL631328,BAO_0000218,,
9300,,,,A,,,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,N,,1,,CHEMBL631329,BAO_0000218,,
9301,,,,A,,,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,N,,1,,CHEMBL627217,BAO_0000218,,
9302,,,,A,,,,Area under curve was determined in male rat,N,,1,,CHEMBL626352,BAO_0000218,,
9303,,,,A,,,,Area under curve was determined in rat after PO administration,N,,1,,CHEMBL626353,BAO_0000218,,
9304,,,,A,,,,Area under curve was determined in rat after a 3 mg/kg of oral dose,N,,1,,CHEMBL626354,BAO_0000218,,
9305,,,,A,,,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,N,,1,,CHEMBL626355,BAO_0000218,,
9306,,,,A,,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,N,,1,,CHEMBL626356,BAO_0000218,,
9307,,,,A,,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,N,,1,,CHEMBL626357,BAO_0000218,,
9308,,,,A,,,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,1,,CHEMBL626358,BAO_0000218,,
9309,,,,A,,,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,1,,CHEMBL626359,BAO_0000218,,
9310,,,Plasma,A,,,,Peak plasma concentration in rat at a dose of 3 mg/kg,N,,1,,CHEMBL626360,BAO_0000218,1969.0,
9311,,,,A,,,,Plasma concentration at 2 hr in rats was evaluated.,N,,1,,CHEMBL626361,BAO_0000218,,
9312,,,,A,,,,Plasma concentration at 2 hr in rats was evaluated; Not available,N,,1,,CHEMBL626362,BAO_0000218,,
9313,,,,A,,,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,1,,CHEMBL626363,BAO_0000218,,
9314,,,,A,,,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,N,,1,,CHEMBL626970,BAO_0000218,,
9315,,,,A,,,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,N,,1,,CHEMBL626971,BAO_0000218,,
9316,,,Plasma,A,,,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,N,,1,,CHEMBL626972,BAO_0000218,1969.0,
9317,,,Plasma,A,,,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,N,,1,,CHEMBL626973,BAO_0000218,1969.0,
9318,,,Plasma,A,,,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,N,,1,,CHEMBL626974,BAO_0000218,1969.0,
9319,,,Plasma,A,,,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,N,,1,,CHEMBL874592,BAO_0000218,1969.0,
9320,,,,A,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,N,,1,,CHEMBL626975,BAO_0000218,,
9321,,,,A,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,N,,1,,CHEMBL626976,BAO_0000218,,
9322,,,,A,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,N,,1,,CHEMBL626977,BAO_0000218,,
9323,,,,A,,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,N,,1,,CHEMBL626978,BAO_0000218,,
9324,,,,A,,,,PK study was carried to determine the relative absorption ranking in rat.,N,,1,,CHEMBL626979,BAO_0000218,,
9325,,In vivo,Plasma,A,,,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,N,,1,,CHEMBL626980,BAO_0000218,1969.0,
9326,,,Blood,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",N,,1,,CHEMBL626981,BAO_0000218,178.0,
9327,,,Blood,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",N,,1,,CHEMBL626982,BAO_0000218,178.0,
9328,,,Blood,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",N,,1,,CHEMBL626983,BAO_0000218,178.0,
9329,,,Blood,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",N,,1,,CHEMBL622522,BAO_0000218,178.0,
9330,,,Blood,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",N,,1,,CHEMBL622523,BAO_0000218,178.0,
9331,,,Blood,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",N,,1,,CHEMBL622524,BAO_0000218,178.0,
9332,,,Brain,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",N,,1,,CHEMBL622525,BAO_0000218,955.0,
9333,,,Brain,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",N,,1,,CHEMBL622526,BAO_0000218,955.0,
9334,,,Brain,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",N,,1,,CHEMBL619849,BAO_0000218,955.0,
9335,,,Brain,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",N,,1,,CHEMBL619850,BAO_0000218,955.0,
9336,,,Brain,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",N,,1,,CHEMBL623864,BAO_0000218,955.0,
9337,,,Brain,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",N,,1,,CHEMBL623865,BAO_0000218,955.0,
9338,,,Heart,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",N,,1,,CHEMBL623866,BAO_0000218,948.0,
9339,,,Heart,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",N,,1,,CHEMBL623867,BAO_0000218,948.0,
9340,,,Heart,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",N,,1,,CHEMBL877615,BAO_0000218,948.0,
9341,,,Heart,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",N,,1,,CHEMBL623868,BAO_0000218,948.0,
9342,,,Heart,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",N,,1,,CHEMBL623869,BAO_0000218,948.0,
9343,,,Heart,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",N,,1,,CHEMBL623870,BAO_0000218,948.0,
9344,,,Lung,A,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,N,,1,,CHEMBL623871,BAO_0000218,2048.0,
9345,,,Lung,A,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,1,,CHEMBL623872,BAO_0000218,2048.0,
9346,,,Lung,A,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,1,,CHEMBL622129,BAO_0000218,2048.0,
9347,,,Lung,A,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,1,,CHEMBL622130,BAO_0000218,2048.0,
9348,,,Lung,A,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,1,,CHEMBL622131,BAO_0000218,2048.0,
9349,,,Lung,A,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,1,,CHEMBL622132,BAO_0000218,2048.0,
9350,,,Lung,A,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,1,,CHEMBL622133,BAO_0000218,2048.0,
9351,,,Lung,A,,,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,1,,CHEMBL622134,BAO_0000218,2048.0,
9352,,,Lung,A,,,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,1,,CHEMBL622135,BAO_0000218,2048.0,
9353,,,Lung,A,,,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,1,,CHEMBL622136,BAO_0000218,2048.0,
9354,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,1,,CHEMBL622137,BAO_0000218,2385.0,
9355,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,1,,CHEMBL622138,BAO_0000218,2385.0,
9356,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,1,,CHEMBL623017,BAO_0000218,2385.0,
9357,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,1,,CHEMBL623018,BAO_0000218,2385.0,
9358,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,1,,CHEMBL623019,BAO_0000218,2385.0,
9359,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,1,,CHEMBL623020,BAO_0000218,2385.0,
9360,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,N,,1,,CHEMBL623021,BAO_0000218,2385.0,
9361,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,N,,1,,CHEMBL623022,BAO_0000218,2385.0,
9362,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,1,,CHEMBL623023,BAO_0000218,2385.0,
9363,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,1,,CHEMBL623024,BAO_0000218,2385.0,
9364,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,1,,CHEMBL623025,BAO_0000218,2385.0,
9365,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,1,,CHEMBL620545,BAO_0000218,2385.0,
9366,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,1,,CHEMBL620546,BAO_0000218,2385.0,
9367,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,1,,CHEMBL620547,BAO_0000218,2385.0,
9368,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,1,,CHEMBL620548,BAO_0000218,2385.0,
9369,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,1,,CHEMBL620549,BAO_0000218,2385.0,
9370,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,1,,CHEMBL620550,BAO_0000218,2385.0,
9371,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,N,,1,,CHEMBL620551,BAO_0000218,2385.0,
9372,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,1,,CHEMBL620552,BAO_0000218,2385.0,
9373,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,1,,CHEMBL620553,BAO_0000218,2385.0,
9374,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,1,,CHEMBL620554,BAO_0000218,2385.0,
9375,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,1,,CHEMBL875845,BAO_0000218,2385.0,
9376,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,1,,CHEMBL620555,BAO_0000218,2385.0,
9377,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,1,,CHEMBL620556,BAO_0000218,2385.0,
9378,,,Muscle tissue,A,,,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,1,,CHEMBL620557,BAO_0000218,2385.0,
9379,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,1,,CHEMBL620558,BAO_0000218,,
9380,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,1,,CHEMBL620559,BAO_0000218,,
9381,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,1,,CHEMBL622939,BAO_0000218,,
9382,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,1,,CHEMBL622940,BAO_0000218,,
9383,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,1,,CHEMBL622941,BAO_0000218,,
9384,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,1,,CHEMBL622942,BAO_0000218,,
9385,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,1,,CHEMBL622943,BAO_0000218,,
9386,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,1,,CHEMBL622944,BAO_0000218,,
9387,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,1,,CHEMBL622945,BAO_0000218,,
9388,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,1,,CHEMBL622946,BAO_0000218,,
9389,,,,A,,,,Compound was evaluated for terminal half life in rat,N,,1,,CHEMBL622947,BAO_0000218,,
9390,,In vivo,Plasma,A,,,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,N,,1,,CHEMBL622948,BAO_0000218,1969.0,
9391,,In vivo,Plasma,A,,,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,N,,1,,CHEMBL622949,BAO_0000218,1969.0,
9392,,,,A,,,,Compound was tested for its half life in rat,N,,1,,CHEMBL622950,BAO_0000218,,
9393,,In vivo,Plasma,A,,,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,U,,1,,CHEMBL622951,BAO_0000218,1969.0,
9394,,,Plasma,A,,,,Compound was tested for its plasma half life in Sprague Dawley rats,U,,1,,CHEMBL622952,BAO_0000366,1969.0,
9395,,,Plasma,A,,,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,U,,1,,CHEMBL622953,BAO_0000366,1969.0,
9396,,,Plasma,A,,,,Compound was tested for plasma half-life period in rat,N,,1,,CHEMBL873818,BAO_0000218,1969.0,
9397,,In vivo,,A,,,,Elimination half life after i.v. administration of compound in rats,N,,1,,CHEMBL622954,BAO_0000218,,
9398,,In vivo,,A,,,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,N,,1,,CHEMBL622955,BAO_0000218,,
9399,,In vivo,,A,,,,Elimination half-life after IV dosing at 1 mg/kg in rat,N,,1,,CHEMBL875229,BAO_0000218,,
9400,,In vivo,,A,,,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,N,,1,,CHEMBL622956,BAO_0000218,,
9401,,In vivo,,A,,,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,N,,1,,CHEMBL622957,BAO_0000218,,
9402,,In vivo,Brain,A,,,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,N,,1,,CHEMBL622958,BAO_0000218,955.0,
9403,,In vivo,Plasma,A,,,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,N,,1,,CHEMBL622959,BAO_0000218,1969.0,
9404,,In vivo,Brain,A,,,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,N,,1,,CHEMBL622960,BAO_0000218,955.0,
9405,,In vivo,Plasma,A,,,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,N,,1,,CHEMBL622961,BAO_0000218,1969.0,
9406,,In vivo,,A,,,,Evaluated for the half life in rat (in vivo),N,,1,,CHEMBL622962,BAO_0000218,,
9407,,,,A,,,,Hafl life in rat,N,,1,,CHEMBL622963,BAO_0000218,,
9408,,,,A,,,,Hafl life rat,N,,1,,CHEMBL622964,BAO_0000218,,
9409,,,,A,,,,Hafl life rat,N,,1,,CHEMBL622965,BAO_0000218,,
9410,,,,A,,,,Hafl life rat; Not determined,N,,1,,CHEMBL622966,BAO_0000218,,
9411,,,,A,,,,Hafl life rat; Not determined,N,,1,,CHEMBL622967,BAO_0000218,,
9412,,In vivo,Kidney,A,,,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,1,,CHEMBL622968,BAO_0000218,2113.0,
9413,,In vivo,Liver,A,,,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,1,,CHEMBL622969,BAO_0000218,2107.0,
9414,,In vivo,Lung,A,,,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,1,,CHEMBL875327,BAO_0000218,2048.0,
9415,,In vivo,,A,,,,Half life in rat after 1 mg/kg i.v. administration,N,,1,,CHEMBL628638,BAO_0000218,,
9416,,In vivo,,A,,,,Half life in rat after 2 mg/kg peroral administration,N,,1,,CHEMBL628639,BAO_0000218,,
9417,,In vivo,,A,,,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,1,,CHEMBL625840,BAO_0000218,,
9418,,In vivo,,A,,,,Half life of 10 mg/kg oral dose determined in rats,N,,1,,CHEMBL625841,BAO_0000218,,
9419,,In vivo,,A,,,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL625842,BAO_0000218,,
9420,,In vivo,,A,,,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL625843,BAO_0000218,,
9421,,In vivo,,A,,,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL625844,BAO_0000218,,
9422,,In vivo,,A,,,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL873822,BAO_0000218,,
9423,,In vivo,,A,,,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL625845,BAO_0000218,,
9424,,In vivo,,A,,,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL627059,BAO_0000218,,
9425,,In vivo,,A,,,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL627060,BAO_0000218,,
9426,,In vivo,,A,,,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL627061,BAO_0000218,,
9427,,In vivo,,A,,,,Half life of compound at 5 mg/kg after po administration was determined in rat,N,,1,,CHEMBL627709,BAO_0000218,,
9428,,In vivo,,A,,,,Half life of compound determined after intravenous administration to rat,N,,1,,CHEMBL627710,BAO_0000218,,
9429,,,,A,,,,Half life of compound was determined in rat,N,,1,,CHEMBL627711,BAO_0000218,,
9430,,In vivo,Plasma,A,,,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,N,,1,,CHEMBL627712,BAO_0000218,1969.0,
9431,,In vivo,,A,,,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,,1,,CHEMBL627713,BAO_0000218,,
9432,,In vivo,,A,,,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,,1,,CHEMBL627714,BAO_0000218,,
9433,,In vivo,,A,,,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,U,,1,,CHEMBL627889,BAO_0000218,,
9434,,In vivo,,A,,,,Half life determined in rat by intravenous administration,U,,1,,CHEMBL627890,BAO_0000218,,
9435,,In vivo,,A,,,,Half life determined in rats after iv administration,N,,1,,CHEMBL627891,BAO_0000218,,
9436,,In vivo,Plasma,A,,,,Half life in rat plasma after administration of 2 mg/kg iv,N,,1,,CHEMBL627892,BAO_0000218,1969.0,
9437,,In vivo,Plasma,A,,,,Half life in rat plasma after administration of 2 mg/kg iv,N,,1,,CHEMBL627893,BAO_0000218,1969.0,
9438,,,Plasma,A,,,,Half life in rat plasma was determined,N,,1,,CHEMBL627894,BAO_0000218,1969.0,
9439,,,Plasma,A,,,,Half life in rat plasma was determined; NA means not applicable,N,,1,,CHEMBL627895,BAO_0000218,1969.0,
9440,,,,A,,,,Half life in rat was tested,N,,1,,CHEMBL627896,BAO_0000218,,
9441,,,Plasma,A,,,,Half life measured in rat plasma,N,,1,,CHEMBL627897,BAO_0000218,1969.0,
9442,,,,A,,,,Half life recorded in rats,N,,1,,CHEMBL627898,BAO_0000218,,
9443,,,,A,,,,Half life was calculated,N,,1,,CHEMBL627899,BAO_0000218,,
9444,,,,A,,,,Half life was calculated in rat,N,,1,,CHEMBL873823,BAO_0000218,,
9445,,,,A,,,,Half life was determined,N,,1,,CHEMBL627900,BAO_0000218,,
9446,,In vivo,,A,,,,Half life after 10 mg/kg oral administration in rat,N,,1,,CHEMBL627901,BAO_0000218,,
9447,,In vivo,,A,,,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,N,,1,,CHEMBL627902,BAO_0000218,,
9448,,In vivo,,A,,,,Half life after administering orally a dose of 30 mg/kg,N,,1,,CHEMBL627903,BAO_0000218,,
9449,,,,A,,,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,N,,1,,CHEMBL627904,BAO_0000218,,
9450,,,,A,,,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,N,,1,,CHEMBL627905,BAO_0000218,,
9451,,,,A,,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,N,,1,,CHEMBL627906,BAO_0000218,,
9452,,,,A,,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,N,,1,,CHEMBL627907,BAO_0000218,,
9453,,,,A,,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,N,,1,,CHEMBL876783,BAO_0000218,,
9454,,,,A,,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,N,,1,,CHEMBL627908,BAO_0000218,,
9455,,,,A,,,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,N,,1,,CHEMBL627909,BAO_0000218,,
9456,,,,A,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,N,,1,,CHEMBL627910,BAO_0000218,,
9457,,,,A,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),N,,1,,CHEMBL627911,BAO_0000218,,
9458,,,,A,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),N,,1,,CHEMBL627912,BAO_0000218,,
9459,,,,A,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),N,,1,,CHEMBL627913,BAO_0000218,,
9460,,,,A,,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),N,,1,,CHEMBL627914,BAO_0000218,,
9461,,,,A,,,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,N,,1,,CHEMBL627915,BAO_0000218,,
9462,,,,A,,,,Area under the curve was evaluated after 20 uM/kg of peroral administration,N,,1,,CHEMBL627916,BAO_0000218,,
9463,,,,A,,,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,N,,1,,CHEMBL627917,BAO_0000218,,
9464,,,,A,,,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,N,,1,,CHEMBL627918,BAO_0000218,,
9465,,,,A,,,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,N,,1,,CHEMBL627919,BAO_0000218,,
9466,,,,A,,,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,N,,1,,CHEMBL627920,BAO_0000218,,
9467,,,,A,,,,Area under the curve was evaluated at an oral dose of 30 mg/kg,N,,1,,CHEMBL627921,BAO_0000218,,
9468,,,,A,,,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,,1,,CHEMBL627922,BAO_0000218,,
9469,,,,A,,,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,,1,,CHEMBL876784,BAO_0000218,,
9470,,,,A,,,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,,1,,CHEMBL627923,BAO_0000218,,
9471,,,,A,,,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,,1,,CHEMBL626208,BAO_0000218,,
9472,,,,A,,,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,,1,,CHEMBL626209,BAO_0000218,,
9473,,,,A,,,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,,1,,CHEMBL626210,BAO_0000218,,
9474,,,Plasma,A,,,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,N,,1,,CHEMBL627994,BAO_0000218,1969.0,
9475,,,,A,,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,N,,1,,CHEMBL627995,BAO_0000218,,
9476,,,,A,,,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,N,,1,,CHEMBL627996,BAO_0000218,,
9477,,,,A,,,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,N,,1,,CHEMBL627997,BAO_0000218,,
9478,,,,A,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,N,,1,,CHEMBL627998,BAO_0000218,,
9479,,,,A,,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,N,,1,,CHEMBL628640,BAO_0000218,,
9480,,,,A,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,N,,1,,CHEMBL628641,BAO_0000218,,
9481,,,,A,,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,N,,1,,CHEMBL628642,BAO_0000218,,
9482,,,,A,,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),N,,1,,CHEMBL628643,BAO_0000218,,
9483,,,,A,,,,Compound was tested for area under curve in rat,N,,1,,CHEMBL628644,BAO_0000218,,
9484,,,,A,,,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,N,,1,,CHEMBL628645,BAO_0000218,,
9485,,,,A,,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,N,,1,,CHEMBL628646,BAO_0000218,,
9486,,,,A,,,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),N,,1,,CHEMBL628647,BAO_0000218,,
9487,,,,A,,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,N,,1,,CHEMBL628648,BAO_0000218,,
9488,,,,A,,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,N,,1,,CHEMBL625358,BAO_0000218,,
9489,,,,A,,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,N,,1,,CHEMBL625359,BAO_0000218,,
9490,,,,A,,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,N,,1,,CHEMBL625360,BAO_0000218,,
9491,,,,A,,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),N,,1,,CHEMBL625361,BAO_0000218,,
9492,,,,A,,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),N,,1,,CHEMBL625362,BAO_0000218,,
9493,,,,A,,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),N,,1,,CHEMBL625363,BAO_0000218,,
9494,,,,A,,,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,N,,1,,CHEMBL625364,BAO_0000218,,
9495,,,,A,,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL625365,BAO_0000218,,
9496,,,,A,,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL625366,BAO_0000218,,
9497,,,,A,,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL625367,BAO_0000218,,
9498,,,Kidney,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",N,,1,,CHEMBL625368,BAO_0000218,2113.0,
9499,,,Kidney,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",N,,1,,CHEMBL625369,BAO_0000218,2113.0,
9500,,,Kidney,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",N,,1,,CHEMBL625370,BAO_0000218,2113.0,
9501,,,Kidney,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",N,,1,,CHEMBL625371,BAO_0000218,2113.0,
9502,,,Kidney,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",N,,1,,CHEMBL625372,BAO_0000218,2113.0,
9503,,,Kidney,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",N,,1,,CHEMBL625373,BAO_0000218,2113.0,
9504,,,Liver,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",N,,1,,CHEMBL625374,BAO_0000218,2107.0,
9505,,,Liver,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",N,,1,,CHEMBL877593,BAO_0000218,2107.0,
9506,,,Liver,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",N,,1,,CHEMBL625375,BAO_0000218,2107.0,
9507,,,Liver,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",N,,1,,CHEMBL625376,BAO_0000218,2107.0,
9508,,,Liver,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",N,,1,,CHEMBL621973,BAO_0000218,2107.0,
9509,,,Liver,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",N,,1,,CHEMBL621974,BAO_0000218,2107.0,
9510,,,Lung,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",N,,1,,CHEMBL621975,BAO_0000218,2048.0,
9511,,,Lung,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",N,,1,,CHEMBL622166,BAO_0000218,2048.0,
9512,,,Lung,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",N,,1,,CHEMBL622167,BAO_0000218,2048.0,
9513,,,Lung,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",N,,1,,CHEMBL622168,BAO_0000218,2048.0,
9514,,,Lung,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",N,,1,,CHEMBL622169,BAO_0000218,2048.0,
9515,,,Lung,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",N,,1,,CHEMBL622170,BAO_0000218,2048.0,
9516,,,Thyroid gland,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",N,,1,,CHEMBL622171,BAO_0000218,2046.0,
9517,,,Thyroid gland,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",N,,1,,CHEMBL622172,BAO_0000218,2046.0,
9518,,,Thyroid gland,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",N,,1,,CHEMBL622173,BAO_0000218,2046.0,
9519,,,Thyroid gland,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",N,,1,,CHEMBL622174,BAO_0000218,2046.0,
9520,,,Thyroid gland,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",N,,1,,CHEMBL622175,BAO_0000218,2046.0,
9521,,,Thyroid gland,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",N,,1,,CHEMBL622176,BAO_0000218,2046.0,
9522,,,Thyroid gland,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",N,,1,,CHEMBL622177,BAO_0000218,2046.0,
9523,,,Thyroid gland,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",N,,1,,CHEMBL622178,BAO_0000218,2046.0,
9524,,,Thyroid gland,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",N,,1,,CHEMBL622179,BAO_0000218,2046.0,
9525,,,Thyroid gland,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",N,,1,,CHEMBL622180,BAO_0000218,2046.0,
9526,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,1,,CHEMBL622181,BAO_0000218,,
9527,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,1,,CHEMBL622182,BAO_0000218,,
9528,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,1,,CHEMBL622183,BAO_0000218,,
9529,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,1,,CHEMBL622184,BAO_0000218,,
9530,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,1,,CHEMBL622185,BAO_0000218,,
9531,,,,A,,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,1,,CHEMBL622186,BAO_0000218,,
9532,,,,A,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,1,,CHEMBL622187,BAO_0000218,,
9533,,,,A,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,N,,1,,CHEMBL625002,BAO_0000218,,
9534,,,,A,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,N,,1,,CHEMBL622090,BAO_0000218,,
9535,,,,A,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,1,,CHEMBL622091,BAO_0000218,,
9536,,,,A,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,1,,CHEMBL622092,BAO_0000218,,
9537,,,,A,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,1,,CHEMBL622093,BAO_0000218,,
9538,,,,A,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,1,,CHEMBL622094,BAO_0000218,,
9539,,,,A,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,1,,CHEMBL622095,BAO_0000218,,
9540,,,,A,,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,1,,CHEMBL622264,BAO_0000218,,
9541,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,1,,CHEMBL622265,BAO_0000218,2106.0,
9542,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,1,,CHEMBL622266,BAO_0000218,2106.0,
9543,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,1,,CHEMBL622267,BAO_0000218,2106.0,
9544,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,1,,CHEMBL622268,BAO_0000218,2106.0,
9545,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,1,,CHEMBL622269,BAO_0000218,2106.0,
9546,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,1,,CHEMBL625071,BAO_0000218,2106.0,
9547,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,1,,CHEMBL621621,BAO_0000218,2106.0,
9548,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,1,,CHEMBL621622,BAO_0000218,2106.0,
9549,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,1,,CHEMBL621623,BAO_0000218,2106.0,
9550,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,1,,CHEMBL621624,BAO_0000218,2106.0,
9551,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,1,,CHEMBL621625,BAO_0000218,2106.0,
9552,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,1,,CHEMBL621626,BAO_0000218,2106.0,
9553,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,1,,CHEMBL621627,BAO_0000218,2106.0,
9554,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,1,,CHEMBL621628,BAO_0000218,2106.0,
9555,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,1,,CHEMBL875328,BAO_0000218,2106.0,
9556,,,Spleen,A,,,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,1,,CHEMBL621629,BAO_0000218,2106.0,
9557,,,Spleen,A,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,1,,CHEMBL621630,BAO_0000218,2106.0,
9558,,,Spleen,A,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,1,,CHEMBL621631,BAO_0000218,2106.0,
9559,,,Spleen,A,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,1,,CHEMBL621632,BAO_0000218,2106.0,
9560,,,Spleen,A,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,1,,CHEMBL621633,BAO_0000218,2106.0,
9561,,,Spleen,A,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,1,,CHEMBL621634,BAO_0000218,2106.0,
9562,,,Spleen,A,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,1,,CHEMBL621635,BAO_0000218,2106.0,
9563,,,Spleen,A,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,1,,CHEMBL621636,BAO_0000218,2106.0,
9564,,,Spleen,A,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,1,,CHEMBL621637,BAO_0000218,2106.0,
9565,,,Spleen,A,,,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,1,,CHEMBL621638,BAO_0000218,2106.0,
9566,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,1,,CHEMBL618883,BAO_0000218,,
9567,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,1,,CHEMBL618884,BAO_0000218,,
9568,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,1,,CHEMBL628627,BAO_0000218,,
9569,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,1,,CHEMBL628628,BAO_0000218,,
9570,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,1,,CHEMBL628629,BAO_0000218,,
9571,,In vivo,,A,,,,Half life after administering orally a dose of 3 mg/kg,N,,1,,CHEMBL628630,BAO_0000218,,
9572,,In vivo,,A,,,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,N,,1,,CHEMBL628631,BAO_0000218,,
9573,,In vivo,,A,,,,Half life after administering intravenously a dose of 1 mg/kg,N,,1,,CHEMBL628632,BAO_0000218,,
9574,,In vivo,,A,,,,Half life after oral dosing in rats,N,,1,,CHEMBL628633,BAO_0000218,,
9575,,In vivo,,A,,,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,N,,1,,CHEMBL628634,BAO_0000218,,
9576,,In vivo,,A,,,,Half life by intravenous administration of 3.4 mg/kg in rat,N,,1,,CHEMBL627789,BAO_0000218,,
9577,,,,A,,,,Half life in rat,N,,1,,CHEMBL627790,BAO_0000218,,
9578,,,,A,,,,Half life in rat,N,,1,,CHEMBL627791,BAO_0000218,,
9579,,,,A,,,,Half life in rat,N,,1,,CHEMBL627792,BAO_0000218,,
9580,,In vivo,,A,,,,Half life in rat after intravenous administration of the compound,N,,1,,CHEMBL627793,BAO_0000218,,
9581,,In vivo,Plasma,A,,,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,N,,1,,CHEMBL627794,BAO_0000218,1969.0,
9582,,In vivo,,A,,,,Half life in rat after po administration of the compound,N,,1,,CHEMBL627795,BAO_0000218,,
9583,,In vivo,,A,,,,Half life in rat after po administration of the compound; ND means Not determined,N,,1,,CHEMBL627796,BAO_0000218,,
9584,,In vivo,Plasma,A,,,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,N,,1,,CHEMBL875335,BAO_0000218,1969.0,
9585,,In vivo,Plasma,A,,,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,N,,1,,CHEMBL627797,BAO_0000218,1969.0,
9586,,In vivo,,A,,,,Half life in rat i.v.,N,,1,,CHEMBL627798,BAO_0000218,,
9587,,In vivo,,A,,,,Half life in rat i.v. at 2 mg/kg concentration,N,,1,,CHEMBL627799,BAO_0000218,,
9588,,,,A,,,,Half life in rats,N,,1,,CHEMBL627800,BAO_0000218,,
9589,,In vivo,,A,,,,Half life in rats after intravenous administration,N,,1,,CHEMBL627801,BAO_0000218,,
9590,,In vivo,,A,,,,Half life in rats at the dose of 1.0 mpk by i.v. administration,N,,1,,CHEMBL627802,BAO_0000218,,
9591,,,,A,,,,Half life in rat,N,,1,,CHEMBL627803,BAO_0000218,,
9592,,In vivo,,A,,,,Half life was evaluated after intravenous administration to rats,N,,1,,CHEMBL873820,BAO_0000218,,
9593,,,,A,,,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),N,,1,,CHEMBL627804,BAO_0000218,,
9594,,,,A,,,,Half life was evaluated in rat,N,,1,,CHEMBL627805,BAO_0000218,,
9595,,,,A,,,,Half life was evaluated in rat,N,,1,,CHEMBL627806,BAO_0000218,,
9596,,,,A,,,,Half life was evaluated in rat; Not tested,N,,1,,CHEMBL627107,BAO_0000218,,
9597,,In vivo,,A,,,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,N,,1,,CHEMBL627108,BAO_0000218,,
9598,,In vivo,,A,,,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,N,,1,,CHEMBL627109,BAO_0000218,,
9599,,In vivo,Blood,A,,,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,N,,1,,CHEMBL627110,BAO_0000218,178.0,
9600,,In vivo,,A,,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,U,,1,,CHEMBL627111,BAO_0000218,,
9601,,In vivo,,A,,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,U,,1,,CHEMBL627112,BAO_0000218,,
9602,,In vivo,,A,,,,Half life was measured in rat at dose of 30 mg/kg by iv administration,U,,1,,CHEMBL627113,BAO_0000218,,
9603,,In vivo,,A,,,,Half life was measured in rat at dose of 30 mg/kg by po administration,U,,1,,CHEMBL627114,BAO_0000218,,
9604,,,,A,,,,Half life (t1/2) was determined,N,,1,,CHEMBL627115,BAO_0000218,,
9605,,,,A,,,,Half life period at a dose of 10 uM/kg in rat was determined,N,,1,,CHEMBL627116,BAO_0000218,,
9606,,In vivo,,A,,,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,N,,1,,CHEMBL627117,BAO_0000218,,
9607,,,,A,,,,Half life period was determined,N,,1,,CHEMBL627118,BAO_0000218,,
9608,,In vivo,,A,,,,Half life period after intravenous administration at 20 mpk in rats,N,,1,,CHEMBL627119,BAO_0000218,,
9609,,In vivo,,A,,,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,N,,1,,CHEMBL627120,BAO_0000218,,
9610,,In vivo,,A,,,,Half life period after intravenous administration in rat,N,,1,,CHEMBL626922,BAO_0000218,,
9611,,In vivo,,A,,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,N,,1,,CHEMBL626923,BAO_0000218,,
9612,,In vivo,,A,,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,N,,1,,CHEMBL626924,BAO_0000218,,
9613,,,Plasma,A,,,,Half life period in 80% rat plasma at 37 degree Centigrade,N,,1,,CHEMBL626925,BAO_0000218,1969.0,
9614,,,,A,,,,Half life period in SD rats,N,,1,,CHEMBL626926,BAO_0000218,,
9615,,,Plasma,A,,,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),N,,1,,CHEMBL626927,BAO_0000218,1969.0,
9616,,,Plasma,A,,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),N,,1,,CHEMBL626928,BAO_0000218,1969.0,
9617,,,Plasma,A,,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,N,,1,,CHEMBL626929,BAO_0000218,1969.0,
9618,,,Plasma,A,,,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,N,,1,,CHEMBL626930,BAO_0000218,1969.0,
9619,,,,A,,,,Half life period in rat,N,,1,,CHEMBL626931,BAO_0000218,,
9620,,,,A,,,,Half life period in rat,N,,1,,CHEMBL626932,BAO_0000218,,
9621,,,,A,,,,Half life period in rat,N,,1,,CHEMBL626933,BAO_0000218,,
9622,,In vivo,,A,,,,Half life period in rat after oral administration at 10.5 mg/kg dose,N,,1,,CHEMBL873826,BAO_0000218,,
9623,,In vivo,,A,,,,Half life period in rat after oral administration at 11.2 mg/kg dose,N,,1,,CHEMBL626934,BAO_0000218,,
9624,,In vivo,,A,,,,Half life period in rat after oral administration at 13 mg/kg dose,N,,1,,CHEMBL626935,BAO_0000218,,
9625,,In vivo,,A,,,,Half life period in rat after oral administration at 9.7 mg/kg dose,N,,1,,CHEMBL626936,BAO_0000218,,
9626,,,,A,,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL626937,BAO_0000218,,
9627,,,,A,,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,N,,1,,CHEMBL625906,BAO_0000218,,
9628,,,,A,,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,N,,1,,CHEMBL625907,BAO_0000218,,
9629,,,,A,,,,PK study was carried to determine AUC (area under curve) value in rat,N,,1,,CHEMBL625908,BAO_0000218,,
9630,,,,A,,,,Pharmacokinetic parameter AUC after intravenous administration to rats,N,,1,,CHEMBL625909,BAO_0000218,,
9631,,,,A,,,,Pharmacokinetic parameter AUC after oral administration to rats,N,,1,,CHEMBL625910,BAO_0000218,,
9632,,,,A,,,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,N,,1,,CHEMBL625911,BAO_0000218,,
9633,,,,A,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,N,,1,,CHEMBL625912,BAO_0000218,,
9634,,,,A,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,N,,1,,CHEMBL626538,BAO_0000218,,
9635,,,,A,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,N,,1,,CHEMBL876794,BAO_0000218,,
9636,,,,A,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,N,,1,,CHEMBL626539,BAO_0000218,,
9637,,,,A,,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,N,,1,,CHEMBL626540,BAO_0000218,,
9638,,,,A,,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,N,,1,,CHEMBL626541,BAO_0000218,,
9639,,,,A,,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,N,,1,,CHEMBL626542,BAO_0000218,,
9640,,,,A,,,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,N,,1,,CHEMBL626543,BAO_0000218,,
9641,,,,A,,,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,N,,1,,CHEMBL626544,BAO_0000218,,
9642,,,,A,,,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,N,,1,,CHEMBL626545,BAO_0000218,,
9643,,,,A,,,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,N,,1,,CHEMBL626546,BAO_0000218,,
9644,,,,A,,,,Pharmacokinetic parameter area under curve was reported,N,,1,,CHEMBL626547,BAO_0000218,,
9645,,,,A,,,,Pharmacokinetic property (AUC) in rat,N,,1,,CHEMBL626548,BAO_0000218,,
9646,,,,A,,,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,N,,1,,CHEMBL626549,BAO_0000218,,
9647,,,,A,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,N,,1,,CHEMBL626550,BAO_0000218,,
9648,,,,A,,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,N,,1,,CHEMBL626551,BAO_0000218,,
9649,,,,A,,,,Pharmacokinetic property was determined,N,,1,,CHEMBL623777,BAO_0000218,,
9650,,,,A,,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,N,,1,,CHEMBL623778,BAO_0000218,,
9651,,,,A,,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,N,,1,,CHEMBL623779,BAO_0000218,,
9652,,,Plasma,A,,,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,N,,1,,CHEMBL623780,BAO_0000218,1969.0,
9653,,,Plasma,A,,,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,N,,1,,CHEMBL622015,BAO_0000218,1969.0,
9654,,,Plasma,A,,,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,N,,1,,CHEMBL622016,BAO_0000218,1969.0,
9655,,,,A,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",N,,1,,CHEMBL622017,BAO_0000218,,
9656,,,,A,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",N,,1,,CHEMBL622018,BAO_0000218,,
9657,,,,A,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",N,,1,,CHEMBL622019,BAO_0000218,,
9658,,,,A,,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",N,,1,,CHEMBL622020,BAO_0000218,,
9659,,,,A,,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,N,,1,,CHEMBL622021,BAO_0000218,,
9660,,,,A,,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,N,,1,,CHEMBL622022,BAO_0000218,,
9661,,,,A,,,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,N,,1,,CHEMBL622023,BAO_0000218,,
9662,,,,A,,,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,N,,1,,CHEMBL622024,BAO_0000218,,
9663,,,,A,,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),N,,1,,CHEMBL622693,BAO_0000218,,
9664,,,,A,,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),N,,1,,CHEMBL622694,BAO_0000218,,
9665,,,,A,,,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",N,,1,,CHEMBL622695,BAO_0000218,,
9666,,,,A,,,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",N,,1,,CHEMBL622696,BAO_0000218,,
9667,,,,A,,,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",N,,1,,CHEMBL622697,BAO_0000218,,
9668,,,,A,,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",N,,1,,CHEMBL622874,BAO_0000218,,
9669,,,,A,,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",N,,1,,CHEMBL622875,BAO_0000218,,
9670,,,,A,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,N,,1,,CHEMBL622876,BAO_0000218,,
9671,,,,A,,,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,N,,1,,CHEMBL622877,BAO_0000218,,
9672,,,,A,,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,N,,1,,CHEMBL622878,BAO_0000218,,
9673,,,Plasma,A,,,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,N,,1,,CHEMBL622879,BAO_0000218,1969.0,
9674,,,,A,,,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,N,,1,,CHEMBL877602,BAO_0000218,,
9675,,,,A,,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL622880,BAO_0000218,,
9676,,,,A,,,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL622881,BAO_0000218,,
9677,,,,A,,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL622882,BAO_0000218,,
9678,,,,A,,,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL622883,BAO_0000218,,
9679,,,Thyroid gland,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",N,,1,,CHEMBL622884,BAO_0000218,2046.0,
9680,,,Thyroid gland,A,,,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",N,,1,,CHEMBL622885,BAO_0000218,2046.0,
9681,,,,A,,,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,N,,1,,CHEMBL622886,BAO_0000218,,
9682,,,,A,,,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,N,,1,,CHEMBL622887,BAO_0000218,,
9683,,,Urine,A,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,N,,1,,CHEMBL622888,BAO_0000218,1088.0,
9684,,In vivo,Blood,A,,,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL622889,BAO_0000218,178.0,
9685,,In vivo,Blood,A,,,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL622890,BAO_0000218,178.0,
9686,,In vivo,Blood,A,,,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL622891,BAO_0000218,178.0,
9687,,In vivo,Blood,A,,,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL877603,BAO_0000218,178.0,
9688,,In vivo,Brain,A,,,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL622892,BAO_0000218,955.0,
9689,,In vivo,Brain,A,,,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL622893,BAO_0000218,955.0,
9690,,In vivo,Brain,A,,,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL622894,BAO_0000218,955.0,
9691,,In vivo,Brain,A,,,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL622895,BAO_0000218,955.0,
9692,,In vivo,Brain,A,,,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,N,,1,,CHEMBL622896,BAO_0000218,955.0,
9693,,In vivo,Heart,A,,,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL622897,BAO_0000218,948.0,
9694,,In vivo,Heart,A,,,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL622898,BAO_0000218,948.0,
9695,,In vivo,Heart,A,,,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL622899,BAO_0000218,948.0,
9696,,In vivo,Kidney,A,,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL622900,BAO_0000218,2113.0,
9697,,In vivo,Kidney,A,,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL624114,BAO_0000218,2113.0,
9698,,In vivo,Kidney,A,,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL624115,BAO_0000218,2113.0,
9699,,In vivo,Kidney,A,,,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL624116,BAO_0000218,2113.0,
9700,,In vivo,Liver,A,,,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL624117,BAO_0000218,2107.0,
9701,,In vivo,Liver,A,,,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL624118,BAO_0000218,2107.0,
9702,,In vivo,Liver,A,,,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL624119,BAO_0000218,2107.0,
9703,,In vivo,Liver,A,,,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL624120,BAO_0000218,2107.0,
9704,,In vivo,Lung,A,,,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL624121,BAO_0000218,2048.0,
9705,,In vivo,Lung,A,,,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL624122,BAO_0000218,2048.0,
9706,,In vivo,Lung,A,,,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL624123,BAO_0000218,2048.0,
9707,,In vivo,Lung,A,,,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL624124,BAO_0000218,2048.0,
9708,,In vivo,Muscle tissue,A,,,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL624125,BAO_0000218,2385.0,
9709,,In vivo,Muscle tissue,A,,,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL624126,BAO_0000218,2385.0,
9710,,In vivo,Muscle tissue,A,,,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL624127,BAO_0000218,2385.0,
9711,,In vivo,Muscle tissue,A,,,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL624128,BAO_0000218,2385.0,
9712,,In vivo,Zone of skin,A,,,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL624129,BAO_0000218,14.0,
9713,,In vivo,Zone of skin,A,,,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL624130,BAO_0000218,14.0,
9714,,In vivo,Zone of skin,A,,,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL622340,BAO_0000218,14.0,
9715,,In vivo,Zone of skin,A,,,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL622341,BAO_0000218,14.0,
9716,,In vivo,Intestine,A,,,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL622342,BAO_0000218,160.0,
9717,,In vivo,Intestine,A,,,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL622343,BAO_0000218,160.0,
9718,,In vivo,Intestine,A,,,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL622344,BAO_0000218,160.0,
9719,,In vivo,Intestine,A,,,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL622345,BAO_0000218,160.0,
9720,,In vivo,Spleen,A,,,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL622346,BAO_0000218,2106.0,
9721,,In vivo,Spleen,A,,,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL622347,BAO_0000218,2106.0,
9722,,In vivo,Spleen,A,,,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL622348,BAO_0000218,2106.0,
9723,,In vivo,Spleen,A,,,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL622349,BAO_0000218,2106.0,
9724,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,1,,CHEMBL622350,BAO_0000218,,
9725,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,1,,CHEMBL622351,BAO_0000218,,
9726,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,1,,CHEMBL622352,BAO_0000218,,
9727,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,1,,CHEMBL622353,BAO_0000218,,
9728,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,1,,CHEMBL622354,BAO_0000218,,
9729,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,1,,CHEMBL622355,BAO_0000218,,
9730,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,1,,CHEMBL622356,BAO_0000218,,
9731,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,1,,CHEMBL622357,BAO_0000218,,
9732,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,1,,CHEMBL622358,BAO_0000218,,
9733,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,1,,CHEMBL622359,BAO_0000218,,
9734,,,,A,,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,1,,CHEMBL874393,BAO_0000218,,
9735,,,,A,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,1,,CHEMBL622872,BAO_0000218,,
9736,,,,A,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,1,,CHEMBL622873,BAO_0000218,,
9737,,,,A,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,1,,CHEMBL623047,BAO_0000218,,
9738,,,,A,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,1,,CHEMBL623048,BAO_0000218,,
9739,,,,A,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,1,,CHEMBL623049,BAO_0000218,,
9740,,,,A,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,1,,CHEMBL623050,BAO_0000218,,
9741,,,,A,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,1,,CHEMBL623051,BAO_0000218,,
9742,,,,A,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,1,,CHEMBL623052,BAO_0000218,,
9743,,,,A,,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,1,,CHEMBL626343,BAO_0000218,,
9744,,,,A,,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,1,,CHEMBL626344,BAO_0000218,,
9745,,,,A,,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,1,,CHEMBL626345,BAO_0000218,,
9746,,,,A,,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,1,,CHEMBL626346,BAO_0000218,,
9747,,,,A,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,1,,CHEMBL626347,BAO_0000218,,
9748,,,,A,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,1,,CHEMBL626348,BAO_0000218,,
9749,,,,A,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,1,,CHEMBL626349,BAO_0000218,,
9750,,,,F,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,1,,CHEMBL626350,BAO_0000218,,
9751,,,,A,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,1,,CHEMBL626351,BAO_0000218,,
9752,,,,A,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,1,,CHEMBL627650,BAO_0000218,,
9753,,,,F,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,1,,CHEMBL627651,BAO_0000218,,
9754,,,,A,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,1,,CHEMBL627652,BAO_0000218,,
9755,,,,A,,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,1,,CHEMBL627653,BAO_0000218,,
9756,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,N,,1,,CHEMBL627654,BAO_0000218,,
9757,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,N,,1,,CHEMBL627835,BAO_0000218,,
9758,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,N,,1,,CHEMBL627836,BAO_0000218,,
9759,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,N,,1,,CHEMBL627837,BAO_0000218,,
9760,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,N,,1,,CHEMBL627838,BAO_0000218,,
9761,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,N,,1,,CHEMBL875338,BAO_0000218,,
9762,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,N,,1,,CHEMBL627839,BAO_0000218,,
9763,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,N,,1,,CHEMBL627840,BAO_0000218,,
9764,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,N,,1,,CHEMBL627841,BAO_0000218,,
9765,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,N,,1,,CHEMBL627842,BAO_0000218,,
9766,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,N,,1,,CHEMBL627843,BAO_0000218,,
9767,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,N,,1,,CHEMBL627844,BAO_0000218,,
9768,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,N,,1,,CHEMBL627845,BAO_0000218,,
9769,,In vivo,,A,,,,Half life period in rat by iv administration at a dose of 3 mg/kg,N,,1,,CHEMBL627846,BAO_0000218,,
9770,,,Plasma,A,,,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),N,,1,,CHEMBL627847,BAO_0000218,1969.0,
9771,,,Plasma,A,,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),N,,1,,CHEMBL873821,BAO_0000218,1969.0,
9772,,,Plasma,A,,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,N,,1,,CHEMBL626079,BAO_0000218,1969.0,
9773,,,Plasma,A,,,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,N,,1,,CHEMBL626080,BAO_0000218,1969.0,
9774,,,Plasma,A,,,,Half life period was evaluated in rat plasma,N,,1,,CHEMBL626081,BAO_0000218,1969.0,
9775,,,Plasma,A,,,,Half life period was evaluated in rat plasma; Not tested,N,,1,,CHEMBL875344,BAO_0000218,1969.0,
9776,,,,A,,,,Half life period was evaluated in rats,N,,1,,CHEMBL626082,BAO_0000218,,
9777,,In vivo,,A,,,,"Half life period was evaluated in rats, iv",N,,1,,CHEMBL626250,BAO_0000218,,
9778,,In vivo,,A,,,,Half life period after intravenous administration at 5 mg/kg in rat,N,,1,,CHEMBL626251,BAO_0000218,,
9779,,In vivo,,A,,,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,N,,1,,CHEMBL626252,BAO_0000218,,
9780,,In vivo,,A,,,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,N,,1,,CHEMBL626253,BAO_0000218,,
9781,,,Plasma,A,,,,Half life stability of compound was evaluated in rat plasma,N,,1,,CHEMBL626254,BAO_0000218,1969.0,
9782,,In vivo,,A,,,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,N,,1,,CHEMBL626255,BAO_0000218,,
9783,,In vivo,,A,,,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,N,,1,,CHEMBL626256,BAO_0000218,,
9784,,In vivo,,A,,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,N,,1,,CHEMBL626257,BAO_0000218,,
9785,,In vivo,,A,,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,N,,1,,CHEMBL626258,BAO_0000218,,
9786,,In vivo,,A,,,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,N,,1,,CHEMBL626259,BAO_0000218,,
9787,,In vivo,,A,,,,Half in rat i.v.,N,,1,,CHEMBL626260,BAO_0000218,,
9788,,In vivo,,A,,,,Half period in rat after intravenous administration,N,,1,,CHEMBL875345,BAO_0000218,,
9789,,In vivo,,A,,,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,N,,1,,CHEMBL626261,BAO_0000218,,
9790,,In vitro,Liver,A,,,,Half-life measured in in vitro Cathepsin B assay in rat liver,N,,1,,CHEMBL626262,BAO_0000218,2107.0,
9791,,,,A,,,,Half-life of compound was determined in rats,N,,1,,CHEMBL626263,BAO_0000218,,
9792,,In vivo,,A,,,,Half-life at 10 mg/kg in rat upon intravenous administration,N,,1,,CHEMBL625270,BAO_0000218,,
9793,,,,A,,,,Half-life determined in rat,N,,1,,CHEMBL625271,BAO_0000218,,
9794,,,,A,,,,Half-life determined in rat,N,,1,,CHEMBL625272,BAO_0000218,,
9795,,In vivo,Brain,A,,,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,N,,1,,CHEMBL625273,BAO_0000218,955.0,
9796,,,Plasma,A,,,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",N,,1,,CHEMBL625274,BAO_0000218,1969.0,
9797,,In vivo,,A,,,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,N,,1,,CHEMBL625275,BAO_0000218,,
9798,,In vivo,Plasma,A,,,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,N,,1,,CHEMBL625276,BAO_0000218,1969.0,
9799,,,Plasma,A,,,,Half-life in rat plasma,N,,1,,CHEMBL625277,BAO_0000218,1969.0,
9800,,,Plasma,A,,,,Half-life in rat plasma was determined,N,,1,,CHEMBL625278,BAO_0000218,1969.0,
9801,,,Plasma,A,,,,Half-life in rat plasma; Not tested,N,,1,,CHEMBL625279,BAO_0000218,1969.0,
9802,,,Serum,A,,,,Half-life in rat serum,N,,1,,CHEMBL625280,BAO_0000218,1977.0,
9803,,,Serum,A,,,,Half-life in rat serum; na is not available,N,,1,,CHEMBL876797,BAO_0000218,1977.0,
9804,,,,A,,,,Half-life was calculated in rat,N,,1,,CHEMBL625281,BAO_0000218,,
9805,,,Plasma,A,,,,Half-life was calculated in rat plasma,N,,1,,CHEMBL873827,BAO_0000218,1969.0,
9806,,,,A,,,,Half-life was determined,N,,1,,CHEMBL625282,BAO_0000218,,
9807,,,,A,,,,Half-life was determined,N,,1,,CHEMBL625283,BAO_0000218,,
9808,,In vivo,,A,,,,Half-life after administration of 20 mg/Kg oral dose in rat,N,,1,,CHEMBL625284,BAO_0000218,,
9809,,In vivo,,A,,,,Half-life after administration of 3.2 mg/kg intravenously in male rat,N,,1,,CHEMBL625285,BAO_0000218,,
9810,,In vivo,,A,,,,Half-life after intravenous administration in female rat,N,,1,,CHEMBL625286,BAO_0000218,,
9811,,In vivo,,A,,,,Half-life after intravenous administration in male rat,N,,1,,CHEMBL625287,BAO_0000218,,
9812,,In vivo,,A,,,,Half-life after intravenous dose in rat,N,,1,,CHEMBL625288,BAO_0000218,,
9813,,,Liver,A,,,,Half-life in a rat liver homogenate preparation,N,,1,,CHEMBL625289,BAO_0000218,2107.0,
9814,,,Plasma,A,,,,Half-life in plasma of rat,N,,1,,CHEMBL625290,BAO_0000218,1969.0,
9815,,,Plasma,A,,,,Half-life in plasma of rat at dose of 3-10 mgkg,N,,1,,CHEMBL876798,BAO_0000218,1969.0,
9816,,,,A,,,,Half-life in rat,N,,1,,CHEMBL625291,BAO_0000218,,
9817,,,,A,,,,Half-life in rat,N,,1,,CHEMBL625292,BAO_0000218,,
9818,,,,A,,,,Half-life in rat,N,,1,,CHEMBL625293,BAO_0000218,,
9819,,,,A,,,,Half-life in rat,N,,1,,CHEMBL622832,BAO_0000218,,
9820,,,,A,,,,Half-life in rat,N,,1,,CHEMBL622833,BAO_0000218,,
9821,,,,A,,,,Half-life in rat,N,,1,,CHEMBL622834,BAO_0000218,,
9822,,In vivo,,A,,,,Half-life in rat after oral administration at 10 mg/kg,N,,1,,CHEMBL622835,BAO_0000218,,
9823,,In vivo,,A,,,,Half-life in rat after po administration at a dose of 10 mg/kg,N,,1,,CHEMBL622836,BAO_0000218,,
9824,,In vivo,,A,,,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,N,,1,,CHEMBL622837,BAO_0000218,,
9825,,In vivo,,A,,,,Half-life in rat at 3 mg/kg dose administered intravenously,N,,1,,CHEMBL622838,BAO_0000218,,
9826,,,Brain,A,,,,Half-life in rat brain homogenate,N,,1,,CHEMBL622839,BAO_0000218,955.0,
9827,,,Plasma,A,,,,Half-life in rat plasma,N,,1,,CHEMBL622840,BAO_0000218,1969.0,
9828,,,,A,,,,Half-life in rats,N,,1,,CHEMBL622841,BAO_0000218,,
9829,,,,A,,,,Half-life in Dawley rats,N,,1,,CHEMBL622842,BAO_0000218,,
9830,,In vitro,Plasma,A,,,,Half-life in vitro in rat plasma,N,,1,,CHEMBL622843,BAO_0000218,1969.0,
9831,,In vitro,Plasma,A,,,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,N,,1,,CHEMBL622844,BAO_0000218,1969.0,
9832,,,,A,,,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",N,,1,,CHEMBL622845,BAO_0000218,,
9833,,,,A,,,,The area under the curve of compound was measured at the dose of 100 umol/kg,N,,1,,CHEMBL622846,BAO_0000218,,
9834,,,,A,,,,The area under the curve of compound was measured at the dose of 300 umol/kg,N,,1,,CHEMBL622847,BAO_0000218,,
9835,,,,A,,,,The area under the curve of compound was measured at the dose of 30 umol/kg,N,,1,,CHEMBL622848,BAO_0000218,,
9836,,In vivo,,A,,,,Bioavailability as oral AUC in rats,N,,1,,CHEMBL622849,BAO_0000218,,
9837,,,Plasma,A,,,,The plasma concentration versus time curve (AUC) was determined,N,,1,,CHEMBL622850,BAO_0000218,1969.0,
9838,,,,A,,,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,1,,CHEMBL876807,BAO_0000218,,
9839,,,,A,,,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,1,,CHEMBL622851,BAO_0000218,,
9840,,,,A,,,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,1,,CHEMBL622852,BAO_0000218,,
9841,,,,A,,,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,N,,1,,CHEMBL622853,BAO_0000218,,
9842,,,,A,,,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,N,,1,,CHEMBL622854,BAO_0000218,,
9843,,,,A,,,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,1,,CHEMBL622855,BAO_0000218,,
9844,,,Plasma,A,,,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",N,,1,,CHEMBL622856,BAO_0000218,1969.0,
9845,,,Plasma,A,,,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",N,,1,,CHEMBL622857,BAO_0000218,1969.0,
9846,,,Plasma,A,,,,AUC in rat after po administration at a dose of 10 mg/kg,N,,1,,CHEMBL622858,BAO_0000218,1969.0,
9847,,,Plasma,A,,,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,N,,1,,CHEMBL622859,BAO_0000218,1969.0,
9848,,,,A,,,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,N,,1,,CHEMBL622860,BAO_0000218,,
9849,,,,A,,,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,N,,1,,CHEMBL622861,BAO_0000218,,
9850,,,,A,,,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,N,,1,,CHEMBL622862,BAO_0000218,,
9851,,,,A,,,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,N,,1,,CHEMBL622863,BAO_0000218,,
9852,,,,A,,,,Area under curve value 6 hr after po administration in rat,N,,1,,CHEMBL623817,BAO_0000218,,
9853,,,,A,,,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,,1,,CHEMBL623818,BAO_0000218,,
9854,,,,A,,,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",N,,1,,CHEMBL623819,BAO_0000218,,
9855,,,,A,,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,,1,,CHEMBL623820,BAO_0000218,,
9856,,,,A,,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,N,,1,,CHEMBL623821,BAO_0000218,,
9857,,,Plasma,A,,,,AUC normalized for dose (AUCN) in rat,N,,1,,CHEMBL623822,BAO_0000218,1969.0,
9858,,,,A,,,,Area under curve in rat after p.o. administration,N,,1,,CHEMBL623823,BAO_0000218,,
9859,,,,A,,,,Area under curve in rat after p.o. administration,N,,1,,CHEMBL623824,BAO_0000218,,
9860,,,,A,,,,Area under curve in rat after p.o. administration; Not determined,N,,1,,CHEMBL623825,BAO_0000218,,
9861,,,,A,,,,Area under curve in rat after peroral administration,N,,1,,CHEMBL622070,BAO_0000218,,
9862,,,,A,,,,Area under curve (carotid artery) value of the compound,N,,1,,CHEMBL622071,BAO_0000218,,
9863,,,,A,,,,Bioavailability expressed as the area under curve of rat carotid artery,N,,1,,CHEMBL622072,BAO_0000218,,
9864,,,,A,,,,Area under curve in male SD rats was observed after intravenous administration in rat,N,,1,,CHEMBL622073,BAO_0000218,,
9865,,,,A,,,,Area under curve of the compound was determined,N,,1,,CHEMBL622074,BAO_0000218,,
9866,,,,A,,,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,N,,1,,CHEMBL622075,BAO_0000218,,
9867,,,Plasma,A,,,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,N,,1,,CHEMBL622076,BAO_0000218,1969.0,
9868,,,Plasma,A,,,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,N,,1,,CHEMBL622077,BAO_0000218,1969.0,
9869,,,,A,,,,Area under curve (portal vein) value of the compound,N,,1,,CHEMBL622078,BAO_0000218,,
9870,,,,A,,,,Bioavailability expressed as the area under curve of rat portal vein,N,,1,,CHEMBL622079,BAO_0000218,,
9871,,,Plasma,A,,,,Area Under plasma concentration time curve in rat upon peroral administration,N,,1,,CHEMBL622080,BAO_0000218,1969.0,
9872,,,,A,,,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,N,,1,,CHEMBL877612,BAO_0000218,,
9873,,,,A,,,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,N,,1,,CHEMBL622081,BAO_0000218,,
9874,,,,A,,,,Compound was evaluated for oral bioavailability in rats,N,,1,,CHEMBL622082,BAO_0000218,,
9875,,,,A,,,,Compound was evaluated for oral bioavailability in rats after iv administration,N,,1,,CHEMBL622083,BAO_0000218,,
9876,,,,A,,,,Compound was evaluated for oral bioavailability in rats; 30-80,N,,1,,CHEMBL622084,BAO_0000218,,
9877,,,,A,,,,Compound was evaluated for oral bioavailability in rats; 50-60,N,,1,,CHEMBL622085,BAO_0000218,,
9878,,,,A,,,,Compound was evaluated for oral bioavailability in rats; no data,N,,1,,CHEMBL622086,BAO_0000218,,
9879,,,,A,,,,Compound was evaluated for oral bioavailability in rats; peptide,N,,1,,CHEMBL622087,BAO_0000218,,
9880,,,Blood,A,,,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",N,,1,,CHEMBL622088,BAO_0000218,178.0,
9881,,,Blood,A,,,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",N,,1,,CHEMBL622089,BAO_0000218,178.0,
9882,,,Blood,A,,,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",N,,1,,CHEMBL623685,BAO_0000218,178.0,
9883,,,Blood,A,,,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",N,,1,,CHEMBL623686,BAO_0000218,178.0,
9884,,In vivo,Stomach,A,,,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL623687,BAO_0000218,945.0,
9885,,In vivo,Stomach,A,,,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL623688,BAO_0000218,945.0,
9886,,In vivo,Stomach,A,,,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL623689,BAO_0000218,945.0,
9887,,In vivo,Stomach,A,,,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL622485,BAO_0000218,945.0,
9888,,In vivo,Thyroid gland,A,,,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL622486,BAO_0000218,2046.0,
9889,,In vivo,Thyroid gland,A,,,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL877613,BAO_0000218,2046.0,
9890,,In vivo,Thyroid gland,A,,,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL622487,BAO_0000218,2046.0,
9891,,In vivo,Thyroid gland,A,,,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL622488,BAO_0000218,2046.0,
9892,,In vivo,Heart,A,,,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,1,,CHEMBL622489,BAO_0000218,948.0,
9893,,,Urine,A,,,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,N,,1,,CHEMBL622490,BAO_0000218,1088.0,
9894,,,Urine,A,,,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,N,,1,,CHEMBL622491,BAO_0000218,1088.0,
9895,,,Liver,A,,,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,N,,1,,CHEMBL622492,BAO_0000218,2107.0,
9896,,,Urine,A,,,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,N,,1,,CHEMBL622493,BAO_0000218,1088.0,
9897,,,Urine,A,,,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,N,,1,,CHEMBL622494,BAO_0000218,1088.0,
9898,,,Muscle tissue,A,,,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,1,,CHEMBL622495,BAO_0000218,2385.0,
9899,,,,A,,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,N,,1,,CHEMBL622496,BAO_0000218,,
9900,,,Urine,A,,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,N,,1,,CHEMBL622497,BAO_0000218,1088.0,
9901,,,,A,,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,N,,1,,CHEMBL622498,BAO_0000218,,
9902,,,Urine,A,,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,N,,1,,CHEMBL624918,BAO_0000218,1088.0,
9903,,,Urine,A,,,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,N,,1,,CHEMBL624919,BAO_0000218,1088.0,
9904,,In vivo,Blood,A,,,,Biodistribution of compound in rat blood after 5 min of administration,N,,1,,CHEMBL624920,BAO_0000218,178.0,
9905,,In vivo,Blood,A,,,,Biodistribution of compound in rat blood after 5 min of administration.,N,,1,,CHEMBL624921,BAO_0000218,178.0,
9906,,In vivo,Brain,A,,,,Biodistribution of compound in rat brain after 5 min of administration,N,,1,,CHEMBL624922,BAO_0000218,955.0,
9907,,In vivo,Heart,A,,,,Biodistribution of compound in rat heart after 5 min of administration,N,,1,,CHEMBL624923,BAO_0000218,948.0,
9908,,In vivo,Heart,A,,,,Biodistribution of compound in rat heart after 5 min of administration.,N,,1,,CHEMBL624924,BAO_0000218,948.0,
9909,,In vivo,Kidney,A,,,,Biodistribution of compound in rat kidney after 5 min of administration,N,,1,,CHEMBL624925,BAO_0000218,2113.0,
9910,,In vivo,Kidney,A,,,,Biodistribution of compound in rat kidney after 5 min of administration.,N,,1,,CHEMBL624926,BAO_0000218,2113.0,
9911,,In vivo,Liver,A,,,,Biodistribution of compound in rat liver after 5 min of administration,N,,1,,CHEMBL624927,BAO_0000218,2107.0,
9912,,In vivo,Liver,A,,,,Biodistribution of compound in rat liver after 5 min of administration.,N,,1,,CHEMBL874402,BAO_0000218,2107.0,
9913,,In vivo,Lung,A,,,,Biodistribution of compound in rat lung after 5 min of administration,N,,1,,CHEMBL624928,BAO_0000218,2048.0,
9914,,In vivo,Lung,A,,,,Biodistribution of compound in rat lung after 5 min of administration.,N,,1,,CHEMBL624929,BAO_0000218,2048.0,
9915,,In vivo,Muscle tissue,A,,,,Biodistribution of compound in rat muscle after 5 min of administration,N,,1,,CHEMBL624930,BAO_0000218,2385.0,
9916,,In vivo,Muscle tissue,A,,,,Biodistribution of compound in rat muscle after 5 min of administration.,N,,1,,CHEMBL624931,BAO_0000218,2385.0,
9917,,,Heart,A,,,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,1,,CHEMBL624932,BAO_0000218,948.0,
9918,,,Heart,A,,,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,1,,CHEMBL624933,BAO_0000218,948.0,
9919,,,Liver,A,,,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,1,,CHEMBL624934,BAO_0000218,2107.0,
9920,,,Liver,A,,,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,1,,CHEMBL624935,BAO_0000218,2107.0,
9921,,,,A,,,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,1,,CHEMBL624936,BAO_0000218,,
9922,,,,A,,,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,1,,CHEMBL624937,BAO_0000218,,
9923,,,Spleen,A,,,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,1,,CHEMBL624938,BAO_0000218,2106.0,
9924,,,Spleen,A,,,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,1,,CHEMBL624939,BAO_0000218,2106.0,
9925,,,,A,,,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,1,,CHEMBL624940,BAO_0000218,,
9926,,,,A,,,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,1,,CHEMBL874403,BAO_0000218,,
9927,,,,A,,,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,N,,1,,CHEMBL624941,BAO_0000218,,
9928,,,Urine,A,,,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,N,,1,,CHEMBL624942,BAO_0000218,1088.0,
9929,,,Urine,A,,,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,N,,1,,CHEMBL624943,BAO_0000218,1088.0,
9930,,In vivo,,A,,,,% Bioavailability after 1 day of the drug administration in rats,N,,1,,CHEMBL624944,BAO_0000218,,
9931,,In vivo,,A,,,,% Bioavailability after 4 day of the drug administration in rats,N,,1,,CHEMBL624945,BAO_0000218,,
9932,,In vivo,,A,,,,Absolute bioavailability was evaluated in rat,N,,1,,CHEMBL624946,BAO_0000218,,
9933,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,N,,1,,CHEMBL624947,BAO_0000218,,
9934,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,N,,1,,CHEMBL624948,BAO_0000218,,
9935,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,N,,1,,CHEMBL624949,BAO_0000218,,
9936,,,Kidney,A,,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,N,,1,,CHEMBL622025,BAO_0000218,2113.0,
9937,,,Kidney,A,,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,N,,1,,CHEMBL622026,BAO_0000218,2113.0,
9938,,,Kidney,A,,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,N,,1,,CHEMBL622027,BAO_0000218,2113.0,
9939,,,Kidney,A,,,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,N,,1,,CHEMBL622028,BAO_0000218,2113.0,
9940,,,Liver,A,,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,N,,1,,CHEMBL622029,BAO_0000218,2107.0,
9941,,,Liver,A,,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,N,,1,,CHEMBL622208,BAO_0000218,2107.0,
9942,,,Liver,A,,,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,N,,1,,CHEMBL622209,BAO_0000218,2107.0,
9943,,,Liver,A,,,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,N,,1,,CHEMBL622210,BAO_0000218,2107.0,
9944,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,N,,1,,CHEMBL622211,BAO_0000218,,
9945,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,N,,1,,CHEMBL622212,BAO_0000218,,
9946,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,N,,1,,CHEMBL622213,BAO_0000218,,
9947,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,N,,1,,CHEMBL874404,BAO_0000218,,
9948,,,Muscle tissue,A,,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,N,,1,,CHEMBL620452,BAO_0000218,2385.0,
9949,,,Muscle tissue,A,,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,N,,1,,CHEMBL620453,BAO_0000218,2385.0,
9950,,,Muscle tissue,A,,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,N,,1,,CHEMBL620454,BAO_0000218,2385.0,
9951,,,Muscle tissue,A,,,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,N,,1,,CHEMBL624067,BAO_0000218,2385.0,
9952,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,N,,1,,CHEMBL624068,BAO_0000218,,
9953,,,Female gonad,A,,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,N,,1,,CHEMBL624069,BAO_0000218,992.0,
9954,,,Female gonad,A,,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,N,,1,,CHEMBL624070,BAO_0000218,992.0,
9955,,,Female gonad,A,,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,N,,1,,CHEMBL624071,BAO_0000218,992.0,
9956,,,Uterus,A,,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,N,,1,,CHEMBL624072,BAO_0000218,995.0,
9957,,,Uterus,A,,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,N,,1,,CHEMBL624073,BAO_0000218,995.0,
9958,,,Uterus,A,,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,N,,1,,CHEMBL624788,BAO_0000218,995.0,
9959,,,Uterus,A,,,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,N,,1,,CHEMBL624789,BAO_0000218,995.0,
9960,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,N,,1,,CHEMBL624790,BAO_0000218,,
9961,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,N,,1,,CHEMBL624791,BAO_0000218,,
9962,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,N,,1,,CHEMBL624792,BAO_0000218,,
9963,,,,A,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,N,,1,,CHEMBL624793,BAO_0000218,,
9964,,,Muscle tissue,A,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,N,,1,,CHEMBL877491,BAO_0000218,2385.0,
9965,,,Muscle tissue,A,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,N,,1,,CHEMBL624957,BAO_0000218,2385.0,
9966,,,Muscle tissue,A,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,N,,1,,CHEMBL624958,BAO_0000218,2385.0,
9967,,,Muscle tissue,A,,,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,N,,1,,CHEMBL624959,BAO_0000218,2385.0,
9968,,,,A,,,,Dissociation constant was determined,N,,1,,CHEMBL624960,BAO_0000218,,
9969,,,,A,,,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",N,,1,,CHEMBL624961,BAO_0000218,,
9970,,,,A,,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL624962,BAO_0000218,,
9971,,,,A,,,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL624963,BAO_0000218,,
9972,,,,A,,,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,N,,1,,CHEMBL624964,BAO_0000218,,
9973,,,,A,,,,LogP value was evaluated in the in situ rat gut perfusion assay,N,,1,,CHEMBL624965,BAO_0000218,,
9974,,In vivo,,A,,,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,N,,1,,CHEMBL624966,BAO_0000218,,
9975,,In vivo,,A,,,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,N,,1,,CHEMBL624967,BAO_0000218,,
9976,,In vivo,,A,,,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,N,,1,,CHEMBL624968,BAO_0000218,,
9977,,,,A,,,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,N,,1,,CHEMBL624969,BAO_0000218,,
9978,,,,F,,,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,N,,1,,CHEMBL624970,BAO_0000218,,
9979,,,,A,,,,Half-life was evaluated after 10 uM/kg of intra arterial administration,N,,1,,CHEMBL624971,BAO_0000218,,
9980,,In vivo,,A,,,,Half-life was evaluated after 20 uM/kg of peroral administration,N,,1,,CHEMBL624972,BAO_0000218,,
9981,,In vivo,,A,,,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,N,,1,,CHEMBL624973,BAO_0000218,,
9982,,,Plasma,A,,,,Half-life was evaluated in plasma of rat,N,,1,,CHEMBL624974,BAO_0000218,1969.0,
9983,,In vivo,,A,,,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,N,,1,,CHEMBL624975,BAO_0000218,,
9984,,In vivo,,A,,,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,N,,1,,CHEMBL877492,BAO_0000218,,
9985,,In vivo,,A,,,,Half-life was measured in rat after an iv dose of 1 mg/kg,N,,1,,CHEMBL624976,BAO_0000218,,
9986,,In vivo,,A,,,,Half-life period of compound in rats after peroral administration,N,,1,,CHEMBL624977,BAO_0000218,,
9987,,,Plasma,A,,,,Half-life period of compound was measured in rat plasma.,N,,1,,CHEMBL626848,BAO_0000218,1969.0,
9988,,,Plasma,A,,,,Half-life period of compound was measured in rat plasma; ND is not determined,N,,1,,CHEMBL626849,BAO_0000218,1969.0,
9989,,,Plasma,A,,,,Half-life period of compound was measured in rat plasma; not determined,N,,1,,CHEMBL626850,BAO_0000218,1969.0,
9990,,In vivo,,A,,,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,N,,1,,CHEMBL626851,BAO_0000218,,
9991,,In vivo,,A,,,,Half-life period in rat by iv administration,N,,1,,CHEMBL626852,BAO_0000218,,
9992,,In vivo,,A,,,,Half-life period in rats following intravenous administration at 2 mg/kg,N,,1,,CHEMBL626853,BAO_0000218,,
9993,,In vivo,,A,,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,1,,CHEMBL626854,BAO_0000218,,
9994,,,,A,,,,Half-life period was determined for the compound in rat,N,,1,,CHEMBL627486,BAO_0000218,,
9995,,In vivo,,A,,,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",N,,1,,CHEMBL627487,BAO_0000218,,
9996,,In vivo,,A,,,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",N,,1,,CHEMBL627488,BAO_0000218,,
9997,,In vivo,,A,,,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,N,,1,,CHEMBL627489,BAO_0000218,,
9998,,In vivo,,A,,,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,N,,1,,CHEMBL627490,BAO_0000218,,
9999,,In vivo,,A,,,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),N,,1,,CHEMBL873829,BAO_0000218,,
10000,,In vivo,,A,,,,Half-life was determined in rat at a dose of 1 mpk i.v.,N,,1,,CHEMBL627655,BAO_0000218,,
10001,,In vivo,,A,,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,N,,1,,CHEMBL625994,BAO_0000218,,
10002,,In vivo,,A,,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,N,,1,,CHEMBL625995,BAO_0000218,,
10003,,,,A,,,,Half-life in rat,N,,1,,CHEMBL625996,BAO_0000218,,
10004,,In vitro,Plasma,A,,,,In vitro half life in rat plasma,N,,1,,CHEMBL625850,BAO_0000218,1969.0,
10005,,In vitro,Plasma,A,,,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",N,,1,,CHEMBL625851,BAO_0000218,1969.0,
10006,,In vitro,,A,,,,In vitro half life in rat,N,,1,,CHEMBL625852,BAO_0000218,,
10007,,In vivo,,A,,,,In vivo half life period after intravenous administration in rat,N,,1,,CHEMBL625853,BAO_0000218,,
10008,,In vivo,,A,,,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,N,,1,,CHEMBL625854,BAO_0000218,,
10009,,In vivo,,A,,,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,N,,1,,CHEMBL874450,BAO_0000218,,
10010,,In vivo,,A,,,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL625855,BAO_0000218,,
10011,,In vivo,,A,,,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL625856,BAO_0000218,,
10012,,In vivo,,A,,,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL625857,BAO_0000218,,
10013,,In vivo,,A,,,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL873831,BAO_0000218,,
10014,,In vivo,,A,,,,Longer half-life in rat (i.v.) at 0.5 mpk,N,,1,,CHEMBL625858,BAO_0000218,,
10015,,In vivo,,A,,,,Longer half-life in rat (p.o.) at 2.0 mpk,N,,1,,CHEMBL625859,BAO_0000218,,
10016,,,,A,,,,Pharmacokinetic property (half life) in rat,N,,1,,CHEMBL625860,BAO_0000218,,
10017,,In vivo,,A,,,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,N,,1,,CHEMBL625861,BAO_0000218,,
10018,,In vivo,,A,,,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,N,,1,,CHEMBL625862,BAO_0000218,,
10019,,In vivo,,A,,,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,N,,1,,CHEMBL625863,BAO_0000218,,
10020,,In vivo,,A,,,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,N,,1,,CHEMBL625864,BAO_0000218,,
10021,,In vivo,,A,,,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,N,,1,,CHEMBL625865,BAO_0000218,,
10022,,In vivo,,A,,,,Pharmacokinetic half time was determined intravenously in rats.,N,,1,,CHEMBL625866,BAO_0000218,,
10023,,In vivo,Plasma,A,,,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,N,,1,,CHEMBL625867,BAO_0000218,1969.0,
10024,,,Plasma,A,,,,Plasma half life of hydrolysis of the compound,N,,1,,CHEMBL625868,BAO_0000218,1969.0,
10025,,In vivo,Plasma,A,,,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,N,,1,,CHEMBL625869,BAO_0000218,1969.0,
10026,,,Plasma,A,,,,Plasma half life period was calculated in rat,N,,1,,CHEMBL874451,BAO_0000218,1969.0,
10027,,,Plasma,A,,,,Plasma half-life in Sprague-Dawley rats,N,,1,,CHEMBL625870,BAO_0000218,1969.0,
10028,,,Plasma,A,,,,Plasma half-life in Sprague-Dawley rats; Not determined,N,,1,,CHEMBL625871,BAO_0000218,1969.0,
10029,,,Plasma,A,,,,Plasma half-life in rats,N,,1,,CHEMBL625872,BAO_0000218,1969.0,
10030,,,Plasma,A,,,,Plasma half-life in rats; <MQL,N,,1,,CHEMBL625873,BAO_0000218,1969.0,
10031,,,Plasma,A,,,,Plasma half-life period (0-8 h) was determined,N,,1,,CHEMBL625874,BAO_0000218,1969.0,
10032,,,Plasma,A,,,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,N,,1,,CHEMBL625875,BAO_0000218,1969.0,
10033,,In vivo,Plasma,A,,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,N,,1,,CHEMBL625876,BAO_0000218,1969.0,
10034,,In vivo,Plasma,A,,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,N,,1,,CHEMBL631258,BAO_0000218,1969.0,
10035,,,Plasma,A,,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,N,,1,,CHEMBL631259,BAO_0000218,1969.0,
10036,,,Plasma,A,,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,N,,1,,CHEMBL631260,BAO_0000218,1969.0,
10037,,,Blood,A,,,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",N,,1,,CHEMBL631261,BAO_0000218,178.0,
10038,,,Blood,A,,,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",N,,1,,CHEMBL631262,BAO_0000218,178.0,
10039,,,Blood,A,,,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",N,,1,,CHEMBL631263,BAO_0000218,178.0,
10040,,,,A,,,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",N,,1,,CHEMBL631264,BAO_0000218,,
10041,,,,A,,,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",N,,1,,CHEMBL631265,BAO_0000218,,
10042,,,,A,,,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",N,,1,,CHEMBL631266,BAO_0000218,,
10043,,,,A,,,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",N,,1,,CHEMBL631267,BAO_0000218,,
10044,,,,A,,,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",N,,1,,CHEMBL631268,BAO_0000218,,
10045,,,,A,,,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",N,,1,,CHEMBL631269,BAO_0000218,,
10046,,,,A,,,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",N,,1,,CHEMBL631270,BAO_0000218,,
10047,,,Heart,A,,,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",N,,1,,CHEMBL631271,BAO_0000218,948.0,
10048,,,Heart,A,,,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",N,,1,,CHEMBL631272,BAO_0000218,948.0,
10049,,,Heart,A,,,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",N,,1,,CHEMBL631273,BAO_0000218,948.0,
10050,,,Heart,A,,,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",N,,1,,CHEMBL631274,BAO_0000218,948.0,
10051,,,Heart,A,,,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",N,,1,,CHEMBL631275,BAO_0000218,948.0,
10052,,,Heart,A,,,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",N,,1,,CHEMBL626984,BAO_0000218,948.0,
10053,,,Heart,A,,,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",N,,1,,CHEMBL626985,BAO_0000218,948.0,
10054,,,Liver,A,,,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",N,,1,,CHEMBL626986,BAO_0000218,2107.0,
10055,,,Liver,A,,,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",N,,1,,CHEMBL626987,BAO_0000218,2107.0,
10056,,,Liver,A,,,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",N,,1,,CHEMBL626988,BAO_0000218,2107.0,
10057,,,Liver,A,,,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",N,,1,,CHEMBL626989,BAO_0000218,2107.0,
10058,,,Liver,A,,,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",N,,1,,CHEMBL626990,BAO_0000218,2107.0,
10059,,,Liver,A,,,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",N,,1,,CHEMBL626991,BAO_0000218,2107.0,
10060,,,Liver,A,,,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",N,,1,,CHEMBL626992,BAO_0000218,2107.0,
10061,,,Lung,A,,,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",N,,1,,CHEMBL626993,BAO_0000218,2048.0,
10062,,,Lung,A,,,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",N,,1,,CHEMBL874593,BAO_0000218,2048.0,
10063,,,Lung,A,,,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",N,,1,,CHEMBL626994,BAO_0000218,2048.0,
10064,,,Lung,A,,,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",N,,1,,CHEMBL626995,BAO_0000218,2048.0,
10065,,,Lung,A,,,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",N,,1,,CHEMBL626190,BAO_0000218,2048.0,
10066,,,Lung,A,,,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",N,,1,,CHEMBL626191,BAO_0000218,2048.0,
10067,,,Lung,A,,,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",N,,1,,CHEMBL626364,BAO_0000218,2048.0,
10068,,,Thyroid gland,A,,,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",N,,1,,CHEMBL626365,BAO_0000218,2046.0,
10069,,,Thyroid gland,A,,,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",N,,1,,CHEMBL626366,BAO_0000218,2046.0,
10070,,,Thyroid gland,A,,,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",N,,1,,CHEMBL626367,BAO_0000218,2046.0,
10071,,,Thyroid gland,A,,,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",N,,1,,CHEMBL626368,BAO_0000218,2046.0,
10072,,,Thyroid gland,A,,,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",N,,1,,CHEMBL626369,BAO_0000218,2046.0,
10073,,,Thyroid gland,A,,,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",N,,1,,CHEMBL626370,BAO_0000218,2046.0,
10074,,In vivo,,A,,,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",N,,1,,CHEMBL626371,BAO_0000218,,
10075,,In vivo,,A,,,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",N,,1,,CHEMBL626372,BAO_0000218,,
10076,,In vivo,,A,,,,Bioavailability after a dose of 10 mg/kg p.o.,N,,1,,CHEMBL626373,BAO_0000218,,
10077,,In vivo,,A,,,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,N,,1,,CHEMBL626374,BAO_0000218,,
10078,,In vivo,,A,,,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,N,,1,,CHEMBL626375,BAO_0000218,,
10079,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),N,,1,,CHEMBL626376,BAO_0000218,,
10080,,In vivo,,A,,,,Bioavailability in rat po was determined,N,,1,,CHEMBL626377,BAO_0000218,,
10081,,In vivo,,A,,,,Bioavailability of compound at 10 mg/kg in rat after oral administration,N,,1,,CHEMBL626378,BAO_0000218,,
10082,,In vivo,,A,,,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,N,,1,,CHEMBL626379,BAO_0000218,,
10083,,In vivo,,A,,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),N,,1,,CHEMBL626380,BAO_0000218,,
10084,,In vivo,,A,,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),N,,1,,CHEMBL626381,BAO_0000218,,
10085,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL626382,BAO_0000218,,
10086,,In vivo,,A,,,,Bioavailability in rat (Sprague-Dawley) (female),N,,1,,CHEMBL626383,BAO_0000218,,
10087,,In vivo,,A,,,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,N,,1,,CHEMBL874652,BAO_0000218,,
10088,,In vivo,,A,,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),N,,1,,CHEMBL626384,BAO_0000218,,
10089,,In vivo,,A,,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,N,,1,,CHEMBL626385,BAO_0000218,,
10090,,In vivo,,A,,,,Bioavailability in rat at an oral dose of 2 mg/kg,N,,1,,CHEMBL626386,BAO_0000218,,
10091,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL626387,BAO_0000218,,
10092,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL626388,BAO_0000218,,
10093,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL626389,BAO_0000218,,
10094,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL626390,BAO_0000218,,
10095,,In vivo,,A,,,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,N,,1,,CHEMBL626391,BAO_0000218,,
10096,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL626392,BAO_0000218,,
10097,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL626393,BAO_0000218,,
10098,,In vivo,,A,,,,Bioavailability was determined in rat,N,,1,,CHEMBL623026,BAO_0000218,,
10099,,In vivo,,A,,,,Bioavailability,N,,1,,CHEMBL623027,BAO_0000218,,
10100,,In vivo,,A,,,,Bioavailability,N,,1,,CHEMBL623028,BAO_0000218,,
10101,,In vivo,,A,,,,Bioavailability in rat after 1 day dosing,N,,1,,CHEMBL623029,BAO_0000218,,
10102,,In vivo,,A,,,,Bioavailability in rat after 4 day dosing,N,,1,,CHEMBL623030,BAO_0000218,,
10103,,In vivo,,A,,,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,N,,1,,CHEMBL623031,BAO_0000218,,
10104,,In vivo,,A,,,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,N,,1,,CHEMBL623032,BAO_0000218,,
10105,,In vivo,,A,,,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,N,,1,,CHEMBL623033,BAO_0000218,,
10106,,In vivo,,A,,,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,N,,1,,CHEMBL623034,BAO_0000218,,
10107,,In vivo,,A,,,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,N,,1,,CHEMBL623035,BAO_0000218,,
10108,,In vivo,,A,,,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,N,,1,,CHEMBL623036,BAO_0000218,,
10109,,In vivo,,A,,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),N,,1,,CHEMBL623037,BAO_0000218,,
10110,,In vivo,,A,,,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,N,,1,,CHEMBL623038,BAO_0000218,,
10111,,In vivo,Plasma,A,,,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,N,,1,,CHEMBL874385,BAO_0000218,1969.0,
10112,,In vivo,,A,,,,Bioavailability in rat (Fisher) (fasted),N,,1,,CHEMBL623039,BAO_0000218,,
10113,,In vivo,,A,,,,Bioavailability in monkey after po administration of 10 mg/kg dose,U,,1,,CHEMBL623040,BAO_0000218,,
10114,,In vivo,,A,,,,Oral bioavailability in monkey (dose 10 mg/kg),U,,1,,CHEMBL623041,BAO_0000218,,
10115,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL623741,BAO_0000218,,
10116,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL623742,BAO_0000218,,
10117,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL623743,BAO_0000218,,
10118,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL623744,BAO_0000218,,
10119,,In vivo,,A,,,,Bioavailability in rat (dose 2.0 mg/kg p.o.),N,,1,,CHEMBL623745,BAO_0000218,,
10120,,In vivo,,A,,,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),N,,1,,CHEMBL623746,BAO_0000218,,
10121,,In vivo,,A,,,,Oral bioavailability in rat (dose 5 mg/kg p.o.),N,,1,,CHEMBL623747,BAO_0000218,,
10122,,In vivo,,A,,,,Bioavailability in rat after po administration of 30 mg/kg dose,U,,1,,CHEMBL623748,BAO_0000218,,
10123,,In vivo,,A,,,,Bioavailability in rat after po administration of 30 mg/kg dose,U,,1,,CHEMBL623916,BAO_0000218,,
10124,,In vivo,,A,,,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,N,,1,,CHEMBL623917,BAO_0000218,,
10125,,In vivo,,A,,,,Bioavailability in rat (dose 2 mg/kg i.v.),N,,1,,CHEMBL623918,BAO_0000218,,
10126,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL874386,BAO_0000218,,
10127,,In vivo,Plasma,A,,,,Bioavailability in rat; Only traces detected in rat plasma,N,,1,,CHEMBL623919,BAO_0000218,1969.0,
10128,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL623920,BAO_0000218,,
10129,,In vivo,,A,,,,Bioavailability upon oral administration of compound,N,,1,,CHEMBL623148,BAO_0000218,,
10130,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),N,,1,,CHEMBL623149,BAO_0000218,,
10131,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL623150,BAO_0000218,,
10132,,In vivo,,A,,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",N,,1,,CHEMBL623151,BAO_0000218,,
10133,,In vivo,,A,,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",N,,1,,CHEMBL623152,BAO_0000218,,
10134,,,,F,,,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,N,,1,,CHEMBL623153,BAO_0000218,,
10135,,,,F,,,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,N,,1,,CHEMBL623154,BAO_0000218,,
10136,,,,A,,,,In vitro and metabolic stability was determined,N,,1,,CHEMBL623155,BAO_0000218,,
10137,,,,A,,,,In vitro metabolic stability in rat hepatocytes,N,,1,,CHEMBL623156,BAO_0000218,,
10138,,,,A,,,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,N,,1,,CHEMBL623157,BAO_0000218,,
10139,,In vitro,Liver,A,Hepatocyte,401.0,,Metabolic rate for compound was observed in rat hepatocytes,N,,1,,CHEMBL623158,BAO_0000218,2107.0,
10140,,,,A,,,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,N,,1,,CHEMBL623159,BAO_0000218,,
10141,,,,A,,,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),N,,1,,CHEMBL874390,BAO_0000218,,
10142,,,,A,,,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),N,,1,,CHEMBL623160,BAO_0000218,,
10143,,,,A,,,,Metabolism of compound in rat S9 microsomes; Trace,N,,1,,CHEMBL623161,BAO_0000218,,
10144,,,,A,,,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,N,,1,,CHEMBL623162,BAO_0000218,,
10145,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,N,,1,,CHEMBL623163,BAO_0000218,,
10146,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,N,,1,,CHEMBL623164,BAO_0000218,,
10147,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,N,,1,,CHEMBL623165,BAO_0000218,,
10148,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,N,,1,,CHEMBL623166,BAO_0000218,,
10149,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,N,,1,,CHEMBL624983,BAO_0000218,,
10150,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,N,,1,,CHEMBL624984,BAO_0000218,,
10151,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,N,,1,,CHEMBL624985,BAO_0000218,,
10152,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,N,,1,,CHEMBL622970,BAO_0000218,,
10153,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,N,,1,,CHEMBL622971,BAO_0000218,,
10154,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,N,,1,,CHEMBL622972,BAO_0000218,,
10155,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,N,,1,,CHEMBL622973,BAO_0000218,,
10156,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,N,,1,,CHEMBL622974,BAO_0000218,,
10157,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,N,,1,,CHEMBL622975,BAO_0000218,,
10158,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,N,,1,,CHEMBL622976,BAO_0000218,,
10159,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,N,,1,,CHEMBL622977,BAO_0000218,,
10160,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,N,,1,,CHEMBL624351,BAO_0000218,,
10161,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,N,,1,,CHEMBL624352,BAO_0000218,,
10162,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,N,,1,,CHEMBL624353,BAO_0000218,,
10163,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,N,,1,,CHEMBL622397,BAO_0000218,,
10164,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,N,,1,,CHEMBL622398,BAO_0000218,,
10165,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,N,,1,,CHEMBL622399,BAO_0000218,,
10166,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,N,,1,,CHEMBL622400,BAO_0000218,,
10167,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,N,,1,,CHEMBL628428,BAO_0000218,,
10168,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,N,,1,,CHEMBL628590,BAO_0000218,,
10169,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,N,,1,,CHEMBL628591,BAO_0000218,,
10170,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,N,,1,,CHEMBL628592,BAO_0000218,,
10171,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,N,,1,,CHEMBL628593,BAO_0000218,,
10172,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,N,,1,,CHEMBL875333,BAO_0000218,,
10173,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,N,,1,,CHEMBL628594,BAO_0000218,,
10174,,,Plasma,A,,,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,N,,1,,CHEMBL628595,BAO_0000218,1969.0,
10175,,,Plasma,A,,,,Stability in rat plasma was determined,N,,1,,CHEMBL628596,BAO_0000218,1969.0,
10176,,,Plasma,A,,,,Stability in rat plasma was determined; ND= no data,N,,1,,CHEMBL628597,BAO_0000218,1969.0,
10177,,,Plasma,A,,,,Tested for plasma half life period in rat (0-8 hr),N,,1,,CHEMBL628598,BAO_0000218,1969.0,
10178,,,Plasma,A,,,,Tested for plasma half life period in rat (0-8 hr); Not determined,N,,1,,CHEMBL628599,BAO_0000218,1969.0,
10179,,In vivo,,A,,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,N,,1,,CHEMBL628600,BAO_0000218,,
10180,,In vivo,,A,,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,N,,1,,CHEMBL628601,BAO_0000218,,
10181,,,,A,,,,Tested for the half life in rat,N,,1,,CHEMBL628602,BAO_0000218,,
10182,,In vitro,,A,,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,N,,1,,CHEMBL628603,BAO_0000218,,
10183,,In vitro,,A,,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,N,,1,,CHEMBL628604,BAO_0000218,,
10184,,In vitro,,A,,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,N,,1,,CHEMBL628605,BAO_0000218,,
10185,,In vitro,,A,,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,N,,1,,CHEMBL628606,BAO_0000218,,
10186,,In vitro,,A,,,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,N,,1,,CHEMBL628607,BAO_0000218,,
10187,,,,A,,,,The biological half life the compound was measured at the dose of 100 umol/kg,N,,1,,CHEMBL628608,BAO_0000218,,
10188,,,,A,,,,The biological half life the compound was measured at the dose of 30 umol/kg,N,,1,,CHEMBL628609,BAO_0000218,,
10189,,,Plasma,A,,,,The compound was evaluated for plasma half life period in rat,N,,1,,CHEMBL628610,BAO_0000218,1969.0,
10190,,In vivo,,A,,,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL873819,BAO_0000218,,
10191,,In vivo,,A,,,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL628611,BAO_0000218,,
10192,,In vivo,,A,,,,The pharmacokinetic parameter half-life period in vivo in rats,N,,1,,CHEMBL628612,BAO_0000218,,
10193,,In vivo,,A,,,,"The pharmacokinetic property, Half-life was determined",N,,1,,CHEMBL628613,BAO_0000218,,
10194,,In vivo,,A,,,,"The pharmacokinetic property, Half-life in rat in vivo",N,,1,,CHEMBL628614,BAO_0000218,,
10195,,In vivo,,A,,,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",N,,1,,CHEMBL628615,BAO_0000218,,
10196,,In vivo,,A,,,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",N,,1,,CHEMBL628616,BAO_0000218,,
10197,,,Plasma,A,,,,The plasma half life period in rats,N,,1,,CHEMBL627924,BAO_0000218,1969.0,
10198,,,Liver,A,,,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,N,,1,,CHEMBL627925,BAO_0000218,2107.0,
10199,,In vivo,,A,,,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,N,,1,,CHEMBL627926,BAO_0000218,,
10200,,,,A,,,,t1/2 (apparent elimination)of the compound was determined,N,,1,,CHEMBL627927,BAO_0000218,,
10201,,,,A,,,,t1/2 value in rat,N,,1,,CHEMBL627928,BAO_0000218,,
10202,,,,A,,,,Half life in rat,N,,1,,CHEMBL627539,BAO_0000218,,
10203,,In vivo,Plasma,A,,,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",N,,1,,CHEMBL876790,BAO_0000218,1969.0,
10204,,In vivo,,A,,,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,N,,1,,CHEMBL858186,BAO_0000218,,
10205,,,,A,,,,Half-life period in fasted rats,N,,1,,CHEMBL627540,BAO_0000218,,
10206,,In vivo,,A,,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,N,,1,,CHEMBL627541,BAO_0000218,,
10207,,In vivo,,A,,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,N,,1,,CHEMBL627715,BAO_0000218,,
10208,,In vivo,,A,,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,N,,1,,CHEMBL627716,BAO_0000218,,
10209,,,,A,,,,Maximum time required to achieve Cmax was determined in rat,N,,1,,CHEMBL627717,BAO_0000218,,
10210,,In vivo,,A,,,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,,1,,CHEMBL627718,BAO_0000218,,
10211,,In vivo,,A,,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,,1,,CHEMBL627719,BAO_0000218,,
10212,,In vivo,,A,,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,N,,1,,CHEMBL627720,BAO_0000218,,
10213,,In vivo,,A,,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,N,,1,,CHEMBL627721,BAO_0000218,,
10214,,In vivo,,A,,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,N,,1,,CHEMBL627722,BAO_0000218,,
10215,,In vivo,,A,,,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL627723,BAO_0000218,,
10216,,In vivo,,A,,,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL626058,BAO_0000218,,
10217,,In vivo,,A,,,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL626059,BAO_0000218,,
10218,,In vivo,,A,,,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL626060,BAO_0000218,,
10219,,In vivo,Plasma,A,,,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,N,,1,,CHEMBL626061,BAO_0000218,1969.0,
10220,,In vivo,,A,,,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,,1,,CHEMBL876791,BAO_0000218,,
10221,,In vivo,,A,,,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,,1,,CHEMBL626062,BAO_0000218,,
10222,,In vivo,,A,,,,Tmax at the dose of 2 mg/Kg administered perorally in rats,N,,1,,CHEMBL626063,BAO_0000218,,
10223,,In vivo,,A,,,,Tmax at the dose of 5 mg/Kg administered perorally in rats,N,,1,,CHEMBL626064,BAO_0000218,,
10224,,In vivo,Plasma,A,,,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,N,,1,,CHEMBL626065,BAO_0000218,1969.0,
10225,,In vivo,Plasma,A,,,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,N,,1,,CHEMBL626066,BAO_0000218,1969.0,
10226,,In vivo,,A,,,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,N,,1,,CHEMBL626067,BAO_0000218,,
10227,,,,F,,,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,N,,1,,CHEMBL626068,BAO_0000218,,
10228,,,,F,,,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,N,,1,,CHEMBL626069,BAO_0000218,,
10229,,,,F,,,,Percent total excretion of 3-methoxyacetaminophen glucuronide,N,,1,,CHEMBL626070,BAO_0000218,,
10230,,,,F,,,,Percent total excretion of N-methoxyacetaminophen glucuronide,N,,1,,CHEMBL626071,BAO_0000218,,
10231,,,,F,,,,Percent total excretion of N-methoxyacetaminophen sulfate,N,,1,,CHEMBL626072,BAO_0000218,,
10232,,,,F,,,,Percent total excretion of acetaminophen,N,,1,,CHEMBL626073,BAO_0000218,,
10233,,,Thyroid gland,A,,,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",N,,1,,CHEMBL626741,BAO_0000218,2046.0,
10234,,,,A,,,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",N,,1,,CHEMBL626742,BAO_0000218,,
10235,,,,A,,,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,N,,1,,CHEMBL626743,BAO_0000218,,
10236,,,,A,,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,N,,1,,CHEMBL876792,BAO_0000218,,
10237,,,,A,,,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,N,,1,,CHEMBL626744,BAO_0000218,,
10238,,,,A,,,,Compound was tested for antidiuretic activity in rats,N,,1,,CHEMBL626745,BAO_0000218,,
10239,,In vivo,Plasma,A,,,,AUC in rat after 3mg/kg oral dose,N,,1,,CHEMBL626746,BAO_0000218,1969.0,
10240,,,,A,,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,N,,1,,CHEMBL626747,BAO_0000218,,
10241,,,,A,,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,N,,1,,CHEMBL626748,BAO_0000218,,
10242,,,,A,,,,Bioavailability administered orally at a dose of 10 mg/kg to rats,N,,1,,CHEMBL626749,BAO_0000218,,
10243,,,,A,,,,Oral Bioavailability was determined,N,,1,,CHEMBL626750,BAO_0000218,,
10244,,,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL626751,BAO_0000218,,
10245,,,,A,,,,Oral bioavailability in rat; Not performed.,N,,1,,CHEMBL626913,BAO_0000218,,
10246,,,,A,,,,Bioavailability,N,,1,,CHEMBL626914,BAO_0000218,,
10247,,,,A,,,,Bioavailability was determined; ND denotes no data,N,,1,,CHEMBL626915,BAO_0000218,,
10248,,,,A,,,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,N,,1,,CHEMBL626916,BAO_0000218,,
10249,,,,A,,,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,N,,1,,CHEMBL626917,BAO_0000218,,
10250,,,,A,,,,Binding towards rat plasma protein at 10 uM,N,,1,,CHEMBL626918,BAO_0000218,,
10251,,,,A,,,,Binding towards rat plasma protein at 100 uM,N,,1,,CHEMBL626919,BAO_0000218,,
10252,,In vivo,,A,,,,Bioavailability in rat (dose 20 mg/kg p.o.),N,,1,,CHEMBL626920,BAO_0000218,,
10253,,In vivo,,A,,,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,N,,1,,CHEMBL621976,BAO_0000218,,
10254,,In vivo,,A,,,,Bioavailability in rat after 5 mg/kg oral gavage,N,,1,,CHEMBL877599,BAO_0000218,,
10255,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL621977,BAO_0000218,,
10256,,In vivo,,A,,,,Bioavailability in rat (dose 1 mg/kg i.v.),N,,1,,CHEMBL621978,BAO_0000218,,
10257,,In vivo,,A,,,,Bioavailability in rat (dose 3 mg/kg p.o.),N,,1,,CHEMBL621979,BAO_0000218,,
10258,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL621980,BAO_0000218,,
10259,,In vivo,,A,,,,Bioavailability of the compound in rats after administration of 30 mg/kg,N,,1,,CHEMBL621981,BAO_0000218,,
10260,,In vivo,,A,,,,Bioavailability after administration of 10 mg/kg in rats,N,,1,,CHEMBL621982,BAO_0000218,,
10261,,In vivo,,A,,,,Bioavailability after administration of 2 mg/kg in rats,N,,1,,CHEMBL882953,BAO_0000218,,
10262,,In vivo,,A,,,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,N,,1,,CHEMBL621983,BAO_0000218,,
10263,,In vivo,,A,,,,Bioavailability in dogs was determined; high,N,,1,,CHEMBL621984,BAO_0000218,,
10264,,In vivo,,A,,,,Bioavailability in monkey after intravenous administration at 1 mpk,N,,1,,CHEMBL621985,BAO_0000218,,
10265,,In vivo,,A,,,,Bioavailability in monkey after peroral administration at 10 mpk,N,,1,,CHEMBL621986,BAO_0000218,,
10266,,In vivo,,A,,,,Bioavailability in rat after intravenous administration at 1 mpk,N,,1,,CHEMBL621987,BAO_0000218,,
10267,,In vivo,,F,,,,Bioavailability in rat after intravenous administration at 2 mpk,N,,1,,CHEMBL877600,BAO_0000218,,
10268,,In vivo,,A,,,,Bioavailability in rat after peroral administration at 30 mpk,N,,1,,CHEMBL621988,BAO_0000218,,
10269,,In vivo,,F,,,,Bioavailability in rat after peroral administration at at 100 mpk,N,,1,,CHEMBL621989,BAO_0000218,,
10270,,In vivo,,A,,,,Bioavailability in rats was evaluated,N,,1,,CHEMBL621990,BAO_0000218,,
10271,,In vivo,,A,,,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,N,,1,,CHEMBL621991,BAO_0000218,,
10272,,In vivo,,A,,,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,N,,1,,CHEMBL621992,BAO_0000218,,
10273,,In vivo,,A,,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,N,,1,,CHEMBL621993,BAO_0000218,,
10274,,In vivo,,A,,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,N,,1,,CHEMBL621994,BAO_0000218,,
10275,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL621995,BAO_0000218,,
10276,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL621996,BAO_0000218,,
10277,,In vivo,,A,,,,Oral bioavailability in rat (dose 10 mg/kg),N,,1,,CHEMBL621997,BAO_0000218,,
10278,,In vivo,,A,,,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,N,,1,,CHEMBL621998,BAO_0000218,,
10279,,In vivo,,A,,,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,N,,1,,CHEMBL621999,BAO_0000218,,
10280,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622000,BAO_0000218,,
10281,,In vivo,,A,,,,Bioavailability was measured in rat after oral administration; 2-4,N,,1,,CHEMBL622001,BAO_0000218,,
10282,,In vivo,,A,,,,Bioavailability was measured in rat after oral administration; 3-7,N,,1,,CHEMBL622002,BAO_0000218,,
10283,,In vivo,,A,,,,Bioavailability in rat (intraduodenal administration),N,,1,,CHEMBL622003,BAO_0000218,,
10284,,In vivo,,A,,,,Bioavailability in rat (intraduodenal administration),N,,1,,CHEMBL877601,BAO_0000218,,
10285,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL624871,BAO_0000218,,
10286,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622004,BAO_0000218,,
10287,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),N,,1,,CHEMBL882954,BAO_0000218,,
10288,,In vivo,,A,,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,N,,1,,CHEMBL622005,BAO_0000218,,
10289,,In vivo,,A,,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,N,,1,,CHEMBL622006,BAO_0000218,,
10290,,In vivo,,A,,,,Bioavailability was measured in rat,N,,1,,CHEMBL622007,BAO_0000218,,
10291,,In vivo,,A,,,,Bioavailability was reported,N,,1,,CHEMBL622008,BAO_0000218,,
10292,,In vivo,,A,,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),N,,1,,CHEMBL622009,BAO_0000218,,
10293,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),N,,1,,CHEMBL622010,BAO_0000218,,
10294,,In vivo,,A,,,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,N,,1,,CHEMBL622011,BAO_0000218,,
10295,,In vivo,,A,,,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),N,,1,,CHEMBL622012,BAO_0000218,,
10296,,In vivo,,A,,,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),N,,1,,CHEMBL622013,BAO_0000218,,
10297,,In vivo,,A,,,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,N,,1,,CHEMBL622014,BAO_0000218,,
10298,,In vivo,,A,,,,Bioavailability was determined at 3 mg/kg po dose in rats,N,,1,,CHEMBL624749,BAO_0000218,,
10299,,In vivo,,A,,,,Oral bioavailability in rat (dose 2 mg/kg),N,,1,,CHEMBL624750,BAO_0000218,,
10300,,In vivo,,A,,,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",N,,1,,CHEMBL624751,BAO_0000218,,
10301,,In vivo,,A,,,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",N,,1,,CHEMBL624752,BAO_0000218,,
10302,,In vivo,,A,,,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",N,,1,,CHEMBL624753,BAO_0000218,,
10303,,In vivo,,A,,,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,N,,1,,CHEMBL624754,BAO_0000218,,
10304,,In vivo,,A,,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,N,,1,,CHEMBL624755,BAO_0000218,,
10305,,In vivo,,A,,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,N,,1,,CHEMBL624756,BAO_0000218,,
10306,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL624757,BAO_0000218,,
10307,,In vivo,,A,,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,N,,1,,CHEMBL624758,BAO_0000218,,
10308,,In vivo,,A,,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,N,,1,,CHEMBL622270,BAO_0000218,,
10309,,In vivo,,A,,,,Bioavailability in rat (Sprague-Dawley),N,,1,,CHEMBL622271,BAO_0000218,,
10310,,In vivo,,A,,,,Bioavailability in rat at the dose of 2 mg/kg,N,,1,,CHEMBL622272,BAO_0000218,,
10311,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622273,BAO_0000218,,
10312,,In vivo,,A,,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),N,,1,,CHEMBL622274,BAO_0000218,,
10313,,In vivo,,A,,,,Bioavailability value of compound in rats was determined after peroral administration,N,,1,,CHEMBL622275,BAO_0000218,,
10314,,In vivo,,A,,,,Oral bioavailability in rat (dose 20 mg/kg),N,,1,,CHEMBL622276,BAO_0000218,,
10315,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622277,BAO_0000218,,
10316,,In vivo,,A,,,,Oral bioavailability in rat (dose 5 mg/kg),N,,1,,CHEMBL622278,BAO_0000218,,
10317,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622279,BAO_0000218,,
10318,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622280,BAO_0000218,,
10319,,In vivo,,A,,,,Compound was evaluated for oral bioavailability in rats; 15-27 %,N,,1,,CHEMBL624083,BAO_0000218,,
10320,,In vivo,,A,,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,N,,1,,CHEMBL624084,BAO_0000218,,
10321,,In vivo,,A,,,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),N,,1,,CHEMBL624085,BAO_0000218,,
10322,,In vivo,,A,,,,Compound was tested for bioavailability in rats,N,,1,,CHEMBL624086,BAO_0000218,,
10323,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL624087,BAO_0000218,,
10324,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL624088,BAO_0000218,,
10325,,In vivo,,A,,,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,U,,1,,CHEMBL624089,BAO_0000218,,
10326,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),U,,1,,CHEMBL624090,BAO_0000218,,
10327,,In vivo,,A,,,,Evaluated for the bioavailability in rat (in vivo),N,,1,,CHEMBL624091,BAO_0000218,,
10328,,In vivo,,A,,,,F value of compound in rats was determined after peroral administration,N,,1,,CHEMBL624092,BAO_0000218,,
10329,,In vivo,,A,,,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL624093,BAO_0000218,,
10330,,In vivo,,A,,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL624094,BAO_0000218,,
10331,,In vivo,,A,,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL624095,BAO_0000218,,
10332,,In vivo,,A,,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,,1,,CHEMBL624096,BAO_0000218,,
10333,,In vivo,,A,,,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",N,,1,,CHEMBL624097,BAO_0000218,,
10334,,In vivo,,A,,,,Maximum fall in carotid flow in rat,N,,1,,CHEMBL624098,BAO_0000218,,
10335,,In vivo,,A,,,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,N,,1,,CHEMBL874392,BAO_0000218,,
10336,,In vivo,,A,,,,Oral bioavailability in rat (dose 5 mg/kg),N,,1,,CHEMBL624099,BAO_0000218,,
10337,,In vivo,,A,,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,N,,1,,CHEMBL624100,BAO_0000218,,
10338,,In vivo,,A,,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,N,,1,,CHEMBL624101,BAO_0000218,,
10339,,In vivo,,A,,,,Oral bioavailability in rat (male Wistar),N,,1,,CHEMBL624102,BAO_0000218,,
10340,,In vivo,,A,,,,Oral bioavailability after administration (30 mg/kg) in rat; good,N,,1,,CHEMBL624103,BAO_0000218,,
10341,,In vivo,,A,,,,Oral bioavailability at the dose of 2 mg/kg in rat,N,,1,,CHEMBL624104,BAO_0000218,,
10342,,In vivo,,A,,,,Oral bioavailability determined in rats,N,,1,,CHEMBL624105,BAO_0000218,,
10343,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),N,,1,,CHEMBL624106,BAO_0000218,,
10344,,In vivo,,A,,,,Oral bioavailability in rat (dose single 10 mg/kg),N,,1,,CHEMBL624107,BAO_0000218,,
10345,,In vivo,,A,,,,Oral bioavailability in rat (dose single 10 mg/kg),N,,1,,CHEMBL623943,BAO_0000218,,
10346,,In vivo,,A,,,,Oral bioavailability in rat (dose 5 mg/kg,N,,1,,CHEMBL623944,BAO_0000218,,
10347,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,N,,1,,CHEMBL623945,BAO_0000218,,
10348,,,,A,,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,N,,1,,CHEMBL623946,BAO_0000218,,
10349,,,,A,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,N,,1,,CHEMBL623947,BAO_0000218,,
10350,,,,A,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,N,,1,,CHEMBL623948,BAO_0000218,,
10351,,,,A,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,N,,1,,CHEMBL623949,BAO_0000218,,
10352,,,,A,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,N,,1,,CHEMBL623950,BAO_0000218,,
10353,,,,A,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,N,,1,,CHEMBL874398,BAO_0000218,,
10354,,,,A,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,N,,1,,CHEMBL623951,BAO_0000218,,
10355,,,,A,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,N,,1,,CHEMBL623952,BAO_0000218,,
10356,,,,A,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,N,,1,,CHEMBL623953,BAO_0000218,,
10357,,,,A,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,N,,1,,CHEMBL623954,BAO_0000218,,
10358,,,,A,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,N,,1,,CHEMBL623955,BAO_0000218,,
10359,,,,A,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,N,,1,,CHEMBL623956,BAO_0000218,,
10360,,,,A,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,N,,1,,CHEMBL627807,BAO_0000218,,
10361,,,,A,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,N,,1,,CHEMBL627808,BAO_0000218,,
10362,,,,A,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,N,,1,,CHEMBL627809,BAO_0000218,,
10363,,,,A,,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,N,,1,,CHEMBL627810,BAO_0000218,,
10364,,,,A,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",N,,1,,CHEMBL627811,BAO_0000218,,
10365,,,,A,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",N,,1,,CHEMBL627812,BAO_0000218,,
10366,,,,A,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",N,,1,,CHEMBL627813,BAO_0000218,,
10367,,,,A,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",N,,1,,CHEMBL627814,BAO_0000218,,
10368,,,,A,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",N,,1,,CHEMBL875336,BAO_0000218,,
10369,,,,A,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",N,,1,,CHEMBL627815,BAO_0000218,,
10370,,,,A,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",N,,1,,CHEMBL627816,BAO_0000218,,
10371,,,,A,,,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",N,,1,,CHEMBL627817,BAO_0000218,,
10372,,,,A,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",N,,1,,CHEMBL627818,BAO_0000218,,
10373,,,,A,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",N,,1,,CHEMBL627819,BAO_0000218,,
10374,,,,A,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",N,,1,,CHEMBL627820,BAO_0000218,,
10375,,,,A,,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",N,,1,,CHEMBL627821,BAO_0000218,,
10376,,,,A,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,N,,1,,CHEMBL628464,BAO_0000218,,
10377,,,,A,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,N,,1,,CHEMBL626239,BAO_0000218,,
10378,,,,A,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,N,,1,,CHEMBL626240,BAO_0000218,,
10379,,,,A,,,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,N,,1,,CHEMBL626241,BAO_0000218,,
10380,,,,A,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,N,,1,,CHEMBL626242,BAO_0000218,,
10381,,,,A,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,N,,1,,CHEMBL626243,BAO_0000218,,
10382,,,,A,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,N,,1,,CHEMBL626244,BAO_0000218,,
10383,,,,A,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,N,,1,,CHEMBL626907,BAO_0000218,,
10384,,,,A,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,N,,1,,CHEMBL626908,BAO_0000218,,
10385,,,,A,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,N,,1,,CHEMBL626909,BAO_0000218,,
10386,,,,A,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,N,,1,,CHEMBL626910,BAO_0000218,,
10387,,,,F,,,,Percent total excretion of acetaminophen cysteine conjugate,N,,1,,CHEMBL875342,BAO_0000218,,
10388,,,,F,,,,Percent total excretion of acetaminophen glucuronide,N,,1,,CHEMBL626911,BAO_0000218,,
10389,,,,F,,,,Percent total excretion of acetaminophen sulfate,N,,1,,CHEMBL626912,BAO_0000218,,
10390,,,,F,,,,Percent total excretion of acetaminophen-mercapturic acid,N,,1,,CHEMBL627065,BAO_0000218,,
10391,,,Urine,A,,,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,N,,1,,CHEMBL627066,BAO_0000218,1088.0,
10392,,In vivo,,A,,,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,N,,1,,CHEMBL627067,BAO_0000218,,
10393,,In vivo,Muscle tissue,A,,,,Biodistribution of compound in rat muscle after 5 min of administration,U,,1,,CHEMBL627068,BAO_0000218,2385.0,
10394,,In vivo,Muscle tissue,A,,,,Biodistribution of compound in rat muscle after 5 min of administration.,U,,1,,CHEMBL627069,BAO_0000218,2385.0,
10395,,In vivo,,A,,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),U,,1,,CHEMBL627070,BAO_0000218,,
10396,,In vivo,,A,,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),U,,1,,CHEMBL627071,BAO_0000218,,
10397,,In vivo,,A,,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),U,,1,,CHEMBL627072,BAO_0000218,,
10398,,In vivo,,A,,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),U,,1,,CHEMBL627073,BAO_0000218,,
10399,,In vivo,,A,,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),U,,1,,CHEMBL625387,BAO_0000218,,
10400,,In vivo,,A,,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),U,,1,,CHEMBL625388,BAO_0000218,,
10401,,In vivo,Plasma,A,,,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),U,,1,,CHEMBL625389,BAO_0000218,1969.0,
10402,,In vivo,Plasma,A,,,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),U,,1,,CHEMBL875343,BAO_0000218,1969.0,
10403,,,,A,,,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),N,,1,,CHEMBL876795,BAO_0000218,,
10404,,,,A,,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,N,,1,,CHEMBL626552,BAO_0000218,,
10405,,,,A,,,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,N,,1,,CHEMBL626553,BAO_0000218,,
10406,,,Plasma,A,,,,The human biological plasma half life of the compound,U,,1,,CHEMBL626554,BAO_0000366,1969.0,
10407,,,Urine,A,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,N,,1,,CHEMBL626555,BAO_0000218,1088.0,
10408,,,,A,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,N,,1,,CHEMBL626556,BAO_0000218,,
10409,,,,A,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,N,,1,,CHEMBL626557,BAO_0000218,,
10410,,,,A,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,N,,1,,CHEMBL626558,BAO_0000218,,
10411,,,,A,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,N,,1,,CHEMBL626559,BAO_0000218,,
10412,,,,A,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,N,,1,,CHEMBL626560,BAO_0000218,,
10413,,,,A,,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,N,,1,,CHEMBL876803,BAO_0000218,,
10414,,,,A,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,N,,1,,CHEMBL627964,BAO_0000218,,
10415,,,,A,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,N,,1,,CHEMBL627965,BAO_0000218,,
10416,,,,A,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,N,,1,,CHEMBL627966,BAO_0000218,,
10417,,,,A,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,N,,1,,CHEMBL627967,BAO_0000218,,
10418,,,,A,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,N,,1,,CHEMBL627968,BAO_0000218,,
10419,,,,A,,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,N,,1,,CHEMBL627969,BAO_0000218,,
10420,,,,A,,,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,N,,1,,CHEMBL627970,BAO_0000218,,
10421,,,Blood,A,,,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,N,,1,,CHEMBL627971,BAO_0000218,178.0,
10422,,,Blood,A,,,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,N,,1,,CHEMBL627972,BAO_0000218,178.0,
10423,,,,B,,,,Dissociation constant against binding to human cyclophilin A,D,,1,,CHEMBL856029,BAO_0000357,,
10424,,,,B,,,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,H,,1,,CHEMBL627973,BAO_0000019,,
10425,,,,A,,,,-Log C was determined by performing the electroshock minimum test,U,,1,,CHEMBL627974,BAO_0000019,,
10426,,,,A,,,,-Log C was determined by performing the foot shock test,U,,1,,CHEMBL627975,BAO_0000019,,
10427,,,,A,,,,-Log C was determined by performing the incl screen test,U,,1,,CHEMBL627976,BAO_0000019,,
10428,,,,A,,,,-Log C was determined by performing the maximum electroshock test,U,,1,,CHEMBL627977,BAO_0000019,,
10429,,,,A,,,,-Log C was determined by performing the pentylenetetrazole test,U,,1,,CHEMBL627978,BAO_0000019,,
10430,,,,A,,,,Tested for experimental arotinoid inhibitory dose,U,,1,,CHEMBL627979,BAO_0000019,,
10431,,,,A,,,,Negative log transformed activity,U,,1,,CHEMBL876804,BAO_0000019,,
10432,,,,A,,,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",U,,1,,CHEMBL627980,BAO_0000019,,
10433,,,,A,,,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,N,,1,,CHEMBL627981,BAO_0000218,,
10434,,,,A,,,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,N,,1,,CHEMBL627982,BAO_0000218,,
10435,,,,A,,,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,N,,1,,CHEMBL627983,BAO_0000218,,
10436,,,Ileum,A,,,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,N,,1,,CHEMBL627984,BAO_0000218,2116.0,
10437,,,,P,,,,Solubility in water was determined; values expressed as -log,U,,1,,CHEMBL627985,BAO_0000100,,
10438,,,,A,,,,Ratio of Kcat to that of Km was determined,U,,1,,CHEMBL627986,BAO_0000019,,
10439,,,,A,,,,Observed first order rate constant,U,,1,,CHEMBL627987,BAO_0000019,,
10440,,,,A,,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,U,,1,,CHEMBL627988,BAO_0000019,,
10441,,In vivo,,A,,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,N,,1,,CHEMBL627989,BAO_0000218,,
10442,,In vivo,,A,,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,N,,1,,CHEMBL627990,BAO_0000218,,
10443,,In vivo,,A,,,,Oral Bioavailability after administration of 10 mg/kg in male rat,N,,1,,CHEMBL876805,BAO_0000218,,
10444,,In vivo,,A,,,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),N,,1,,CHEMBL627991,BAO_0000218,,
10445,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL627992,BAO_0000218,,
10446,,In vivo,,A,,,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,N,,1,,CHEMBL627993,BAO_0000218,,
10447,,In vivo,,A,,,,Oral bioavailability at 1 mg/kg was determined in rat,N,,1,,CHEMBL622817,BAO_0000218,,
10448,,In vivo,,A,,,,Oral bioavailability at 10 mg/kg was determined in rat,N,,1,,CHEMBL622818,BAO_0000218,,
10449,,In vivo,,A,,,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",N,,1,,CHEMBL622819,BAO_0000218,,
10450,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL872267,BAO_0000218,,
10451,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622820,BAO_0000218,,
10452,,In vivo,,A,,,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,N,,1,,CHEMBL622821,BAO_0000218,,
10453,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622822,BAO_0000218,,
10454,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622823,BAO_0000218,,
10455,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622824,BAO_0000218,,
10456,,In vivo,,A,,,,Oral bioavailability in rat at a dose of 3 mg/kg,N,,1,,CHEMBL622825,BAO_0000218,,
10457,,In vivo,,A,,,,Oral bioavailability in rat after oral administration at 10 mg/kg,N,,1,,CHEMBL622901,BAO_0000218,,
10458,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622902,BAO_0000218,,
10459,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL621844,BAO_0000218,,
10460,,In vivo,,A,,,,Oral bioavailability in Dawley rats,N,,1,,CHEMBL621845,BAO_0000218,,
10461,,In vivo,,A,,,,Oral bioavailability,N,,1,,CHEMBL621846,BAO_0000218,,
10462,,In vivo,,A,,,,Oral bioavailability in rat (dose 30 mg/kg),N,,1,,CHEMBL621847,BAO_0000218,,
10463,,In vivo,,A,,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,N,,1,,CHEMBL877609,BAO_0000218,,
10464,,In vivo,,A,,,,Bioavailability in rat (dose 3 mg/kg i.v.),N,,1,,CHEMBL621848,BAO_0000218,,
10465,,In vivo,,A,,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,N,,1,,CHEMBL621849,BAO_0000218,,
10466,,In vivo,,A,,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),N,,1,,CHEMBL622030,BAO_0000218,,
10467,,In vivo,,A,,,,Percent oral bioavailability determined in rats,N,,1,,CHEMBL622031,BAO_0000218,,
10468,,In vivo,,A,,,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,N,,1,,CHEMBL622032,BAO_0000218,,
10469,,In vivo,,A,,,,The compound was evaluated for bioavailability in rats; 32-51,N,,1,,CHEMBL622033,BAO_0000218,,
10470,,In vivo,,A,,,,Bioavailability in rat (dose 20 mg/kg p.o.),N,,1,,CHEMBL622034,BAO_0000218,,
10471,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622035,BAO_0000218,,
10472,,In vivo,,A,,,,Bioavailability percent in rat at the dose of 2 mg/kg,N,,1,,CHEMBL882966,BAO_0000218,,
10473,,In vivo,,A,,,,Bioavailability was evaluated after 20 uM/kg of peroral administration,N,,1,,CHEMBL622036,BAO_0000218,,
10474,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622037,BAO_0000218,,
10475,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622038,BAO_0000218,,
10476,,In vivo,,A,,,,Bioavailability in rats,N,,1,,CHEMBL622039,BAO_0000218,,
10477,,In vivo,Blood,A,,,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,N,,1,,CHEMBL622040,BAO_0000218,178.0,
10478,,In vivo,Blood,A,,,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,N,,1,,CHEMBL622041,BAO_0000218,178.0,
10479,,In vivo,Blood,A,,,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,N,,1,,CHEMBL622042,BAO_0000218,178.0,
10480,,In vivo,Blood,A,,,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,N,,1,,CHEMBL622043,BAO_0000218,178.0,
10481,,In vivo,Blood,A,,,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,N,,1,,CHEMBL622044,BAO_0000218,178.0,
10482,,In vivo,Bone,A,,,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,N,,1,,CHEMBL622045,BAO_0000218,10000001.0,
10483,,In vivo,Bone,A,,,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,N,,1,,CHEMBL622046,BAO_0000218,10000001.0,
10484,,In vivo,Bone,A,,,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,N,,1,,CHEMBL622047,BAO_0000218,10000001.0,
10485,,In vivo,Bone,A,,,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,N,,1,,CHEMBL877610,BAO_0000218,10000001.0,
10486,,In vivo,Brain,A,,,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,N,,1,,CHEMBL622048,BAO_0000218,955.0,
10487,,In vivo,Brain,A,,,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,N,,1,,CHEMBL622049,BAO_0000218,955.0,
10488,,In vivo,Brain,A,,,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,N,,1,,CHEMBL622050,BAO_0000218,955.0,
10489,,In vivo,Brain,A,,,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,N,,1,,CHEMBL622051,BAO_0000218,955.0,
10490,,In vivo,,A,,,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,N,,1,,CHEMBL622052,BAO_0000218,,
10491,,In vivo,,A,,,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,N,,1,,CHEMBL622053,BAO_0000218,,
10492,,In vivo,,A,,,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,N,,1,,CHEMBL622054,BAO_0000218,,
10493,,In vivo,,A,,,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,N,,1,,CHEMBL622055,BAO_0000218,,
10494,,In vivo,,A,,,,Oral bioavailability in rats was determined; High,N,,1,,CHEMBL622056,BAO_0000218,,
10495,,In vivo,,A,,,,Oral bioavailability in the rat was determined,N,,1,,CHEMBL622057,BAO_0000218,,
10496,,In vivo,,A,,,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,N,,1,,CHEMBL628008,BAO_0000218,,
10497,,In vivo,,A,,,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),N,,1,,CHEMBL622058,BAO_0000218,,
10498,,In vivo,,A,,,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL622059,BAO_0000218,,
10499,,In vivo,,A,,,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL622060,BAO_0000218,,
10500,,In vivo,,A,,,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL622061,BAO_0000218,,
10501,,In vivo,,A,,,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,1,,CHEMBL622062,BAO_0000218,,
10502,,In vivo,,A,,,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,N,,1,,CHEMBL622063,BAO_0000218,,
10503,,In vivo,,A,,,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,N,,1,,CHEMBL877611,BAO_0000218,,
10504,,In vivo,,A,,,,Oral bioavailability of compound in Sprague Dawley rats,N,,1,,CHEMBL622064,BAO_0000218,,
10505,,In vivo,,A,,,,Oral bioavailability of compound in rat,N,,1,,CHEMBL622065,BAO_0000218,,
10506,,In vivo,,A,,,,Oral bioavailability in rat (dose 2 mg/kg),N,,1,,CHEMBL622066,BAO_0000218,,
10507,,In vivo,,A,,,,Oral bioavailability of compound in rat was determined,N,,1,,CHEMBL622067,BAO_0000218,,
10508,,In vivo,,A,,,,Oral bioavailability of compound in rats,N,,1,,CHEMBL622068,BAO_0000218,,
10509,,In vivo,,A,,,,Oral bioavailability of compound was determined in rats,N,,1,,CHEMBL622069,BAO_0000218,,
10510,,In vivo,,A,,,,Oral bioavailability at a dose of 30 mg/kg in rats,N,,1,,CHEMBL624796,BAO_0000218,,
10511,,In vivo,,A,,,,Oral bioavailability in rat (dose 10 mg/kg),N,,1,,CHEMBL624797,BAO_0000218,,
10512,,In vivo,,A,,,,Oral bioavailability in rat (dose 10 mg/kg),N,,1,,CHEMBL623053,BAO_0000218,,
10513,,In vivo,,A,,,,Oral bioavailability evaluated in rat,N,,1,,CHEMBL623054,BAO_0000218,,
10514,,In vivo,,A,,,,Oral bioavailability in fasted rat,N,,1,,CHEMBL623055,BAO_0000218,,
10515,,In vivo,,A,,,,Oral bioavailability in fed rat,N,,1,,CHEMBL623056,BAO_0000218,,
10516,,In vivo,,A,,,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),N,,1,,CHEMBL623057,BAO_0000218,,
10517,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623058,BAO_0000218,,
10518,,In vivo,,A,,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),N,,1,,CHEMBL623059,BAO_0000218,,
10519,,In vivo,,A,,,,Oral bioavailability in rat after administration of 10 mg/kg po,N,,1,,CHEMBL623060,BAO_0000218,,
10520,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623061,BAO_0000218,,
10521,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623062,BAO_0000218,,
10522,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623063,BAO_0000218,,
10523,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623064,BAO_0000218,,
10524,,In vivo,,A,,,,Oral bioavailability in ratrs,N,,1,,CHEMBL623065,BAO_0000218,,
10525,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623066,BAO_0000218,,
10526,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623067,BAO_0000218,,
10527,,In vivo,,A,,,,Oral bioavailability in rats was determined; High,N,,1,,CHEMBL623068,BAO_0000218,,
10528,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623069,BAO_0000218,,
10529,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623070,BAO_0000218,,
10530,,In vivo,,A,,,,Oral bioavailability was calculated in rat,N,,1,,CHEMBL623071,BAO_0000218,,
10531,,In vivo,,A,,,,Oral bioavailability,N,,1,,CHEMBL623072,BAO_0000218,,
10532,,In vivo,,A,,,,Oral bioavailability,N,,1,,CHEMBL623073,BAO_0000218,,
10533,,In vivo,,A,,,,Oral bioavailability,N,,1,,CHEMBL623074,BAO_0000218,,
10534,,In vivo,,A,,,,Oral bioavailability,N,,1,,CHEMBL623075,BAO_0000218,,
10535,,In vivo,,A,,,,Oral bioavailability after i.v. administration,N,,1,,CHEMBL623076,BAO_0000218,,
10536,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),N,,1,,CHEMBL623077,BAO_0000218,,
10537,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley),N,,1,,CHEMBL623078,BAO_0000218,,
10538,,In vivo,,A,,,,Oral bioavailability in Sprague-Dawley rats,N,,1,,CHEMBL623079,BAO_0000218,,
10539,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),N,,1,,CHEMBL623080,BAO_0000218,,
10540,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),N,,1,,CHEMBL623081,BAO_0000218,,
10541,,In vivo,,A,,,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,N,,1,,CHEMBL623082,BAO_0000218,,
10542,,In vivo,,A,,,,Oral bioavailability in fasted rat,N,,1,,CHEMBL874400,BAO_0000218,,
10543,,In vivo,,A,,,,Oral bioavailability in fed rat,N,,1,,CHEMBL623083,BAO_0000218,,
10544,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623084,BAO_0000218,,
10545,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623085,BAO_0000218,,
10546,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623086,BAO_0000218,,
10547,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623087,BAO_0000218,,
10548,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623088,BAO_0000218,,
10549,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623089,BAO_0000218,,
10550,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623090,BAO_0000218,,
10551,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623091,BAO_0000218,,
10552,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623092,BAO_0000218,,
10553,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623093,BAO_0000218,,
10554,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL874401,BAO_0000218,,
10555,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623094,BAO_0000218,,
10556,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL623095,BAO_0000218,,
10557,,In vivo,,A,,,,Oral bioavailability in rat after peroral administration at 10 mg/kg,N,,1,,CHEMBL623096,BAO_0000218,,
10558,,In vivo,,A,,,,Oral bioavailability in rat after peroral administration at 5 mg/kg,N,,1,,CHEMBL624913,BAO_0000218,,
10559,,In vivo,,A,,,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),N,,1,,CHEMBL624914,BAO_0000218,,
10560,,In vivo,,A,,,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,N,,1,,CHEMBL624915,BAO_0000218,,
10561,,In vivo,,A,,,,Oral bioavailability in rat; Not measured,N,,1,,CHEMBL624916,BAO_0000218,,
10562,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL624917,BAO_0000218,,
10563,,,,A,,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,N,,1,,CHEMBL625157,BAO_0000218,,
10564,,,Liver,A,,,,In vitro metabolic potential in rat liver microsomes,N,,1,,CHEMBL625158,BAO_0000218,2107.0,
10565,,In vivo,,A,,,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",N,,1,,CHEMBL625159,BAO_0000218,,
10566,,In vivo,,A,,,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",N,,1,,CHEMBL625160,BAO_0000218,,
10567,,In vivo,,A,,,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,N,,1,,CHEMBL625161,BAO_0000218,,
10568,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL625162,BAO_0000218,,
10569,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL625163,BAO_0000218,,
10570,,In vivo,,A,,,,Oral bioavailability in rats at 10 mg/kg,N,,1,,CHEMBL625164,BAO_0000218,,
10571,,In vivo,,A,,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,1,,CHEMBL625165,BAO_0000218,,
10572,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL625166,BAO_0000218,,
10573,,,,A,,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,N,,1,,CHEMBL625167,BAO_0000218,,
10574,,,,A,,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,N,,1,,CHEMBL625168,BAO_0000218,,
10575,,In vivo,,A,,,,Plasma clearance of the compound,N,,1,,CHEMBL625169,BAO_0000218,,
10576,,In vivo,,A,,,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,N,,1,,CHEMBL626264,BAO_0000218,,
10577,,In vivo,,A,,,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,N,,1,,CHEMBL626265,BAO_0000218,,
10578,,In vivo,Plasma,A,,,,The compound was tested for plasma clearance in rat,N,,1,,CHEMBL626266,BAO_0000218,1969.0,
10579,,In vivo,Plasma,A,,,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,N,,1,,CHEMBL626267,BAO_0000218,1969.0,
10580,,,,A,,,,Plasma concentration upon oral administration of 1 mg/Kg in rats,N,,1,,CHEMBL626268,BAO_0000218,,
10581,,,,A,,,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,N,,1,,CHEMBL626269,BAO_0000218,,
10582,,,,A,,,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,N,,1,,CHEMBL626270,BAO_0000218,,
10583,,,,A,,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,N,,1,,CHEMBL626271,BAO_0000218,,
10584,,,,A,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",N,,1,,CHEMBL626272,BAO_0000218,,
10585,,,,A,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",N,,1,,CHEMBL626273,BAO_0000218,,
10586,,,,A,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",N,,1,,CHEMBL875346,BAO_0000218,,
10587,,,,A,,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",N,,1,,CHEMBL626274,BAO_0000218,,
10588,,,,A,,,,Compound was tested for protein binding in rat plasma,N,,1,,CHEMBL626275,BAO_0000218,,
10589,,,,A,,,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,N,,1,,CHEMBL624646,BAO_0000218,,
10590,,,,A,,,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,N,,1,,CHEMBL624647,BAO_0000218,,
10591,,,Liver,A,,,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,N,,1,,CHEMBL624648,BAO_0000218,2107.0,
10592,,,,A,,,,Area under curve ratio was determined (po/iv) in rat,N,,1,,CHEMBL624649,BAO_0000218,,
10593,,,,A,,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,N,,1,,CHEMBL624650,BAO_0000218,,
10594,,,,A,,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,N,,1,,CHEMBL624651,BAO_0000218,,
10595,,,,A,,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,N,,1,,CHEMBL624652,BAO_0000218,,
10596,,,,A,,,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,N,,1,,CHEMBL624653,BAO_0000218,,
10597,,,,A,,,,Ratio of AUCbrain to AUCplasma,N,,1,,CHEMBL624654,BAO_0000218,,
10598,,,,A,,,,Ratio of brain to plasma,N,,1,,CHEMBL624655,BAO_0000218,,
10599,,,,A,,,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,N,,1,,CHEMBL624656,BAO_0000218,,
10600,,,,A,,,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,N,,1,,CHEMBL624657,BAO_0000218,,
10601,,,,A,,,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,N,,1,,CHEMBL624658,BAO_0000218,,
10602,,,,A,,,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,N,,1,,CHEMBL624659,BAO_0000218,,
10603,,,,A,,,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,N,,1,,CHEMBL624660,BAO_0000218,,
10604,,,,A,,,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,N,,1,,CHEMBL624661,BAO_0000218,,
10605,,,,A,,,,Steady state brain :blood ratio was determined,N,,1,,CHEMBL624662,BAO_0000218,,
10606,,,,A,,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,N,,1,,CHEMBL625199,BAO_0000218,,
10607,,,,A,,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,N,,1,,CHEMBL625200,BAO_0000218,,
10608,,,,A,,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,N,,1,,CHEMBL625201,BAO_0000218,,
10609,,,,A,,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,N,,1,,CHEMBL625202,BAO_0000218,,
10610,,,,A,,,,Percentage recovery after 3h incubation with rat hapatocytes was determined,N,,1,,CHEMBL625203,BAO_0000218,,
10611,,,,A,,,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,N,,1,,CHEMBL625204,BAO_0000218,,
10612,,,,A,,,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,N,,1,,CHEMBL625205,BAO_0000218,,
10613,,,,A,,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,N,,1,,CHEMBL625206,BAO_0000218,,
10614,,,,A,,,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",U,,1,,CHEMBL625207,BAO_0000019,,
10615,,,,A,,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,U,,1,,CHEMBL625208,BAO_0000019,,
10616,,,,A,Caco-2,495.0,,In vivo absorption in Caco-2 cell line monolayers was determined,N,,1,,CHEMBL625209,BAO_0000218,,
10617,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625210,BAO_0000100,,
10618,,,,A,,,,Area under curve was determine after peroral administration at 10 mpk in Rat,N,,1,,CHEMBL625211,BAO_0000218,,
10619,,,,A,,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,N,,1,,CHEMBL625212,BAO_0000218,,
10620,,,,A,,,,Area under curve was determine after peroral administration at 160 mpk in Rat,N,,1,,CHEMBL625213,BAO_0000218,,
10621,,,,A,,,,Area under curve was determine after peroral administration at 20 mpk in Rat,N,,1,,CHEMBL625214,BAO_0000218,,
10622,,,,A,,,,Area under curve was determine after peroral administration at 50 mpk in Rat,N,,1,,CHEMBL874542,BAO_0000218,,
10623,,,,P,,,,Calculated partition coefficient (clogP) (AlogP),U,,1,,CHEMBL625215,BAO_0000100,,
10624,,,,A,,,,Activated partial thromboplastin time measured,U,,1,,CHEMBL625216,BAO_0000019,,
10625,,,,P,,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),U,,1,,CHEMBL625217,BAO_0000100,,
10626,,,,P,,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),U,,1,,CHEMBL625218,BAO_0000100,,
10627,,,Plasma,A,,,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,N,,1,,CHEMBL622864,BAO_0000218,1969.0,
10628,,,Plasma,A,,,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,N,,1,,CHEMBL622865,BAO_0000218,1969.0,
10629,,,Plasma,A,,,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,N,,1,,CHEMBL622866,BAO_0000218,1969.0,
10630,,,Plasma,A,,,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,N,,1,,CHEMBL622867,BAO_0000218,1969.0,
10631,,,Plasma,A,,,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,N,,1,,CHEMBL876808,BAO_0000218,1969.0,
10632,,,Brain,A,,,,AUC in brain,U,,1,,CHEMBL627725,BAO_0000019,955.0,
10633,,,Serum,A,,,,AUC in serum,U,,1,,CHEMBL627726,BAO_0000019,1977.0,
10634,,,Plasma,A,,,,AUC was determined,U,,1,,CHEMBL627727,BAO_0000019,1969.0,
10635,,,Plasma,A,,,,AUC of the compound.,U,,1,,CHEMBL627728,BAO_0000019,1969.0,
10636,,,Plasma,A,,,,AUC value (0-4 hr),U,,1,,CHEMBL627729,BAO_0000019,1969.0,
10637,,,Plasma,A,,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",U,,1,,CHEMBL627730,BAO_0000019,1969.0,
10638,,,Plasma,A,,,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,U,,1,,CHEMBL627731,BAO_0000019,1969.0,
10639,,,Plasma,A,,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",U,,1,,CHEMBL627732,BAO_0000019,1969.0,
10640,,,Plasma,A,,,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",U,,1,,CHEMBL627733,BAO_0000019,1969.0,
10641,,,Plasma,A,,,,AUC(area under curve) was determined after intravenous administration in rats,N,,1,,CHEMBL627734,BAO_0000218,1969.0,
10642,,,Plasma,A,,,,AUC(area under curve) was determined after oral administration in rats,N,,1,,CHEMBL627735,BAO_0000218,1969.0,
10643,,,Plasma,A,,,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,N,,1,,CHEMBL627736,BAO_0000218,1969.0,
10644,,,Plasma,A,,,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,N,,1,,CHEMBL876809,BAO_0000218,1969.0,
10645,,,,A,,,,Area Under Curve after oral dosing of 100 uM/Kg,U,,1,,CHEMBL627737,BAO_0000019,,
10646,,,,A,,,,Area Under Curve after oral dosing of 30 uM/Kg,U,,1,,CHEMBL627738,BAO_0000019,,
10647,,,,A,,,,Area Under Curve was measured by ploting the graph between concentration verses time,U,,1,,CHEMBL627739,BAO_0000019,,
10648,,,,A,,,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,N,,1,,CHEMBL626143,BAO_0000218,,
10649,,,,A,,,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,U,,1,,CHEMBL626144,BAO_0000218,,
10650,,,,A,,,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,N,,1,,CHEMBL626145,BAO_0000218,,
10651,,,,A,,,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,N,,1,,CHEMBL626146,BAO_0000218,,
10652,,,Blood,A,,,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,N,,1,,CHEMBL626147,BAO_0000218,178.0,
10653,,,,A,,,,Area under curve (AUC) was determined,U,,1,,CHEMBL626148,BAO_0000019,,
10654,,,,A,,,,Area under curve (AUC) following ip administration at 1 mg/kg,U,,1,,CHEMBL626149,BAO_0000218,,
10655,,,,A,,,,Area under curve (AUC) was determined; ND is Not determined,U,,1,,CHEMBL626150,BAO_0000019,,
10656,,,,A,,,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,N,,1,,CHEMBL626151,BAO_0000218,,
10657,,,,A,,,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,N,,1,,CHEMBL626152,BAO_0000218,,
10658,,,,A,,,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,N,,1,,CHEMBL626153,BAO_0000218,,
10659,,,,A,,,,Area under curve (AUR) was determined,U,,1,,CHEMBL626154,BAO_0000019,,
10660,,,,A,,,,Area under curve at 1 uM/dg administered intravenously,U,,1,,CHEMBL626155,BAO_0000019,,
10661,,,,A,,,,Area under curve at 10 uM/dg administered perorally,U,,1,,CHEMBL626156,BAO_0000019,,
10662,,,,A,,,,Area under curve at 2 uM/dg administered intravenously,U,,1,,CHEMBL626157,BAO_0000019,,
10663,,,,A,,,,Area under curve at 20 uM/dg administered perorally,U,,1,,CHEMBL626158,BAO_0000019,,
10664,,,,A,,,,Area under curve at a peroral dose of 3 mg/kg in dog,N,,1,,CHEMBL626159,BAO_0000218,,
10665,,,,A,,,,Area under curve at a peroral dose of 3 mg/kg in rat,N,,1,,CHEMBL626160,BAO_0000218,,
10666,,,,A,,,,Area under curve at an iv dose of 1 mg/kg in dog,N,,1,,CHEMBL626161,BAO_0000218,,
10667,,,,A,,,,Area under curve at an iv dose of 1 mg/kg in rat,N,,1,,CHEMBL626162,BAO_0000218,,
10668,,,,A,,,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,U,,1,,CHEMBL626163,BAO_0000019,,
10669,,,,A,,,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,U,,1,,CHEMBL626164,BAO_0000019,,
10670,,,,A,,,,Area under curve measured as conc vs time after intravenous administration to mice.,N,,1,,CHEMBL626165,BAO_0000218,,
10671,,,,A,,,,Area under curve measured as conc vs time after peroral administration to mice.,N,,1,,CHEMBL626166,BAO_0000218,,
10672,,,,A,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,N,,1,,CHEMBL626167,BAO_0000218,,
10673,,,,A,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,N,,1,,CHEMBL626168,BAO_0000218,,
10674,,,,A,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,N,,1,,CHEMBL877463,BAO_0000218,,
10675,,,,A,,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,N,,1,,CHEMBL626169,BAO_0000218,,
10676,,In vivo,Heart,A,,,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,N,,1,,CHEMBL626170,BAO_0000218,948.0,
10677,,In vivo,Heart,A,,,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,N,,1,,CHEMBL626171,BAO_0000218,948.0,
10678,,In vivo,Heart,A,,,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,N,,1,,CHEMBL626172,BAO_0000218,948.0,
10679,,In vivo,Heart,A,,,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,N,,1,,CHEMBL626173,BAO_0000218,948.0,
10680,,In vivo,Kidney,A,,,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,N,,1,,CHEMBL626174,BAO_0000218,2113.0,
10681,,In vivo,Kidney,A,,,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,N,,1,,CHEMBL626175,BAO_0000218,2113.0,
10682,,In vivo,Kidney,A,,,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,N,,1,,CHEMBL626176,BAO_0000218,2113.0,
10683,,In vivo,Kidney,A,,,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,N,,1,,CHEMBL626177,BAO_0000218,2113.0,
10684,,In vivo,Kidney,A,,,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,N,,1,,CHEMBL622499,BAO_0000218,2113.0,
10685,,In vivo,Liver,A,,,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,N,,1,,CHEMBL622500,BAO_0000218,2107.0,
10686,,In vivo,Liver,A,,,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,N,,1,,CHEMBL622501,BAO_0000218,2107.0,
10687,,In vivo,Liver,A,,,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,N,,1,,CHEMBL622502,BAO_0000218,2107.0,
10688,,In vivo,Liver,A,,,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,N,,1,,CHEMBL622503,BAO_0000218,2107.0,
10689,,In vivo,Liver,A,,,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,N,,1,,CHEMBL877614,BAO_0000218,2107.0,
10690,,In vivo,Lung,A,,,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,N,,1,,CHEMBL624839,BAO_0000218,2048.0,
10691,,In vivo,Lung,A,,,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,N,,1,,CHEMBL624840,BAO_0000218,2048.0,
10692,,In vivo,Lung,A,,,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,N,,1,,CHEMBL624841,BAO_0000218,2048.0,
10693,,In vivo,Lung,A,,,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,N,,1,,CHEMBL624842,BAO_0000218,2048.0,
10694,,In vivo,Muscle tissue,A,,,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,N,,1,,CHEMBL624843,BAO_0000218,2385.0,
10695,,In vivo,Muscle tissue,A,,,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,N,,1,,CHEMBL624844,BAO_0000218,2385.0,
10696,,In vivo,Muscle tissue,A,,,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,N,,1,,CHEMBL624845,BAO_0000218,2385.0,
10697,,In vivo,Muscle tissue,A,,,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,N,,1,,CHEMBL621904,BAO_0000218,2385.0,
10698,,In vivo,Blood,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,N,,1,,CHEMBL621905,BAO_0000218,178.0,
10699,,In vivo,Blood,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,N,,1,,CHEMBL874382,BAO_0000218,178.0,
10700,,In vivo,Blood,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,N,,1,,CHEMBL621906,BAO_0000218,178.0,
10701,,In vivo,Brain,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,N,,1,,CHEMBL621907,BAO_0000218,955.0,
10702,,In vivo,Brain,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,N,,1,,CHEMBL622096,BAO_0000218,955.0,
10703,,In vivo,Brain,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,N,,1,,CHEMBL622097,BAO_0000218,955.0,
10704,,In vivo,Heart,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,N,,1,,CHEMBL622098,BAO_0000218,948.0,
10705,,In vivo,Heart,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,N,,1,,CHEMBL622099,BAO_0000218,948.0,
10706,,In vivo,Heart,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,N,,1,,CHEMBL622100,BAO_0000218,948.0,
10707,,In vivo,Kidney,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,N,,1,,CHEMBL622101,BAO_0000218,2113.0,
10708,,In vivo,Kidney,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,N,,1,,CHEMBL622102,BAO_0000218,2113.0,
10709,,In vivo,Kidney,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,N,,1,,CHEMBL622103,BAO_0000218,2113.0,
10710,,In vivo,Liver,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,N,,1,,CHEMBL622104,BAO_0000218,2107.0,
10711,,In vivo,Liver,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,N,,1,,CHEMBL622105,BAO_0000218,2107.0,
10712,,In vivo,Liver,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,N,,1,,CHEMBL622106,BAO_0000218,2107.0,
10713,,In vivo,Lung,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,N,,1,,CHEMBL622107,BAO_0000218,2048.0,
10714,,In vivo,Lung,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,N,,1,,CHEMBL622108,BAO_0000218,2048.0,
10715,,In vivo,Lung,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,N,,1,,CHEMBL622109,BAO_0000218,2048.0,
10716,,In vivo,Muscle tissue,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,N,,1,,CHEMBL622110,BAO_0000218,2385.0,
10717,,In vivo,Muscle tissue,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,N,,1,,CHEMBL622111,BAO_0000218,2385.0,
10718,,In vivo,Muscle tissue,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,N,,1,,CHEMBL874383,BAO_0000218,2385.0,
10719,,In vivo,Zone of skin,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,N,,1,,CHEMBL622112,BAO_0000218,14.0,
10720,,In vivo,Zone of skin,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,N,,1,,CHEMBL622113,BAO_0000218,14.0,
10721,,In vivo,Zone of skin,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,N,,1,,CHEMBL622114,BAO_0000218,14.0,
10722,,In vivo,Spleen,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,N,,1,,CHEMBL622115,BAO_0000218,2106.0,
10723,,In vivo,Spleen,A,,,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,N,,1,,CHEMBL622116,BAO_0000218,2106.0,
10724,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622117,BAO_0000218,,
10725,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622118,BAO_0000218,,
10726,,In vivo,,A,,,,Oral bioavailability in rats at 6 mg/kg,N,,1,,CHEMBL622119,BAO_0000218,,
10727,,In vivo,,A,,,,Oral bioavailability in rat (dose 6 mg/kg),N,,1,,CHEMBL622120,BAO_0000218,,
10728,,In vivo,,A,,,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,N,,1,,CHEMBL622121,BAO_0000218,,
10729,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622122,BAO_0000218,,
10730,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622123,BAO_0000218,,
10731,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL622124,BAO_0000218,,
10732,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL622125,BAO_0000218,,
10733,,In vivo,,A,,,,Oral bioavailability,N,,1,,CHEMBL622126,BAO_0000218,,
10734,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),N,,1,,CHEMBL620455,BAO_0000218,,
10735,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL620456,BAO_0000218,,
10736,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL620457,BAO_0000218,,
10737,,In vivo,,A,,,,Oral bioavailability was evaluated; Not tested,N,,1,,CHEMBL620458,BAO_0000218,,
10738,,In vivo,,A,,,,Oral bioavailability,N,,1,,CHEMBL620459,BAO_0000218,,
10739,,In vivo,,A,,,,Oral bioavailability in rat by oral dosing,N,,1,,CHEMBL620460,BAO_0000218,,
10740,,In vivo,,A,,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),N,,1,,CHEMBL620461,BAO_0000218,,
10741,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley),N,,1,,CHEMBL620462,BAO_0000218,,
10742,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),N,,1,,CHEMBL620463,BAO_0000218,,
10743,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),N,,1,,CHEMBL620464,BAO_0000218,,
10744,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),N,,1,,CHEMBL620465,BAO_0000218,,
10745,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),N,,1,,CHEMBL620466,BAO_0000218,,
10746,,In vivo,,A,,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,N,,1,,CHEMBL620467,BAO_0000218,,
10747,,In vivo,,A,,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,N,,1,,CHEMBL620468,BAO_0000218,,
10748,,In vivo,,A,,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,N,,1,,CHEMBL620469,BAO_0000218,,
10749,,In vivo,,A,,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,N,,1,,CHEMBL620470,BAO_0000218,,
10750,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL620471,BAO_0000218,,
10751,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL620472,BAO_0000218,,
10752,,In vivo,,A,,,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,N,,1,,CHEMBL620473,BAO_0000218,,
10753,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL620474,BAO_0000218,,
10754,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),N,,1,,CHEMBL620475,BAO_0000218,,
10755,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL620476,BAO_0000218,,
10756,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL620477,BAO_0000218,,
10757,,In vivo,,A,,,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,N,,1,,CHEMBL620478,BAO_0000218,,
10758,,In vivo,,A,,,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,N,,1,,CHEMBL618768,BAO_0000218,,
10759,,In vivo,,A,,,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,N,,1,,CHEMBL618769,BAO_0000218,,
10760,,In vivo,,A,,,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,N,,1,,CHEMBL618770,BAO_0000218,,
10761,,In vivo,,A,,,,Oral bioavailability (dose 20 mg/kg p.o.),N,,1,,CHEMBL618771,BAO_0000218,,
10762,,In vivo,,A,,,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,N,,1,,CHEMBL618772,BAO_0000218,,
10763,,In vivo,,A,,,,Oral bioavailability in rat at 10 mg/kg of the compound,N,,1,,CHEMBL618773,BAO_0000218,,
10764,,In vivo,,A,,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,N,,1,,CHEMBL875842,BAO_0000218,,
10765,,In vivo,,A,,,,Bioavailability in rat (dose 3 mg/kg i.v.),N,,1,,CHEMBL618774,BAO_0000218,,
10766,,In vivo,,A,,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,N,,1,,CHEMBL618775,BAO_0000218,,
10767,,In vivo,,A,,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),N,,1,,CHEMBL618776,BAO_0000218,,
10768,,In vivo,,A,,,,Percent bioavailability (F) in rats after iv administration,N,,1,,CHEMBL618777,BAO_0000218,,
10769,,In vivo,,A,,,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,N,,1,,CHEMBL618778,BAO_0000218,,
10770,,In vivo,,A,,,,Bioavailability in rat (dose 5 uM/kg p.o.),N,,1,,CHEMBL618779,BAO_0000218,,
10771,,In vivo,,A,,,,Oral bioavailability,N,,1,,CHEMBL618780,BAO_0000218,,
10772,,In vivo,,A,,,,Bioavailability in rat (dose 2 mg/kg p.o.),N,,1,,CHEMBL618781,BAO_0000218,,
10773,,In vivo,,A,,,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,N,,1,,CHEMBL618782,BAO_0000218,,
10774,,In vivo,,A,,,,Oral bioavailability in rat (dose 20 mg/kg),N,,1,,CHEMBL618783,BAO_0000218,,
10775,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL618784,BAO_0000218,,
10776,,In vivo,,A,,,,Percent oral bioavailability evaluated in rat,N,,1,,CHEMBL618785,BAO_0000218,,
10777,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL618786,BAO_0000218,,
10778,,In vivo,,A,,,,Percent oral bioavailability in rat; Not determined,N,,1,,CHEMBL618787,BAO_0000218,,
10779,,In vivo,,A,,,,Oral bioavailability in rat,N,,1,,CHEMBL618788,BAO_0000218,,
10780,,In vivo,,A,,,,Bioavailability in rat,N,,1,,CHEMBL618789,BAO_0000218,,
10781,,In vivo,,A,,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),N,,1,,CHEMBL618790,BAO_0000218,,
10782,,In vivo,,A,,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),N,,1,,CHEMBL618791,BAO_0000218,,
10783,,In vivo,,A,,,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,N,,1,,CHEMBL875843,BAO_0000218,,
10784,,In vivo,,A,,,,Oral bioavailability in rat (dose 20 mg/kg p.o.),N,,1,,CHEMBL618792,BAO_0000218,,
10785,,In vivo,,A,,,,Cmax at a dose of 30 mg/kg in rat,N,,1,,CHEMBL623395,BAO_0000218,,
10786,,In vivo,,A,,,,Cmax in monkeys at a dose of 1 mg/kg,U,,1,,CHEMBL623396,BAO_0000218,,
10787,,In vivo,,A,,,,Cmax in rat,N,,1,,CHEMBL623397,BAO_0000218,,
10788,,In vivo,,A,,,,Cmax in rats at a dose of 1 mg/kg,N,,1,,CHEMBL623398,BAO_0000218,,
10789,,In vivo,,A,,,,Cmax was measured in mice after an oral dose of 50 mg/kg.,N,,1,,CHEMBL623399,BAO_0000218,,
10790,,In vivo,,A,,,,"Cmax value at a dose of 12.7 uM/kg, po",U,,1,,CHEMBL623400,BAO_0000218,,
10791,,In vivo,,A,,,,"Cmax value at a dose of 6.3 uM/kg, iv",U,,1,,CHEMBL623401,BAO_0000218,,
10792,,In vivo,,A,,,,"Cmax value at a dose of 7.1 uM/kg, iv",U,,1,,CHEMBL623402,BAO_0000218,,
10793,,In vivo,,A,,,,Cmax value of compound was determined after 1 hr,U,,1,,CHEMBL623403,BAO_0000218,,
10794,,In vivo,,A,,,,Cmax value of the compound,U,,1,,CHEMBL623404,BAO_0000218,,
10795,,In vivo,,A,,,,Cmax value administered intraintestinal in rats.,N,,1,,CHEMBL625997,BAO_0000218,,
10796,,In vivo,,A,,,,Cmax value administered perorally was determined in rat; Not determined,N,,1,,CHEMBL625998,BAO_0000218,,
10797,,In vivo,,A,,,,Cmax value at the dose of 2.3 mg/kg,U,,1,,CHEMBL625999,BAO_0000218,,
10798,,In vivo,,A,,,,Cmax value at the dose of 5 mg/kg,U,,1,,CHEMBL626000,BAO_0000218,,
10799,,In vivo,,A,,,,Cmax value in the period of 8 hr after dosing. ,U,,1,,CHEMBL626001,BAO_0000218,,
10800,,In vivo,,A,,,,Cmax value at a oral dose of 20 mg/kg; Not tested,U,,1,,CHEMBL626002,BAO_0000218,,
10801,,In vivo,,A,,,,Cmax value at a oral dose of 20 mg/kg,U,,1,,CHEMBL626003,BAO_0000218,,
10802,,In vivo,,A,,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,N,,1,,CHEMBL626004,BAO_0000218,,
10803,,In vivo,,A,,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,N,,1,,CHEMBL626005,BAO_0000218,,
10804,,In vivo,,A,,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,N,,1,,CHEMBL626006,BAO_0000218,,
10805,,In vivo,Plasma,A,,,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,N,,1,,CHEMBL626007,BAO_0000218,1969.0,
10806,,In vivo,Plasma,A,,,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,N,,1,,CHEMBL626008,BAO_0000218,1969.0,
10807,,In vivo,Liver,A,,,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,N,,1,,CHEMBL626009,BAO_0000218,2107.0,
10808,,In vivo,,A,,,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,N,,1,,CHEMBL626010,BAO_0000218,,
10809,,In vivo,Blood,A,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,N,,1,,CHEMBL626011,BAO_0000218,178.0,
10810,,In vivo,Blood,A,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,N,,1,,CHEMBL626012,BAO_0000218,178.0,
10811,,In vivo,Blood,A,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,N,,1,,CHEMBL626013,BAO_0000218,178.0,
10812,,In vivo,Blood,A,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,N,,1,,CHEMBL626014,BAO_0000218,178.0,
10813,,In vivo,Blood,A,,,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,N,,1,,CHEMBL877496,BAO_0000218,178.0,
10814,,In vivo,,F,,,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,N,,1,,CHEMBL626015,BAO_0000218,,
10815,,In vivo,,F,,,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,N,,1,,CHEMBL626016,BAO_0000218,,
10816,,In vivo,,F,,,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,N,,1,,CHEMBL626017,BAO_0000218,,
10817,,In vivo,Plasma,A,,,,Bioavailability as maximal plasma concentration in dogs,N,,1,,CHEMBL626018,BAO_0000218,1969.0,
10818,,In vivo,Plasma,A,,,,Bioavailability as maximal plasma concentration in dogs,N,,1,,CHEMBL626692,BAO_0000218,1969.0,
10819,,In vivo,Plasma,A,,,,Bioavailability as maximal plasma concentration in rats,N,,1,,CHEMBL626693,BAO_0000218,1969.0,
10820,,In vivo,Plasma,A,,,,Bioavailability as maximal plasma concentration in rats,U,,1,,CHEMBL626694,BAO_0000218,1969.0,
10821,,In vivo,Blood,A,,,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,N,,1,,CHEMBL626695,BAO_0000218,178.0,
10822,,In vivo,Blood,A,,,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,N,,1,,CHEMBL626696,BAO_0000218,178.0,
10823,,In vivo,Blood,A,,,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,N,,1,,CHEMBL626697,BAO_0000218,178.0,
10824,,In vivo,Blood,A,,,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,N,,1,,CHEMBL626859,BAO_0000218,178.0,
10825,,In vivo,Blood,A,,,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,N,,1,,CHEMBL626860,BAO_0000218,178.0,
10826,,In vivo,Blood,A,,,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,N,,1,,CHEMBL626861,BAO_0000218,178.0,
10827,,In vivo,,A,,,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,N,,1,,CHEMBL626296,BAO_0000218,,
10828,,In vivo,,A,,,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,U,,1,,CHEMBL626297,BAO_0000218,,
10829,,In vivo,Plasma,A,,,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,U,,1,,CHEMBL626298,BAO_0000218,1969.0,
10830,,In vivo,Plasma,A,,,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",N,,1,,CHEMBL626299,BAO_0000218,1969.0,
10831,,In vivo,Plasma,A,,,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,N,,1,,CHEMBL626300,BAO_0000218,1969.0,
10832,,In vivo,Plasma,A,,,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,N,,1,,CHEMBL626301,BAO_0000218,1969.0,
10833,,In vivo,Plasma,A,,,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,N,,1,,CHEMBL626962,BAO_0000218,1969.0,
10834,,In vivo,Plasma,A,,,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,N,,1,,CHEMBL626963,BAO_0000218,1969.0,
10835,,In vivo,Plasma,A,,,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,N,,1,,CHEMBL626964,BAO_0000218,1969.0,
10836,,In vivo,Plasma,A,,,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,N,,1,,CHEMBL626965,BAO_0000218,1969.0,
10837,,In vivo,Plasma,A,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,,1,,CHEMBL626966,BAO_0000218,1969.0,
10838,,In vivo,Plasma,A,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,,1,,CHEMBL626967,BAO_0000218,1969.0,
10839,,In vivo,Plasma,A,,,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,N,,1,,CHEMBL626968,BAO_0000218,1969.0,
10840,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,N,,1,,CHEMBL626969,BAO_0000218,948.0,
10841,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,N,,1,,CHEMBL627126,BAO_0000218,948.0,
10842,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,N,,1,,CHEMBL631276,BAO_0000218,948.0,
10843,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,N,,1,,CHEMBL631277,BAO_0000218,948.0,
10844,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,N,,1,,CHEMBL631278,BAO_0000218,948.0,
10845,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,N,,1,,CHEMBL874457,BAO_0000218,948.0,
10846,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,N,,1,,CHEMBL631279,BAO_0000218,948.0,
10847,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,N,,1,,CHEMBL631280,BAO_0000218,948.0,
10848,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,N,,1,,CHEMBL631281,BAO_0000218,948.0,
10849,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,N,,1,,CHEMBL631968,BAO_0000218,948.0,
10850,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,N,,1,,CHEMBL631969,BAO_0000218,948.0,
10851,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,N,,1,,CHEMBL631970,BAO_0000218,948.0,
10852,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,N,,1,,CHEMBL631971,BAO_0000218,948.0,
10853,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,N,,1,,CHEMBL631972,BAO_0000218,948.0,
10854,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,N,,1,,CHEMBL630435,BAO_0000218,948.0,
10855,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,N,,1,,CHEMBL630436,BAO_0000218,948.0,
10856,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,N,,1,,CHEMBL630437,BAO_0000218,948.0,
10857,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,N,,1,,CHEMBL630438,BAO_0000218,948.0,
10858,,,Heart,A,,,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,N,,1,,CHEMBL630439,BAO_0000218,948.0,
10859,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,N,,1,,CHEMBL630440,BAO_0000218,2113.0,
10860,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,N,,1,,CHEMBL630441,BAO_0000218,2113.0,
10861,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,N,,1,,CHEMBL630442,BAO_0000218,2113.0,
10862,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,N,,1,,CHEMBL625234,BAO_0000218,2113.0,
10863,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,N,,1,,CHEMBL625235,BAO_0000218,2113.0,
10864,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,N,,1,,CHEMBL625236,BAO_0000218,2113.0,
10865,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,N,,1,,CHEMBL625237,BAO_0000218,2113.0,
10866,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,N,,1,,CHEMBL626125,BAO_0000218,2113.0,
10867,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,N,,1,,CHEMBL626126,BAO_0000218,2113.0,
10868,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,N,,1,,CHEMBL626127,BAO_0000218,2113.0,
10869,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,N,,1,,CHEMBL626128,BAO_0000218,2113.0,
10870,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,N,,1,,CHEMBL626129,BAO_0000218,2113.0,
10871,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,N,,1,,CHEMBL626130,BAO_0000218,2113.0,
10872,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,N,,1,,CHEMBL626131,BAO_0000218,2113.0,
10873,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,N,,1,,CHEMBL626132,BAO_0000218,2113.0,
10874,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,N,,1,,CHEMBL626752,BAO_0000218,2113.0,
10875,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,N,,1,,CHEMBL626753,BAO_0000218,2113.0,
10876,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,N,,1,,CHEMBL626754,BAO_0000218,2113.0,
10877,,,Kidney,A,,,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,N,,1,,CHEMBL626755,BAO_0000218,2113.0,
10878,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,N,,1,,CHEMBL626756,BAO_0000218,2107.0,
10879,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,N,,1,,CHEMBL626757,BAO_0000218,2107.0,
10880,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,N,,1,,CHEMBL626758,BAO_0000218,2107.0,
10881,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,N,,1,,CHEMBL626759,BAO_0000218,2107.0,
10882,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,N,,1,,CHEMBL626760,BAO_0000218,2107.0,
10883,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL626394,BAO_0000218,,
10884,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,N,,1,,CHEMBL626395,BAO_0000218,,
10885,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),N,,1,,CHEMBL626396,BAO_0000218,,
10886,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),N,,1,,CHEMBL626397,BAO_0000218,,
10887,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),N,,1,,CHEMBL626398,BAO_0000218,,
10888,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL626399,BAO_0000218,,
10889,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,N,,1,,CHEMBL874653,BAO_0000218,,
10890,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL626400,BAO_0000218,,
10891,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),N,,1,,CHEMBL626401,BAO_0000218,,
10892,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),N,,1,,CHEMBL626402,BAO_0000218,,
10893,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),N,,1,,CHEMBL626403,BAO_0000218,,
10894,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL626404,BAO_0000218,,
10895,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,N,,1,,CHEMBL626405,BAO_0000218,,
10896,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL625529,BAO_0000218,,
10897,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),N,,1,,CHEMBL625530,BAO_0000218,,
10898,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),N,,1,,CHEMBL625531,BAO_0000218,,
10899,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),N,,1,,CHEMBL625532,BAO_0000218,,
10900,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL625533,BAO_0000218,,
10901,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,N,,1,,CHEMBL875474,BAO_0000218,,
10902,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL625534,BAO_0000218,,
10903,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),N,,1,,CHEMBL625535,BAO_0000218,,
10904,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),N,,1,,CHEMBL625536,BAO_0000218,,
10905,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),N,,1,,CHEMBL625537,BAO_0000218,,
10906,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL625538,BAO_0000218,,
10907,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,N,,1,,CHEMBL625539,BAO_0000218,,
10908,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL625540,BAO_0000218,,
10909,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),N,,1,,CHEMBL625541,BAO_0000218,,
10910,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),N,,1,,CHEMBL625542,BAO_0000218,,
10911,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),N,,1,,CHEMBL625543,BAO_0000218,,
10912,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL625544,BAO_0000218,,
10913,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,N,,1,,CHEMBL625545,BAO_0000218,,
10914,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),N,,1,,CHEMBL625546,BAO_0000218,,
10915,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,N,,1,,CHEMBL625547,BAO_0000218,,
10916,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL625548,BAO_0000218,,
10917,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL625549,BAO_0000218,,
10918,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),N,,1,,CHEMBL625550,BAO_0000218,,
10919,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL625551,BAO_0000218,,
10920,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL875475,BAO_0000218,,
10921,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL625552,BAO_0000218,,
10922,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),N,,1,,CHEMBL625553,BAO_0000218,,
10923,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),N,,1,,CHEMBL625554,BAO_0000218,,
10924,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),N,,1,,CHEMBL625555,BAO_0000218,,
10925,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL625556,BAO_0000218,,
10926,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,N,,1,,CHEMBL624986,BAO_0000218,,
10927,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),N,,1,,CHEMBL624987,BAO_0000218,,
10928,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),N,,1,,CHEMBL624988,BAO_0000218,,
10929,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,N,,1,,CHEMBL624989,BAO_0000218,1637.0,
10930,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,N,,1,,CHEMBL624990,BAO_0000218,1637.0,
10931,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,N,,1,,CHEMBL874391,BAO_0000218,1637.0,
10932,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,N,,1,,CHEMBL624991,BAO_0000218,1637.0,
10933,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,N,,1,,CHEMBL624992,BAO_0000218,1637.0,
10934,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,N,,1,,CHEMBL624993,BAO_0000218,1637.0,
10935,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,N,,1,,CHEMBL624994,BAO_0000218,1637.0,
10936,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,N,,1,,CHEMBL624995,BAO_0000218,1637.0,
10937,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,N,,1,,CHEMBL624996,BAO_0000218,1637.0,
10938,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,N,,1,,CHEMBL624997,BAO_0000218,1637.0,
10939,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,N,,1,,CHEMBL624998,BAO_0000218,1637.0,
10940,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,N,,1,,CHEMBL624999,BAO_0000218,1637.0,
10941,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,N,,1,,CHEMBL882955,BAO_0000218,1637.0,
10942,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,N,,1,,CHEMBL625000,BAO_0000218,1637.0,
10943,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,N,,1,,CHEMBL625001,BAO_0000218,1637.0,
10944,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,N,,1,,CHEMBL625089,BAO_0000218,1637.0,
10945,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,N,,1,,CHEMBL625090,BAO_0000218,1637.0,
10946,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,N,,1,,CHEMBL625091,BAO_0000218,1637.0,
10947,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,N,,1,,CHEMBL625092,BAO_0000218,1637.0,
10948,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,N,,1,,CHEMBL625093,BAO_0000218,1637.0,
10949,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,N,,1,,CHEMBL625094,BAO_0000218,1637.0,
10950,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,N,,1,,CHEMBL625095,BAO_0000218,1637.0,
10951,,In vivo,,A,,,,Compound was evaluated for its bioavailability in the dogs,N,,1,,CHEMBL625096,BAO_0000218,,
10952,,In vivo,,A,,,,Compound was evaluated for its bioavailability in the rats,N,,1,,CHEMBL625097,BAO_0000218,,
10953,,In vivo,,A,,,,Compound was evaluated for oral bioavailability,U,,1,,CHEMBL882956,BAO_0000218,,
10954,,In vivo,,A,,,,Compound was evaluated for percentage of Oral bioavailability in rats,N,,1,,CHEMBL625098,BAO_0000218,,
10955,,In vivo,,A,,,,Bioavailability in guinea pig,U,,1,,CHEMBL625099,BAO_0000218,,
10956,,In vivo,,A,,,,Compound was evaluated for the oral bioavailability in rat,N,,1,,CHEMBL625100,BAO_0000218,,
10957,,In vivo,,A,,,,Compound was evaluated for the oral bioavailability in dog,N,,1,,CHEMBL625101,BAO_0000218,,
10958,,In vivo,,A,,,,Compound was evaluated for the oral bioavailability in rat,N,,1,,CHEMBL874396,BAO_0000218,,
10959,,In vivo,,F,,,,Bioavailability in dog (dosed i.v.),U,,1,,CHEMBL625102,BAO_0000218,,
10960,,In vivo,,A,,,,Compound was tested for in vivo bioavailability in dog,N,,1,,CHEMBL625103,BAO_0000218,,
10961,,In vivo,,A,,,,Compound was tested for in vivo bioavailability in hamsters,N,,1,,CHEMBL625104,BAO_0000218,,
10962,,In vivo,,A,,,,Compound was tested for in vivo bioavailability in monkey,U,,1,,CHEMBL625105,BAO_0000218,,
10963,,In vivo,,A,,,,Compound was tested for in vivo bioavailability in rat,N,,1,,CHEMBL625106,BAO_0000218,,
10964,,In vivo,,A,,,,Oral bioavailability in mouse,U,,1,,CHEMBL625107,BAO_0000218,,
10965,,In vivo,,A,,,,Compound was tested for percent of oral bioavailability in mice; 56-74,N,,1,,CHEMBL625108,BAO_0000218,,
10966,,In vivo,,A,,,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),U,,1,,CHEMBL625109,BAO_0000218,,
10967,,In vivo,,A,,,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),U,,1,,CHEMBL625110,BAO_0000218,,
10968,,In vivo,,A,,,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),U,,1,,CHEMBL625111,BAO_0000218,,
10969,,In vivo,,A,,,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),N,,1,,CHEMBL625112,BAO_0000218,,
10970,,In vivo,,A,,,,Oral bioavailability in nude mice,N,,1,,CHEMBL875334,BAO_0000218,,
10971,,In vivo,,A,,,,Bioavailability in monkey (i.d. dosing),U,,1,,CHEMBL628617,BAO_0000218,,
10972,,In vivo,,A,,,,Bioavailability in rat,U,,1,,CHEMBL628618,BAO_0000218,,
10973,,In vivo,,A,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,U,,1,,CHEMBL628619,BAO_0000218,,
10974,,In vivo,,A,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,U,,1,,CHEMBL628620,BAO_0000218,,
10975,,In vivo,,A,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",N,,1,,CHEMBL628621,BAO_0000218,,
10976,,In vivo,,A,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",N,,1,,CHEMBL628622,BAO_0000218,,
10977,,In vivo,,A,,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",N,,1,,CHEMBL628623,BAO_0000218,,
10978,,In vivo,Plasma,A,,,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,N,,1,,CHEMBL628624,BAO_0000218,1969.0,
10979,,In vivo,Plasma,A,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,,1,,CHEMBL628625,BAO_0000218,1969.0,
10980,,In vivo,Plasma,A,,,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,N,,1,,CHEMBL628626,BAO_0000218,1969.0,
10981,,In vivo,Plasma,A,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,,1,,CHEMBL627041,BAO_0000218,1969.0,
10982,,In vivo,Plasma,A,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,,1,,CHEMBL627042,BAO_0000218,1969.0,
10983,,In vivo,Plasma,A,,,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,,1,,CHEMBL627043,BAO_0000218,1969.0,
10984,,In vivo,Plasma,A,,,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,U,,1,,CHEMBL627044,BAO_0000218,1969.0,
10985,,In vivo,Plasma,A,,,,Cmax in mouse plasma,N,,1,,CHEMBL627045,BAO_0000218,1969.0,
10986,,In vivo,Plasma,A,,,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,U,,1,,CHEMBL627046,BAO_0000218,1969.0,
10987,,In vivo,Plasma,A,,,,Maximal plasma concentration in rat,N,,1,,CHEMBL627047,BAO_0000218,1969.0,
10988,,In vivo,Plasma,A,,,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,N,,1,,CHEMBL627048,BAO_0000218,1969.0,
10989,,In vivo,,A,,,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,N,,1,,CHEMBL627049,BAO_0000218,,
10990,,In vivo,,A,,,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,N,,1,,CHEMBL627050,BAO_0000218,,
10991,,In vivo,,A,,,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,N,,1,,CHEMBL627051,BAO_0000218,,
10992,,In vivo,,A,,,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,N,,1,,CHEMBL627052,BAO_0000218,,
10993,,In vivo,,A,,,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,N,,1,,CHEMBL627053,BAO_0000218,,
10994,,In vivo,,A,,,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,N,,1,,CHEMBL627054,BAO_0000218,,
10995,,In vivo,,A,,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,N,,1,,CHEMBL627055,BAO_0000218,,
10996,,In vivo,,A,,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,N,,1,,CHEMBL627056,BAO_0000218,,
10997,,In vivo,,A,,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),N,,1,,CHEMBL627057,BAO_0000218,,
10998,,In vivo,,A,,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,N,,1,,CHEMBL627058,BAO_0000218,,
10999,,In vivo,,A,,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,N,,1,,CHEMBL626211,BAO_0000218,,
11000,,In vivo,,A,,,,Maximum Concentration of the compound.,U,,1,,CHEMBL626212,BAO_0000218,,
11001,,In vivo,,A,,,,Maximum Concentration was measured after iv administration into Beagle dog,N,,1,,CHEMBL626213,BAO_0000218,,
11002,,In vivo,,A,,,,Maximum Concentration was measured after iv administration into Beagle dog.,N,,1,,CHEMBL626214,BAO_0000218,,
11003,,In vivo,,A,,,,Maximum Concentration was measured after po administration into Beagle dog,N,,1,,CHEMBL626215,BAO_0000218,,
11004,,In vivo,,A,,,,Maximum Concentration was measured after po administration into Beagle dog.,N,,1,,CHEMBL626216,BAO_0000218,,
11005,,In vivo,Blood,A,,,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,U,,1,,CHEMBL626217,BAO_0000218,178.0,
11006,,In vivo,Blood,A,,,,Maximum blood level reached after an iv dose of 12.2 uM/kg,U,,1,,CHEMBL626218,BAO_0000218,178.0,
11007,,In vivo,Blood,A,,,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,U,,1,,CHEMBL626219,BAO_0000218,178.0,
11008,,In vivo,Blood,A,,,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,U,,1,,CHEMBL626220,BAO_0000218,178.0,
11009,,In vivo,Blood,A,,,,Maximum blood level reached after an oral dose of 5.0 mg/kg,U,,1,,CHEMBL626221,BAO_0000218,178.0,
11010,,In vivo,Blood,A,,,,Maximum blood level reached at dose of 10.6 uM/kg orally,U,,1,,CHEMBL626222,BAO_0000218,178.0,
11011,,In vivo,,A,,,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,N,,1,,CHEMBL626223,BAO_0000218,,
11012,,In vivo,,A,,,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,N,,1,,CHEMBL626224,BAO_0000218,,
11013,,In vivo,Brain,A,,,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,N,,1,,CHEMBL626225,BAO_0000218,955.0,
11014,,In vivo,Brain,A,,,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,N,,1,,CHEMBL626226,BAO_0000218,955.0,
11015,,In vivo,Brain,A,,,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,N,,1,,CHEMBL626227,BAO_0000218,955.0,
11016,,In vivo,Brain,A,,,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,N,,1,,CHEMBL626228,BAO_0000218,955.0,
11017,,In vivo,,A,,,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,N,,1,,CHEMBL626229,BAO_0000218,,
11018,,In vivo,,A,,,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,N,,1,,CHEMBL626921,BAO_0000218,,
11019,,In vivo,,A,,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,N,,1,,CHEMBL876793,BAO_0000218,,
11020,,In vivo,,A,,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,N,,1,,CHEMBL625309,BAO_0000218,,
11021,,In vivo,,A,,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),N,,1,,CHEMBL625310,BAO_0000218,,
11022,,In vivo,,A,,,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,U,,1,,CHEMBL625311,BAO_0000218,,
11023,,In vivo,,A,,,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,N,,1,,CHEMBL625312,BAO_0000218,,
11024,,In vivo,,A,,,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,U,,1,,CHEMBL625313,BAO_0000218,,
11025,,In vivo,,A,,,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,N,,1,,CHEMBL625314,BAO_0000218,,
11026,,In vivo,,A,,,,Maximum concentration in male rats after iv administration of 20 mg/kg,N,,1,,CHEMBL625315,BAO_0000218,,
11027,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,N,,1,,CHEMBL625316,BAO_0000218,2107.0,
11028,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,N,,1,,CHEMBL625317,BAO_0000218,2107.0,
11029,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,N,,1,,CHEMBL625318,BAO_0000218,2107.0,
11030,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,N,,1,,CHEMBL625319,BAO_0000218,2107.0,
11031,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,N,,1,,CHEMBL625320,BAO_0000218,2107.0,
11032,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,N,,1,,CHEMBL625321,BAO_0000218,2107.0,
11033,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,N,,1,,CHEMBL625322,BAO_0000218,2107.0,
11034,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,N,,1,,CHEMBL876801,BAO_0000218,2107.0,
11035,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,N,,1,,CHEMBL625323,BAO_0000218,2107.0,
11036,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,N,,1,,CHEMBL625324,BAO_0000218,2107.0,
11037,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,N,,1,,CHEMBL625325,BAO_0000218,2107.0,
11038,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,N,,1,,CHEMBL625326,BAO_0000218,2107.0,
11039,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,N,,1,,CHEMBL625327,BAO_0000218,2107.0,
11040,,,Liver,A,,,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,N,,1,,CHEMBL625328,BAO_0000218,2107.0,
11041,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,N,,1,,CHEMBL625329,BAO_0000218,2048.0,
11042,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,N,,1,,CHEMBL625330,BAO_0000218,2048.0,
11043,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,N,,1,,CHEMBL627774,BAO_0000218,2048.0,
11044,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,N,,1,,CHEMBL627775,BAO_0000218,2048.0,
11045,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,N,,1,,CHEMBL627949,BAO_0000218,2048.0,
11046,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,N,,1,,CHEMBL627950,BAO_0000218,2048.0,
11047,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,N,,1,,CHEMBL627951,BAO_0000218,2048.0,
11048,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,N,,1,,CHEMBL627952,BAO_0000218,2048.0,
11049,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,N,,1,,CHEMBL627953,BAO_0000218,2048.0,
11050,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,N,,1,,CHEMBL627954,BAO_0000218,2048.0,
11051,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,N,,1,,CHEMBL627955,BAO_0000218,2048.0,
11052,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,N,,1,,CHEMBL627956,BAO_0000218,2048.0,
11053,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,N,,1,,CHEMBL876802,BAO_0000218,2048.0,
11054,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,N,,1,,CHEMBL627957,BAO_0000218,2048.0,
11055,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,N,,1,,CHEMBL627958,BAO_0000218,2048.0,
11056,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,N,,1,,CHEMBL627959,BAO_0000218,2048.0,
11057,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,N,,1,,CHEMBL627960,BAO_0000218,2048.0,
11058,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,N,,1,,CHEMBL627961,BAO_0000218,2048.0,
11059,,,Lung,A,,,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,N,,1,,CHEMBL627962,BAO_0000218,2048.0,
11060,,,,A,,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,N,,1,,CHEMBL627963,BAO_0000218,,
11061,,,,A,,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,N,,1,,CHEMBL624759,BAO_0000218,,
11062,,,,A,,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,N,,1,,CHEMBL624760,BAO_0000218,,
11063,,,,A,,,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,N,,1,,CHEMBL624761,BAO_0000218,,
11064,,,,A,,,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,N,,1,,CHEMBL877607,BAO_0000218,,
11065,,,Liver,A,,,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,N,,1,,CHEMBL624762,BAO_0000218,2107.0,
11066,,,Liver,A,,,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,N,,1,,CHEMBL624763,BAO_0000218,2107.0,
11067,,,Liver,A,,,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,N,,1,,CHEMBL624764,BAO_0000218,2107.0,
11068,,,Liver,A,,,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,N,,1,,CHEMBL624765,BAO_0000218,2107.0,
11069,,,Liver,A,,,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,N,,1,,CHEMBL624766,BAO_0000218,2107.0,
11070,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL624767,BAO_0000218,,
11071,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,N,,1,,CHEMBL624768,BAO_0000218,,
11072,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),N,,1,,CHEMBL624769,BAO_0000218,,
11073,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),N,,1,,CHEMBL624770,BAO_0000218,,
11074,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),N,,1,,CHEMBL624771,BAO_0000218,,
11075,,,,A,,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL624772,BAO_0000218,,
11076,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,N,,1,,CHEMBL624773,BAO_0000218,,
11077,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL624774,BAO_0000218,,
11078,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),N,,1,,CHEMBL624775,BAO_0000218,,
11079,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),N,,1,,CHEMBL624776,BAO_0000218,,
11080,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),N,,1,,CHEMBL624777,BAO_0000218,,
11081,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL624778,BAO_0000218,,
11082,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,N,,1,,CHEMBL624779,BAO_0000218,,
11083,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),N,,1,,CHEMBL624780,BAO_0000218,,
11084,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),N,,1,,CHEMBL624781,BAO_0000218,,
11085,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL877608,BAO_0000218,,
11086,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),N,,1,,CHEMBL624782,BAO_0000218,,
11087,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL624783,BAO_0000218,,
11088,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,N,,1,,CHEMBL624784,BAO_0000218,,
11089,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL624785,BAO_0000218,,
11090,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),N,,1,,CHEMBL624786,BAO_0000218,,
11091,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),N,,1,,CHEMBL624787,BAO_0000218,,
11092,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL628676,BAO_0000218,,
11093,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,N,,1,,CHEMBL621842,BAO_0000218,,
11094,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL621843,BAO_0000218,,
11095,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),N,,1,,CHEMBL623873,BAO_0000218,,
11096,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),N,,1,,CHEMBL623874,BAO_0000218,,
11097,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),N,,1,,CHEMBL623875,BAO_0000218,,
11098,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL623876,BAO_0000218,,
11099,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,N,,1,,CHEMBL623877,BAO_0000218,,
11100,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),N,,1,,CHEMBL623878,BAO_0000218,,
11101,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,N,,1,,CHEMBL623879,BAO_0000218,,
11102,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL623880,BAO_0000218,,
11103,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL623881,BAO_0000218,,
11104,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),N,,1,,CHEMBL623957,BAO_0000218,,
11105,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL623958,BAO_0000218,,
11106,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL623959,BAO_0000218,,
11107,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL623960,BAO_0000218,,
11108,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),N,,1,,CHEMBL623961,BAO_0000218,,
11109,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),N,,1,,CHEMBL623962,BAO_0000218,,
11110,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),N,,1,,CHEMBL624676,BAO_0000218,,
11111,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL624677,BAO_0000218,,
11112,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,N,,1,,CHEMBL624678,BAO_0000218,,
11113,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),N,,1,,CHEMBL624679,BAO_0000218,,
11114,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),N,,1,,CHEMBL624680,BAO_0000218,,
11115,,In vivo,,A,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,U,,1,,CHEMBL624849,BAO_0000218,,
11116,,In vivo,,A,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,U,,1,,CHEMBL624850,BAO_0000218,,
11117,,In vivo,,A,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,U,,1,,CHEMBL874399,BAO_0000218,,
11118,,In vivo,,A,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,U,,1,,CHEMBL624851,BAO_0000218,,
11119,,In vivo,,A,,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,U,,1,,CHEMBL624852,BAO_0000218,,
11120,,In vivo,,A,,,,Oral bioavailability in rat (dose 10 mg/kg),U,,1,,CHEMBL624853,BAO_0000218,,
11121,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley),U,,1,,CHEMBL624854,BAO_0000218,,
11122,,In vivo,,A,,,,Oral bioavailability in rat,U,,1,,CHEMBL624855,BAO_0000218,,
11123,,In vivo,,A,,,,Oral bioavailability in rats was determined in vivo,U,,1,,CHEMBL624856,BAO_0000218,,
11124,,In vivo,,A,,,,Oral bioavailability in dog,U,,1,,CHEMBL882957,BAO_0000218,,
11125,,In vivo,,A,,,,Oral bioavailability of compound in monkey,U,,1,,CHEMBL624857,BAO_0000218,,
11126,,In vivo,,A,,,,Oral bioavailability of compound in rat,N,,1,,CHEMBL622202,BAO_0000218,,
11127,,In vivo,,A,,,,Bioavailability in rat of PMEA prodrug,U,,1,,CHEMBL622203,BAO_0000218,,
11128,,In vivo,,A,,,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,N,,1,,CHEMBL625522,BAO_0000218,,
11129,,In vivo,,A,,,,Serum conc at 3 hours following 25 mg/kg dose,U,,1,,CHEMBL622868,BAO_0000218,,
11130,,In vivo,Urine,A,,,,Urine conc 0-5 hours following 25 mg/kg dose,U,,1,,CHEMBL622869,BAO_0000218,1088.0,
11131,,In vivo,Urine,A,,,,Urine conc 0-24 hours following 25 mg/kg dose,U,,1,,CHEMBL622870,BAO_0000218,1088.0,
11132,,In vivo,,A,,,,Oral bioavailability in African green monkeys; 20-25,U,,1,,CHEMBL622871,BAO_0000218,,
11133,,In vivo,,A,,,,Oral bioavailability in cynomolgus monkey.,N,,1,,CHEMBL620560,BAO_0000218,,
11134,,In vivo,,A,,,,Oral bioavailability in dog,U,,1,,CHEMBL620561,BAO_0000218,,
11135,,In vivo,,A,,,,Oral bioavailability in dog at 10 mg/kg oral dose,N,,1,,CHEMBL620562,BAO_0000218,,
11136,,In vivo,,A,,,,Oral bioavailability in hamster at 10 mg/kg oral dose,N,,1,,CHEMBL620563,BAO_0000218,,
11137,,In vivo,,A,,,,Oral bioavailability in rat at 10 mg/kg oral dose,N,,1,,CHEMBL620564,BAO_0000218,,
11138,,In vivo,,A,,,,Oral bioavailability in rat,U,,1,,CHEMBL872265,BAO_0000218,,
11139,,In vivo,,A,,,,Oral bioavailability in rat,U,,1,,CHEMBL620565,BAO_0000218,,
11140,,In vivo,,A,,,,Oral bioavailability,U,,1,,CHEMBL620566,BAO_0000218,,
11141,,In vivo,,A,,,,Oral bioavailability was determined; range 49-102%,U,,1,,CHEMBL620567,BAO_0000218,,
11142,,In vivo,,A,,,,Oral bioavailability was determined in dogs,N,,1,,CHEMBL620568,BAO_0000218,,
11143,,In vivo,,A,,,,Oral bioavailability in rat,U,,1,,CHEMBL620569,BAO_0000218,,
11144,,In vivo,,A,,,,Oral bioavailability,U,,1,,CHEMBL620570,BAO_0000218,,
11145,,In vivo,,A,,,,Oral bioavailability was determined; Not orally available,U,,1,,CHEMBL620571,BAO_0000218,,
11146,,In vivo,,A,,,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),N,,1,,CHEMBL620572,BAO_0000218,,
11147,,In vivo,,A,,,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),U,,1,,CHEMBL620573,BAO_0000218,,
11148,,In vivo,,A,,,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,U,,1,,CHEMBL620574,BAO_0000218,,
11149,,In vivo,,A,,,,Oral bioavailability in Rhesus monkey,U,,1,,CHEMBL620575,BAO_0000218,,
11150,,In vivo,,A,,,,Oral bioavailability in dog (female mongrel),U,,1,,CHEMBL620576,BAO_0000218,,
11151,,In vivo,,A,,,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,U,,1,,CHEMBL875846,BAO_0000218,,
11152,,In vivo,,A,,,,Oral bioavailability in dog,U,,1,,CHEMBL620577,BAO_0000218,,
11153,,In vivo,,A,,,,Percentage Bioavailability was evaluated.,U,,1,,CHEMBL620578,BAO_0000218,,
11154,,In vivo,,A,,,,Bioavailability in rat administered i.d.,U,,1,,CHEMBL620579,BAO_0000218,,
11155,,In vivo,,A,,,,Bioavailability,U,,1,,CHEMBL621248,BAO_0000218,,
11156,,In vivo,,A,,,,Bioavailability in dog (male Beagle) i.v. administration,U,,1,,CHEMBL625390,BAO_0000218,,
11157,,In vivo,,A,,,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",U,,1,,CHEMBL625391,BAO_0000218,,
11158,,In vivo,,A,,,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),U,,1,,CHEMBL872266,BAO_0000218,,
11159,,In vivo,,A,,,,Oral bioavailability in rat (Sprague-Dawley) (male),U,,1,,CHEMBL625392,BAO_0000218,,
11160,,In vivo,,A,,,,The oral bioavailability was measured on rats after oral administration,N,,1,,CHEMBL625393,BAO_0000218,,
11161,,In vivo,,A,,,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,N,,1,,CHEMBL625394,BAO_0000218,,
11162,,In vivo,,A,,,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,N,,1,,CHEMBL625395,BAO_0000218,,
11163,,In vivo,,A,,,,Bioavailability in rat (dose 10 mg/kg i.d.),U,,1,,CHEMBL625396,BAO_0000218,,
11164,,In vivo,,A,,,,Bioavailability in dog (male Beagle) i.v. administration,U,,1,,CHEMBL625397,BAO_0000218,,
11165,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL625398,BAO_0000218,,
11166,,In vivo,Blood,A,,,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL625399,BAO_0000218,178.0,
11167,,In vivo,Cerebellum,A,,,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL626074,BAO_0000218,2037.0,
11168,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL626075,BAO_0000218,,
11169,,In vivo,Plasma,A,,,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,N,,1,,CHEMBL626076,BAO_0000218,1969.0,
11170,,In vivo,Plasma,A,,,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,N,,1,,CHEMBL626077,BAO_0000218,1969.0,
11171,,In vivo,Blood,A,,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),N,,1,,CHEMBL626078,BAO_0000218,178.0,
11172,,In vivo,Blood,A,,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),U,,1,,CHEMBL625846,BAO_0000218,178.0,
11173,,In vivo,Blood,A,,,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),U,,1,,CHEMBL625847,BAO_0000218,178.0,
11174,,In vivo,,A,,,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,N,,1,,CHEMBL625848,BAO_0000218,,
11175,,In vivo,Plasma,A,,,,Maximum concentration of compound in plasma administered orally to rats,N,,1,,CHEMBL625849,BAO_0000218,1969.0,
11176,,In vivo,Plasma,A,,,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",N,,1,,CHEMBL626023,BAO_0000218,1969.0,
11177,,In vivo,Plasma,A,,,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",N,,1,,CHEMBL626024,BAO_0000218,1969.0,
11178,,In vivo,Plasma,A,,,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",N,,1,,CHEMBL626025,BAO_0000218,1969.0,
11179,,In vivo,,A,,,,Maximum concentration after 10 mg/kg by oral administration,U,,1,,CHEMBL626026,BAO_0000218,,
11180,,In vivo,,A,,,,Maximum concentration at a dose of 1.5 mg/kg,U,,1,,CHEMBL626027,BAO_0000218,,
11181,,In vivo,,A,,,,Maximum concentration at a dose of 2.0 mg/kg,U,,1,,CHEMBL626028,BAO_0000218,,
11182,,In vivo,Plasma,A,,,,Maximum concentration in dog plasma,N,,1,,CHEMBL626029,BAO_0000218,1969.0,
11183,,In vivo,Plasma,A,,,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,U,,1,,CHEMBL626030,BAO_0000218,1969.0,
11184,,In vivo,Plasma,A,,,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,U,,1,,CHEMBL626031,BAO_0000218,1969.0,
11185,,In vivo,Plasma,A,,,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,U,,1,,CHEMBL626032,BAO_0000218,1969.0,
11186,,In vivo,Plasma,A,,,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,U,,1,,CHEMBL626033,BAO_0000218,1969.0,
11187,,In vivo,Plasma,A,,,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,U,,1,,CHEMBL626034,BAO_0000218,1969.0,
11188,,In vivo,Plasma,A,,,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),N,,1,,CHEMBL626035,BAO_0000218,1969.0,
11189,,In vivo,Plasma,A,,,,Maximum concentration in plasma at Tmax,U,,1,,CHEMBL626036,BAO_0000218,1969.0,
11190,,In vivo,Plasma,A,,,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,N,,1,,CHEMBL626037,BAO_0000218,1969.0,
11191,,In vivo,Plasma,A,,,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,N,,1,,CHEMBL626038,BAO_0000218,1969.0,
11192,,In vivo,Plasma,A,,,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,N,,1,,CHEMBL626039,BAO_0000218,1969.0,
11193,,In vivo,Plasma,A,,,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,N,,1,,CHEMBL626040,BAO_0000218,1969.0,
11194,,In vivo,Plasma,A,,,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,N,,1,,CHEMBL626041,BAO_0000218,1969.0,
11195,,In vivo,,A,,,,Maximum concentration was calculated,U,,1,,CHEMBL626042,BAO_0000218,,
11196,,In vivo,,A,,,,Maximum concentration was calculated.,U,,1,,CHEMBL626043,BAO_0000218,,
11197,,In vivo,,A,,,,Maximum concentration at a peroral dose of 10 mg/kg,U,,1,,CHEMBL626044,BAO_0000218,,
11198,,In vivo,,A,,,,Maximum concentration of the drug at 10 uM/dg administered perorally,U,,1,,CHEMBL626045,BAO_0000218,,
11199,,In vivo,,A,,,,Maximum concentration of the drug at 2 uM/dg administered intravenously,U,,1,,CHEMBL626046,BAO_0000218,,
11200,,In vivo,Plasma,A,,,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",N,,1,,CHEMBL626047,BAO_0000218,1969.0,
11201,,In vivo,Plasma,A,,,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",N,,1,,CHEMBL626048,BAO_0000218,1969.0,
11202,,In vivo,Plasma,A,,,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",N,,1,,CHEMBL626049,BAO_0000218,1969.0,
11203,,In vivo,Plasma,A,,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,N,,1,,CHEMBL626050,BAO_0000218,1969.0,
11204,,In vivo,Plasma,A,,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,N,,1,,CHEMBL874541,BAO_0000218,1969.0,
11205,,In vivo,Plasma,A,,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,N,,1,,CHEMBL622826,BAO_0000218,1969.0,
11206,,In vivo,Plasma,A,,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,N,,1,,CHEMBL622827,BAO_0000218,1969.0,
11207,,In vivo,Plasma,A,,,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,N,,1,,CHEMBL622828,BAO_0000218,1969.0,
11208,,In vivo,Plasma,A,,,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,N,,1,,CHEMBL622829,BAO_0000218,1969.0,
11209,,In vivo,,A,,,,Maximum concentration reached following intravenous administration in male rat,N,,1,,CHEMBL876806,BAO_0000218,,
11210,,In vivo,,A,,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,N,,1,,CHEMBL622830,BAO_0000218,,
11211,,In vivo,,A,,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,N,,1,,CHEMBL622831,BAO_0000218,,
11212,,In vivo,,A,,,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,N,,1,,CHEMBL626794,BAO_0000218,,
11213,,In vivo,,A,,,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,N,,1,,CHEMBL626795,BAO_0000218,,
11214,,In vivo,,A,,,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,N,,1,,CHEMBL626796,BAO_0000218,,
11215,,In vivo,,A,,,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,N,,1,,CHEMBL626797,BAO_0000218,,
11216,,In vivo,,A,,,,Maximum drug concentration is determined after oral dosing in rats.,N,,1,,CHEMBL626798,BAO_0000218,,
11217,,In vivo,,A,,,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,N,,1,,CHEMBL626799,BAO_0000218,,
11218,,In vivo,,A,,,,Maximum observed concentration in oral (5 mg/kg) fed dogs,N,,1,,CHEMBL626800,BAO_0000218,,
11219,,In vivo,Plasma,A,,,,Maximum plasma concentration,U,,1,,CHEMBL626801,BAO_0000218,1969.0,
11220,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,N,,1,,CHEMBL876816,BAO_0000218,1969.0,
11221,,In vivo,Plasma,A,,,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,N,,1,,CHEMBL626802,BAO_0000218,1969.0,
11222,,In vivo,Plasma,A,,,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,N,,1,,CHEMBL626803,BAO_0000218,1969.0,
11223,,In vivo,Plasma,A,,,,Maximum plasma concentration following oral administration of 30 umol/kg,U,,1,,CHEMBL626804,BAO_0000218,1969.0,
11224,,,Plasma,A,,,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,N,,1,,CHEMBL626805,BAO_0000218,1969.0,
11225,,,Plasma,A,,,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,N,,1,,CHEMBL626309,BAO_0000218,1969.0,
11226,,,Plasma,A,,,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,N,,1,,CHEMBL626310,BAO_0000218,1969.0,
11227,,,Plasma,A,,,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,N,,1,,CHEMBL626311,BAO_0000218,1969.0,
11228,,,Plasma,A,,,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,N,,1,,CHEMBL626312,BAO_0000218,1969.0,
11229,,,Uterus,A,,,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,N,,1,,CHEMBL626313,BAO_0000218,995.0,
11230,,,Uterus,A,,,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,N,,1,,CHEMBL626314,BAO_0000218,995.0,
11231,,,Uterus,A,,,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,N,,1,,CHEMBL626315,BAO_0000218,995.0,
11232,,,Uterus,A,,,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,N,,1,,CHEMBL626316,BAO_0000218,995.0,
11233,,,Uterus,A,,,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,N,,1,,CHEMBL626317,BAO_0000218,995.0,
11234,,,,A,,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),N,,1,,CHEMBL626318,BAO_0000218,,
11235,,,,A,,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),N,,1,,CHEMBL626319,BAO_0000218,,
11236,,,,A,,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),N,,1,,CHEMBL626320,BAO_0000218,,
11237,,,,A,,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),N,,1,,CHEMBL875053,BAO_0000218,,
11238,,,,A,,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),N,,1,,CHEMBL626321,BAO_0000218,,
11239,,,,A,,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),N,,1,,CHEMBL626322,BAO_0000218,,
11240,,,,A,,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),N,,1,,CHEMBL626323,BAO_0000218,,
11241,,,,A,,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),N,,1,,CHEMBL626324,BAO_0000218,,
11242,,,,A,,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),N,,1,,CHEMBL626325,BAO_0000218,,
11243,,,,A,,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),N,,1,,CHEMBL626326,BAO_0000218,,
11244,,,,A,,,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),N,,1,,CHEMBL626327,BAO_0000218,,
11245,,,,A,,,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),N,,1,,CHEMBL626328,BAO_0000218,,
11246,,,Blood,A,,,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL626329,BAO_0000218,178.0,
11247,,,Blood,A,,,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL626330,BAO_0000218,178.0,
11248,,,Blood,A,,,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL626331,BAO_0000218,178.0,
11249,,,Blood,A,,,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL626332,BAO_0000218,178.0,
11250,,,Blood,A,,,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL626333,BAO_0000218,178.0,
11251,,,Blood,A,,,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL626334,BAO_0000218,178.0,
11252,,,Blood,A,,,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL626335,BAO_0000218,178.0,
11253,,,Blood,A,,,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624798,BAO_0000218,178.0,
11254,,,Brain,A,,,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",N,,1,,CHEMBL624799,BAO_0000218,955.0,
11255,,,Brain,A,,,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",N,,1,,CHEMBL624800,BAO_0000218,955.0,
11256,,,Brain,A,,,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",N,,1,,CHEMBL624801,BAO_0000218,955.0,
11257,,,Brain,A,,,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",N,,1,,CHEMBL624802,BAO_0000218,955.0,
11258,,,Brain,A,,,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",N,,1,,CHEMBL624803,BAO_0000218,955.0,
11259,,,Brain,A,,,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",N,,1,,CHEMBL624804,BAO_0000218,955.0,
11260,,,Brain,A,,,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",N,,1,,CHEMBL624805,BAO_0000218,955.0,
11261,,,Brain,A,,,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",N,,1,,CHEMBL624806,BAO_0000218,955.0,
11262,,,,A,,,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624807,BAO_0000218,,
11263,,,,A,,,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624808,BAO_0000218,,
11264,,,,A,,,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624809,BAO_0000218,,
11265,,,,A,,,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624810,BAO_0000218,,
11266,,,,A,,,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL877618,BAO_0000218,,
11267,,,,A,,,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624811,BAO_0000218,,
11268,,,,A,,,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624812,BAO_0000218,,
11269,,,,A,,,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624813,BAO_0000218,,
11270,,,,A,,,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624814,BAO_0000218,,
11271,,,,A,,,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624815,BAO_0000218,,
11272,,,,A,,,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624816,BAO_0000218,,
11273,,,,A,,,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624817,BAO_0000218,,
11274,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL624818,BAO_0000218,,
11275,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,N,,1,,CHEMBL624819,BAO_0000218,,
11276,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),N,,1,,CHEMBL624820,BAO_0000218,,
11277,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),N,,1,,CHEMBL624821,BAO_0000218,,
11278,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),N,,1,,CHEMBL624822,BAO_0000218,,
11279,,,,A,,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL624823,BAO_0000218,,
11280,,,,A,,,,Observed diffusion coefficient in organic solvent for Escherichia coli,N,,1,,CHEMBL624824,BAO_0000218,,
11281,,,Blood,A,,,,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,,1,,CHEMBL624825,BAO_0000218,178.0,
11282,,,Blood,A,,,,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,,1,,CHEMBL624826,BAO_0000218,178.0,
11283,,,Cardiac atrium,A,,,,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,,1,,CHEMBL876817,BAO_0000218,2081.0,
11284,,,Cardiac atrium,A,,,,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,,1,,CHEMBL624827,BAO_0000218,2081.0,
11285,,,,A,,,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,,1,,CHEMBL624828,BAO_0000218,,
11286,,,,A,,,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,,1,,CHEMBL624829,BAO_0000218,,
11287,,,Liver,A,,,,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,,1,,CHEMBL624830,BAO_0000218,2107.0,
11288,,,Liver,A,,,,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,,1,,CHEMBL624831,BAO_0000218,2107.0,
11289,,,Cardiac atrium,A,,,,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,,1,,CHEMBL624832,BAO_0000218,2081.0,
11290,,,Cardiac atrium,A,,,,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,,1,,CHEMBL624833,BAO_0000218,2081.0,
11291,,,,A,,,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,,1,,CHEMBL624834,BAO_0000218,,
11292,,,,A,,,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,,1,,CHEMBL624835,BAO_0000218,,
11293,,,Spleen,A,,,,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,,1,,CHEMBL624836,BAO_0000218,2106.0,
11294,,,Spleen,A,,,,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,,1,,CHEMBL624837,BAO_0000218,2106.0,
11295,,,Blood,A,,,,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,N,,1,,CHEMBL624838,BAO_0000218,178.0,
11296,,,Blood,A,,,,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,N,,1,,CHEMBL622188,BAO_0000218,178.0,
11297,,,Heart,A,,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,N,,1,,CHEMBL622189,BAO_0000218,948.0,
11298,,,Heart,A,,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,N,,1,,CHEMBL622190,BAO_0000218,948.0,
11299,,,Heart,A,,,,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,N,,1,,CHEMBL625170,BAO_0000218,948.0,
11300,,,Kidney,A,,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,N,,1,,CHEMBL625171,BAO_0000218,2113.0,
11301,,,Kidney,A,,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,N,,1,,CHEMBL625172,BAO_0000218,2113.0,
11302,,,Kidney,A,,,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,N,,1,,CHEMBL625173,BAO_0000218,2113.0,
11303,,,Liver,A,,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,N,,1,,CHEMBL625174,BAO_0000218,2107.0,
11304,,,Liver,A,,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,N,,1,,CHEMBL625175,BAO_0000218,2107.0,
11305,,,Liver,A,,,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,N,,1,,CHEMBL625176,BAO_0000218,2107.0,
11306,,,Lung,A,,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,N,,1,,CHEMBL625177,BAO_0000218,2048.0,
11307,,,Lung,A,,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,N,,1,,CHEMBL625178,BAO_0000218,2048.0,
11308,,,Lung,A,,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,N,,1,,CHEMBL625179,BAO_0000218,2048.0,
11309,,,Lung,A,,,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,N,,1,,CHEMBL625180,BAO_0000218,2048.0,
11310,,,,A,,,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",U,,1,,CHEMBL625181,BAO_0000218,,
11311,,,Urine,A,,,,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,N,,1,,CHEMBL625182,BAO_0000218,1088.0,
11312,,,,A,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,N,,1,,CHEMBL625183,BAO_0000218,,
11313,,,,A,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,N,,1,,CHEMBL875848,BAO_0000218,,
11314,,,,A,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,N,,1,,CHEMBL622260,BAO_0000218,,
11315,,,,A,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,N,,1,,CHEMBL622261,BAO_0000218,,
11316,,,,A,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,N,,1,,CHEMBL622262,BAO_0000218,,
11317,,,Kidney,A,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,N,,1,,CHEMBL622263,BAO_0000218,2113.0,
11318,,,Kidney,A,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,N,,1,,CHEMBL622418,BAO_0000218,2113.0,
11319,,,Liver,A,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,N,,1,,CHEMBL622419,BAO_0000218,2107.0,
11320,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL623388,BAO_0000218,,
11321,,In vivo,Liver,A,,,,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL623389,BAO_0000218,2107.0,
11322,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL623390,BAO_0000218,,
11323,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL623391,BAO_0000218,,
11324,,In vivo,Blood,A,,,,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL623392,BAO_0000218,178.0,
11325,,In vivo,Cerebellum,A,,,,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL623393,BAO_0000218,2037.0,
11326,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL623394,BAO_0000218,,
11327,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL618885,BAO_0000218,,
11328,,In vivo,Liver,A,,,,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL618886,BAO_0000218,2107.0,
11329,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL618887,BAO_0000218,,
11330,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL619535,BAO_0000218,,
11331,,In vivo,Blood,A,,,,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL619536,BAO_0000218,178.0,
11332,,In vivo,Cerebellum,A,,,,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL619537,BAO_0000218,2037.0,
11333,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL619705,BAO_0000218,,
11334,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL619706,BAO_0000218,,
11335,,In vivo,Liver,A,,,,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL619707,BAO_0000218,2107.0,
11336,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL619708,BAO_0000218,,
11337,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL625219,BAO_0000218,,
11338,,In vivo,Blood,A,,,,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL625220,BAO_0000218,178.0,
11339,,In vivo,Cerebellum,A,,,,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL625221,BAO_0000218,2037.0,
11340,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL625222,BAO_0000218,,
11341,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL625223,BAO_0000218,,
11342,,In vivo,Liver,A,,,,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL625224,BAO_0000218,2107.0,
11343,,In vivo,,A,,,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,1,,CHEMBL625225,BAO_0000218,,
11344,,In vivo,Blood,A,,,,Biodistribution in Rat blood after 24 hours of iv administration,N,,1,,CHEMBL625226,BAO_0000218,178.0,
11345,,In vivo,Blood,A,,,,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,N,,1,,CHEMBL625227,BAO_0000218,178.0,
11346,,In vivo,Blood,A,,,,Biodistribution in Rat blood after 30 minutes of iv administration,N,,1,,CHEMBL625228,BAO_0000218,178.0,
11347,,In vivo,Blood,A,,,,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,N,,1,,CHEMBL875354,BAO_0000218,178.0,
11348,,In vivo,Blood,A,,,,Biodistribution in Rat blood after 5 minutes of iv administration,N,,1,,CHEMBL625229,BAO_0000218,178.0,
11349,,In vivo,Blood,A,,,,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,N,,1,,CHEMBL625230,BAO_0000218,178.0,
11350,,In vivo,Heart,A,,,,Biodistribution in Rat heart after 24 hours of iv administration,N,,1,,CHEMBL625231,BAO_0000218,948.0,
11351,,In vivo,Heart,A,,,,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,N,,1,,CHEMBL625900,BAO_0000218,948.0,
11352,,In vivo,Heart,A,,,,Biodistribution in Rat heart after 30 minutes of iv administration,N,,1,,CHEMBL625901,BAO_0000218,948.0,
11353,,In vivo,Heart,A,,,,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,N,,1,,CHEMBL625902,BAO_0000218,948.0,
11354,,In vivo,Heart,A,,,,Biodistribution in Rat heart after 5 minutes of iv administration,N,,1,,CHEMBL625903,BAO_0000218,948.0,
11355,,In vivo,Heart,A,,,,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,N,,1,,CHEMBL625904,BAO_0000218,948.0,
11356,,In vivo,Liver,A,,,,Biodistribution in Rat liver after 24 hours of iv administration,N,,1,,CHEMBL625905,BAO_0000218,2107.0,
11357,,In vivo,Liver,A,,,,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,N,,1,,CHEMBL627861,BAO_0000218,2107.0,
11358,,In vivo,Liver,A,,,,Biodistribution in Rat liver after 30 minutes of iv administration,N,,1,,CHEMBL627862,BAO_0000218,2107.0,
11359,,In vivo,Liver,A,,,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,N,,1,,CHEMBL627863,BAO_0000218,2107.0,
11360,,In vivo,Liver,A,,,,Biodistribution in Rat liver after 30 minutes of iv administration,N,,1,,CHEMBL627769,BAO_0000218,2107.0,
11361,,In vivo,Plasma,A,,,,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,N,,1,,CHEMBL627770,BAO_0000218,1969.0,
11362,,In vivo,,A,,,,Cmax in cynomolgus monkey (PO dose),N,,1,,CHEMBL627771,BAO_0000218,,
11363,,In vivo,,A,,,,Cmax in rat (PO dose),N,,1,,CHEMBL627772,BAO_0000218,,
11364,,In vivo,,A,,,,Cmax in rat (PO dose),N,,1,,CHEMBL627773,BAO_0000218,,
11365,,In vivo,Plasma,A,,,,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,N,,1,,CHEMBL621922,BAO_0000218,1969.0,
11366,,In vivo,Plasma,A,,,,Cmax in rat plasma after oral dose (10 mg/kg),N,,1,,CHEMBL621923,BAO_0000218,1969.0,
11367,,In vivo,Plasma,A,,,,Cmax in plasma after oral dose (10 mg/kg),U,,1,,CHEMBL621924,BAO_0000218,1969.0,
11368,,In vivo,Plasma,A,,,,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,N,,1,,CHEMBL621925,BAO_0000218,1969.0,
11369,,In vivo,Plasma,A,,,,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,U,,1,,CHEMBL621926,BAO_0000218,1969.0,
11370,,In vivo,Plasma,A,,,,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,N,,1,,CHEMBL621927,BAO_0000218,1969.0,
11371,,In vivo,Plasma,A,,,,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,N,,1,,CHEMBL621928,BAO_0000218,1969.0,
11372,,In vivo,Plasma,A,,,,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,N,,1,,CHEMBL621929,BAO_0000218,1969.0,
11373,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,N,,1,,CHEMBL621930,BAO_0000218,1969.0,
11374,,In vivo,Plasma,A,,,,Maximum plasma concentration after oral dosing in rat,N,,1,,CHEMBL621931,BAO_0000218,1969.0,
11375,,In vivo,Plasma,A,,,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,U,,1,,CHEMBL621932,BAO_0000218,1969.0,
11376,,In vivo,Plasma,A,,,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,U,,1,,CHEMBL621933,BAO_0000218,1969.0,
11377,,In vivo,Plasma,A,,,,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,N,,1,,CHEMBL621934,BAO_0000218,1969.0,
11378,,In vivo,Plasma,A,,,,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,N,,1,,CHEMBL621935,BAO_0000218,1969.0,
11379,,In vivo,Plasma,A,,,,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,N,,1,,CHEMBL621936,BAO_0000218,1969.0,
11380,,In vivo,Plasma,A,,,,Maximum plasma concentration was determined,U,,1,,CHEMBL621937,BAO_0000218,1969.0,
11381,,In vivo,Plasma,A,,,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,U,,1,,CHEMBL621938,BAO_0000218,1969.0,
11382,,In vivo,Plasma,A,,,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,U,,1,,CHEMBL621939,BAO_0000218,1969.0,
11383,,In vivo,Plasma,A,,,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,U,,1,,CHEMBL621940,BAO_0000218,1969.0,
11384,,In vivo,Plasma,A,,,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,U,,1,,CHEMBL621941,BAO_0000218,1969.0,
11385,,In vivo,Plasma,A,,,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,U,,1,,CHEMBL621942,BAO_0000218,1969.0,
11386,,In vivo,Plasma,A,,,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,U,,1,,CHEMBL626178,BAO_0000218,1969.0,
11387,,In vivo,Plasma,A,,,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,U,,1,,CHEMBL626179,BAO_0000218,1969.0,
11388,,In vivo,Plasma,A,,,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,U,,1,,CHEMBL626180,BAO_0000218,1969.0,
11389,,In vivo,Plasma,A,,,,Plasma Cmax in rat (PO dose),N,,1,,CHEMBL626181,BAO_0000218,1969.0,
11390,,In vivo,,A,,,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,N,,1,,CHEMBL626182,BAO_0000218,,
11391,,In vivo,,A,,,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,N,,1,,CHEMBL626183,BAO_0000218,,
11392,,In vivo,,A,,,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,N,,1,,CHEMBL626184,BAO_0000218,,
11393,,In vivo,,A,,,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,N,,1,,CHEMBL626185,BAO_0000218,,
11394,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,N,,1,,CHEMBL626186,BAO_0000218,1969.0,
11395,,In vivo,Plasma,A,,,,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,N,,1,,CHEMBL877589,BAO_0000218,1969.0,
11396,,In vivo,,A,,,,Maximum concentration of the drug at 1 uM/dg administered intravenously,U,,1,,CHEMBL626187,BAO_0000218,,
11397,,In vivo,,A,,,,Maximum concentration of the drug at 20 uM/dg administered perorally,U,,1,,CHEMBL626188,BAO_0000218,,
11398,,In vivo,,A,,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,U,,1,,CHEMBL626189,BAO_0000218,,
11399,,In vivo,Blood,A,,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,U,,1,,CHEMBL626855,BAO_0000218,178.0,
11400,,In vivo,Blood,A,,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,U,,1,,CHEMBL623781,BAO_0000218,178.0,
11401,,In vivo,Blood,A,,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,U,,1,,CHEMBL623782,BAO_0000218,178.0,
11402,,In vivo,Plasma,A,,,,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,N,,1,,CHEMBL623783,BAO_0000218,1969.0,
11403,,In vivo,Plasma,A,,,,Cmax in dog plasma after 1mg/kg oral dose,N,,1,,CHEMBL623784,BAO_0000218,1969.0,
11404,,In vivo,Plasma,A,,,,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,N,,1,,CHEMBL623785,BAO_0000218,1969.0,
11405,,In vivo,Plasma,A,,,,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,N,,1,,CHEMBL623786,BAO_0000218,1969.0,
11406,,In vivo,,A,,,,Oral maximum concentration in rat,N,,1,,CHEMBL623787,BAO_0000218,,
11407,,In vivo,,A,,,,Oral maximum concentration in rat,N,,1,,CHEMBL623788,BAO_0000218,,
11408,,In vivo,Plasma,A,,,,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,N,,1,,CHEMBL623789,BAO_0000218,1969.0,
11409,,In vivo,Blood,A,,,,Peak concentration in blood after intravenous administration to mice,N,,1,,CHEMBL623790,BAO_0000218,178.0,
11410,,In vivo,Blood,A,,,,Peak concentration in blood after peroral administration to mice,N,,1,,CHEMBL623791,BAO_0000218,178.0,
11411,,In vivo,Plasma,A,,,,Peak concentration in rat plasma was determined,N,,1,,CHEMBL623792,BAO_0000218,1969.0,
11412,,In vivo,Plasma,A,,,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,U,,1,,CHEMBL623793,BAO_0000218,1969.0,
11413,,In vivo,Plasma,A,,,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,N,,1,,CHEMBL623794,BAO_0000218,1969.0,
11414,,In vivo,Plasma,A,,,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,N,,1,,CHEMBL623795,BAO_0000218,1969.0,
11415,,,,A,,,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL623796,BAO_0000218,,
11416,,,,A,,,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL623797,BAO_0000218,,
11417,,,,A,,,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL623798,BAO_0000218,,
11418,,,,A,,,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL623799,BAO_0000218,,
11419,,,Intestine,A,,,,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624490,BAO_0000218,160.0,
11420,,,Intestine,A,,,,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624491,BAO_0000218,160.0,
11421,,,Intestine,A,,,,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624492,BAO_0000218,160.0,
11422,,,Intestine,A,,,,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624493,BAO_0000218,160.0,
11423,,,Intestine,A,,,,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL877595,BAO_0000218,160.0,
11424,,,Intestine,A,,,,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624494,BAO_0000218,160.0,
11425,,,Intestine,A,,,,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624495,BAO_0000218,160.0,
11426,,,Intestine,A,,,,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624681,BAO_0000218,160.0,
11427,,,,A,,,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624682,BAO_0000218,,
11428,,,,A,,,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624683,BAO_0000218,,
11429,,,,A,,,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624684,BAO_0000218,,
11430,,,,A,,,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624685,BAO_0000218,,
11431,,,,A,,,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624686,BAO_0000218,,
11432,,,,A,,,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624687,BAO_0000218,,
11433,,,,A,,,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624688,BAO_0000218,,
11434,,,,A,,,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL627161,BAO_0000218,,
11435,,,,A,,,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL622127,BAO_0000218,,
11436,,,,A,,,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL622128,BAO_0000218,,
11437,,,,A,,,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL874384,BAO_0000218,,
11438,,,,A,,,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624898,BAO_0000218,,
11439,,,,A,,,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624899,BAO_0000218,,
11440,,,,A,,,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624900,BAO_0000218,,
11441,,,,A,,,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624901,BAO_0000218,,
11442,,,,A,,,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624902,BAO_0000218,,
11443,,,,A,,,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624903,BAO_0000218,,
11444,,,,A,,,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624904,BAO_0000218,,
11445,,,,A,,,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624905,BAO_0000218,,
11446,,,,A,,,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624906,BAO_0000218,,
11447,,,,A,,,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624907,BAO_0000218,,
11448,,,,A,,,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624908,BAO_0000218,,
11449,,,,A,,,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624909,BAO_0000218,,
11450,,,,A,,,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624910,BAO_0000218,,
11451,,,Muscle tissue,A,,,,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL624911,BAO_0000218,2385.0,
11452,,,Muscle tissue,A,,,,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL874388,BAO_0000218,2385.0,
11453,,,Muscle tissue,A,,,,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL624912,BAO_0000218,2385.0,
11454,,,Muscle tissue,A,,,,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL622930,BAO_0000218,2385.0,
11455,,,Muscle tissue,A,,,,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL623121,BAO_0000218,2385.0,
11456,,,Muscle tissue,A,,,,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL623122,BAO_0000218,2385.0,
11457,,,Muscle tissue,A,,,,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL623123,BAO_0000218,2385.0,
11458,,,Muscle tissue,A,,,,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL623124,BAO_0000218,2385.0,
11459,,,,A,,,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL623125,BAO_0000218,,
11460,,,,A,,,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL623126,BAO_0000218,,
11461,,,,A,,,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL623127,BAO_0000218,,
11462,,,,A,,,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL623128,BAO_0000218,,
11463,,,,A,,,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL623129,BAO_0000218,,
11464,,,,A,,,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL623130,BAO_0000218,,
11465,,,,A,,,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL623131,BAO_0000218,,
11466,,,,A,,,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL623132,BAO_0000218,,
11467,,,Liver,A,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,N,,1,,CHEMBL623133,BAO_0000218,2107.0,
11468,,,,A,,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,N,,1,,CHEMBL623134,BAO_0000218,,
11469,,,,A,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,N,,1,,CHEMBL874389,BAO_0000218,,
11470,,,,A,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,N,,1,,CHEMBL623135,BAO_0000218,,
11471,,,,A,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,N,,1,,CHEMBL623136,BAO_0000218,,
11472,,,,A,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,N,,1,,CHEMBL623137,BAO_0000218,,
11473,,,,A,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,N,,1,,CHEMBL623138,BAO_0000218,,
11474,,,Kidney,A,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,N,,1,,CHEMBL623139,BAO_0000218,2113.0,
11475,,,Kidney,A,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,N,,1,,CHEMBL623140,BAO_0000218,2113.0,
11476,,,Liver,A,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,N,,1,,CHEMBL623141,BAO_0000218,2107.0,
11477,,,Liver,A,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,N,,1,,CHEMBL623142,BAO_0000218,2107.0,
11478,,,,A,,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,N,,1,,CHEMBL623143,BAO_0000218,,
11479,,,Urine,A,,,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,N,,1,,CHEMBL623144,BAO_0000218,1088.0,
11480,,,Urine,A,,,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,N,,1,,CHEMBL623405,BAO_0000218,1088.0,
11481,,,,A,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,N,,1,,CHEMBL624074,BAO_0000218,,
11482,,,,A,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,N,,1,,CHEMBL624075,BAO_0000218,,
11483,,,,A,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,N,,1,,CHEMBL624076,BAO_0000218,,
11484,,,,A,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,N,,1,,CHEMBL624077,BAO_0000218,,
11485,,,,A,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,N,,1,,CHEMBL624078,BAO_0000218,,
11486,,,Kidney,A,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,N,,1,,CHEMBL624079,BAO_0000218,2113.0,
11487,,,Kidney,A,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,N,,1,,CHEMBL624261,BAO_0000218,2113.0,
11488,,,,A,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,N,,1,,CHEMBL624262,BAO_0000218,,
11489,,,,A,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,N,,1,,CHEMBL624263,BAO_0000218,,
11490,,,,A,,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,N,,1,,CHEMBL624264,BAO_0000218,,
11491,,,,A,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,N,,1,,CHEMBL624265,BAO_0000218,,
11492,,,,A,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,N,,1,,CHEMBL624266,BAO_0000218,,
11493,,,,A,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,N,,1,,CHEMBL624267,BAO_0000218,,
11494,,,,A,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,N,,1,,CHEMBL624268,BAO_0000218,,
11495,,,,A,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,N,,1,,CHEMBL875227,BAO_0000218,,
11496,,,Kidney,A,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,N,,1,,CHEMBL624269,BAO_0000218,2113.0,
11497,,,Kidney,A,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,N,,1,,CHEMBL624270,BAO_0000218,2113.0,
11498,,,,A,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,N,,1,,CHEMBL624271,BAO_0000218,,
11499,,,,A,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,N,,1,,CHEMBL624272,BAO_0000218,,
11500,,,,A,,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,N,,1,,CHEMBL624273,BAO_0000218,,
11501,,,Urine,A,,,,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,N,,1,,CHEMBL624274,BAO_0000218,1088.0,
11502,,,Urine,A,,,,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,N,,1,,CHEMBL624275,BAO_0000218,1088.0,
11503,,,Urine,A,,,,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,N,,1,,CHEMBL624276,BAO_0000218,1088.0,
11504,,,Urine,A,,,,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,N,,1,,CHEMBL624277,BAO_0000218,1088.0,
11505,,,,A,,,,% dose converted to 2-amino-5-chlorophenyl sulfate,U,,1,,CHEMBL624278,BAO_0000019,,
11506,,,,A,,,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),U,,1,,CHEMBL624279,BAO_0000019,,
11507,,,Feces,A,,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",N,,1,,CHEMBL624280,BAO_0000218,1988.0,
11508,,,Feces,A,,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",N,,1,,CHEMBL624281,BAO_0000218,1988.0,
11509,,,Feces,A,,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",N,,1,,CHEMBL622933,BAO_0000218,1988.0,
11510,,,Feces,A,,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",N,,1,,CHEMBL622934,BAO_0000218,1988.0,
11511,,In vivo,Liver,A,,,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,N,,1,,CHEMBL622935,BAO_0000218,2107.0,
11512,,In vivo,Liver,A,,,,Biodistribution in Rat liver after 5 minutes of iv administration,N,,1,,CHEMBL622936,BAO_0000218,2107.0,
11513,,In vivo,Liver,A,,,,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,N,,1,,CHEMBL875228,BAO_0000218,2107.0,
11514,,In vivo,Lung,A,,,,Biodistribution in Rat lung after 24 hours of iv administration,N,,1,,CHEMBL622937,BAO_0000218,2048.0,
11515,,In vivo,Lung,A,,,,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,N,,1,,CHEMBL622938,BAO_0000218,2048.0,
11516,,In vivo,Lung,A,,,,Biodistribution in Rat lung after 30 minutes of iv administration,N,,1,,CHEMBL619736,BAO_0000218,2048.0,
11517,,In vivo,Lung,A,,,,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,N,,1,,CHEMBL625117,BAO_0000218,2048.0,
11518,,In vivo,Lung,A,,,,Biodistribution in Rat lung after 5 minutes of iv administration,N,,1,,CHEMBL625118,BAO_0000218,2048.0,
11519,,In vivo,Lung,A,,,,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,N,,1,,CHEMBL625119,BAO_0000218,2048.0,
11520,,In vivo,Cerebellum,A,,,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",N,,1,,CHEMBL625120,BAO_0000218,2037.0,
11521,,In vivo,,A,,,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",N,,1,,CHEMBL625121,BAO_0000218,,
11522,,In vivo,Thalamus,A,,,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",N,,1,,CHEMBL625122,BAO_0000218,10000006.0,
11523,,In vivo,Blood,A,,,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,1,,CHEMBL622204,BAO_0000218,178.0,
11524,,In vivo,Blood,A,,,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,1,,CHEMBL877503,BAO_0000218,178.0,
11525,,In vivo,Blood,A,,,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,1,,CHEMBL627127,BAO_0000218,178.0,
11526,,In vivo,Hippocampus,A,,,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,U,,1,,CHEMBL627128,BAO_0000218,10000000.0,
11527,,In vivo,Hippocampus,A,,,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,U,,1,,CHEMBL627129,BAO_0000218,10000000.0,
11528,,In vivo,Hippocampus,A,,,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,U,,1,,CHEMBL627130,BAO_0000218,10000000.0,
11529,,In vivo,Brain,A,,,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,1,,CHEMBL627131,BAO_0000218,955.0,
11530,,In vivo,Brain,A,,,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,1,,CHEMBL627132,BAO_0000218,955.0,
11531,,In vivo,Brain,A,,,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,1,,CHEMBL627133,BAO_0000218,955.0,
11532,,In vivo,Cerebellum,A,,,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,1,,CHEMBL627134,BAO_0000218,2037.0,
11533,,In vivo,Cerebellum,A,,,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,1,,CHEMBL627135,BAO_0000218,2037.0,
11534,,In vivo,Cerebellum,A,,,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,1,,CHEMBL627136,BAO_0000218,2037.0,
11535,,In vivo,,A,,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,1,,CHEMBL628435,BAO_0000218,,
11536,,In vivo,,A,,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,1,,CHEMBL628436,BAO_0000218,,
11537,,In vivo,,A,,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,1,,CHEMBL628437,BAO_0000218,,
11538,,In vivo,Heart,A,,,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,1,,CHEMBL628438,BAO_0000218,948.0,
11539,,In vivo,Heart,A,,,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,1,,CHEMBL628439,BAO_0000218,948.0,
11540,,In vivo,Heart,A,,,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,1,,CHEMBL628440,BAO_0000218,948.0,
11541,,In vivo,Hippocampus,A,,,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,1,,CHEMBL628441,BAO_0000218,10000000.0,
11542,,In vivo,Hippocampus,A,,,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,1,,CHEMBL628442,BAO_0000218,10000000.0,
11543,,In vivo,Hippocampus,A,,,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,1,,CHEMBL628443,BAO_0000218,10000000.0,
11544,,In vivo,Kidney,A,,,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,1,,CHEMBL628444,BAO_0000218,2113.0,
11545,,In vivo,Kidney,A,,,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,1,,CHEMBL628445,BAO_0000218,2113.0,
11546,,In vivo,Kidney,A,,,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,1,,CHEMBL877504,BAO_0000218,2113.0,
11547,,In vivo,Liver,A,,,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,1,,CHEMBL628446,BAO_0000218,2107.0,
11548,,In vivo,Liver,A,,,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,1,,CHEMBL626874,BAO_0000218,2107.0,
11549,,In vivo,Liver,A,,,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,1,,CHEMBL626875,BAO_0000218,2107.0,
11550,,In vivo,Lung,A,,,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,1,,CHEMBL626876,BAO_0000218,2048.0,
11551,,In vivo,Lung,A,,,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,1,,CHEMBL626877,BAO_0000218,2048.0,
11552,,In vivo,Lung,A,,,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,1,,CHEMBL626878,BAO_0000218,2048.0,
11553,,In vivo,Muscle tissue,A,,,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,1,,CHEMBL626879,BAO_0000218,2385.0,
11554,,In vivo,Plasma,A,,,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,U,,1,,CHEMBL626880,BAO_0000218,1969.0,
11555,,In vivo,Plasma,A,,,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,N,,1,,CHEMBL626881,BAO_0000218,1969.0,
11556,,In vivo,Plasma,A,,,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,N,,1,,CHEMBL626882,BAO_0000218,1969.0,
11557,,In vivo,Plasma,A,,,,Peak plasma concentration was measured in dogs,N,,1,,CHEMBL626883,BAO_0000218,1969.0,
11558,,In vivo,,A,,,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,,1,,CHEMBL626884,BAO_0000218,,
11559,,In vivo,,A,,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,N,,1,,CHEMBL626885,BAO_0000218,,
11560,,In vivo,,A,,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,N,,1,,CHEMBL626886,BAO_0000218,,
11561,,In vivo,,A,,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,N,,1,,CHEMBL626887,BAO_0000218,,
11562,,In vivo,,A,,,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,,1,,CHEMBL626888,BAO_0000218,,
11563,,In vivo,,A,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,N,,1,,CHEMBL626889,BAO_0000218,,
11564,,In vivo,,A,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,U,,1,,CHEMBL626761,BAO_0000218,,
11565,,In vivo,,A,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,N,,1,,CHEMBL626762,BAO_0000218,,
11566,,In vivo,,A,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,N,,1,,CHEMBL626763,BAO_0000218,,
11567,,In vivo,,A,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,N,,1,,CHEMBL626764,BAO_0000218,,
11568,,In vivo,,A,,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,N,,1,,CHEMBL626765,BAO_0000218,,
11569,,In vivo,,A,,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,N,,1,,CHEMBL626766,BAO_0000218,,
11570,,In vivo,,A,,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,N,,1,,CHEMBL626767,BAO_0000218,,
11571,,In vivo,,A,,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,N,,1,,CHEMBL626768,BAO_0000218,,
11572,,In vivo,,A,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,N,,1,,CHEMBL626769,BAO_0000218,,
11573,,In vivo,,A,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,N,,1,,CHEMBL874463,BAO_0000218,,
11574,,In vivo,,A,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,U,,1,,CHEMBL626770,BAO_0000218,,
11575,,In vivo,,A,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,U,,1,,CHEMBL626771,BAO_0000218,,
11576,,In vivo,,A,,,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,N,,1,,CHEMBL626772,BAO_0000218,,
11577,,In vivo,,A,,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,N,,1,,CHEMBL626773,BAO_0000218,,
11578,,In vivo,,A,,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,N,,1,,CHEMBL626774,BAO_0000218,,
11579,,In vivo,,A,,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,N,,1,,CHEMBL626775,BAO_0000218,,
11580,,In vivo,,A,,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,N,,1,,CHEMBL626776,BAO_0000218,,
11581,,In vivo,,A,,,,Maximum concentration (Cmax) in rat when administered orally,N,,1,,CHEMBL626777,BAO_0000218,,
11582,,In vivo,Plasma,A,,,,Maximal concentration in monkey plasma after 25 mg/kg oral dose,U,,1,,CHEMBL626778,BAO_0000218,1969.0,
11583,,In vivo,,A,,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",U,,1,,CHEMBL626779,BAO_0000218,,
11584,,In vivo,,A,,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",U,,1,,CHEMBL626780,BAO_0000218,,
11585,,In vivo,Plasma,A,,,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,U,,1,,CHEMBL626781,BAO_0000218,1969.0,
11586,,In vivo,,A,,,,Pharmacokinetic profile Cmax was evaluated in rats,N,,1,,CHEMBL632164,BAO_0000218,,
11587,,In vivo,,A,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),N,,1,,CHEMBL632165,BAO_0000218,,
11588,,In vivo,,A,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),N,,1,,CHEMBL632166,BAO_0000218,,
11589,,In vivo,,A,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),N,,1,,CHEMBL632167,BAO_0000218,,
11590,,In vivo,,A,,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),N,,1,,CHEMBL632168,BAO_0000218,,
11591,,In vivo,Plasma,A,,,,Cmax in rat plasma,U,,1,,CHEMBL632169,BAO_0000218,1969.0,
11592,,In vivo,Plasma,A,,,,Cmax in dog plasma after 30mg/kg oral dose,N,,1,,CHEMBL632170,BAO_0000218,1969.0,
11593,,In vivo,Plasma,A,,,,Cmax in rat plasma after 30mg/kg oral dose,N,,1,,CHEMBL632171,BAO_0000218,1969.0,
11594,,In vivo,Plasma,A,,,,Plasma level in rats at 30 mg/kg,N,,1,,CHEMBL632172,BAO_0000218,1969.0,
11595,,In vivo,Plasma,A,,,,Tested for maximum plasma concentration in mice,N,,1,,CHEMBL632173,BAO_0000218,1969.0,
11596,,In vivo,,A,,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL632174,BAO_0000218,,
11597,,In vivo,,A,,,,The Cmax values in female wistar rats.,N,,1,,CHEMBL632175,BAO_0000218,,
11598,,In vivo,Plasma,A,,,,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,N,,1,,CHEMBL632176,BAO_0000218,1969.0,
11599,,In vivo,Plasma,A,,,,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,N,,1,,CHEMBL632177,BAO_0000218,1969.0,
11600,,In vivo,Plasma,A,,,,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,N,,1,,CHEMBL632178,BAO_0000218,1969.0,
11601,,In vivo,,A,,,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,N,,1,,CHEMBL632179,BAO_0000218,,
11602,,In vivo,Blood,A,,,,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,N,,1,,CHEMBL632180,BAO_0000218,178.0,
11603,,In vivo,Blood,A,,,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,N,,1,,CHEMBL632181,BAO_0000218,178.0,
11604,,In vivo,Blood,A,,,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,N,,1,,CHEMBL632182,BAO_0000218,178.0,
11605,,In vivo,Blood,A,,,,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,U,,1,,CHEMBL632183,BAO_0000218,178.0,
11606,,In vivo,,A,,,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,N,,1,,CHEMBL632184,BAO_0000218,,
11607,,In vivo,,A,,,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,N,,1,,CHEMBL874470,BAO_0000218,,
11608,,,,A,,,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL631302,BAO_0000218,,
11609,,,,A,,,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL631303,BAO_0000218,,
11610,,,,A,,,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL631304,BAO_0000218,,
11611,,,,A,,,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL631305,BAO_0000218,,
11612,,,,A,,,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL631306,BAO_0000218,,
11613,,,,A,,,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL631307,BAO_0000218,,
11614,,,,A,,,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL631308,BAO_0000218,,
11615,,,,A,,,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL625557,BAO_0000218,,
11616,,,Spleen,A,,,,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL625558,BAO_0000218,2106.0,
11617,,,Spleen,A,,,,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL625559,BAO_0000218,2106.0,
11618,,,Spleen,A,,,,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL625560,BAO_0000218,2106.0,
11619,,,Spleen,A,,,,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL625561,BAO_0000218,2106.0,
11620,,,Spleen,A,,,,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL625562,BAO_0000218,2106.0,
11621,,,Spleen,A,,,,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL875320,BAO_0000218,2106.0,
11622,,,Spleen,A,,,,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL625563,BAO_0000218,2106.0,
11623,,,Spleen,A,,,,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL625564,BAO_0000218,2106.0,
11624,,,Uterus,A,,,,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL625565,BAO_0000218,995.0,
11625,,,Uterus,A,,,,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL625566,BAO_0000218,995.0,
11626,,,Uterus,A,,,,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL625567,BAO_0000218,995.0,
11627,,,Uterus,A,,,,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL625568,BAO_0000218,995.0,
11628,,,Uterus,A,,,,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL628217,BAO_0000218,995.0,
11629,,,Uterus,A,,,,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",N,,1,,CHEMBL628218,BAO_0000218,995.0,
11630,,,Uterus,A,,,,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL628219,BAO_0000218,995.0,
11631,,,Uterus,A,,,,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",N,,1,,CHEMBL628220,BAO_0000218,995.0,
11632,,,,A,,,,Distribution in the blood after 120 min of intravenous administration,U,,1,,CHEMBL628221,BAO_0000019,,
11633,,,,A,,,,Distribution in the blood after 15 min of intravenous administration,U,,1,,CHEMBL628222,BAO_0000019,,
11634,,,,A,,,,Distribution in the blood after 30 min of intravenous administration,U,,1,,CHEMBL628223,BAO_0000019,,
11635,,,,A,,,,Distribution in the blood after 5 min of intravenous administration,U,,1,,CHEMBL628224,BAO_0000019,,
11636,,,,A,,,,Distribution in the blood after 60 min of intravenous administration,U,,1,,CHEMBL628225,BAO_0000019,,
11637,,,,A,,,,Distribution in the blood after 90 min of intravenous administration,U,,1,,CHEMBL628226,BAO_0000019,,
11638,,,,A,,,,Distribution in the bone after 120 min of intravenous administration,U,,1,,CHEMBL628227,BAO_0000019,,
11639,,,,A,,,,Distribution in the bone after 15 min of intravenous administration,U,,1,,CHEMBL875481,BAO_0000019,,
11640,,,,A,,,,Distribution in the bone after 30 min of intravenous administration,U,,1,,CHEMBL628228,BAO_0000019,,
11641,,,,A,,,,Distribution in the bone after 5 min of intravenous administration,U,,1,,CHEMBL628229,BAO_0000019,,
11642,,,,A,,,,Distribution in the bone after 60 min of intravenous administration,U,,1,,CHEMBL628230,BAO_0000019,,
11643,,,,A,,,,Distribution in the bone after 90 min of intravenous administration,U,,1,,CHEMBL628231,BAO_0000019,,
11644,,,,A,,,,Distribution in the heart after 120 min of intravenous administration,U,,1,,CHEMBL628232,BAO_0000019,,
11645,,,,A,,,,Distribution in the heart after 15 min of intravenous administration,U,,1,,CHEMBL628233,BAO_0000019,,
11646,,,,A,,,,Distribution in the heart after 30 min of intravenous administration,U,,1,,CHEMBL628234,BAO_0000019,,
11647,,,,A,,,,Distribution in the heart after 5 min of intravenous administration,U,,1,,CHEMBL628235,BAO_0000019,,
11648,,,,A,,,,Distribution in the heart after 60 min of intravenous administration,U,,1,,CHEMBL628236,BAO_0000019,,
11649,,,,A,,,,Distribution in the heart after 90 min of intravenous administration,U,,1,,CHEMBL628237,BAO_0000019,,
11650,,,,A,,,,Distribution in the kidneys after 120 min of intravenous administration,U,,1,,CHEMBL628238,BAO_0000019,,
11651,,,,A,,,,Distribution in the kidneys after 15 min of intravenous administration,U,,1,,CHEMBL628239,BAO_0000019,,
11652,,,,A,,,,Distribution in the kidneys after 30 min of intravenous administration,U,,1,,CHEMBL628240,BAO_0000019,,
11653,,,,A,,,,Distribution in the kidneys after 5 min of intravenous administration,U,,1,,CHEMBL628241,BAO_0000019,,
11654,,,,A,,,,Distribution in the kidneys after 60 min of intravenous administration,U,,1,,CHEMBL628242,BAO_0000019,,
11655,,,,A,,,,Distribution in the kidneys after 90 min of intravenous administration,U,,1,,CHEMBL875482,BAO_0000019,,
11656,,,,A,,,,Distribution in the liver after 120 min of intravenous administration,U,,1,,CHEMBL628243,BAO_0000019,,
11657,,,,A,,,,Distribution in the liver after 15 min of intravenous administration,U,,1,,CHEMBL628244,BAO_0000019,,
11658,,,,A,,,,Distribution in the liver after 30 min of intravenous administration,U,,1,,CHEMBL628245,BAO_0000019,,
11659,,,,A,,,,Distribution in the liver after 5 min of intravenous administration,U,,1,,CHEMBL628246,BAO_0000019,,
11660,,,,A,,,,Distribution in the liver after 60 min of intravenous administration,U,,1,,CHEMBL628247,BAO_0000019,,
11661,,,,A,,,,Distribution in the liver after 90 min of intravenous administration,U,,1,,CHEMBL628248,BAO_0000019,,
11662,,,,A,,,,Distribution in the lung after 120 min of intravenous administration,U,,1,,CHEMBL628249,BAO_0000019,,
11663,,,,A,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",N,,1,,CHEMBL625452,BAO_0000218,,
11664,,,,A,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",N,,1,,CHEMBL625453,BAO_0000218,,
11665,,,,A,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",N,,1,,CHEMBL625454,BAO_0000218,,
11666,,,,A,,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",N,,1,,CHEMBL623844,BAO_0000218,,
11667,,,,A,,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,N,,1,,CHEMBL623845,BAO_0000218,,
11668,,,,A,,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,N,,1,,CHEMBL623846,BAO_0000218,,
11669,,,,A,,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,U,,1,,CHEMBL623847,BAO_0000218,,
11670,,,,A,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,N,,1,,CHEMBL623848,BAO_0000218,,
11671,,,,A,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,N,,1,,CHEMBL623849,BAO_0000218,,
11672,,,,A,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,N,,1,,CHEMBL623850,BAO_0000218,,
11673,,,,A,,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,N,,1,,CHEMBL623851,BAO_0000218,,
11674,,,,A,,,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,U,,1,,CHEMBL623852,BAO_0000218,,
11675,,,,A,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,N,,1,,CHEMBL624551,BAO_0000218,,
11676,,,,A,,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",N,,1,,CHEMBL624552,BAO_0000218,,
11677,,,,A,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,U,,1,,CHEMBL624553,BAO_0000218,,
11678,,,,A,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,U,,1,,CHEMBL624554,BAO_0000218,,
11679,,,,A,,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,N,,1,,CHEMBL624555,BAO_0000218,,
11680,,,,A,,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",N,,1,,CHEMBL624741,BAO_0000218,,
11681,,,,A,,,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",N,,1,,CHEMBL624742,BAO_0000218,,
11682,,,,A,,,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",N,,1,,CHEMBL624743,BAO_0000218,,
11683,,,,A,,,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",N,,1,,CHEMBL877606,BAO_0000218,,
11684,,,,A,,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,U,,1,,CHEMBL624744,BAO_0000218,,
11685,,,Blood,A,,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,U,,1,,CHEMBL624745,BAO_0000218,178.0,
11686,,,Blood,A,,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,U,,1,,CHEMBL624746,BAO_0000218,178.0,
11687,,,Blood,A,,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,U,,1,,CHEMBL624747,BAO_0000218,178.0,
11688,,,,A,,,,Oral absorption expressed as Area under curve was determined,U,,1,,CHEMBL624748,BAO_0000019,,
11689,,,,A,,,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,N,,1,,CHEMBL622504,BAO_0000218,,
11690,,,,A,,,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",N,,1,,CHEMBL622505,BAO_0000218,,
11691,,,,A,,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",N,,1,,CHEMBL622506,BAO_0000218,,
11692,,,,A,,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",N,,1,,CHEMBL622507,BAO_0000218,,
11693,,,,A,,,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",N,,1,,CHEMBL622508,BAO_0000218,,
11694,,,,A,,,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,U,,1,,CHEMBL622509,BAO_0000019,,
11695,,,,A,,,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,,1,,CHEMBL622510,BAO_0000218,,
11696,,,,A,,,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),N,,1,,CHEMBL622511,BAO_0000218,,
11697,,,,A,,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,N,,1,,CHEMBL622512,BAO_0000218,,
11698,,,,A,,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,N,,1,,CHEMBL622513,BAO_0000218,,
11699,,,,A,,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,N,,1,,CHEMBL622514,BAO_0000218,,
11700,,,,A,,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,N,,1,,CHEMBL622515,BAO_0000218,,
11701,,,,A,,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,N,,1,,CHEMBL622516,BAO_0000218,,
11702,,,,A,,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,N,,1,,CHEMBL622517,BAO_0000218,,
11703,,,,A,,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,N,,1,,CHEMBL622518,BAO_0000218,,
11704,,,,A,,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,N,,1,,CHEMBL622519,BAO_0000218,,
11705,,In vivo,Muscle tissue,A,,,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,1,,CHEMBL622520,BAO_0000218,2385.0,
11706,,In vivo,Muscle tissue,A,,,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,1,,CHEMBL622521,BAO_0000218,2385.0,
11707,,In vivo,Zone of skin,A,,,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,1,,CHEMBL625113,BAO_0000218,14.0,
11708,,In vivo,Zone of skin,A,,,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,1,,CHEMBL625114,BAO_0000218,14.0,
11709,,In vivo,Zone of skin,A,,,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,1,,CHEMBL874397,BAO_0000218,14.0,
11710,,In vivo,Spleen,A,,,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,1,,CHEMBL625115,BAO_0000218,2106.0,
11711,,In vivo,Spleen,A,,,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,1,,CHEMBL625116,BAO_0000218,2106.0,
11712,,In vivo,Spleen,A,,,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,1,,CHEMBL623932,BAO_0000218,2106.0,
11713,,In vivo,Striatum,A,,,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,1,,CHEMBL623933,BAO_0000218,2435.0,
11714,,In vivo,Striatum,A,,,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,1,,CHEMBL623934,BAO_0000218,2435.0,
11715,,In vivo,Striatum,A,,,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,1,,CHEMBL623935,BAO_0000218,2435.0,
11716,,In vivo,Thyroid gland,A,,,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,1,,CHEMBL623936,BAO_0000218,2046.0,
11717,,In vivo,Thyroid gland,A,,,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,1,,CHEMBL623937,BAO_0000218,2046.0,
11718,,In vivo,Thyroid gland,A,,,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,1,,CHEMBL623938,BAO_0000218,2046.0,
11719,,,,A,,,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,1,,CHEMBL623939,BAO_0000218,,
11720,,,,A,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,N,,1,,CHEMBL623940,BAO_0000218,,
11721,,,,A,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,N,,1,,CHEMBL623941,BAO_0000218,,
11722,,,,A,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,1,,CHEMBL627216,BAO_0000218,,
11723,,,,A,,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,1,,CHEMBL623942,BAO_0000218,,
11724,,,Brain,A,,,,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,1,,CHEMBL618793,BAO_0000218,955.0,
11725,,,Brain,A,,,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,1,,CHEMBL618794,BAO_0000218,955.0,
11726,,,Brain,A,,,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,1,,CHEMBL618795,BAO_0000218,955.0,
11727,,,,A,,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,1,,CHEMBL618796,BAO_0000218,,
11728,,,,A,,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,1,,CHEMBL618797,BAO_0000218,,
11729,,,Kidney,A,,,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,N,,1,,CHEMBL618798,BAO_0000218,2113.0,
11730,,,Kidney,A,,,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,1,,CHEMBL618799,BAO_0000218,2113.0,
11731,,,Kidney,A,,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,N,,1,,CHEMBL618800,BAO_0000218,2113.0,
11732,,,Kidney,A,,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,N,,1,,CHEMBL618801,BAO_0000218,2113.0,
11733,,,Kidney,A,,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,1,,CHEMBL618802,BAO_0000218,2113.0,
11734,,,Kidney,A,,,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,1,,CHEMBL618803,BAO_0000218,2113.0,
11735,,,Liver,A,,,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,N,,1,,CHEMBL618804,BAO_0000218,2107.0,
11736,,,Liver,A,,,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,1,,CHEMBL618805,BAO_0000218,2107.0,
11737,,,Liver,A,,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,N,,1,,CHEMBL618806,BAO_0000218,2107.0,
11738,,,Liver,A,,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,N,,1,,CHEMBL618807,BAO_0000218,2107.0,
11739,,,Liver,A,,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,1,,CHEMBL618808,BAO_0000218,2107.0,
11740,,,Liver,A,,,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,1,,CHEMBL618809,BAO_0000218,2107.0,
11741,,,Muscle tissue,A,,,,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,1,,CHEMBL618810,BAO_0000218,2385.0,
11742,,,Muscle tissue,A,,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,N,,1,,CHEMBL618811,BAO_0000218,2385.0,
11743,,,Muscle tissue,A,,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,N,,1,,CHEMBL875844,BAO_0000218,2385.0,
11744,,,Muscle tissue,A,,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,1,,CHEMBL618812,BAO_0000218,2385.0,
11745,,,Muscle tissue,A,,,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,1,,CHEMBL618813,BAO_0000218,2385.0,
11746,,,,A,,,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,1,,CHEMBL618814,BAO_0000218,,
11747,,,,A,,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,1,,CHEMBL618815,BAO_0000218,,
11748,,,,A,,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,1,,CHEMBL618816,BAO_0000218,,
11749,,,,A,,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,1,,CHEMBL618817,BAO_0000218,,
11750,,,,A,,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,1,,CHEMBL620544,BAO_0000218,,
11751,,In vivo,,A,,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,N,,1,,CHEMBL626230,BAO_0000218,,
11752,,In vivo,,A,,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,N,,1,,CHEMBL626231,BAO_0000218,,
11753,,In vivo,,A,,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,N,,1,,CHEMBL626232,BAO_0000218,,
11754,,In vivo,Plasma,A,,,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,N,,1,,CHEMBL626233,BAO_0000218,1969.0,
11755,,In vivo,Plasma,A,,,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,N,,1,,CHEMBL626234,BAO_0000218,1969.0,
11756,,In vivo,Plasma,A,,,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,N,,1,,CHEMBL875341,BAO_0000218,1969.0,
11757,,In vivo,Plasma,A,,,,The maximum plasma concentration (100 mg/kg) administered orally in human,N,,1,,CHEMBL626235,BAO_0000218,1969.0,
11758,,In vivo,Plasma,A,,,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,U,,1,,CHEMBL626236,BAO_0000218,1969.0,
11759,,In vivo,Plasma,A,,,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,U,,1,,CHEMBL626237,BAO_0000218,1969.0,
11760,,In vivo,Plasma,A,,,,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,N,,1,,CHEMBL626238,BAO_0000218,1969.0,
11761,,In vivo,Plasma,A,,,,The maximum plasma concentration (200 mg/kg) administered orally in human,N,,1,,CHEMBL622412,BAO_0000218,1969.0,
11762,,In vivo,Plasma,A,,,,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,N,,1,,CHEMBL623114,BAO_0000218,1969.0,
11763,,In vivo,Plasma,A,,,,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,U,,1,,CHEMBL623115,BAO_0000218,1969.0,
11764,,In vivo,Plasma,A,,,,The maximum plasma concentration (25 mg/kg) administered orally in monkey,U,,1,,CHEMBL623116,BAO_0000218,1969.0,
11765,,In vivo,Plasma,A,,,,The maximum plasma concentration (30 mg/kg) administered orally in dog,U,,1,,CHEMBL623117,BAO_0000218,1969.0,
11766,,In vivo,Plasma,A,,,,The maximum plasma concentration (400 mg/kg) administered orally in human,N,,1,,CHEMBL623118,BAO_0000218,1969.0,
11767,,In vivo,Plasma,A,,,,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,N,,1,,CHEMBL623119,BAO_0000218,1969.0,
11768,,In vivo,Plasma,A,,,,The maximum plasma concentration (50 mg/kg) administered orally in rat,N,,1,,CHEMBL623120,BAO_0000218,1969.0,
11769,,In vivo,Plasma,A,,,,The maximum plasma concentration (800 mg/kg) administered orally in human,N,,1,,CHEMBL623286,BAO_0000218,1969.0,
11770,,In vivo,Plasma,A,,,,The maximum plasma concentration was measured on rats,N,,1,,CHEMBL623287,BAO_0000218,1969.0,
11771,,In vivo,Plasma,A,,,,The maximum plasma concentration was measured on rats after oral administration,N,,1,,CHEMBL623288,BAO_0000218,1969.0,
11772,,In vivo,Plasma,A,,,,Plasma drug Cmax in rat (PO dose),N,,1,,CHEMBL623289,BAO_0000218,1969.0,
11773,,In vivo,,A,,,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,U,,1,,CHEMBL623290,BAO_0000218,,
11774,,In vivo,Plasma,A,,,,maximum Plasma concentration in Dog was determined after Peroral administration,N,,1,,CHEMBL623291,BAO_0000218,1969.0,
11775,,In vivo,Plasma,A,,,,maximum Plasma concentration in Rats was determined after Peroral administration,N,,1,,CHEMBL623292,BAO_0000218,1969.0,
11776,,In vivo,Plasma,A,,,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,N,,1,,CHEMBL623293,BAO_0000218,1969.0,
11777,,In vivo,Plasma,A,,,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,U,,1,,CHEMBL623294,BAO_0000218,1969.0,
11778,,In vivo,Plasma,A,,,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,N,,1,,CHEMBL623295,BAO_0000218,1969.0,
11779,,In vivo,,A,,,,maximum concentration was measured when administered through oral route in mice,N,,1,,CHEMBL623296,BAO_0000218,,
11780,,,,A,,,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,N,,1,,CHEMBL875349,BAO_0000218,,
11781,,,,A,,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,U,,1,,CHEMBL623297,BAO_0000019,,
11782,,,,A,,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,U,,1,,CHEMBL623298,BAO_0000019,,
11783,,,,A,,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,U,,1,,CHEMBL623299,BAO_0000019,,
11784,,,,A,,,,Pharmacokinetic parameter was evaluated in rats,N,,1,,CHEMBL623300,BAO_0000218,,
11785,,,,A,,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,N,,1,,CHEMBL623301,BAO_0000218,,
11786,,,,A,,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,N,,1,,CHEMBL623302,BAO_0000218,,
11787,,,,A,,,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,N,,1,,CHEMBL623303,BAO_0000218,,
11788,,,,A,,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,N,,1,,CHEMBL623304,BAO_0000218,,
11789,,,,A,,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,N,,1,,CHEMBL623305,BAO_0000218,,
11790,,,Plasma,A,,,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,N,,1,,CHEMBL623306,BAO_0000218,1969.0,
11791,,,Plasma,A,,,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,N,,1,,CHEMBL623307,BAO_0000218,1969.0,
11792,,,Plasma,A,,,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,N,,1,,CHEMBL623308,BAO_0000218,1969.0,
11793,,,Plasma,A,,,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,N,,1,,CHEMBL623309,BAO_0000218,1969.0,
11794,,,,A,,,,Plasma Concentration after 120 min of oral administration to mice,N,,1,,CHEMBL623310,BAO_0000218,,
11795,,,,A,,,,Plasma Concentration after 30 min of oral administration to mice,N,,1,,CHEMBL623311,BAO_0000218,,
11796,,,,A,,,,Plasma Concentration after 60 min of oral administration to mice,N,,1,,CHEMBL623312,BAO_0000218,,
11797,,,,A,,,,Plasma Concentration after 60 min of oral administration to mice; Not determined,N,,1,,CHEMBL875350,BAO_0000218,,
11798,,,,A,,,,Plasma Concentration after 90 min of oral administration to mice,N,,1,,CHEMBL628635,BAO_0000218,,
11799,,,,A,,,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,N,,1,,CHEMBL628636,BAO_0000218,,
11800,,,,A,,,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,N,,1,,CHEMBL628637,BAO_0000218,,
11801,,,,A,,,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,N,,1,,CHEMBL628058,BAO_0000218,,
11802,,,,A,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,N,,1,,CHEMBL628059,BAO_0000218,,
11803,,,,A,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,N,,1,,CHEMBL628060,BAO_0000218,,
11804,,,,A,,,,Distribution in the lung after 15 min of intravenous administration,U,,1,,CHEMBL628061,BAO_0000019,,
11805,,,,A,,,,Distribution in the lung after 30 min of intravenous administration,U,,1,,CHEMBL628062,BAO_0000019,,
11806,,,,A,,,,Distribution in the lung after 5 min of intravenous administration,U,,1,,CHEMBL628063,BAO_0000019,,
11807,,,,A,,,,Distribution in the lung after 60 min of intravenous administration,U,,1,,CHEMBL628064,BAO_0000019,,
11808,,,,A,,,,Distribution in the lung after 90 min of intravenous administration,U,,1,,CHEMBL628065,BAO_0000019,,
11809,,,Muscle tissue,A,,,,Distribution in the muscle after 120 min of intravenous administration,U,,1,,CHEMBL628066,BAO_0000019,2385.0,
11810,,,Muscle tissue,A,,,,Distribution in the muscle after 15 min of intravenous administration,U,,1,,CHEMBL628067,BAO_0000019,2385.0,
11811,,,Muscle tissue,A,,,,Distribution in the muscle after 30 min of intravenous administration,N,,1,,CHEMBL874646,BAO_0000218,2385.0,
11812,,,Muscle tissue,A,,,,Distribution in the muscle after 5 min of intravenous administration,U,,1,,CHEMBL628068,BAO_0000019,2385.0,
11813,,,Muscle tissue,A,,,,Distribution in the muscle after 60 min of intravenous administration,U,,1,,CHEMBL628069,BAO_0000019,2385.0,
11814,,,Muscle tissue,A,,,,Distribution in the muscle after 90 min of intravenous administration,U,,1,,CHEMBL628070,BAO_0000019,2385.0,
11815,,,Spleen,A,,,,Distribution in the spleen after 120 min of intravenous administration,U,,1,,CHEMBL628071,BAO_0000019,2106.0,
11816,,,Spleen,A,,,,Distribution in the spleen after 15 min of intravenous administration,U,,1,,CHEMBL628072,BAO_0000019,2106.0,
11817,,,Spleen,A,,,,Distribution in the spleen after 30 min of intravenous administration,U,,1,,CHEMBL628073,BAO_0000019,2106.0,
11818,,,Spleen,A,,,,Distribution in the spleen after 5 min of intravenous administration,U,,1,,CHEMBL628074,BAO_0000019,2106.0,
11819,,,Spleen,A,,,,Distribution in the spleen after 60 min of intravenous administration,U,,1,,CHEMBL628075,BAO_0000019,2106.0,
11820,,,Spleen,A,,,,Distribution in the spleen after 90 min of intravenous administration,U,,1,,CHEMBL628076,BAO_0000019,2106.0,
11821,,,Adrenal cortex,A,,,,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,N,,1,,CHEMBL628077,BAO_0000218,1235.0,
11822,,,Blood,A,,,,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,N,,1,,CHEMBL628078,BAO_0000218,178.0,
11823,,,Liver,A,,,,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,N,,1,,CHEMBL628079,BAO_0000218,2107.0,
11824,,,Female gonad,A,,,,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,N,,1,,CHEMBL628080,BAO_0000218,992.0,
11825,,,Thyroid gland,A,,,,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,N,,1,,CHEMBL628081,BAO_0000218,2046.0,
11826,,,Adrenal cortex,A,,,,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,N,,1,,CHEMBL628082,BAO_0000218,1235.0,
11827,,,Blood,A,,,,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,N,,1,,CHEMBL874647,BAO_0000218,178.0,
11828,,,Liver,A,,,,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,N,,1,,CHEMBL626406,BAO_0000218,2107.0,
11829,,,Female gonad,A,,,,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,N,,1,,CHEMBL626407,BAO_0000218,992.0,
11830,,,Thyroid gland,A,,,,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,N,,1,,CHEMBL626408,BAO_0000218,2046.0,
11831,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",N,,1,,CHEMBL626409,BAO_0000218,178.0,
11832,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",N,,1,,CHEMBL626410,BAO_0000218,178.0,
11833,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",N,,1,,CHEMBL626411,BAO_0000218,178.0,
11834,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",N,,1,,CHEMBL626412,BAO_0000218,178.0,
11835,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",N,,1,,CHEMBL626413,BAO_0000218,178.0,
11836,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",N,,1,,CHEMBL626414,BAO_0000218,178.0,
11837,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",N,,1,,CHEMBL626415,BAO_0000218,178.0,
11838,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",N,,1,,CHEMBL626416,BAO_0000218,178.0,
11839,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",N,,1,,CHEMBL627062,BAO_0000218,178.0,
11840,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",N,,1,,CHEMBL627063,BAO_0000218,178.0,
11841,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",N,,1,,CHEMBL627064,BAO_0000218,178.0,
11842,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",N,,1,,CHEMBL627227,BAO_0000218,178.0,
11843,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",N,,1,,CHEMBL627228,BAO_0000218,178.0,
11844,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",N,,1,,CHEMBL627229,BAO_0000218,178.0,
11845,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",N,,1,,CHEMBL625792,BAO_0000218,178.0,
11846,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",N,,1,,CHEMBL625793,BAO_0000218,178.0,
11847,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",N,,1,,CHEMBL625794,BAO_0000218,178.0,
11848,,,Blood,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",N,,1,,CHEMBL625795,BAO_0000218,178.0,
11849,,,,A,,,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,N,,1,,CHEMBL625796,BAO_0000218,,
11850,,,,A,,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,N,,1,,CHEMBL625797,BAO_0000218,,
11851,,,,A,,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,N,,1,,CHEMBL625798,BAO_0000218,,
11852,,,,A,,,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,U,,1,,CHEMBL875613,BAO_0000218,,
11853,,,,A,,,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,U,,1,,CHEMBL625799,BAO_0000218,,
11854,,,,A,,,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,U,,1,,CHEMBL625800,BAO_0000218,,
11855,,,,A,,,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,U,,1,,CHEMBL625801,BAO_0000218,,
11856,,,,A,,,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,U,,1,,CHEMBL625802,BAO_0000218,,
11857,,,,A,,,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,U,,1,,CHEMBL625803,BAO_0000218,,
11858,,,,A,,,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,U,,1,,CHEMBL625804,BAO_0000019,,
11859,,,,A,,,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,U,,1,,CHEMBL622530,BAO_0000218,,
11860,,,,A,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,N,,1,,CHEMBL622531,BAO_0000218,,
11861,,,,A,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),N,,1,,CHEMBL622532,BAO_0000218,,
11862,,,,A,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),N,,1,,CHEMBL623176,BAO_0000218,,
11863,,,,A,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),N,,1,,CHEMBL623177,BAO_0000218,,
11864,,,,A,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),N,,1,,CHEMBL623178,BAO_0000218,,
11865,,,,A,,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,N,,1,,CHEMBL623179,BAO_0000218,,
11866,,,,A,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),N,,1,,CHEMBL623180,BAO_0000218,,
11867,,,,A,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),N,,1,,CHEMBL623181,BAO_0000218,,
11868,,,,A,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),N,,1,,CHEMBL624131,BAO_0000218,,
11869,,,,A,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),N,,1,,CHEMBL624132,BAO_0000218,,
11870,,,,A,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),N,,1,,CHEMBL624133,BAO_0000218,,
11871,,,,A,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,N,,1,,CHEMBL624846,BAO_0000218,,
11872,,,,A,,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),N,,1,,CHEMBL624847,BAO_0000218,,
11873,,,,A,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),N,,1,,CHEMBL624848,BAO_0000218,,
11874,,,,A,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),N,,1,,CHEMBL625012,BAO_0000218,,
11875,,,,A,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),N,,1,,CHEMBL625013,BAO_0000218,,
11876,,,,A,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,N,,1,,CHEMBL625014,BAO_0000218,,
11877,,,,A,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),N,,1,,CHEMBL625015,BAO_0000218,,
11878,,,,A,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),N,,1,,CHEMBL625016,BAO_0000218,,
11879,,,,A,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,N,,1,,CHEMBL625017,BAO_0000218,,
11880,,,,A,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),N,,1,,CHEMBL625018,BAO_0000218,,
11881,,,,A,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),N,,1,,CHEMBL625019,BAO_0000218,,
11882,,,,A,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),N,,1,,CHEMBL625020,BAO_0000218,,
11883,,,,A,,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,N,,1,,CHEMBL625021,BAO_0000218,,
11884,,,,A,,,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,,1,,CHEMBL625022,BAO_0000218,,
11885,,,,A,,,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,N,,1,,CHEMBL625023,BAO_0000218,,
11886,,,,A,,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,N,,1,,CHEMBL625024,BAO_0000218,,
11887,,,,A,,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,N,,1,,CHEMBL627626,BAO_0000218,,
11888,,,Brain,A,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,U,,1,,CHEMBL627627,BAO_0000218,955.0,
11889,,,Serum,A,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,U,,1,,CHEMBL627628,BAO_0000218,1977.0,
11890,,,Brain,A,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,U,,1,,CHEMBL627629,BAO_0000218,955.0,
11891,,,Serum,A,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,U,,1,,CHEMBL627630,BAO_0000218,1977.0,
11892,,,,A,,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),U,,1,,CHEMBL627631,BAO_0000019,,
11893,,,,A,,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),U,,1,,CHEMBL629515,BAO_0000218,,
11894,,,Spleen,A,,,,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,1,,CHEMBL629516,BAO_0000218,2106.0,
11895,,,Spleen,A,,,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,1,,CHEMBL629517,BAO_0000218,2106.0,
11896,,,Spleen,A,,,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,1,,CHEMBL629518,BAO_0000218,2106.0,
11897,,,,A,,,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,1,,CHEMBL877499,BAO_0000218,,
11898,,,,A,,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,N,,1,,CHEMBL629519,BAO_0000218,,
11899,,,,A,,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,1,,CHEMBL629520,BAO_0000218,,
11900,,,,A,,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,1,,CHEMBL629521,BAO_0000218,,
11901,,,,A,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),N,,1,,CHEMBL629522,BAO_0000218,,
11902,,,,A,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),N,,1,,CHEMBL629523,BAO_0000218,,
11903,,,,A,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),N,,1,,CHEMBL629524,BAO_0000218,,
11904,,,,A,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),N,,1,,CHEMBL629525,BAO_0000218,,
11905,,,,A,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),N,,1,,CHEMBL629526,BAO_0000218,,
11906,,,,A,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),N,,1,,CHEMBL629527,BAO_0000218,,
11907,,,,A,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),N,,1,,CHEMBL629528,BAO_0000218,,
11908,,,,A,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),N,,1,,CHEMBL629529,BAO_0000218,,
11909,,,,A,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),N,,1,,CHEMBL629530,BAO_0000218,,
11910,,,,A,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),N,,1,,CHEMBL629531,BAO_0000218,,
11911,,,,A,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),N,,1,,CHEMBL628656,BAO_0000218,,
11912,,,,A,,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),N,,1,,CHEMBL628657,BAO_0000218,,
11913,,In vivo,,A,,,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",N,,1,,CHEMBL628658,BAO_0000218,,
11914,,In vivo,,A,,,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,1,,CHEMBL628659,BAO_0000218,,
11915,,In vivo,,A,,,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,1,,CHEMBL877500,BAO_0000218,,
11916,,In vivo,,A,,,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,1,,CHEMBL628660,BAO_0000218,,
11917,,In vivo,,A,,,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,1,,CHEMBL628661,BAO_0000218,,
11918,,In vivo,,A,,,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,1,,CHEMBL628662,BAO_0000218,,
11919,,In vivo,,A,,,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,1,,CHEMBL628663,BAO_0000218,,
11920,,In vivo,,A,,,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,1,,CHEMBL628664,BAO_0000218,,
11921,,In vivo,Blood,A,,,,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,1,,CHEMBL628665,BAO_0000218,178.0,
11922,,In vivo,Blood,A,,,,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,1,,CHEMBL628666,BAO_0000218,178.0,
11923,,In vivo,Blood,A,,,,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,1,,CHEMBL628667,BAO_0000218,178.0,
11924,,In vivo,Blood,A,,,,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,1,,CHEMBL628668,BAO_0000218,178.0,
11925,,In vivo,Blood,A,,,,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,1,,CHEMBL628669,BAO_0000218,178.0,
11926,,In vivo,Blood,A,,,,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,1,,CHEMBL628670,BAO_0000218,178.0,
11927,,In vivo,Blood,A,,,,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,1,,CHEMBL628671,BAO_0000218,178.0,
11928,,In vivo,Bone,A,,,,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,1,,CHEMBL628672,BAO_0000218,10000001.0,
11929,,In vivo,Bone,A,,,,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,1,,CHEMBL630300,BAO_0000218,10000001.0,
11930,,In vivo,Bone,A,,,,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,1,,CHEMBL629787,BAO_0000218,10000001.0,
11931,,In vivo,Bone,A,,,,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,1,,CHEMBL629788,BAO_0000218,10000001.0,
11932,,In vivo,Brain,A,,,,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,1,,CHEMBL629789,BAO_0000218,955.0,
11933,,In vivo,Brain,A,,,,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,1,,CHEMBL629790,BAO_0000218,955.0,
11934,,In vivo,Brain,A,,,,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,1,,CHEMBL629791,BAO_0000218,955.0,
11935,,In vivo,Brain,A,,,,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,1,,CHEMBL629792,BAO_0000218,955.0,
11936,,In vivo,Brain,A,,,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,1,,CHEMBL629793,BAO_0000218,955.0,
11937,,In vivo,Brain,A,,,,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,1,,CHEMBL629794,BAO_0000218,955.0,
11938,,,,A,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,N,,1,,CHEMBL874459,BAO_0000218,,
11939,,,,A,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,N,,1,,CHEMBL629795,BAO_0000218,,
11940,,,,A,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,N,,1,,CHEMBL629796,BAO_0000218,,
11941,,,,A,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,N,,1,,CHEMBL629797,BAO_0000218,,
11942,,,,A,,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,N,,1,,CHEMBL629798,BAO_0000218,,
11943,,In vivo,Adrenal gland,A,,,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629799,BAO_0000218,2369.0,
11944,,In vivo,Adrenal gland,A,,,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629800,BAO_0000218,2369.0,
11945,,In vivo,Adrenal gland,A,,,,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629801,BAO_0000218,2369.0,
11946,,In vivo,Adrenal gland,A,,,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,N,,1,,CHEMBL629802,BAO_0000218,2369.0,
11947,,In vivo,Adrenal gland,A,,,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629803,BAO_0000218,2369.0,
11948,,In vivo,Blood,A,,,,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629804,BAO_0000218,178.0,
11949,,In vivo,Blood,A,,,,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629805,BAO_0000218,178.0,
11950,,In vivo,Blood,A,,,,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629806,BAO_0000218,178.0,
11951,,In vivo,Blood,A,,,,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629807,BAO_0000218,178.0,
11952,,In vivo,Blood,A,,,,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629808,BAO_0000218,178.0,
11953,,In vivo,Brain,A,,,,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629809,BAO_0000218,955.0,
11954,,In vivo,Brain,A,,,,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629810,BAO_0000218,955.0,
11955,,In vivo,Brain,A,,,,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629811,BAO_0000218,955.0,
11956,,In vivo,Brain,A,,,,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629812,BAO_0000218,955.0,
11957,,In vivo,Brain,A,,,,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629813,BAO_0000218,955.0,
11958,,In vivo,Brain,A,,,,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL874460,BAO_0000218,955.0,
11959,,In vivo,,A,,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629814,BAO_0000218,,
11960,,In vivo,,A,,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629815,BAO_0000218,,
11961,,In vivo,,A,,,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629816,BAO_0000218,,
11962,,In vivo,,A,,,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL629817,BAO_0000218,,
11963,,In vivo,Kidney,A,,,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,1,,CHEMBL626643,BAO_0000218,2113.0,
11964,,In vivo,Kidney,A,,,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL626644,BAO_0000218,2113.0,
11965,,In vivo,Kidney,A,,,,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL626806,BAO_0000218,2113.0,
11966,,In vivo,Kidney,A,,,,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL626807,BAO_0000218,2113.0,
11967,,In vivo,Liver,A,,,,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627261,BAO_0000218,2107.0,
11968,,In vivo,Liver,A,,,,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627262,BAO_0000218,2107.0,
11969,,In vivo,Liver,A,,,,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627263,BAO_0000218,2107.0,
11970,,In vivo,Liver,A,,,,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627264,BAO_0000218,2107.0,
11971,,In vivo,Lung,A,,,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627265,BAO_0000218,2048.0,
11972,,In vivo,Lung,A,,,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627266,BAO_0000218,2048.0,
11973,,In vivo,Lung,A,,,,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627267,BAO_0000218,2048.0,
11974,,In vivo,Lung,A,,,,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627268,BAO_0000218,2048.0,
11975,,In vivo,Muscle tissue,A,,,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627269,BAO_0000218,2385.0,
11976,,In vivo,Muscle tissue,A,,,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627270,BAO_0000218,2385.0,
11977,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",N,,1,,CHEMBL627271,BAO_0000218,,
11978,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",N,,1,,CHEMBL627946,BAO_0000218,,
11979,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",N,,1,,CHEMBL875472,BAO_0000218,,
11980,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",N,,1,,CHEMBL627947,BAO_0000218,,
11981,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",N,,1,,CHEMBL627948,BAO_0000218,,
11982,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",N,,1,,CHEMBL628113,BAO_0000218,,
11983,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",N,,1,,CHEMBL628114,BAO_0000218,,
11984,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",N,,1,,CHEMBL628115,BAO_0000218,,
11985,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",N,,1,,CHEMBL628116,BAO_0000218,,
11986,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",N,,1,,CHEMBL628117,BAO_0000218,,
11987,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",N,,1,,CHEMBL628118,BAO_0000218,,
11988,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",N,,1,,CHEMBL628119,BAO_0000218,,
11989,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",N,,1,,CHEMBL628120,BAO_0000218,,
11990,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",N,,1,,CHEMBL628121,BAO_0000218,,
11991,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",N,,1,,CHEMBL628122,BAO_0000218,,
11992,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",N,,1,,CHEMBL627297,BAO_0000218,,
11993,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",N,,1,,CHEMBL627298,BAO_0000218,,
11994,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",N,,1,,CHEMBL627299,BAO_0000218,,
11995,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",N,,1,,CHEMBL627300,BAO_0000218,,
11996,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",N,,1,,CHEMBL627301,BAO_0000218,,
11997,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",N,,1,,CHEMBL627302,BAO_0000218,,
11998,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",N,,1,,CHEMBL627303,BAO_0000218,,
11999,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",N,,1,,CHEMBL627304,BAO_0000218,,
12000,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",N,,1,,CHEMBL627305,BAO_0000218,,
12001,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",N,,1,,CHEMBL627306,BAO_0000218,,
12002,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",N,,1,,CHEMBL623982,BAO_0000218,,
12003,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",N,,1,,CHEMBL623983,BAO_0000218,,
12004,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",N,,1,,CHEMBL623984,BAO_0000218,,
12005,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",N,,1,,CHEMBL623985,BAO_0000218,,
12006,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",N,,1,,CHEMBL623986,BAO_0000218,,
12007,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",N,,1,,CHEMBL623987,BAO_0000218,,
12008,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",N,,1,,CHEMBL623988,BAO_0000218,,
12009,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",N,,1,,CHEMBL623989,BAO_0000218,,
12010,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",N,,1,,CHEMBL622215,BAO_0000218,,
12011,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",N,,1,,CHEMBL622216,BAO_0000218,,
12012,,,,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",N,,1,,CHEMBL877481,BAO_0000218,,
12013,,,,A,,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),U,,1,,CHEMBL622217,BAO_0000218,,
12014,,,,A,,,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),N,,1,,CHEMBL622218,BAO_0000218,,
12015,,,,A,,,,Pharmacokinetic profile AUC was evaluated in rats,N,,1,,CHEMBL622219,BAO_0000218,,
12016,,,,A,,,,Pharmacokinetic property (Area under curve),U,,1,,CHEMBL622220,BAO_0000019,,
12017,,,,A,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",N,,1,,CHEMBL622221,BAO_0000218,,
12018,,,,A,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",N,,1,,CHEMBL622222,BAO_0000218,,
12019,,,,A,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",N,,1,,CHEMBL622223,BAO_0000218,,
12020,,,,A,,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",N,,1,,CHEMBL622224,BAO_0000218,,
12021,,,,A,,,,Plasma concentration (AUC) was determined,U,,1,,CHEMBL622225,BAO_0000019,,
12022,,,,A,,,,Plasma concentration (AUC) was determined; Not detectable,U,,1,,CHEMBL622226,BAO_0000019,,
12023,,,,A,,,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),N,,1,,CHEMBL624154,BAO_0000218,,
12024,,,,A,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,N,,1,,CHEMBL624155,BAO_0000218,,
12025,,,,A,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,N,,1,,CHEMBL624156,BAO_0000218,,
12026,,,,A,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,N,,1,,CHEMBL624157,BAO_0000218,,
12027,,,,A,,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,N,,1,,CHEMBL624158,BAO_0000218,,
12028,,,,A,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,N,,1,,CHEMBL624159,BAO_0000218,,
12029,,,,A,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,N,,1,,CHEMBL624160,BAO_0000218,,
12030,,,,A,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,N,,1,,CHEMBL624161,BAO_0000218,,
12031,,,,A,,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,N,,1,,CHEMBL624162,BAO_0000218,,
12032,,,,A,,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,N,,1,,CHEMBL624163,BAO_0000218,,
12033,,,,A,,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL624164,BAO_0000218,,
12034,,,,A,,,,The AUC(0-infinity) values in female wistar rats.,N,,1,,CHEMBL624165,BAO_0000218,,
12035,,,,A,,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL624166,BAO_0000218,,
12036,,,,A,,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",N,,1,,CHEMBL624167,BAO_0000218,,
12037,,,,A,,,,The AUC(0-t)values in female wistar rats.,N,,1,,CHEMBL624168,BAO_0000218,,
12038,,,,A,,,,The Area under the concentration time curve of compound was measured on rats,N,,1,,CHEMBL624169,BAO_0000218,,
12039,,,,A,,,,The area under curve (100 mg/kg) administered orally in humans,N,,1,,CHEMBL624170,BAO_0000218,,
12040,,,,A,,,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,U,,1,,CHEMBL624171,BAO_0000218,,
12041,,,,A,,,,The area under curve (12.5 mg/kg) administered intravenously in monkey,U,,1,,CHEMBL624172,BAO_0000218,,
12042,,,,A,,,,The area under curve (15 mg/kg) administered intravenously in dog,N,,1,,CHEMBL624173,BAO_0000218,,
12043,,,,A,,,,The area under curve (200 mg/kg) administered orally in humans,N,,1,,CHEMBL877488,BAO_0000218,,
12044,,,,A,,,,The area under curve (25 mg/kg) administered intravenously in rat,N,,1,,CHEMBL624174,BAO_0000218,,
12045,,,,A,,,,The area under curve (25 mg/kg) administered orally in marmoset,U,,1,,CHEMBL624175,BAO_0000218,,
12046,,,,A,,,,The area under curve (25 mg/kg) administered orally in monkey,U,,1,,CHEMBL624176,BAO_0000218,,
12047,,,,A,,,,The area under curve (30 mg/kg) administered orally in dog,N,,1,,CHEMBL624177,BAO_0000218,,
12048,,,,A,,,,The area under curve (400 mg/kg) administered orally in humans,N,,1,,CHEMBL624178,BAO_0000218,,
12049,,,,A,,,,The area under curve (50 mg/kg) administered orally in fasted rat,N,,1,,CHEMBL624179,BAO_0000218,,
12050,,,,A,,,,The area under curve (50 mg/kg) administered orally in rat,N,,1,,CHEMBL627689,BAO_0000218,,
12051,,,,A,,,,The area under curve (800 mg/kg) administered orally in humans,N,,1,,CHEMBL627690,BAO_0000218,,
12052,,,,A,,,,The compound was evaluated for area under the curve,U,,1,,CHEMBL627691,BAO_0000019,,
12053,,,,A,,,,The compound was evaluated for area under the curve in marmosets,U,,1,,CHEMBL627692,BAO_0000019,,
12054,,,,A,,,,The compound was evaluated for area under the curve in marmosets,U,,1,,CHEMBL627693,BAO_0000019,,
12055,,,,A,,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,N,,1,,CHEMBL627694,BAO_0000218,,
12056,,,,A,,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,N,,1,,CHEMBL627695,BAO_0000218,,
12057,,,,A,,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),U,,1,,CHEMBL627696,BAO_0000218,,
12058,,,,A,,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,N,,1,,CHEMBL627697,BAO_0000218,,
12059,,,,A,,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,N,,1,,CHEMBL627698,BAO_0000218,,
12060,,,,A,,,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,N,,1,,CHEMBL627699,BAO_0000218,,
12061,,,,A,,,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,N,,1,,CHEMBL627700,BAO_0000218,,
12062,,,,A,,,,Total drug exposure is determined after oral dosing in rats.,N,,1,,CHEMBL627701,BAO_0000218,,
12063,,,,A,,,,Total drug exposure (5 mg/kg) when administered intravenously,U,,1,,CHEMBL627702,BAO_0000218,,
12064,,,,A,,,,Total drug exposure (5 mg/kg) when administered orally,U,,1,,CHEMBL627703,BAO_0000218,,
12065,,,,A,,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,U,,1,,CHEMBL626873,BAO_0000218,,
12066,,,,A,,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,N,,1,,CHEMBL629583,BAO_0000218,,
12067,,,,A,,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,N,,1,,CHEMBL629584,BAO_0000218,,
12068,,,,A,,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,N,,1,,CHEMBL629585,BAO_0000218,,
12069,,In vivo,Brain,A,,,,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,1,,CHEMBL629586,BAO_0000218,955.0,
12070,,In vivo,Brain,A,,,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,1,,CHEMBL629587,BAO_0000218,955.0,
12071,,In vivo,,A,,,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,1,,CHEMBL629588,BAO_0000218,,
12072,,In vivo,,A,,,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,1,,CHEMBL629589,BAO_0000218,,
12073,,In vivo,,A,,,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,1,,CHEMBL629590,BAO_0000218,,
12074,,In vivo,,A,,,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,1,,CHEMBL629591,BAO_0000218,,
12075,,In vivo,,A,,,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,1,,CHEMBL629592,BAO_0000218,,
12076,,In vivo,,A,,,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,1,,CHEMBL629593,BAO_0000218,,
12077,,In vivo,,A,,,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,1,,CHEMBL629594,BAO_0000218,,
12078,,In vivo,Heart,A,,,,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,1,,CHEMBL629595,BAO_0000218,948.0,
12079,,In vivo,Heart,A,,,,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,1,,CHEMBL630290,BAO_0000218,948.0,
12080,,In vivo,Heart,A,,,,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,1,,CHEMBL627137,BAO_0000218,948.0,
12081,,In vivo,Heart,A,,,,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,1,,CHEMBL627138,BAO_0000218,948.0,
12082,,In vivo,Heart,A,,,,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,1,,CHEMBL627139,BAO_0000218,948.0,
12083,,In vivo,Heart,A,,,,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,1,,CHEMBL627140,BAO_0000218,948.0,
12084,,In vivo,Heart,A,,,,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,1,,CHEMBL627141,BAO_0000218,948.0,
12085,,In vivo,Kidney,A,,,,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,1,,CHEMBL627142,BAO_0000218,2113.0,
12086,,In vivo,Kidney,A,,,,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,1,,CHEMBL627143,BAO_0000218,2113.0,
12087,,In vivo,Kidney,A,,,,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,1,,CHEMBL874449,BAO_0000218,2113.0,
12088,,In vivo,Kidney,A,,,,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,1,,CHEMBL627144,BAO_0000218,2113.0,
12089,,In vivo,Kidney,A,,,,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,1,,CHEMBL627145,BAO_0000218,2113.0,
12090,,In vivo,Kidney,A,,,,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,1,,CHEMBL627146,BAO_0000218,2113.0,
12091,,In vivo,Kidney,A,,,,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,1,,CHEMBL627147,BAO_0000218,2113.0,
12092,,In vivo,Liver,A,,,,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,1,,CHEMBL627148,BAO_0000218,2107.0,
12093,,In vivo,Lung,A,,,,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,1,,CHEMBL627149,BAO_0000218,2048.0,
12094,,In vivo,Lung,A,,,,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,1,,CHEMBL632160,BAO_0000218,2048.0,
12095,,In vivo,Lung,A,,,,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,1,,CHEMBL632161,BAO_0000218,2048.0,
12096,,In vivo,Lung,A,,,,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,1,,CHEMBL632162,BAO_0000218,2048.0,
12097,,In vivo,Lung,A,,,,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,1,,CHEMBL632163,BAO_0000218,2048.0,
12098,,In vivo,Lung,A,,,,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,1,,CHEMBL874469,BAO_0000218,2048.0,
12099,,In vivo,Lung,A,,,,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,1,,CHEMBL627182,BAO_0000218,2048.0,
12100,,In vivo,Muscle tissue,A,,,,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,1,,CHEMBL627183,BAO_0000218,2385.0,
12101,,In vivo,Muscle tissue,A,,,,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,1,,CHEMBL627184,BAO_0000218,2385.0,
12102,,In vivo,Muscle tissue,A,,,,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,1,,CHEMBL627185,BAO_0000218,2385.0,
12103,,In vivo,Muscle tissue,A,,,,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,1,,CHEMBL627186,BAO_0000218,2385.0,
12104,,In vivo,Muscle tissue,A,,,,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,1,,CHEMBL627187,BAO_0000218,2385.0,
12105,,In vivo,Muscle tissue,A,,,,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,1,,CHEMBL627188,BAO_0000218,2385.0,
12106,,In vivo,Muscle tissue,A,,,,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,1,,CHEMBL627189,BAO_0000218,2385.0,
12107,,In vivo,,A,,,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,1,,CHEMBL627190,BAO_0000218,,
12108,,In vivo,Liver,A,,,,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,1,,CHEMBL627191,BAO_0000218,2107.0,
12109,,In vivo,Liver,A,,,,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,1,,CHEMBL627192,BAO_0000218,2107.0,
12110,,In vivo,Liver,A,,,,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,1,,CHEMBL627193,BAO_0000218,2107.0,
12111,,In vivo,Muscle tissue,A,,,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,N,,1,,CHEMBL874590,BAO_0000218,2385.0,
12112,,In vivo,Muscle tissue,A,,,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627194,BAO_0000218,2385.0,
12113,,In vivo,Muscle tissue,A,,,,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627195,BAO_0000218,2385.0,
12114,,In vivo,Female gonad,A,,,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627196,BAO_0000218,992.0,
12115,,In vivo,Female gonad,A,,,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627197,BAO_0000218,992.0,
12116,,In vivo,Female gonad,A,,,,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627198,BAO_0000218,992.0,
12117,,In vivo,Female gonad,A,,,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,N,,1,,CHEMBL627199,BAO_0000218,992.0,
12118,,In vivo,Female gonad,A,,,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627200,BAO_0000218,992.0,
12119,,In vivo,Plasma,A,,,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627201,BAO_0000218,1969.0,
12120,,In vivo,Plasma,A,,,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627202,BAO_0000218,1969.0,
12121,,In vivo,Plasma,A,,,,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627203,BAO_0000218,1969.0,
12122,,In vivo,Plasma,A,,,,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627204,BAO_0000218,1969.0,
12123,,In vivo,Spleen,A,,,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627205,BAO_0000218,2106.0,
12124,,In vivo,Spleen,A,,,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627206,BAO_0000218,2106.0,
12125,,In vivo,Spleen,A,,,,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627207,BAO_0000218,2106.0,
12126,,In vivo,Spleen,A,,,,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627208,BAO_0000218,2106.0,
12127,,In vivo,Thyroid gland,A,,,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627209,BAO_0000218,2046.0,
12128,,In vivo,Thyroid gland,A,,,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627210,BAO_0000218,2046.0,
12129,,In vivo,Thyroid gland,A,,,,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627211,BAO_0000218,2046.0,
12130,,In vivo,Thyroid gland,A,,,,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627212,BAO_0000218,2046.0,
12131,,In vivo,Uterus,A,,,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,1,,CHEMBL627213,BAO_0000218,995.0,
12132,,In vivo,Uterus,A,,,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL626599,BAO_0000218,995.0,
12133,,In vivo,Uterus,A,,,,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL626600,BAO_0000218,995.0,
12134,,In vivo,Uterus,A,,,,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,1,,CHEMBL626601,BAO_0000218,995.0,
12135,,,,A,,,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,U,,1,,CHEMBL627484,BAO_0000019,,
12136,,,Plasma,A,,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),N,,1,,CHEMBL627485,BAO_0000218,1969.0,
12137,,,Plasma,A,,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,N,,1,,CHEMBL628147,BAO_0000218,1969.0,
12138,,,Plasma,A,,,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,N,,1,,CHEMBL628148,BAO_0000218,1969.0,
12139,,,Plasma,A,,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),N,,1,,CHEMBL628149,BAO_0000218,1969.0,
12140,,,Plasma,A,,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,N,,1,,CHEMBL628150,BAO_0000218,1969.0,
12141,,,Plasma,A,,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,N,,1,,CHEMBL628318,BAO_0000218,1969.0,
12142,,,Plasma,A,,,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,N,,1,,CHEMBL628319,BAO_0000218,1969.0,
12143,,,,A,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",N,,1,,CHEMBL875609,BAO_0000218,,
12144,,,,A,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,U,,1,,CHEMBL628320,BAO_0000019,,
12145,,,,A,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,U,,1,,CHEMBL628321,BAO_0000019,,
12146,,,,A,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,U,,1,,CHEMBL628322,BAO_0000019,,
12147,,,,A,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,U,,1,,CHEMBL628323,BAO_0000019,,
12148,,,,A,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,U,,1,,CHEMBL628324,BAO_0000019,,
12149,,,,A,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,U,,1,,CHEMBL628325,BAO_0000019,,
12150,,,,A,,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,U,,1,,CHEMBL628326,BAO_0000019,,
12151,,,Adrenal medulla,A,,,,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",N,,1,,CHEMBL628327,BAO_0000218,1236.0,
12152,,,Adrenal medulla,A,,,,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",N,,1,,CHEMBL628328,BAO_0000218,1236.0,
12153,,,Blood,A,,,,"Concentration of compound in blood of dog 1, after administering intravenously",N,,1,,CHEMBL628329,BAO_0000218,178.0,
12154,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",N,,1,,CHEMBL628330,BAO_0000218,2107.0,
12155,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",N,,1,,CHEMBL628331,BAO_0000218,2107.0,
12156,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",N,,1,,CHEMBL628332,BAO_0000218,2107.0,
12157,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",N,,1,,CHEMBL628333,BAO_0000218,2107.0,
12158,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",N,,1,,CHEMBL628334,BAO_0000218,2107.0,
12159,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",N,,1,,CHEMBL628335,BAO_0000218,2107.0,
12160,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",N,,1,,CHEMBL628336,BAO_0000218,2107.0,
12161,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",N,,1,,CHEMBL628337,BAO_0000218,2107.0,
12162,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",N,,1,,CHEMBL628338,BAO_0000218,2107.0,
12163,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",N,,1,,CHEMBL875610,BAO_0000218,2107.0,
12164,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",N,,1,,CHEMBL628339,BAO_0000218,2107.0,
12165,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",N,,1,,CHEMBL628340,BAO_0000218,2107.0,
12166,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",N,,1,,CHEMBL628341,BAO_0000218,2107.0,
12167,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",N,,1,,CHEMBL622214,BAO_0000218,2107.0,
12168,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",N,,1,,CHEMBL623167,BAO_0000218,2107.0,
12169,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",N,,1,,CHEMBL623168,BAO_0000218,2107.0,
12170,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",N,,1,,CHEMBL623169,BAO_0000218,2107.0,
12171,,,Liver,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",N,,1,,CHEMBL623170,BAO_0000218,2107.0,
12172,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",N,,1,,CHEMBL627224,BAO_0000218,2048.0,
12173,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",N,,1,,CHEMBL875634,BAO_0000218,2048.0,
12174,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",N,,1,,CHEMBL627225,BAO_0000218,2048.0,
12175,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",N,,1,,CHEMBL627226,BAO_0000218,2048.0,
12176,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",N,,1,,CHEMBL626083,BAO_0000218,2048.0,
12177,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",N,,1,,CHEMBL626084,BAO_0000218,2048.0,
12178,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",N,,1,,CHEMBL626085,BAO_0000218,2048.0,
12179,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",N,,1,,CHEMBL626086,BAO_0000218,2048.0,
12180,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",N,,1,,CHEMBL626087,BAO_0000218,2048.0,
12181,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",N,,1,,CHEMBL626088,BAO_0000218,2048.0,
12182,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",N,,1,,CHEMBL626089,BAO_0000218,2048.0,
12183,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",N,,1,,CHEMBL626090,BAO_0000218,2048.0,
12184,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",N,,1,,CHEMBL626091,BAO_0000218,2048.0,
12185,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",N,,1,,CHEMBL626092,BAO_0000218,2048.0,
12186,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",N,,1,,CHEMBL626093,BAO_0000218,2048.0,
12187,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",N,,1,,CHEMBL626094,BAO_0000218,2048.0,
12188,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",N,,1,,CHEMBL626095,BAO_0000218,2048.0,
12189,,,Lung,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",N,,1,,CHEMBL626096,BAO_0000218,2048.0,
12190,,,,A,,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,U,,1,,CHEMBL626097,BAO_0000218,,
12191,,,,A,,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,N,,1,,CHEMBL626098,BAO_0000218,,
12192,,,Plasma,A,,,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,U,,1,,CHEMBL626099,BAO_0000218,1969.0,
12193,,,Plasma,A,,,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,U,,1,,CHEMBL626100,BAO_0000218,1969.0,
12194,,,Plasma,A,,,,AUC 0-inf in dog,N,,1,,CHEMBL626101,BAO_0000218,1969.0,
12195,,,Plasma,A,,,,AUC 0-inf in guinea pig,N,,1,,CHEMBL626102,BAO_0000218,1969.0,
12196,,,Plasma,A,,,,AUC 0-t in dog,N,,1,,CHEMBL626103,BAO_0000218,1969.0,
12197,,,Plasma,A,,,,AUC 0-t in guinea pig,N,,1,,CHEMBL628391,BAO_0000218,1969.0,
12198,,,,A,,,,The compound was tested for brain to plasma partition in rat,N,,1,,CHEMBL628392,BAO_0000218,,
12199,,,,A,,,,The compound was tested for brain to plasma partition in rat.,N,,1,,CHEMBL628393,BAO_0000218,,
12200,,,Blood,A,,,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,U,,1,,CHEMBL628394,BAO_0000019,178.0,
12201,,,,A,,,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,N,,1,,CHEMBL628395,BAO_0000218,,
12202,,,,A,,,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,U,,1,,CHEMBL628396,BAO_0000218,,
12203,,,,A,,,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,N,,1,,CHEMBL628397,BAO_0000218,,
12204,,,,A,,,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,N,,1,,CHEMBL628398,BAO_0000218,,
12205,,,,A,,,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,N,,1,,CHEMBL628399,BAO_0000218,,
12206,,,,A,,,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,N,,1,,CHEMBL628400,BAO_0000218,,
12207,,,,A,,,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,N,,1,,CHEMBL874907,BAO_0000218,,
12208,,,,A,,,,Area under curve of the compound was determined,U,,1,,CHEMBL628401,BAO_0000019,,
12209,,,Plasma,A,,,,AUC in monkeys at a dose of 1 mg/kg,U,,1,,CHEMBL628402,BAO_0000218,1969.0,
12210,,,Plasma,A,,,,AUC in rats at a dose of 1 mg/kg,N,,1,,CHEMBL628403,BAO_0000218,1969.0,
12211,,,,A,,,,Compound was evaluated for the overall absorbance loss at pH of 2,U,,1,,CHEMBL628404,BAO_0000019,,
12212,,,,A,,,,Compound was evaluated for the overall absorbance loss at pH of 4,U,,1,,CHEMBL628405,BAO_0000019,,
12213,,,,A,,,,Compound was evaluated for the overall absorbance loss at pH of 7,U,,1,,CHEMBL628406,BAO_0000019,,
12214,,,,A,,,,Compound was evaluated for its absorption in the rats,N,,1,,CHEMBL628407,BAO_0000218,,
12215,,,Urine,A,,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,N,,1,,CHEMBL628408,BAO_0000218,1088.0,
12216,,,Urine,A,,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,N,,1,,CHEMBL629171,BAO_0000218,1088.0,
12217,,,Urine,A,,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,N,,1,,CHEMBL629172,BAO_0000218,1088.0,
12218,,,Urine,A,,,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,N,,1,,CHEMBL629173,BAO_0000218,1088.0,
12219,,,,A,,,,In vitro percent permeability into rat ileum,N,,1,,CHEMBL629174,BAO_0000218,,
12220,,,,A,,,,In vitro percent permeability into rat ileum; Range is 10-17,N,,1,,CHEMBL629175,BAO_0000218,,
12221,,,,A,,,,In vitro percent permeability into rat ileum; Range is 10-18,N,,1,,CHEMBL629176,BAO_0000218,,
12222,,,,A,,,,In vitro percent permeability into rat ileum; Range is 10-19,N,,1,,CHEMBL629177,BAO_0000218,,
12223,,,,A,,,,In vitro percent permeability into rat ileum; Range is 12-15,N,,1,,CHEMBL629178,BAO_0000218,,
12224,,,,A,,,,In vitro percent permeability into rat ileum; Range is 13-19,N,,1,,CHEMBL631869,BAO_0000218,,
12225,,,,A,,,,In vitro percent permeability into rat ileum; Range is 14-17,N,,1,,CHEMBL631870,BAO_0000218,,
12226,,,,A,,,,In vitro percent permeability into rat ileum; Range is 15-18,N,,1,,CHEMBL631871,BAO_0000218,,
12227,,,,A,,,,In vitro percent permeability into rat ileum; Range is 2-5,N,,1,,CHEMBL631872,BAO_0000218,,
12228,,,Ileum,A,,,,In vitro percent permeability into rat ileum; Range is 23-42,U,,1,,CHEMBL875775,BAO_0000221,2116.0,
12229,,,,A,,,,In vitro percent permeability into rat ileum; Range is 28-36,N,,1,,CHEMBL631873,BAO_0000218,,
12230,,,,A,,,,In vitro percent permeability into rat ileum; Range is 29-35,N,,1,,CHEMBL631874,BAO_0000218,,
12231,,,,A,,,,In vitro percent permeability into rat ileum; Range is 46-66,N,,1,,CHEMBL631875,BAO_0000218,,
12232,,,,A,,,,In vitro percent permeability into rat ileum; Range is 50-68,N,,1,,CHEMBL631876,BAO_0000218,,
12233,,,,A,,,,In vitro percent permeability into rat ileum; Range is 78-81,N,,1,,CHEMBL631877,BAO_0000218,,
12234,,,,A,,,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,N,,1,,CHEMBL631878,BAO_0000218,,
12235,,,,A,,,,In vitro percent permeability into rat ileum; nd indicates not detected,N,,1,,CHEMBL631879,BAO_0000218,,
12236,,,,A,,,,In vitro percent permeability into rat ileum; nt indicates not detected,N,,1,,CHEMBL631880,BAO_0000218,,
12237,,,,A,,,,In vitro percent permeability into rat ileum; nt indicates not tested,N,,1,,CHEMBL631881,BAO_0000218,,
12238,,,,A,,,,Compound was tested for oral absorption in bile-duct cannulated rats,N,,1,,CHEMBL631882,BAO_0000218,,
12239,,,,A,,,,Compound was tested for oral absorption in bile-duct cannulated rats.,N,,1,,CHEMBL630749,BAO_0000218,,
12240,,,,A,,,,Oral absorption using Caco-2 cell monolayers.,N,,1,,CHEMBL630750,BAO_0000218,,
12241,,,,A,,,,Percent of the drug absorbed after administration to humans was determined,N,,1,,CHEMBL630253,BAO_0000218,,
12242,,,Plasma,A,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,N,,1,,CHEMBL630254,BAO_0000218,1969.0,
12243,,,Plasma,A,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,N,,1,,CHEMBL630255,BAO_0000218,1969.0,
12244,,,Plasma,A,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,N,,1,,CHEMBL630256,BAO_0000218,1969.0,
12245,,In vivo,Liver,A,,,,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,1,,CHEMBL875781,BAO_0000218,2107.0,
12246,,In vivo,Liver,A,,,,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,1,,CHEMBL630257,BAO_0000218,2107.0,
12247,,In vivo,Liver,A,,,,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,1,,CHEMBL630258,BAO_0000218,2107.0,
12248,,,,A,,,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",N,,1,,CHEMBL630259,BAO_0000218,,
12249,,,Striatum,A,,,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",N,,1,,CHEMBL630260,BAO_0000218,2435.0,
12250,,,Striatum,A,,,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",N,,1,,CHEMBL630261,BAO_0000218,2435.0,
12251,,,,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,N,,1,,CHEMBL630262,BAO_0000218,,
12252,,,,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,N,,1,,CHEMBL630263,BAO_0000218,,
12253,,,,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,N,,1,,CHEMBL630264,BAO_0000218,,
12254,,,,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,N,,1,,CHEMBL630265,BAO_0000218,,
12255,,,,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,N,,1,,CHEMBL630266,BAO_0000218,,
12256,,,Kidney,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,N,,1,,CHEMBL630267,BAO_0000218,2113.0,
12257,,,Kidney,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,N,,1,,CHEMBL630268,BAO_0000218,2113.0,
12258,,,,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,N,,1,,CHEMBL630269,BAO_0000218,,
12259,,,,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,N,,1,,CHEMBL630270,BAO_0000218,,
12260,,,Lung,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,N,,1,,CHEMBL630141,BAO_0000218,2048.0,
12261,,,Lung,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,N,,1,,CHEMBL630142,BAO_0000218,2048.0,
12262,,,Muscle tissue,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,N,,1,,CHEMBL630143,BAO_0000218,2385.0,
12263,,,Muscle tissue,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,N,,1,,CHEMBL630144,BAO_0000218,2385.0,
12264,,,Prostate gland,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,N,,1,,CHEMBL630145,BAO_0000218,2367.0,
12265,,,Prostate gland,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,N,,1,,CHEMBL630146,BAO_0000218,2367.0,
12266,,,,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,N,,1,,CHEMBL630147,BAO_0000218,,
12267,,,,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,N,,1,,CHEMBL630148,BAO_0000218,,
12268,,,,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,N,,1,,CHEMBL630149,BAO_0000218,,
12269,,,Spleen,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,N,,1,,CHEMBL630150,BAO_0000218,2106.0,
12270,,,Spleen,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,N,,1,,CHEMBL630151,BAO_0000218,2106.0,
12271,,,Thyroid gland,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,N,,1,,CHEMBL632031,BAO_0000218,2046.0,
12272,,,Thyroid gland,A,,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,N,,1,,CHEMBL632032,BAO_0000218,2046.0,
12273,,,,A,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,N,,1,,CHEMBL632033,BAO_0000218,,
12274,,,,A,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,N,,1,,CHEMBL632034,BAO_0000218,,
12275,,,Muscle tissue,A,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,N,,1,,CHEMBL632035,BAO_0000218,2385.0,
12276,,,,A,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,N,,1,,CHEMBL632036,BAO_0000218,,
12277,,,Thyroid gland,A,,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,N,,1,,CHEMBL632037,BAO_0000218,2046.0,
12278,,,Blood,A,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,N,,1,,CHEMBL632038,BAO_0000218,178.0,
12279,,,Blood,A,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,N,,1,,CHEMBL632039,BAO_0000218,178.0,
12280,,,Blood,A,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,N,,1,,CHEMBL632040,BAO_0000218,178.0,
12281,,,Blood,A,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,N,,1,,CHEMBL632041,BAO_0000218,178.0,
12282,,,Blood,A,,,,"Concentration of compound in blood of dog 2, after administering intravenously",N,,1,,CHEMBL632042,BAO_0000218,178.0,
12283,,,,A,,,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",N,,1,,CHEMBL632043,BAO_0000218,,
12284,,,,A,,,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",N,,1,,CHEMBL632044,BAO_0000218,,
12285,,,Liver,A,,,,"Concentration of compound in liver of dog 1, after administering intravenously",N,,1,,CHEMBL632045,BAO_0000218,2107.0,
12286,,,Liver,A,,,,"Concentration of compound in liver of dog 2, after administering intravenously",N,,1,,CHEMBL632046,BAO_0000218,2107.0,
12287,,,Lung,A,,,,"Concentration of compound in lung of dog 1, after administering intravenously",N,,1,,CHEMBL632047,BAO_0000218,2048.0,
12288,,,Lung,A,,,,"Concentration of compound in lung of dog 2, after administering intravenously",N,,1,,CHEMBL632048,BAO_0000218,2048.0,
12289,,,Muscle tissue,A,,,,"Concentration of compound in muscle of dog 1, after administering intravenously",N,,1,,CHEMBL632049,BAO_0000218,2385.0,
12290,,,Muscle tissue,A,,,,"Concentration of compound in muscle of dog 2, after administering intravenously",N,,1,,CHEMBL876418,BAO_0000218,2385.0,
12291,,,Spleen,A,,,,"Concentration of compound in spleen of dog 1,after administering intravenously",N,,1,,CHEMBL632050,BAO_0000218,2106.0,
12292,,,Spleen,A,,,,"Concentration of compound in spleen of dog 2, after administering intravenously",N,,1,,CHEMBL632051,BAO_0000218,2106.0,
12293,,,,F,,,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,U,,1,,CHEMBL632052,BAO_0000218,,
12294,,,,F,,,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,U,,1,,CHEMBL632053,BAO_0000218,,
12295,,,,A,,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,U,,1,,CHEMBL632054,BAO_0000218,,
12296,,,,F,,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,U,,1,,CHEMBL632055,BAO_0000218,,
12297,,,,F,,,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,U,,1,,CHEMBL631181,BAO_0000218,,
12298,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,U,,1,,CHEMBL631182,BAO_0000218,,
12299,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,U,,1,,CHEMBL631183,BAO_0000218,,
12300,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,U,,1,,CHEMBL631184,BAO_0000218,,
12301,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,U,,1,,CHEMBL629774,BAO_0000218,,
12302,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,U,,1,,CHEMBL629775,BAO_0000218,,
12303,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,U,,1,,CHEMBL876549,BAO_0000218,,
12304,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,U,,1,,CHEMBL628172,BAO_0000218,,
12305,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,U,,1,,CHEMBL628173,BAO_0000218,,
12306,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,U,,1,,CHEMBL628174,BAO_0000218,,
12307,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,U,,1,,CHEMBL628175,BAO_0000218,,
12308,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,U,,1,,CHEMBL628176,BAO_0000218,,
12309,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,U,,1,,CHEMBL628177,BAO_0000218,,
12310,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,U,,1,,CHEMBL628178,BAO_0000218,,
12311,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,U,,1,,CHEMBL628179,BAO_0000218,,
12312,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,U,,1,,CHEMBL628180,BAO_0000218,,
12313,,,,A,,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,U,,1,,CHEMBL628181,BAO_0000218,,
12314,,,,A,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,U,,1,,CHEMBL628182,BAO_0000218,,
12315,,,,A,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,U,,1,,CHEMBL628183,BAO_0000218,,
12316,,,,A,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,U,,1,,CHEMBL628184,BAO_0000218,,
12317,,,,A,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,U,,1,,CHEMBL628185,BAO_0000218,,
12318,,,,A,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,U,,1,,CHEMBL875617,BAO_0000218,,
12319,,,,A,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,U,,1,,CHEMBL628186,BAO_0000218,,
12320,,,,A,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,U,,1,,CHEMBL628187,BAO_0000218,,
12321,,,,A,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,U,,1,,CHEMBL628188,BAO_0000218,,
12322,,,,A,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,U,,1,,CHEMBL628189,BAO_0000218,,
12323,,,,A,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,U,,1,,CHEMBL628190,BAO_0000218,,
12324,,,,A,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,U,,1,,CHEMBL628191,BAO_0000218,,
12325,,,,A,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,U,,1,,CHEMBL626513,BAO_0000218,,
12326,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",N,,1,,CHEMBL626514,BAO_0000218,2046.0,
12327,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",N,,1,,CHEMBL626515,BAO_0000218,2046.0,
12328,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",N,,1,,CHEMBL626516,BAO_0000218,2046.0,
12329,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",N,,1,,CHEMBL626517,BAO_0000218,2046.0,
12330,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",N,,1,,CHEMBL626518,BAO_0000218,2046.0,
12331,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",N,,1,,CHEMBL626519,BAO_0000218,2046.0,
12332,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",N,,1,,CHEMBL626520,BAO_0000218,2046.0,
12333,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",N,,1,,CHEMBL626521,BAO_0000218,2046.0,
12334,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",N,,1,,CHEMBL626522,BAO_0000218,2046.0,
12335,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",N,,1,,CHEMBL626523,BAO_0000218,2046.0,
12336,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",N,,1,,CHEMBL626524,BAO_0000218,2046.0,
12337,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",N,,1,,CHEMBL626688,BAO_0000218,2046.0,
12338,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",N,,1,,CHEMBL626689,BAO_0000218,2046.0,
12339,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",N,,1,,CHEMBL626690,BAO_0000218,2046.0,
12340,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",N,,1,,CHEMBL626691,BAO_0000218,2046.0,
12341,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",N,,1,,CHEMBL627319,BAO_0000218,2046.0,
12342,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",N,,1,,CHEMBL624052,BAO_0000218,2046.0,
12343,,,Thyroid gland,A,,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",N,,1,,CHEMBL624053,BAO_0000218,2046.0,
12344,,,,A,,,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,1,,CHEMBL624054,BAO_0000218,,
12345,,,,A,,,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,1,,CHEMBL624055,BAO_0000218,,
12346,,,,A,,,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,1,,CHEMBL624056,BAO_0000218,,
12347,,,Uterus,A,,,,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,1,,CHEMBL624057,BAO_0000218,995.0,
12348,,,Uterus,A,,,,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,1,,CHEMBL622281,BAO_0000218,995.0,
12349,,,Uterus,A,,,,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,1,,CHEMBL622282,BAO_0000218,995.0,
12350,,,Uterus,A,,,,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,1,,CHEMBL622283,BAO_0000218,995.0,
12351,,,Uterus,A,,,,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,1,,CHEMBL622284,BAO_0000218,995.0,
12352,,,Uterus,A,,,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,1,,CHEMBL622285,BAO_0000218,995.0,
12353,,,Uterus,A,,,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,1,,CHEMBL622286,BAO_0000218,995.0,
12354,,,,P,,,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,U,,1,,CHEMBL622287,BAO_0000100,,
12355,,,,A,,,,Partition coefficient (logD7.4),N,,1,,CHEMBL622288,BAO_0000218,,
12356,,,,A,,,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",N,,1,,CHEMBL622289,BAO_0000218,,
12357,,,Brain,A,,,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",N,,1,,CHEMBL622290,BAO_0000218,955.0,
12358,,,,A,,,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,N,,1,,CHEMBL622291,BAO_0000218,,
12359,,,Brain,A,,,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,N,,1,,CHEMBL622292,BAO_0000218,955.0,
12360,,,,A,,,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",N,,1,,CHEMBL622293,BAO_0000218,,
12361,,,Brain,A,,,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",N,,1,,CHEMBL622294,BAO_0000218,955.0,
12362,,,,A,,,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,N,,1,,CHEMBL622295,BAO_0000218,,
12363,,,Brain,A,,,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,N,,1,,CHEMBL622296,BAO_0000218,955.0,
12364,,,Plasma,A,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,N,,1,,CHEMBL874409,BAO_0000218,1969.0,
12365,,,Plasma,A,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,N,,1,,CHEMBL622297,BAO_0000218,1969.0,
12366,,,Plasma,A,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,N,,1,,CHEMBL622298,BAO_0000218,1969.0,
12367,,,Plasma,A,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,N,,1,,CHEMBL622299,BAO_0000218,1969.0,
12368,,,Plasma,A,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,N,,1,,CHEMBL622300,BAO_0000218,1969.0,
12369,,,Plasma,A,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,N,,1,,CHEMBL622301,BAO_0000218,1969.0,
12370,,,Plasma,A,,,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,N,,1,,CHEMBL622302,BAO_0000218,1969.0,
12371,,,Plasma,A,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,N,,1,,CHEMBL622303,BAO_0000218,1969.0,
12372,,,Plasma,A,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,N,,1,,CHEMBL622304,BAO_0000218,1969.0,
12373,,,Plasma,A,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,N,,1,,CHEMBL622305,BAO_0000218,1969.0,
12374,,,Plasma,A,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,N,,1,,CHEMBL622306,BAO_0000218,1969.0,
12375,,,Plasma,A,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,N,,1,,CHEMBL626864,BAO_0000218,1969.0,
12376,,,Plasma,A,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,N,,1,,CHEMBL626865,BAO_0000218,1969.0,
12377,,,Plasma,A,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,N,,1,,CHEMBL626866,BAO_0000218,1969.0,
12378,,,Plasma,A,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,N,,1,,CHEMBL626867,BAO_0000218,1969.0,
12379,,,Plasma,A,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,N,,1,,CHEMBL626868,BAO_0000218,1969.0,
12380,,,Plasma,A,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,N,,1,,CHEMBL626869,BAO_0000218,1969.0,
12381,,,Plasma,A,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,N,,1,,CHEMBL626870,BAO_0000218,1969.0,
12382,,,Plasma,A,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,N,,1,,CHEMBL626871,BAO_0000218,1969.0,
12383,,,Plasma,A,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,N,,1,,CHEMBL626872,BAO_0000218,1969.0,
12384,,,Plasma,A,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,N,,1,,CHEMBL632185,BAO_0000218,1969.0,
12385,,,Plasma,A,,,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,N,,1,,CHEMBL632186,BAO_0000218,1969.0,
12386,,,,A,,,,Amount of acetic acid produced by the compound,U,,1,,CHEMBL629310,BAO_0000019,,
12387,,,,A,,,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,U,,1,,CHEMBL629311,BAO_0000019,,
12388,,,,A,,,,Log of (Cbrain/Cblood) in rats,N,,1,,CHEMBL629312,BAO_0000218,,
12389,,,,A,,,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),U,,1,,CHEMBL629313,BAO_0000221,,
12390,,,,A,,,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),U,,1,,CHEMBL629314,BAO_0000221,,
12391,,,,A,,,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),U,,1,,CHEMBL629315,BAO_0000221,,
12392,,,,B,,,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),U,,1,,CHEMBL629316,BAO_0000219,,
12393,,,,A,,,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),U,,1,,CHEMBL629317,BAO_0000221,,
12394,,,,A,,,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),U,,1,,CHEMBL629318,BAO_0000019,,
12395,,,,A,,,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),U,,1,,CHEMBL877497,BAO_0000019,,
12396,,,,A,,,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),U,,1,,CHEMBL629319,BAO_0000019,,
12397,,,,A,,,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),U,,1,,CHEMBL629320,BAO_0000019,,
12398,,,,A,,,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),U,,1,,CHEMBL629496,BAO_0000019,,
12399,,,,A,,,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),U,,1,,CHEMBL629497,BAO_0000019,,
12400,,,,A,,,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),U,,1,,CHEMBL629498,BAO_0000019,,
12401,,,,A,,,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),U,,1,,CHEMBL629499,BAO_0000019,,
12402,,,,A,,,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),U,,1,,CHEMBL629500,BAO_0000019,,
12403,,,,A,,,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),U,,1,,CHEMBL629501,BAO_0000019,,
12404,,,,A,,,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),U,,1,,CHEMBL629502,BAO_0000019,,
12405,,In vivo,,F,,,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,U,,1,,CHEMBL629503,BAO_0000218,,
12406,,,,A,,,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,N,,1,,CHEMBL629504,BAO_0000218,,
12407,,,,A,,,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,U,,1,,CHEMBL629505,BAO_0000019,,
12408,,,,A,,,,Compound was evaluated for total body clearance,U,,1,,CHEMBL629506,BAO_0000019,,
12409,,,,A,,,,Compound was evaluated for volume of distribution at steady state,U,,1,,CHEMBL629507,BAO_0000019,,
12410,,,,A,,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,U,,1,,CHEMBL877498,BAO_0000019,,
12411,,,,A,,,,Percentage of the diamine which is monoprotonated at pH 7.4,U,,1,,CHEMBL629508,BAO_0000019,,
12412,,,,A,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,U,,1,,CHEMBL629509,BAO_0000019,,
12413,,,Blood,A,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,N,,1,,CHEMBL629510,BAO_0000218,178.0,
12414,,,Blood,A,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,N,,1,,CHEMBL629511,BAO_0000218,178.0,
12415,,,Blood,A,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,N,,1,,CHEMBL629512,BAO_0000218,178.0,
12416,,,Blood,A,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,N,,1,,CHEMBL629513,BAO_0000218,178.0,
12417,,,Blood,A,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,N,,1,,CHEMBL629514,BAO_0000218,178.0,
12418,,,Blood,A,,,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,N,,1,,CHEMBL628447,BAO_0000218,178.0,
12419,,,Blood,A,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,N,,1,,CHEMBL628448,BAO_0000218,178.0,
12420,,,Blood,A,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,N,,1,,CHEMBL628449,BAO_0000218,178.0,
12421,,,Blood,A,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,N,,1,,CHEMBL631119,BAO_0000218,178.0,
12422,,,Blood,A,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,N,,1,,CHEMBL631120,BAO_0000218,178.0,
12423,,,Blood,A,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,N,,1,,CHEMBL631121,BAO_0000218,178.0,
12424,,,Blood,A,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,N,,1,,CHEMBL874458,BAO_0000218,178.0,
12425,,,Blood,A,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,N,,1,,CHEMBL631122,BAO_0000218,178.0,
12426,,,Blood,A,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,N,,1,,CHEMBL631123,BAO_0000218,178.0,
12427,,,Blood,A,,,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,N,,1,,CHEMBL631124,BAO_0000218,178.0,
12428,,,Blood,A,,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,N,,1,,CHEMBL631125,BAO_0000218,178.0,
12429,,,Blood,A,,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,N,,1,,CHEMBL631290,BAO_0000218,178.0,
12430,,,Blood,A,,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,N,,1,,CHEMBL631291,BAO_0000218,178.0,
12431,,,Blood,A,,,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,N,,1,,CHEMBL631292,BAO_0000218,178.0,
12432,,,Blood,A,,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,N,,1,,CHEMBL631293,BAO_0000218,178.0,
12433,,,Blood,A,,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,N,,1,,CHEMBL631294,BAO_0000218,178.0,
12434,,,Blood,A,,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,N,,1,,CHEMBL631295,BAO_0000218,178.0,
12435,,,Blood,A,,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,N,,1,,CHEMBL631296,BAO_0000218,178.0,
12436,,,Blood,A,,,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,N,,1,,CHEMBL631297,BAO_0000218,178.0,
12437,,,,A,,,,Maximum biodistribution (Bmax) was determined.,U,,1,,CHEMBL631298,BAO_0000218,,
12438,,,,A,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,N,,1,,CHEMBL631299,BAO_0000218,,
12439,,,,A,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,N,,1,,CHEMBL631300,BAO_0000218,,
12440,,,,A,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,N,,1,,CHEMBL631301,BAO_0000218,,
12441,,,,A,,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,N,,1,,CHEMBL630291,BAO_0000218,,
12442,,,,A,,,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,U,,1,,CHEMBL630292,BAO_0000218,,
12443,,,,A,,,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,U,,1,,CHEMBL630293,BAO_0000218,,
12444,,,,A,,,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,U,,1,,CHEMBL630294,BAO_0000218,,
12445,,,,A,,,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,U,,1,,CHEMBL630295,BAO_0000218,,
12446,,,,A,,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,U,,1,,CHEMBL630296,BAO_0000218,,
12447,,,,A,,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,U,,1,,CHEMBL626782,BAO_0000218,,
12448,,,,A,,,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,U,,1,,CHEMBL626783,BAO_0000218,,
12449,,,,A,,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,U,,1,,CHEMBL626784,BAO_0000218,,
12450,,,,A,,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,U,,1,,CHEMBL626785,BAO_0000218,,
12451,,,,A,,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,U,,1,,CHEMBL626786,BAO_0000218,,
12452,,,,A,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,U,,1,,CHEMBL626787,BAO_0000218,,
12453,,,,A,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,U,,1,,CHEMBL626788,BAO_0000218,,
12454,,,,A,,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,U,,1,,CHEMBL625927,BAO_0000218,,
12455,,,Blood,A,,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL625928,BAO_0000218,178.0,
12456,,,Blood,A,,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,,1,,CHEMBL625929,BAO_0000218,178.0,
12457,,,Blood,A,,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,N,,1,,CHEMBL625930,BAO_0000218,178.0,
12458,,,Blood,A,,,,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",N,,1,,CHEMBL625931,BAO_0000218,178.0,
12459,,,Blood,A,,,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,N,,1,,CHEMBL627230,BAO_0000218,178.0,
12460,,,Blood,A,,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627231,BAO_0000218,178.0,
12461,,,Blood,A,,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,,1,,CHEMBL627232,BAO_0000218,178.0,
12462,,,Blood,A,,,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,N,,1,,CHEMBL627233,BAO_0000218,178.0,
12463,,,Blood,A,,,,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL875470,BAO_0000218,178.0,
12464,,,Blood,A,,,,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627234,BAO_0000218,178.0,
12465,,,Blood,A,,,,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627235,BAO_0000218,178.0,
12466,,,Blood,A,,,,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627236,BAO_0000218,178.0,
12467,,,Blood,A,,,,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627237,BAO_0000218,178.0,
12468,,,Blood,A,,,,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627238,BAO_0000218,178.0,
12469,,,Blood,A,,,,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627239,BAO_0000218,178.0,
12470,,,Blood,A,,,,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627240,BAO_0000218,178.0,
12471,,,Blood,A,,,,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627241,BAO_0000218,178.0,
12472,,,Blood,A,,,,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627242,BAO_0000218,178.0,
12473,,,Blood,A,,,,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,N,,1,,CHEMBL627243,BAO_0000218,178.0,
12474,,,Blood,A,,,,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,,1,,CHEMBL627244,BAO_0000218,178.0,
12475,,,Blood,A,,,,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627245,BAO_0000218,178.0,
12476,,,Blood,A,,,,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627246,BAO_0000218,178.0,
12477,,,Blood,A,,,,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627247,BAO_0000218,178.0,
12478,,,Blood,A,,,,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627248,BAO_0000218,178.0,
12479,,,Blood,A,,,,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627249,BAO_0000218,178.0,
12480,,,Blood,A,,,,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL625569,BAO_0000218,178.0,
12481,,,Blood,A,,,,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL625570,BAO_0000218,178.0,
12482,,,Blood,A,,,,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL625571,BAO_0000218,178.0,
12483,,,Blood,A,,,,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,,1,,CHEMBL625572,BAO_0000218,178.0,
12484,,,Blood,A,,,,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,,1,,CHEMBL625573,BAO_0000218,178.0,
12485,,,Blood,A,,,,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,N,,1,,CHEMBL625574,BAO_0000218,178.0,
12486,,,Blood,A,,,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,,1,,CHEMBL626245,BAO_0000218,178.0,
12487,,,Blood,A,,,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL626246,BAO_0000218,178.0,
12488,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,U,,1,,CHEMBL626247,BAO_0000218,,
12489,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,U,,1,,CHEMBL626248,BAO_0000218,,
12490,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,U,,1,,CHEMBL626249,BAO_0000218,,
12491,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,U,,1,,CHEMBL626420,BAO_0000218,,
12492,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,U,,1,,CHEMBL626421,BAO_0000218,,
12493,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,U,,1,,CHEMBL626422,BAO_0000218,,
12494,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,U,,1,,CHEMBL626423,BAO_0000218,,
12495,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,U,,1,,CHEMBL626424,BAO_0000218,,
12496,,,,A,,,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,N,,1,,CHEMBL626425,BAO_0000218,,
12497,,,,A,,,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,N,,1,,CHEMBL875476,BAO_0000218,,
12498,,,,A,,,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,N,,1,,CHEMBL626426,BAO_0000218,,
12499,,,,P,,,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,U,,1,,CHEMBL626427,BAO_0000100,,
12500,,,,P,,,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,U,,1,,CHEMBL626428,BAO_0000100,,
12501,,,,A,,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,U,,1,,CHEMBL626429,BAO_0000019,,
12502,,,Urine,A,,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,U,,1,,CHEMBL625025,BAO_0000019,1088.0,
12503,,,Blood,A,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,,1,,CHEMBL625026,BAO_0000218,178.0,
12504,,,Blood,A,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,,1,,CHEMBL625027,BAO_0000218,178.0,
12505,,,Blood,A,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,,1,,CHEMBL874410,BAO_0000218,178.0,
12506,,,Blood,A,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,,1,,CHEMBL625028,BAO_0000218,178.0,
12507,,,Blood,A,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,,1,,CHEMBL625029,BAO_0000218,178.0,
12508,,,Blood,A,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,,1,,CHEMBL625030,BAO_0000218,178.0,
12509,,,Blood,A,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,1,,CHEMBL625031,BAO_0000218,178.0,
12510,,,Blood,A,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,,1,,CHEMBL625032,BAO_0000218,178.0,
12511,,,Blood,A,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,,1,,CHEMBL625033,BAO_0000218,178.0,
12512,,,Blood,A,,,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,,1,,CHEMBL625034,BAO_0000218,178.0,
12513,,,Heart,A,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,,1,,CHEMBL624872,BAO_0000218,948.0,
12514,,,Heart,A,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL624873,BAO_0000218,948.0,
12515,,,Heart,A,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,,1,,CHEMBL624874,BAO_0000218,948.0,
12516,,,Heart,A,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,,1,,CHEMBL624875,BAO_0000218,948.0,
12517,,,Heart,A,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,,1,,CHEMBL624876,BAO_0000218,948.0,
12518,,,Heart,A,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,,1,,CHEMBL624877,BAO_0000218,948.0,
12519,,,Heart,A,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,,1,,CHEMBL624878,BAO_0000218,948.0,
12520,,,Heart,A,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,,1,,CHEMBL624879,BAO_0000218,948.0,
12521,,,Heart,A,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,1,,CHEMBL624880,BAO_0000218,948.0,
12522,,,Heart,A,,,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,N,,1,,CHEMBL624881,BAO_0000218,948.0,
12523,,,Heart,A,,,,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",N,,1,,CHEMBL624882,BAO_0000218,948.0,
12524,,,Kidney,A,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,,1,,CHEMBL624883,BAO_0000218,2113.0,
12525,,,Kidney,A,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,,1,,CHEMBL624884,BAO_0000218,2113.0,
12526,,,Kidney,A,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,,1,,CHEMBL624885,BAO_0000218,2113.0,
12527,,,Kidney,A,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,,1,,CHEMBL624886,BAO_0000218,2113.0,
12528,,,Kidney,A,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,,1,,CHEMBL624887,BAO_0000218,2113.0,
12529,,,Kidney,A,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,,1,,CHEMBL624888,BAO_0000218,2113.0,
12530,,,Kidney,A,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,,1,,CHEMBL624889,BAO_0000218,2113.0,
12531,,,Kidney,A,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,,1,,CHEMBL624890,BAO_0000218,2113.0,
12532,,,Kidney,A,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,1,,CHEMBL621964,BAO_0000218,2113.0,
12533,,,Kidney,A,,,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,,1,,CHEMBL621965,BAO_0000218,2113.0,
12534,,,Liver,A,,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,,1,,CHEMBL621966,BAO_0000218,2107.0,
12535,,,Liver,A,,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,,1,,CHEMBL621967,BAO_0000218,2107.0,
12536,,,Liver,A,,,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,,1,,CHEMBL622164,BAO_0000218,2107.0,
12537,,,,A,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),U,,1,,CHEMBL623097,BAO_0000019,,
12538,,,,A,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),U,,1,,CHEMBL623098,BAO_0000019,,
12539,,,,A,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,U,,1,,CHEMBL623099,BAO_0000019,,
12540,,,,A,,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,U,,1,,CHEMBL623100,BAO_0000019,,
12541,,,,A,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",N,,1,,CHEMBL628673,BAO_0000218,,
12542,,,,A,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",N,,1,,CHEMBL628674,BAO_0000218,,
12543,,,,A,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",N,,1,,CHEMBL628675,BAO_0000218,,
12544,,,,A,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",N,,1,,CHEMBL627644,BAO_0000218,,
12545,,,,A,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",N,,1,,CHEMBL627645,BAO_0000218,,
12546,,,,A,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",N,,1,,CHEMBL627646,BAO_0000218,,
12547,,,,A,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",N,,1,,CHEMBL627647,BAO_0000218,,
12548,,,,A,,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",N,,1,,CHEMBL627648,BAO_0000218,,
12549,,,,A,,,,Free level in rat plasma,N,,1,,CHEMBL627649,BAO_0000218,,
12550,,,,A,,,,Level reaching in blood plasma of rat or human was determined,U,,1,,CHEMBL628313,BAO_0000019,,
12551,,,,A,,,,Log (Cbrain/Cblood) in rats,N,,1,,CHEMBL628314,BAO_0000218,,
12552,,,,A,,,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,U,,1,,CHEMBL628315,BAO_0000019,,
12553,,,,A,,,,Mean percentage of compound transport through membrane; expressed as membrane transport,U,,1,,CHEMBL628316,BAO_0000019,,
12554,,,,A,,,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,U,,1,,CHEMBL628317,BAO_0000218,,
12555,,,,A,,,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,U,,1,,CHEMBL628473,BAO_0000019,,
12556,,,,A,,,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",U,,1,,CHEMBL628474,BAO_0000019,,
12557,,,,A,,,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,U,,1,,CHEMBL628475,BAO_0000019,,
12558,,,,A,,,,Net water uptake by a carrier mediated transport (%cm) mechanism,U,,1,,CHEMBL628476,BAO_0000019,,
12559,,,,A,,,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,U,,1,,CHEMBL628477,BAO_0000218,,
12560,,,,A,,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,N,,1,,CHEMBL628478,BAO_0000218,,
12561,,,,A,,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",N,,1,,CHEMBL628479,BAO_0000218,,
12562,,,,A,,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,U,,1,,CHEMBL628480,BAO_0000218,,
12563,,,,A,,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",U,,1,,CHEMBL628481,BAO_0000218,,
12564,,,,A,,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,N,,1,,CHEMBL628482,BAO_0000218,,
12565,,,,A,,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",N,,1,,CHEMBL628483,BAO_0000218,,
12566,,,Plasma,A,,,,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",N,,1,,CHEMBL628484,BAO_0000218,1969.0,
12567,,,Plasma,A,,,,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",N,,1,,CHEMBL628485,BAO_0000218,1969.0,
12568,,,Plasma,A,,,,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",N,,1,,CHEMBL628486,BAO_0000218,1969.0,
12569,,,Plasma,A,,,,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",N,,1,,CHEMBL628487,BAO_0000218,1969.0,
12570,,,Plasma,A,,,,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",N,,1,,CHEMBL628488,BAO_0000218,1969.0,
12571,,,Plasma,A,,,,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",N,,1,,CHEMBL628489,BAO_0000218,1969.0,
12572,,,Plasma,A,,,,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",N,,1,,CHEMBL628490,BAO_0000218,1969.0,
12573,,,,A,,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,N,,1,,CHEMBL628491,BAO_0000218,,
12574,,,,A,,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,N,,1,,CHEMBL877507,BAO_0000218,,
12575,,,,A,,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,U,,1,,CHEMBL628492,BAO_0000218,,
12576,,,,A,,,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),U,,1,,CHEMBL628493,BAO_0000019,,
12577,,,,A,,,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),U,,1,,CHEMBL628494,BAO_0000019,,
12578,,,,A,,,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),U,,1,,CHEMBL628495,BAO_0000019,,
12579,,,,A,,,,Permeability in Caco-2 assay at 10E-6,N,,1,,CHEMBL628496,BAO_0000218,,
12580,,,Brain,A,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,U,,1,,CHEMBL628497,BAO_0000218,955.0,
12581,,,Brain,A,,,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,U,,1,,CHEMBL628498,BAO_0000218,955.0,
12582,,,,A,,,,Plasma protein binding was determined,U,,1,,CHEMBL628499,BAO_0000019,,
12583,,,,A,,,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,U,,1,,CHEMBL627656,BAO_0000218,,
12584,,,,A,,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,U,,1,,CHEMBL627657,BAO_0000218,,
12585,,,,A,,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,U,,1,,CHEMBL626808,BAO_0000218,,
12586,,,,A,,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,U,,1,,CHEMBL626809,BAO_0000218,,
12587,,,,A,,,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,U,,1,,CHEMBL626810,BAO_0000218,,
12588,,,,A,,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,U,,1,,CHEMBL626811,BAO_0000218,,
12589,,,,A,,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,U,,1,,CHEMBL874465,BAO_0000218,,
12590,,,,A,,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,U,,1,,CHEMBL626812,BAO_0000218,,
12591,,,,A,,,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,U,,1,,CHEMBL626813,BAO_0000218,,
12592,,,,A,,,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,U,,1,,CHEMBL626814,BAO_0000218,,
12593,,,,A,,,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,U,,1,,CHEMBL626815,BAO_0000019,,
12594,,,,A,,,,Partition coefficient (logP),U,,1,,CHEMBL628566,BAO_0000019,,
12595,,,,P,,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),U,,1,,CHEMBL628567,BAO_0000100,,
12596,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL628568,BAO_0000100,,
12597,,In vivo,,A,,,,C max in dog,N,,1,,CHEMBL628569,BAO_0000218,,
12598,,In vivo,,A,,,,C max in guinea pig,N,,1,,CHEMBL628570,BAO_0000218,,
12599,,In vivo,,A,,,,C max value was evaluated,U,,1,,CHEMBL628571,BAO_0000218,,
12600,,In vivo,,A,,,,Cmax value after oral dose of 0.1 mg//kg,U,,1,,CHEMBL628572,BAO_0000218,,
12601,,In vivo,,A,,,,Cmax value after oral dose of 0.3 mg/kg,U,,1,,CHEMBL628573,BAO_0000218,,
12602,,In vivo,,A,,,,Cmax value after oral dose of 1 mg/kg,U,,1,,CHEMBL628574,BAO_0000218,,
12603,,In vivo,,A,,,,Cmax value after oral dose of 10 mg/kg,U,,1,,CHEMBL628575,BAO_0000218,,
12604,,In vivo,,A,,,,Cmax value after oral dose of 23.4 mg/kg,U,,1,,CHEMBL628576,BAO_0000218,,
12605,,In vivo,,A,,,,Cmax value after oral dose of 3 mg/kg,U,,1,,CHEMBL628577,BAO_0000218,,
12606,,In vivo,,A,,,,Cmax value after oral dose of 3.87 mg/kg,U,,1,,CHEMBL628578,BAO_0000218,,
12607,,In vivo,,A,,,,Cmax value in female Beagle dogs,N,,1,,CHEMBL874466,BAO_0000218,,
12608,,In vivo,,A,,,,Cmax value in male rats,N,,1,,CHEMBL628579,BAO_0000218,,
12609,,In vivo,Plasma,A,,,,Cmax value in rat plasma when administered 20 mg/kg perorally,N,,1,,CHEMBL628580,BAO_0000218,1969.0,
12610,,In vivo,Plasma,A,,,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,N,,1,,CHEMBL628581,BAO_0000218,1969.0,
12611,,In vivo,Plasma,A,,,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,N,,1,,CHEMBL628582,BAO_0000218,1969.0,
12612,,,,A,,,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,N,,1,,CHEMBL628583,BAO_0000218,,
12613,,,,A,,,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,U,,1,,CHEMBL625782,BAO_0000218,,
12614,,,,A,,,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,N,,1,,CHEMBL625783,BAO_0000218,,
12615,,,,A,,,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,N,,1,,CHEMBL625784,BAO_0000218,,
12616,,,Plasma,A,,,,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,N,,1,,CHEMBL625785,BAO_0000218,1969.0,
12617,,,,A,,,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,N,,1,,CHEMBL625786,BAO_0000218,,
12618,,,,A,,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,U,,1,,CHEMBL874467,BAO_0000019,,
12619,,,,A,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",N,,1,,CHEMBL625787,BAO_0000218,,
12620,,,,A,,,,cytotoxicity against HIV protease enzyme.,N,,1,,CHEMBL625964,BAO_0000218,,
12621,,,,A,,,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,N,,1,,CHEMBL625965,BAO_0000218,,
12622,,,,A,,,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,N,,1,,CHEMBL625966,BAO_0000218,,
12623,,In vivo,Plasma,A,,,,The plasma clearance in dog.,N,,1,,CHEMBL625967,BAO_0000218,1969.0,
12624,,In vivo,Plasma,A,,,,The plasma clearance in rat.,N,,1,,CHEMBL625968,BAO_0000218,1969.0,
12625,,In vivo,Plasma,A,,,,Clearance from plasma in male Sprague-Dawley rats,N,,1,,CHEMBL625969,BAO_0000218,1969.0,
12626,,In vivo,Plasma,A,,,,Clearance from plasma in male cynomolgus monkeys,N,,1,,CHEMBL625970,BAO_0000218,1969.0,
12627,,In vivo,Plasma,A,,,,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",N,,1,,CHEMBL625971,BAO_0000218,1969.0,
12628,,In vivo,Plasma,A,,,,Clearance of compound in dog plasma,N,,1,,CHEMBL625972,BAO_0000218,1969.0,
12629,,In vivo,Plasma,A,,,,Clearance of compound in human plasma,N,,1,,CHEMBL625973,BAO_0000218,1969.0,
12630,,In vivo,,A,,,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,N,,1,,CHEMBL625974,BAO_0000218,,
12631,,In vivo,,A,,,,Clearance of compound when administered intravenously as an individual dose to a single dog.,N,,1,,CHEMBL625975,BAO_0000218,,
12632,,In vivo,Plasma,A,,,,"Clearance (10 mg/kg, intravenously) in dog plasma",N,,1,,CHEMBL625976,BAO_0000218,1969.0,
12633,,In vivo,,A,,,,Clearance value in dog,N,,1,,CHEMBL625977,BAO_0000218,,
12634,,In vivo,,A,,,,Clearance value in guinea pig,N,,1,,CHEMBL625978,BAO_0000218,,
12635,,In vivo,,A,,,,Clearance values in rats after iv administration.,N,,1,,CHEMBL874468,BAO_0000218,,
12636,,In vivo,Plasma,A,,,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,U,,1,,CHEMBL625421,BAO_0000218,1969.0,
12637,,In vivo,,A,,,,In vivo clearance (5 mg/kg) was determined in rabbits,N,,1,,CHEMBL625422,BAO_0000218,,
12638,,In vivo,,A,,,,Plasma Clearance rate was determined for the compound in rats,N,,1,,CHEMBL625423,BAO_0000218,,
12639,,In vivo,,A,,,,Plasma Clearance rate was determined for the compound in squirrel monkeys,U,,1,,CHEMBL625424,BAO_0000218,,
12640,,In vivo,,A,,,,Plasma clearance in rat,N,,1,,CHEMBL625425,BAO_0000218,,
12641,,In vivo,,A,,,,Plasma clearance of the compound,U,,1,,CHEMBL625426,BAO_0000218,,
12642,,In vivo,,A,,,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,N,,1,,CHEMBL625427,BAO_0000218,,
12643,,In vivo,,A,,,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,N,,1,,CHEMBL625428,BAO_0000218,,
12644,,In vivo,,A,,,,Plasma clearance was determined,U,,1,,CHEMBL625429,BAO_0000218,,
12645,,In vivo,,A,,,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,N,,1,,CHEMBL625430,BAO_0000218,,
12646,,In vivo,,A,,,,Plasma clearance rate was determined for the compound in rats,N,,1,,CHEMBL625431,BAO_0000218,,
12647,,In vivo,,A,,,,Plasma clearance rate was determined for the compound in squirrel monkeys,U,,1,,CHEMBL627307,BAO_0000218,,
12648,,In vivo,,A,,,,Slow clearance (CL) was determined,U,,1,,CHEMBL627308,BAO_0000218,,
12649,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,U,,1,,CHEMBL627309,BAO_0000218,,
12650,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,U,,1,,CHEMBL627310,BAO_0000218,,
12651,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,U,,1,,CHEMBL627311,BAO_0000218,,
12652,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,U,,1,,CHEMBL627312,BAO_0000218,,
12653,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,U,,1,,CHEMBL627313,BAO_0000218,,
12654,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,U,,1,,CHEMBL627314,BAO_0000218,,
12655,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,U,,1,,CHEMBL627315,BAO_0000218,,
12656,,,,A,,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,U,,1,,CHEMBL627316,BAO_0000218,,
12657,,,,A,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,U,,1,,CHEMBL627317,BAO_0000218,,
12658,,,,A,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,U,,1,,CHEMBL627318,BAO_0000218,,
12659,,,,A,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,U,,1,,CHEMBL627999,BAO_0000218,,
12660,,,,A,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,U,,1,,CHEMBL628000,BAO_0000218,,
12661,,,,A,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,U,,1,,CHEMBL628001,BAO_0000218,,
12662,,,,A,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,U,,1,,CHEMBL628002,BAO_0000218,,
12663,,,,A,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,U,,1,,CHEMBL625610,BAO_0000218,,
12664,,,,A,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,U,,1,,CHEMBL625611,BAO_0000218,,
12665,,,,A,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,U,,1,,CHEMBL625612,BAO_0000218,,
12666,,,,A,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,U,,1,,CHEMBL625613,BAO_0000218,,
12667,,,,A,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,U,,1,,CHEMBL875479,BAO_0000218,,
12668,,,,A,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,U,,1,,CHEMBL625614,BAO_0000218,,
12669,,,,A,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,U,,1,,CHEMBL625615,BAO_0000218,,
12670,,,,A,,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,U,,1,,CHEMBL626302,BAO_0000218,,
12671,,,Blood,A,,,,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL626303,BAO_0000218,178.0,
12672,,,Blood,A,,,,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,1,,CHEMBL627420,BAO_0000218,178.0,
12673,,,,A,,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,N,,1,,CHEMBL627421,BAO_0000218,,
12674,,,,A,,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,N,,1,,CHEMBL625695,BAO_0000218,,
12675,,,,A,,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,N,,1,,CHEMBL625696,BAO_0000218,,
12676,,,Brain,A,,,,Distribution of compound in mice brain was measured after 1 hr,N,,1,,CHEMBL875606,BAO_0000218,955.0,
12677,,,Brain,A,,,,Distribution of compound in mice brain was measured after 24 hr r,N,,1,,CHEMBL625697,BAO_0000218,955.0,
12678,,,Brain,A,,,,Distribution of compound in mice brain was measured after 2 hr,N,,1,,CHEMBL625698,BAO_0000218,955.0,
12679,,,Brain,A,,,,Distribution of compound in mice brain was measured after 3 hr,N,,1,,CHEMBL625699,BAO_0000218,955.0,
12680,,,Brain,A,,,,Distribution of compound in mice brain was measured after 6 hr,N,,1,,CHEMBL625700,BAO_0000218,955.0,
12681,,,,A,,,,Distribution of compound in mice liver was measured after 1 hr,N,,1,,CHEMBL625701,BAO_0000218,,
12682,,,,A,,,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,N,,1,,CHEMBL625702,BAO_0000218,,
12683,,,,A,,,,Distribution of compound in mice liver was measured after 2 hr,N,,1,,CHEMBL625703,BAO_0000218,,
12684,,,,A,,,,Distribution of compound in mice liver was measured after 3 hr,N,,1,,CHEMBL625704,BAO_0000218,,
12685,,,,A,,,,Distribution of compound in mice liver was measured after 6 hr,N,,1,,CHEMBL625705,BAO_0000218,,
12686,,,Adrenal medulla,A,,,,Distribution in dog adrenal medulla 30 min after administration.,N,,1,,CHEMBL625706,BAO_0000218,1236.0,
12687,,,Adrenal medulla,A,,,,Distribution in dog adrenal medulla 72 hours after administration.,N,,1,,CHEMBL625707,BAO_0000218,1236.0,
12688,,,,A,,,,Distribution in female dog Ovary 24 hours after administration.,N,,1,,CHEMBL625708,BAO_0000218,,
12689,,,,A,,,,Distribution in female dog Ovary 72 hours after administration.,N,,1,,CHEMBL625709,BAO_0000218,,
12690,,,,A,,,,Distribution in female dog adipose 24 hours after administration.,N,,1,,CHEMBL624180,BAO_0000218,,
12691,,,,A,,,,Distribution in female dog adipose 72 hours after administration.,N,,1,,CHEMBL624181,BAO_0000218,,
12692,,,Adrenal cortex,A,,,,Distribution in female dog adrenal cortex 72 hours after administration.,N,,1,,CHEMBL624182,BAO_0000218,1235.0,
12693,,,Adrenal cortex,A,,,,Distribution in female dog adrenal cortex 72 hours after administration.,N,,1,,CHEMBL624183,BAO_0000218,1235.0,
12694,,,Liver,A,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,,1,,CHEMBL624184,BAO_0000218,2107.0,
12695,,,Liver,A,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,,1,,CHEMBL877489,BAO_0000218,2107.0,
12696,,,Liver,A,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,1,,CHEMBL624185,BAO_0000218,2107.0,
12697,,,Liver,A,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,,1,,CHEMBL624186,BAO_0000218,2107.0,
12698,,,Liver,A,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,,1,,CHEMBL624187,BAO_0000218,2107.0,
12699,,,Liver,A,,,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,,1,,CHEMBL624188,BAO_0000218,2107.0,
12700,,,Lung,A,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,,1,,CHEMBL624189,BAO_0000218,2048.0,
12701,,,Lung,A,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,,1,,CHEMBL624190,BAO_0000218,2048.0,
12702,,,Lung,A,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,,1,,CHEMBL624191,BAO_0000218,2048.0,
12703,,,Lung,A,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,,1,,CHEMBL624192,BAO_0000218,2048.0,
12704,,,Lung,A,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,,1,,CHEMBL624193,BAO_0000218,2048.0,
12705,,,Lung,A,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,,1,,CHEMBL624194,BAO_0000218,2048.0,
12706,,,Lung,A,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,,1,,CHEMBL624891,BAO_0000218,2048.0,
12707,,,Lung,A,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,,1,,CHEMBL624892,BAO_0000218,2048.0,
12708,,,Lung,A,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,,1,,CHEMBL624893,BAO_0000218,2048.0,
12709,,,Lung,A,,,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,1,,CHEMBL627632,BAO_0000218,2048.0,
12710,,,,A,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,,1,,CHEMBL627633,BAO_0000218,,
12711,,,,A,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,,1,,CHEMBL627634,BAO_0000218,,
12712,,,,A,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,,1,,CHEMBL627635,BAO_0000218,,
12713,,,,A,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,,1,,CHEMBL627636,BAO_0000218,,
12714,,,,A,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,,1,,CHEMBL626816,BAO_0000218,,
12715,,,,A,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,,1,,CHEMBL626817,BAO_0000218,,
12716,,,,A,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,,1,,CHEMBL626818,BAO_0000218,,
12717,,,,A,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,,1,,CHEMBL626819,BAO_0000218,,
12718,,,,A,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,,1,,CHEMBL626820,BAO_0000218,,
12719,,,,A,,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,1,,CHEMBL626821,BAO_0000218,,
12720,,,Thyroid gland,A,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,,1,,CHEMBL626822,BAO_0000218,2046.0,
12721,,,Thyroid gland,A,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,,1,,CHEMBL626823,BAO_0000218,2046.0,
12722,,,Thyroid gland,A,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,,1,,CHEMBL626824,BAO_0000218,2046.0,
12723,,,Thyroid gland,A,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,,1,,CHEMBL626825,BAO_0000218,2046.0,
12724,,,Thyroid gland,A,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,,1,,CHEMBL626826,BAO_0000218,2046.0,
12725,,,Thyroid gland,A,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,,1,,CHEMBL626827,BAO_0000218,2046.0,
12726,,,Thyroid gland,A,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,,1,,CHEMBL626828,BAO_0000218,2046.0,
12727,,,Thyroid gland,A,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,,1,,CHEMBL626829,BAO_0000218,2046.0,
12728,,,Thyroid gland,A,,,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,1,,CHEMBL626830,BAO_0000218,2046.0,
12729,,,,A,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,,1,,CHEMBL627150,BAO_0000218,,
12730,,,,A,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,1,,CHEMBL627151,BAO_0000218,,
12731,,,,A,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,,1,,CHEMBL627152,BAO_0000218,,
12732,,,,A,,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,1,,CHEMBL627153,BAO_0000218,,
12733,,,,A,,,,Rate of acetate production by the compound was determined,U,,1,,CHEMBL627154,BAO_0000019,,
12734,,,,A,,,,Rate of acetate production by the compound was determined; Not determined,U,,1,,CHEMBL627155,BAO_0000019,,
12735,,,,A,,,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,U,,1,,CHEMBL627156,BAO_0000019,,
12736,,,,A,,,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,U,,1,,CHEMBL627157,BAO_0000019,,
12737,,,,A,,,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,N,,1,,CHEMBL627158,BAO_0000218,,
12738,,,Plasma,A,,,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,N,,1,,CHEMBL627159,BAO_0000218,1969.0,
12739,,,,A,,,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,N,,1,,CHEMBL627160,BAO_0000218,,
12740,,,,A,,,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,N,,1,,CHEMBL628540,BAO_0000218,,
12741,,,Plasma,A,,,,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,N,,1,,CHEMBL628541,BAO_0000218,1969.0,
12742,,,Plasma,A,,,,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,N,,1,,CHEMBL628542,BAO_0000218,1969.0,
12743,,,,P,,,,Solubility after at a pH 1.2,U,,1,,CHEMBL628543,BAO_0000100,,
12744,,,,P,,,,Solubility after at pH 1.2,U,,1,,CHEMBL628544,BAO_0000100,,
12745,,,,P,,,,Solubility after injection of water,U,,1,,CHEMBL628545,BAO_0000100,,
12746,,,,A,,,,Statistical significance of IC 50 values; Expressed as R value,U,,1,,CHEMBL628546,BAO_0000019,,
12747,,,,A,,,,Systemic availability with respect to methyldopa was determined,U,,1,,CHEMBL874455,BAO_0000019,,
12748,,,,A,,,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,N,,1,,CHEMBL628547,BAO_0000218,,
12749,,,Plasma,A,,,,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,N,,1,,CHEMBL628548,BAO_0000218,1969.0,
12750,,,Feces,A,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",N,,1,,CHEMBL628549,BAO_0000218,1988.0,
12751,,,Feces,A,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",N,,1,,CHEMBL628550,BAO_0000218,1988.0,
12752,,,Feces,A,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",N,,1,,CHEMBL628551,BAO_0000218,1988.0,
12753,,,Urine,A,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",N,,1,,CHEMBL628552,BAO_0000218,1088.0,
12754,,,Urine,A,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",N,,1,,CHEMBL628553,BAO_0000218,1088.0,
12755,,,Urine,A,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",N,,1,,CHEMBL628554,BAO_0000218,1088.0,
12756,,,Urine,A,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",N,,1,,CHEMBL628555,BAO_0000218,1088.0,
12757,,,Urine,A,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",N,,1,,CHEMBL628556,BAO_0000218,1088.0,
12758,,,Kidney,A,,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",N,,1,,CHEMBL628557,BAO_0000218,2113.0,
12759,,,Feces,A,,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",N,,1,,CHEMBL628558,BAO_0000218,1988.0,
12760,,,Feces,A,,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",N,,1,,CHEMBL628559,BAO_0000218,1988.0,
12761,,,Feces,A,,,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",N,,1,,CHEMBL628560,BAO_0000218,1988.0,
12762,,,Urine,A,,,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",N,,1,,CHEMBL874456,BAO_0000218,1088.0,
12763,,,Feces,A,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",N,,1,,CHEMBL628561,BAO_0000218,1988.0,
12764,,,Feces,A,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",N,,1,,CHEMBL628562,BAO_0000218,1988.0,
12765,,,Urine,A,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",N,,1,,CHEMBL628563,BAO_0000218,1088.0,
12766,,,Urine,A,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",N,,1,,CHEMBL628564,BAO_0000218,1088.0,
12767,,,Urine,A,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",N,,1,,CHEMBL628565,BAO_0000218,1088.0,
12768,,,Urine,A,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",N,,1,,CHEMBL631248,BAO_0000218,1088.0,
12769,,,Urine,A,,,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",N,,1,,CHEMBL631249,BAO_0000218,1088.0,
12770,,,Kidney,A,,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",N,,1,,CHEMBL627214,BAO_0000218,2113.0,
12771,,,Feces,A,,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",N,,1,,CHEMBL874591,BAO_0000218,1988.0,
12772,,,Feces,A,,,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",N,,1,,CHEMBL627215,BAO_0000218,1988.0,
12773,,,Feces,A,,,,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,N,,1,,CHEMBL625471,BAO_0000218,1988.0,
12774,,,,A,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,N,,1,,CHEMBL625472,BAO_0000218,,
12775,,,,A,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,N,,1,,CHEMBL625473,BAO_0000218,,
12776,,In vivo,,A,,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,N,,1,,CHEMBL625474,BAO_0000218,,
12777,,In vivo,,A,,,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,N,,1,,CHEMBL625475,BAO_0000218,,
12778,,In vivo,,A,,,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,N,,1,,CHEMBL625476,BAO_0000218,,
12779,,In vivo,,A,,,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,N,,1,,CHEMBL625477,BAO_0000218,,
12780,,In vivo,,A,,,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,N,,1,,CHEMBL625478,BAO_0000218,,
12781,,In vitro,esophageal tunica muscularis mucosae,A,,,,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,N,,1,,CHEMBL625479,BAO_0000218,,
12782,,In vitro,esophageal tunica muscularis mucosae,A,,,,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,N,,1,,CHEMBL625480,BAO_0000218,,
12783,,In vivo,Plasma,A,,,,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,N,,1,,CHEMBL625481,BAO_0000218,1969.0,
12784,,In vivo,,A,,,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,N,,1,,CHEMBL625482,BAO_0000218,,
12785,,In vivo,,A,,,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,N,,1,,CHEMBL625483,BAO_0000218,,
12786,,In vivo,,A,,,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,N,,1,,CHEMBL625484,BAO_0000218,,
12787,,In vivo,,A,,,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,N,,1,,CHEMBL625485,BAO_0000218,,
12788,,In vivo,Plasma,A,,,,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,N,,1,,CHEMBL625486,BAO_0000218,1969.0,
12789,,In vivo,Plasma,A,,,,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,N,,1,,CHEMBL625487,BAO_0000218,1969.0,
12790,,In vivo,Plasma,A,,,,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,N,,1,,CHEMBL625488,BAO_0000218,1969.0,
12791,,In vivo,Plasma,A,,,,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,N,,1,,CHEMBL625489,BAO_0000218,1969.0,
12792,,In vivo,Plasma,A,,,,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,N,,1,,CHEMBL625490,BAO_0000218,1969.0,
12793,,In vivo,Plasma,A,,,,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,N,,1,,CHEMBL625491,BAO_0000218,1969.0,
12794,,In vivo,Plasma,A,,,,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,N,,1,,CHEMBL625492,BAO_0000218,1969.0,
12795,,In vivo,Plasma,A,,,,plasma clearance in human,N,,1,,CHEMBL625493,BAO_0000218,1969.0,
12796,,In vivo,,A,,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,N,,1,,CHEMBL625494,BAO_0000218,,
12797,,In vivo,,A,,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,N,,1,,CHEMBL625495,BAO_0000218,,
12798,,In vivo,,A,,,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,N,,1,,CHEMBL625496,BAO_0000218,,
12799,,,,P,,,,1-Octanol/water partition coefficient measured at 7.4,U,,1,,CHEMBL625497,BAO_0000100,,
12800,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625498,BAO_0000100,,
12801,,,,A,,,,Partition coefficient (logP),U,,1,,CHEMBL625499,BAO_0000019,,
12802,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625500,BAO_0000100,,
12803,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625501,BAO_0000100,,
12804,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625502,BAO_0000100,,
12805,,,,P,,,,Calculated partition coefficient (clogP) (relative to BAY K 8644),U,,1,,CHEMBL625503,BAO_0000100,,
12806,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625504,BAO_0000100,,
12807,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625505,BAO_0000100,,
12808,,,,P,,,,Calculated partition coefficient of the compound,U,,1,,CHEMBL625506,BAO_0000100,,
12809,,,,A,,,,Partition coefficient (logP),U,,1,,CHEMBL625507,BAO_0000019,,
12810,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625508,BAO_0000100,,
12811,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625509,BAO_0000100,,
12812,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625510,BAO_0000100,,
12813,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL883125,BAO_0000100,,
12814,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625511,BAO_0000100,,
12815,,,,A,,,,Partition coefficient of the compound,U,,1,,CHEMBL874650,BAO_0000019,,
12816,,,,A,,,,Partition coefficient of the compound,U,,1,,CHEMBL625512,BAO_0000019,,
12817,,,,A,,,,Partition coefficient of compound was determined,U,,1,,CHEMBL625513,BAO_0000019,,
12818,,,,A,,,,Partition coefficient was determined,U,,1,,CHEMBL625514,BAO_0000019,,
12819,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625515,BAO_0000100,,
12820,,,,P,,,,partition coefficient of compound was determined,U,,1,,CHEMBL625516,BAO_0000100,,
12821,,In vivo,,A,,,,The total body administered intravenously in dog,N,,1,,CHEMBL625517,BAO_0000218,,
12822,,In vivo,,A,,,,The total body administered intravenously in rats,N,,1,,CHEMBL625518,BAO_0000218,,
12823,,,,A,,,,Time taken for the administration to female NIH mice weighing 25-30 g.,N,,1,,CHEMBL625519,BAO_0000218,,
12824,,,,A,,,,Time taken for the administration,U,,1,,CHEMBL625520,BAO_0000019,,
12825,,In vivo,,A,,,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,N,,1,,CHEMBL874651,BAO_0000218,,
12826,,In vivo,,A,,,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,U,,1,,CHEMBL625521,BAO_0000218,,
12827,,In vivo,,A,,,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,N,,1,,CHEMBL623171,BAO_0000218,,
12828,,In vivo,,A,,,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,N,,1,,CHEMBL623853,BAO_0000218,,
12829,,,,A,,,,Plasma clearance for the compound was determined.,U,,1,,CHEMBL623854,BAO_0000019,,
12830,,,,P,,,,CLog P value of the compound,U,,1,,CHEMBL874405,BAO_0000100,,
12831,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL623855,BAO_0000100,,
12832,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL623856,BAO_0000100,,
12833,,,,P,,,,ClogP value of the compound; nd ='no data',U,,1,,CHEMBL623857,BAO_0000100,,
12834,,,,P,,,,ClogP value of the compound; nd ='not determined',U,,1,,CHEMBL623858,BAO_0000100,,
12835,,,,P,,,,CLog P was determined,U,,1,,CHEMBL623859,BAO_0000100,,
12836,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL839829,BAO_0000100,,
12837,,,,A,,,,CLogP was calculated,U,,1,,CHEMBL623860,BAO_0000019,,
12838,,,,A,,,,CLogP value was determined,U,,1,,CHEMBL623861,BAO_0000019,,
12839,,,,A,,,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,U,,1,,CHEMBL623862,BAO_0000019,,
12840,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL874406,BAO_0000100,,
12841,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL623863,BAO_0000100,,
12842,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL624021,BAO_0000100,,
12843,,,Adrenal medulla,A,,,,Distribution in female dog adrenal medulla 24 hours after administration.,N,,1,,CHEMBL624022,BAO_0000218,1236.0,
12844,,,Adrenal medulla,A,,,,Distribution in female dog adrenal medulla 72 hours after administration.,N,,1,,CHEMBL624023,BAO_0000218,1236.0,
12845,,,,A,,,,Distribution in female dog bile 24 hours after administration.,N,,1,,CHEMBL624024,BAO_0000218,,
12846,,,,A,,,,Distribution in female dog bile 72 hr after administration.,N,,1,,CHEMBL624025,BAO_0000218,,
12847,,,,A,,,,Distribution in female dog blood 24 hours after administration.,N,,1,,CHEMBL624026,BAO_0000218,,
12848,,,,A,,,,Distribution in female dog blood 72 hours after administration.,N,,1,,CHEMBL624027,BAO_0000218,,
12849,,,,A,,,,Distribution in female dog heart 24 hours after administration.,N,,1,,CHEMBL624028,BAO_0000218,,
12850,,,,A,,,,Distribution in female dog heart 72 hours after administration.,N,,1,,CHEMBL624029,BAO_0000218,,
12851,,,,A,,,,Distribution in female dog kidney 24 hours after administration.,N,,1,,CHEMBL624030,BAO_0000218,,
12852,,,,A,,,,Distribution in female dog kidney 72 hours after administration.,N,,1,,CHEMBL624031,BAO_0000218,,
12853,,,Intestine,A,,,,Distribution in female dog large intestine 24 hours after administration.,N,,1,,CHEMBL624032,BAO_0000218,160.0,
12854,,,Intestine,A,,,,Distribution in female dog large intestine 72 hours after administration.,N,,1,,CHEMBL874407,BAO_0000218,160.0,
12855,,,,A,,,,Distribution in female dog liver 24 hours after administration.,N,,1,,CHEMBL624033,BAO_0000218,,
12856,,,,A,,,,Distribution in female dog liver 72 hours after administration.,N,,1,,CHEMBL624034,BAO_0000218,,
12857,,,,A,,,,Distribution in female dog lung 24 hours after administration.,N,,1,,CHEMBL624035,BAO_0000218,,
12858,,,,A,,,,Distribution in female dog lung 72 hours after administration.,N,,1,,CHEMBL624036,BAO_0000218,,
12859,,,Muscle tissue,A,,,,Distribution in female dog muscle 24 hours after administration.,N,,1,,CHEMBL624037,BAO_0000218,2385.0,
12860,,,Muscle tissue,A,,,,Distribution in female dog muscle 72 hours after administration.,N,,1,,CHEMBL624038,BAO_0000218,2385.0,
12861,,,,A,,,,Distribution in female dog pancreas 24 hours after administration.,N,,1,,CHEMBL624039,BAO_0000218,,
12862,,,,A,,,,Distribution in female dog pancreas 72 hours after administration.,N,,1,,CHEMBL624040,BAO_0000218,,
12863,,,Intestine,A,,,,Distribution in female dog small intestine 24 hours after administration.,N,,1,,CHEMBL624041,BAO_0000218,160.0,
12864,,,Intestine,A,,,,Distribution in female dog small intestine 72 hours after administration.,N,,1,,CHEMBL624042,BAO_0000218,160.0,
12865,,,Spleen,A,,,,Distribution in female dog spleen 24 hours after administration.,N,,1,,CHEMBL624043,BAO_0000218,2106.0,
12866,,,Spleen,A,,,,Distribution in female dog spleen 72 hours after administration.,N,,1,,CHEMBL624044,BAO_0000218,2106.0,
12867,,,Stomach,A,,,,Distribution in female dog stomach 24 hours after administration.,N,,1,,CHEMBL624045,BAO_0000218,945.0,
12868,,,Stomach,A,,,,Distribution in female dog stomach 72 hours after administration.,N,,1,,CHEMBL624046,BAO_0000218,945.0,
12869,,,Thyroid gland,A,,,,Distribution in female dog thyroid 24 hours after administration.,N,,1,,CHEMBL624047,BAO_0000218,2046.0,
12870,,,Thyroid gland,A,,,,Distribution in female dog thyroid 72 hours after administration.,N,,1,,CHEMBL624048,BAO_0000218,2046.0,
12871,,,Urine,A,,,,Distribution in female dog urine 24 hours after administration.,N,,1,,CHEMBL874408,BAO_0000218,1088.0,
12872,,,Urine,A,,,,Distribution in female dog urine 72 hr after administration.,N,,1,,CHEMBL624049,BAO_0000218,1088.0,
12873,,,Plasma,A,,,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,U,,1,,CHEMBL624050,BAO_0000218,1969.0,
12874,,,,A,,,,Plasma concentration at 7 hr after intravenous dosing,U,,1,,CHEMBL624051,BAO_0000019,,
12875,,,,A,,,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,N,,1,,CHEMBL623278,BAO_0000218,,
12876,,,,A,,,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,N,,1,,CHEMBL623279,BAO_0000218,,
12877,,,,A,,,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,N,,1,,CHEMBL623280,BAO_0000218,,
12878,,,,A,,,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,N,,1,,CHEMBL623963,BAO_0000218,,
12879,,,,A,,,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,N,,1,,CHEMBL623964,BAO_0000218,,
12880,,,,A,,,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,N,,1,,CHEMBL623965,BAO_0000218,,
12881,,,,A,,,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,N,,1,,CHEMBL623966,BAO_0000218,,
12882,,,,A,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,N,,1,,CHEMBL874415,BAO_0000218,,
12883,,,,A,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,N,,1,,CHEMBL623967,BAO_0000218,,
12884,,,,A,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,N,,1,,CHEMBL623968,BAO_0000218,,
12885,,,,A,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,N,,1,,CHEMBL623969,BAO_0000218,,
12886,,,,A,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,N,,1,,CHEMBL628409,BAO_0000218,,
12887,,,,A,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,N,,1,,CHEMBL628410,BAO_0000218,,
12888,,,,A,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,N,,1,,CHEMBL628411,BAO_0000218,,
12889,,,,A,,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,N,,1,,CHEMBL628412,BAO_0000218,,
12890,,,,A,,,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,U,,1,,CHEMBL628413,BAO_0000019,,
12891,,,Plasma,A,,,,The concentration in plasmat; Not determined,U,,1,,CHEMBL628414,BAO_0000019,1969.0,
12892,,,,A,,,,Tissue level at 10 mg/kg/po in wistar rats in blood,N,,1,,CHEMBL628415,BAO_0000218,,
12893,,,,A,,,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,N,,1,,CHEMBL628416,BAO_0000218,,
12894,,,,A,,,,Tissue level at 10 mg/kg/po in wistar rats in heart,N,,1,,CHEMBL628417,BAO_0000218,,
12895,,,Liver,A,,,,Tissue level at 10 mg/kg/po in wistar rats in liver,N,,1,,CHEMBL874908,BAO_0000218,2107.0,
12896,,,,A,,,,Tissue level at 10 mg/kg/po in wistar rats in plasma,N,,1,,CHEMBL628418,BAO_0000218,,
12897,,,Muscle tissue,A,,,,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,N,,1,,CHEMBL628419,BAO_0000218,2385.0,
12898,,,,A,,,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,N,,1,,CHEMBL628420,BAO_0000218,,
12899,,,,A,,,,Water solubility at 37 degree C.,U,,1,,CHEMBL628421,BAO_0000019,,
12900,,,,P,,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,U,,1,,CHEMBL626726,BAO_0000100,,
12901,,,,P,,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,U,,1,,CHEMBL626727,BAO_0000100,,
12902,,,Blood,A,,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL626728,BAO_0000218,178.0,
12903,,,Blood,A,,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL626729,BAO_0000218,178.0,
12904,,,Blood,A,,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL626730,BAO_0000218,178.0,
12905,,,Blood,A,,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL626731,BAO_0000218,178.0,
12906,,,Blood,A,,,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL626732,BAO_0000218,178.0,
12907,,,Heart,A,,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL626733,BAO_0000218,948.0,
12908,,,Heart,A,,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL626734,BAO_0000218,948.0,
12909,,,Heart,A,,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL626735,BAO_0000218,948.0,
12910,,,Heart,A,,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL874909,BAO_0000218,948.0,
12911,,,Heart,A,,,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL626736,BAO_0000218,948.0,
12912,,,Kidney,A,,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL626737,BAO_0000218,2113.0,
12913,,,Kidney,A,,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL630999,BAO_0000218,2113.0,
12914,,,Kidney,A,,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL631000,BAO_0000218,2113.0,
12915,,,Kidney,A,,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL631001,BAO_0000218,2113.0,
12916,,,Kidney,A,,,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL631002,BAO_0000218,2113.0,
12917,,,Liver,A,,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL631003,BAO_0000218,2107.0,
12918,,,Liver,A,,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL631004,BAO_0000218,2107.0,
12919,,,Liver,A,,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL631005,BAO_0000218,2107.0,
12920,,,Liver,A,,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL631006,BAO_0000218,2107.0,
12921,,,Liver,A,,,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL631007,BAO_0000218,2107.0,
12922,,,Lung,A,,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL631008,BAO_0000218,2048.0,
12923,,,Lung,A,,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL631009,BAO_0000218,2048.0,
12924,,,Lung,A,,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL631010,BAO_0000218,2048.0,
12925,,,Lung,A,,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL631011,BAO_0000218,2048.0,
12926,,,Lung,A,,,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL631012,BAO_0000218,2048.0,
12927,,,Thyroid gland,A,,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL630271,BAO_0000218,2046.0,
12928,,,Thyroid gland,A,,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL630272,BAO_0000218,2046.0,
12929,,,Thyroid gland,A,,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL630273,BAO_0000218,2046.0,
12930,,,Thyroid gland,A,,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL630274,BAO_0000218,2046.0,
12931,,,Thyroid gland,A,,,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL630275,BAO_0000218,2046.0,
12932,,,,A,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL875782,BAO_0000218,,
12933,,,,A,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL630276,BAO_0000218,,
12934,,,,A,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL630277,BAO_0000218,,
12935,,,,A,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL630278,BAO_0000218,,
12936,,,,A,,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,N,,1,,CHEMBL630279,BAO_0000218,,
12937,,,,A,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,U,,1,,CHEMBL630280,BAO_0000019,,
12938,,,,A,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,U,,1,,CHEMBL630281,BAO_0000019,,
12939,,,,A,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,N,,1,,CHEMBL630282,BAO_0000218,,
12940,,,,A,,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,N,,1,,CHEMBL630283,BAO_0000218,,
12941,,,,A,,,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),U,,1,,CHEMBL630284,BAO_0000019,,
12942,,,,A,,,,Alkylating activity was determined,U,,1,,CHEMBL630285,BAO_0000019,,
12943,Microsomes,,,A,,,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),U,,1,,CHEMBL630286,BAO_0000251,,
12944,,,,A,,,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",N,,1,,CHEMBL630069,BAO_0000218,,
12945,,,,A,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",N,,1,,CHEMBL630070,BAO_0000218,,
12946,,,,A,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",N,,1,,CHEMBL630071,BAO_0000218,,
12947,,,,A,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",N,,1,,CHEMBL630072,BAO_0000218,,
12948,,,,A,,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",N,,1,,CHEMBL875110,BAO_0000218,,
12949,,,,A,,,,Compound was tested for antidiuretic activity in rats,N,,1,,CHEMBL630073,BAO_0000218,,
12950,,,,A,,,,Compound was tested for inactivation kinetic values,U,,1,,CHEMBL630074,BAO_0000019,,
12951,,In vivo,,A,,,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,U,,1,,CHEMBL630075,BAO_0000218,,
12952,,,,A,,,,Dissociation rate calculated from the first-order equation using the t1/2 value,U,,1,,CHEMBL630076,BAO_0000019,,
12953,,,,P,,,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,U,,1,,CHEMBL630077,BAO_0000100,,
12954,,,,P,,,,Aqueous solubility was measured,U,,1,,CHEMBL630078,BAO_0000100,,
12955,,,,P,,,,Aqueous solubility was measured at a pH 4,U,,1,,CHEMBL630079,BAO_0000100,,
12956,,,,P,,,,Aqueous solubility (pH 7),U,,1,,CHEMBL630080,BAO_0000100,,
12957,,,,P,,,,Aqueous solubility was measured at a pH 9,U,,1,,CHEMBL630081,BAO_0000100,,
12958,,,,A,,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",U,,1,,CHEMBL630082,BAO_0000019,,
12959,,,,A,,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",U,,1,,CHEMBL630083,BAO_0000019,,
12960,,,,A,,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",U,,1,,CHEMBL630084,BAO_0000019,,
12961,,,,P,,,,Aqueous solubility of the compound,U,,1,,CHEMBL629198,BAO_0000100,,
12962,,,,P,,,,Aqueous solubility at 37 degree Celsius at pH 7.38,U,,1,,CHEMBL629199,BAO_0000100,,
12963,,,,P,,,,Aqueous solubility in pH 7.4 phosphate buffer,U,,1,,CHEMBL629200,BAO_0000100,,
12964,,,,A,,,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,N,,1,,CHEMBL629201,BAO_0000218,,
12965,,,,A,,,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,N,,1,,CHEMBL629202,BAO_0000218,,
12966,,,,A,,,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,N,,1,,CHEMBL875111,BAO_0000218,,
12967,,,,A,,,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,N,,1,,CHEMBL629203,BAO_0000218,,
12968,,,,A,,,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,N,,1,,CHEMBL629204,BAO_0000218,,
12969,,,,A,,,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,N,,1,,CHEMBL629205,BAO_0000218,,
12970,,,,A,,,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,N,,1,,CHEMBL629206,BAO_0000218,,
12971,,,,A,,,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,U,,1,,CHEMBL631185,BAO_0000019,,
12972,,,,A,,,,Compound was evaluated for the average bile flow rat in rats,N,,1,,CHEMBL631186,BAO_0000218,,
12973,,,,A,,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",N,,1,,CHEMBL631187,BAO_0000218,,
12974,,,,A,,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",N,,1,,CHEMBL631188,BAO_0000218,,
12975,,,,A,,,,Average half life period was determined,U,,1,,CHEMBL876419,BAO_0000019,,
12976,,,,A,,,,Average half life period was determined,U,,1,,CHEMBL631189,BAO_0000019,,
12977,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,N,,1,,CHEMBL631190,BAO_0000218,,
12978,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,N,,1,,CHEMBL631191,BAO_0000218,,
12979,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,N,,1,,CHEMBL631192,BAO_0000218,,
12980,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,N,,1,,CHEMBL632400,BAO_0000218,,
12981,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,N,,1,,CHEMBL630564,BAO_0000218,,
12982,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,N,,1,,CHEMBL630565,BAO_0000218,,
12983,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,N,,1,,CHEMBL630566,BAO_0000218,,
12984,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,N,,1,,CHEMBL631229,BAO_0000218,,
12985,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,N,,1,,CHEMBL631230,BAO_0000218,,
12986,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL876428,BAO_0000100,,
12987,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL631231,BAO_0000100,,
12988,,,,P,,,,Calculated partition coefficient (clogP) (MacLogP),U,,1,,CHEMBL631232,BAO_0000100,,
12989,,,,A,,,,Hydrophilicity was determined,U,,1,,CHEMBL631233,BAO_0000019,,
12990,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL631234,BAO_0000100,,
12991,,,,A,,,,Increased absorption was determined,U,,1,,CHEMBL883126,BAO_0000019,,
12992,,,,P,,,,Lipophilicity value was evaluated,U,,1,,CHEMBL631235,BAO_0000100,,
12993,,,,P,,,,Log P value of the compound.,U,,1,,CHEMBL631236,BAO_0000100,,
12994,,,,A,,,,Partition coefficient of compound was determined,U,,1,,CHEMBL631237,BAO_0000019,,
12995,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL631238,BAO_0000100,,
12996,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL876429,BAO_0000100,,
12997,,,,A,,,,Partition coefficient was measured by medchem software; Not calculated,U,,1,,CHEMBL631414,BAO_0000019,,
12998,,,,P,,,,Partition coefficient was measured by octanol-water using standard shake-flask method,U,,1,,CHEMBL631415,BAO_0000100,,
12999,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL631416,BAO_0000100,,
13000,,,,A,,,,Partition coefficient (logP),U,,1,,CHEMBL631417,BAO_0000019,,
13001,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL631418,BAO_0000100,,
13002,,,,P,,,,The Octanol/Water partition coefficient CLogP,U,,1,,CHEMBL631419,BAO_0000100,,
13003,,,,A,,,,The pharmacokinetic parameter C Log p was reported,U,,1,,CHEMBL631420,BAO_0000019,,
13004,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL631421,BAO_0000100,,
13005,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL631422,BAO_0000100,,
13006,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL631423,BAO_0000100,,
13007,,In vivo,Plasma,A,,,,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,N,,1,,CHEMBL876430,BAO_0000218,1969.0,
13008,,In vivo,Plasma,A,,,,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,N,,1,,CHEMBL631424,BAO_0000218,1969.0,
13009,,In vivo,Plasma,A,,,,Compound was administered intravenously in dog to evaluate plasma clearance values,N,,1,,CHEMBL631425,BAO_0000218,1969.0,
13010,,In vivo,Plasma,A,,,,Compound was administered intravenously in monkey to evaluate plasma clearance values,U,,1,,CHEMBL631426,BAO_0000218,1969.0,
13011,,In vivo,Plasma,A,,,,Compound was administered intravenously in mouse to evaluate plasma clearance values,N,,1,,CHEMBL631427,BAO_0000218,1969.0,
13012,,In vivo,Plasma,A,,,,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,N,,1,,CHEMBL631428,BAO_0000218,1969.0,
13013,Microsomes,In vitro,Liver,A,,,,Intrinsic clearance in Rhesus liver microsome,N,,1,,CHEMBL631429,BAO_0000218,2107.0,
13014,Microsomes,In vitro,Liver,A,,,,Intrinsic clearance in dog liver microsome,N,,1,,CHEMBL631430,BAO_0000218,2107.0,
13015,Microsomes,In vitro,Liver,A,,,,Intrinsic clearance in rat liver microsome,N,,1,,CHEMBL631431,BAO_0000218,2107.0,
13016,,In vivo,Plasma,A,,,,Low plasma clearance was calculated in rhesus monkey,N,,1,,CHEMBL631432,BAO_0000218,1969.0,
13017,,In vivo,,A,,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,N,,1,,CHEMBL631433,BAO_0000218,,
13018,,In vivo,,A,,,,Plasma clearance after intravenous dose of 0.3 mg/kg,U,,1,,CHEMBL631434,BAO_0000218,,
13019,,In vivo,,A,,,,Plasma clearance after intravenous dose of 1 mg/kg,U,,1,,CHEMBL631435,BAO_0000218,,
13020,,In vivo,,A,,,,Plasma clearance after intravenous dose of 3 mg/kg,U,,1,,CHEMBL631436,BAO_0000218,,
13021,,In vivo,,A,,,,Plasma clearance after intravenous dose of 3.87 mg/kg,U,,1,,CHEMBL631437,BAO_0000218,,
13022,,In vivo,,A,,,,Plasma clearance after peroral administration at 10 mpk in Rat,N,,1,,CHEMBL631438,BAO_0000218,,
13023,,In vivo,,A,,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,N,,1,,CHEMBL876431,BAO_0000218,,
13024,,In vivo,,A,,,,Plasma clearance after peroral administration at 10 mpk in dog,N,,1,,CHEMBL631439,BAO_0000218,,
13025,,In vivo,,A,,,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,N,,1,,CHEMBL631440,BAO_0000218,,
13026,,,,A,,,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),U,,1,,CHEMBL631441,BAO_0000019,,
13027,,,,A,,,,Critical Micellar concentration was determined,U,,1,,CHEMBL631442,BAO_0000019,,
13028,,,,A,,,,Critical Micellar concentration of the compound. was determined,U,,1,,CHEMBL626525,BAO_0000019,,
13029,,,,A,,,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,U,,1,,CHEMBL627168,BAO_0000019,,
13030,,,,A,,,,Critical micellar concentration was measured in water by the dye solubilization method,U,,1,,CHEMBL875618,BAO_0000019,,
13031,,,,B,,,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,U,,1,,CHEMBL626612,BAO_0000019,,
13032,,,,A,,,,CMR value (relative to BAY K 8644),U,,1,,CHEMBL626613,BAO_0000019,,
13033,,,,A,,,,Carbamoylating activity was determined,U,,1,,CHEMBL626614,BAO_0000019,,
13034,,,,A,,,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,U,,1,,CHEMBL626615,BAO_0000218,,
13035,,,,A,,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,U,,1,,CHEMBL626616,BAO_0000019,,
13036,,,,A,,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,U,,1,,CHEMBL626617,BAO_0000019,,
13037,,In vivo,Plasma,A,,,,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,N,,1,,CHEMBL626618,BAO_0000218,1969.0,
13038,,In vivo,Plasma,A,,,,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,N,,1,,CHEMBL626619,BAO_0000218,1969.0,
13039,,In vivo,,A,,,,"Clearance rate at 0.46 mg/kg, iv, in dogs",N,,1,,CHEMBL626620,BAO_0000218,,
13040,,In vivo,,A,,,,"Clearance rate at 5.5 mg/kg, iv, in rat",N,,1,,CHEMBL626621,BAO_0000218,,
13041,,In vivo,,A,,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,N,,1,,CHEMBL626622,BAO_0000218,,
13042,,In vivo,,A,,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,N,,1,,CHEMBL626623,BAO_0000218,,
13043,,In vivo,,A,,,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,N,,1,,CHEMBL626624,BAO_0000218,,
13044,,In vivo,,A,,,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,N,,1,,CHEMBL626625,BAO_0000218,,
13045,,Ex vivo,Liver,A,,,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,N,,1,,CHEMBL626626,BAO_0000218,2107.0,
13046,,In vivo,,A,,,,Tested for the total clearance of the compound,U,,1,,CHEMBL626627,BAO_0000218,,
13047,,In vivo,,A,,,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,N,,1,,CHEMBL626628,BAO_0000218,,
13048,,In vivo,,A,,,,Total body clearance was determined,U,,1,,CHEMBL626629,BAO_0000218,,
13049,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,N,,1,,CHEMBL626630,BAO_0000218,,
13050,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,N,,1,,CHEMBL626631,BAO_0000218,,
13051,,,,P,,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,U,,1,,CHEMBL626632,BAO_0000100,,
13052,,,,P,,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,U,,1,,CHEMBL626633,BAO_0000100,,
13053,,,,P,,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,U,,1,,CHEMBL626634,BAO_0000100,,
13054,,,,P,,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,U,,1,,CHEMBL626635,BAO_0000100,,
13055,,,,P,,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,U,,1,,CHEMBL626636,BAO_0000100,,
13056,,,,P,,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,U,,1,,CHEMBL626637,BAO_0000100,,
13057,,,,A,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),N,,1,,CHEMBL626638,BAO_0000218,,
13058,,,,A,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,N,,1,,CHEMBL626639,BAO_0000218,,
13059,,,,A,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,N,,1,,CHEMBL626640,BAO_0000218,,
13060,,,,A,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,N,,1,,CHEMBL626641,BAO_0000218,,
13061,,,,A,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,N,,1,,CHEMBL627272,BAO_0000218,,
13062,,,,A,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,N,,1,,CHEMBL627273,BAO_0000218,,
13063,,,,A,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),N,,1,,CHEMBL627441,BAO_0000218,,
13064,,,,A,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),N,,1,,CHEMBL628355,BAO_0000218,,
13065,,,,A,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),N,,1,,CHEMBL628356,BAO_0000218,,
13066,,,,A,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),N,,1,,CHEMBL628357,BAO_0000218,,
13067,,,,A,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),N,,1,,CHEMBL628358,BAO_0000218,,
13068,,,,A,,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),N,,1,,CHEMBL622307,BAO_0000218,,
13069,,,,A,,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,U,,1,,CHEMBL622527,BAO_0000019,,
13070,,,,A,,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,U,,1,,CHEMBL622528,BAO_0000019,,
13071,,,,A,,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,U,,1,,CHEMBL622529,BAO_0000019,,
13072,,,,A,,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,U,,1,,CHEMBL622992,BAO_0000019,,
13073,,,,A,,,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,U,,1,,CHEMBL622993,BAO_0000019,,
13074,,,,A,,,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,U,,1,,CHEMBL622994,BAO_0000019,,
13075,,,,A,,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",N,,1,,CHEMBL622995,BAO_0000218,,
13076,,,,A,,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",N,,1,,CHEMBL622996,BAO_0000218,,
13077,,,,A,,,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",N,,1,,CHEMBL622997,BAO_0000218,,
13078,,,,A,,,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",N,,1,,CHEMBL622998,BAO_0000218,,
13079,,,,A,,,,Cp max following ip administration at 1 mg/kg,U,,1,,CHEMBL622999,BAO_0000218,,
13080,,In vivo,Plasma,A,,,,Maximum concentration in plasma was reported at 0.5 hour,U,,1,,CHEMBL623000,BAO_0000218,1969.0,
13081,,In vivo,Plasma,A,,,,Maximum concentration in plasma was reported at 2 hour,U,,1,,CHEMBL623001,BAO_0000218,1969.0,
13082,,,,A,,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,N,,1,,CHEMBL623002,BAO_0000218,,
13083,,,,P,,,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),U,,1,,CHEMBL623003,BAO_0000100,,
13084,,,,A,,,,Steady state concentration was evaluated,U,,1,,CHEMBL623004,BAO_0000019,,
13085,,,,A,,,,Partition coefficient (logP),U,,1,,CHEMBL623005,BAO_0000019,,
13086,,,,A,,,,Partition coefficient (logD7.4),U,,1,,CHEMBL623006,BAO_0000019,,
13087,,In vivo,Liver,A,,,,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,N,,1,,CHEMBL623007,BAO_0000218,2107.0,
13088,,In vivo,Bone,A,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,N,,1,,CHEMBL623008,BAO_0000218,10000001.0,
13089,,In vivo,Cerebellum,A,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,N,,1,,CHEMBL876654,BAO_0000218,2037.0,
13090,,In vivo,,A,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,N,,1,,CHEMBL623009,BAO_0000218,,
13091,,In vivo,,A,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,N,,1,,CHEMBL623010,BAO_0000218,,
13092,,In vivo,Heart,A,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,N,,1,,CHEMBL623011,BAO_0000218,948.0,
13093,,In vivo,Intestine,A,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,N,,1,,CHEMBL623012,BAO_0000218,160.0,
13094,,,,A,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,U,,1,,CHEMBL623013,BAO_0000019,,
13095,,,,A,,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,U,,1,,CHEMBL623014,BAO_0000019,,
13096,,,Urine,A,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,U,,1,,CHEMBL623015,BAO_0000019,1088.0,
13097,,,Urine,A,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,U,,1,,CHEMBL623016,BAO_0000019,1088.0,
13098,,,Urine,A,,,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,U,,1,,CHEMBL624858,BAO_0000019,1088.0,
13099,,,,A,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,N,,1,,CHEMBL624859,BAO_0000218,,
13100,,,,A,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,N,,1,,CHEMBL624860,BAO_0000218,,
13101,,,,A,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,N,,1,,CHEMBL624861,BAO_0000218,,
13102,,,,A,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,N,,1,,CHEMBL624862,BAO_0000218,,
13103,,,,A,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,N,,1,,CHEMBL624863,BAO_0000218,,
13104,,,,A,,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,N,,1,,CHEMBL876655,BAO_0000218,,
13105,,,,A,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,N,,1,,CHEMBL624864,BAO_0000218,,
13106,,,,A,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,N,,1,,CHEMBL624865,BAO_0000218,,
13107,,,,A,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,N,,1,,CHEMBL624866,BAO_0000218,,
13108,,,,F,,,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,N,,1,,CHEMBL624867,BAO_0000218,,
13109,,,,A,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,N,,1,,CHEMBL624868,BAO_0000218,,
13110,,,,A,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,N,,1,,CHEMBL628450,BAO_0000218,,
13111,,,,A,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,N,,1,,CHEMBL628451,BAO_0000218,,
13112,,,,A,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,N,,1,,CHEMBL628452,BAO_0000218,,
13113,,,,A,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,N,,1,,CHEMBL628453,BAO_0000218,,
13114,,,,A,,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,N,,1,,CHEMBL628454,BAO_0000218,,
13115,,,,A,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,N,,1,,CHEMBL628455,BAO_0000218,,
13116,,,,A,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,N,,1,,CHEMBL628456,BAO_0000218,,
13117,,,,A,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,N,,1,,CHEMBL628457,BAO_0000218,,
13118,,,,A,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,N,,1,,CHEMBL877505,BAO_0000218,,
13119,,,,A,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,N,,1,,CHEMBL628458,BAO_0000218,,
13120,,,,A,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,N,,1,,CHEMBL628459,BAO_0000218,,
13121,,,,A,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,N,,1,,CHEMBL628460,BAO_0000218,,
13122,,,,A,,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,N,,1,,CHEMBL628461,BAO_0000218,,
13123,,,,B,,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",U,,1,,CHEMBL628462,BAO_0000218,,
13124,,,,A,,,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,N,,1,,CHEMBL628463,BAO_0000218,,
13125,,,,F,,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",N,,1,,CHEMBL625666,BAO_0000218,,
13126,,,,B,,,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,U,,1,,CHEMBL625667,BAO_0000218,,
13127,,,,A,,,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,N,,1,,CHEMBL625668,BAO_0000218,,
13128,,,,A,,,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,N,,1,,CHEMBL625669,BAO_0000218,,
13129,,,,A,,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,U,,1,,CHEMBL625670,BAO_0000019,,
13130,,,,A,,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,N,,1,,CHEMBL625671,BAO_0000218,,
13131,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,N,,1,,CHEMBL625672,BAO_0000218,,
13132,,,,A,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,N,,1,,CHEMBL625673,BAO_0000218,,
13133,,,,A,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,N,,1,,CHEMBL625674,BAO_0000218,,
13134,,,,A,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,N,,1,,CHEMBL625675,BAO_0000218,,
13135,,,,A,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,N,,1,,CHEMBL627637,BAO_0000218,,
13136,,,,A,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,N,,1,,CHEMBL627638,BAO_0000218,,
13137,,,,A,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,N,,1,,CHEMBL627639,BAO_0000218,,
13138,,,,A,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,N,,1,,CHEMBL627640,BAO_0000218,,
13139,,,,A,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,N,,1,,CHEMBL627641,BAO_0000218,,
13140,,,,A,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,N,,1,,CHEMBL627642,BAO_0000218,,
13141,,,,A,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,N,,1,,CHEMBL877506,BAO_0000218,,
13142,,,,A,,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,N,,1,,CHEMBL627275,BAO_0000218,,
13143,,,,A,,,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",N,,1,,CHEMBL627643,BAO_0000218,,
13144,,,,A,,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",N,,1,,CHEMBL631246,BAO_0000218,,
13145,,,,A,,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",N,,1,,CHEMBL631247,BAO_0000218,,
13146,,,,A,,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,N,,1,,CHEMBL629532,BAO_0000218,,
13147,,,,A,,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,N,,1,,CHEMBL629533,BAO_0000218,,
13148,,,,A,,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,N,,1,,CHEMBL629534,BAO_0000218,,
13149,,,,A,,,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,N,,1,,CHEMBL629535,BAO_0000218,,
13150,,,,A,,,,Pharmacokinetic parameter :drug bound to plasma was reported,U,,1,,CHEMBL625932,BAO_0000019,,
13151,,,,A,,,,compound was evaluated for drug bound in plasma,U,,1,,CHEMBL625933,BAO_0000019,,
13152,,,,A,,,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,N,,1,,CHEMBL625934,BAO_0000218,,
13153,,,,A,,,,Bioavailability,U,,1,,CHEMBL625935,BAO_0000218,,
13154,,,,A,,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,N,,1,,CHEMBL625936,BAO_0000218,,
13155,,,,A,,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,N,,1,,CHEMBL625937,BAO_0000218,,
13156,,,,A,,,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,N,,1,,CHEMBL625938,BAO_0000218,,
13157,,,Bile,A,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,N,,1,,CHEMBL625939,BAO_0000218,1970.0,
13158,,,Bile,A,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,N,,1,,CHEMBL625940,BAO_0000218,1970.0,
13159,,,Bile,A,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,N,,1,,CHEMBL874464,BAO_0000218,1970.0,
13160,,,Bile,A,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,N,,1,,CHEMBL625941,BAO_0000218,1970.0,
13161,,,Bile,A,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,N,,1,,CHEMBL625942,BAO_0000218,1970.0,
13162,,,Bile,A,,,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,N,,1,,CHEMBL625943,BAO_0000218,1970.0,
13163,,,Serum,A,,,,In vitro protein binding in human serum at 5 ug/ml,N,,1,,CHEMBL625944,BAO_0000218,1977.0,
13164,,,,A,,,,Serum protein binding ability was measured,U,,1,,CHEMBL625945,BAO_0000019,,
13165,,,,A,,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),U,,1,,CHEMBL625946,BAO_0000019,,
13166,,In vivo,,A,,,,Oral bioavailability in dog,U,,1,,CHEMBL625947,BAO_0000218,,
13167,,In vivo,,A,,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,N,,1,,CHEMBL625948,BAO_0000218,,
13168,,In vivo,,A,,,,Absolute oral bioavailability at an iv dose of 14 mg/kg,U,,1,,CHEMBL625949,BAO_0000218,,
13169,,In vivo,,A,,,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,U,,1,,CHEMBL625950,BAO_0000218,,
13170,,In vivo,,A,,,,Oral bioavailability (dose 15 mg/kg i.v.),U,,1,,CHEMBL625951,BAO_0000218,,
13171,,In vivo,,A,,,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,U,,1,,CHEMBL625952,BAO_0000218,,
13172,,In vivo,,A,,,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,U,,1,,CHEMBL625953,BAO_0000218,,
13173,,In vivo,,A,,,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,U,,1,,CHEMBL625954,BAO_0000218,,
13174,,In vivo,,A,,,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,U,,1,,CHEMBL882959,BAO_0000218,,
13175,,In vivo,,A,,,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,N,,1,,CHEMBL625955,BAO_0000218,,
13176,,In vivo,,A,,,,Bioavailability in ferret,U,,1,,CHEMBL625956,BAO_0000218,,
13177,,In vivo,,A,,,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,N,,1,,CHEMBL625957,BAO_0000218,,
13178,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,N,,1,,CHEMBL625958,BAO_0000218,,
13179,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,N,,1,,CHEMBL625959,BAO_0000218,,
13180,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,N,,1,,CHEMBL626642,BAO_0000218,,
13181,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,N,,1,,CHEMBL631330,BAO_0000218,,
13182,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,N,,1,,CHEMBL631331,BAO_0000218,,
13183,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,N,,1,,CHEMBL631332,BAO_0000218,,
13184,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,N,,1,,CHEMBL631333,BAO_0000218,,
13185,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,N,,1,,CHEMBL632018,BAO_0000218,,
13186,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,N,,1,,CHEMBL632019,BAO_0000218,,
13187,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,N,,1,,CHEMBL632020,BAO_0000218,,
13188,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,N,,1,,CHEMBL632021,BAO_0000218,,
13189,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,N,,1,,CHEMBL632022,BAO_0000218,,
13190,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,N,,1,,CHEMBL632023,BAO_0000218,,
13191,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,N,,1,,CHEMBL632024,BAO_0000218,,
13192,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,N,,1,,CHEMBL874472,BAO_0000218,,
13193,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,N,,1,,CHEMBL632025,BAO_0000218,,
13194,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,N,,1,,CHEMBL632026,BAO_0000218,,
13195,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,N,,1,,CHEMBL632027,BAO_0000218,,
13196,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,N,,1,,CHEMBL632028,BAO_0000218,,
13197,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,N,,1,,CHEMBL626430,BAO_0000218,,
13198,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,N,,1,,CHEMBL626431,BAO_0000218,,
13199,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,N,,1,,CHEMBL626432,BAO_0000218,,
13200,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,N,,1,,CHEMBL626433,BAO_0000218,,
13201,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,N,,1,,CHEMBL626434,BAO_0000218,,
13202,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,N,,1,,CHEMBL627280,BAO_0000218,,
13203,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,N,,1,,CHEMBL627281,BAO_0000218,,
13204,,,,A,,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,N,,1,,CHEMBL627282,BAO_0000218,,
13205,,,,A,,,,Total body clearance was measured at given dose,U,,1,,CHEMBL627283,BAO_0000019,,
13206,,,,A,,,,Total body clearance was measured at given dose.,U,,1,,CHEMBL627284,BAO_0000218,,
13207,,,,A,,,,Metabolic clearance from the body in rat,N,,1,,CHEMBL627285,BAO_0000218,,
13208,,In vivo,,A,,,,Renal clearance from the body,U,,1,,CHEMBL627286,BAO_0000218,,
13209,,In vivo,,A,,,,Renal clearance from the body in rat,N,,1,,CHEMBL875477,BAO_0000218,,
13210,,In vivo,,A,,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,N,,1,,CHEMBL627287,BAO_0000218,,
13211,,In vivo,,A,,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,N,,1,,CHEMBL627288,BAO_0000218,,
13212,,,,A,,,,Total clearance from the body in rat,N,,1,,CHEMBL627289,BAO_0000218,,
13213,,In vivo,Plasma,A,,,,Clearance into cortex from rat plasma or PBS,N,,1,,CHEMBL627290,BAO_0000218,1969.0,
13214,,In vivo,,A,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,U,,1,,CHEMBL627291,BAO_0000218,,
13215,,In vivo,,A,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,U,,1,,CHEMBL627292,BAO_0000218,,
13216,,In vivo,,A,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,U,,1,,CHEMBL627293,BAO_0000218,,
13217,,In vivo,,A,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,U,,1,,CHEMBL627294,BAO_0000218,,
13218,,In vivo,,A,,,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,U,,1,,CHEMBL875478,BAO_0000218,,
13219,,In vivo,,A,,,,Clearance was determined,U,,1,,CHEMBL627295,BAO_0000218,,
13220,,In vivo,,A,,,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,N,,1,,CHEMBL627296,BAO_0000218,,
13221,,In vivo,,A,,,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,N,,1,,CHEMBL626119,BAO_0000218,,
13222,,In vivo,,A,,,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,N,,1,,CHEMBL626120,BAO_0000218,,
13223,,In vivo,,A,,,,Clearance in rat after iv dose (100 ug/kg),N,,1,,CHEMBL626121,BAO_0000218,,
13224,,In vivo,,A,,,,Clearance in guinea pig,U,,1,,CHEMBL626122,BAO_0000218,,
13225,,In vivo,,A,,,,Compound was evaluated for clearance in rat,N,,1,,CHEMBL626123,BAO_0000218,,
13226,,In vivo,,A,,,,Compound was evaluated for the clearance in dog,N,,1,,CHEMBL623456,BAO_0000218,,
13227,,In vivo,,A,,,,Compound was evaluated for the clearance in rat,N,,1,,CHEMBL623457,BAO_0000218,,
13228,,In vivo,,A,,,,Compound was tested in vivo for clearance after iv administration in the rat,N,,1,,CHEMBL623458,BAO_0000218,,
13229,,In vivo,,A,,,,IV clearance determined at an iv dose of 14 mg/kg,U,,1,,CHEMBL623459,BAO_0000218,,
13230,,In vivo,,A,,,,IV clearance determined at an iv dose of 15.2 mg/kg,U,,1,,CHEMBL875484,BAO_0000218,,
13231,,In vivo,,A,,,,IV clearance determined at an iv dose of 15 mg/kg,U,,1,,CHEMBL623460,BAO_0000218,,
13232,,In vivo,,A,,,,IV clearance determined at an peroral dose of 30 mg/kg.,U,,1,,CHEMBL623461,BAO_0000218,,
13233,,In vivo,,A,,,,IV clearance determined at an peroral dose of 30.2 mg/kg.,U,,1,,CHEMBL623462,BAO_0000218,,
13234,,In vivo,,A,,,,IV clearance determined at an peroral dose of 30.3 mg/kg.,U,,1,,CHEMBL627386,BAO_0000218,,
13235,,In vivo,Kidney,A,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,N,,1,,CHEMBL627387,BAO_0000218,2113.0,
13236,,In vivo,Liver,A,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,N,,1,,CHEMBL627388,BAO_0000218,2107.0,
13237,,In vivo,Lung,A,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,N,,1,,CHEMBL627389,BAO_0000218,2048.0,
13238,,In vivo,Muscle tissue,A,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,N,,1,,CHEMBL627390,BAO_0000218,2385.0,
13239,,In vivo,Plasma,A,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,N,,1,,CHEMBL627391,BAO_0000218,1969.0,
13240,,In vivo,,A,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,N,,1,,CHEMBL627392,BAO_0000218,,
13241,,In vivo,Spleen,A,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,N,,1,,CHEMBL627393,BAO_0000218,2106.0,
13242,,In vivo,Trachea,A,,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,N,,1,,CHEMBL627394,BAO_0000218,3126.0,
13243,,In vivo,Bone,A,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,N,,1,,CHEMBL627395,BAO_0000218,10000001.0,
13244,,In vivo,Cerebellum,A,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,N,,1,,CHEMBL875485,BAO_0000218,2037.0,
13245,,In vivo,,A,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,N,,1,,CHEMBL627396,BAO_0000218,,
13246,,In vivo,,A,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,N,,1,,CHEMBL627397,BAO_0000218,,
13247,,In vivo,Heart,A,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,N,,1,,CHEMBL627398,BAO_0000218,948.0,
13248,,In vivo,Bone,A,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,N,,1,,CHEMBL627399,BAO_0000218,10000001.0,
13249,,In vivo,Kidney,A,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,N,,1,,CHEMBL627400,BAO_0000218,2113.0,
13250,,In vivo,Liver,A,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,N,,1,,CHEMBL627401,BAO_0000218,2107.0,
13251,,In vivo,Lung,A,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,N,,1,,CHEMBL627402,BAO_0000218,2048.0,
13252,,In vivo,Muscle tissue,A,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,N,,1,,CHEMBL627403,BAO_0000218,2385.0,
13253,,In vivo,Plasma,A,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,N,,1,,CHEMBL627404,BAO_0000218,1969.0,
13254,,In vivo,,A,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,N,,1,,CHEMBL623101,BAO_0000218,,
13255,,In vivo,Spleen,A,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,N,,1,,CHEMBL877480,BAO_0000218,2106.0,
13256,,In vivo,Trachea,A,,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,N,,1,,CHEMBL623102,BAO_0000218,3126.0,
13257,,In vivo,Bone,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,N,,1,,CHEMBL623103,BAO_0000218,10000001.0,
13258,,In vivo,Cerebellum,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,N,,1,,CHEMBL623104,BAO_0000218,2037.0,
13259,,In vivo,,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,N,,1,,CHEMBL623105,BAO_0000218,,
13260,,In vivo,,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,N,,1,,CHEMBL623106,BAO_0000218,,
13261,,In vivo,Heart,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,N,,1,,CHEMBL623107,BAO_0000218,948.0,
13262,,In vivo,Intestine,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,N,,1,,CHEMBL623108,BAO_0000218,160.0,
13263,,In vivo,Kidney,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,N,,1,,CHEMBL623109,BAO_0000218,2113.0,
13264,,In vivo,Liver,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,N,,1,,CHEMBL623110,BAO_0000218,2107.0,
13265,,In vivo,Lung,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,N,,1,,CHEMBL623111,BAO_0000218,2048.0,
13266,,In vivo,Muscle tissue,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,N,,1,,CHEMBL625060,BAO_0000218,2385.0,
13267,,In vivo,Plasma,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,N,,1,,CHEMBL625061,BAO_0000218,1969.0,
13268,,In vivo,,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,N,,1,,CHEMBL625062,BAO_0000218,,
13269,,In vivo,Spleen,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,N,,1,,CHEMBL625063,BAO_0000218,2106.0,
13270,,In vivo,Trachea,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,N,,1,,CHEMBL625064,BAO_0000218,3126.0,
13271,,In vivo,Bone,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,N,,1,,CHEMBL625065,BAO_0000218,10000001.0,
13272,,In vivo,Cerebellum,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,N,,1,,CHEMBL625066,BAO_0000218,2037.0,
13273,,In vivo,,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,N,,1,,CHEMBL625067,BAO_0000218,,
13274,,In vivo,,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,N,,1,,CHEMBL625068,BAO_0000218,,
13275,,In vivo,Heart,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,N,,1,,CHEMBL622159,BAO_0000218,948.0,
13276,,In vivo,Intestine,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,N,,1,,CHEMBL622160,BAO_0000218,160.0,
13277,,In vivo,Kidney,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,N,,1,,CHEMBL622161,BAO_0000218,2113.0,
13278,,In vivo,Lung,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,N,,1,,CHEMBL622162,BAO_0000218,2048.0,
13279,,In vivo,Muscle tissue,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,N,,1,,CHEMBL622163,BAO_0000218,2385.0,
13280,,In vivo,Plasma,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,N,,1,,CHEMBL622313,BAO_0000218,1969.0,
13281,,In vivo,,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,N,,1,,CHEMBL622314,BAO_0000218,,
13282,,In vivo,Spleen,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,N,,1,,CHEMBL622315,BAO_0000218,2106.0,
13283,,In vivo,Trachea,A,,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,N,,1,,CHEMBL622316,BAO_0000218,3126.0,
13284,,,,A,,,,Normal diffusion coefficient in water for Escherichia coli,N,,1,,CHEMBL877486,BAO_0000218,,
13285,,,,A,,,,Average max percent decrease in RVR (renal vascular resistance) was determined,U,,1,,CHEMBL622317,BAO_0000019,,
13286,,,,A,,,,Average max percent decrease in RVR (renal vascular resistance) was determined.,U,,1,,CHEMBL622318,BAO_0000019,,
13287,,,,A,,,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,U,,1,,CHEMBL622319,BAO_0000019,,
13288,,,,A,,,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,U,,1,,CHEMBL622320,BAO_0000019,,
13289,,,,A,,,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,U,,1,,CHEMBL622321,BAO_0000019,,
13290,,,,A,,,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,U,,1,,CHEMBL622322,BAO_0000019,,
13291,,,,A,,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,U,,1,,CHEMBL622323,BAO_0000019,,
13292,,,,A,,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,N,,1,,CHEMBL622324,BAO_0000218,,
13293,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",N,,1,,CHEMBL622325,BAO_0000218,1088.0,
13294,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",N,,1,,CHEMBL622326,BAO_0000218,1088.0,
13295,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",N,,1,,CHEMBL877487,BAO_0000218,1088.0,
13296,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",N,,1,,CHEMBL622327,BAO_0000218,1088.0,
13297,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",N,,1,,CHEMBL622328,BAO_0000218,1088.0,
13298,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",N,,1,,CHEMBL622329,BAO_0000218,1088.0,
13299,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",N,,1,,CHEMBL622330,BAO_0000218,1088.0,
13300,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",N,,1,,CHEMBL622331,BAO_0000218,1088.0,
13301,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",N,,1,,CHEMBL622332,BAO_0000218,1088.0,
13302,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",N,,1,,CHEMBL622333,BAO_0000218,1088.0,
13303,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",U,,1,,CHEMBL627658,BAO_0000218,1088.0,
13304,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",U,,1,,CHEMBL630428,BAO_0000218,1088.0,
13305,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",U,,1,,CHEMBL630429,BAO_0000218,1088.0,
13306,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",U,,1,,CHEMBL630430,BAO_0000218,1088.0,
13307,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",U,,1,,CHEMBL630431,BAO_0000218,1088.0,
13308,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",N,,1,,CHEMBL630432,BAO_0000218,1088.0,
13309,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",N,,1,,CHEMBL630433,BAO_0000218,1088.0,
13310,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",N,,1,,CHEMBL630434,BAO_0000218,1088.0,
13311,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",N,,1,,CHEMBL629372,BAO_0000218,1088.0,
13312,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",N,,1,,CHEMBL629553,BAO_0000218,1088.0,
13313,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",N,,1,,CHEMBL629554,BAO_0000218,1088.0,
13314,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",N,,1,,CHEMBL874447,BAO_0000218,1088.0,
13315,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",N,,1,,CHEMBL629555,BAO_0000218,1088.0,
13316,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",N,,1,,CHEMBL629556,BAO_0000218,1088.0,
13317,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",N,,1,,CHEMBL629557,BAO_0000218,1088.0,
13318,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",N,,1,,CHEMBL629558,BAO_0000218,1088.0,
13319,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",N,,1,,CHEMBL629559,BAO_0000218,1088.0,
13320,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",N,,1,,CHEMBL629560,BAO_0000218,1088.0,
13321,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",N,,1,,CHEMBL629561,BAO_0000218,1088.0,
13322,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",N,,1,,CHEMBL629562,BAO_0000218,1088.0,
13323,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",N,,1,,CHEMBL629563,BAO_0000218,1088.0,
13324,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",N,,1,,CHEMBL629564,BAO_0000218,1088.0,
13325,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",N,,1,,CHEMBL629565,BAO_0000218,1088.0,
13326,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",N,,1,,CHEMBL629566,BAO_0000218,1088.0,
13327,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",N,,1,,CHEMBL629567,BAO_0000218,1088.0,
13328,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",N,,1,,CHEMBL629568,BAO_0000218,1088.0,
13329,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",N,,1,,CHEMBL629569,BAO_0000218,1088.0,
13330,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",N,,1,,CHEMBL629570,BAO_0000218,1088.0,
13331,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",U,,1,,CHEMBL629571,BAO_0000218,1088.0,
13332,,In vivo,,A,,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,U,,1,,CHEMBL629572,BAO_0000218,,
13333,,In vivo,,A,,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,U,,1,,CHEMBL629573,BAO_0000218,,
13334,,In vivo,,A,,,,Bioavailability (dose 20 mg/kg),U,,1,,CHEMBL629574,BAO_0000218,,
13335,,In vivo,,A,,,,Bioavailability in dog,U,,1,,CHEMBL629575,BAO_0000218,,
13336,,In vivo,,A,,,,Bioavailability in rat (Sprague-Dawley) (male),U,,1,,CHEMBL874448,BAO_0000218,,
13337,,In vivo,,A,,,,Bioavailability in monkey (dose 10 mg/kg i.d.),U,,1,,CHEMBL629576,BAO_0000218,,
13338,,In vivo,,A,,,,Bioavailability in rat,U,,1,,CHEMBL629577,BAO_0000218,,
13339,,In vivo,,A,,,,Bioavailability in rat,U,,1,,CHEMBL629578,BAO_0000218,,
13340,,In vivo,,A,,,,Bioavailability in dog (dose 3.0 mg/kg p.o.),U,,1,,CHEMBL629579,BAO_0000218,,
13341,,In vivo,,A,,,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,U,,1,,CHEMBL882958,BAO_0000218,,
13342,,In vivo,,A,,,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,N,,1,,CHEMBL629580,BAO_0000218,,
13343,,In vivo,,A,,,,Bioavailability,U,,1,,CHEMBL629581,BAO_0000218,,
13344,,In vivo,,A,,,,Bioavailability in squirrel monkey,U,,1,,CHEMBL629582,BAO_0000218,,
13345,,In vivo,,A,,,,Bioavailability was evaluated in dog,N,,1,,CHEMBL628522,BAO_0000218,,
13346,,In vivo,,A,,,,Bioavailability was evaluated in hamster,N,,1,,CHEMBL625432,BAO_0000218,,
13347,,In vivo,,A,,,,Bioavailability in rat,U,,1,,CHEMBL625433,BAO_0000218,,
13348,,In vivo,Plasma,A,,,,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,N,,1,,CHEMBL625434,BAO_0000218,1969.0,
13349,,In vivo,Plasma,A,,,,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,N,,1,,CHEMBL625435,BAO_0000218,1969.0,
13350,,In vivo,,A,,,,Bioavailability in rat (dose 10 mg/kg p.o.),U,,1,,CHEMBL625436,BAO_0000218,,
13351,,In vivo,,A,,,,Bioavailability was measured in cynomolgus monkeys.,N,,1,,CHEMBL874588,BAO_0000218,,
13352,,In vivo,,A,,,,Bioavailability was measured in nude mice.,N,,1,,CHEMBL625437,BAO_0000218,,
13353,,In vivo,,A,,,,Bioavailability in ferret (dose 10 mg/kg i.d.),U,,1,,CHEMBL625438,BAO_0000218,,
13354,,In vivo,,A,,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),U,,1,,CHEMBL625439,BAO_0000218,,
13355,,In vivo,,A,,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",U,,1,,CHEMBL625440,BAO_0000218,,
13356,,In vivo,,A,,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),U,,1,,CHEMBL625441,BAO_0000218,,
13357,,In vivo,,A,,,,Bioavailability in rat (dose 10 mg/kg i.d.),U,,1,,CHEMBL625442,BAO_0000218,,
13358,,In vivo,,A,,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",N,,1,,CHEMBL625443,BAO_0000218,,
13359,,In vivo,,A,,,,Bioavailability was determined; extremely poor,U,,1,,CHEMBL625444,BAO_0000218,,
13360,,In vivo,,A,,,,% bioavailability in mice after oral administration of prodrug,N,,1,,CHEMBL625445,BAO_0000218,,
13361,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,N,,1,,CHEMBL625446,BAO_0000218,,
13362,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,N,,1,,CHEMBL882960,BAO_0000218,,
13363,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,N,,1,,CHEMBL625447,BAO_0000218,,
13364,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,N,,1,,CHEMBL625448,BAO_0000218,,
13365,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,N,,1,,CHEMBL625449,BAO_0000218,,
13366,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),N,,1,,CHEMBL874589,BAO_0000218,,
13367,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,N,,1,,CHEMBL625450,BAO_0000218,,
13368,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,N,,1,,CHEMBL625451,BAO_0000218,,
13369,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,N,,1,,CHEMBL626584,BAO_0000218,,
13370,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,N,,1,,CHEMBL626585,BAO_0000218,,
13371,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,N,,1,,CHEMBL626586,BAO_0000218,,
13372,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,N,,1,,CHEMBL626587,BAO_0000218,,
13373,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,N,,1,,CHEMBL626588,BAO_0000218,,
13374,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,N,,1,,CHEMBL626589,BAO_0000218,,
13375,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,N,,1,,CHEMBL626590,BAO_0000218,,
13376,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,N,,1,,CHEMBL626591,BAO_0000218,,
13377,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,N,,1,,CHEMBL627181,BAO_0000218,,
13378,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,N,,1,,CHEMBL628083,BAO_0000218,,
13379,,In vivo,,A,,,,IV clearance determined at an peroral dose of 15 mg/kg.,U,,1,,CHEMBL628084,BAO_0000218,,
13380,,In vivo,,F,,,,Mouse oral clearance was measured against Hymenolepiasis nana.,N,,1,,CHEMBL628085,BAO_0000218,,
13381,,In vivo,,F,,,,Mouse oral clearance was measured against Nematospiroides dubius,N,,1,,CHEMBL628086,BAO_0000218,,
13382,,In vivo,,F,,,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,U,,1,,CHEMBL628087,BAO_0000218,,
13383,,In vivo,,A,,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,N,,1,,CHEMBL628088,BAO_0000218,,
13384,,In vivo,,B,,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,U,,1,,CHEMBL628089,BAO_0000218,,
13385,,In vivo,,A,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,U,,1,,CHEMBL628090,BAO_0000218,,
13386,,In vivo,,A,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,U,,1,,CHEMBL628091,BAO_0000218,,
13387,,In vivo,,A,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,U,,1,,CHEMBL628092,BAO_0000218,,
13388,,In vivo,,A,,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,U,,1,,CHEMBL628093,BAO_0000218,,
13389,,In vivo,,A,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,U,,1,,CHEMBL875607,BAO_0000218,,
13390,,In vivo,,A,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,U,,1,,CHEMBL625710,BAO_0000218,,
13391,,In vivo,,A,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,U,,1,,CHEMBL625711,BAO_0000218,,
13392,,In vivo,,A,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,U,,1,,CHEMBL625712,BAO_0000218,,
13393,,In vivo,,A,,,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,U,,1,,CHEMBL625713,BAO_0000218,,
13394,,In vivo,,A,,,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,N,,1,,CHEMBL625714,BAO_0000218,,
13395,,In vivo,,A,,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,N,,1,,CHEMBL625715,BAO_0000218,,
13396,,In vivo,,A,,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,N,,1,,CHEMBL625716,BAO_0000218,,
13397,,In vivo,,A,,,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,N,,1,,CHEMBL625717,BAO_0000218,,
13398,,In vivo,,A,,,,Plasma clearance was determined for the compound in rats,N,,1,,CHEMBL625718,BAO_0000218,,
13399,,In vivo,,A,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,N,,1,,CHEMBL625719,BAO_0000218,,
13400,,In vivo,,A,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,N,,1,,CHEMBL625720,BAO_0000218,,
13401,,In vivo,,A,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,N,,1,,CHEMBL625721,BAO_0000218,,
13402,,In vivo,,A,,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,N,,1,,CHEMBL625722,BAO_0000218,,
13403,,In vivo,,A,,,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,N,,1,,CHEMBL625723,BAO_0000218,,
13404,,In vivo,,A,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,N,,1,,CHEMBL625724,BAO_0000218,,
13405,,In vivo,,A,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,N,,1,,CHEMBL625725,BAO_0000218,,
13406,,In vivo,,A,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,N,,1,,CHEMBL625726,BAO_0000218,,
13407,,In vivo,,A,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,N,,1,,CHEMBL875608,BAO_0000218,,
13408,,In vivo,,A,,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,N,,1,,CHEMBL625727,BAO_0000218,,
13409,,In vivo,Urine,A,,,,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,U,,1,,CHEMBL625728,BAO_0000218,1088.0,
13410,,In vivo,,A,,,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,U,,1,,CHEMBL625729,BAO_0000218,,
13411,,In vivo,,A,,,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,U,,1,,CHEMBL625730,BAO_0000218,,
13412,,In vivo,Urine,A,,,,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,U,,1,,CHEMBL625731,BAO_0000218,1088.0,
13413,,In vivo,Urine,A,,,,Urinary clearance was determined in rat at 25 mg/kg os dosage,U,,1,,CHEMBL626417,BAO_0000218,1088.0,
13414,,In vivo,Urine,A,,,,Urinary clearance was determined at 100 mg/kg oral dosage in human,N,,1,,CHEMBL626418,BAO_0000218,1088.0,
13415,,In vivo,Urine,A,,,,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,N,,1,,CHEMBL626419,BAO_0000218,1088.0,
13416,,In vivo,Plasma,A,,,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,N,,1,,CHEMBL626592,BAO_0000218,1969.0,
13417,,In vivo,Plasma,A,,,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,N,,1,,CHEMBL626593,BAO_0000218,1969.0,
13418,,In vivo,,A,,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,N,,1,,CHEMBL626594,BAO_0000218,,
13419,,In vivo,,A,,,,Clearance rate in dogs,N,,1,,CHEMBL625035,BAO_0000218,,
13420,,In vitro,,A,,,,Compound was measured for intrinsic clearance,U,,1,,CHEMBL625036,BAO_0000019,,
13421,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625037,BAO_0000100,,
13422,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625038,BAO_0000100,,
13423,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625039,BAO_0000100,,
13424,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625040,BAO_0000100,,
13425,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625041,BAO_0000100,,
13426,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625042,BAO_0000100,,
13427,,,,A,,,,Partition coefficient of the compound,U,,1,,CHEMBL874411,BAO_0000019,,
13428,,,,A,,,,Permeability,U,,1,,CHEMBL625043,BAO_0000019,,
13429,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625044,BAO_0000100,,
13430,,,,A,,,,Partition coefficient (logD),U,,1,,CHEMBL625045,BAO_0000019,,
13431,,,,P,,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),U,,1,,CHEMBL625046,BAO_0000100,,
13432,,,,P,,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),U,,1,,CHEMBL625047,BAO_0000100,,
13433,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625048,BAO_0000100,,
13434,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625049,BAO_0000100,,
13435,,,,P,,,,Calculated logarithm of partition coefficient (P) was determined,U,,1,,CHEMBL625050,BAO_0000100,,
13436,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625051,BAO_0000100,,
13437,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL874412,BAO_0000100,,
13438,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625052,BAO_0000100,,
13439,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL625053,BAO_0000100,,
13440,,,,A,,,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,U,,1,,CHEMBL623250,BAO_0000019,,
13441,,,,A,,,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,U,,1,,CHEMBL623251,BAO_0000019,,
13442,,,,A,,,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,U,,1,,CHEMBL623252,BAO_0000019,,
13443,,,,A,,,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,U,,1,,CHEMBL623253,BAO_0000019,,
13444,,,,A,,,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,U,,1,,CHEMBL623254,BAO_0000019,,
13445,,,,A,,,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,U,,1,,CHEMBL623255,BAO_0000019,,
13446,,,,A,,,,Percent degradation of compound at a pH of 1 over a 18 hr period,U,,1,,CHEMBL626831,BAO_0000019,,
13447,,,,A,,,,Percent degradation of compound at pH of 1 over an 18 hr period,U,,1,,CHEMBL877494,BAO_0000019,,
13448,,,,A,,,,Delta Logarithm of Partition Coefficient value was determined.,U,,1,,CHEMBL626832,BAO_0000019,,
13449,,,,A,,,,Delta logPoct-cyc,U,,1,,CHEMBL626833,BAO_0000019,,
13450,,,,P,,,,Lipophilicity estimated on reversed phase TLC,U,,1,,CHEMBL626834,BAO_0000100,,
13451,,,,A,,,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,U,,1,,CHEMBL626835,BAO_0000019,,
13452,,,,A,,,,Delta logPoct-cyc,U,,1,,CHEMBL626836,BAO_0000019,,
13453,,,,P,,,,Change in logarithm of partition coefficient of the compound,U,,1,,CHEMBL626837,BAO_0000100,,
13454,,,,A,,,,Delta logD (pH 6.5),U,,1,,CHEMBL626838,BAO_0000019,,
13455,,,,P,,,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",U,,1,,CHEMBL626839,BAO_0000100,,
13456,,,,A,,,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,U,,1,,CHEMBL626840,BAO_0000019,,
13457,,,,A,,,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),U,,1,,CHEMBL626841,BAO_0000019,,
13458,,,,A,,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,U,,1,,CHEMBL626842,BAO_0000219,,
13459,,,,A,,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,U,,1,,CHEMBL626843,BAO_0000219,,
13460,,,,A,,,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,N,,1,,CHEMBL626844,BAO_0000218,,
13461,,,,A,,,,Amount of deuterium retained was reported after normal workup in rats,N,,1,,CHEMBL877495,BAO_0000218,,
13462,,,,A,,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,N,,1,,CHEMBL626845,BAO_0000218,,
13463,,,,A,,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,N,,1,,CHEMBL626846,BAO_0000218,,
13464,,,,A,,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,N,,1,,CHEMBL626847,BAO_0000218,,
13465,,,,A,,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,N,,1,,CHEMBL628677,BAO_0000218,,
13466,,,,A,,,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,N,,1,,CHEMBL628678,BAO_0000218,,
13467,,,,A,,,,Compound was subjected to electrochemical oxidation,U,,1,,CHEMBL628679,BAO_0000019,,
13468,,,,A,,,,Compound was subjected to photochemical oxidation,U,,1,,CHEMBL628680,BAO_0000019,,
13469,,,,A,,,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,U,,1,,CHEMBL628681,BAO_0000019,,
13470,,,,A,,,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,U,,1,,CHEMBL628682,BAO_0000019,,
13471,,,,A,,,,Oxidation of compound by methemoglobin in presence of hydroperoxide,U,,1,,CHEMBL628683,BAO_0000019,,
13472,,,,A,,,,Percent diffusion through fuzzy rat skin after 48 h of incubation,N,,1,,CHEMBL628684,BAO_0000218,,
13473,,,,P,,,,Dissociation constant (pKa),U,,1,,CHEMBL877501,BAO_0000100,,
13474,,,,P,,,,Dissociation constant value of the compound; ND means not determined.,U,,1,,CHEMBL628685,BAO_0000100,,
13475,,,Blood,A,,,,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,N,,1,,CHEMBL628686,BAO_0000218,178.0,
13476,,,Blood,A,,,,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,N,,1,,CHEMBL628687,BAO_0000218,178.0,
13477,,,,A,,,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,N,,1,,CHEMBL628688,BAO_0000218,,
13478,,,,A,,,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,N,,1,,CHEMBL628689,BAO_0000218,,
13479,,,Liver,A,,,,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,N,,1,,CHEMBL628690,BAO_0000218,2107.0,
13480,,,Liver,A,,,,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,N,,1,,CHEMBL629363,BAO_0000218,2107.0,
13481,,,Spleen,A,,,,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,N,,1,,CHEMBL629364,BAO_0000218,2106.0,
13482,,,Spleen,A,,,,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,N,,1,,CHEMBL629365,BAO_0000218,2106.0,
13483,,,,A,,,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,N,,1,,CHEMBL629366,BAO_0000218,,
13484,,,Urine,A,,,,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,N,,1,,CHEMBL629367,BAO_0000218,1088.0,
13485,,,Feces,A,,,,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,N,,1,,CHEMBL629368,BAO_0000218,1988.0,
13486,,,Urine,A,,,,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,N,,1,,CHEMBL877502,BAO_0000218,1088.0,
13487,,,Cerebellum,A,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,N,,1,,CHEMBL629369,BAO_0000218,2037.0,
13488,,,Brain,A,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,N,,1,,CHEMBL629370,BAO_0000218,955.0,
13489,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",U,,1,,CHEMBL629371,BAO_0000218,1088.0,
13490,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",U,,1,,CHEMBL626276,BAO_0000218,1088.0,
13491,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",U,,1,,CHEMBL626277,BAO_0000218,1088.0,
13492,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",U,,1,,CHEMBL631250,BAO_0000218,1088.0,
13493,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",N,,1,,CHEMBL631251,BAO_0000218,1088.0,
13494,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",N,,1,,CHEMBL631252,BAO_0000218,1088.0,
13495,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",N,,1,,CHEMBL631253,BAO_0000218,1088.0,
13496,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",N,,1,,CHEMBL631254,BAO_0000218,1088.0,
13497,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",N,,1,,CHEMBL631255,BAO_0000218,1088.0,
13498,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",N,,1,,CHEMBL631256,BAO_0000218,1088.0,
13499,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",N,,1,,CHEMBL631257,BAO_0000218,1088.0,
13500,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",N,,1,,CHEMBL628009,BAO_0000218,1088.0,
13501,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",N,,1,,CHEMBL628010,BAO_0000218,1088.0,
13502,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",N,,1,,CHEMBL628011,BAO_0000218,1088.0,
13503,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",N,,1,,CHEMBL628012,BAO_0000218,1088.0,
13504,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",N,,1,,CHEMBL628013,BAO_0000218,1088.0,
13505,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",N,,1,,CHEMBL628014,BAO_0000218,1088.0,
13506,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",N,,1,,CHEMBL628015,BAO_0000218,1088.0,
13507,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",N,,1,,CHEMBL628016,BAO_0000218,1088.0,
13508,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",N,,1,,CHEMBL874461,BAO_0000218,1088.0,
13509,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",N,,1,,CHEMBL628017,BAO_0000218,1088.0,
13510,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",N,,1,,CHEMBL628018,BAO_0000218,1088.0,
13511,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",N,,1,,CHEMBL628019,BAO_0000218,1088.0,
13512,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",N,,1,,CHEMBL628020,BAO_0000218,1088.0,
13513,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",N,,1,,CHEMBL628021,BAO_0000218,1088.0,
13514,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",N,,1,,CHEMBL628022,BAO_0000218,1088.0,
13515,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",N,,1,,CHEMBL628023,BAO_0000218,1088.0,
13516,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",U,,1,,CHEMBL628024,BAO_0000218,1088.0,
13517,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",U,,1,,CHEMBL628025,BAO_0000218,1088.0,
13518,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",U,,1,,CHEMBL628026,BAO_0000218,1088.0,
13519,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",U,,1,,CHEMBL628027,BAO_0000218,1088.0,
13520,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",U,,1,,CHEMBL628028,BAO_0000218,1088.0,
13521,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",N,,1,,CHEMBL628029,BAO_0000218,1088.0,
13522,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",N,,1,,CHEMBL628030,BAO_0000218,1088.0,
13523,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",N,,1,,CHEMBL628031,BAO_0000218,1088.0,
13524,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",N,,1,,CHEMBL628032,BAO_0000218,1088.0,
13525,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",N,,1,,CHEMBL628033,BAO_0000218,1088.0,
13526,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",N,,1,,CHEMBL628034,BAO_0000218,1088.0,
13527,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",N,,1,,CHEMBL628035,BAO_0000218,1088.0,
13528,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",N,,1,,CHEMBL628036,BAO_0000218,1088.0,
13529,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",N,,1,,CHEMBL874462,BAO_0000218,1088.0,
13530,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,N,,1,,CHEMBL628037,BAO_0000218,,
13531,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,N,,1,,CHEMBL628123,BAO_0000218,,
13532,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,N,,1,,CHEMBL628124,BAO_0000218,,
13533,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,N,,1,,CHEMBL628125,BAO_0000218,,
13534,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,N,,1,,CHEMBL628126,BAO_0000218,,
13535,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),N,,1,,CHEMBL628127,BAO_0000218,,
13536,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,N,,1,,CHEMBL628128,BAO_0000218,,
13537,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,N,,1,,CHEMBL628129,BAO_0000218,,
13538,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,N,,1,,CHEMBL628130,BAO_0000218,,
13539,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,N,,1,,CHEMBL628131,BAO_0000218,,
13540,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,N,,1,,CHEMBL628132,BAO_0000218,,
13541,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,N,,1,,CHEMBL628133,BAO_0000218,,
13542,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,N,,1,,CHEMBL628134,BAO_0000218,,
13543,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,N,,1,,CHEMBL628135,BAO_0000218,,
13544,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,N,,1,,CHEMBL628136,BAO_0000218,,
13545,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,N,,1,,CHEMBL628137,BAO_0000218,,
13546,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,N,,1,,CHEMBL628138,BAO_0000218,,
13547,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,N,,1,,CHEMBL628139,BAO_0000218,,
13548,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,N,,1,,CHEMBL628140,BAO_0000218,,
13549,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,N,,1,,CHEMBL628141,BAO_0000218,,
13550,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,N,,1,,CHEMBL628142,BAO_0000218,,
13551,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,N,,1,,CHEMBL628143,BAO_0000218,,
13552,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,N,,1,,CHEMBL628144,BAO_0000218,,
13553,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,N,,1,,CHEMBL628145,BAO_0000218,,
13554,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,N,,1,,CHEMBL628146,BAO_0000218,,
13555,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,N,,1,,CHEMBL625355,BAO_0000218,,
13556,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,N,,1,,CHEMBL625356,BAO_0000218,,
13557,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,N,,1,,CHEMBL625357,BAO_0000218,,
13558,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,N,,1,,CHEMBL625527,BAO_0000218,,
13559,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),N,,1,,CHEMBL875473,BAO_0000218,,
13560,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,N,,1,,CHEMBL625528,BAO_0000218,,
13561,,In vivo,,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,N,,1,,CHEMBL626304,BAO_0000218,,
13562,,In vivo,Artery,A,,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,N,,1,,CHEMBL624138,BAO_0000218,1637.0,
13563,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL624139,BAO_0000100,,
13564,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL624140,BAO_0000100,,
13565,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL624141,BAO_0000100,,
13566,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL624142,BAO_0000100,,
13567,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL624143,BAO_0000100,,
13568,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL624144,BAO_0000100,,
13569,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL624145,BAO_0000100,,
13570,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL624146,BAO_0000100,,
13571,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL624147,BAO_0000100,,
13572,,,,P,,,,Calculated partition coefficient (clogP) (MacLogP),U,,1,,CHEMBL883123,BAO_0000100,,
13573,,,,A,,,,Partition coefficient (logP),U,,1,,CHEMBL624148,BAO_0000019,,
13574,,,,A,,,,Kinetic parameter was determined,U,,1,,CHEMBL874416,BAO_0000019,,
13575,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL624149,BAO_0000100,,
13576,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL624150,BAO_0000100,,
13577,,,,P,,,,Lipophilicity was determined,U,,1,,CHEMBL624151,BAO_0000100,,
13578,,,,P,,,,Lipophilicity was determined,U,,1,,CHEMBL624152,BAO_0000100,,
13579,,,,P,,,,Lipophilicity was determined,U,,1,,CHEMBL622139,BAO_0000100,,
13580,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL622140,BAO_0000100,,
13581,,,,P,,,,Lipophilicity was determined,U,,1,,CHEMBL622141,BAO_0000100,,
13582,,,,P,,,,Lipophilicity in octanol-water,U,,1,,CHEMBL622142,BAO_0000100,,
13583,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL622143,BAO_0000100,,
13584,,,,P,,,,Octanol-water partition coefficient was determined,U,,1,,CHEMBL622144,BAO_0000100,,
13585,,,,A,,,,Partition coefficient (logP),U,,1,,CHEMBL877473,BAO_0000019,,
13586,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL622145,BAO_0000100,,
13587,,,,A,,,,Partition coefficient was determined; ND means not determined,U,,1,,CHEMBL622146,BAO_0000019,,
13588,,,,P,,,,Calculated partition coefficient (clogP),U,,1,,CHEMBL622147,BAO_0000100,,
13589,,,,A,,,,Partition coefficient of the compound,U,,1,,CHEMBL622148,BAO_0000019,,
13590,,,,A,,,,Permeability was determined,U,,1,,CHEMBL883124,BAO_0000019,,
13591,,,,P,,,,The compound was evaluated for the partition coefficient,U,,1,,CHEMBL622149,BAO_0000100,,
13592,,,,A,,,,Partition coefficient (logP),U,,1,,CHEMBL622150,BAO_0000019,,
13593,,,,P,,,,The lipophilicity was reported,U,,1,,CHEMBL622151,BAO_0000100,,
13594,,,,P,,,,logarithm of the octanol-water partition coefficient for the compound,U,,1,,CHEMBL622152,BAO_0000100,,
13595,,,,A,,,,Clogp value was determined,U,,1,,CHEMBL622153,BAO_0000019,,
13596,,In vivo,,A,,,,Clp at a dose of 1.5 mg/kg,U,,1,,CHEMBL877474,BAO_0000218,,
13597,,In vivo,,A,,,,Clp at a dose of 2.0 mg/kg,U,,1,,CHEMBL622154,BAO_0000218,,
13598,,In vivo,Plasma,A,,,,"Clp, plasma clearance at a dose of 10 mg/kg",U,,1,,CHEMBL622155,BAO_0000218,1969.0,
13599,,In vivo,Plasma,A,,,,"Clp, plasma clearance at a dose of 50 mg/kg",U,,1,,CHEMBL622156,BAO_0000218,1969.0,
13600,,In vivo,Plasma,A,,,,Compound was tested for plasma clearance in rat,N,,1,,CHEMBL622157,BAO_0000218,1969.0,
13601,,In vivo,Plasma,A,,,,Compound was tested for plasma clearance in rat; Not determined,N,,1,,CHEMBL622158,BAO_0000218,1969.0,
13602,,In vivo,,A,,,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,N,,1,,CHEMBL622807,BAO_0000218,,
13603,,In vivo,,A,,,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,N,,1,,CHEMBL622808,BAO_0000218,,
13604,,In vivo,,A,,,,Plasma clearance by iv administration at a dose 0.003 ug/mL,U,,1,,CHEMBL622809,BAO_0000218,,
13605,,In vivo,,A,,,,Plasma clearance determined,U,,1,,CHEMBL622810,BAO_0000218,,
13606,,In vivo,,A,,,,Plasma clearance after iv administration at 3 mg/kg in hamster,N,,1,,CHEMBL876653,BAO_0000218,,
13607,,In vivo,,A,,,,Plasma clearance after iv administration at 4 mg/kg in hamster,N,,1,,CHEMBL622811,BAO_0000218,,
13608,,In vivo,,A,,,,Rate of clearance in rat was determined,N,,1,,CHEMBL622986,BAO_0000218,,
13609,,In vivo,Plasma,A,,,,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,N,,1,,CHEMBL622987,BAO_0000218,1969.0,
13610,,In vivo,Plasma,A,,,,Total plasma clearance after iv dose of 5.10 mg/kg in rats,N,,1,,CHEMBL622988,BAO_0000218,1969.0,
13611,,In vivo,Plasma,A,,,,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,N,,1,,CHEMBL622989,BAO_0000218,1969.0,
13612,,In vivo,Plasma,A,,,,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,N,,1,,CHEMBL622990,BAO_0000218,1969.0,
13613,,In vivo,Plasma,A,,,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,U,,1,,CHEMBL622991,BAO_0000218,1969.0,
13614,,In vivo,Plasma,A,,,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,N,,1,,CHEMBL622227,BAO_0000218,1969.0,
13615,,In vivo,Plasma,A,,,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,N,,1,,CHEMBL622228,BAO_0000218,1969.0,
13616,,In vivo,,A,,,,Clpl value in rat,N,,1,,CHEMBL622229,BAO_0000218,,
13617,,In vivo,,A,,,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,N,,1,,CHEMBL622230,BAO_0000218,,
13618,,In vivo,,A,,,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,N,,1,,CHEMBL622231,BAO_0000218,,
13619,,In vivo,,A,,,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,N,,1,,CHEMBL622232,BAO_0000218,,
13620,,In vivo,,A,,,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,U,,1,,CHEMBL622233,BAO_0000218,,
13621,,In vivo,,A,,,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,U,,1,,CHEMBL622234,BAO_0000218,,
13622,,In vivo,,A,,,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,U,,1,,CHEMBL622235,BAO_0000218,,
13623,,In vivo,,A,,,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,U,,1,,CHEMBL622236,BAO_0000218,,
13624,,In vivo,,A,,,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,U,,1,,CHEMBL622237,BAO_0000218,,
13625,,In vivo,,A,,,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,U,,1,,CHEMBL877482,BAO_0000218,,
13626,,In vivo,,A,,,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,U,,1,,CHEMBL622238,BAO_0000218,,
13627,,In vivo,,A,,,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,U,,1,,CHEMBL622239,BAO_0000218,,
13628,,In vivo,Blood,A,,,,Cmax was calculated as maximum concentration reached in the blood,U,,1,,CHEMBL622240,BAO_0000218,178.0,
13629,,In vivo,Blood,A,,,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,U,,1,,CHEMBL622241,BAO_0000218,178.0,
13630,,In vivo,,A,,,,Cmax was determine after peroral administration at 10 mpk in Rat,N,,1,,CHEMBL631013,BAO_0000218,,
13631,,In vivo,,A,,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,N,,1,,CHEMBL631014,BAO_0000218,,
13632,,In vivo,,A,,,,Cmax was determine after peroral administration at 10 mpk in dog,N,,1,,CHEMBL631015,BAO_0000218,,
13633,,In vivo,,A,,,,Cmax was determine after peroral administration at 160 mpk in Rat,N,,1,,CHEMBL631016,BAO_0000218,,
13634,,In vivo,,A,,,,Cmax was determine after peroral administration at 20 mpk in Rat,N,,1,,CHEMBL631017,BAO_0000218,,
13635,,In vivo,,A,,,,Cmax was determine after peroral administration at 50 mpk in Rat,N,,1,,CHEMBL631018,BAO_0000218,,
13636,,In vivo,,A,,,,Cmax was determined,U,,1,,CHEMBL631019,BAO_0000218,,
13637,,,Brain,A,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,N,,1,,CHEMBL875761,BAO_0000218,955.0,
13638,,,Brain,A,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,N,,1,,CHEMBL631020,BAO_0000218,955.0,
13639,,,Brain,A,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,N,,1,,CHEMBL631669,BAO_0000218,955.0,
13640,,,Brain,A,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,N,,1,,CHEMBL631670,BAO_0000218,955.0,
13641,,,Striatum,A,,,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,N,,1,,CHEMBL631671,BAO_0000218,2435.0,
13642,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,N,,1,,CHEMBL631672,BAO_0000218,178.0,
13643,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,N,,1,,CHEMBL631673,BAO_0000218,178.0,
13644,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,N,,1,,CHEMBL631856,BAO_0000218,178.0,
13645,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,N,,1,,CHEMBL631857,BAO_0000218,178.0,
13646,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,N,,1,,CHEMBL631858,BAO_0000218,178.0,
13647,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,N,,1,,CHEMBL631859,BAO_0000218,178.0,
13648,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,N,,1,,CHEMBL631860,BAO_0000218,178.0,
13649,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,N,,1,,CHEMBL631861,BAO_0000218,178.0,
13650,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,N,,1,,CHEMBL631862,BAO_0000218,178.0,
13651,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,N,,1,,CHEMBL631863,BAO_0000218,178.0,
13652,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,N,,1,,CHEMBL631864,BAO_0000218,178.0,
13653,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,N,,1,,CHEMBL631865,BAO_0000218,178.0,
13654,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,N,,1,,CHEMBL631866,BAO_0000218,178.0,
13655,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,N,,1,,CHEMBL629360,BAO_0000218,178.0,
13656,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,N,,1,,CHEMBL629361,BAO_0000218,178.0,
13657,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,N,,1,,CHEMBL629362,BAO_0000218,178.0,
13658,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,N,,1,,CHEMBL630740,BAO_0000218,178.0,
13659,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,N,,1,,CHEMBL630741,BAO_0000218,178.0,
13660,,,Blood,A,,,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,N,,1,,CHEMBL630742,BAO_0000218,178.0,
13661,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,N,,1,,CHEMBL630743,BAO_0000218,,
13662,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,N,,1,,CHEMBL630744,BAO_0000218,,
13663,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,N,,1,,CHEMBL630745,BAO_0000218,,
13664,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,N,,1,,CHEMBL630746,BAO_0000218,,
13665,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,N,,1,,CHEMBL630747,BAO_0000218,,
13666,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,N,,1,,CHEMBL630748,BAO_0000218,,
13667,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,N,,1,,CHEMBL632056,BAO_0000218,,
13668,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,N,,1,,CHEMBL632057,BAO_0000218,,
13669,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,N,,1,,CHEMBL632058,BAO_0000218,,
13670,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,N,,1,,CHEMBL632059,BAO_0000218,,
13671,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,N,,1,,CHEMBL632060,BAO_0000218,,
13672,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,N,,1,,CHEMBL632061,BAO_0000218,,
13673,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,N,,1,,CHEMBL629207,BAO_0000218,,
13674,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,N,,1,,CHEMBL629208,BAO_0000218,,
13675,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,N,,1,,CHEMBL629209,BAO_0000218,,
13676,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,N,,1,,CHEMBL629210,BAO_0000218,,
13677,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,N,,1,,CHEMBL629211,BAO_0000218,,
13678,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,N,,1,,CHEMBL629212,BAO_0000218,,
13679,,,,A,,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,N,,1,,CHEMBL629213,BAO_0000218,,
13680,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",N,,1,,CHEMBL629214,BAO_0000218,1088.0,
13681,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",N,,1,,CHEMBL629215,BAO_0000218,1088.0,
13682,,,Urine,A,,,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",N,,1,,CHEMBL635154,BAO_0000218,1088.0,
13683,,,,A,,,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),N,,1,,CHEMBL629216,BAO_0000218,,
13684,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,N,,1,,CHEMBL629217,BAO_0000218,,
13685,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL629218,BAO_0000218,,
13686,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),N,,1,,CHEMBL629219,BAO_0000218,,
13687,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),N,,1,,CHEMBL629220,BAO_0000218,,
13688,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),N,,1,,CHEMBL629221,BAO_0000218,,
13689,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL631127,BAO_0000218,,
13690,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,N,,1,,CHEMBL631128,BAO_0000218,,
13691,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL631129,BAO_0000218,,
13692,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),N,,1,,CHEMBL631130,BAO_0000218,,
13693,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),N,,1,,CHEMBL631131,BAO_0000218,,
13694,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),N,,1,,CHEMBL631132,BAO_0000218,,
13695,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL631133,BAO_0000218,,
13696,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,N,,1,,CHEMBL631134,BAO_0000218,,
13697,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL875120,BAO_0000218,,
13698,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),N,,1,,CHEMBL631135,BAO_0000218,,
13699,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),N,,1,,CHEMBL631136,BAO_0000218,,
13700,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),N,,1,,CHEMBL631137,BAO_0000218,,
13701,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL631138,BAO_0000218,,
13702,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,N,,1,,CHEMBL631139,BAO_0000218,,
13703,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL631140,BAO_0000218,,
13704,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),N,,1,,CHEMBL631141,BAO_0000218,,
13705,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),N,,1,,CHEMBL631142,BAO_0000218,,
13706,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),N,,1,,CHEMBL631143,BAO_0000218,,
13707,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,,1,,CHEMBL631144,BAO_0000218,,
13708,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,N,,1,,CHEMBL631145,BAO_0000218,,
13709,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),N,,1,,CHEMBL631146,BAO_0000218,,
13710,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,N,,1,,CHEMBL631147,BAO_0000218,,
13711,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL631148,BAO_0000218,,
13712,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL631149,BAO_0000218,,
13713,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),N,,1,,CHEMBL631150,BAO_0000218,,
13714,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL631151,BAO_0000218,,
13715,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL631152,BAO_0000218,,
13716,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL631443,BAO_0000218,,
13717,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),N,,1,,CHEMBL631444,BAO_0000218,,
13718,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),N,,1,,CHEMBL631445,BAO_0000218,,
13719,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),N,,1,,CHEMBL631446,BAO_0000218,,
13720,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),N,,1,,CHEMBL631447,BAO_0000218,,
13721,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),N,,1,,CHEMBL631448,BAO_0000218,,
13722,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,N,,1,,CHEMBL631449,BAO_0000218,,
13723,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),N,,1,,CHEMBL631450,BAO_0000218,,
13724,,,,A,,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),N,,1,,CHEMBL629724,BAO_0000218,,
13725,,In vivo,Zone of skin,A,,,,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,1,,CHEMBL629725,BAO_0000218,14.0,
13726,,In vivo,Zone of skin,A,,,,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,1,,CHEMBL629726,BAO_0000218,14.0,
13727,,In vivo,Spleen,A,,,,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,1,,CHEMBL629727,BAO_0000218,2106.0,
13728,,In vivo,Spleen,A,,,,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,1,,CHEMBL630404,BAO_0000218,2106.0,
13729,,In vivo,Spleen,A,,,,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,1,,CHEMBL630405,BAO_0000218,2106.0,
13730,,In vivo,Spleen,A,,,,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,1,,CHEMBL630406,BAO_0000218,2106.0,
13731,,In vivo,Stomach,A,,,,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,1,,CHEMBL630407,BAO_0000218,945.0,
13732,,In vivo,Stomach,A,,,,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,1,,CHEMBL630573,BAO_0000218,945.0,
13733,,In vivo,Stomach,A,,,,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,1,,CHEMBL630574,BAO_0000218,945.0,
13734,,In vivo,Stomach,A,,,,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,1,,CHEMBL630575,BAO_0000218,945.0,
13735,,In vivo,,A,,,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,1,,CHEMBL630576,BAO_0000218,,
13736,,In vivo,,A,,,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,1,,CHEMBL630577,BAO_0000218,,
13737,,In vivo,,A,,,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,1,,CHEMBL630578,BAO_0000218,,
13738,,In vivo,,A,,,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,1,,CHEMBL630579,BAO_0000218,,
13739,,,Kidney,A,,,,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),N,,1,,CHEMBL630580,BAO_0000218,2113.0,
13740,,,Kidney,A,,,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,N,,1,,CHEMBL630581,BAO_0000218,2113.0,
13741,,,Kidney,A,,,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),N,,1,,CHEMBL630582,BAO_0000218,2113.0,
13742,,,,A,,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,N,,1,,CHEMBL630583,BAO_0000218,,
13743,,,,A,,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),N,,1,,CHEMBL630584,BAO_0000218,,
13744,,,,A,,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,N,,1,,CHEMBL630585,BAO_0000218,,
13745,,,,A,,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),N,,1,,CHEMBL630586,BAO_0000218,,
13746,,,,A,,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,N,,1,,CHEMBL630587,BAO_0000218,,
13747,,,,A,,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),N,,1,,CHEMBL630588,BAO_0000218,,
13748,,,,A,,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,N,,1,,CHEMBL630589,BAO_0000218,,
13749,,,,A,,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),N,,1,,CHEMBL630590,BAO_0000218,,
13750,,,Feces,A,,,,Removal of 238-Plutonium(IV) in feces at 24 h,U,,1,,CHEMBL630591,BAO_0000019,1988.0,
13751,,,Feces,A,,,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),U,,1,,CHEMBL630592,BAO_0000019,1988.0,
13752,,,,A,,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,U,,1,,CHEMBL630593,BAO_0000019,,
13753,,,,A,,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),U,,1,,CHEMBL630594,BAO_0000019,,
13754,,,Urine,A,,,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),U,,1,,CHEMBL630595,BAO_0000019,1088.0,
13755,,,Urine,A,,,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),U,,1,,CHEMBL630596,BAO_0000019,1088.0,
13756,,,Urine,A,,,,Removal of 238-Plutonium(IV) in urine after 0-24 h,U,,1,,CHEMBL630597,BAO_0000019,1088.0,
13757,,,Urine,A,,,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),U,,1,,CHEMBL630598,BAO_0000019,1088.0,
13758,,,Urine,A,,,,Removal of 238-Plutonium(IV) in urine after 0-4 h,U,,1,,CHEMBL630599,BAO_0000019,1088.0,
13759,,,Urine,A,,,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),U,,1,,CHEMBL630600,BAO_0000019,1088.0,
13760,,,Urine,A,,,,Removal of 238-Plutonium(IV) in urine after 4-24 h,U,,1,,CHEMBL630601,BAO_0000019,1088.0,
13761,,,Urine,A,,,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),U,,1,,CHEMBL630602,BAO_0000019,1088.0,
13762,,,Urine,A,,,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),U,,1,,CHEMBL630603,BAO_0000019,1088.0,
13763,,,Urine,A,,,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),U,,1,,CHEMBL630604,BAO_0000019,1088.0,
13764,,In vivo,Blood,A,,,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL624869,BAO_0000218,178.0,
13765,,In vivo,Blood,A,,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL624870,BAO_0000218,178.0,
13766,,In vivo,Blood,A,,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL623189,BAO_0000218,178.0,
13767,,In vivo,Blood,A,,,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL623190,BAO_0000218,178.0,
13768,,In vivo,Blood,A,,,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL623191,BAO_0000218,178.0,
13769,,In vivo,,A,,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL623192,BAO_0000218,,
13770,,In vivo,,A,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL623193,BAO_0000218,,
13771,,In vivo,,A,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL623194,BAO_0000218,,
13772,,In vivo,,A,,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL623195,BAO_0000218,,
13773,,In vivo,,A,,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL623196,BAO_0000218,,
13774,,,,A,,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,N,,1,,CHEMBL623197,BAO_0000218,,
13775,,,,A,,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,N,,1,,CHEMBL623198,BAO_0000218,,
13776,,,,A,,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,N,,1,,CHEMBL623199,BAO_0000218,,
13777,,,Muscle tissue,A,,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,N,,1,,CHEMBL623200,BAO_0000218,2385.0,
13778,,,Muscle tissue,A,,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,N,,1,,CHEMBL623201,BAO_0000218,2385.0,
13779,,,Muscle tissue,A,,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,N,,1,,CHEMBL623202,BAO_0000218,2385.0,
13780,,,Muscle tissue,A,,,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,N,,1,,CHEMBL623203,BAO_0000218,2385.0,
13781,,,Muscle tissue,A,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,N,,1,,CHEMBL623204,BAO_0000218,2385.0,
13782,,,Muscle tissue,A,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,N,,1,,CHEMBL623205,BAO_0000218,2385.0,
13783,,,Muscle tissue,A,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,N,,1,,CHEMBL623206,BAO_0000218,2385.0,
13784,,,Muscle tissue,A,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,N,,1,,CHEMBL623207,BAO_0000218,2385.0,
13785,,,Muscle tissue,A,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,N,,1,,CHEMBL623208,BAO_0000218,2385.0,
13786,,,Muscle tissue,A,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,N,,1,,CHEMBL623209,BAO_0000218,2385.0,
13787,,,Muscle tissue,A,,,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,N,,1,,CHEMBL623210,BAO_0000218,2385.0,
13788,,,,A,,,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,N,,1,,CHEMBL623211,BAO_0000218,,
13789,,,Uterus,A,,,,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,N,,1,,CHEMBL623212,BAO_0000218,995.0,
13790,,,,A,,,,Tested in vitro for intrinsic activity relative to quinpirole,U,,1,,CHEMBL623213,BAO_0000019,,
13791,,,,A,,,,"Relative ion enhancement, determined in pulsed ultrafiltration",U,,1,,CHEMBL623214,BAO_0000019,,
13792,,,,A,,,,% ionization at the pH 7.4 at 37 degree Centigrade,U,,1,,CHEMBL623215,BAO_0000019,,
13793,,,,A,,,,Percentage ionization was measured,U,,1,,CHEMBL623216,BAO_0000019,,
13794,,,,A,,,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,N,,1,,CHEMBL623217,BAO_0000218,,
13795,,,,A,,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,U,,1,,CHEMBL623218,BAO_0000019,,
13796,,,,A,,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,U,,1,,CHEMBL623913,BAO_0000019,,
13797,,,,A,,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,U,,1,,CHEMBL623914,BAO_0000019,,
13798,,,,P,,,,Compound was evaluated for the partition coefficient in octanol/water,U,,1,,CHEMBL623915,BAO_0000100,,
13799,,,,P,,,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),U,,1,,CHEMBL624080,BAO_0000100,,
13800,,,,A,,,,Equilibrium constant measured by the pulse radiolysis at pH 7,U,,1,,CHEMBL624081,BAO_0000019,,
13801,,,,A,,,,In vitro hydrolytic rate constant determined in human blood,N,,1,,CHEMBL624082,BAO_0000218,,
13802,,,,A,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,N,,1,,CHEMBL625054,BAO_0000218,,
13803,,,,A,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,U,,1,,CHEMBL877485,BAO_0000019,,
13804,,,,A,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,N,,1,,CHEMBL625055,BAO_0000218,,
13805,,,,A,,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,N,,1,,CHEMBL625056,BAO_0000218,,
13806,,,,A,,,,In vitro oxidation of compound in presence of human plasma,N,,1,,CHEMBL625057,BAO_0000218,,
13807,,,,A,,,,In vitro oxidation of compound in presence of hydrogen peroxide,U,,1,,CHEMBL625058,BAO_0000019,,
13808,,,,A,,,,In vitro oxidation of compound in presence of mouse brain homogenate,N,,1,,CHEMBL625059,BAO_0000218,,
13809,,,,A,,,,In vitro oxidation of compound in presence of mouse liver homogenate,N,,1,,CHEMBL629536,BAO_0000218,,
13810,,,,A,,,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,N,,1,,CHEMBL629537,BAO_0000218,,
13811,,,,A,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,N,,1,,CHEMBL629538,BAO_0000218,,
13812,,,,A,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,N,,1,,CHEMBL629539,BAO_0000218,,
13813,,,,A,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,N,,1,,CHEMBL874445,BAO_0000218,,
13814,,,,A,,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,N,,1,,CHEMBL629540,BAO_0000218,,
13815,,,,A,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,N,,1,,CHEMBL629541,BAO_0000218,,
13816,,,,A,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,N,,1,,CHEMBL629542,BAO_0000218,,
13817,,,,A,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,N,,1,,CHEMBL630243,BAO_0000218,,
13818,,,,A,,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,N,,1,,CHEMBL630244,BAO_0000218,,
13819,,,,A,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,N,,1,,CHEMBL630245,BAO_0000218,,
13820,,,,A,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,N,,1,,CHEMBL630246,BAO_0000218,,
13821,,,,A,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,N,,1,,CHEMBL630247,BAO_0000218,,
13822,,,,A,,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,N,,1,,CHEMBL630248,BAO_0000218,,
13823,,In vivo,Blood,A,,,,Biodistribution in rat blood at 240 minutes after dose administration.,N,,1,,CHEMBL630249,BAO_0000218,178.0,
13824,,In vivo,Blood,A,,,,Biodistribution in rat blood at 30 minutes after dose administration.,N,,1,,CHEMBL630250,BAO_0000218,178.0,
13825,,In vivo,Blood,A,,,,Biodistribution in rat blood at 360 minutes after dose administration.,N,,1,,CHEMBL630251,BAO_0000218,178.0,
13826,,In vivo,Blood,A,,,,Biodistribution in rat blood at 3 hr after dose administration.,N,,1,,CHEMBL630252,BAO_0000218,178.0,
13827,,In vivo,Blood,A,,,,Biodistribution in rat blood at 60 minutes after dose administration.,N,,1,,CHEMBL630408,BAO_0000218,178.0,
13828,,In vivo,Cerebellum,A,,,,Biodistribution in rat cerebellum at 120 minutes after dose administration.,N,,1,,CHEMBL630409,BAO_0000218,2037.0,
13829,,In vivo,Cerebellum,A,,,,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,N,,1,,CHEMBL874446,BAO_0000218,2037.0,
13830,,In vivo,Cerebellum,A,,,,Biodistribution in rat cerebellum at 15 minutes after dose administration.,N,,1,,CHEMBL630410,BAO_0000218,2037.0,
13831,,In vivo,Cerebellum,A,,,,Biodistribution in rat cerebellum at 240 minutes after dose administration.,N,,1,,CHEMBL630411,BAO_0000218,2037.0,
13832,,In vivo,Cerebellum,A,,,,Biodistribution in rat cerebellum at 30 minutes after dose administration.,N,,1,,CHEMBL630412,BAO_0000218,2037.0,
13833,,In vivo,Cerebellum,A,,,,Biodistribution in rat cerebellum at 360 minutes after dose administration.,N,,1,,CHEMBL630413,BAO_0000218,2037.0,
13834,,In vivo,Cerebellum,A,,,,Biodistribution in rat cerebellum at 3 hr after dose administration.,N,,1,,CHEMBL630414,BAO_0000218,2037.0,
13835,,In vivo,Cerebellum,A,,,,Biodistribution in rat cerebellum at 60 minutes after dose administration.,N,,1,,CHEMBL630415,BAO_0000218,2037.0,
13836,,In vivo,,A,,,,Biodistribution in rat cortex at 120 minutes after dose administration.,N,,1,,CHEMBL630416,BAO_0000218,,
13837,,In vivo,,A,,,,Biodistribution in rat cortex at 1440 minutes after dose administration.,N,,1,,CHEMBL630417,BAO_0000218,,
13838,,In vivo,,A,,,,Biodistribution in rat cortex at 15 minutes after dose administration.,N,,1,,CHEMBL630418,BAO_0000218,,
13839,,In vivo,,A,,,,Biodistribution in rat cortex at 240 minutes after dose administration.,N,,1,,CHEMBL630419,BAO_0000218,,
13840,,In vivo,,A,,,,Biodistribution in rat cortex at 30 minutes after dose administration.,N,,1,,CHEMBL630420,BAO_0000218,,
13841,,In vivo,,A,,,,Biodistribution in rat cortex at 360 minutes after dose administration.,N,,1,,CHEMBL630421,BAO_0000218,,
13842,,In vivo,,A,,,,Biodistribution in rat cortex at 3 hr after dose administration.,N,,1,,CHEMBL630422,BAO_0000218,,
13843,,In vivo,,A,,,,Biodistribution in rat cortex at 60 minutes after dose administration.,N,,1,,CHEMBL630423,BAO_0000218,,
13844,,In vivo,Heart,A,,,,Biodistribution in rat heart at 120 minutes after dose administration.,N,,1,,CHEMBL630424,BAO_0000218,948.0,
13845,,In vivo,Heart,A,,,,Biodistribution in rat heart at 15 minutes after dose administration.,N,,1,,CHEMBL630425,BAO_0000218,948.0,
13846,,In vivo,Heart,A,,,,Biodistribution in rat heart at 240 minutes after dose administration.,N,,1,,CHEMBL629462,BAO_0000218,948.0,
13847,,In vivo,Heart,A,,,,Biodistribution in rat heart at 30 minutes after dose administration.,N,,1,,CHEMBL630426,BAO_0000218,948.0,
13848,,In vivo,Heart,A,,,,Biodistribution in rat heart at 360 minutes after dose administration.,N,,1,,CHEMBL630427,BAO_0000218,948.0,
13849,,In vivo,Heart,A,,,,Biodistribution in rat heart at 3 hr after dose administration.,N,,1,,CHEMBL625877,BAO_0000218,948.0,
13850,,In vivo,Heart,A,,,,Biodistribution in rat heart at 60 minutes after dose administration.,N,,1,,CHEMBL625878,BAO_0000218,948.0,
13851,,In vivo,Hippocampus,A,,,,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,N,,1,,CHEMBL625879,BAO_0000218,10000000.0,
13852,,In vivo,Hippocampus,A,,,,Biodistribution in rat hippocampus at 240 minutes after dose administration.,N,,1,,CHEMBL625880,BAO_0000218,10000000.0,
13853,,In vivo,Hippocampus,A,,,,Biodistribution in rat hippocampus at 30 minutes after dose administration.,N,,1,,CHEMBL625881,BAO_0000218,10000000.0,
13854,,In vivo,Hippocampus,A,,,,Biodistribution in rat hippocampus at 360 minutes after dose administration.,N,,1,,CHEMBL625882,BAO_0000218,10000000.0,
13855,,In vivo,Hippocampus,A,,,,Biodistribution in rat hippocampus at 15 minutes after dose administration.,N,,1,,CHEMBL625883,BAO_0000218,10000000.0,
13856,,In vivo,Kidney,A,,,,Biodistribution in rat kidney at 120 minutes after dose administration.,N,,1,,CHEMBL625884,BAO_0000218,2113.0,
13857,,In vivo,Kidney,A,,,,Biodistribution in rat kidney at 1440 minutes after dose administration.,N,,1,,CHEMBL625885,BAO_0000218,2113.0,
13858,,In vivo,Kidney,A,,,,Biodistribution in rat kidney at 15 minutes after dose administration.,N,,1,,CHEMBL628649,BAO_0000218,2113.0,
13859,,In vivo,Kidney,A,,,,Biodistribution in rat kidney at 240 minutes after dose administration.,N,,1,,CHEMBL628650,BAO_0000218,2113.0,
13860,,In vivo,Kidney,A,,,,Biodistribution in rat kidney at 30 minutes after dose administration.,N,,1,,CHEMBL628651,BAO_0000218,2113.0,
13861,,In vivo,Kidney,A,,,,Biodistribution in rat kidney at 360 minutes after dose administration.,N,,1,,CHEMBL628652,BAO_0000218,2113.0,
13862,,In vivo,Kidney,A,,,,Biodistribution in rat kidney at 60 minutes after dose administration.,N,,1,,CHEMBL628653,BAO_0000218,2113.0,
13863,,In vivo,Liver,A,,,,Biodistribution in rat liver at 120 minutes after dose administration.,N,,1,,CHEMBL628654,BAO_0000218,2107.0,
13864,,In vivo,Liver,A,,,,Biodistribution in rat liver at 1440 minutes after dose administration.,N,,1,,CHEMBL628655,BAO_0000218,2107.0,
13865,,In vivo,Liver,A,,,,Biodistribution in rat liver at 15 minutes after dose administration.,N,,1,,CHEMBL625238,BAO_0000218,2107.0,
13866,,In vivo,Liver,A,,,,Biodistribution in rat liver at 240 minutes after dose administration.,N,,1,,CHEMBL625239,BAO_0000218,2107.0,
13867,,In vivo,Liver,A,,,,Biodistribution in rat liver at 30 minutes after dose administration.,N,,1,,CHEMBL625240,BAO_0000218,2107.0,
13868,,In vivo,Liver,A,,,,Biodistribution in rat liver at 360 minutes after dose administration.,N,,1,,CHEMBL625241,BAO_0000218,2107.0,
13869,,In vivo,Liver,A,,,,Biodistribution in rat liver at 60 minutes after dose administration.,N,,1,,CHEMBL625242,BAO_0000218,2107.0,
13870,,In vivo,Lung,A,,,,Biodistribution in rat lung at 120 minutes after dose administration.,N,,1,,CHEMBL874587,BAO_0000218,2048.0,
13871,,In vivo,Lung,A,,,,Biodistribution in rat lung at 1440 minutes after dose administration.,N,,1,,CHEMBL625405,BAO_0000218,2048.0,
13872,,In vivo,Lung,A,,,,Biodistribution in rat lung at 15 minutes after dose administration.,N,,1,,CHEMBL625406,BAO_0000218,2048.0,
13873,,In vivo,Lung,A,,,,Biodistribution in rat lung at 240 minutes after dose administration.,N,,1,,CHEMBL625407,BAO_0000218,2048.0,
13874,,In vivo,Lung,A,,,,Biodistribution in rat lung at 30 minutes after dose administration.,N,,1,,CHEMBL625408,BAO_0000218,2048.0,
13875,,In vivo,Lung,A,,,,Biodistribution in rat lung at 360 minutes after dose administration.,N,,1,,CHEMBL625409,BAO_0000218,2048.0,
13876,,,Thoracic aorta,A,,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,N,,1,,CHEMBL625410,BAO_0000218,1515.0,
13877,,,Thoracic aorta,A,,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,N,,1,,CHEMBL625411,BAO_0000218,1515.0,
13878,,,Thoracic aorta,A,,,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,N,,1,,CHEMBL625412,BAO_0000218,1515.0,
13879,,,Thoracic aorta,A,,,,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,N,,1,,CHEMBL625413,BAO_0000218,1515.0,
13880,,,Thoracic aorta,A,,,,Percent of maximal contractile response to compound in rat thoracic aorta strips v,N,,1,,CHEMBL625414,BAO_0000218,1515.0,
13881,,,Thoracic aorta,A,,,,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,N,,1,,CHEMBL625415,BAO_0000218,1515.0,
13882,,,Thoracic aorta,A,,,,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,N,,1,,CHEMBL625416,BAO_0000218,1515.0,
13883,,,Urine,A,,,,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,N,,1,,CHEMBL625417,BAO_0000218,1088.0,
13884,,,Feces,A,,,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,N,,1,,CHEMBL625418,BAO_0000218,1988.0,
13885,,,Urine,A,,,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,N,,1,,CHEMBL625419,BAO_0000218,1088.0,
13886,,,,A,,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,N,,1,,CHEMBL625420,BAO_0000218,,
13887,,,,A,,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,N,,1,,CHEMBL626996,BAO_0000218,,
13888,,,Feces,A,,,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",N,,1,,CHEMBL626997,BAO_0000218,1988.0,
13889,,,Urine,A,,,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",N,,1,,CHEMBL626998,BAO_0000218,1088.0,
13890,,,,A,,,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",N,,1,,CHEMBL626999,BAO_0000218,,
13891,,,,A,,,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,N,,1,,CHEMBL627000,BAO_0000218,,
13892,,,,A,,,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,N,,1,,CHEMBL627001,BAO_0000218,,
13893,,,,A,,,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,N,,1,,CHEMBL627002,BAO_0000218,,
13894,,,,A,,,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,N,,1,,CHEMBL627003,BAO_0000218,,
13895,,,Urine,A,,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,N,,1,,CHEMBL627004,BAO_0000218,1088.0,
13896,,,Urine,A,,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,N,,1,,CHEMBL627005,BAO_0000218,1088.0,
13897,,,Urine,A,,,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,N,,1,,CHEMBL874594,BAO_0000218,1088.0,
13898,,,Urine,A,,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,N,,1,,CHEMBL627006,BAO_0000218,1088.0,
13899,,,Urine,A,,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,N,,1,,CHEMBL627007,BAO_0000218,1088.0,
13900,,,Urine,A,,,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,N,,1,,CHEMBL627884,BAO_0000218,1088.0,
13901,,,Urine,A,,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,N,,1,,CHEMBL627885,BAO_0000218,1088.0,
13902,,,Urine,A,,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,N,,1,,CHEMBL627886,BAO_0000218,1088.0,
13903,,,Urine,A,,,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,N,,1,,CHEMBL627887,BAO_0000218,1088.0,
13904,,,Urine,A,,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,N,,1,,CHEMBL627888,BAO_0000218,1088.0,
13905,,,Urine,A,,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,N,,1,,CHEMBL628057,BAO_0000218,1088.0,
13906,,,Urine,A,,,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,N,,1,,CHEMBL627405,BAO_0000218,1088.0,
13907,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,N,,1,,CHEMBL627406,BAO_0000218,1088.0,
13908,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,N,,1,,CHEMBL627407,BAO_0000218,1088.0,
13909,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,N,,1,,CHEMBL627408,BAO_0000218,1088.0,
13910,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,N,,1,,CHEMBL627409,BAO_0000218,1088.0,
13911,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,N,,1,,CHEMBL875486,BAO_0000218,1088.0,
13912,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,N,,1,,CHEMBL627410,BAO_0000218,1088.0,
13913,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,N,,1,,CHEMBL627411,BAO_0000218,1088.0,
13914,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,N,,1,,CHEMBL627412,BAO_0000218,1088.0,
13915,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,N,,1,,CHEMBL627413,BAO_0000218,1088.0,
13916,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,N,,1,,CHEMBL627414,BAO_0000218,1088.0,
13917,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,N,,1,,CHEMBL627415,BAO_0000218,1088.0,
13918,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,N,,1,,CHEMBL627416,BAO_0000218,1088.0,
13919,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,N,,1,,CHEMBL627417,BAO_0000218,1088.0,
13920,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,N,,1,,CHEMBL627418,BAO_0000218,1088.0,
13921,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,N,,1,,CHEMBL627419,BAO_0000218,1088.0,
13922,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,N,,1,,CHEMBL627320,BAO_0000218,1088.0,
13923,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,N,,1,,CHEMBL627321,BAO_0000218,1088.0,
13924,,In vivo,Kidney,A,,,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL627322,BAO_0000218,2113.0,
13925,,In vivo,Kidney,A,,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL627323,BAO_0000218,2113.0,
13926,,In vivo,Kidney,A,,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL627491,BAO_0000218,2113.0,
13927,,In vivo,Kidney,A,,,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL627492,BAO_0000218,2113.0,
13928,,In vivo,Kidney,A,,,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL627493,BAO_0000218,2113.0,
13929,,In vivo,Liver,A,,,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL627494,BAO_0000218,2107.0,
13930,,In vivo,Liver,A,,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL627495,BAO_0000218,2107.0,
13931,,In vivo,Liver,A,,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL627496,BAO_0000218,2107.0,
13932,,In vivo,Liver,A,,,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL627497,BAO_0000218,2107.0,
13933,,In vivo,Liver,A,,,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL627498,BAO_0000218,2107.0,
13934,,In vivo,Lung,A,,,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL627499,BAO_0000218,2048.0,
13935,,In vivo,Lung,A,,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL627500,BAO_0000218,2048.0,
13936,,In vivo,Lung,A,,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL627501,BAO_0000218,2048.0,
13937,,In vivo,Lung,A,,,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL625616,BAO_0000218,2048.0,
13938,,In vivo,Lung,A,,,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL625617,BAO_0000218,2048.0,
13939,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL625618,BAO_0000218,2385.0,
13940,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL625619,BAO_0000218,2385.0,
13941,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL625620,BAO_0000218,2385.0,
13942,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL625621,BAO_0000218,2385.0,
13943,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL625622,BAO_0000218,2385.0,
13944,,In vivo,Spleen,A,,,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL625788,BAO_0000218,2106.0,
13945,,In vivo,Spleen,A,,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL625789,BAO_0000218,2106.0,
13946,,In vivo,Spleen,A,,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL625790,BAO_0000218,2106.0,
13947,,In vivo,Spleen,A,,,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL625791,BAO_0000218,2106.0,
13948,,In vivo,Spleen,A,,,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL622334,BAO_0000218,2106.0,
13949,,In vivo,Thyroid gland,A,,,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL622335,BAO_0000218,2046.0,
13950,,In vivo,Thyroid gland,A,,,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL622336,BAO_0000218,2046.0,
13951,,In vivo,Thyroid gland,A,,,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL622337,BAO_0000218,2046.0,
13952,,In vivo,Thyroid gland,A,,,,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL622338,BAO_0000218,2046.0,
13953,,In vivo,Thyroid gland,A,,,,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL622339,BAO_0000218,2046.0,
13954,,In vivo,,A,,,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL624153,BAO_0000218,,
13955,,In vivo,,A,,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL628430,BAO_0000218,,
13956,,In vivo,,A,,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL628431,BAO_0000218,,
13957,,In vivo,,A,,,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL628432,BAO_0000218,,
13958,,In vivo,,A,,,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL628433,BAO_0000218,,
13959,,In vivo,Spleen,A,,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,,1,,CHEMBL628434,BAO_0000218,2106.0,
13960,,In vivo,Spleen,A,,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,,1,,CHEMBL626789,BAO_0000218,2106.0,
13961,,In vivo,Spleen,A,,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",N,,1,,CHEMBL626790,BAO_0000218,2106.0,
13962,,In vivo,Spleen,A,,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,,1,,CHEMBL626791,BAO_0000218,2106.0,
13963,,In vivo,Spleen,A,,,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,,1,,CHEMBL626792,BAO_0000218,2106.0,
13964,,In vivo,Spleen,A,,,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,,1,,CHEMBL626793,BAO_0000218,2106.0,
13965,,,,A,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,N,,1,,CHEMBL627436,BAO_0000218,,
13966,,,,A,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,N,,1,,CHEMBL627437,BAO_0000218,,
13967,,,,A,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,N,,1,,CHEMBL627438,BAO_0000218,,
13968,,,,A,,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,N,,1,,CHEMBL627439,BAO_0000218,,
13969,,,,A,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,N,,1,,CHEMBL627440,BAO_0000218,,
13970,,,,A,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,N,,1,,CHEMBL627602,BAO_0000218,,
13971,,,,A,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,N,,1,,CHEMBL627603,BAO_0000218,,
13972,,,,A,,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,N,,1,,CHEMBL627604,BAO_0000218,,
13973,,,,A,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,N,,1,,CHEMBL627605,BAO_0000218,,
13974,,,,A,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,N,,1,,CHEMBL627606,BAO_0000218,,
13975,,,,A,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,N,,1,,CHEMBL627607,BAO_0000218,,
13976,,,,A,,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,N,,1,,CHEMBL627608,BAO_0000218,,
13977,,,,A,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,N,,1,,CHEMBL627609,BAO_0000218,,
13978,,,,A,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,N,,1,,CHEMBL627610,BAO_0000218,,
13979,,,,A,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,N,,1,,CHEMBL627611,BAO_0000218,,
13980,,,,A,,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,N,,1,,CHEMBL627612,BAO_0000218,,
13981,,,,P,,,,Octanol:water partition coefficient is evaluated,U,,1,,CHEMBL627613,BAO_0000100,,
13982,,,,P,,,,Partition coefficient in 1-octanol/water system,U,,1,,CHEMBL627614,BAO_0000100,,
13983,,,,P,,,,Partition coefficient in 1-octanol/water system measured using radio active compounds,U,,1,,CHEMBL627615,BAO_0000100,,
13984,,,,P,,,,Partition coefficient in octanol/water system was determined,U,,1,,CHEMBL627616,BAO_0000100,,
13985,,,,P,,,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,U,,1,,CHEMBL627617,BAO_0000100,,
13986,,,,A,,,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,U,,1,,CHEMBL627618,BAO_0000019,,
13987,,,,A,,,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",U,,1,,CHEMBL627619,BAO_0000019,,
13988,,,,A,,,,Pseudo-first-order rate constant of the compound,U,,1,,CHEMBL627620,BAO_0000019,,
13989,,,,A,,,,Pseudo-first-order rate constant with 1-min time point,U,,1,,CHEMBL627621,BAO_0000019,,
13990,,,,A,,,,Pseudo-first-order rate constant without 1-min time point,U,,1,,CHEMBL627622,BAO_0000019,,
13991,,,,A,,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,U,,1,,CHEMBL627623,BAO_0000019,,
13992,,,,A,,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,U,,1,,CHEMBL627624,BAO_0000019,,
13993,,,,A,,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,U,,1,,CHEMBL627625,BAO_0000019,,
13994,,,,A,,,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,U,,1,,CHEMBL628523,BAO_0000019,,
13995,,,,A,,,,The alkaline hydrolysis second order rate constant(K OH) of the compound,U,,1,,CHEMBL628524,BAO_0000019,,
13996,,,,A,,,,The efflux rate constant of the compound,U,,1,,CHEMBL628525,BAO_0000019,,
13997,,,,A,,,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,U,,1,,CHEMBL625732,BAO_0000019,,
13998,,,,A,,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,U,,1,,CHEMBL625733,BAO_0000019,,
13999,,,,F,,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,U,,1,,CHEMBL625734,BAO_0000019,,
14000,,,,A,,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,U,,1,,CHEMBL625913,BAO_0000019,,
14001,,,,A,,,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,U,,1,,CHEMBL625914,BAO_0000019,,
14002,,,,A,,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,U,,1,,CHEMBL625915,BAO_0000019,,
14003,,,,A,,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,U,,1,,CHEMBL625916,BAO_0000019,,
14004,,,,A,,,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),U,,1,,CHEMBL625917,BAO_0000019,,
14005,,,,A,,,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL625918,BAO_0000019,,
14006,,,,A,,,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL625919,BAO_0000019,,
14007,,,,A,,,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL625920,BAO_0000019,,
14008,,,,A,,,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL874453,BAO_0000019,,
14009,,,,A,,,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL625921,BAO_0000019,,
14010,,,,A,,,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,U,,1,,CHEMBL625922,BAO_0000019,,
14011,,,,A,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL625923,BAO_0000019,,
14012,,,,A,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL625924,BAO_0000019,,
14013,,,,A,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL625925,BAO_0000019,,
14014,,,,A,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL625926,BAO_0000019,,
14015,,In vivo,Lung,A,,,,Biodistribution in rat lung at 60 minutes after dose administration.,N,,1,,CHEMBL627704,BAO_0000218,2048.0,
14016,,In vivo,,A,,,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,N,,1,,CHEMBL627705,BAO_0000218,,
14017,,In vivo,,A,,,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,N,,1,,CHEMBL627706,BAO_0000218,,
14018,,In vivo,,A,,,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,N,,1,,CHEMBL627707,BAO_0000218,,
14019,,In vivo,,A,,,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,N,,1,,CHEMBL627708,BAO_0000218,,
14020,,In vivo,,A,,,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,N,,1,,CHEMBL628361,BAO_0000218,,
14021,,In vivo,,A,,,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,N,,1,,CHEMBL628362,BAO_0000218,,
14022,,In vivo,Striatum,A,,,,Biodistribution in rat striatum at 120 minutes after dose administration.,N,,1,,CHEMBL628363,BAO_0000218,2435.0,
14023,,In vivo,Striatum,A,,,,Biodistribution in rat striatum at 1440 minutes after dose administration.,N,,1,,CHEMBL628364,BAO_0000218,2435.0,
14024,,In vivo,Striatum,A,,,,Biodistribution in rat striatum at 15 minutes after dose administration.,N,,1,,CHEMBL628365,BAO_0000218,2435.0,
14025,,In vivo,Striatum,A,,,,Biodistribution in rat striatum at 240 minutes after dose administration.,N,,1,,CHEMBL874454,BAO_0000218,2435.0,
14026,,In vivo,Striatum,A,,,,Biodistribution in rat striatum at 30 minutes after dose administration.,N,,1,,CHEMBL628531,BAO_0000218,2435.0,
14027,,In vivo,Striatum,A,,,,Biodistribution in rat striatum at 360 minutes after dose administration.,N,,1,,CHEMBL628532,BAO_0000218,2435.0,
14028,,In vivo,Striatum,A,,,,Biodistribution in rat striatum at 3 hr after dose administration.,N,,1,,CHEMBL628533,BAO_0000218,2435.0,
14029,,In vivo,Striatum,A,,,,Biodistribution in rat striatum at 60 minutes after dose administration.,N,,1,,CHEMBL628534,BAO_0000218,2435.0,
14030,,In vivo,Thyroid gland,A,,,,Biodistribution in rat thyroid at 120 minutes after dose administration.,N,,1,,CHEMBL628535,BAO_0000218,2046.0,
14031,,In vivo,Thyroid gland,A,,,,Biodistribution in rat thyroid at 1440 minutes after dose administration.,N,,1,,CHEMBL628536,BAO_0000218,2046.0,
14032,,In vivo,Thyroid gland,A,,,,Biodistribution in rat thyroid at 15 minutes after dose administration.,N,,1,,CHEMBL628537,BAO_0000218,2046.0,
14033,,In vivo,Thyroid gland,A,,,,Biodistribution in rat thyroid at 240 minutes after dose administration.,N,,1,,CHEMBL628538,BAO_0000218,2046.0,
14034,,In vivo,Thyroid gland,A,,,,Biodistribution in rat thyroid at 30 minutes after dose administration.,N,,1,,CHEMBL628539,BAO_0000218,2046.0,
14035,,In vivo,Thyroid gland,A,,,,Biodistribution in rat thyroid at 360 minutes after dose administration.,N,,1,,CHEMBL630297,BAO_0000218,2046.0,
14036,,In vivo,Thyroid gland,A,,,,Biodistribution in rat thyroid at 60 minutes after dose administration.,N,,1,,CHEMBL630298,BAO_0000218,2046.0,
14037,,In vivo,Brain,A,,,,Biodistribution in rest of brain of rat 120 minutes after dose administration.,N,,1,,CHEMBL630299,BAO_0000218,955.0,
14038,,In vivo,Brain,A,,,,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,N,,1,,CHEMBL628094,BAO_0000218,955.0,
14039,,In vivo,Brain,A,,,,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,N,,1,,CHEMBL628095,BAO_0000218,955.0,
14040,,In vivo,Brain,A,,,,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,N,,1,,CHEMBL874648,BAO_0000218,955.0,
14041,,In vivo,Brain,A,,,,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,N,,1,,CHEMBL628096,BAO_0000218,955.0,
14042,,In vivo,Brain,A,,,,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,N,,1,,CHEMBL628097,BAO_0000218,955.0,
14043,,In vivo,Brain,A,,,,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,N,,1,,CHEMBL628098,BAO_0000218,955.0,
14044,,,,A,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",U,,1,,CHEMBL628099,BAO_0000019,,
14045,,,,A,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",U,,1,,CHEMBL628100,BAO_0000019,,
14046,,,,A,,,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),U,,1,,CHEMBL628101,BAO_0000019,,
14047,,,,A,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",U,,1,,CHEMBL628102,BAO_0000019,,
14048,,,,A,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",U,,1,,CHEMBL628103,BAO_0000019,,
14049,,,,A,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",U,,1,,CHEMBL628104,BAO_0000019,,
14050,,,,A,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",U,,1,,CHEMBL628105,BAO_0000019,,
14051,,,,A,,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",U,,1,,CHEMBL628106,BAO_0000019,,
14052,,,Urine,A,,,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,N,,1,,CHEMBL628107,BAO_0000218,1088.0,
14053,,,Urine,F,,,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,U,,1,,CHEMBL628108,BAO_0000218,1088.0,
14054,,,Urine,A,,,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,N,,1,,CHEMBL628109,BAO_0000218,1088.0,
14055,,,Urine,F,,,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,U,,1,,CHEMBL625299,BAO_0000218,1088.0,
14056,,,Urine,A,,,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,N,,1,,CHEMBL625300,BAO_0000218,1088.0,
14057,,,Urine,A,,,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,N,,1,,CHEMBL625301,BAO_0000218,1088.0,
14058,,,Urine,A,,,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,N,,1,,CHEMBL625302,BAO_0000218,1088.0,
14059,,,Urine,A,,,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,N,,1,,CHEMBL874649,BAO_0000218,1088.0,
14060,,,,A,,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,N,,1,,CHEMBL625303,BAO_0000218,,
14061,,,,A,,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,N,,1,,CHEMBL625463,BAO_0000218,,
14062,,,Liver,A,,,,In vitro metabolism in human liver microsomes,N,,1,,CHEMBL625464,BAO_0000218,2107.0,
14063,,,,A,,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,N,,1,,CHEMBL625465,BAO_0000218,,
14064,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,N,,1,,CHEMBL625466,BAO_0000218,1088.0,
14065,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,N,,1,,CHEMBL625467,BAO_0000218,1088.0,
14066,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,N,,1,,CHEMBL625468,BAO_0000218,1088.0,
14067,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,N,,1,,CHEMBL625469,BAO_0000218,1088.0,
14068,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,N,,1,,CHEMBL625470,BAO_0000218,1088.0,
14069,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,N,,1,,CHEMBL632418,BAO_0000218,1088.0,
14070,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,N,,1,,CHEMBL627250,BAO_0000218,1088.0,
14071,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,N,,1,,CHEMBL627251,BAO_0000218,1088.0,
14072,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,N,,1,,CHEMBL627252,BAO_0000218,1088.0,
14073,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,N,,1,,CHEMBL627253,BAO_0000218,1088.0,
14074,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,N,,1,,CHEMBL627254,BAO_0000218,1088.0,
14075,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,N,,1,,CHEMBL875471,BAO_0000218,1088.0,
14076,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,N,,1,,CHEMBL627255,BAO_0000218,1088.0,
14077,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,N,,1,,CHEMBL627256,BAO_0000218,1088.0,
14078,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,N,,1,,CHEMBL627257,BAO_0000218,1088.0,
14079,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,N,,1,,CHEMBL627258,BAO_0000218,1088.0,
14080,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,N,,1,,CHEMBL627259,BAO_0000218,1088.0,
14081,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,N,,1,,CHEMBL627260,BAO_0000218,1088.0,
14082,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,N,,1,,CHEMBL623256,BAO_0000218,1088.0,
14083,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,N,,1,,CHEMBL874413,BAO_0000218,1088.0,
14084,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,N,,1,,CHEMBL623257,BAO_0000218,1088.0,
14085,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,N,,1,,CHEMBL623258,BAO_0000218,1088.0,
14086,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,N,,1,,CHEMBL623259,BAO_0000218,1088.0,
14087,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,N,,1,,CHEMBL623260,BAO_0000218,1088.0,
14088,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,N,,1,,CHEMBL623261,BAO_0000218,1088.0,
14089,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,N,,1,,CHEMBL623262,BAO_0000218,1088.0,
14090,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,N,,1,,CHEMBL623263,BAO_0000218,1088.0,
14091,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,N,,1,,CHEMBL623264,BAO_0000218,1088.0,
14092,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,N,,1,,CHEMBL623265,BAO_0000218,1088.0,
14093,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,N,,1,,CHEMBL623266,BAO_0000218,1088.0,
14094,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,N,,1,,CHEMBL623267,BAO_0000218,1088.0,
14095,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,N,,1,,CHEMBL623268,BAO_0000218,1088.0,
14096,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,N,,1,,CHEMBL623269,BAO_0000218,1088.0,
14097,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,N,,1,,CHEMBL623270,BAO_0000218,1088.0,
14098,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,N,,1,,CHEMBL623271,BAO_0000218,1088.0,
14099,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,N,,1,,CHEMBL623272,BAO_0000218,1088.0,
14100,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,N,,1,,CHEMBL623273,BAO_0000218,1088.0,
14101,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,N,,1,,CHEMBL623274,BAO_0000218,1088.0,
14102,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,N,,1,,CHEMBL874414,BAO_0000218,1088.0,
14103,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,N,,1,,CHEMBL623275,BAO_0000218,1088.0,
14104,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,N,,1,,CHEMBL629150,BAO_0000218,1088.0,
14105,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,N,,1,,CHEMBL623276,BAO_0000218,1088.0,
14106,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,N,,1,,CHEMBL623277,BAO_0000218,1088.0,
14107,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,N,,1,,CHEMBL623112,BAO_0000218,1088.0,
14108,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,N,,1,,CHEMBL623113,BAO_0000218,1088.0,
14109,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,N,,1,,CHEMBL623800,BAO_0000218,1088.0,
14110,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,N,,1,,CHEMBL623801,BAO_0000218,1088.0,
14111,,In vivo,Spleen,A,,,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,,1,,CHEMBL623802,BAO_0000218,2106.0,
14112,,In vivo,Uterus,A,,,,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL623803,BAO_0000218,995.0,
14113,,In vivo,Uterus,A,,,,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL623970,BAO_0000218,995.0,
14114,,In vivo,Uterus,A,,,,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL623971,BAO_0000218,995.0,
14115,,In vivo,Blood,A,,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),N,,1,,CHEMBL623972,BAO_0000218,178.0,
14116,,In vivo,Blood,A,,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),N,,1,,CHEMBL623973,BAO_0000218,178.0,
14117,,In vivo,Blood,A,,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),N,,1,,CHEMBL623974,BAO_0000218,178.0,
14118,,In vivo,Blood,A,,,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),N,,1,,CHEMBL623975,BAO_0000218,178.0,
14119,,In vivo,Brain,A,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),N,,1,,CHEMBL623976,BAO_0000218,955.0,
14120,,In vivo,Brain,A,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),N,,1,,CHEMBL623977,BAO_0000218,955.0,
14121,,In vivo,Brain,A,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),N,,1,,CHEMBL623978,BAO_0000218,955.0,
14122,,In vivo,Brain,A,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),N,,1,,CHEMBL623979,BAO_0000218,955.0,
14123,,In vivo,,A,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),N,,1,,CHEMBL623980,BAO_0000218,,
14124,,In vivo,,A,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),N,,1,,CHEMBL623981,BAO_0000218,,
14125,,In vivo,,A,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),N,,1,,CHEMBL626278,BAO_0000218,,
14126,,In vivo,,A,,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),N,,1,,CHEMBL626279,BAO_0000218,,
14127,,In vivo,,A,,,,Biodistribution in mice bladder plus excreted urine was determined,N,,1,,CHEMBL626280,BAO_0000218,,
14128,,,,A,,,,"Percentage biodistribution in mouse blood, 10 minutes post injection",N,,1,,CHEMBL626281,BAO_0000218,,
14129,,,,A,,,,"Percentage biodistribution in mouse blood, 30 minutes post injection",N,,1,,CHEMBL626282,BAO_0000218,,
14130,,,,A,,,,"Percentage biodistribution in mouse blood, 5 minutes post injection",N,,1,,CHEMBL626283,BAO_0000218,,
14131,,,,A,,,,"Percentage biodistribution in mouse blood, 60 minutes post injection",N,,1,,CHEMBL626284,BAO_0000218,,
14132,,,Brain,A,,,,"Percentage biodistribution in mouse brain, 10 minutes post injection",N,,1,,CHEMBL626285,BAO_0000218,955.0,
14133,,,Brain,A,,,,"Percentage biodistribution in mouse brain, 30 minutes post injection",N,,1,,CHEMBL626286,BAO_0000218,955.0,
14134,,,Brain,A,,,,"Percentage biodistribution in mouse brain, 5 minutes post injection",N,,1,,CHEMBL626287,BAO_0000218,955.0,
14135,,,Brain,A,,,,"Percentage biodistribution in mouse brain, 60 minutes post injection",N,,1,,CHEMBL626288,BAO_0000218,955.0,
14136,,,,A,,,,"Percentage biodistribution in mouse heart, 10 minutes post injection",N,,1,,CHEMBL626289,BAO_0000218,,
14137,,,,A,,,,"Percentage biodistribution in mouse heart, 30 minutes post injection",N,,1,,CHEMBL626290,BAO_0000218,,
14138,,,,A,,,,"Percentage biodistribution in mouse heart, 5 minutes post injection",N,,1,,CHEMBL626291,BAO_0000218,,
14139,,,,A,,,,"Percentage biodistribution in mouse heart, 60 minutes post injection",N,,1,,CHEMBL839888,BAO_0000218,,
14140,,,Intestine,A,,,,"Percentage biodistribution in mouse intestine, 10 minutes post injection",N,,1,,CHEMBL626292,BAO_0000218,160.0,
14141,,,Intestine,A,,,,"Percentage biodistribution in mouse intestine, 30 minutes post injection",N,,1,,CHEMBL626293,BAO_0000218,160.0,
14142,,,Intestine,A,,,,"Percentage biodistribution in mouse intestine, 5 minutes post injection",N,,1,,CHEMBL626294,BAO_0000218,160.0,
14143,,,Intestine,A,,,,"Percentage biodistribution in mouse intestine, 60 minutes post injection",N,,1,,CHEMBL626295,BAO_0000218,160.0,
14144,,,Liver,A,,,,"Percentage biodistribution in mouse liver, 10 minutes post injection",N,,1,,CHEMBL627659,BAO_0000218,2107.0,
14145,,,Liver,A,,,,"Percentage biodistribution in mouse liver, 30 minutes of post injection",N,,1,,CHEMBL627660,BAO_0000218,2107.0,
14146,,,Liver,A,,,,"Percentage biodistribution in mouse liver, 5 minutes post injection",N,,1,,CHEMBL627661,BAO_0000218,2107.0,
14147,,In vivo,Liver,A,,,,Biodistribution in mice liver at 60 minutes of post injection,N,,1,,CHEMBL627662,BAO_0000218,2107.0,
14148,,In vivo,Lung,A,,,,Biodistribution in mice lungs at 10 min of post injection,N,,1,,CHEMBL627663,BAO_0000218,2048.0,
14149,,,,A,,,,"Percentage biodistribution in mouse lung, 30 minutes post injection",N,,1,,CHEMBL627664,BAO_0000218,,
14150,,,,A,,,,"Percentage biodistribution in mousee lung, 5 minutes post injection",N,,1,,CHEMBL627665,BAO_0000218,,
14151,,In vivo,Lung,A,,,,Biodistribution in mice lungs at 60 min of post injection,N,,1,,CHEMBL627666,BAO_0000218,2048.0,
14152,,,Spleen,A,,,,Percentage biodistribution in mouse spleen,N,,1,,CHEMBL627667,BAO_0000218,2106.0,
14153,,,Stomach,A,,,,Percentage biodistribution in mouse stomach,N,,1,,CHEMBL627668,BAO_0000218,945.0,
14154,,,Urine,A,,,,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,N,,1,,CHEMBL627669,BAO_0000218,1088.0,
14155,,In vivo,Urinary bladder,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,U,,1,,CHEMBL627670,BAO_0000218,1255.0,
14156,,In vivo,Blood,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,U,,1,,CHEMBL627671,BAO_0000218,178.0,
14157,,In vivo,Bone element,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,U,,1,,CHEMBL627672,BAO_0000218,1474.0,
14158,,In vivo,,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,U,,1,,CHEMBL627673,BAO_0000218,,
14159,,In vivo,Kidney,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,U,,1,,CHEMBL627674,BAO_0000218,2113.0,
14160,,In vivo,Liver,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,U,,1,,CHEMBL627675,BAO_0000218,2107.0,
14161,,In vivo,Lung,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,U,,1,,CHEMBL627676,BAO_0000218,2048.0,
14162,,In vivo,Muscle tissue,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,U,,1,,CHEMBL627677,BAO_0000218,2385.0,
14163,,,,A,,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL627678,BAO_0000019,,
14164,,,Serum,A,,,,Affinity for protein binding expressed as association constant in fresh rat serum,N,,1,,CHEMBL627679,BAO_0000218,1977.0,
14165,,,,A,,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,U,,1,,CHEMBL627680,BAO_0000019,,
14166,,,,A,,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,U,,1,,CHEMBL627681,BAO_0000019,,
14167,,,,A,,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,U,,1,,CHEMBL627682,BAO_0000019,,
14168,,,,A,,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,U,,1,,CHEMBL627683,BAO_0000019,,
14169,,,,A,,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,U,,1,,CHEMBL627684,BAO_0000019,,
14170,,,,A,,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",U,,1,,CHEMBL874441,BAO_0000019,,
14171,,,,A,,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,U,,1,,CHEMBL627685,BAO_0000019,,
14172,,,,A,,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",U,,1,,CHEMBL627686,BAO_0000019,,
14173,,,,A,,,,Apparent rate constant Koff for inactivation of dTMP synthase.,U,,1,,CHEMBL627687,BAO_0000019,,
14174,,,,A,,,,The irreversible inhibitor activity by second order rate equation.,U,,1,,CHEMBL627688,BAO_0000019,,
14175,,,,A,,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,N,,1,,CHEMBL628038,BAO_0000218,,
14176,,,,A,,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,N,,1,,CHEMBL628039,BAO_0000218,,
14177,,,,A,,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,N,,1,,CHEMBL628040,BAO_0000218,,
14178,,,,A,,,,Dissociation rate calculated from the first-order equation using t1/2 value,U,,1,,CHEMBL628041,BAO_0000019,,
14179,,,,A,,,,The compound was tested for Binding constant against DNA,U,,1,,CHEMBL630226,BAO_0000019,,
14180,,,,A,,,,First order rate constant for cyclization of the compound,U,,1,,CHEMBL628042,BAO_0000019,,
14181,,,,A,,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,U,,1,,CHEMBL625232,BAO_0000019,,
14182,,,,A,,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,U,,1,,CHEMBL625233,BAO_0000019,,
14183,,,,A,,,,Hydrolysis rate constant was determined,U,,1,,CHEMBL625979,BAO_0000019,,
14184,,,,A,,,,Observed first order rate constant,U,,1,,CHEMBL625980,BAO_0000019,,
14185,,,,A,,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,U,,1,,CHEMBL625981,BAO_0000019,,
14186,,,,A,,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,U,,1,,CHEMBL625982,BAO_0000019,,
14187,,,,A,,,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,U,,1,,CHEMBL625983,BAO_0000019,,
14188,,,,A,,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL625984,BAO_0000019,,
14189,,,,A,,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL625985,BAO_0000019,,
14190,,,,A,,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL625986,BAO_0000019,,
14191,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL625987,BAO_0000019,,
14192,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL625988,BAO_0000019,,
14193,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL625989,BAO_0000019,,
14194,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL625990,BAO_0000019,,
14195,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL625991,BAO_0000019,,
14196,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL625992,BAO_0000019,,
14197,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL625993,BAO_0000019,,
14198,,,,A,,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL631973,BAO_0000019,,
14199,,,,A,,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL632143,BAO_0000019,,
14200,,,,A,,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL632144,BAO_0000019,,
14201,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL632145,BAO_0000019,,
14202,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL632146,BAO_0000019,,
14203,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL632147,BAO_0000019,,
14204,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL632148,BAO_0000019,,
14205,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL632149,BAO_0000019,,
14206,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL632150,BAO_0000019,,
14207,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL632151,BAO_0000019,,
14208,,,,A,,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,N,,1,,CHEMBL632152,BAO_0000218,,
14209,,,,A,,,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,N,,1,,CHEMBL632153,BAO_0000218,,
14210,,,,A,,,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,N,,1,,CHEMBL632154,BAO_0000218,,
14211,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,N,,1,,CHEMBL632155,BAO_0000218,,
14212,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,N,,1,,CHEMBL632156,BAO_0000218,,
14213,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,N,,1,,CHEMBL632157,BAO_0000218,,
14214,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,N,,1,,CHEMBL632158,BAO_0000218,,
14215,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,N,,1,,CHEMBL632159,BAO_0000218,,
14216,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,N,,1,,CHEMBL626305,BAO_0000218,,
14217,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,N,,1,,CHEMBL626306,BAO_0000218,,
14218,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,N,,1,,CHEMBL626307,BAO_0000218,,
14219,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,N,,1,,CHEMBL626308,BAO_0000218,,
14220,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,N,,1,,CHEMBL626479,BAO_0000218,,
14221,,,,A,,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,N,,1,,CHEMBL626480,BAO_0000218,,
14222,,,,P,,,,Calculated partition coefficient (clogP) (MlogP),U,,1,,CHEMBL626481,BAO_0000100,,
14223,,,,A,,,,Equipotent potent ratio relative to carbachol (nicotinic activity),U,,1,,CHEMBL626482,BAO_0000019,,
14224,,,,A,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",N,,1,,CHEMBL626483,BAO_0000218,,
14225,,,,A,,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",N,,1,,CHEMBL626484,BAO_0000218,,
14226,,,,P,,,,Solubility at pH 7.4 in micro g/mL;NA denotes available,U,,1,,CHEMBL626485,BAO_0000100,,
14227,,,,P,,,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,U,,1,,CHEMBL626486,BAO_0000100,,
14228,,,,P,,,,Solubility at pH 7.4 in ug/mL;NA denotes not available,U,,1,,CHEMBL626487,BAO_0000100,,
14229,,In vivo,Plasma,A,,,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,N,,1,,CHEMBL626488,BAO_0000218,1969.0,
14230,,,Serum,A,,,,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,N,,1,,CHEMBL626489,BAO_0000218,1977.0,
14231,,,,A,,,,Area under the MAP curve measured over 5 min; ND means Not determined,U,,1,,CHEMBL626490,BAO_0000019,,
14232,,,,P,,,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,U,,1,,CHEMBL626491,BAO_0000100,,
14233,,,,P,,,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,U,,1,,CHEMBL626492,BAO_0000100,,
14234,,,,A,,,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,U,,1,,CHEMBL626493,BAO_0000019,,
14235,,In vivo,,A,,,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,N,,1,,CHEMBL626494,BAO_0000218,,
14236,,In vivo,,A,,,,Half life after oral tested,U,,1,,CHEMBL626495,BAO_0000218,,
14237,,,Plasma,A,,,,Half life was determined in plasma of rat; NT indicates not tested,N,,1,,CHEMBL626496,BAO_0000218,1969.0,
14238,,In vivo,,A,,,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,N,,1,,CHEMBL626497,BAO_0000218,,
14239,,In vivo,,A,,,,Oral bioavailability after oral tested,U,,1,,CHEMBL626498,BAO_0000218,,
14240,,,,A,,,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),N,,1,,CHEMBL626499,BAO_0000218,,
14241,,,,A,,,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),N,,1,,CHEMBL626500,BAO_0000218,,
14242,,,Plasma,A,,,,half life was determined in plasma of rat; NT indicates not tested,N,,1,,CHEMBL626501,BAO_0000218,1969.0,
14243,,,Plasma,A,,,,half life was determined in plasma of rat; NT means not tested,N,,1,,CHEMBL626502,BAO_0000218,1969.0,
14244,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,N,,1,,CHEMBL626503,BAO_0000218,,
14245,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,N,,1,,CHEMBL626504,BAO_0000218,,
14246,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,N,,1,,CHEMBL626505,BAO_0000218,,
14247,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,N,,1,,CHEMBL626506,BAO_0000218,,
14248,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,N,,1,,CHEMBL626507,BAO_0000218,,
14249,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,N,,1,,CHEMBL626508,BAO_0000218,,
14250,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,N,,1,,CHEMBL626509,BAO_0000218,,
14251,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,N,,1,,CHEMBL875480,BAO_0000218,,
14252,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,N,,1,,CHEMBL626510,BAO_0000218,,
14253,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,N,,1,,CHEMBL626511,BAO_0000218,,
14254,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,N,,1,,CHEMBL626512,BAO_0000218,,
14255,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,N,,1,,CHEMBL628208,BAO_0000218,,
14256,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,N,,1,,CHEMBL628209,BAO_0000218,,
14257,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,N,,1,,CHEMBL628210,BAO_0000218,,
14258,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,N,,1,,CHEMBL628211,BAO_0000218,,
14259,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,N,,1,,CHEMBL628212,BAO_0000218,,
14260,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,N,,1,,CHEMBL628213,BAO_0000218,,
14261,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,N,,1,,CHEMBL628214,BAO_0000218,1088.0,
14262,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,N,,1,,CHEMBL628215,BAO_0000218,1088.0,
14263,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,N,,1,,CHEMBL628216,BAO_0000218,1088.0,
14264,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,N,,1,,CHEMBL626595,BAO_0000218,1088.0,
14265,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,N,,1,,CHEMBL626596,BAO_0000218,1088.0,
14266,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,N,,1,,CHEMBL626597,BAO_0000218,1088.0,
14267,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,N,,1,,CHEMBL626598,BAO_0000218,1088.0,
14268,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,N,,1,,CHEMBL622242,BAO_0000218,1088.0,
14269,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,N,,1,,CHEMBL622243,BAO_0000218,1088.0,
14270,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,N,,1,,CHEMBL622244,BAO_0000218,1088.0,
14271,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,N,,1,,CHEMBL622245,BAO_0000218,1088.0,
14272,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,N,,1,,CHEMBL622246,BAO_0000218,1088.0,
14273,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,N,,1,,CHEMBL622247,BAO_0000218,1088.0,
14274,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,N,,1,,CHEMBL622248,BAO_0000218,1088.0,
14275,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,N,,1,,CHEMBL877483,BAO_0000218,1088.0,
14276,,,Urine,A,,,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,N,,1,,CHEMBL622249,BAO_0000218,1088.0,
14277,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,N,,1,,CHEMBL622250,BAO_0000218,1088.0,
14278,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,N,,1,,CHEMBL622251,BAO_0000218,1088.0,
14279,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,N,,1,,CHEMBL622252,BAO_0000218,1088.0,
14280,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,N,,1,,CHEMBL622253,BAO_0000218,1088.0,
14281,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,N,,1,,CHEMBL622254,BAO_0000218,1088.0,
14282,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,N,,1,,CHEMBL622255,BAO_0000218,1088.0,
14283,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,N,,1,,CHEMBL622256,BAO_0000218,1088.0,
14284,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,N,,1,,CHEMBL622257,BAO_0000218,1088.0,
14285,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,N,,1,,CHEMBL622258,BAO_0000218,1088.0,
14286,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,N,,1,,CHEMBL622259,BAO_0000218,1088.0,
14287,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,N,,1,,CHEMBL622927,BAO_0000218,1088.0,
14288,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,N,,1,,CHEMBL622928,BAO_0000218,1088.0,
14289,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,N,,1,,CHEMBL622929,BAO_0000218,1088.0,
14290,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,N,,1,,CHEMBL623182,BAO_0000218,1088.0,
14291,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,N,,1,,CHEMBL623183,BAO_0000218,1088.0,
14292,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,N,,1,,CHEMBL623184,BAO_0000218,1088.0,
14293,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,N,,1,,CHEMBL623185,BAO_0000218,1088.0,
14294,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,N,,1,,CHEMBL877484,BAO_0000218,1088.0,
14295,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,N,,1,,CHEMBL627274,BAO_0000218,1088.0,
14296,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,N,,1,,CHEMBL623186,BAO_0000218,1088.0,
14297,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,N,,1,,CHEMBL623187,BAO_0000218,1088.0,
14298,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,N,,1,,CHEMBL623188,BAO_0000218,1088.0,
14299,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,N,,1,,CHEMBL628055,BAO_0000218,1088.0,
14300,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,N,,1,,CHEMBL628056,BAO_0000218,1088.0,
14301,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,N,,1,,CHEMBL628200,BAO_0000218,1088.0,
14302,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,N,,1,,CHEMBL628201,BAO_0000218,1088.0,
14303,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,N,,1,,CHEMBL628202,BAO_0000218,1088.0,
14304,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,N,,1,,CHEMBL628203,BAO_0000218,1088.0,
14305,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,N,,1,,CHEMBL628204,BAO_0000218,1088.0,
14306,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,N,,1,,CHEMBL628205,BAO_0000218,1088.0,
14307,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,N,,1,,CHEMBL628206,BAO_0000218,1088.0,
14308,,In vivo,Prostate gland,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),U,,1,,CHEMBL628207,BAO_0000218,2367.0,
14309,,In vivo,Prostate gland,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,U,,1,,CHEMBL627220,BAO_0000218,2367.0,
14310,,In vivo,Muscle tissue,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,U,,1,,CHEMBL627221,BAO_0000218,2385.0,
14311,,In vivo,Prostate gland,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),U,,1,,CHEMBL627222,BAO_0000218,2367.0,
14312,,In vivo,,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,U,,1,,CHEMBL627223,BAO_0000218,,
14313,,In vivo,Muscle tissue,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,U,,1,,CHEMBL632062,BAO_0000218,2385.0,
14314,,In vivo,Spleen,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,U,,1,,CHEMBL632063,BAO_0000218,2106.0,
14315,,In vivo,Urinary bladder,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,U,,1,,CHEMBL632064,BAO_0000218,1255.0,
14316,,In vivo,Blood,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,U,,1,,CHEMBL632065,BAO_0000218,178.0,
14317,,In vivo,Bone element,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,U,,1,,CHEMBL632066,BAO_0000218,1474.0,
14318,,In vivo,,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,U,,1,,CHEMBL632067,BAO_0000218,,
14319,,In vivo,Kidney,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,U,,1,,CHEMBL629188,BAO_0000218,2113.0,
14320,,In vivo,Liver,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,U,,1,,CHEMBL629189,BAO_0000218,2107.0,
14321,,In vivo,Lung,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,U,,1,,CHEMBL629190,BAO_0000218,2048.0,
14322,,In vivo,Muscle tissue,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,U,,1,,CHEMBL629191,BAO_0000218,2385.0,
14323,,In vivo,Prostate gland,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),U,,1,,CHEMBL629192,BAO_0000218,2367.0,
14324,,In vivo,Muscle tissue,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,U,,1,,CHEMBL629193,BAO_0000218,2385.0,
14325,,In vivo,Prostate gland,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),U,,1,,CHEMBL629194,BAO_0000218,2367.0,
14326,,In vivo,,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,U,,1,,CHEMBL629195,BAO_0000218,,
14327,,In vivo,Muscle tissue,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,U,,1,,CHEMBL629373,BAO_0000218,2385.0,
14328,,In vivo,Spleen,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,U,,1,,CHEMBL629374,BAO_0000218,2106.0,
14329,,In vivo,Prostate gland,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,U,,1,,CHEMBL629375,BAO_0000218,2367.0,
14330,,In vivo,Urinary bladder,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,U,,1,,CHEMBL629376,BAO_0000218,1255.0,
14331,,In vivo,Blood,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,U,,1,,CHEMBL629377,BAO_0000218,178.0,
14332,,In vivo,Bone element,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,U,,1,,CHEMBL629378,BAO_0000218,1474.0,
14333,,In vivo,,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,U,,1,,CHEMBL629379,BAO_0000218,,
14334,,In vivo,Kidney,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,U,,1,,CHEMBL629151,BAO_0000218,2113.0,
14335,,In vivo,Liver,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,U,,1,,CHEMBL629152,BAO_0000218,2107.0,
14336,,In vivo,Lung,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,U,,1,,CHEMBL629153,BAO_0000218,2048.0,
14337,,In vivo,Muscle tissue,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,U,,1,,CHEMBL629154,BAO_0000218,2385.0,
14338,,In vivo,Prostate gland,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),U,,1,,CHEMBL629155,BAO_0000218,2367.0,
14339,,In vivo,Prostate gland,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,U,,1,,CHEMBL629156,BAO_0000218,2367.0,
14340,,In vivo,Muscle tissue,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,U,,1,,CHEMBL629157,BAO_0000218,2385.0,
14341,,In vivo,Prostate gland,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),U,,1,,CHEMBL629158,BAO_0000218,2367.0,
14342,,In vivo,,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,U,,1,,CHEMBL629159,BAO_0000218,,
14343,,In vivo,Muscle tissue,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,U,,1,,CHEMBL629160,BAO_0000218,2385.0,
14344,,In vivo,Spleen,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,U,,1,,CHEMBL629161,BAO_0000218,2106.0,
14345,,In vivo,Urinary bladder,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,U,,1,,CHEMBL629162,BAO_0000218,1255.0,
14346,,In vivo,Blood,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,U,,1,,CHEMBL629163,BAO_0000218,178.0,
14347,,In vivo,Bone element,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,U,,1,,CHEMBL629164,BAO_0000218,1474.0,
14348,,In vivo,,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,U,,1,,CHEMBL629165,BAO_0000218,,
14349,,In vivo,Liver,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,U,,1,,CHEMBL629166,BAO_0000218,2107.0,
14350,,In vivo,Lung,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,U,,1,,CHEMBL629167,BAO_0000218,2048.0,
14351,,In vivo,Muscle tissue,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,U,,1,,CHEMBL629168,BAO_0000218,2385.0,
14352,,,,A,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,U,,1,,CHEMBL629169,BAO_0000019,,
14353,,,,A,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,U,,1,,CHEMBL629170,BAO_0000019,,
14354,,,,A,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,U,,1,,CHEMBL631153,BAO_0000019,,
14355,,,,A,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,U,,1,,CHEMBL875121,BAO_0000019,,
14356,,,,A,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,U,,1,,CHEMBL631154,BAO_0000019,,
14357,,,,A,,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,U,,1,,CHEMBL631155,BAO_0000019,,
14358,,,,A,,,,Hydrolysis rate constant was determined,U,,1,,CHEMBL631156,BAO_0000019,,
14359,,,,A,,,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",U,,1,,CHEMBL631157,BAO_0000019,,
14360,,,,A,,,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",U,,1,,CHEMBL631158,BAO_0000019,,
14361,,,,A,,,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",U,,1,,CHEMBL631159,BAO_0000019,,
14362,,,,A,,,,Observed second order rate constant,U,,1,,CHEMBL631160,BAO_0000019,,
14363,,,,A,,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,U,,1,,CHEMBL631161,BAO_0000019,,
14364,,,,A,,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,U,,1,,CHEMBL631162,BAO_0000019,,
14365,,,,A,,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,U,,1,,CHEMBL630313,BAO_0000019,,
14366,,,,A,,,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",U,,1,,CHEMBL630314,BAO_0000019,,
14367,,,,A,,,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",U,,1,,CHEMBL630315,BAO_0000019,,
14368,,,,A,,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL630316,BAO_0000019,,
14369,,,,A,,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL630986,BAO_0000019,,
14370,,,,A,,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL630987,BAO_0000019,,
14371,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL630988,BAO_0000019,,
14372,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL630989,BAO_0000019,,
14373,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL630990,BAO_0000019,,
14374,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL630991,BAO_0000019,,
14375,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL630992,BAO_0000019,,
14376,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL630993,BAO_0000019,,
14377,,,,A,,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,1,,CHEMBL630994,BAO_0000019,,
14378,,,,A,,,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,N,,1,,CHEMBL630995,BAO_0000218,,
14379,,,,A,,,,Association constant for compound at 31 degree C was determined,U,,1,,CHEMBL629252,BAO_0000019,,
14380,,,,A,,,,Calculated antagonist equilibrium dissociation constant of the compound,U,,1,,CHEMBL629253,BAO_0000019,,
14381,,,,A,,,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,U,,1,,CHEMBL629944,BAO_0000019,,
14382,,,Trachea,A,,,,Dissociation constants vs LTE4 on guinea pig trachea,N,,1,,CHEMBL629945,BAO_0000218,3126.0,
14383,,,,A,,,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",U,,1,,CHEMBL629946,BAO_0000019,,
14384,,,,A,,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",U,,1,,CHEMBL629947,BAO_0000019,,
14385,,,,A,,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",U,,1,,CHEMBL629948,BAO_0000019,,
14386,,,,A,,,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",U,,1,,CHEMBL856024,BAO_0000019,,
14387,,,,A,,,,Affinity constant KD value was derived from TMP,U,,1,,CHEMBL629949,BAO_0000019,,
14388,,,,A,,,,Apparent dissociation (binding) rate constant was evaluated,U,,1,,CHEMBL629950,BAO_0000019,,
14389,,,,P,,,,Dissociation constant (KD) of the compound,U,,1,,CHEMBL630127,BAO_0000100,,
14390,,,,P,,,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,U,,1,,CHEMBL630128,BAO_0000100,,
14391,,,,P,,,,Dissociation constant from ESR titration experiments,U,,1,,CHEMBL630129,BAO_0000100,,
14392,,,,,,,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),U,,1,,CHEMBL630130,BAO_0000019,,
14393,,,,P,,,,Dissociation constant was evaluated.,U,,1,,CHEMBL875234,BAO_0000100,,
14394,,,,P,,,,Dissociation constant was reported,U,,1,,CHEMBL630131,BAO_0000100,,
14395,,,,A,,,,Dissociation constant was determined in rat pituitary cells.,N,,1,,CHEMBL630132,BAO_0000218,,
14396,,,,A,,,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,U,,1,,CHEMBL630133,BAO_0000019,,
14397,,,,A,,,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,U,,1,,CHEMBL630134,BAO_0000019,,
14398,,,,A,,,,Equilibrium dissociation constant of the compound,U,,1,,CHEMBL630135,BAO_0000019,,
14399,,,,A,,,,Equilibrium dissociation constant was determined,U,,1,,CHEMBL630136,BAO_0000019,,
14400,,,,A,,,,Kinetic constant KD was evaluated,U,,1,,CHEMBL630137,BAO_0000019,,
14401,,,,A,,,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,U,,1,,CHEMBL630138,BAO_0000019,,
14402,,,,A,,,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,U,,1,,CHEMBL630139,BAO_0000019,,
14403,,,,A,,,,Rate constant for hydrolysis in aqueous acetone.,U,,1,,CHEMBL630140,BAO_0000019,,
14404,,,,A,,,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,U,,1,,CHEMBL875235,BAO_0000019,,
14405,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,N,,1,,CHEMBL876439,BAO_0000218,,
14406,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,N,,1,,CHEMBL630605,BAO_0000218,,
14407,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,N,,1,,CHEMBL630606,BAO_0000218,,
14408,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,N,,1,,CHEMBL630607,BAO_0000218,,
14409,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,N,,1,,CHEMBL630608,BAO_0000218,,
14410,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,N,,1,,CHEMBL630609,BAO_0000218,,
14411,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,N,,1,,CHEMBL630610,BAO_0000218,,
14412,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,N,,1,,CHEMBL630611,BAO_0000218,,
14413,,,,A,,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,N,,1,,CHEMBL629552,BAO_0000218,,
14414,,,,A,,,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,N,,1,,CHEMBL629733,BAO_0000218,,
14415,,,,A,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,N,,1,,CHEMBL629734,BAO_0000218,,
14416,,,,A,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,N,,1,,CHEMBL629735,BAO_0000218,,
14417,,,,A,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,N,,1,,CHEMBL629736,BAO_0000218,,
14418,,,,A,,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,N,,1,,CHEMBL629737,BAO_0000218,,
14419,,,,A,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,N,,1,,CHEMBL629738,BAO_0000218,,
14420,,,,A,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,N,,1,,CHEMBL629739,BAO_0000218,,
14421,,,,A,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,N,,1,,CHEMBL629740,BAO_0000218,,
14422,,,,A,,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,N,,1,,CHEMBL629741,BAO_0000218,,
14423,,,,A,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,N,,1,,CHEMBL629742,BAO_0000218,,
14424,,,,A,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,N,,1,,CHEMBL629743,BAO_0000218,,
14425,,,,A,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,N,,1,,CHEMBL629744,BAO_0000218,,
14426,,,,A,,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,N,,1,,CHEMBL629745,BAO_0000218,,
14427,,,,A,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,N,,1,,CHEMBL629746,BAO_0000218,,
14428,,,,A,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,N,,1,,CHEMBL629747,BAO_0000218,,
14429,,,,A,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,N,,1,,CHEMBL629748,BAO_0000218,,
14430,,,,A,,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,N,,1,,CHEMBL629749,BAO_0000218,,
14431,,,,A,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,N,,1,,CHEMBL629750,BAO_0000218,,
14432,,,,A,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,N,,1,,CHEMBL629751,BAO_0000218,,
14433,,,,A,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,N,,1,,CHEMBL629752,BAO_0000218,,
14434,,,,A,,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,N,,1,,CHEMBL629753,BAO_0000218,,
14435,,,,A,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,N,,1,,CHEMBL629754,BAO_0000218,,
14436,,,,A,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,N,,1,,CHEMBL629755,BAO_0000218,,
14437,,,,A,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,N,,1,,CHEMBL629756,BAO_0000218,,
14438,,,,A,,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,N,,1,,CHEMBL629757,BAO_0000218,,
14439,,,,A,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,N,,1,,CHEMBL629758,BAO_0000218,,
14440,,,,A,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,N,,1,,CHEMBL629759,BAO_0000218,,
14441,,,,A,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,N,,1,,CHEMBL629760,BAO_0000218,,
14442,,,,A,,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,N,,1,,CHEMBL876443,BAO_0000218,,
14443,,,,A,,,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,N,,1,,CHEMBL629761,BAO_0000218,,
14444,,,,A,,,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,N,,1,,CHEMBL629762,BAO_0000218,,
14445,,,,A,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,N,,1,,CHEMBL629763,BAO_0000218,,
14446,,,,A,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,N,,1,,CHEMBL629764,BAO_0000218,,
14447,,,,A,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,N,,1,,CHEMBL629765,BAO_0000218,,
14448,,,,A,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,N,,1,,CHEMBL629766,BAO_0000218,,
14449,,,,A,,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,N,,1,,CHEMBL629767,BAO_0000218,,
14450,,,,A,,,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,N,,1,,CHEMBL629768,BAO_0000218,,
14451,,,,A,,,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,N,,1,,CHEMBL629769,BAO_0000218,,
14452,,,,A,,,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,N,,1,,CHEMBL629770,BAO_0000218,,
14453,,,,A,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,N,,1,,CHEMBL629771,BAO_0000218,,
14454,,,,A,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,N,,1,,CHEMBL629772,BAO_0000218,,
14455,,,,A,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,N,,1,,CHEMBL629773,BAO_0000218,,
14456,,,,A,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,N,,1,,CHEMBL625455,BAO_0000218,,
14457,,,,A,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,N,,1,,CHEMBL625456,BAO_0000218,,
14458,,,,A,,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,N,,1,,CHEMBL625457,BAO_0000218,,
14459,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,N,,1,,CHEMBL625458,BAO_0000218,1088.0,
14460,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,N,,1,,CHEMBL625459,BAO_0000218,1088.0,
14461,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,N,,1,,CHEMBL875483,BAO_0000218,1088.0,
14462,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,N,,1,,CHEMBL634779,BAO_0000218,1088.0,
14463,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,N,,1,,CHEMBL625460,BAO_0000218,1088.0,
14464,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,N,,1,,CHEMBL626117,BAO_0000218,1088.0,
14465,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,N,,1,,CHEMBL626118,BAO_0000218,1088.0,
14466,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,N,,1,,CHEMBL628342,BAO_0000218,1088.0,
14467,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,N,,1,,CHEMBL628343,BAO_0000218,1088.0,
14468,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,N,,1,,CHEMBL628344,BAO_0000218,1088.0,
14469,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,N,,1,,CHEMBL628345,BAO_0000218,1088.0,
14470,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,N,,1,,CHEMBL628346,BAO_0000218,1088.0,
14471,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,N,,1,,CHEMBL628347,BAO_0000218,1088.0,
14472,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,N,,1,,CHEMBL628348,BAO_0000218,1088.0,
14473,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,N,,1,,CHEMBL628349,BAO_0000218,1088.0,
14474,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,N,,1,,CHEMBL875611,BAO_0000218,1088.0,
14475,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,N,,1,,CHEMBL628350,BAO_0000218,1088.0,
14476,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,N,,1,,CHEMBL628351,BAO_0000218,1088.0,
14477,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,N,,1,,CHEMBL628352,BAO_0000218,1088.0,
14478,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,N,,1,,CHEMBL628353,BAO_0000218,1088.0,
14479,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,N,,1,,CHEMBL628354,BAO_0000218,1088.0,
14480,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,N,,1,,CHEMBL626667,BAO_0000218,1088.0,
14481,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,N,,1,,CHEMBL626668,BAO_0000218,1088.0,
14482,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,N,,1,,CHEMBL626669,BAO_0000218,1088.0,
14483,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,N,,1,,CHEMBL626670,BAO_0000218,1088.0,
14484,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,N,,1,,CHEMBL626671,BAO_0000218,1088.0,
14485,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,N,,1,,CHEMBL626672,BAO_0000218,1088.0,
14486,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,N,,1,,CHEMBL626673,BAO_0000218,1088.0,
14487,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,N,,1,,CHEMBL626674,BAO_0000218,1088.0,
14488,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,N,,1,,CHEMBL626675,BAO_0000218,1088.0,
14489,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,N,,1,,CHEMBL626676,BAO_0000218,1088.0,
14490,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,N,,1,,CHEMBL626677,BAO_0000218,1088.0,
14491,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,N,,1,,CHEMBL626678,BAO_0000218,1088.0,
14492,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,N,,1,,CHEMBL626679,BAO_0000218,1088.0,
14493,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,N,,1,,CHEMBL875612,BAO_0000218,1088.0,
14494,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,N,,1,,CHEMBL626680,BAO_0000218,1088.0,
14495,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,N,,1,,CHEMBL626681,BAO_0000218,1088.0,
14496,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,N,,1,,CHEMBL626682,BAO_0000218,1088.0,
14497,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,N,,1,,CHEMBL626683,BAO_0000218,1088.0,
14498,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,N,,1,,CHEMBL626684,BAO_0000218,1088.0,
14499,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,N,,1,,CHEMBL626685,BAO_0000218,1088.0,
14500,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,N,,1,,CHEMBL626686,BAO_0000218,1088.0,
14501,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,N,,1,,CHEMBL626687,BAO_0000218,1088.0,
14502,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,N,,1,,CHEMBL624978,BAO_0000218,1088.0,
14503,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,N,,1,,CHEMBL624979,BAO_0000218,1088.0,
14504,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,N,,1,,CHEMBL624980,BAO_0000218,1088.0,
14505,,,Urine,A,,,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,N,,1,,CHEMBL624981,BAO_0000218,1088.0,
14506,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,N,,1,,CHEMBL624982,BAO_0000218,1088.0,
14507,,In vivo,Prostate gland,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),U,,1,,CHEMBL627564,BAO_0000218,2367.0,
14508,,In vivo,Prostate gland,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),U,,1,,CHEMBL627565,BAO_0000218,2367.0,
14509,,In vivo,,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,U,,1,,CHEMBL627566,BAO_0000218,,
14510,,In vivo,Muscle tissue,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,U,,1,,CHEMBL627567,BAO_0000218,2385.0,
14511,,In vivo,Spleen,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,U,,1,,CHEMBL627568,BAO_0000218,2106.0,
14512,,In vivo,Kidney,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,U,,1,,CHEMBL627569,BAO_0000218,2113.0,
14513,,In vivo,Urinary bladder,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,U,,1,,CHEMBL627570,BAO_0000218,1255.0,
14514,,In vivo,Blood,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,U,,1,,CHEMBL627571,BAO_0000218,178.0,
14515,,In vivo,Bone element,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,U,,1,,CHEMBL627572,BAO_0000218,1474.0,
14516,,In vivo,,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,U,,1,,CHEMBL627573,BAO_0000218,,
14517,,In vivo,Kidney,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,U,,1,,CHEMBL627574,BAO_0000218,2113.0,
14518,,In vivo,Liver,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,U,,1,,CHEMBL627575,BAO_0000218,2107.0,
14519,,In vivo,Lung,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,U,,1,,CHEMBL627576,BAO_0000218,2048.0,
14520,,In vivo,Muscle tissue,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,U,,1,,CHEMBL627577,BAO_0000218,2385.0,
14521,,In vivo,Prostate gland,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),U,,1,,CHEMBL627578,BAO_0000218,2367.0,
14522,,In vivo,Prostate gland,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,U,,1,,CHEMBL627579,BAO_0000218,2367.0,
14523,,In vivo,Muscle tissue,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,U,,1,,CHEMBL627580,BAO_0000218,2385.0,
14524,,In vivo,Prostate gland,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),U,,1,,CHEMBL627581,BAO_0000218,2367.0,
14525,,In vivo,,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,U,,1,,CHEMBL627582,BAO_0000218,,
14526,,In vivo,Muscle tissue,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,U,,1,,CHEMBL627583,BAO_0000218,2385.0,
14527,,In vivo,Spleen,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,U,,1,,CHEMBL627584,BAO_0000218,2106.0,
14528,,In vivo,Prostate gland,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,U,,1,,CHEMBL627585,BAO_0000218,2367.0,
14529,,In vivo,Muscle tissue,A,,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,U,,1,,CHEMBL627586,BAO_0000218,2385.0,
14530,,In vivo,,A,,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,N,,1,,CHEMBL627587,BAO_0000218,,
14531,,In vivo,,A,,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,N,,1,,CHEMBL627588,BAO_0000218,,
14532,,In vivo,,A,,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,N,,1,,CHEMBL628250,BAO_0000218,,
14533,,In vivo,,A,,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,N,,1,,CHEMBL628251,BAO_0000218,,
14534,,In vivo,Hippocampus,A,,,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,N,,1,,CHEMBL628252,BAO_0000218,10000000.0,
14535,,In vivo,Hippocampus,A,,,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,N,,1,,CHEMBL628253,BAO_0000218,10000000.0,
14536,,In vivo,Hypothalamus,A,,,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,N,,1,,CHEMBL628254,BAO_0000218,1898.0,
14537,,In vivo,Hypothalamus,A,,,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,N,,1,,CHEMBL877493,BAO_0000218,1898.0,
14538,,In vivo,,A,,,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,N,,1,,CHEMBL628255,BAO_0000218,,
14539,,In vivo,,A,,,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,N,,1,,CHEMBL628256,BAO_0000218,,
14540,,In vivo,Hippocampus,A,,,,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,N,,1,,CHEMBL628257,BAO_0000218,10000000.0,
14541,,In vivo,Hypothalamus,A,,,,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,N,,1,,CHEMBL628258,BAO_0000218,1898.0,
14542,,In vivo,,A,,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,N,,1,,CHEMBL628259,BAO_0000218,,
14543,,In vivo,,A,,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,N,,1,,CHEMBL628429,BAO_0000218,,
14544,,In vivo,Hippocampus,A,,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,N,,1,,CHEMBL626862,BAO_0000218,10000000.0,
14545,,In vivo,Hypothalamus,A,,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,N,,1,,CHEMBL626863,BAO_0000218,1898.0,
14546,,In vivo,Cerebellum,A,,,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,N,,1,,CHEMBL625886,BAO_0000218,2037.0,
14547,,In vivo,Cerebellum,A,,,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,N,,1,,CHEMBL625887,BAO_0000218,2037.0,
14548,,In vivo,,A,,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,N,,1,,CHEMBL625888,BAO_0000218,,
14549,,In vivo,,A,,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,N,,1,,CHEMBL625889,BAO_0000218,,
14550,,In vivo,Hippocampus,A,,,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,N,,1,,CHEMBL625890,BAO_0000218,10000000.0,
14551,,In vivo,Hippocampus,A,,,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,N,,1,,CHEMBL625891,BAO_0000218,10000000.0,
14552,,In vivo,Hypothalamus,A,,,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,N,,1,,CHEMBL625892,BAO_0000218,1898.0,
14553,,In vivo,Hypothalamus,A,,,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,N,,1,,CHEMBL625893,BAO_0000218,1898.0,
14554,,In vivo,Cerebellum,A,,,,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,N,,1,,CHEMBL625894,BAO_0000218,2037.0,
14555,,In vivo,,A,,,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,N,,1,,CHEMBL625895,BAO_0000218,,
14556,,,,A,,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,U,,1,,CHEMBL625896,BAO_0000019,,
14557,,,,A,,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",U,,1,,CHEMBL625897,BAO_0000019,,
14558,,,,A,,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",U,,1,,CHEMBL625898,BAO_0000019,,
14559,,,,A,,,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",U,,1,,CHEMBL625899,BAO_0000019,,
14560,,,,A,,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,U,,1,,CHEMBL626124,BAO_0000019,,
14561,,,,A,,,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,N,,1,,CHEMBL628500,BAO_0000218,,
14562,,,,A,,,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",N,,1,,CHEMBL857856,BAO_0000218,,
14563,,,,A,,,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",N,,1,,CHEMBL628501,BAO_0000218,,
14564,,,,A,,,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",U,,1,,CHEMBL628502,BAO_0000019,,
14565,,,,A,,,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,U,,1,,CHEMBL628503,BAO_0000019,,
14566,,,,A,,,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,U,,1,,CHEMBL628504,BAO_0000019,,
14567,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",U,,1,,CHEMBL628505,BAO_0000019,,
14568,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",U,,1,,CHEMBL874452,BAO_0000019,,
14569,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",U,,1,,CHEMBL628506,BAO_0000019,,
14570,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",U,,1,,CHEMBL628507,BAO_0000019,,
14571,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",U,,1,,CHEMBL628508,BAO_0000019,,
14572,,,,A,,,,Michaelis constant (KM) was evaluated,U,,1,,CHEMBL628509,BAO_0000019,,
14573,,,,A,,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,U,,1,,CHEMBL628510,BAO_0000019,,
14574,,,,B,,,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,U,,1,,CHEMBL628511,BAO_0000019,,
14575,,,,B,,,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,U,,1,,CHEMBL628512,BAO_0000019,,
14576,,,,B,,,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,U,,1,,CHEMBL628513,BAO_0000019,,
14577,,,,B,,,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,U,,1,,CHEMBL628514,BAO_0000019,,
14578,,,,A,,,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,U,,1,,CHEMBL628515,BAO_0000019,,
14579,,,,A,,,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,U,,1,,CHEMBL628516,BAO_0000019,,
14580,,,,A,,,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),U,,1,,CHEMBL628517,BAO_0000019,,
14581,,,,A,,,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),U,,1,,CHEMBL628518,BAO_0000019,,
14582,,,,A,,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,U,,1,,CHEMBL628519,BAO_0000019,,
14583,,,,A,,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,U,,1,,CHEMBL628520,BAO_0000019,,
14584,,,,A,,,,Binding constant was determined,U,,1,,CHEMBL628521,BAO_0000019,,
14585,,,,A,,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,U,,1,,CHEMBL630443,BAO_0000019,,
14586,,,,A,,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,U,,1,,CHEMBL630444,BAO_0000019,,
14587,,,,A,,,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,U,,1,,CHEMBL857732,BAO_0000019,,
14588,,,,P,,,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,U,,1,,CHEMBL630445,BAO_0000100,,
14589,,,,A,,,,Catalytic rate constant of the compound,U,,1,,CHEMBL630446,BAO_0000019,,
14590,,,,B,,,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,U,,1,,CHEMBL630447,BAO_0000019,,
14591,,,,A,,,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),U,,1,,CHEMBL630448,BAO_0000019,,
14592,,,,A,,,,Catalytic rate constant against phospholipase A2 was determined,U,,1,,CHEMBL630449,BAO_0000019,,
14593,,,,A,,,,"Compound was evaluated for catalytic constant, Kcat",U,,1,,CHEMBL630450,BAO_0000019,,
14594,,,,A,,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,U,,1,,CHEMBL630451,BAO_0000019,,
14595,,,,A,,,,Kcat calculated from 0.693/T1/2,U,,1,,CHEMBL630452,BAO_0000019,,
14596,,,,A,,,,Kcat was determined,U,,1,,CHEMBL630453,BAO_0000019,,
14597,,,,A,,,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,U,,1,,CHEMBL630454,BAO_0000019,,
14598,,,,A,,,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,U,,1,,CHEMBL630455,BAO_0000019,,
14599,,,,A,,,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,U,,1,,CHEMBL631487,BAO_0000019,,
14600,,,,A,,,,Kcat value was determined,U,,1,,CHEMBL631488,BAO_0000019,,
14601,,,,A,,,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,U,,1,,CHEMBL876440,BAO_0000019,,
14602,,,,A,,,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,U,,1,,CHEMBL631489,BAO_0000019,,
14603,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",U,,1,,CHEMBL857742,BAO_0000019,,
14604,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",U,,1,,CHEMBL631490,BAO_0000019,,
14605,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",U,,1,,CHEMBL631491,BAO_0000019,,
14606,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",U,,1,,CHEMBL631492,BAO_0000019,,
14607,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",U,,1,,CHEMBL631493,BAO_0000019,,
14608,,,,A,,,,Kinetic parameter for rate of conversion to PABA was determined,U,,1,,CHEMBL631494,BAO_0000019,,
14609,,,,A,,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,U,,1,,CHEMBL631495,BAO_0000019,,
14610,,,Feces,A,,,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",N,,1,,CHEMBL631496,BAO_0000218,1988.0,
14611,,,Urine,A,,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",N,,1,,CHEMBL631497,BAO_0000218,1088.0,
14612,,,Urine,A,,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",N,,1,,CHEMBL631498,BAO_0000218,1088.0,
14613,,,Urine,A,,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",N,,1,,CHEMBL629776,BAO_0000218,1088.0,
14614,,,Urine,A,,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",N,,1,,CHEMBL629777,BAO_0000218,1088.0,
14615,,,Urine,A,,,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",N,,1,,CHEMBL629778,BAO_0000218,1088.0,
14616,,,,A,,,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,N,,1,,CHEMBL630456,BAO_0000218,,
14617,,,,A,,,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,N,,1,,CHEMBL630457,BAO_0000218,,
14618,,,,A,,,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,N,,1,,CHEMBL630458,BAO_0000218,,
14619,,,,A,,,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,N,,1,,CHEMBL630459,BAO_0000218,,
14620,,,,A,,,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,N,,1,,CHEMBL630460,BAO_0000218,,
14621,,,,A,,,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,N,,1,,CHEMBL876550,BAO_0000218,,
14622,,,,A,,,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,N,,1,,CHEMBL630461,BAO_0000218,,
14623,,,,A,,,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,N,,1,,CHEMBL630462,BAO_0000218,,
14624,,,,A,,,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,N,,1,,CHEMBL630463,BAO_0000218,,
14625,,,,A,,,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,N,,1,,CHEMBL630464,BAO_0000218,,
14626,,,,A,,,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,N,,1,,CHEMBL630465,BAO_0000218,,
14627,,,,A,,,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,N,,1,,CHEMBL630466,BAO_0000218,,
14628,,,,A,,,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,N,,1,,CHEMBL630467,BAO_0000218,,
14629,,,,A,,,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,N,,1,,CHEMBL630633,BAO_0000218,,
14630,,,,A,,,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,N,,1,,CHEMBL630634,BAO_0000218,,
14631,,,,A,,,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,N,,1,,CHEMBL630635,BAO_0000218,,
14632,,,,A,,,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,N,,1,,CHEMBL630636,BAO_0000218,,
14633,,,,A,,,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,N,,1,,CHEMBL630637,BAO_0000218,,
14634,,,Feces,A,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",N,,1,,CHEMBL630638,BAO_0000218,1988.0,
14635,,,Feces,A,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",N,,1,,CHEMBL630639,BAO_0000218,1988.0,
14636,,,Feces,A,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",N,,1,,CHEMBL630640,BAO_0000218,1988.0,
14637,,,Feces,A,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",N,,1,,CHEMBL876551,BAO_0000218,1988.0,
14638,,,Urine,A,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",N,,1,,CHEMBL630641,BAO_0000218,1088.0,
14639,,,Urine,A,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",N,,1,,CHEMBL630642,BAO_0000218,1088.0,
14640,,,Urine,A,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",N,,1,,CHEMBL630643,BAO_0000218,1088.0,
14641,,,Urine,A,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",N,,1,,CHEMBL630644,BAO_0000218,1088.0,
14642,,,Urine,A,,,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",N,,1,,CHEMBL630645,BAO_0000218,1088.0,
14643,,,Feces,A,,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",N,,1,,CHEMBL625599,BAO_0000218,1988.0,
14644,,,Feces,A,,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",N,,1,,CHEMBL625600,BAO_0000218,1988.0,
14645,,,Feces,A,,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",N,,1,,CHEMBL625601,BAO_0000218,1988.0,
14646,,,Feces,A,,,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",N,,1,,CHEMBL625602,BAO_0000218,1988.0,
14647,,,Urine,A,,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",N,,1,,CHEMBL627470,BAO_0000218,1088.0,
14648,,,Urine,A,,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",N,,1,,CHEMBL627471,BAO_0000218,1088.0,
14649,,,Urine,A,,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",N,,1,,CHEMBL627472,BAO_0000218,1088.0,
14650,,,Urine,A,,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",N,,1,,CHEMBL627473,BAO_0000218,1088.0,
14651,,,Urine,A,,,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",N,,1,,CHEMBL627474,BAO_0000218,1088.0,
14652,,In vivo,Blood,A,,,,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL627475,BAO_0000218,178.0,
14653,,In vivo,Blood,A,,,,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL627476,BAO_0000218,178.0,
14654,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,N,,1,,CHEMBL627477,BAO_0000218,1088.0,
14655,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,N,,1,,CHEMBL627478,BAO_0000218,1088.0,
14656,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,N,,1,,CHEMBL627479,BAO_0000218,1088.0,
14657,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,N,,1,,CHEMBL627480,BAO_0000218,1088.0,
14658,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,N,,1,,CHEMBL627481,BAO_0000218,1088.0,
14659,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,N,,1,,CHEMBL627482,BAO_0000218,1088.0,
14660,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,N,,1,,CHEMBL627483,BAO_0000218,1088.0,
14661,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,N,,1,,CHEMBL875636,BAO_0000218,1088.0,
14662,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,N,,1,,CHEMBL625764,BAO_0000218,1088.0,
14663,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,N,,1,,CHEMBL625765,BAO_0000218,1088.0,
14664,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,N,,1,,CHEMBL625766,BAO_0000218,1088.0,
14665,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,N,,1,,CHEMBL625767,BAO_0000218,1088.0,
14666,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,N,,1,,CHEMBL625768,BAO_0000218,1088.0,
14667,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,N,,1,,CHEMBL625769,BAO_0000218,1088.0,
14668,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,N,,1,,CHEMBL625770,BAO_0000218,1088.0,
14669,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,N,,1,,CHEMBL625771,BAO_0000218,1088.0,
14670,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,N,,1,,CHEMBL625772,BAO_0000218,1088.0,
14671,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,N,,1,,CHEMBL625773,BAO_0000218,1088.0,
14672,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,N,,1,,CHEMBL625774,BAO_0000218,1088.0,
14673,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,N,,1,,CHEMBL625775,BAO_0000218,1088.0,
14674,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,N,,1,,CHEMBL625776,BAO_0000218,1088.0,
14675,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,N,,1,,CHEMBL625777,BAO_0000218,1088.0,
14676,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,N,,1,,CHEMBL625778,BAO_0000218,1088.0,
14677,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,N,,1,,CHEMBL625779,BAO_0000218,1088.0,
14678,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,N,,1,,CHEMBL625780,BAO_0000218,1088.0,
14679,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,N,,1,,CHEMBL625781,BAO_0000218,1088.0,
14680,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,N,,1,,CHEMBL875637,BAO_0000218,1088.0,
14681,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,N,,1,,CHEMBL626473,BAO_0000218,1088.0,
14682,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,N,,1,,CHEMBL626474,BAO_0000218,1088.0,
14683,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,N,,1,,CHEMBL626475,BAO_0000218,1088.0,
14684,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,N,,1,,CHEMBL626476,BAO_0000218,1088.0,
14685,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,N,,1,,CHEMBL634397,BAO_0000218,1088.0,
14686,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,N,,1,,CHEMBL626477,BAO_0000218,1088.0,
14687,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,N,,1,,CHEMBL631069,BAO_0000218,1088.0,
14688,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,N,,1,,CHEMBL631070,BAO_0000218,1088.0,
14689,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,N,,1,,CHEMBL631071,BAO_0000218,1088.0,
14690,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,N,,1,,CHEMBL631072,BAO_0000218,1088.0,
14691,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,N,,1,,CHEMBL631073,BAO_0000218,1088.0,
14692,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,N,,1,,CHEMBL631074,BAO_0000218,1088.0,
14693,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,N,,1,,CHEMBL631075,BAO_0000218,1088.0,
14694,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,N,,1,,CHEMBL631725,BAO_0000218,1088.0,
14695,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,N,,1,,CHEMBL631726,BAO_0000218,1088.0,
14696,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,N,,1,,CHEMBL631727,BAO_0000218,1088.0,
14697,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,N,,1,,CHEMBL631728,BAO_0000218,1088.0,
14698,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,N,,1,,CHEMBL631729,BAO_0000218,1088.0,
14699,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,N,,1,,CHEMBL631730,BAO_0000218,1088.0,
14700,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,N,,1,,CHEMBL631731,BAO_0000218,1088.0,
14701,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,N,,1,,CHEMBL631910,BAO_0000218,1088.0,
14702,,In vivo,Hippocampus,A,,,,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,N,,1,,CHEMBL631911,BAO_0000218,10000000.0,
14703,,In vivo,Hypothalamus,A,,,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,N,,1,,CHEMBL631912,BAO_0000218,1898.0,
14704,,In vivo,Hypothalamus,A,,,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,N,,1,,CHEMBL631913,BAO_0000218,1898.0,
14705,,In vivo,Blood,A,,,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631914,BAO_0000218,178.0,
14706,,In vivo,Blood,A,,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631915,BAO_0000218,178.0,
14707,,In vivo,Blood,A,,,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL875778,BAO_0000218,178.0,
14708,,In vivo,Blood,A,,,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631916,BAO_0000218,178.0,
14709,,In vivo,Blood,A,,,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631917,BAO_0000218,178.0,
14710,,In vivo,Blood,A,,,,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631918,BAO_0000218,178.0,
14711,,In vivo,Blood,A,,,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631919,BAO_0000218,178.0,
14712,,In vivo,Blood,A,,,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL631920,BAO_0000218,178.0,
14713,,In vivo,Blood,A,,,,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631921,BAO_0000218,178.0,
14714,,In vivo,Blood,A,,,,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631922,BAO_0000218,178.0,
14715,,In vivo,Blood,A,,,,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL631923,BAO_0000218,178.0,
14716,,In vivo,,A,,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631924,BAO_0000218,,
14717,,In vivo,,A,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630234,BAO_0000218,,
14718,,In vivo,,A,,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL630235,BAO_0000218,,
14719,,In vivo,,A,,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630236,BAO_0000218,,
14720,,In vivo,,A,,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630237,BAO_0000218,,
14721,,In vivo,,A,,,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630238,BAO_0000218,,
14722,,In vivo,,A,,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630239,BAO_0000218,,
14723,,In vivo,,A,,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL630303,BAO_0000218,,
14724,,In vivo,,A,,,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630304,BAO_0000218,,
14725,,In vivo,,A,,,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630305,BAO_0000218,,
14726,,In vivo,Kidney,A,,,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630306,BAO_0000218,2113.0,
14727,,In vivo,Kidney,A,,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630307,BAO_0000218,2113.0,
14728,,In vivo,Kidney,A,,,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL630308,BAO_0000218,2113.0,
14729,,In vivo,Kidney,A,,,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630309,BAO_0000218,2113.0,
14730,,In vivo,Kidney,A,,,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL629309,BAO_0000218,2113.0,
14731,,In vivo,Kidney,A,,,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL629993,BAO_0000218,2113.0,
14732,,In vivo,Kidney,A,,,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL629994,BAO_0000218,2113.0,
14733,,In vivo,Kidney,A,,,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL629995,BAO_0000218,2113.0,
14734,,In vivo,Kidney,A,,,,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631993,BAO_0000218,2113.0,
14735,,In vivo,Kidney,A,,,,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631994,BAO_0000218,2113.0,
14736,,In vivo,Kidney,A,,,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631995,BAO_0000218,2113.0,
14737,,In vivo,Liver,A,,,,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL631996,BAO_0000218,2107.0,
14738,,In vivo,Liver,A,,,,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631997,BAO_0000218,2107.0,
14739,,In vivo,Liver,A,,,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631998,BAO_0000218,2107.0,
14740,,In vivo,Liver,A,,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631999,BAO_0000218,2107.0,
14741,,In vivo,Liver,A,,,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL632000,BAO_0000218,2107.0,
14742,,In vivo,Liver,A,,,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL632001,BAO_0000218,2107.0,
14743,,In vivo,Liver,A,,,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL874424,BAO_0000218,2107.0,
14744,,In vivo,Liver,A,,,,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL632002,BAO_0000218,2107.0,
14745,,In vivo,Liver,A,,,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL632003,BAO_0000218,2107.0,
14746,,,,A,,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,U,,1,,CHEMBL632004,BAO_0000019,,
14747,,,,A,,,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,U,,1,,CHEMBL632005,BAO_0000019,,
14748,,,,A,,,,Compound was tested for amidase rate in the presence of N62C screen enzyme,U,,1,,CHEMBL632006,BAO_0000019,,
14749,,,,A,,,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,U,,1,,CHEMBL632007,BAO_0000019,,
14750,,,,A,,,,Compound was tested for amidase rate in the presence of S166C screen enzyme,U,,1,,CHEMBL632008,BAO_0000019,,
14751,,,,A,,,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,U,,1,,CHEMBL632009,BAO_0000019,,
14752,,,,A,,,,Compound was tested for esterase rate in the presence of N62C screen enzyme,U,,1,,CHEMBL632010,BAO_0000019,,
14753,,,,A,,,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,U,,1,,CHEMBL857750,BAO_0000019,,
14754,,,,A,,,,Compound was tested for esterase rate in the presence of S166C screen enzyme,U,,1,,CHEMBL632011,BAO_0000019,,
14755,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",U,,1,,CHEMBL632012,BAO_0000019,,
14756,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",U,,1,,CHEMBL632013,BAO_0000019,,
14757,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",U,,1,,CHEMBL632014,BAO_0000019,,
14758,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",U,,1,,CHEMBL629622,BAO_0000019,,
14759,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",U,,1,,CHEMBL629623,BAO_0000019,,
14760,,,,A,,,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",U,,1,,CHEMBL629624,BAO_0000019,,
14761,,,,A,,,,Ratio of Kcat to that of Km was determined,U,,1,,CHEMBL629625,BAO_0000019,,
14762,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",U,,1,,CHEMBL629626,BAO_0000019,,
14763,,,,A,,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",U,,1,,CHEMBL629627,BAO_0000019,,
14764,,,,A,,,,"Compound was evaluated for constant, Kd",U,,1,,CHEMBL629628,BAO_0000019,,
14765,,,,A,,,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,U,,1,,CHEMBL629629,BAO_0000019,,
14766,,,,A,,,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,U,,1,,CHEMBL629630,BAO_0000019,,
14767,,,,A,,,,Dissociation Constant of compound determined,U,,1,,CHEMBL856030,BAO_0000019,,
14768,,,,B,,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,U,,1,,CHEMBL629631,BAO_0000019,,
14769,,,,B,,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,U,,1,,CHEMBL629632,BAO_0000019,,
14770,,,,P,,,,Dissociation constant of compound with Fructose was determined,U,,1,,CHEMBL629633,BAO_0000100,,
14771,,,,P,,,,Dissociation constant of compound with Fructose was determined; Not determined,U,,1,,CHEMBL629634,BAO_0000100,,
14772,,,,P,,,,Dissociation constant of compound with Lactulose was determined,U,,1,,CHEMBL629635,BAO_0000100,,
14773,,,,P,,,,Dissociation constant of compound with Lactulose was determined; Not determined,U,,1,,CHEMBL629636,BAO_0000100,,
14774,,,,P,,,,Dissociation constant of the Compound,U,,1,,CHEMBL629637,BAO_0000100,,
14775,,,,P,,,,Dissociation constant by non-linear regression analysis,U,,1,,CHEMBL629638,BAO_0000100,,
14776,,,,P,,,,Dissociation constant was determined,U,,1,,CHEMBL629639,BAO_0000100,,
14777,,,,P,,,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,U,,1,,CHEMBL629640,BAO_0000100,,
14778,,,,P,,,,Dissociation constant was determined,U,,1,,CHEMBL629641,BAO_0000100,,
14779,,,,P,,,,Dissociation constant was determined,U,,1,,CHEMBL631344,BAO_0000100,,
14780,,,Muscle tissue,A,,,,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,N,,1,,CHEMBL631345,BAO_0000218,2385.0,
14781,,,,A,,,,The dissociation constant determined by fluorescence displacement assay,U,,1,,CHEMBL631346,BAO_0000019,,
14782,,,,A,,,,kd value surface plasmon resonance (SPR) method,U,,1,,CHEMBL631524,BAO_0000019,,
14783,,,Muscle tissue,A,,,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,N,,1,,CHEMBL631525,BAO_0000218,2385.0,
14784,,,,F,,,,First dissociation constant of the binding of compound to V30M TTR,U,,1,,CHEMBL631526,BAO_0000019,,
14785,,,,F,,,,Second dissociation constant of the binding of compound to V30M TTR,U,,1,,CHEMBL631527,BAO_0000019,,
14786,,,,A,,,,"Compound was evaluated for equilibrium constant, Ke",U,,1,,CHEMBL631528,BAO_0000019,,
14787,,,Hypothalamus,A,,,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,U,,1,,CHEMBL631529,BAO_0000019,1898.0,
14788,,,Hypothalamus,A,,,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,U,,1,,CHEMBL631530,BAO_0000019,1898.0,
14789,,,,A,,,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,U,,1,,CHEMBL631531,BAO_0000019,,
14790,,,,A,,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,U,,1,,CHEMBL631532,BAO_0000019,,
14791,,,,A,,,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,U,,1,,CHEMBL631533,BAO_0000019,,
14792,,,,A,,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,N,,1,,CHEMBL876552,BAO_0000218,,
14793,,,,A,,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,N,,1,,CHEMBL631534,BAO_0000218,,
14794,,,,A,,,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,N,,1,,CHEMBL631535,BAO_0000218,,
14795,,,,A,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,N,,1,,CHEMBL631536,BAO_0000218,,
14796,,,,A,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,N,,1,,CHEMBL631537,BAO_0000218,,
14797,,,,A,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,N,,1,,CHEMBL631538,BAO_0000218,,
14798,,,,A,,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,N,,1,,CHEMBL631539,BAO_0000218,,
14799,,,,A,,,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,N,,1,,CHEMBL631540,BAO_0000218,,
14800,,,,A,,,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,,1,,CHEMBL625637,BAO_0000218,,
14801,,,,A,,,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,,1,,CHEMBL625638,BAO_0000218,,
14802,,,,A,,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",N,,1,,CHEMBL625639,BAO_0000218,,
14803,,In vivo,Brain,A,,,,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625640,BAO_0000218,955.0,
14804,,In vivo,Brain,A,,,,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625641,BAO_0000218,955.0,
14805,,In vivo,Heart,A,,,,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625642,BAO_0000218,948.0,
14806,,In vivo,Heart,A,,,,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625643,BAO_0000218,948.0,
14807,,In vivo,Kidney,A,,,,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625644,BAO_0000218,2113.0,
14808,,In vivo,Kidney,A,,,,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625645,BAO_0000218,2113.0,
14809,,In vivo,Liver,A,,,,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625646,BAO_0000218,2107.0,
14810,,In vivo,Liver,A,,,,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625647,BAO_0000218,2107.0,
14811,,In vivo,Lung,A,,,,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625648,BAO_0000218,2048.0,
14812,,In vivo,Lung,A,,,,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625649,BAO_0000218,2048.0,
14813,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625650,BAO_0000218,2385.0,
14814,,In vivo,Muscle tissue,A,,,,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625651,BAO_0000218,2385.0,
14815,,In vivo,Zone of skin,A,,,,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625652,BAO_0000218,14.0,
14816,,In vivo,Zone of skin,A,,,,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625653,BAO_0000218,14.0,
14817,,In vivo,Spleen,A,,,,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625654,BAO_0000218,2106.0,
14818,,In vivo,Spleen,A,,,,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,1,,CHEMBL625655,BAO_0000218,2106.0,
14819,,In vivo,Blood,A,,,,Biodistribution of Compound in rat blood after 15 minutes of administration,N,,1,,CHEMBL625656,BAO_0000218,178.0,
14820,,In vivo,Blood,A,,,,Biodistribution of Compound in rat blood after 2 minutes of administration,N,,1,,CHEMBL625657,BAO_0000218,178.0,
14821,,In vivo,Brain,A,,,,Biodistribution of Compound in rat brain after 15 minutes of administration,N,,1,,CHEMBL625658,BAO_0000218,955.0,
14822,,In vivo,Brain,A,,,,Biodistribution of Compound in rat brain after 2 minutes of administration,N,,1,,CHEMBL625659,BAO_0000218,955.0,
14823,,In vivo,Heart,A,,,,Biodistribution of Compound in rat heart after 15 minutes of administration,N,,1,,CHEMBL625660,BAO_0000218,948.0,
14824,,In vivo,Heart,A,,,,Biodistribution of Compound in rat heart after 2 minutes of administration,N,,1,,CHEMBL625661,BAO_0000218,948.0,
14825,,In vivo,Liver,A,,,,Biodistribution of Compound in rat liver after 15 minutes of administration,N,,1,,CHEMBL625662,BAO_0000218,2107.0,
14826,,In vivo,Liver,A,,,,Biodistribution of Compound in rat liver after 2 minutes of administration,N,,1,,CHEMBL625663,BAO_0000218,2107.0,
14827,,In vivo,Lung,A,,,,Biodistribution of Compound in rat lung after 15 minutes of administration,N,,1,,CHEMBL875621,BAO_0000218,2048.0,
14828,,In vivo,Lung,A,,,,Biodistribution of Compound in rat lung after 2 minutes of administration,N,,1,,CHEMBL628382,BAO_0000218,2048.0,
14829,,In vivo,Muscle tissue,A,,,,Biodistribution of Compound in rat muscle after 15 minutes of administration,N,,1,,CHEMBL628383,BAO_0000218,2385.0,
14830,,In vivo,Muscle tissue,A,,,,Biodistribution of Compound in rat muscle after 2 minutes of administration,N,,1,,CHEMBL628384,BAO_0000218,2385.0,
14831,,,,A,,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,N,,1,,CHEMBL628385,BAO_0000218,,
14832,,,,A,,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,N,,1,,CHEMBL875753,BAO_0000218,,
14833,,,,A,,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,N,,1,,CHEMBL628386,BAO_0000218,,
14834,,,,A,,,,Organ distribution in rat blood 2 minutes after intravenous injection,N,,1,,CHEMBL628387,BAO_0000218,,
14835,,,,A,,,,Organ distribution in rat blood 2 hr after intravenous injection,N,,1,,CHEMBL628388,BAO_0000218,,
14836,,,,A,,,,Organ distribution in rat blood 30 minutes after intravenous injection,N,,1,,CHEMBL628389,BAO_0000218,,
14837,,,,A,,,,Organ distribution in rat blood 30 min after intravenous injection,N,,1,,CHEMBL632756,BAO_0000218,,
14838,,,,A,,,,Organ distribution in rat brain 2 minutes after intravenous injection,N,,1,,CHEMBL628390,BAO_0000218,,
14839,,,,A,,,,Organ distribution in rat brain 2 hr after intravenous injection,N,,1,,CHEMBL631811,BAO_0000218,,
14840,,,,A,,,,Organ distribution in rat brain 30 minutes after intravenous injection,N,,1,,CHEMBL631812,BAO_0000218,,
14841,,,,A,,,,Organ distribution in rat heart 2 minutes after intravenous injection,N,,1,,CHEMBL631813,BAO_0000218,,
14842,,,,A,,,,Organ distribution in rat heart 2 hr after intravenous injection,N,,1,,CHEMBL631814,BAO_0000218,,
14843,,,,A,,,,Organ distribution in rat heart 30 minutes after intravenous injection,N,,1,,CHEMBL631815,BAO_0000218,,
14844,,,,A,,,,Organ distribution in rat kidney 2 minutes after intravenous injection,N,,1,,CHEMBL631816,BAO_0000218,,
14845,,,,A,,,,Organ distribution in rat kidney 2 hr after intravenous injection,N,,1,,CHEMBL875758,BAO_0000218,,
14846,,,,A,,,,Organ distribution in rat kidney 30 minutes after intravenous injection,N,,1,,CHEMBL631817,BAO_0000218,,
14847,,,Liver,A,,,,Organ distribution in rat liver 2 minutes after intravenous injection,N,,1,,CHEMBL631818,BAO_0000218,2107.0,
14848,,,Liver,A,,,,Organ distribution in rat liver 2 hr after intravenous injection,N,,1,,CHEMBL631819,BAO_0000218,2107.0,
14849,,,Liver,A,,,,Organ distribution in rat liver 30 minutes after intravenous injection,N,,1,,CHEMBL631820,BAO_0000218,2107.0,
14850,,,,A,,,,Organ distribution in rat lung 2 minutes after intravenous injection,N,,1,,CHEMBL631821,BAO_0000218,,
14851,,,,A,,,,Organ distribution in rat lung 2 hr after intravenous injection,N,,1,,CHEMBL631822,BAO_0000218,,
14852,,,,A,,,,Organ distribution in rat lung 30 minutes after intravenous injection,N,,1,,CHEMBL631823,BAO_0000218,,
14853,,,Muscle tissue,A,,,,Organ distribution in rat muscle 2 minutes after intravenous injection,N,,1,,CHEMBL631824,BAO_0000218,2385.0,
14854,,,Muscle tissue,A,,,,Organ distribution in rat muscle 2 hr after intravenous injection,N,,1,,CHEMBL631825,BAO_0000218,2385.0,
14855,,,Muscle tissue,A,,,,Organ distribution in rat muscle 30 minutes after intravenous injection,N,,1,,CHEMBL631826,BAO_0000218,2385.0,
14856,,In vivo,,A,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),N,,1,,CHEMBL631827,BAO_0000218,,
14857,,In vivo,,A,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),N,,1,,CHEMBL631828,BAO_0000218,,
14858,,In vivo,,A,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),N,,1,,CHEMBL631829,BAO_0000218,,
14859,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,N,,1,,CHEMBL875759,BAO_0000218,1088.0,
14860,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,N,,1,,CHEMBL631830,BAO_0000218,1088.0,
14861,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,N,,1,,CHEMBL631831,BAO_0000218,1088.0,
14862,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,N,,1,,CHEMBL631832,BAO_0000218,1088.0,
14863,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,N,,1,,CHEMBL631833,BAO_0000218,1088.0,
14864,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,N,,1,,CHEMBL631834,BAO_0000218,1088.0,
14865,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,N,,1,,CHEMBL631835,BAO_0000218,1088.0,
14866,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,N,,1,,CHEMBL631836,BAO_0000218,1088.0,
14867,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,N,,1,,CHEMBL631837,BAO_0000218,1088.0,
14868,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,N,,1,,CHEMBL631838,BAO_0000218,1088.0,
14869,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,N,,1,,CHEMBL631839,BAO_0000218,1088.0,
14870,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,N,,1,,CHEMBL631840,BAO_0000218,1088.0,
14871,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,N,,1,,CHEMBL631841,BAO_0000218,1088.0,
14872,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,N,,1,,CHEMBL631842,BAO_0000218,1088.0,
14873,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,N,,1,,CHEMBL631843,BAO_0000218,1088.0,
14874,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,N,,1,,CHEMBL631844,BAO_0000218,1088.0,
14875,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,N,,1,,CHEMBL631845,BAO_0000218,1088.0,
14876,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,N,,1,,CHEMBL631846,BAO_0000218,1088.0,
14877,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,N,,1,,CHEMBL875760,BAO_0000218,1088.0,
14878,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,N,,1,,CHEMBL632199,BAO_0000218,1088.0,
14879,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,N,,1,,CHEMBL631847,BAO_0000218,1088.0,
14880,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,N,,1,,CHEMBL631848,BAO_0000218,1088.0,
14881,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,N,,1,,CHEMBL628707,BAO_0000218,1088.0,
14882,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,N,,1,,CHEMBL628708,BAO_0000218,1088.0,
14883,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,N,,1,,CHEMBL628709,BAO_0000218,1088.0,
14884,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,N,,1,,CHEMBL628710,BAO_0000218,1088.0,
14885,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,N,,1,,CHEMBL628711,BAO_0000218,1088.0,
14886,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,N,,1,,CHEMBL628712,BAO_0000218,1088.0,
14887,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,N,,1,,CHEMBL628713,BAO_0000218,1088.0,
14888,,,Urine,A,,,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,N,,1,,CHEMBL628714,BAO_0000218,1088.0,
14889,,,,A,,,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",N,,1,,CHEMBL628715,BAO_0000218,,
14890,,,,A,,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,U,,1,,CHEMBL629179,BAO_0000019,,
14891,,,,A,,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,U,,1,,CHEMBL629180,BAO_0000019,,
14892,,,,A,,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,U,,1,,CHEMBL875108,BAO_0000019,,
14893,,,Adrenal cortex,A,,,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,U,,1,,CHEMBL629181,BAO_0000019,1235.0,
14894,,,Adrenal cortex,A,,,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,U,,1,,CHEMBL629182,BAO_0000019,1235.0,
14895,,,,A,,,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,U,,1,,CHEMBL629183,BAO_0000019,,
14896,,,,A,,,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,U,,1,,CHEMBL629184,BAO_0000019,,
14897,,,Adrenal cortex,A,,,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,U,,1,,CHEMBL629185,BAO_0000019,1235.0,
14898,,,Adrenal cortex,A,,,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,U,,1,,CHEMBL629186,BAO_0000019,1235.0,
14899,,,,A,,,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,U,,1,,CHEMBL629187,BAO_0000019,,
14900,,,,A,,,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,U,,1,,CHEMBL629887,BAO_0000019,,
14901,,,,A,,,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,U,,1,,CHEMBL629888,BAO_0000019,,
14902,,,,A,,,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,U,,1,,CHEMBL629889,BAO_0000019,,
14903,,,Adrenal cortex,A,,,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,U,,1,,CHEMBL629890,BAO_0000019,1235.0,
14904,,,,A,,,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,U,,1,,CHEMBL629891,BAO_0000019,,
14905,,,,A,,,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,U,,1,,CHEMBL629892,BAO_0000019,,
14906,,,Adrenal cortex,A,,,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,U,,1,,CHEMBL629893,BAO_0000019,1235.0,
14907,,,,A,,,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,U,,1,,CHEMBL629894,BAO_0000019,,
14908,,,,A,,,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,U,,1,,CHEMBL629895,BAO_0000019,,
14909,,In vivo,,A,,,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",U,,1,,CHEMBL875109,BAO_0000218,,
14910,,In vivo,,A,,,,Absolute bioavailability in male cynomolgus monkeys,U,,1,,CHEMBL629896,BAO_0000218,,
14911,,In vivo,,A,,,,Absolute bioavailability in maleSprague-Dawley rats,U,,1,,CHEMBL629897,BAO_0000218,,
14912,,In vivo,Liver,A,,,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL629898,BAO_0000218,2107.0,
14913,,In vivo,Liver,A,,,,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630057,BAO_0000218,2107.0,
14914,,In vivo,Liver,A,,,,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630058,BAO_0000218,2107.0,
14915,,In vivo,Lung,A,,,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630059,BAO_0000218,2048.0,
14916,,In vivo,Lung,A,,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630060,BAO_0000218,2048.0,
14917,,In vivo,Lung,A,,,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL630061,BAO_0000218,2048.0,
14918,,In vivo,Lung,A,,,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630062,BAO_0000218,2048.0,
14919,,In vivo,Lung,A,,,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630063,BAO_0000218,2048.0,
14920,,In vivo,Lung,A,,,,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630064,BAO_0000218,2048.0,
14921,,In vivo,Lung,A,,,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630065,BAO_0000218,2048.0,
14922,,In vivo,Lung,A,,,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL630066,BAO_0000218,2048.0,
14923,,In vivo,Lung,A,,,,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630067,BAO_0000218,2048.0,
14924,,In vivo,Lung,A,,,,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630068,BAO_0000218,2048.0,
14925,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631113,BAO_0000218,2385.0,
14926,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631114,BAO_0000218,2385.0,
14927,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL631115,BAO_0000218,2385.0,
14928,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL631116,BAO_0000218,2385.0,
14929,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630528,BAO_0000218,2385.0,
14930,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630529,BAO_0000218,2385.0,
14931,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630530,BAO_0000218,2385.0,
14932,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL630531,BAO_0000218,2385.0,
14933,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630532,BAO_0000218,2385.0,
14934,,In vivo,Muscle tissue,A,,,,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630533,BAO_0000218,2385.0,
14935,,In vivo,Blood,A,,,,Biodistribution in normal mice blood after 120 hr,N,,1,,CHEMBL630534,BAO_0000218,178.0,
14936,,In vivo,Blood,A,,,,Biodistribution in normal mice blood after 24 hr,N,,1,,CHEMBL630535,BAO_0000218,178.0,
14937,,In vivo,Blood,A,,,,Biodistribution in normal mice blood after 4 hr,N,,1,,CHEMBL630536,BAO_0000218,178.0,
14938,,In vivo,Bone,A,,,,Biodistribution in normal mice bone after 120 hr,N,,1,,CHEMBL630537,BAO_0000218,10000001.0,
14939,,In vivo,Bone,A,,,,Biodistribution in normal mice bone after 24 hr,N,,1,,CHEMBL630538,BAO_0000218,10000001.0,
14940,,In vivo,Bone,A,,,,Biodistribution in normal mice bone after 4 hr,N,,1,,CHEMBL630539,BAO_0000218,10000001.0,
14941,,In vivo,Heart,A,,,,Biodistribution in normal mice heart after 120 hr,N,,1,,CHEMBL630540,BAO_0000218,948.0,
14942,,In vivo,Heart,A,,,,Biodistribution in normal mice heart after 24 hr,N,,1,,CHEMBL630541,BAO_0000218,948.0,
14943,,In vivo,Heart,A,,,,Biodistribution in normal mice heart after 4 hr,N,,1,,CHEMBL630542,BAO_0000218,948.0,
14944,,In vivo,Kidney,A,,,,Biodistribution in normal mice kidney after 120 hr,N,,1,,CHEMBL630543,BAO_0000218,2113.0,
14945,,In vivo,Kidney,A,,,,Biodistribution in normal mice kidney after 24 hr,N,,1,,CHEMBL630544,BAO_0000218,2113.0,
14946,,In vivo,Kidney,A,,,,Biodistribution in normal mice kidney after 4 hr,N,,1,,CHEMBL630545,BAO_0000218,2113.0,
14947,,In vivo,Liver,A,,,,Biodistribution in normal mice liver after 120 hr,N,,1,,CHEMBL630546,BAO_0000218,2107.0,
14948,,In vivo,Liver,A,,,,Biodistribution in normal mice liver after 24 hr,N,,1,,CHEMBL630547,BAO_0000218,2107.0,
14949,,In vivo,Liver,A,,,,Biodistribution in normal mice liver after 4 hr,N,,1,,CHEMBL630548,BAO_0000218,2107.0,
14950,,In vivo,Spleen,A,,,,Biodistribution in normal mice spleen after 120 hr,N,,1,,CHEMBL630549,BAO_0000218,2106.0,
14951,,In vivo,Spleen,A,,,,Biodistribution in normal mice spleen after 24 hr,N,,1,,CHEMBL630550,BAO_0000218,2106.0,
14952,,In vivo,Spleen,A,,,,Biodistribution in normal mice spleen after 4 hr,N,,1,,CHEMBL876426,BAO_0000218,2106.0,
14953,,In vivo,Spleen,A,,,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630551,BAO_0000218,2106.0,
14954,,In vivo,Spleen,A,,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630552,BAO_0000218,2106.0,
14955,,In vivo,Spleen,A,,,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL630553,BAO_0000218,2106.0,
14956,,In vivo,Spleen,A,,,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630554,BAO_0000218,2106.0,
14957,,In vivo,Spleen,A,,,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630555,BAO_0000218,2106.0,
14958,,In vivo,Spleen,A,,,,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630556,BAO_0000218,2106.0,
14959,,In vivo,Spleen,A,,,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630557,BAO_0000218,2106.0,
14960,,In vivo,Spleen,A,,,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,1,,CHEMBL630558,BAO_0000218,2106.0,
14961,,In vivo,Spleen,A,,,,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630559,BAO_0000218,2106.0,
14962,,In vivo,Spleen,A,,,,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL630560,BAO_0000218,2106.0,
14963,,In vivo,Thyroid gland,A,,,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,1,,CHEMBL876427,BAO_0000218,2046.0,
14964,,,,A,,,,The Kel values in female wistar rats.,N,,1,,CHEMBL630561,BAO_0000218,,
14965,,,,A,,,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,U,,1,,CHEMBL630562,BAO_0000019,,
14966,,,,A,,,,Hydrolysis rate constant of the compound,U,,1,,CHEMBL630563,BAO_0000019,,
14967,,,,P,,,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,U,,1,,CHEMBL629673,BAO_0000100,,
14968,,,,A,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",U,,1,,CHEMBL629674,BAO_0000019,,
14969,,,,A,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",U,,1,,CHEMBL629675,BAO_0000019,,
14970,,,,A,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",U,,1,,CHEMBL629676,BAO_0000019,,
14971,,,,A,,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",U,,1,,CHEMBL629677,BAO_0000019,,
14972,,,,A,,,,Apparent inactivation rate constant was evaluated,U,,1,,CHEMBL629678,BAO_0000019,,
14973,,,,A,,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,U,,1,,CHEMBL629679,BAO_0000019,,
14974,,,,A,,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,U,,1,,CHEMBL629680,BAO_0000019,,
14975,,,,A,,,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,U,,1,,CHEMBL629681,BAO_0000019,,
14976,,,,A,,,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,U,,1,,CHEMBL629682,BAO_0000019,,
14977,,,,A,,,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,U,,1,,CHEMBL629683,BAO_0000019,,
14978,,,,F,,,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,U,,1,,CHEMBL629684,BAO_0000019,,
14979,,,,P,,,,Dissociation constant was determined,U,,1,,CHEMBL629685,BAO_0000100,,
14980,,,,P,,,,Dissociation constant was determined,U,,1,,CHEMBL629686,BAO_0000100,,
14981,,,,P,,,,Dissociation constant at pH 7.4,U,,1,,CHEMBL872932,BAO_0000100,,
14982,,,,P,,,,Dissociation constant in presence of 1 mM dithiothreitol,U,,1,,CHEMBL629687,BAO_0000100,,
14983,,,,A,,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,U,,1,,CHEMBL872931,BAO_0000019,,
14984,,,,A,,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,U,,1,,CHEMBL628151,BAO_0000019,,
14985,,,,A,,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,U,,1,,CHEMBL628152,BAO_0000019,,
14986,,,,A,,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,U,,1,,CHEMBL628153,BAO_0000019,,
14987,,,,A,,,,Kinetic constant for aromatization of androstenedione,U,,1,,CHEMBL628154,BAO_0000019,,
14988,,,,A,,,,Kinetic constant for aromatization of testosterone,U,,1,,CHEMBL628155,BAO_0000019,,
14989,,,,A,,,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,U,,1,,CHEMBL628156,BAO_0000019,,
14990,,,,A,,,,Local inhibition constant was determined,U,,1,,CHEMBL628157,BAO_0000019,,
14991,,,,A,,,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,N,,1,,CHEMBL857533,BAO_0000218,,
14992,,,,P,,,,Dissociation constant value of the compound,U,,1,,CHEMBL628158,BAO_0000100,,
14993,,,Cornea,A,,,,In vitro permeability through cornea without epithelium,U,,1,,CHEMBL628159,BAO_0000019,964.0,
14994,,,Cornea,A,,,,In vitro permeability through intact cornea,U,,1,,CHEMBL875616,BAO_0000019,964.0,
14995,,,Cornea,A,,,,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,N,,1,,CHEMBL628160,BAO_0000218,964.0,
14996,,,,A,,,,Rate of enzyme inactivation for the compound was determined,U,,1,,CHEMBL628161,BAO_0000019,,
14997,,,Cornea,A,,,,In vitro permeability through cornea without epithelium,U,,1,,CHEMBL628162,BAO_0000019,964.0,
14998,,,Cornea,A,,,,In vitro permeability through intact cornea,U,,1,,CHEMBL628163,BAO_0000019,964.0,
14999,,,,A,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL628164,BAO_0000019,,
15000,,,,A,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL628165,BAO_0000019,,
15001,,,,A,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL628166,BAO_0000019,,
15002,,,,A,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL628167,BAO_0000019,,
15003,,,,A,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL628168,BAO_0000019,,
15004,,,,A,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL628169,BAO_0000019,,
15005,,,,A,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL628170,BAO_0000019,,
15006,,,,A,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL628171,BAO_0000019,,
15007,,,,A,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL627434,BAO_0000019,,
15008,,,,A,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL627435,BAO_0000019,,
15009,,,,A,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL628110,BAO_0000019,,
15010,,,,A,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL628111,BAO_0000019,,
15011,,,,A,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL628112,BAO_0000019,,
15012,,,,A,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL628260,BAO_0000019,,
15013,,,,A,,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,1,,CHEMBL628261,BAO_0000019,,
15014,,In vivo,,A,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),N,,1,,CHEMBL628262,BAO_0000218,,
15015,,In vivo,,A,,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,N,,1,,CHEMBL628263,BAO_0000218,,
15016,,In vivo,,A,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),N,,1,,CHEMBL628264,BAO_0000218,,
15017,,In vivo,,A,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),N,,1,,CHEMBL628265,BAO_0000218,,
15018,,In vivo,,A,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),N,,1,,CHEMBL628266,BAO_0000218,,
15019,,In vivo,,A,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),N,,1,,CHEMBL628267,BAO_0000218,,
15020,,In vivo,,A,,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,N,,1,,CHEMBL628268,BAO_0000218,,
15021,,In vivo,,A,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),N,,1,,CHEMBL628269,BAO_0000218,,
15022,,In vivo,,A,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),N,,1,,CHEMBL628270,BAO_0000218,,
15023,,In vivo,,A,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),N,,1,,CHEMBL628271,BAO_0000218,,
15024,,In vivo,,A,,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),N,,1,,CHEMBL628272,BAO_0000218,,
